<?xml version="1.0" encoding="utf-8"?>
<rdf:RDF
  xmlns:ddiem="http://ddiem.phenomebrowser.net/"
  xmlns:obo="http://purl.obolibrary.org/obo/"
  xmlns:dcterms="http://purl.org/dc/terms/"
  xmlns:foaf="http://xmlns.com/foaf/0.1/"
  xmlns:rdfs="http://www.w3.org/2000/01/rdf-schema#"
  xmlns:dc="http://purl.org/dc/elements/1.1/"
  xmlns:owl="http://www.w3.org/2002/07/owl#"
  xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#"
  xmlns:void="http://rdfs.org/ns/void#"
>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/ea13f7c6-44a4-4b34-9a77-2b1d482dddc2">
    <ddiem:keggEntryId>K01599</ddiem:keggEntryId>
    <ddiem:uniprotId>P06132</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/7efebd51-4cdf-42e8-8366-05c293bc7eb7">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/7389</dc:identifier>
        <rdfs:label>UROD</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/8be7ae64-4310-4ba7-8788-f8ebd25b7baa">
        <rdfs:label>HEF</rdfs:label>
        <dc:identifier>https://ghr.nlm.nih.gov/gene/HEF</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:ecNumber>4.1.1.37</ddiem:ecNumber>
    <rdfs:label>uroporphyrinogen decarboxylase/Hereditary hemochromatosis protein</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/681b830e-bbcc-464b-a1bd-3f931d707d20">
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/feee8175-af10-4f42-a7ed-b23be088eb74">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/c25d2c17-1b66-4959-a629-046209ee1323"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/607330">
        <ddiem:iembaseAccessionNumber>196</ddiem:iembaseAccessionNumber>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/196</ddiem:iembaseUrl>
        <dc:identifier>https://www.omim.org/entry/607330</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/c9e4a4fd-d291-4678-b7e1-f12e8b98be59"/>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>LATHOSTEROLOSIS</rdfs:label>
      </ddiem:Disease>
    </obo:RO_0002599>
    <obo:RO_0002558>
      <ddiem:Evidence rdf:about="http://ddiem.phenomebrowser.net/ECO:0000352">
        <dc:identifier>ECO:0000352</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/ECO_0000352</ddiem:url>
      </ddiem:Evidence>
    </obo:RO_0002558>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/572fa1a7-378b-43af-af3b-8be975ce6911">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/a46230d8-b198-4fdf-9e77-f0c43e776003"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/362cfa6f-3abb-4811-9d7d-4050cfb6c53a">
        <rdfs:label>Abnormal blood lathosterol level</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001939</ddiem:url>
        <dc:identifier>HP:0001939*</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30097991</dc:provenance>
    <rdfs:comment>There was no studies, but since there is an observation of low plasma serine conc. in untreated CBS-deficient patients that merits further exploration since supplementation with serine might be a novel and safe component of treatment of homocystinuria.</rdfs:comment>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000015"/>
  </obo:OGMS_0000112>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/b6b249c0-3285-4ad3-a7e3-0f2585914e5a">
    <ddiem:uniprotId>Q01968</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/011a0fa0-9b10-4853-a0f9-60965261efe0">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/4952</dc:identifier>
        <rdfs:label>OCRL</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K01099</ddiem:keggEntryId>
    <ddiem:ecNumber>3.1.3.36; 3.1.3.56; 3.1.3.86</ddiem:ecNumber>
    <rdfs:label>inositol polyphosphate 5-phosphatase OCRL-1</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/03741edc-6ffd-46fb-bfc0-2f7293555ba8">
    <rdfs:label>zinc/iron-regulated transporter-like protein</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/806654ec-b935-4282-846c-6599e2af109d">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/55630</dc:identifier>
        <rdfs:label>SLC39A4</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>Q6P5W5</ddiem:uniprotId>
    <ddiem:keggEntryId>K14710</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/06ae7664-0c7f-43df-b6b9-31678228096e">
    <ddiem:uniprotId>P49638</ddiem:uniprotId>
    <ddiem:keggEntryId>""</ddiem:keggEntryId>
    <rdfs:label>Î±-tocopherol transfer protein</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/a94295fc-0062-44ea-abad-71c95893feb7">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/7274</dc:identifier>
        <rdfs:label>TTPA</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/5df526db-cccc-444f-8d6e-9e1d1ac6a8e9">
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/b3b91803-46c6-4398-8030-a8feea3ea9bc">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/9c64e16f-4768-4d55-91b3-6aace3b1b298"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <rdfs:comment>The drug was administered through intravitreal injection.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21310277</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/79d44480-aca4-4c37-8b4e-b20a0d413380">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/3c742415-210d-4972-838a-e1442e7e2c47"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21310276</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0f964d7f-8a1f-44fe-b0dd-d00dca031a44">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0025546</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Abnormal hemoglobin level</rdfs:label>
        <dc:identifier>HP:0025546</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01212744</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5399848c-45b7-491d-a5f0-4e1c08a147a2">
        <rdfs:label>Abnormal MCV level</rdfs:label>
        <dc:identifier>HP:0025065</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0025065</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26095523</dc:provenance>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/613839">
        <rdfs:label>MEGALOBLASTIC ANEMIA DUE TO DIHYDROFOLATE REDUCTASE DEFICIENCY</rdfs:label>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/a2ed14b2-bf23-46f1-aeaa-510bd228826b"/>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>https://www.omim.org/entry/613839</dc:identifier>
      </ddiem:Disease>
    </obo:RO_0002599>
  </obo:DDIEM_0000007>
  <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/2209d642-4627-47b9-bc1b-456999763e07">
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/235555">
        <dc:identifier>https://www.omim.org/entry/235555</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>BILE ACID SYNTHESIS DEFECT, CONGENITAL, 2; CBAS2</rdfs:label>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/72591caf-750c-474b-a625-5f5936f83163"/>
      </ddiem:Disease>
    </obo:RO_0002599>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2d0ddaaa-7e1f-48b4-8c63-d71db84fdfd6">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Abnormal bilirubin level</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11067870</dc:provenance>
    <rdfs:comment>While is probably the drug of choic in treating this disease, There is an urge to take cautions in using it in patients with high plasma concentration of chenodeoxycholic acid (and thus we would not use it in a patient with secondary 5p-reductase deficiency). The reason for this is that,if the plasma concentration of chenodeoxycholic acid is increased,it is probable that the hepatocyte concentration is also increased and hydrophobic dihydroxy bile acids such as chenodeoxycholic acid are thought to contribute to the liver cell damage that occurs in cholestasis. https://www.ncbi.nlm.nih.gov/pubmed/8707100</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18570303</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20619503</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/aed6c48a-f146-4e90-b66c-2d10ac790a96">
        <rdfs:label>Abnormal liver function tests</rdfs:label>
        <dc:identifier>HP:0002910</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002910</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4503963</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/92c3b1d3-33c5-486d-b556-1796756b308e">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Liver biopsy abnormalities</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19087156</dc:provenance>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/805548af-9efd-4822-a8b8-b2f38190cf3e">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/0ef1d372-c166-4d8e-b153-4b027dd785ce"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8707100</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/21ba206b-4ec3-4104-9c8a-670f005b9320">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/83fdf574-72bc-4616-809a-501f32b32881"/>
      </rdf:Alt>
    </obo:RO_0000057>
  </obo:DDIEM_0000007>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/bcce5362-1b0c-4985-981d-4920559bebaf">
    <ddiem:uniprotId>Q8NAT1</ddiem:uniprotId>
    <rdfs:label>Protein O-linked-mannose beta-1,4-N-acetylglucosaminyltransferase 2</rdfs:label>
    <ddiem:keggEntryId>K18207</ddiem:keggEntryId>
    <ddiem:ecNumber>2.4.1.312</ddiem:ecNumber>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/592ea377-c20c-4a0e-aac2-fb0f7b3db439">
        <rdfs:label>POMGNT2</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/84892</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/18c8f132-83be-455a-9ada-0277ff0df26c">
    <ddiem:keggEntryId>K12389</ddiem:keggEntryId>
    <ddiem:uniprotId>Q13286</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/6b977732-edfc-4777-81cf-7a0d949196bf">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/1201</dc:identifier>
        <rdfs:label>CLN3</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>battenin</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/d271d539-3f73-47e8-a445-fe6f9becf918">
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/7b517ff3-fc9a-449b-a7f3-1355c1eb4688">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/4b7f9ab4-71fe-4d4a-87ae-5bdd5a1fcf5a"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/af72c454-8e59-41e7-ab5e-57c09a2f7a98">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/c5957b38-4ef2-4c4f-a9a6-67c8e3bb6727"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17397529</dc:provenance>
    <rdfs:comment>An experimental study done on a mice with GMNT knocked out. suggesting considering Nicotinamide as atreatment option in patients with GNMT deficiency.  https://www.ncbi.nlm.nih.gov/pubmed/20578266/</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ccab2880-9b4c-4edb-950b-651d8fee9ed1">
        <rdfs:label>Elevated urine 5-oxoproline</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7375069</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/6b36ca46-5e87-4637-b6e9-73189ff35f01">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/a28a95b0-e791-4012-b97f-998450eb09c5"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/76e590fa-f89d-4d64-a7a3-c08485b7023c">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001942</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Metabolic acidosis</rdfs:label>
        <dc:identifier>HP:0001942</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/5634a50b-fb00-426a-b60d-3c73c68634d7">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/d37012a9-445b-4a7e-8f4a-eddbf92b9d19"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/266130">
        <dc:identifier>https://www.omim.org/entry/266130</dc:identifier>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/512</ddiem:iembaseUrl>
        <rdfs:label>GLUTATHIONE SYNTHETASE DEFICIENCY; GSSD</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseAccessionNumber>512</ddiem:iembaseAccessionNumber>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/3bb3879a-0617-4739-a549-20de5b0fbe42"/>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/c7568be9-e6b5-4e41-9ee1-202e43e5338f">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/29d08099-ee36-45ed-a955-50a8dfb9578e"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/1e563444-127e-40f7-8c83-93768b346275">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/24544a47-9da8-40f2-9d20-abd9e73478c5"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c75f2e34-57ee-4a1b-9a41-995b2564f33a">
        <rdfs:label>Decreased blood free carnitine</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0008315</ddiem:url>
        <dc:identifier>HP:0008315</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/345f7321-2b9d-4b63-8db8-6f154976000d">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Hypoglycemia</rdfs:label>
        <dc:identifier>HP:0001943</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001943</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/db6d42d0-bc1e-458c-9a99-e1e2fe9a00d1">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/161d5461-ddf5-45da-aeb5-a55f94f2997f"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25851806</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19019309</dc:provenance>
  </obo:OGMS_0000112>
  <obo:DDIEM_0000011 rdf:about="http://ddiem.phenomebrowser.net/9c0f0460-76c1-4999-a764-c789bdb2bc07">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1899474</dc:provenance>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/261630">
        <ddiem:iembaseAccessionNumber>5</ddiem:iembaseAccessionNumber>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/5</ddiem:iembaseUrl>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/1909b02a-b024-4806-a90a-b956d08bb2d3"/>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>https://www.omim.org/entry/261630</dc:identifier>
        <rdfs:label>HYPERPHENYLALANINEMIA, BH4-DEFICIENT, C; HPABH4C</rdfs:label>
      </ddiem:Disease>
    </obo:RO_0002599>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8163996</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/78f3d001-4887-4d42-8777-a38dce39096e">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/dd902a9f-5bd6-425b-9c6d-d0fa954c2068"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000009"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26817292</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/50005958-9eaa-41ee-84a4-e0440169c9da">
        <rdfs:label>High serum  prolactin</rdfs:label>
        <dc:identifier>HP:0040086</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0040086</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16891685</dc:provenance>
    <rdfs:comment>Alhough therapy with desmopressin cannot be recommended based on the results of a single case, the outcome presented here is intriguing and suggests that larger studies in such patients is warranted to assess the broader application of such an intervention.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7760062</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/e26f58c5-3e77-453b-8c30-5df2c9c700e9">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/450aeff4-e097-4eb5-83c7-6dd75cfc1fde"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/51d5c67e-91a3-4b97-8d43-220f40f40ed9">
        <dc:identifier>HP:0000707</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000707</ddiem:url>
        <rdfs:label>Neurological abnormalities</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b036786b-4b44-4acf-8163-38ca61c36fe9">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0004923</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0004923</ddiem:url>
        <rdfs:label>high plasma phenylalanine level</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/eaaf9027-4c41-4602-84af-d8b3c062c460">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>abnormal blood Phe levels</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0010893</ddiem:url>
        <dc:identifier>HP:0010893</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12084887</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18425437</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/ac9e4c34-6622-410a-8b39-d4b71217d40b">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/9025b6f7-ed36-45d7-a6ba-78fe5f66bad8"/>
      </rdf:Alt>
    </obo:RO_0000057>
  </obo:DDIEM_0000011>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/1f053d6c-d4b7-4dd6-aa69-688e90e217a2">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/cd810eea-40f1-4ce9-9186-f3e4bdeb2201">
        <rdfs:label>Fasting hypoglycemia</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003162</ddiem:url>
        <dc:identifier>HP:0003162</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000010"/>
    <obo:RO_0002558>
      <ddiem:Evidence rdf:about="http://ddiem.phenomebrowser.net/ECO:0007121">
        <ddiem:url>http://purl.obolibrary.org/obo/ECO_0007121</ddiem:url>
        <dc:identifier>ECO:0007121</dc:identifier>
      </ddiem:Evidence>
    </obo:RO_0002558>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29223626</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17514432</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e8e31867-cd3c-41f1-abbc-ed93c5f7de6e">
        <dc:identifier>HP:0025142*</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0025142</ddiem:url>
        <rdfs:label>Low quality of life(Constitutional symptoms)*</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18996862</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02054832</dc:provenance>
    <rdfs:comment>Anti-inflammatory medications, including derivatives of 5-aminosalicylic acid (5-ASA), might be a helpful adjunct for treating gastrointestinal complaints in GSD Ib patients, if renal function is carefully monitored . https://www.ncbi.nlm.nih.gov/pubmed/12373585</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/af1ed24e-fbcf-4222-8d67-24e64b51ee9c">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002360</ddiem:url>
        <rdfs:comment>The therapy may allow patients with GSD to sleep through the night without awakening for therapy https://www.ncbi.nlm.nih.gov/pubmed/18996862</rdfs:comment>
        <rdfs:label>Sleep disturbance,Poor sleep qaulity</rdfs:label>
        <dc:identifier>HP:0002360</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/0449a602-c972-47e0-94b5-36cdaafb335b">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/74c6cf6b-ea38-4bc1-b02e-ddb84f408dae"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/232220">
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/9b1182d5-8514-414d-b245-69ceac73955a"/>
        <dc:identifier>https://www.omim.org/entry/232220</dc:identifier>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/485</ddiem:iembaseUrl>
        <rdfs:label>GLYCOGEN STORAGE DISEASE Ib; GSD1B</rdfs:label>
        <ddiem:iembaseAccessionNumber>485</ddiem:iembaseAccessionNumber>
        <rdfs:comment></rdfs:comment>
      </ddiem:Disease>
    </obo:RO_0002599>
  </obo:OGMS_0000112>
  <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/c3a0d71f-ba29-4975-a036-97265ecdacb2">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17921858</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22791294</dc:provenance>
    <rdfs:comment>There was no clinical effect, but amild reduction in the plasma level of desmosterol was observed.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28883274</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/2b4f3e8f-5986-49cf-943f-48e013660d88">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/0e2b3e26-d27a-4ba2-9e00-bde6d5349467"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/1cbfe780-074e-4883-9c7d-c7b1847865a4">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/2386b499-3a71-44c8-9968-0e811244de58"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24744655</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3e1fb772-3868-4561-b538-7eabf3c84653">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001903</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0001903</dc:identifier>
        <rdfs:label>low Hb level</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/105650">
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/ba7bf103-312d-4e79-9f52-c77fbbf34228"/>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/ee2091fa-625c-425b-9590-99a1bf048eca"/>
        <dc:identifier>https://www.omim.org/entry/105650</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/6f0c1f84-cdba-4f9e-8b0a-bb155392b399"/>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/d76facd0-2f14-452e-a94b-c6d70b527177"/>
        <rdfs:label>DIAMOND-BLACKFAN ANEMIA 1; DBA1</rdfs:label>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/a1ec28db-fddf-4db2-af8e-3f54232a4592"/>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/42800046-b63a-4e9d-a366-ef7a16d05514"/>
        <rdfs:comment></rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/8dbe64a5-87b6-4d35-909a-293a7bda28a1"/>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/fad7cf77-bab6-4165-ac20-a151d4ce6aa6"/>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/c74b8370-33c5-4ca7-9b2d-cbe9c456cde1"/>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/3a9ab509-62d6-46ea-aca2-d5fd7a5f381d"/>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/83f650ca-87b1-4304-802c-ea4ad1bccd07"/>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12351372</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10779036</dc:provenance>
  </obo:DDIEM_0000007>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/bdfbb130-c9ab-474b-ab44-6672d17256bc">
    <ddiem:uniprotId>Q02252</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/f08e7764-f73f-4558-91e7-093628ea759d">
        <rdfs:label>ALDH6A1</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/4329</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K00140</ddiem:keggEntryId>
    <ddiem:ecNumber>1.2.1.18; 1.2.1.27</ddiem:ecNumber>
    <rdfs:label>3-hydroxyisobutyrate dehydrogenase</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/609917c5-0dbf-41cd-889d-20e7ef46708a">
    <rdfs:label>dysferlin</rdfs:label>
    <ddiem:uniprotId>O75923</ddiem:uniprotId>
    <ddiem:keggEntryId>K18261</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/3d321481-bef9-40d8-bf69-ecc0b534d543">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/8291</dc:identifier>
        <rdfs:label>DYSF</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/c224f036-85fc-4d63-9bb6-f6b983c94144">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15963056</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/53099ecb-bb57-4f2c-9b1a-1251ef527911">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/7690efb8-56de-4721-affe-307ee96026ad"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:comment>Ad vectors, HDAd is completely devoid of all viral protein genes and has been shown to display markedly reduced toxicity in mice.https://www.ncbi.nlm.nih.gov/pubmed/15753292</rdfs:comment>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/232200">
        <dc:identifier>https://www.omim.org/entry/232200</dc:identifier>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/484</ddiem:iembaseUrl>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/7c8463fa-57bf-4aae-a56c-5e21beb73b73"/>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>GLYCOGEN STORAGE DISEASE Ia; GSD1A</rdfs:label>
        <ddiem:iembaseAccessionNumber>484</ddiem:iembaseAccessionNumber>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17514432</dc:provenance>
    <dc:provenance>https://www.semanticscholar.org/paper/Glycogen-storage-diseases%3A-Diagnosis%2C-treatment-and-Chen-Weinstein/439025d057229db1b3a117cb02b3c7e6f2bd3580</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/553a0521-9aea-4bab-9d16-7c12f577a082">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/1e2621f0-7627-409f-b884-3130d9a972fb"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002558>
      <ddiem:Evidence rdf:about="http://ddiem.phenomebrowser.net/ECO:0007764">
        <dc:identifier>ECO:0007764</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/ECO_0007764</ddiem:url>
      </ddiem:Evidence>
    </obo:RO_0002558>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/71596f73-e035-4075-8dde-e92136c484bd">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0000112</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000112</ddiem:url>
        <rdfs:label>Nephropathy</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18996862</dc:provenance>
  </obo:DDIEM_0000013>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/6704a698-74ad-4b6f-8b52-ca9b5bd187fa">
    <ddiem:uniprotId>O60494</ddiem:uniprotId>
    <ddiem:keggEntryId>K18259</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/b0cf640e-9847-4799-9630-a4f50ac0f2ad">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/8029</dc:identifier>
        <rdfs:label>CUBN</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/7209539c-a72b-47df-8072-3dbde7cea8d7">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/81693</dc:identifier>
        <rdfs:label>AMN</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>cubilin/amnion associated transmembrane protein</rdfs:label>
    <ddiem:uniprotId>Q9BXJ7</ddiem:uniprotId>
    <ddiem:keggEntryId>K14616</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/f52dbd44-fa2b-4e90-8fd5-01a3d8bd0fa6">
    <ddiem:uniprotId>O75845</ddiem:uniprotId>
    <rdfs:label>3-beta-hydroxysteroid-delta-5-desaturase</rdfs:label>
    <ddiem:keggEntryId>K00227</ddiem:keggEntryId>
    <ddiem:ecNumber>1.14.19.20</ddiem:ecNumber>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/c9e4a4fd-d291-4678-b7e1-f12e8b98be59">
        <rdfs:label>SC5D</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/6309</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/156211f3-85da-4b3a-843b-4f630e0f74d8">
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1059131117301243</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9ddcb73e-afca-4c9f-85c7-808e8288b96c">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003288</ddiem:url>
        <dc:identifier>HP:0003288</dc:identifier>
        <rdfs:label>High resting plasma lactate concentration</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17080429</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/6b36ca46-5e87-4637-b6e9-73189ff35f01"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/a298fcb2-6e04-4335-bdff-d0b444f22cf1">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/4039362c-307d-4a41-b469-35c971e7bbcb"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <dc:provenance>https://link.springer.com/article/10.1007/s11940-011-0131-z</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/4556601b-4e58-4413-90b1-df627cd415d1">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/cd476638-fa93-4ed6-82bb-607675598ef0"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/545000">
        <dc:identifier>https://www.omim.org/entry/545000</dc:identifier>
        <rdfs:comment>Mitochondrion-toxic agents, including mitochondrion-toxic AEDs, such as valproate, carbamazepine, phenytoin, and barbiturates, should be avoided as well as AEDs potentially enhancing the frequency of myoclonus, such as phenytoin, carbamazepine, lamotrigine, vigabatrin, tiagabine, gabapentin, pregabalin, and oxcarbazepine.</rdfs:comment>
        <ddiem:iembaseAccessionNumber>400</ddiem:iembaseAccessionNumber>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/1abaf40f-2a9b-43e9-9c9c-053c92416972"/>
        <rdfs:label>MYOCLONIC EPILEPSY ASSOCIATED WITH RAGGED-RED FIBERS; MERRF</rdfs:label>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/400</ddiem:iembaseUrl>
      </ddiem:Disease>
    </obo:RO_0002599>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d4b64f39-0410-4da3-88dc-8e90867798a5">
        <dc:identifier>HP:0003287</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003287</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Ankle weakness progression(Disease progression)*</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/books/NBK1520</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17275787</dc:provenance>
    <rdfs:comment>Clonazepam is a useful adjunct for myoclonus and can be used in combination with lamotrigine to avoid lamotrigineâs myoclonic effects . 
Zonisamide should remain a second-line adjunct in the treatment of JME, owing to the lack of supportive data.
https://link.springer.com/article/10.1007/s11940-011-0131-z</rdfs:comment>
  </obo:OGMS_0000112>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/a9f1b568-0eae-467e-b3be-37130d80371e">
    <rdfs:label>Deoxyguanosine kinase, mitochondrial</rdfs:label>
    <ddiem:uniprotId>Q16854</ddiem:uniprotId>
    <ddiem:ecNumber>2.7.1.113</ddiem:ecNumber>
    <ddiem:keggEntryId>K00904</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/60786166-eacf-44ea-a8d2-9d2985227fb7">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/1716</dc:identifier>
        <rdfs:label>DGUOK</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/615249">
    <rdfs:comment></rdfs:comment>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/1122</ddiem:iembaseUrl>
    <ddiem:iembaseAccessionNumber>1122</ddiem:iembaseAccessionNumber>
    <rdfs:label>MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH BRAIN AND EYE ANOMALIES), TYPE A, 12; MDDGA12</rdfs:label>
    <dc:identifier>https://www.omim.org/entry/615249</dc:identifier>
    <obo:RO_0004020>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/5bf09476-1d76-4de1-aaaa-a61db3d757ea">
        <rdfs:label>POMK</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/84197</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0004020>
  </ddiem:Disease>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/fe559f46-db08-4a85-a567-6b7e2c245989">
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/fee6d538-da4d-4b13-9e0f-526f5277f305">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/d04ff30b-6bb0-409d-bce2-6b31e9418c73"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c0b96ae6-084b-4b23-adfd-7cda91f1bc80">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0000991</dc:identifier>
        <rdfs:label>xanthomas</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000991</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e4b3775e-437a-446d-b2b2-5e258eb64184">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001677</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>stenotic coronary atherosclerosis</rdfs:label>
        <dc:identifier>HP:0001677</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/27c31550-9d48-4ec0-a005-d6dc8fc89c76">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/48fbe5a5-c316-49db-a9fb-6ca1c62a824b"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2065040</dc:provenance>
    <dc:provenance>https://link.springer.com/article/10.1007%2Fs11883-014-0440-2</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000012"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:comment>clinicians might only switch to combination therapy in FD patients who remain severely hypertriglyceridemic and/or hypercholesterolemic on monotherapy instead of prescribing combined statin-fibrate therapy to all FD patients that do not meet the non-HDL-C target.https://www.ncbi.nlm.nih.gov/pubmed/25768710</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3162680</dc:provenance>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/617347">
        <rdfs:label>HYPERLIPOPROTEINEMIA, TYPE III</rdfs:label>
        <ddiem:iembaseAccessionNumber>507</ddiem:iembaseAccessionNumber>
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/507</ddiem:iembaseUrl>
        <dc:identifier>https://www.omim.org/entry/617347</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/9760c659-8c67-492f-b63b-60b1f475b082"/>
      </ddiem:Disease>
    </obo:RO_0002599>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/cb6bd741-1adf-47e1-be0d-a5017ba7633c">
        <rdfs:label>angina pectoris</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001681</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0001681</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25079293</dc:provenance>
  </obo:DDIEM_0000013>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/cb8bfd75-7bcc-4cc6-96a8-840a664ac429">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/cef848b7-30f3-4f72-983d-7aafe77c340f">
        <rdfs:label>Stroke-like attacks</rdfs:label>
        <dc:identifier>HP:0002401</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002401</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/749c4e05-a067-4dbf-bfde-b25a6123b0e0">
        <dc:identifier>HP:0000707</dc:identifier>
        <rdfs:label>Neurological abnormality</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000707</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/7d14658a-4b9d-4e36-848b-28462edf1aa3">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/5bb2229c-a9d1-4207-b16b-3831a00ef961"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/23a0469e-c7a0-4ccf-b410-cefc6fcd45e1">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0030890</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0030890</dc:identifier>
        <rdfs:label>Hyperintensity of cerebral white matter on MRI</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/af72c454-8e59-41e7-ab5e-57c09a2f7a98"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11382201</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01212744</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3d170503-c688-4944-8d4e-53faec7c33a3">
        <rdfs:label>Abnormal EEG (focal epileptiform activity)</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002353</ddiem:url>
        <dc:identifier>HP:0002353</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/540000">
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/5fee6004-d41c-4939-853c-6d22496f293c"/>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/f5b4e0fe-8f48-4ef0-a7a2-e716a36737cc"/>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/2bf1b12f-923e-43a7-97e8-9778d7c2b3b2"/>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/a665b7db-c424-45bd-9f7b-268c6f4b7cdd"/>
        <rdfs:label>MITOCHONDRIAL MYOPATHY, ENCEPHALOPATHY, LACTIC ACIDOSIS, AND STROKE-LIKE EPISODES; MELAS</rdfs:label>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/91ebf6d2-58c0-4350-862c-3e2a6b4fa89d"/>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/1abaf40f-2a9b-43e9-9c9c-053c92416972"/>
        <rdfs:comment>MELAS syndrome can be caused by mutation in several genes, including MT-TL1/ MT-TQ /MT-TH/MT-TK / MTTC/ MTTS1/ MTND1/ MTND5/ MTND6/ MTTS2. https://www.omim.org/entry/540000</rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/2b4b4144-8fa8-4ef5-84a2-783bc8471175"/>
        <dc:identifier>https://www.omim.org/entry/540000</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/f25d4e54-b37b-4a71-876e-328ff89f9566"/>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/47ef309f-d257-450f-8c9b-8440060d880f"/>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/27cf12eb-db1f-49f7-ba20-908346f6c667"/>
        <ddiem:iembaseAccessionNumber>399</ddiem:iembaseAccessionNumber>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/399</ddiem:iembaseUrl>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8757046</dc:provenance>
    <rdfs:comment>The drug was administered through intravitreal injection.</rdfs:comment>
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26095523</dc:provenance>
  </obo:OGMS_0000112>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/dd79c4db-2bb6-4204-85cb-fb55b5a7e5b9">
    <ddiem:uniprotId>P15328</ddiem:uniprotId>
    <ddiem:keggEntryId>K13649</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/947414be-40c2-41cc-a06c-4270e7cb2e77">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/2348</dc:identifier>
        <rdfs:label>FOLR1</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>Folate receptor alpha</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/50ef44a7-2351-47dc-9ae5-aa50377eefb5">
    <ddiem:keggEntryId>K05032</ddiem:keggEntryId>
    <rdfs:label>ATP binding cassette subfamily C member 8</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/79a4ab26-af1c-4d68-9b28-b9eac158b063">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/6833</dc:identifier>
        <rdfs:label>ABCC8</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>Q09428</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/616896">
    <dc:identifier>https://www.omim.org/entry/616896</dc:identifier>
    <obo:RO_0004020>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/3483bfdd-bbbf-48ce-b56d-020bcf9c4e58">
        <rdfs:label>OPA1</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/4976</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0004020>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>MITOCHONDRIAL DNA DEPLETION SYNDROME 14 (CARDIOENCEPHALOMYOPATHIC TYPE); MTDPS14</rdfs:label>
  </ddiem:Disease>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/0bf72780-b1b5-4497-aa96-a29057353b82">
    <ddiem:ecNumber>2.3.1.21</ddiem:ecNumber>
    <rdfs:label>carnitine palmitoyltransferase 1A</rdfs:label>
    <ddiem:keggEntryId>K08765</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/86db9b47-29e8-4e38-be01-5e205caa32e8">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/1374</dc:identifier>
        <rdfs:label>CPT1A</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>P50416</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/615041">
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/640</ddiem:iembaseUrl>
    <dc:identifier>https://www.omim.org/entry/615041</dc:identifier>
    <rdfs:label>MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH BRAIN AND EYE ANOMALIES), TYPE A, 10; MDDGA10</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <obo:RO_0004020>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/41503358-cc3e-4e8b-ac18-da60ddb867f4">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/10329</dc:identifier>
        <rdfs:label>RXYLT1</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0004020>
    <ddiem:iembaseAccessionNumber>640</ddiem:iembaseAccessionNumber>
  </ddiem:Disease>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/c562f625-bf33-47de-a6c7-d537095b2cf4">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28649527</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29058386</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25859380</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24886114</dc:provenance>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/222700">
        <rdfs:comment>General therapeutic management remains empirical with 3 major axes: prevention of hyperammonemia, nutritional supplementation and prevention of specific complications. There is a general consensus that a hypoproteinemic regimen should be initiated with an objective of 1 g/kg/d. associated with L-citrulline supplementation, L-carnitine 20-50 mg/kg/d., vitamins and other nutritional supplementation, if necessary. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5217205/  https://www.ncbi.nlm.nih.gov/pubmed/21308987/.  https://www.ncbi.nlm.nih.gov/pubmed/22402328/</rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/d3304fbc-06ca-4312-b80a-c82ed0a8b0ad"/>
        <ddiem:iembaseAccessionNumber>51</ddiem:iembaseAccessionNumber>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/51</ddiem:iembaseUrl>
        <rdfs:label>LYSINURIC PROTEIN INTOLERANCE; LPI</rdfs:label>
        <dc:identifier>https://www.omim.org/entry/222700</dc:identifier>
      </ddiem:Disease>
    </obo:RO_0002599>
    <rdfs:comment>The regimen was accomapanied with a protein-restricted diet. https://www.ncbi.nlm.nih.gov/pubmed/27567650</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28087478</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21110863</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/c7bbce4e-bbe2-4090-8287-ee48481c6418">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/328cca9e-db93-4544-b87d-172410b626d6"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/86e570a4-cdba-4d73-8baf-a7638b33eb00">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/cf1ed284-af61-4ea9-b813-440abbb99ed8"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3a5ce904-1948-4f01-b475-a00a55c9e815">
        <rdfs:label>membranoproliferative glomerulonephritis</rdfs:label>
        <dc:identifier>HP:0000793</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000793</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </obo:OGMS_0000112>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/7f7fb406-84a1-4569-b68d-cce3a2a3c236">
    <ddiem:uniprotId>P07101</ddiem:uniprotId>
    <ddiem:ecNumber>1.14.16.2</ddiem:ecNumber>
    <rdfs:label>Tyrosine hydroxylase</rdfs:label>
    <ddiem:keggEntryId>K00501</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/9676fa84-21f6-4244-a68b-4ff450096189">
        <rdfs:label>TH</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/7054</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/89573c06-55db-4cc8-9fc4-b61eaf26a554">
    <ddiem:keggEntryId>K00166</ddiem:keggEntryId>
    <ddiem:uniprotId>P12694</ddiem:uniprotId>
    <ddiem:ecNumber>1.2.4.4</ddiem:ecNumber>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/c5118f18-25c7-47a0-a03b-2b15998cb743">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/593</dc:identifier>
        <rdfs:label>BCKDHA</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>2-oxoisovalerate dehydrogenase subunit alpha, mitochondrial</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/38eca6a4-b19b-4657-9cd6-aa3b3ffd2325">
    <ddiem:uniprotId>P45954</ddiem:uniprotId>
    <ddiem:keggEntryId>K09478</ddiem:keggEntryId>
    <ddiem:ecNumber>1.3.8.5</ddiem:ecNumber>
    <rdfs:label>3-hydroxy-2-methylbutyryl-CoA dehydrogenase</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/ec0ee0bd-a4d2-4278-86f1-d129c73c5e85">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/36</dc:identifier>
        <rdfs:label>ACADSB</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/bf496d0c-562e-4621-adae-03eac991bfc6">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/602473">
        <ddiem:iembaseAccessionNumber>172</ddiem:iembaseAccessionNumber>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/8a732a3a-7b73-4305-a9a3-748478f0af92"/>
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/172</ddiem:iembaseUrl>
        <rdfs:label>ENCEPHALOPATHY, ETHYLMALONIC; EE</rdfs:label>
        <dc:identifier>https://www.omim.org/entry/602473</dc:identifier>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29526615</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/37794b5a-9214-4ce8-a859-cbd9ec661a85">
        <dc:identifier>HP:0000967</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000967</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Petechiae</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e90a4831-ed94-4573-9f28-00b04e1a4b36">
        <rdfs:label>Cognitive impairment</rdfs:label>
        <dc:identifier>HP:0100543</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0100543</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>A drug regimen that was after liver transplataion surgery to maintain the achieved metabolic results.</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4391b4d9-a461-4cf9-b43a-5b23e0a6ea20">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0004302</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0004302</dc:identifier>
        <rdfs:label>Functional motor deficit</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/352ebec7-cb9f-4b6b-bcd9-d94ec47ab375">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0045045</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0045045</ddiem:url>
        <rdfs:label>Elevated plasma acylcarnitine levels</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11916321</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0022202X15352507</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/4556601b-4e58-4413-90b1-df627cd415d1"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/af72c454-8e59-41e7-ab5e-57c09a2f7a98"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4d1a1e77-38e5-4339-b741-11951b3621d7">
        <rdfs:label>Chronic mucoid diarrhea</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002028</ddiem:url>
        <dc:identifier>HP:0002028</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17712735</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4e014208-de52-49da-ba99-3122f0405c4b">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0025356</dc:identifier>
        <rdfs:label>Psychomotor retardation</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0025356</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </obo:OGMS_0000112>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/d6561328-ef6e-4302-915f-3d42958071a9">
    <ddiem:uniprotId>Q96S06</ddiem:uniprotId>
    <rdfs:label>lipase maturation factor 1</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/7f7f4e78-e62a-4510-bb57-8109a959f96b">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/64788</dc:identifier>
        <rdfs:label>LMF1</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K23555</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <obo:direct_complementation_of_a_genetically_defective_protein_by_gene_therapy rdf:about="http://ddiem.phenomebrowser.net/df0f96c9-aa32-4d94-89a7-cb58af5c496d">
    <dc:provenance>https://link.springer.com/article/10.1007/s11940-011-0131-z</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b2e722ac-ef7a-428c-9e80-5a2a05c4a830">
        <rdfs:label>Muscle dystrophy</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0006785</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0006785</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1059131117301243</dc:provenance>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/613154">
        <dc:identifier>https://www.omim.org/entry/613154</dc:identifier>
        <ddiem:iembaseAccessionNumber>1125</ddiem:iembaseAccessionNumber>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH BRAIN AND EYE ANOMALIES), TYPE A, 6; MDDGA6</rdfs:label>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/1125</ddiem:iembaseUrl>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/5cefcd24-5e21-406c-b7e7-a277879685da"/>
      </ddiem:Disease>
    </obo:RO_0002599>
    <obo:RO_0002558>
      <ddiem:Evidence rdf:about="http://ddiem.phenomebrowser.net/ECO:0005542">
        <ddiem:url>http://purl.obolibrary.org/obo/ECO_0005542</ddiem:url>
        <dc:identifier>ECO:0005542</dc:identifier>
      </ddiem:Evidence>
    </obo:RO_0002558>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/771666f5-dccc-4d6d-bdd9-8158f1ab0f07">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/6d2800e4-9e6b-4277-ab21-dc7495676942"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/books/NBK1520</dc:provenance>
    <rdfs:comment>In a different study IV administration of Glucose wasn't effective.https://www.ncbi.nlm.nih.gov/pubmed/22238410</rdfs:comment>
    <dc:provenance>https://www.nature.com/articles/nm1059</dc:provenance>
  </obo:direct_complementation_of_a_genetically_defective_protein_by_gene_therapy>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/65620e25-e3ca-46e6-b193-bc26e13289b3">
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/540000"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8757046</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/7d14658a-4b9d-4e36-848b-28462edf1aa3"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f89260ec-5bbc-48ba-92fd-68bca1417e0e">
        <dc:identifier>HP:0002353</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Abnormal EEG</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002353</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/0022510X89901123</dc:provenance>
    <rdfs:comment>The drug was administered through intravitreal injection.</rdfs:comment>
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/4556601b-4e58-4413-90b1-df627cd415d1"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01212744</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26095523</dc:provenance>
    <dc:provenance>https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117</dc:provenance>
  </obo:DDIEM_0000013>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/c6222ad9-a6db-4b32-8fc8-ea4112d867b2">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/48062b3a-490d-4c19-8fb5-a03313826273">
        <rdfs:label>PHKA2</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/5256</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>Phosphorylase b kinase regulatory subunit alpha, liver isoform</rdfs:label>
    <ddiem:uniprotId>P46019</ddiem:uniprotId>
    <ddiem:keggEntryId>K07190</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/a07a6d08-610e-423e-8be8-64e173520783">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/56fd25a9-0b1d-4839-910f-0b819cdf67ae">
        <rdfs:label>Increased number of splenic myeloid cells</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000015"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25717099</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31248418</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19750228</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d3bf738c-811d-4776-8523-218ef1b106de">
        <rdfs:label>Abnormality of lipid metabolism</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003119</ddiem:url>
        <dc:identifier>HP:0003119</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11787939</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/d046be7f-8385-48c8-aefe-91fd23ce0110">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/537f6c64-f94d-4074-a7af-3e8b26ce516e"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/7d11f64a-c733-4317-be41-2350f6066b48">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/00267b03-ee2b-4aa5-a062-7d27685fc92f"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:comment>One of the studies that was carried on mice provides useful information for developing the optimal dosage regimen for HPBCD therapy when administered intravenously to NPC patients.https://www.ncbi.nlm.nih.gov/pubmed/26027824</rdfs:comment>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/4359fd49-c128-4118-8b96-b9368bcb6de5">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/ed74406f-cb3a-412d-bb67-211930709f61"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5f49780c-4a13-4331-ab93-04256ef43c84">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002180</ddiem:url>
        <rdfs:label>Cerebeller neurodegeneration( neurodegeneration)*</rdfs:label>
        <dc:identifier>HP:0002180*</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19415691</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23948640</dc:provenance>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/257220">
        <rdfs:label>NIEMANN-PICK DISEASE, TYPE C1; NPC1</rdfs:label>
        <ddiem:iembaseAccessionNumber>303</ddiem:iembaseAccessionNumber>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/303</ddiem:iembaseUrl>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>https://www.omim.org/entry/257220</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/77b36c2e-942a-4400-8341-29ed8dbbbe39"/>
      </ddiem:Disease>
    </obo:RO_0002599>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/570080fd-0ed1-4e38-bf51-59ada0a95f14">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002275</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0002275</dc:identifier>
        <rdfs:label>Motor function impairment</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25400034</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28803710</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/58250b72-3547-4fc5-9ce4-6143de5e8f5d">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Splenomegaly</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001744</ddiem:url>
        <dc:identifier>HP:0001744</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02534844</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
  </obo:OGMS_0000112>
  <obo:DDIEM_0000009 rdf:about="http://ddiem.phenomebrowser.net/ad8c3e47-d58a-4d6a-8339-94a9a3a6a3a1">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719213003661</dc:provenance>
    <rdfs:comment>Sodium phenylbutyrate lowers the resynthesis of arginine from ornithine via the urea cycle.https://www.ncbi.nlm.nih.gov/pubmed/24268530</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8813986</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/85ce8119-1e09-46a3-a820-d08b8f8e92d0">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/8b3157f4-514a-4424-9ea3-3760cdf23f2f"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/81ef2c4d-b7c6-4946-9915-b9446d90401d">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/99956867-9a65-48f8-98a2-c0b2981bb0df"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000015"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16855203</dc:provenance>
    <dc:provenance>https://rarediseases.info.nih.gov/diseases/2578/guanidinoacetate-methyltransferase-deficiency</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719212002971</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/58ae599e-1ea7-4e4b-829f-9d4c68e2bf81">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>High plasma guanidinoacetate levels</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29506905</dc:provenance>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/612736">
        <dc:identifier>https://www.omim.org/entry/612736</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/104</ddiem:iembaseUrl>
        <ddiem:iembaseAccessionNumber>104</ddiem:iembaseAccessionNumber>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/d92b5b46-aac4-4c08-8d4a-73dc7dbdf9af"/>
        <rdfs:label>CEREBRAL CREATINE DEFICIENCY SYNDROME 2; CCDS2</rdfs:label>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24268530</dc:provenance>
  </obo:DDIEM_0000009>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/1c5476f0-1c27-499c-9e91-8985803f4e10">
    <ddiem:ecNumber>3.1.-.-; 3.6.4.12</ddiem:ecNumber>
    <ddiem:uniprotId>P51530</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/2b5d3307-9dd6-42fb-8b09-cf1d89a0caf4">
        <rdfs:label>DNA2</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/1763</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>DNA replication ATP-dependent helicase/nuclease DNA2</rdfs:label>
    <ddiem:keggEntryId>K10742</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/14798471-ca1a-44ef-91e7-984bfa7d2dfa">
    <ddiem:keggEntryId>K13624</ddiem:keggEntryId>
    <ddiem:ecNumber>1.16.3.1</ddiem:ecNumber>
    <ddiem:uniprotId>P00450</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/731f7536-3e68-450a-9737-344aa967656d">
        <rdfs:label>CP</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/1356</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>Ferroxidase</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/ca25562b-3b43-474d-858c-0922c8ceb4b7">
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/af72c454-8e59-41e7-ab5e-57c09a2f7a98"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3b7b768c-634c-4845-bbf7-1dbac52c9525">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003107</ddiem:url>
        <rdfs:comment>The change was not statistically significant.</rdfs:comment>
        <rdfs:label>High desmosterol levelsÂ (Abnormality of cholesterol metabolism)*</rdfs:label>
        <dc:identifier>HP:0003107*</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e301e282-7bd4-426a-984d-4916978dea0e">
        <rdfs:comment>The change was not statistically significant.</rdfs:comment>
        <dc:identifier>HP:0003107*</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003107</ddiem:url>
        <rdfs:label>High desmosterol,cholesterol ratio</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/602398">
        <dc:identifier>https://www.omim.org/entry/602398</dc:identifier>
        <rdfs:label>DESMOSTEROLOSIS</rdfs:label>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/195</ddiem:iembaseUrl>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/2d4fb5f9-4762-4039-9348-f5f1f4df96f7"/>
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseAccessionNumber>195</ddiem:iembaseAccessionNumber>
      </ddiem:Disease>
    </obo:RO_0002599>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/36c1fa40-979f-4e77-9931-51df096fd815">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/d1b97875-bef3-4849-b5af-62eee072cce5"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/c7568be9-e6b5-4e41-9ee1-202e43e5338f"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24816443</dc:provenance>
    <rdfs:comment>The treatment regimen resulted in neuroleptic malignant syndrome.</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007764"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000012"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4995031</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28856097</dc:provenance>
  </obo:OGMS_0000112>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/fbace6fb-9f15-48a4-b5ab-85771d49c842">
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/210200">
        <dc:identifier>https://www.omim.org/entry/210200</dc:identifier>
        <ddiem:iembaseAccessionNumber>1284</ddiem:iembaseAccessionNumber>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/362c0606-4acc-42f8-97cf-9bcf5bffe3c2"/>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/1284</ddiem:iembaseUrl>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>3-METHYLCROTONYL-CoA CARBOXYLASE 1 DEFICIENCY; MCC1D</rdfs:label>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/66f7aed7-a93c-4abc-b849-2c406b46e19e"/>
      </ddiem:Disease>
    </obo:RO_0002599>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f8abdf6e-4cde-4932-a0bc-cffdd41f66ab">
        <rdfs:label>Acute metabolic crisis ( Metabolism abnormality)*</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001939 </ddiem:url>
        <dc:identifier>HP:0001939 *</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <dc:provenance>https://www.jci.org/articles/view/11948</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/6b36ca46-5e87-4637-b6e9-73189ff35f01"/>
    <dc:provenance>https://www.babysfirsttest.org/newborn-screening/conditions/3-methylcrotonyl-coa-carboxylase-deficiency</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/003a62bf-932a-417a-9887-b6b58bf0132f">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/b26b2524-02fd-412e-b31e-bdc5bc7b62db"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18155630</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c52bda41-e4a3-4d65-aeef-27e5f01b4af2">
        <dc:identifier>HP:0001939 *</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001939 </ddiem:url>
        <rdfs:label>Accumulation of 3-methylcrotonyl-CoA metabolite level ( Metabolism abnormality)*</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8831079</dc:provenance>
    <dc:provenance>https://link.springer.com/article/10.1007/BF00710419</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:comment>Effect of glycine in treating the condition is variable among literatures.  "Case reports have noted variable results regarding the effect of glycine administration. Some studies have found that supplemental glycine results in increased excretion of 3-methylcrotonyl glycine, while others have not found a persistent effect; no studies have observed clinical improvement of symptoms on treatment and no randomized clinical trials have been published" https://www.sciencedirect.com/science/article/pii/S1096719207005975?via%3Dihub#bib11
https://www.ncbi.nlm.nih.gov/pubmed/8831079
https://www.ncbi.nlm.nih.gov/pubmed/7474896</rdfs:comment>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16835865</dc:provenance>
  </obo:OGMS_0000112>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/616538">
    <dc:identifier>https://www.omim.org/entry/616538</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <obo:RO_0004020>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/928dbda0-de95-46b8-ba1b-7d6ea9e6c93b">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/1605</dc:identifier>
        <rdfs:label>DAG1</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0004020>
    <rdfs:label>MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH BRAIN AND EYE ANOMALIES), TYPE A, 9; MDDGA9</rdfs:label>
  </ddiem:Disease>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/ca597094-1ad2-4883-9d20-f9172f1dd6d2">
    <rdfs:label>Î1-pyrroline 5-carboxylate dehydrogenase</rdfs:label>
    <ddiem:keggEntryId>K00294</ddiem:keggEntryId>
    <ddiem:uniprotId>P30038</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/a1833994-238d-4fb7-9153-db5b4e554840">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/8659</dc:identifier>
        <rdfs:label>ALDH4A1</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:ecNumber>1.2.1.88</ddiem:ecNumber>
  </ddiem:ProtienOrEnzyme>
  <obo:DDIEM_0000015 rdf:about="http://ddiem.phenomebrowser.net/d2ca12b5-a276-494e-8cb4-5702ab99a61c">
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/612736"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719213003661</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29506905</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/79da5e40-6e2a-4ae8-adb2-6f6bff50a5ea">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>High CSF guanidinoacetate levels</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/66aa6980-9d73-4eee-8a52-f80a6ead8bf9">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/ef64aef2-384b-4689-92ec-10462ab2a3b5"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/85ce8119-1e09-46a3-a820-d08b8f8e92d0"/>
    <rdfs:comment>The treatment reduces glycine levels, which reduces production of guanidinoacetate by conjugation and renal excretion however in one study it was mentioned that sodium benzoateÂ did not improve moderate intellectual disability or normalize guanidinoacetate accumulation in the central nervous system.https://www.ncbi.nlm.nih.gov/pubmed/24766785
Sodium benzoate has been proposed as an additional approach to reduce the production of GAA via conjugation with glycine to form hippuric acid which is rapidly excreted by the kidneys</rdfs:comment>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719212002971</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719213003107</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12557293</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/cb5070a3-ac95-4c75-b102-192ca4b450a2">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/1775622c-ffec-4e91-bc61-82add3b4b6ea"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8813986</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24071436</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/58ae599e-1ea7-4e4b-829f-9d4c68e2bf81"/>
  </obo:DDIEM_0000015>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/053cbf76-3fe4-42ba-9e20-6ea78a7b17d6">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15131757</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28590052</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/f5919ed0-0d88-482f-843b-0e629ced7671">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/099a15cb-8840-450b-ad8d-aad67f5cdd8e"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f3b66559-98e6-43a3-9033-ae289d652d97">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000103</ddiem:url>
        <dc:identifier>HP:0000103</dc:identifier>
        <rdfs:label>Polyuria</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26153518</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/855cf5b9-8721-485c-8070-7a064dba8967">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/4d209536-2375-4bb0-bb98-141fa60ea117"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
    <rdfs:comment>This combined drug therapy proved effective in all three cases: the good antidiuretic effect of chlorpropamide at high dosage is impaired by hypoglycaemia; the combination of carbamazepine allowed the dosage of chlorpropamide to be decreased without impairment of the obtained antidiuretic effect and with avoidance of hypoglycaemia and other side effects. https://www.ncbi.nlm.nih.gov/pubmed/1220254</rdfs:comment>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/125700">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>DIABETES INSIPIDUS, NEUROHYPOPHYSEAL</rdfs:label>
        <dc:identifier>https://www.omim.org/entry/125700</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/77bed3eb-ece9-4901-b472-739df6f69bef"/>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1220254</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30804055</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1ea6210c-2e41-44c6-8bca-4d4147423242">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001943</ddiem:url>
        <dc:identifier>HP:0001943*</dc:identifier>
        <rdfs:label>chlorpropamide-induced hypoglycaemia (Hypoglycemia)*</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1316120</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
  </obo:DDIEM_0000013>
  <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/5ae1e662-c45b-4f3e-aacd-b607a6ca452f">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12003346</dc:provenance>
    <dc:provenance>https://www.babysfirsttest.org/newborn-screening/conditions/3-methylcrotonyl-coa-carboxylase-deficiency</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5361854f-7f31-45a0-9196-7a2a5e838318">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0001263</dc:identifier>
        <rdfs:label>Developmental delay</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001263</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/78f3d001-4887-4d42-8777-a38dce39096e"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/fbef989d-48e7-466b-af73-dc4c9225818a">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Delayed receptive language</rdfs:label>
        <dc:identifier>HP:0010863</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0010863</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7110811</dc:provenance>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/ac9e4c34-6622-410a-8b39-d4b71217d40b"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3755580</dc:provenance>
    <rdfs:comment>It's an investigational therapy where Positive results from using a selective monoamine oxidase (MAO) B inhibitor or non-ergot dopamine agonist pramipexole as an adjunct therapy have been described in the medical literature. This use of such an inhibitor can allow for lower doses of neurotransmitter precursor to be used. However, the long-term safety (e.g. effects on neonatal brain development) and effectiveness of this therapy is unknown and more research is required to determine what role, if any, selective monoamine oxidase B inhibitors play in the treatment of individuals with tetrahydrobiopterin deficiency. https://rarediseases.org/rare-diseases/tetrahydrobiopterin-deficiency/. https://www.researchgate.net/publication/233414693_Deprenyl_in_6-Pyruvoyl_Tetrahydropterin_Synthase_Deficiency. https://www.degruyter.com/downloadpdf/j/pteridines.1995.6.issue-3/pteridines.1995.6.3.144/pteridines.1995.6.3.144.pdf</rdfs:comment>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/f60f7003-670c-4239-89f8-4ac59b0b1ead">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/49a82ce1-00ef-4653-9d0f-710f6fe5b751"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/efd3056c-4cdd-4941-ac56-6784d9cee1f8">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0000707</dc:identifier>
        <rdfs:label>Neurological impairment</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000707</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/261630"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c576bad9-b514-49c9-a2f8-c639d5e8fd3f">
        <dc:identifier>HP:0004923</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Hyperphenylalaninemia</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0004923</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23138986</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/c4633604-cb41-4d90-84d5-44841bde9fef">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/dab7ddb9-5505-4be0-b330-1839922f8082"/>
      </rdf:Alt>
    </obo:RO_0000057>
  </obo:DDIEM_0000007>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/f6a7e718-1564-4b90-ad26-812e5b1bfc64">
    <ddiem:keggEntryId>K00597</ddiem:keggEntryId>
    <rdfs:label>Methionine synthase reductase</rdfs:label>
    <ddiem:ecNumber>1.16.1.8</ddiem:ecNumber>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/8b7778d7-bbe1-43c4-ab00-0f7a9d613a6c">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/4552</dc:identifier>
        <rdfs:label>MTRR</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>Q9UBK8</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <obo:DDIEM_0000012 rdf:about="http://ddiem.phenomebrowser.net/9119e7ed-af1e-4143-bcca-b4b6c0324d67">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f70bdb4e-9ff7-46ae-b295-1db5a38dae82">
        <dc:identifier>HP:0003124</dc:identifier>
        <rdfs:label>hypercholesterolemia</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003124</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/21636aca-11ac-467e-aa7f-80153e6d0a3f">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/30c76492-8dfb-4373-ab9f-89285d1fd417"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/617347"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25768710</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28098593</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/866674f7-6686-4955-b72a-3e13de23b98e">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/cddbf40a-92a0-4ea1-9c32-e82f2e4fe718"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:comment>clinicians might only switch to combination therapy in FD patients who remain severely hypertriglyceridemic and/or hypercholesterolemic on monotherapy instead of prescribing combined statin-fibrate therapy to all FD patients that do not meet the non-HDL-C target.https://www.ncbi.nlm.nih.gov/pubmed/25768710</rdfs:comment>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0021915015001379</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3162680</dc:provenance>
  </obo:DDIEM_0000012>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/db3b301a-4fda-47f9-aeda-5b983608eda8">
    <rdfs:label>Glycogen phosphorylase, Muscle form</rdfs:label>
    <ddiem:ecNumber>2.4.1.1</ddiem:ecNumber>
    <ddiem:uniprotId>P11217</ddiem:uniprotId>
    <ddiem:keggEntryId>K00688</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/a19ce879-c539-4e20-a2ed-68addb2c0d6a">
        <rdfs:label>PYGM</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/5837</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/51e1eddd-e060-4d87-a136-9a6f8ec68a1a">
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/c148d200-9479-4b6a-a50f-1e30c7044a3f">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/ef084c4b-8daa-4216-bf61-9b96f7574128"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28590052</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30804055</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/6b36ca46-5e87-4637-b6e9-73189ff35f01"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19452263</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15131757</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/804ee22e-7659-4fb5-abaf-b520bf18ba46">
        <dc:identifier>HP:0001263</dc:identifier>
        <rdfs:label>developmental delay</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001263</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>Drug name: Intranasal dDAVP, because of efficacy, long duration of action, and infrequent side effects, is the preferred treatment of neurogenic diabetes insipidus in children and adults.https://www.ncbi.nlm.nih.gov/pubmed/626447</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/fe7e81c0-fdb4-40cb-8776-3305412724f5">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003234</ddiem:url>
        <rdfs:label>Hypocarnitinemia</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0003234</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17508264</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26153518</dc:provenance>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/212138">
        <ddiem:iembaseAccessionNumber>229</ddiem:iembaseAccessionNumber>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/dac9335f-10e1-4e20-b109-1990e641a7d3"/>
        <dc:identifier>https://www.omim.org/entry/212138</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/229</ddiem:iembaseUrl>
        <rdfs:label>CARNITINE-ACYLCARNITINE TRANSLOCASE DEFICIENCY; CACTD</rdfs:label>
      </ddiem:Disease>
    </obo:RO_0002599>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6d5ca02b-e1bc-417e-99d3-f0018dfd3155">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>High plasma long-chain acylcarnitines</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0045045</ddiem:url>
        <dc:identifier>HP:0045045</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </obo:DDIEM_0000007>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/26645f0b-aa06-4d93-8b4a-7767943d8453">
    <ddiem:keggEntryId>K14426</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/23b0fb34-a4db-4681-bc22-999d01cdd3a6">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/6559</dc:identifier>
        <rdfs:label>SLC12A3</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>P55017</ddiem:uniprotId>
    <ddiem:uniprotId>P51801</ddiem:uniprotId>
    <ddiem:keggEntryId>K05018</ddiem:keggEntryId>
    <rdfs:label>sodium chloride co-transporter/ chloride channel called ClC-Kb</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/c06450ee-9a24-4ac2-9aba-5af25939894c">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/1188</dc:identifier>
        <rdfs:label>CLCNKB</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/92859cd8-7345-4535-a331-9143714dced6">
    <rdfs:label>isobutyryl-CoA dehydrogenase</rdfs:label>
    <ddiem:uniprotId>Q9UKU7</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/dcce1a88-50a5-4ddf-8b98-22f7a2197d38">
        <rdfs:label>ACAD8</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/27034</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:ecNumber>1.3.8.-</ddiem:ecNumber>
    <ddiem:keggEntryId>K11538</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <owl:Class rdf:about="http://purl.obolibrary.org/obo/DDIEM_0000014">
    <rdfs:label xml:lang="en">surgical or physical treatment procedure</rdfs:label>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/metabolic_disease_treatment"/>
    <dc:date rdf:datatype="http://www.w3.org/2001/XMLSchema#dateTime">2019-07-15T18:08:30+00:00</dc:date>
    <obo:IAO_0000115 xml:lang="en">A therapeutic procedure to mitigate the immediate or future effects of the presence of a genetically defective protein which involves physical conditioning or anatomical modification.[PNS]</obo:IAO_0000115>
    <dc:creator>leechuck</dc:creator>
  </owl:Class>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/33bf7f07-40b2-43d1-a7de-3c0b192dd558">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/21d9b574-ac72-415a-a794-818b33ec46af">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/19</dc:identifier>
        <rdfs:label>ABCA1</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>O95477</ddiem:uniprotId>
    <ddiem:keggEntryId>K05641</ddiem:keggEntryId>
    <rdfs:label>Phospholipid-transporting ATPase ABCA1</rdfs:label>
    <ddiem:ecNumber>7.6.2.1</ddiem:ecNumber>
  </ddiem:ProtienOrEnzyme>
  <obo:DDIEM_0000011 rdf:about="http://ddiem.phenomebrowser.net/1cb3cade-c93e-47cd-9048-4188d51fbc43">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19415691</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14632789</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7b09e6b6-143d-4567-8234-c04e019ca44a">
        <rdfs:label>Increased plasma iron concentration(Increased serum iron)</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003452</ddiem:url>
        <dc:identifier>HP:0003452</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/604250">
        <ddiem:iembaseAccessionNumber>582</ddiem:iembaseAccessionNumber>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/582</ddiem:iembaseUrl>
        <dc:identifier>https://www.omim.org/entry/604250</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/39532e9e-392f-414d-bff4-c38a61df5f4c"/>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>HEMOCHROMATOSIS, TYPE 3; HFE3</rdfs:label>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://www.semanticscholar.org/paper/The-Incidence-of-Transient-Neonatal-Tyrosinemia-a-Zea-Rey-Cruz-Camino/b66304a0a56304f686380af915a92b2b860e9305</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1895089</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25717099</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/a1c9459a-4272-4af9-9252-b2f5a029d733">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/3a5287c4-25e8-4b03-8b75-e70bff68a5ec"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:comment>One of the studies that was carried on mice provides useful information for developing the optimal dosage regimen for HPBCD therapy when administered intravenously to NPC patients.https://www.ncbi.nlm.nih.gov/pubmed/26027824</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007764"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00001203</dc:provenance>
  </obo:DDIEM_0000011>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/5ae89572-0816-4e85-94ff-6586f72465a5">
    <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
    <dc:provenance>https://www.clinicaltrialsregister.eu/ctr-search/search</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8582405</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23494656</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S109671921200265X</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2ce2a3f0-914c-481a-8b67-1c6a3499311d">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001987</ddiem:url>
        <rdfs:label>Hyperammonemia</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0001987</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/207900">
        <ddiem:iembaseAccessionNumber>15</ddiem:iembaseAccessionNumber>
        <rdfs:label>ARGININOSUCCINIC ACIDURIA</rdfs:label>
        <dc:identifier>https://www.omim.org/entry/207900</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/a10b2f6d-46a3-49d0-8f7a-c2fb76d8dabc"/>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/15</ddiem:iembaseUrl>
        <rdfs:comment></rdfs:comment>
      </ddiem:Disease>
    </obo:RO_0002599>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/8f6287e5-3030-453a-a94d-aa9da3cde6a7">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/8a976b2c-e088-45f1-b9a1-b0b8d7181535"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <rdfs:comment>Alternative pathway therapy has limited effectiveness in preventing hyperammonemia and must be combined with effective dietary management. https://www.ncbi.nlm.nih.gov/pubmed/11148549</rdfs:comment>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/81ef2c4d-b7c6-4946-9915-b9446d90401d"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00345605</dc:provenance>
    <dc:provenance>https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813</dc:provenance>
  </obo:OGMS_0000112>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/439f2077-01be-448b-a30d-423016c5febd">
    <ddiem:ecNumber>2.4.2.-</ddiem:ecNumber>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/0c3b7789-2618-4531-9ff4-f72ad4a608d1">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/2218</dc:identifier>
        <rdfs:label>FKTN</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>O75072</ddiem:uniprotId>
    <rdfs:label>fukutin</rdfs:label>
    <ddiem:keggEntryId>K19872</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/f84e94b8-529f-4247-8d64-2f7a545f467c">
    <ddiem:keggEntryId>K00252</ddiem:keggEntryId>
    <ddiem:uniprotId>Q92947</ddiem:uniprotId>
    <ddiem:ecNumber>1.3.8.6</ddiem:ecNumber>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/366ddfc3-49a8-4a6f-b03a-a534f62c960f">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/2639</dc:identifier>
        <rdfs:label>GCDH</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>glutaryl-CoA dehydrogenase, mitochondrial</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/2e847367-6c8d-4700-812f-dc5a76358f12">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3202309</dc:provenance>
    <dc:provenance>https://rarediseases.org/rare-diseases/lesch-nyhan-syndrome</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24093206</dc:provenance>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/300322">
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/145</ddiem:iembaseUrl>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>https://www.omim.org/entry/300322</dc:identifier>
        <ddiem:iembaseAccessionNumber>145</ddiem:iembaseAccessionNumber>
        <rdfs:label>LESCH-NYHAN SYNDROME; LNS</rdfs:label>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/802f69af-881e-468b-b30e-f8b4fb5bd049"/>
      </ddiem:Disease>
    </obo:RO_0002599>
    <rdfs:comment>Treatment with allopurinol was associated with xanthine lithiasis. https://www.ncbi.nlm.nih.gov/pubmed/17065067 
https://www.ncbi.nlm.nih.gov/pubmed/16773422/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27179999</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/ff5e395d-975f-446c-a5c0-2c6349abf7a5">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/2323d461-704d-43b4-b726-5330467b4233"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/263d66f6-657e-4c3f-85c2-b7b6e8033a90">
        <rdfs:label>Chorea</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0002072</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002072</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12593632</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29054473</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/98a69309-00f5-4c38-8570-cacb7e2c44b1">
        <dc:identifier>HP:0001332</dc:identifier>
        <rdfs:label>Dystonia</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001332</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/78f3d001-4887-4d42-8777-a38dce39096e"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21483849</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2455472</dc:provenance>
  </obo:OGMS_0000112>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/1b32da43-727f-41d3-a4b7-9ca7958197f0">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/bb5e4251-1843-4446-8a93-d2ecfeccb1bd">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/1738</dc:identifier>
        <rdfs:label>DLD</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>P09622</ddiem:uniprotId>
    <ddiem:ecNumber>1.8.1.4</ddiem:ecNumber>
    <ddiem:keggEntryId>K00382</ddiem:keggEntryId>
    <rdfs:label>Dihydrolipoyl dehydrogenase, mitochondrial</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <obo:DDIEM_0000011 rdf:about="http://ddiem.phenomebrowser.net/24691790-813e-4b8c-b6f6-9e39d34caab6">
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/78f3d001-4887-4d42-8777-a38dce39096e"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18425437</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7760062</dc:provenance>
    <rdfs:comment>Alhough therapy with desmopressin cannot be recommended based on the results of a single case, the outcome presented here is intriguing and suggests that larger studies in such patients is warranted to assess the broader application of such an intervention.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26817292</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/ff5e395d-975f-446c-a5c0-2c6349abf7a5"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b036786b-4b44-4acf-8163-38ca61c36fe9"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16891685</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/ac9e4c34-6622-410a-8b39-d4b71217d40b"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/261630"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1899474</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12084887</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8163996</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/035c76c1-6daa-40f4-9fce-11bc9786802e">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/76493a1c-30e6-47ad-9be1-35b97ddf6308"/>
      </rdf:Alt>
    </obo:RO_0000057>
  </obo:DDIEM_0000011>
  <obo:DDIEM_0000015 rdf:about="http://ddiem.phenomebrowser.net/f2636f91-8c18-463c-a6f0-e207c0157c19">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c01abbcb-658c-4121-9049-0eec83df8cdd">
        <rdfs:label>low brain creatine phosphate</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719213003107</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/58ae599e-1ea7-4e4b-829f-9d4c68e2bf81"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16855203</dc:provenance>
    <dc:provenance>https://rarediseases.info.nih.gov/diseases/2578/guanidinoacetate-methyltransferase-deficiency</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719212002971</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2fd1b9ea-7e53-4364-9534-271c5caa3a36">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0011443</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0011443</dc:identifier>
        <rdfs:label>abnormal coordination of movements</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5ed5b969-367c-47bd-b5df-dba8c9664295">
        <dc:identifier>HP:0000708</dc:identifier>
        <rdfs:label>behavioralÂ abnormalities</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000708</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/16c01e82-d0e2-4e31-8644-d16a678cd529">
        <rdfs:label>low urinary creatine excretion</rdfs:label>
        <dc:identifier>HP:0012113</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012113</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24268530</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29506905</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719213003661</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9ce9fd46-ebd7-4cd5-a7c9-2a6ef0967d23">
        <rdfs:label>low cerebral creatine</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0025051</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0025051</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000009"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/eebe8355-1b7b-472c-a6a6-9b5ee94e56bb">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0001250</dc:identifier>
        <rdfs:label>Epilepsy</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001250</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/85ce8119-1e09-46a3-a820-d08b8f8e92d0"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8813986</dc:provenance>
    <rdfs:comment>This drug combination is accompained by arginine restriction.https://www.ncbi.nlm.nih.gov/pubmed/16855203</rdfs:comment>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/66aa6980-9d73-4eee-8a52-f80a6ead8bf9"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12557293</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/612736"/>
  </obo:DDIEM_0000015>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/222748">
    <rdfs:label>DIHYDROPYRIMIDINASE DEFICIENCY; DPYSD</rdfs:label>
    <obo:RO_0004020>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/e25c9da5-1972-44c3-9294-ea13388f33bf">
        <rdfs:label>DPYS</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/1807</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0004020>
    <ddiem:iembaseAccessionNumber>268</ddiem:iembaseAccessionNumber>
    <dc:identifier>https://www.omim.org/entry/222748</dc:identifier>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/268</ddiem:iembaseUrl>
    <rdfs:comment></rdfs:comment>
  </ddiem:Disease>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/1479f46b-2141-41d2-90b5-edad505488c8">
    <ddiem:keggEntryId>K00850</ddiem:keggEntryId>
    <rdfs:label>ATP-dependent 6-phosphofructokinase, muscle type</rdfs:label>
    <ddiem:uniprotId>P08237</ddiem:uniprotId>
    <ddiem:ecNumber>2.7.1.11</ddiem:ecNumber>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/217956c3-c849-4252-96ca-46d76ca449b7">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/5213</dc:identifier>
        <rdfs:label>PFKM</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/611881">
    <rdfs:comment></rdfs:comment>
    <ddiem:iembaseAccessionNumber>500</ddiem:iembaseAccessionNumber>
    <obo:RO_0004020>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/186371a3-abf5-4efe-88fd-b60b2daed9d9">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/226</dc:identifier>
        <rdfs:label>ALDOA</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0004020>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/500</ddiem:iembaseUrl>
    <rdfs:label>GLYCOGEN STORAGE DISEASE XII; GSD12</rdfs:label>
    <dc:identifier>https://www.omim.org/entry/611881</dc:identifier>
  </ddiem:Disease>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/b7136770-e361-4aea-8528-daeabf1f0917">
    <rdfs:label>Glycogen debranching enzyme (4-alpha-glucanotransferase+Amylo-1,6-glucosidase)</rdfs:label>
    <ddiem:keggEntryId>K01196</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/8416dd8e-87a3-4132-b85f-991652ee4e85">
        <rdfs:label>AGL</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/178</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>P35573</ddiem:uniprotId>
    <ddiem:ecNumber>2.4.1.25; 3.2.1.33</ddiem:ecNumber>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/988098c5-1dd5-4b40-9340-f5436a0863fa">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/7688167e-f2e2-49c6-81e7-684954b030b6">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/3425</dc:identifier>
        <rdfs:label>IDUA</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>iduronidase, alpha-L</rdfs:label>
    <ddiem:uniprotId>P35475</ddiem:uniprotId>
    <ddiem:keggEntryId>K01217</ddiem:keggEntryId>
    <ddiem:ecNumber>3.2.1.76</ddiem:ecNumber>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/2716e3de-1bbc-49c8-b08b-5c85360510c8">
    <ddiem:uniprotId>Q96RR1</ddiem:uniprotId>
    <ddiem:ecNumber>3.6.4.12</ddiem:ecNumber>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/8d52e39b-1eef-42a7-ac2d-bbf9181101e1">
        <rdfs:label>TWNK</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/56652</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K17680</ddiem:keggEntryId>
    <rdfs:label>twinkle mtDNA helicase</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/615042">
    <rdfs:comment></rdfs:comment>
    <dc:identifier>https://www.omim.org/entry/615042</dc:identifier>
    <ddiem:iembaseAccessionNumber>604</ddiem:iembaseAccessionNumber>
    <rdfs:label>CONGENITAL DISORDER OF GLYCOSYLATION, TYPE Iu; CDG1U</rdfs:label>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/604</ddiem:iembaseUrl>
    <obo:RO_0004020>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/af416c45-b362-445e-80cb-0f249f0d1cb8">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/8818</dc:identifier>
        <rdfs:label>DPM2</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0004020>
  </ddiem:Disease>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/f4c53b5a-2a85-4540-8b53-bbc4deb305bf">
    <ddiem:keggEntryId>K01201</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/6b58a1f4-ac8c-4ddc-bce7-4e5f6fb332d0">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/2629</dc:identifier>
        <rdfs:label>GBA</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>P04062</ddiem:uniprotId>
    <ddiem:ecNumber>3.2.1.45; 2.4.1.-; 3.2.1.104</ddiem:ecNumber>
    <rdfs:label>beta-glucocerebrosidase</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/b81f7d77-3da2-4cc0-bb12-01e963d1d622">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25851806</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7375069</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/6b36ca46-5e87-4637-b6e9-73189ff35f01"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ccab2880-9b4c-4edb-950b-651d8fee9ed1"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19019309</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/5634a50b-fb00-426a-b60d-3c73c68634d7"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/db6d42d0-bc1e-458c-9a99-e1e2fe9a00d1"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/266130"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/c75f2e34-57ee-4a1b-9a41-995b2564f33a"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17397529</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/c7568be9-e6b5-4e41-9ee1-202e43e5338f"/>
    <rdfs:comment>An experimental study done on a mice with GMNT knocked out. suggesting considering Nicotinamide as atreatment option in patients with GNMT deficiency.  https://www.ncbi.nlm.nih.gov/pubmed/20578266/</rdfs:comment>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/1e563444-127e-40f7-8c83-93768b346275"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
  </obo:OGMS_0000112>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/b4d915a9-6774-4261-b787-c44be04f42c7">
    <rdfs:label>Glucose-6-phosphate exchanger SLC37A4 (glucose 6-phosphate translocase)</rdfs:label>
    <ddiem:keggEntryId>K08171</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/9b1182d5-8514-414d-b245-69ceac73955a">
        <rdfs:label>SLC37A4</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/2542</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>O43826</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/650e9bb2-0d66-4fcd-8eb6-4a3b5b2a3d6b">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/c068ffc7-956c-4ff4-8e4f-0068e48c9a03">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/50814</dc:identifier>
        <rdfs:label>NSDHL</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>NAD(P) dependent steroid dehydrogenase-like</rdfs:label>
    <ddiem:keggEntryId>K07748</ddiem:keggEntryId>
    <ddiem:uniprotId>Q15738</ddiem:uniprotId>
    <ddiem:ecNumber>1.1.1.170</ddiem:ecNumber>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/7e4057d7-e8fb-4509-886d-78e516d5a23d">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/dbd3002b-0066-48f4-9139-ab8fa765de32">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/1200</dc:identifier>
        <rdfs:label>TPP1</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K01279</ddiem:keggEntryId>
    <ddiem:ecNumber>3.4.14.9</ddiem:ecNumber>
    <rdfs:label>TRIPEPTIDYL PEPTIDASE I</rdfs:label>
    <ddiem:uniprotId>O14773</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/8fa6e66a-e479-4ff4-baba-107b9fb3c593">
    <ddiem:uniprotId>Q9H9J2</ddiem:uniprotId>
    <rdfs:label>MITOCHONDRIAL RIBOSOMAL PROTEIN L44</rdfs:label>
    <ddiem:ecNumber>3.1.26.-</ddiem:ecNumber>
    <ddiem:keggEntryId>K17425</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/261d8c79-bb84-43fa-9100-61805093b94d">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/65080</dc:identifier>
        <rdfs:label>MRPL44</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/23cb5095-b593-4eb3-9ada-743a99832bbc">
    <ddiem:ecNumber>2.1.2.5; 4.3.1.4</ddiem:ecNumber>
    <ddiem:keggEntryId>K13990</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/a871a7af-8f57-4642-bf6b-e7fa750fb2c4">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/10841</dc:identifier>
        <rdfs:label>FTCD</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>O95954</ddiem:uniprotId>
    <rdfs:label>formiminotransferase cyclodeaminase</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/268a7ef5-5079-4025-b775-cc241e78622c">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31211405</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00638547</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31082797</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30755342</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6125e440-55f0-4ea8-91ad-5b81d24bd3c8">
        <dc:identifier>HP:0001290</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001290</ddiem:url>
        <rdfs:label>low muscle tone</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/603174">
        <rdfs:label>HOMOCYSTEINEMIA</rdfs:label>
        <dc:identifier>https://www.omim.org/entry/603174</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/22b1a9c8-e093-48b4-9085-2521e92bd0c6"/>
      </ddiem:Disease>
    </obo:RO_0002599>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/cd539122-ae66-4ad2-8241-d43b66dbe01f">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/cd994311-f58f-471c-8778-fdf7c002e669"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/cc73db55-e9e7-4d3f-8821-8bf1da41ea3d">
        <rdfs:label>Abnormality of homocysteine metabolism</rdfs:label>
        <dc:identifier>HP:0010919</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0010919</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31434105</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/e26f58c5-3e77-453b-8c30-5df2c9c700e9"/>
    <rdfs:comment>The responce to treatment reported to be poor in two patients, may be due to delayed start of treatment and the coexistence of 2 very harmful mutations, which, together with the p.A222V polymorphism, are known to reduce MTHFR enzyme activity. https://www.ncbi.nlm.nih.gov/pubmed/12673793?dopt=Abstract</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31196723</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30081189</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25024447</dc:provenance>
  </obo:OGMS_0000112>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/2435f954-4d94-4c02-b62c-50a460de26bc">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/3f093a92-a356-4d97-96da-c328be153824">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/1373</dc:identifier>
        <rdfs:label>CPS1</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>P31327</ddiem:uniprotId>
    <ddiem:keggEntryId>K01948</ddiem:keggEntryId>
    <rdfs:label>Carbamoyl-phosphate synthase (ammonia</rdfs:label>
    <ddiem:ecNumber>6.3.4.16</ddiem:ecNumber>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/ea6742fe-9caa-4f4f-bc37-d95bdf4ec535">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/78e53042-3518-49c0-aedc-e7f2981c0b86">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/4598</dc:identifier>
        <rdfs:label>MVK</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>Q03426</ddiem:uniprotId>
    <ddiem:keggEntryId>K00869</ddiem:keggEntryId>
    <ddiem:ecNumber>2.7.1.36</ddiem:ecNumber>
    <rdfs:label>mevalonate kinase</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <void:Dataset rdf:about="http://ddiem.phenomebrowser.net/DDIEM">
    <dcterms:creator>
      <foaf:Person rdf:about="Resource(https://www.pdn.cam.ac.uk)/PaulSchofield">
        <foaf:mbox rdf:resource="mailto:pns12@cam.ac.uk"/>
        <rdfs:label>Dr Paul Schofield</rdfs:label>
      </foaf:Person>
    </dcterms:creator>
    <dcterms:creator>
      <foaf:Person rdf:about="Resource(https://www.kaust.edu.sa)/RobertHoehndorf">
        <foaf:mbox rdf:resource="mailto:robert.hoehndorf@kaust.edu.sa"/>
        <rdfs:label>Robert Hoehndorf</rdfs:label>
      </foaf:Person>
    </dcterms:creator>
    <dcterms:contributor>
      <foaf:Organization rdf:about="https://www.kaust.edu.sa">
        <rdfs:label>King Abdullah University of Science and Technology</rdfs:label>
      </foaf:Organization>
    </dcterms:contributor>
    <dcterms:contributor>
      <foaf:Organization rdf:about="https://www.pdn.cam.ac.uk">
        <rdfs:label>University of Cambridge</rdfs:label>
      </foaf:Organization>
    </dcterms:contributor>
    <dcterms:creator>
      <foaf:Person rdf:about="Resource(https://www.kaust.edu.sa)/AliRazaSyed">
        <rdfs:label>Ali Raza Syed</rdfs:label>
        <foaf:mbox rdf:resource="mailto:ali.syed@kaust.edu.sa"/>
      </foaf:Person>
    </dcterms:creator>
    <dcterms:creator>
      <foaf:Person rdf:about="Resource(https://www.kaust.edu.sa)/MarwaAbdelhakim">
        <rdfs:label>Marwa Abdelhakim</rdfs:label>
        <foaf:mbox rdf:resource="mailto:marwa.abdelhakim@kaust.edu.sa"/>
      </foaf:Person>
    </dcterms:creator>
    <dcterms:modified>2019-11-19</dcterms:modified>
    <dcterms:creator>
      <foaf:Person rdf:about="Resource(https://www.kaust.edu.sa)/SenayKafkas">
        <rdfs:label>Senay Kafkas</rdfs:label>
        <foaf:mbox rdf:resource="mailto:senay.kafkas@kaust.edu.sa"/>
      </foaf:Person>
    </dcterms:creator>
    <void:feature rdf:resource="http://www.w3.org/ns/formats/RDF_XML"/>
    <foaf:homepage rdf:resource="http://ddiem.phenomebrowser.net/"/>
    <foaf:page rdf:resource="https://github.com/bio-ontology-research-group/DDIEM"/>
    <void:sparqlEndpoint rdf:resource="http://ddiem.phenomebrowser.net/sparql"/>
    <dcterms:license rdf:resource="https://creativecommons.org/licenses/by/4.0/"/>
    <dcterms:description>DDIEM - Drug database for inborn errors of metabolism is a database on therapeutic strategies
     for inborn errors of metabolism. These strategies are classified by mechanism and outcome in DDIEM Ontology. 
     DDIEM uses this ontology to categprise the experimental treatments that have been proposed or applied. It 
     includes descriptions of the phenotypes addressed by the treatment and drugs participating in treatment and procedures.</dcterms:description>
    <dcterms:creator>
      <foaf:Person rdf:about="Resource(https://www.kaust.edu.sa)/AllanKamau">
        <foaf:mbox rdf:resource="mailto:allan.kamau@kaust.edu.sa"/>
        <rdfs:label>Allan Kamau</rdfs:label>
      </foaf:Person>
    </dcterms:creator>
    <dcterms:title>DDIEM - Drug Database for Inborn Error of Metabolism</dcterms:title>
  </void:Dataset>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/82fedbff-a059-4756-bef1-a4f139e54e68">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6169684</dc:provenance>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/246700">
        <rdfs:label>CHYLOMICRON RETENTION DISEASE; CMRD</rdfs:label>
        <ddiem:iembaseAccessionNumber>1083</ddiem:iembaseAccessionNumber>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/cca27114-b6a4-4a77-ba25-1da0d809da77"/>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>https://www.omim.org/entry/246700</dc:identifier>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/1083</ddiem:iembaseUrl>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22832289</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21102543</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19285442</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23329770</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/887793b3-eacf-454d-9d75-36868d219b9e">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/2079daf5-3d71-478d-b8cd-d89d19d3aa07"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/db6d42d0-bc1e-458c-9a99-e1e2fe9a00d1"/>
    <rdfs:comment>"Oral tocofersolan was more bio available than the water-soluble formulation in children with chronic cholestasis and similarly bio available in CF. This suggests that water-soluble vitamin E may represent an alternative to painful intramuscular vitamin E injections in chronic cholestasis, or other oral formulations in CF. However, the mechanism responsible for fat malabsorption in CRD concerns the absorptive phase as opposed to the digestive phase in CF and cholestatic syndromes. To our knowledge, no specific studies with these new vitamin E preparations have been conducted in CRD." https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717/</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6af6dcd4-5c42-4c04-8cca-ff5e85ac47f4">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Minor visual abnormalities</rdfs:label>
        <dc:identifier>HP:0000505</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000505</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/749c4e05-a067-4dbf-bfde-b25a6123b0e0"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4223155</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/603c6f5e-5e6e-416b-8db3-181a88f078a0">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0012638</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012638</ddiem:url>
        <rdfs:label>Muscular abnormality</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </obo:OGMS_0000112>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/58ac6bdf-007c-4a0c-b2de-a7415c9b0531">
    <ddiem:ecNumber>1.1.99.2</ddiem:ecNumber>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/79b4c332-a20b-40af-b9cc-8691e11899ff">
        <rdfs:label>L2HGDH</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/79944</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>Q9H9P8</ddiem:uniprotId>
    <rdfs:label>L-2-hydroxyglutarate dehydrogenase.</rdfs:label>
    <ddiem:keggEntryId>K00109</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/815b14bf-a3b9-4c06-b18d-9c63757c0320">
    <ddiem:ecNumber>2.8.2.35</ddiem:ecNumber>
    <rdfs:label>Dermatan-4-sulfotransferase-1</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/7a5784c8-3014-455f-9008-e3beda930d2b">
        <rdfs:label>CHST14</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/113189</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K08105</ddiem:keggEntryId>
    <ddiem:uniprotId>Q8NCH0</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/51525297-c9f9-4f95-80fe-4e43f20a6117">
    <ddiem:uniprotId>P48048</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/dda24f3e-5352-4e05-99e8-ecabf70d0a83">
        <rdfs:label>KCNJ1</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/3758</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>ATP-sensitive inward rectifier potassium channel 1</rdfs:label>
    <ddiem:keggEntryId>K04995</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/f542aa45-4143-4846-b4da-31edf1b1bab7">
    <rdfs:label>PALMITOYL-PROTEIN THIOESTERASE</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/f4d9db52-0dbf-4469-8156-250211ad425d">
        <rdfs:label>PPT1</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/5538</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>P50897</ddiem:uniprotId>
    <ddiem:keggEntryId>K01074</ddiem:keggEntryId>
    <ddiem:ecNumber>3.1.2.22</ddiem:ecNumber>
  </ddiem:ProtienOrEnzyme>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/01696553-93c8-43c7-b9b9-3a398cf469c4">
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000012"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11486915</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10896280</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28883274</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/661bba58-9ffe-44fd-a248-e5fef6420449">
        <rdfs:label>low visual acuity</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0007663</ddiem:url>
        <dc:identifier>HP:0007663</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000009"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22791294</dc:provenance>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/258870">
        <rdfs:comment></rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/6abb68ef-f40e-4774-8e86-7ac7faa4cb80"/>
        <ddiem:iembaseAccessionNumber>562</ddiem:iembaseAccessionNumber>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/562</ddiem:iembaseUrl>
        <dc:identifier>https://www.omim.org/entry/258870</dc:identifier>
        <rdfs:label>GYRATE ATROPHY OF CHOROID AND RETINA; GACR</rdfs:label>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28388263</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24082780</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a449a7c4-4d81-439e-992b-180400fb2ba8">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0011505</ddiem:url>
        <rdfs:label>cystoid macular edema</rdfs:label>
        <dc:identifier>HP:0011505</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29654911</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/eb5152ff-7294-4a87-a512-7b1cec024750">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/2d078c1d-a418-4550-8d95-46ef5ff4a27d"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/19d18d16-d582-4b93-ad73-0788911e9fa8">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/7cfa2b4b-4c95-4231-89be-de2e569f0f0d"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:comment>There was no clinical effect, but amild reduction in the plasma level of desmosterol was observed.</rdfs:comment>
  </obo:OGMS_0000112>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/644c3bef-6414-42ba-aa14-13d6a392b260">
    <ddiem:uniprotId>O60733</ddiem:uniprotId>
    <rdfs:label>Phospholipase A(2)</rdfs:label>
    <ddiem:keggEntryId>K16343</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/ff8290eb-e268-4f16-8549-1638f8374cf9">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/8398</dc:identifier>
        <rdfs:label>PLA2G6</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:ecNumber>3.1.1.4</ddiem:ecNumber>
  </ddiem:ProtienOrEnzyme>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/58113b75-0a84-465c-a08c-1944540aebb2">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19821145</dc:provenance>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/610131">
        <rdfs:comment></rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/3950d2fd-124a-4d5b-81af-7be4152d547a"/>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/942</ddiem:iembaseUrl>
        <rdfs:label>PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA WITH MITOCHONDRIAL DNA DELETIONS, AUTOSOMAL DOMINANT 4; PEOA4</rdfs:label>
        <ddiem:iembaseAccessionNumber>942</ddiem:iembaseAccessionNumber>
        <dc:identifier>https://www.omim.org/entry/610131</dc:identifier>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
    <dc:provenance>https://link.springer.com/article/10.1023/A:1005353530303</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3950820</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/23ecce48-b7ae-4193-ad6c-c109e0329680">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/3697f7e6-ee9a-4399-950b-84ea5dca7805"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a6fa190d-84cf-4719-ab6e-cc04dd51f497">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Mitochondrial epilepsy(Epilepsy)*</rdfs:label>
        <dc:identifier>HP:0001250*</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001250</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23248042</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/de2f9565-d217-424d-b54d-5a9be0514a37">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/e9d9b4d9-29be-4f65-a32d-a59a787defac"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01793090</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/e44d719c-72fa-49ee-8a1d-3b73d9ef19c9">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/bbfcd248-0ca9-4260-9064-0e23c5cb04e1"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:comment>The combination of three antiepileptic drugs and LGIT"modified KD" is effective and well tolerated as treatment for severe episodes of POLG-related mitochondrial epilepsy. They suggest as well that combining LGIT to antiepileptic drug treatment should be considered in this potentially life-threatening condition.https://www.ncbi.nlm.nih.gov/pubmed/23248042?dopt=Abstract</rdfs:comment>
  </obo:OGMS_0000112>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/606812">
    <rdfs:label>FUMARASE DEFICIENCY; FMRD</rdfs:label>
    <rdfs:comment>The high fat, low carbohydrate diet may has a possible disease modifying effect. https://www.ncbi.nlm.nih.gov/pubmed/29052812</rdfs:comment>
    <obo:RO_0004020>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/81952674-f6c9-4ba7-b718-1db027ade688">
        <rdfs:label>FH</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/2271</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0004020>
    <ddiem:iembaseAccessionNumber>174</ddiem:iembaseAccessionNumber>
    <dc:identifier>https://www.omim.org/entry/606812</dc:identifier>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/174</ddiem:iembaseUrl>
  </ddiem:Disease>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/5557e48b-cc5d-4d43-b7b6-78c62c1307d0">
    <ddiem:ecNumber>3.5.1.23; 3.5.1.-</ddiem:ecNumber>
    <rdfs:label>acid ceramidase</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/dc9a15a5-ffb5-4b3b-82b0-2a6b4add5c5f">
        <rdfs:label>ASAH1</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/427</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K12348</ddiem:keggEntryId>
    <ddiem:uniprotId>Q13510</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/8f5705c0-b779-4c55-82e9-03a80e2cfb64">
    <rdfs:label>isovaleryl-CoA dehydrogenase</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/0b529989-e44f-4416-a95d-0eeeccab6c8b">
        <rdfs:label>IVD</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/3712</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:ecNumber>1.3.8.4</ddiem:ecNumber>
    <ddiem:uniprotId>P26440</ddiem:uniprotId>
    <ddiem:keggEntryId>K00253</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/3c8ec972-5564-4b66-8f2f-d8015c70c64f">
    <ddiem:uniprotId>Q695T7</ddiem:uniprotId>
    <ddiem:uniprotId>Q9NP91</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/f05fd3a8-d8dd-4945-9ed5-9069767ac8dd">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/340024</dc:identifier>
        <rdfs:label>SLC6A19</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K14209</ddiem:keggEntryId>
    <rdfs:label>solute carrier family 36 member 2 +solute carrier family 6 member 20 or solute carrier family 6 member 19</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/5f443741-d452-4841-b557-944229a9b4a2">
        <rdfs:label>SLC36A2</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/153201</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>Q495M3</ddiem:uniprotId>
    <ddiem:keggEntryId>K05048</ddiem:keggEntryId>
    <ddiem:keggEntryId>K05334</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/d59c100d-3095-4947-9485-7e4b8363a993">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/54716</dc:identifier>
        <rdfs:label>SLC6A20</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/e6a7a280-9062-4397-9a67-c40b8404e7cb">
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/229100">
        <dc:identifier>https://www.omim.org/entry/229100</dc:identifier>
        <rdfs:comment>The majority of individuals with FTCD deficiency detected by newborn screening are asymptomatic. https://www.ncbi.nlm.nih.gov/pubmed/30740726</rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/a871a7af-8f57-4642-bf6b-e7fa750fb2c4"/>
        <ddiem:iembaseAccessionNumber>47</ddiem:iembaseAccessionNumber>
        <rdfs:label>GLUTAMATE FORMIMINOTRANSFERASE DEFICIENCY</rdfs:label>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/47</ddiem:iembaseUrl>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/77c657d7-e0e3-44ec-a1cb-2836f73f6f15">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001889</ddiem:url>
        <dc:identifier>HP:0001889</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Megaloblastic anemia</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/eb5152ff-7294-4a87-a512-7b1cec024750"/>
    <rdfs:comment>Synergism inmproves results</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22830360</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27775558</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/5301410</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/79d44480-aca4-4c37-8b4e-b20a0d413380"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25896882</dc:provenance>
  </obo:DDIEM_0000007>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/57d1cb55-d5c3-43aa-b71c-55867790f7f2">
    <ddiem:uniprotId>Q9H5K3</ddiem:uniprotId>
    <ddiem:ecNumber>2.7.1.183</ddiem:ecNumber>
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/5bf09476-1d76-4de1-aaaa-a61db3d757ea"/>
    <rdfs:label>Protein O-mannose kinase</rdfs:label>
    <ddiem:keggEntryId>K17547</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/881363ef-60ec-4aeb-a5ce-a003f9f6e1dd">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/d515eb90-ae73-4803-b380-7787227e81fb">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/2998</dc:identifier>
        <rdfs:label>GYS2</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:ecNumber>2.4.1.11</ddiem:ecNumber>
    <ddiem:uniprotId>P54840</ddiem:uniprotId>
    <ddiem:keggEntryId>K00693</ddiem:keggEntryId>
    <rdfs:label>glycogen synthase 2</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/c25082a6-8ede-4915-b9f9-1c29fb6e5b50">
    <ddiem:keggEntryId>K00357</ddiem:keggEntryId>
    <rdfs:label>quinoid dihydropteridine reductase</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/1909b02a-b024-4806-a90a-b956d08bb2d3">
        <rdfs:label>QDPR</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/5860</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>P09417</ddiem:uniprotId>
    <ddiem:ecNumber>1.5.1.34</ddiem:ecNumber>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/03b9c26b-f5d0-471a-b046-3406c9ab1bc7">
    <ddiem:uniprotId>P39019</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/83f650ca-87b1-4304-802c-ea4ad1bccd07">
        <rdfs:label>RPL11</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/6135</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/c74b8370-33c5-4ca7-9b2d-cbe9c456cde1">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/6223</dc:identifier>
        <rdfs:label>RPS19</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>P62854</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/a1ec28db-fddf-4db2-af8e-3f54232a4592">
        <rdfs:label>RPL5</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/6125</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K02993</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/8dbe64a5-87b6-4d35-909a-293a7bda28a1">
        <rdfs:label>RPL35A</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/6165</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>P46777</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/42800046-b63a-4e9d-a366-ef7a16d05514">
        <rdfs:label>RPS17</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/6218</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K09182</ddiem:keggEntryId>
    <ddiem:uniprotId>P62081</ddiem:uniprotId>
    <ddiem:uniprotId>P18077</ddiem:uniprotId>
    <ddiem:keggEntryId>K02976</ddiem:keggEntryId>
    <rdfs:label>40S ribosomal protein S19</rdfs:label>
    <ddiem:keggEntryId>K02917</ddiem:keggEntryId>
    <ddiem:uniprotId>P15976</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/d76facd0-2f14-452e-a94b-c6d70b527177">
        <dc:identifier>https://ghr.nlm.nih.gov/gene/and</dc:identifier>
        <rdfs:label>and</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K02962</ddiem:keggEntryId>
    <ddiem:uniprotId>P46783</ddiem:uniprotId>
    <ddiem:keggEntryId>K02974</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/3a9ab509-62d6-46ea-aca2-d5fd7a5f381d">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/6204</dc:identifier>
        <rdfs:label>RPS10</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K02947</ddiem:keggEntryId>
    <ddiem:uniprotId>P08708</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/ee2091fa-625c-425b-9590-99a1bf048eca">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/2623</dc:identifier>
        <rdfs:label>GATA1</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/ba7bf103-312d-4e79-9f52-c77fbbf34228">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/6231</dc:identifier>
        <rdfs:label>RPS26</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>P62913</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/fad7cf77-bab6-4165-ac20-a151d4ce6aa6">
        <rdfs:label>RPS7</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/6201</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K02966</ddiem:keggEntryId>
    <ddiem:keggEntryId>K02932</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/6f0c1f84-cdba-4f9e-8b0a-bb155392b399">
        <rdfs:label>RPS24</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/6229</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K02868</ddiem:keggEntryId>
    <ddiem:uniprotId>P62847</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/8c6f5df5-c9d1-4aea-914f-c6f11b741521">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27423595</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26817292</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12084887</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8a0b1c81-342a-4d3b-a3c5-0cb70c343df4">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0030186</ddiem:url>
        <dc:identifier>HP:0030186</dc:identifier>
        <rdfs:label>Kinetic tremor</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16891685</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/ee4a9b6a-7a61-40be-9922-9241a030e98b">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/74c58ee6-583c-4c05-8b29-3c48a3b02245"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1899474</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/ff5e395d-975f-446c-a5c0-2c6349abf7a5"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25707872</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8163996</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/98a69309-00f5-4c38-8570-cacb7e2c44b1"/>
    <rdfs:comment>Beneficial effects were initially observed on parkinsonian symptoms. However, dyskinesia and dystonic features re-emerged after three months of treatment.</rdfs:comment>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/261630"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e633b13f-37a5-4151-9136-f8c732717d34">
        <dc:identifier>HP:0001300</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001300</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>parkinsonian symptoms</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e7c38356-860d-43d9-8139-062ac8db180d">
        <dc:identifier>HP:0002174</dc:identifier>
        <rdfs:label>Postural tremor</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002174</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ff1f5283-8e7f-44f3-adf7-58cf8fe1291f">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002067</ddiem:url>
        <dc:identifier>HP:0002067</dc:identifier>
        <rdfs:label>Bradykinesia</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/78f3d001-4887-4d42-8777-a38dce39096e"/>
  </obo:OGMS_0000112>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/f51e5e96-c705-4783-8156-433afa4781d0">
    <ddiem:keggEntryId>K01444</ddiem:keggEntryId>
    <rdfs:label>N(4)-(beta-N-acetylglucosaminyl)-L-asparaginase</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/3f3cedb6-1df7-414c-88c3-1e0249caa279">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/175</dc:identifier>
        <rdfs:label>AGA</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:ecNumber>3.5.1.26</ddiem:ecNumber>
    <ddiem:uniprotId>P20933</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/a0458b65-8b3b-4d7a-a05e-fe30c2b3f315">
    <ddiem:keggEntryId>K23106</ddiem:keggEntryId>
    <ddiem:uniprotId>P81172</ddiem:uniprotId>
    <ddiem:uniprotId>Q6ZVN8</ddiem:uniprotId>
    <ddiem:keggEntryId>K23100</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/2f4259fc-582d-403d-9e49-213d288ccfc5">
        <rdfs:label>HAMP</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/57817</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/367d029c-3614-4e9d-b855-f67d81d73a92">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/148738</dc:identifier>
        <rdfs:label>HJV</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>hemojuvelin/hepcidin</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/c3042d4e-d7e4-430c-90a0-818e420fd201">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20975743</dc:provenance>
    <dc:provenance>https://www.semanticscholar.org/paper/Glycogen-storage-diseases%3A-Diagnosis%2C-treatment-and-Chen-Weinstein/439025d057229db1b3a117cb02b3c7e6f2bd3580</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17514432</dc:provenance>
    <dc:provenance>https://www.researchgate.net/publication/307584174_Glycogen_storage_diseases_Diagnosis_treatment_and_outcome</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/345f7321-2b9d-4b63-8db8-6f154976000d"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/e4fe8128-15d7-4874-b568-8ddad4ec30c7">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/67d676c6-8efa-4c4a-b6fd-ca0e6b3aef1a"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:comment>Ad vectors, HDAd is completely devoid of all viral protein genes and has been shown to display markedly reduced toxicity in mice.https://www.ncbi.nlm.nih.gov/pubmed/15753292</rdfs:comment>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000010"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/19d18d16-d582-4b93-ad73-0788911e9fa8"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/232200"/>
  </obo:OGMS_0000112>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/5c1a67f0-54db-4b68-a0fa-c38ed03e7b78">
    <ddiem:ecNumber>2.4.1.1</ddiem:ecNumber>
    <ddiem:keggEntryId>K00688</ddiem:keggEntryId>
    <ddiem:uniprotId>P06737</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/a4ebaa38-8c11-4637-92f5-33ce2e9c4deb">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/5836</dc:identifier>
        <rdfs:label>PYGL</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>Glycogen phosphorylase, liver form</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/614643">
    <obo:RO_0004020>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/c498e3bf-893e-4009-8a65-92d9c3475b15">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/""</dc:identifier>
        <rdfs:label>ISPD</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0004020>
    <dc:identifier>https://www.omim.org/entry/614643</dc:identifier>
    <rdfs:label>MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH BRAIN AND EYE ANOMALIES), TYPE A, 7; MDDGA7</rdfs:label>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/641</ddiem:iembaseUrl>
    <ddiem:iembaseAccessionNumber>641</ddiem:iembaseAccessionNumber>
    <rdfs:comment></rdfs:comment>
  </ddiem:Disease>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/5817ba12-22d1-4136-9016-2aa32261cad2">
    <ddiem:uniprotId>Q92887</ddiem:uniprotId>
    <rdfs:label>MultidrugÂ resistanceÂ protein-2</rdfs:label>
    <ddiem:ecNumber>7.6.2.2</ddiem:ecNumber>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/e35ecfa0-efdd-4788-af0e-4fc1c9e10675">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/1244</dc:identifier>
        <rdfs:label>ABCC2</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K05666</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/613724">
    <rdfs:comment></rdfs:comment>
    <ddiem:iembaseAccessionNumber>1114</ddiem:iembaseAccessionNumber>
    <dc:identifier>https://www.omim.org/entry/613724</dc:identifier>
    <obo:RO_0004020>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/e896dec4-248d-49d0-bcc7-a800f520a633">
        <rdfs:label>SCP2</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/6342</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0004020>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/1114</ddiem:iembaseUrl>
    <rdfs:label>LEUKOENCEPHALOPATHY WITH DYSTONIA AND MOTOR NEUROPATHY; LKDMN</rdfs:label>
  </ddiem:Disease>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/14d9b52d-3d5a-4e26-8874-b3bf4ff9b762">
    <ddiem:keggEntryId>K03165</ddiem:keggEntryId>
    <ddiem:uniprotId>Q13472</ddiem:uniprotId>
    <ddiem:ecNumber>5.6.2.1</ddiem:ecNumber>
    <rdfs:label>DNA topoisomerase 3-alpha</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/29d89d9f-550a-48c7-9dd3-de3279a6612e">
        <rdfs:label>TOP3A</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/7156</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/50c8cd43-d913-405a-9c0d-7f6da2db23c8">
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/af72c454-8e59-41e7-ab5e-57c09a2f7a98"/>
    <dc:provenance>https://www.nature.com/articles/s41436-019-0451-z</dc:provenance>
    <rdfs:comment>The drug was more effective in some mutations than others, so if the results are analysed according to the mutation there is an advantage for migalastat.https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6370600/
 Miglustat stabilises specific mutant (amenable) forms of Î±-Gal to facilitate normal lysosomal trafficking. https://www.ncbi.nlm.nih.gov/pubmed/27834756/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/books/NBK6803</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19666145</dc:provenance>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/612073">
        <dc:identifier>https://www.omim.org/entry/612073</dc:identifier>
        <rdfs:label>MITOCHONDRIAL DNA DEPLETION SYNDROME 5 (ENCEPHALOMYOPATHIC WITH OR WITHOUT METHYLMALONIC ACIDURIA); MTDPS5</rdfs:label>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/503</ddiem:iembaseUrl>
        <rdfs:comment></rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/8c841bc4-5de7-4cee-8bd3-eee09b6c2f4a"/>
        <ddiem:iembaseAccessionNumber>503</ddiem:iembaseAccessionNumber>
      </ddiem:Disease>
    </obo:RO_0002599>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01458119</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/48f0eae9-c050-47a4-8918-9b66e9cc570d">
        <dc:identifier>HP:0025464</dc:identifier>
        <rdfs:label>Oxidative stress</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0025464</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/c7568be9-e6b5-4e41-9ee1-202e43e5338f"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00925301</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30723321</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01218659</dc:provenance>
  </obo:DDIEM_0000013>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/8c33f314-1a0b-4b18-915d-1ba01a9f9d7c">
    <rdfs:label>tRNA-LEU MITOCHONDRIAL 1/tRNA-GLU MITOCHONDRIAL/tRNA-LYS MITOCHONDRIAL</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/a665b7db-c424-45bd-9f7b-268c6f4b7cdd">
        <dc:identifier>https://ghr.nlm.nih.gov/gene/MTTC</dc:identifier>
        <rdfs:label>MTTC</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/47ef309f-d257-450f-8c9b-8440060d880f">
        <rdfs:label>MT-TS1</rdfs:label>
        <dc:identifier>https://ghr.nlm.nih.gov/gene/MT-TS1</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/e8fb24f7-308e-4736-836b-f600761996e6">
        <dc:identifier>https://ghr.nlm.nih.gov/gene/MT-TE</dc:identifier>
        <rdfs:label>MT-TE</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/f5b4e0fe-8f48-4ef0-a7a2-e716a36737cc">
        <rdfs:label>MT-ND6</rdfs:label>
        <dc:identifier>https://ghr.nlm.nih.gov/gene/MT-ND6</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/2bf1b12f-923e-43a7-97e8-9778d7c2b3b2">
        <dc:identifier>https://ghr.nlm.nih.gov/gene/MT-ND1</dc:identifier>
        <rdfs:label>MT-ND1</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/5fee6004-d41c-4939-853c-6d22496f293c">
        <dc:identifier>https://ghr.nlm.nih.gov/gene/MT-TS2</dc:identifier>
        <rdfs:label>MT-TS2</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/2b4b4144-8fa8-4ef5-84a2-783bc8471175">
        <rdfs:label>MT-TQ</rdfs:label>
        <dc:identifier>https://ghr.nlm.nih.gov/gene/MT-TQ</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/91ebf6d2-58c0-4350-862c-3e2a6b4fa89d">
        <rdfs:label>MT-ND5</rdfs:label>
        <dc:identifier>https://ghr.nlm.nih.gov/gene/MT-ND5</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/1abaf40f-2a9b-43e9-9c9c-053c92416972">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/""</dc:identifier>
        <rdfs:label>MT-TK</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/f25d4e54-b37b-4a71-876e-328ff89f9566">
        <rdfs:label>MT-TH</rdfs:label>
        <dc:identifier>https://ghr.nlm.nih.gov/gene/MT-TH</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/27cf12eb-db1f-49f7-ba20-908346f6c667">
        <dc:identifier>https://ghr.nlm.nih.gov/gene/MT-TL1</dc:identifier>
        <rdfs:label>MT-TL1</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/4f3586db-e8e5-4bff-87dc-c77a1df35418">
    <ddiem:keggEntryId>K12386</ddiem:keggEntryId>
    <rdfs:label>cystinosin</rdfs:label>
    <ddiem:uniprotId>O60931</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/8237daba-9339-4e48-8926-93512a872681">
        <rdfs:label>CTNS</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/1497</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/2d421cb7-2ed4-4ee4-aa0b-b6988255d143">
    <ddiem:uniprotId>P35520</ddiem:uniprotId>
    <ddiem:keggEntryId>K01697</ddiem:keggEntryId>
    <rdfs:label>cystathionine beta-synthase</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/75fecfc9-fdc1-4e5b-9d87-41fe8c14fc77">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/875</dc:identifier>
        <rdfs:label>CBS</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:ecNumber>4.2.1.22</ddiem:ecNumber>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/014ccc73-9bd3-417f-986d-dfc416f825c1">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/737ee446-9735-41b2-b94f-9d80dd3f7155">
        <rdfs:label>PGM1</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/5236</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>P36871</ddiem:uniprotId>
    <rdfs:label>Phosphoglucomutase-1</rdfs:label>
    <ddiem:keggEntryId>K01835</ddiem:keggEntryId>
    <ddiem:ecNumber>5.4.2.2</ddiem:ecNumber>
  </ddiem:ProtienOrEnzyme>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/611307">
    <obo:RO_0004020>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/803445df-02b0-4340-92b7-8f093d7e85a1">
        <rdfs:label>ANO5</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/203859</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0004020>
    <dc:identifier>https://www.omim.org/entry/611307</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>MUSCULAR DYSTROPHY, LIMB-GIRDLE, AUTOSOMAL RECESSIVE 12; LGMDR12</rdfs:label>
  </ddiem:Disease>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/615287">
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/1124</ddiem:iembaseUrl>
    <rdfs:label>MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH BRAIN AND EYE ANOMALIES), TYPE A, 13; MDDGA13</rdfs:label>
    <obo:RO_0004020>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/07533464-77d1-4214-b600-fd44d8215370">
        <rdfs:label>B4GAT1</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/11041</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0004020>
    <rdfs:comment></rdfs:comment>
    <ddiem:iembaseAccessionNumber>1124</ddiem:iembaseAccessionNumber>
    <dc:identifier>https://www.omim.org/entry/615287</dc:identifier>
  </ddiem:Disease>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/f47550d6-5499-4a44-84af-e35b0e007219">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8410522</dc:provenance>
    <rdfs:comment>The results of this study suggest that octreotide may aid in the acute or long-term treatment of congenital hyperinsulinism in a limited number of selected cases.https://www.ncbi.nlm.nih.gov/pubmed/8410522/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26962538</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/1272f181-4d3e-4c37-962d-f5af1e907617">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/e45ad19e-1b5b-4f87-af9c-7196d6432f6a"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0003304>W99L</obo:RO_0003304>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25781533</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/65084b83-5349-48d3-b185-b9c2720ab857">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/85359197-0b8f-40bb-9e89-95e1179f1e64"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://onlinelibrary.wiley.com/doi/epdf/10.1002/dmrr.448</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/345f7321-2b9d-4b63-8db8-6f154976000d"/>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/602485">
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/0d032c9e-26e2-4931-af66-d117e8507669"/>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/1289</ddiem:iembaseUrl>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>HYPERINSULINEMIC HYPOGLYCEMIA, FAMILIAL, 3; HHF3</rdfs:label>
        <ddiem:iembaseAccessionNumber>1289</ddiem:iembaseAccessionNumber>
        <dc:identifier>https://www.omim.org/entry/602485</dc:identifier>
      </ddiem:Disease>
    </obo:RO_0002599>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
  </obo:OGMS_0000112>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/2a86e880-319e-4d59-a7f6-db0db75eca50">
    <ddiem:keggEntryId>K21032</ddiem:keggEntryId>
    <ddiem:uniprotId>O43505</ddiem:uniprotId>
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/07533464-77d1-4214-b600-fd44d8215370"/>
    <ddiem:ecNumber>2.4.1.-</ddiem:ecNumber>
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/1abaf40f-2a9b-43e9-9c9c-053c92416972"/>
    <rdfs:label>Beta-1,4-glucuronyltransferase 1</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/2ae002c0-a726-4c6c-9167-e0b33b590425">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12003346</dc:provenance>
    <dc:provenance>https://www.babysfirsttest.org/newborn-screening/conditions/3-methylcrotonyl-coa-carboxylase-deficiency</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f9a77486-4d72-414c-a70c-319926397041">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0004923</ddiem:url>
        <rdfs:label>Elevated blood phenylalanine concentration</rdfs:label>
        <dc:identifier>HP:0004923</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/78f3d001-4887-4d42-8777-a38dce39096e"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/749c4e05-a067-4dbf-bfde-b25a6123b0e0"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7110811</dc:provenance>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/ac9e4c34-6622-410a-8b39-d4b71217d40b"/>
    <rdfs:comment>It's an investigational therapy where Positive results from using a selective monoamine oxidase (MAO) B inhibitor or non-ergot dopamine agonist pramipexole as an adjunct therapy have been described in the medical literature. This use of such an inhibitor can allow for lower doses of neurotransmitter precursor to be used. However, the long-term safety (e.g. effects on neonatal brain development) and effectiveness of this therapy is unknown and more research is required to determine what role, if any, selective monoamine oxidase B inhibitors play in the treatment of individuals with tetrahydrobiopterin deficiency. https://rarediseases.org/rare-diseases/tetrahydrobiopterin-deficiency/. https://www.researchgate.net/publication/233414693_Deprenyl_in_6-Pyruvoyl_Tetrahydropterin_Synthase_Deficiency. https://www.degruyter.com/downloadpdf/j/pteridines.1995.6.issue-3/pteridines.1995.6.3.144/pteridines.1995.6.3.144.pdf</rdfs:comment>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/261630"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23138986</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/50b11d07-6d6c-485b-b3af-1f6d0e4d644e">
        <dc:identifier>HP:0012535</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012535</ddiem:url>
        <rdfs:label>Abnormality of neurotransmitter metabolism</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/c4633604-cb41-4d90-84d5-44841bde9fef"/>
  </obo:OGMS_0000112>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/453e1f8f-ecd1-428f-801f-335f984fb57a">
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/f5b4e0fe-8f48-4ef0-a7a2-e716a36737cc"/>
    <rdfs:label>mitochondrially encoded NADH dehydrogenase 1/mitochondrially encoded NADH 4L dehydrogenase/ mitochondrially encoded NADH dehydrogenase 6</rdfs:label>
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/2bf1b12f-923e-43a7-97e8-9778d7c2b3b2"/>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/2cd18068-2555-4da9-b6bd-133168eb6c42">
        <dc:identifier>https://ghr.nlm.nih.gov/gene/MT-ND4L</dc:identifier>
        <rdfs:label>MT-ND4L</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/f3e701fa-faad-4d03-a6da-1f285468716d">
    <ddiem:ecNumber>2.6.1.13</ddiem:ecNumber>
    <ddiem:keggEntryId>K00819</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/6abb68ef-f40e-4774-8e86-7ac7faa4cb80">
        <rdfs:label>OAT</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/4942</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>P04181</ddiem:uniprotId>
    <rdfs:label>ornithine aminotransferase</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/26d3a348-dd45-4ccf-9fca-bf710f79b9de">
    <ddiem:keggEntryId>K07515</ddiem:keggEntryId>
    <ddiem:uniprotId>P40939</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/7d431472-f90d-4587-a235-42204a097e12">
        <rdfs:label>HADHA</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/3030</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>3-hydroxyacyl-CoA dehydrogenase/enoyl-CoA hydratase</rdfs:label>
    <ddiem:ecNumber>2.3.1.-; 4.2.1.17; 1.1.1.211</ddiem:ecNumber>
  </ddiem:ProtienOrEnzyme>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/db878ce6-9c1e-4f0b-b29d-becd77b53f1a">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20657580</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26917598</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/09a71b4e-6ddc-43c4-a9cd-5b8e64eec05b">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/5e56fac8-1f7a-4e2f-ae8c-42ccfcccf559"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0022202X15352507</dc:provenance>
    <rdfs:comment>A drug regimen that was after liver transplataion surgery to maintain the achieved metabolic results.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29526615</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/602473"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/6b36ca46-5e87-4637-b6e9-73189ff35f01"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
  </obo:OGMS_0000112>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/948450bc-0a4e-4cf6-a9ea-ff704e89fb2b">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/d749ac05-3491-469f-b34f-8e747980d9b1">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/3ba70329-27af-452d-a7e2-d7107dae9287"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00461799</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/685033e2-b541-4129-9ae2-c8c6b261c120">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Study is still recruiting</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/218800">
        <rdfs:label>CRIGLER-NAJJAR SYNDROME, TYPE I</rdfs:label>
        <ddiem:iembaseAccessionNumber>661</ddiem:iembaseAccessionNumber>
        <dc:identifier>https://www.omim.org/entry/218800</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/661</ddiem:iembaseUrl>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/f2173f45-1505-4676-9ee8-be970d33771b"/>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT03466463</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583863</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15726662</dc:provenance>
    <rdfs:comment>Information about the Study can be ound in https://gmoinfo.jrc.ec.europa.eu/bsnifs-gmo/B-NL-17-001.pdf</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3306242</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14517515</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/direct_complementation_of_a_genetically_defective_protein_by_gene_therapy"/>
  </obo:OGMS_0000112>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/c7aa751b-65b0-4359-a56c-f97c7d9772a5">
    <rdfs:label>Ribitol-5-phosphate xylosyltransferase 1</rdfs:label>
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/41503358-cc3e-4e8b-ac18-da60ddb867f4"/>
    <ddiem:uniprotId>""</ddiem:uniprotId>
    <ddiem:keggEntryId>""</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/a8748969-a3a6-44b3-881f-5c5ab9b7efff">
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/88a76fdd-4215-4f44-872c-9344ac76a05a">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/66432d86-5496-4976-a3aa-07f19bf8ed9d"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28589525</dc:provenance>
    <obo:RO_0002558>
      <ddiem:Evidence rdf:about="http://ddiem.phenomebrowser.net/ECO:0001565">
        <ddiem:url>http://purl.obolibrary.org/obo/ECO_0001565</ddiem:url>
        <dc:identifier>ECO:0001565</dc:identifier>
      </ddiem:Evidence>
    </obo:RO_0002558>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/204500">
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/306</ddiem:iembaseUrl>
        <rdfs:label>CEROID LIPOFUSCINOSIS, NEURONAL, 2; CLN2</rdfs:label>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/dbd3002b-0066-48f4-9139-ab8fa765de32"/>
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseAccessionNumber>306</ddiem:iembaseAccessionNumber>
        <dc:identifier>https://www.omim.org/entry/204500</dc:identifier>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01907087</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5891977</dc:provenance>
    <dc:provenance>https://emedicine.medscape.com/article/1178391-treatment</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4263309</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d516cb33-b62e-4211-803b-1df600eb7047">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012444</ddiem:url>
        <dc:identifier>HP:0012444</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>brain atrophy</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>A combination therapy of Î´-tocopherol and HPBCD further improved the effect compared to that of either drug used as a single therapy.</rdfs:comment>
  </obo:OGMS_0000112>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/ead3a2c6-3d29-4ad3-aedb-810a73d08629">
    <ddiem:keggEntryId>""</ddiem:keggEntryId>
    <ddiem:uniprotId>""</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/22f08369-976f-410c-8981-79d7b997fbe5">
        <rdfs:label>LRPPRC</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/10128</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>leucine-rich pentatricopeptide repeat-containing protein</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/f764f37d-9a49-434a-b8ea-bb392214b075">
    <rdfs:label>mitochondrial aspartyl-tRNA synthetase</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/3042faba-a8a1-4c09-972a-0793f1a132b7">
        <rdfs:label>DARS2</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/55157</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>Q6PI48</ddiem:uniprotId>
    <ddiem:keggEntryId>K01876</ddiem:keggEntryId>
    <ddiem:ecNumber>6.1.1.12</ddiem:ecNumber>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/7953ca73-42ee-45c5-bb7c-7ad8d56b7e3f">
    <ddiem:uniprotId>Q9NVS9</ddiem:uniprotId>
    <ddiem:ecNumber>1.4.3.5</ddiem:ecNumber>
    <rdfs:label>Pyridoxamine 5'-phosphate oxidase</rdfs:label>
    <ddiem:keggEntryId>K00275</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/afb655f4-dfaf-440d-95ba-511a2ec0c523">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/55163</dc:identifier>
        <rdfs:label>PNPO</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/f22fed40-2438-441e-9fcc-6b068593b514">
    <rdfs:label>DNA polymerase subunit gamma-1</rdfs:label>
    <ddiem:ecNumber>2.7.7.7</ddiem:ecNumber>
    <ddiem:uniprotId>P54098</ddiem:uniprotId>
    <ddiem:keggEntryId>K02332</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/42910152-5855-4c4b-bc8a-f9d7f0ec1dba">
        <rdfs:label>POLG</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/5428</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/b62dd109-e64c-42c8-9a4b-c1c2ca2e8ddf">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/ea4ce278-1989-43db-bad7-f74d9468cf3a">
        <rdfs:label>GK</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/2710</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:ecNumber>2.7.1.30</ddiem:ecNumber>
    <ddiem:keggEntryId>K00864</ddiem:keggEntryId>
    <ddiem:uniprotId>P32189</ddiem:uniprotId>
    <rdfs:label>Glycerol kinase</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <obo:direct_complementation_of_a_genetically_defective_protein_by_gene_therapy rdf:about="http://ddiem.phenomebrowser.net/b1c6c523-a66e-498d-87b9-3a5274ff4f48">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15726662</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583863</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3306242</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14517515</dc:provenance>
    <rdfs:comment>Clinically relevant response to orlistat treatment was not correlated with age, sex, CN type, BMI, or co-treatment with phototherapy or phenobarbital, but appeared correlated with a relatively lower dietary fat intake.https://www.ncbi.nlm.nih.gov/pubmed/17957158. The Drug works through increasing fecal fat excretion so dietary fat intake may determine the responsiveness to orlistat treatment.</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/8938e65d-6865-4d44-9e15-b72cad773859">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/d814410e-e2d2-4d45-898b-7a26bd0bbe0c"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/44bed0bb-d1bd-482c-a3c5-ade3cb6070e6">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002904</ddiem:url>
        <rdfs:label>Study was suspended based on Sponsor Decision.</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0002904</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00461799</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/218800"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT03223194</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
  </obo:direct_complementation_of_a_genetically_defective_protein_by_gene_therapy>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/25e1ff1b-e921-4329-b78f-c7aabd2db409">
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/603174"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31434105</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31211405</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31196723</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/1e563444-127e-40f7-8c83-93768b346275"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/cac2442d-7a1e-4517-a24b-e1ac48625a88">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0010919</dc:identifier>
        <rdfs:label>High plasma homocysteine level(Abnormal homocysteine level)*</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0010919</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/79d44480-aca4-4c37-8b4e-b20a0d413380"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/cd539122-ae66-4ad2-8241-d43b66dbe01f"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30755342</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00638547</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29246599</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30081189</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31082797</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/eb5152ff-7294-4a87-a512-7b1cec024750"/>
    <rdfs:comment>The responce to treatment reported to be poor in two patients, may be due to delayed start of treatment and the coexistence of 2 very harmful mutations, which, together with the p.A222V polymorphism, are known to reduce MTHFR enzyme activity. https://www.ncbi.nlm.nih.gov/pubmed/12673793?dopt=Abstract</rdfs:comment>
  </obo:OGMS_0000112>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/bbb125cf-43e2-44df-a144-bd5ef30b866f">
    <ddiem:keggEntryId>K01230</ddiem:keggEntryId>
    <ddiem:uniprotId>Q9UKM7</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/5bee6dab-88ea-4576-aad2-e9159ce257ae">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/11253</dc:identifier>
        <rdfs:label>MAN1B1</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>mannosidase alpha class 1B member 1</rdfs:label>
    <ddiem:ecNumber>3.2.1.113</ddiem:ecNumber>
  </ddiem:ProtienOrEnzyme>
  <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/6eb46df7-d432-4c70-8df9-16882dc18608">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29054473</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/5634a50b-fb00-426a-b60d-3c73c68634d7"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02771379</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3202309</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/1e563444-127e-40f7-8c83-93768b346275"/>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/535000">
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/402</ddiem:iembaseUrl>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>https://www.omim.org/entry/535000</dc:identifier>
        <ddiem:iembaseAccessionNumber>402</ddiem:iembaseAccessionNumber>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/78de30dc-3662-4faf-a9c7-a25ca2fca939"/>
        <rdfs:label>LEBER OPTIC ATROPHY</rdfs:label>
      </ddiem:Disease>
    </obo:RO_0002599>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e97e126f-9dc0-447e-80cd-927a59956339">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Slow recovery</rdfs:label>
        <dc:identifier>HP:0012823*</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012823</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21483849</dc:provenance>
    <rdfs:comment>Author: "The therapeutic potential of idebenone therapy is likely to have the highest impact if therapy is initiated early in the disease at a time when retinal ganglion cell loss is still minimal.https://www.ncbi.nlm.nih.gov/pubmed/21810891/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21810891</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01495715</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21788663</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11001192</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/7d14658a-4b9d-4e36-848b-28462edf1aa3"/>
  </obo:DDIEM_0000007>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/db7b99be-7331-407e-8241-6a336e467688">
    <ddiem:uniprotId>P48775</ddiem:uniprotId>
    <ddiem:keggEntryId>K00453</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/954ddf18-17b5-439c-9add-83f5b9907d50">
        <rdfs:label>TDO2</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/6999</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>tryptophan 2,3-dioxygenase</rdfs:label>
    <ddiem:ecNumber>1.13.11.11</ddiem:ecNumber>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/db478015-3aba-40a3-8740-833ea57e47a9">
    <ddiem:uniprotId>Q16134</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/75cfd7bf-d73e-4bfb-b3ae-478945e9a2b8">
        <rdfs:label>ETFA</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/2108</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>P38117</ddiem:uniprotId>
    <ddiem:keggEntryId>K00311</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/4d5cb998-91ac-4ec5-b925-7ca79430fb69">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/2109</dc:identifier>
        <rdfs:label>ETFB</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>electron transfer flavoprotein (Alpha subunit), electron transfer flavoprotein (Beta subunit), electron transfer flavoprotein dehydrogenase</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/e1f4d28c-6cd3-4f88-ad61-4aae6782ccd6">
        <rdfs:label>ETFDH</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/2110</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>P13804</ddiem:uniprotId>
    <ddiem:ecNumber>1.5.5.1</ddiem:ecNumber>
    <ddiem:keggEntryId>K03522</ddiem:keggEntryId>
    <ddiem:keggEntryId>K03521</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/bfa8a59b-0f06-41c0-a342-988ff91b7d92">
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/8f6287e5-3030-453a-a94d-aa9da3cde6a7"/>
    <rdfs:comment>The combination was accompanied by Low L-lysine diet</rdfs:comment>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/21636aca-11ac-467e-aa7f-80153e6d0a3f"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e966ed84-be50-40af-a8f6-beb0a0a7691e">
        <dc:identifier>HP:0003530</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003530</ddiem:url>
        <rdfs:comment>Treatment with clofibrate decreased cerebral and hepatic concentrations of glutaric acid in glutaryl-coenzyme A dehydrogenase-deficient mice. This finding opens new therapeutic perspectives such as pharmacological stimulation of alternative L-lysine oxidation in peroxisomes.https://www.ncbi.nlm.nih.gov/pubmed/20923787</rdfs:comment>
        <rdfs:label>Glutaric acidemia</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/6b36ca46-5e87-4637-b6e9-73189ff35f01"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17397529</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16368216</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20923787</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/834144f0-fa47-4662-b309-8f0f1ba7918a">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/0af26475-da77-4fe5-867e-c5509cd684d2"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>http://www.ncbi.nlm.nih.gov/pubmed/16368216</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/231670">
        <rdfs:label>GLUTARIC ACIDEMIA I; GA1</rdfs:label>
        <dc:identifier>https://www.omim.org/entry/231670</dc:identifier>
        <ddiem:iembaseAccessionNumber>163</ddiem:iembaseAccessionNumber>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/163</ddiem:iembaseUrl>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/366ddfc3-49a8-4a6f-b03a-a534f62c960f"/>
        <rdfs:comment>It has been shown that in the majority of neonatally diagnosed patients striatal injury can be prevented by combined metabolic treatment. Metabolic treatment that includes a low lysine diet, carnitine supplementation and intensified emergency treatment during acute episodes of intercurrent illness should be introduced and monitored by an experienced interdisciplinary team. https://www.ncbi.nlm.nih.gov/pubmed/21431622</rdfs:comment>
      </ddiem:Disease>
    </obo:RO_0002599>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000012"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
  </obo:DDIEM_0000007>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/c9854ef6-ad88-4ce7-ae2d-0cd3430b8da3">
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/243500">
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/56</ddiem:iembaseUrl>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/0b529989-e44f-4416-a95d-0eeeccab6c8b"/>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>https://www.omim.org/entry/243500</dc:identifier>
        <ddiem:iembaseAccessionNumber>56</ddiem:iembaseAccessionNumber>
        <rdfs:label>ISOVALERIC ACIDEMIA; IVA</rdfs:label>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17299485</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ff6c419e-a7e1-41b2-a95b-b09a11335582">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001942</ddiem:url>
        <dc:identifier>HP:0001942</dc:identifier>
        <rdfs:comment>The regimen maximally increases isovaleryl conjugate excretion during metabolic stress rather than under stable conditions.</rdfs:comment>
        <rdfs:label>Metabolic stress</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/76e590fa-f89d-4d64-a7a3-c08485b7023c"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/576c43e2-7cb9-432a-8430-d1315b7bd5a9">
        <rdfs:label>"abnormal Na+,K+-ATPase activity"</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/5361854f-7f31-45a0-9196-7a2a5e838318"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19210957</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000015"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/003a62bf-932a-417a-9887-b6b58bf0132f"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21290185</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/6b36ca46-5e87-4637-b6e9-73189ff35f01"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8804338</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12069539</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20807522</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ada3178f-a2ee-41ef-9637-b3c39b9267cc">
        <rdfs:label>High 3-hydroxyisovaleric acid level (C5)</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15624372</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/964688a9-ece7-4f0e-9fba-bd09b81115fc">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>High toxic acyl-CoA level</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>1-Combined therapy with carnitine and glycine has been shown to maximize the total excretion of isovaleryl-CoA conjugates, but the clinical benefit of combined versus single therapy has not been established through controlled studies. 2- The relative merits of the two therapies either singly or together in patients with more severe presentations including recurrent crises remains a matter of debate. (https://www.ncbi.nlm.nih.gov/pubmed/16602101) 3- Combined glycine and L-carnitine therapy maximally increases isovaleryl conjugate excretion during metabolic stress but not under stable conditions. https://www.ncbi.nlm.nih.gov/pubmed/8804338</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16602101</dc:provenance>
  </obo:OGMS_0000112>
  <obo:DDIEM_0000012 rdf:about="http://ddiem.phenomebrowser.net/5c4eef51-e6cc-4f5b-bca9-15e7a43bc0fe">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6ad131d5-f730-432f-b14c-59a9244bbf65">
        <dc:identifier>HP:0002015</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002015</ddiem:url>
        <rdfs:label>Dysphagia</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/af72c454-8e59-41e7-ab5e-57c09a2f7a98"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/4556601b-4e58-4413-90b1-df627cd415d1"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d4d9fa5f-c501-42d6-89e7-9156e0c4f1f3">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Difficulty walking</rdfs:label>
        <dc:identifier>HP:0002355</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002355</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ed2abaf1-0f46-4129-bbe3-ae60472ececb">
        <rdfs:label>Secondary Carnitine deficiency( Carnitine deficiency)*</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003234</ddiem:url>
        <dc:identifier>HP:0003234*</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10723193</dc:provenance>
    <rdfs:comment>Synergism inmproves results</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26236614</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19249206</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16368216</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/6b36ca46-5e87-4637-b6e9-73189ff35f01"/>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/231680">
        <dc:identifier>https://www.omim.org/entry/231680</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseAccessionNumber>1257</ddiem:iembaseAccessionNumber>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/1257</ddiem:iembaseUrl>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/4d5cb998-91ac-4ec5-b925-7ca79430fb69"/>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/e1f4d28c-6cd3-4f88-ad61-4aae6782ccd6"/>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/75cfd7bf-d73e-4bfb-b3ae-478945e9a2b8"/>
        <rdfs:label>MULTIPLE ACYL-CoA DEHYDROGENASE DEFICIENCY; MADD</rdfs:label>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
  </obo:DDIEM_0000012>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/f71f7ff7-4d38-4e65-a987-110bbe694476">
    <ddiem:keggEntryId>K15279</ddiem:keggEntryId>
    <rdfs:label>GDP-fucose transporter 1</rdfs:label>
    <ddiem:uniprotId>Q96A29</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/b7729871-edf8-4c8e-a63f-9ee6501210f6">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/55343</dc:identifier>
        <rdfs:label>SLC35C1</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/86e836d2-1520-4bc4-b735-81c6af32785d">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/77b36c2e-942a-4400-8341-29ed8dbbbe39">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/4864</dc:identifier>
        <rdfs:label>NPC1</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>O15118</ddiem:uniprotId>
    <ddiem:keggEntryId>K12385</ddiem:keggEntryId>
    <rdfs:label>NPC intracellular cholesterol transporter 1</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/d50efa7b-5d46-4052-af35-981dc9f3e14b">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19249206</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3229565</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/6b36ca46-5e87-4637-b6e9-73189ff35f01"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000012"/>
    <rdfs:comment>Synergism inmproves results</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16368216</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/003a62bf-932a-417a-9887-b6b58bf0132f"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/202b2073-9e0f-4323-b4bc-9fcf095b645b">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0001324</dc:identifier>
        <rdfs:label>Muscle weakness</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001324</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/231680"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/af72c454-8e59-41e7-ab5e-57c09a2f7a98"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
  </obo:DDIEM_0000007>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/c9773063-c33b-447e-8074-709287dbcb9c">
    <rdfs:label>Frataxin, mitochondrial</rdfs:label>
    <ddiem:ecNumber>1.16.3.1</ddiem:ecNumber>
    <ddiem:uniprotId>Q16595</ddiem:uniprotId>
    <ddiem:keggEntryId>K19054</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/0fc0465f-a7f0-4412-bde9-2b577c2b01f2">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/2395</dc:identifier>
        <rdfs:label>FXN</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/6b4c005c-fe39-4608-a640-8cc9e726ba07">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17431913</dc:provenance>
    <rdfs:comment>Bartholomwe et al. have suggested in their paper in 1988 that daily injections of OH-B12 are not necessary to maintain metabolic control and that orally administered OH-B12 is unlikely to be effective. Betaine appears to act synergistically with OH-B12 and should be part of the treatment regimen. Although there are theoretical reasons for using L-carnitine and folinic acid, we could not document their effectiveness in these two patients. https://www.ncbi.nlm.nih.gov/pubmed/3257264/</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b962f88a-a849-4148-ba7a-fa3e9c0cd40e">
        <rdfs:label>Dementia</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000726</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0000726</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
    <dc:provenance>https://link.springer.com/article/10.1023/A:1005353530303</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3950820</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25511120</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2873525</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/bb44cafe-7430-411a-abdd-750c3e1e2f55">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012120</ddiem:url>
        <rdfs:label>High urine methylmalonic acid level</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0012120</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/49851e7a-d8cc-4d78-9ba2-0564cc67e1c3">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Elevated total plasma homocysteine</rdfs:label>
        <dc:identifier>HP:0002160</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002160</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7ee6dbfc-06e2-4b49-b8be-84a8489f7746">
        <rdfs:label>Emotional lability</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0000712</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000712</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/149ef70f-486b-4837-b95f-f928e9dc9a73">
        <dc:identifier>HP:0100543</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0100543</ddiem:url>
        <rdfs:label>Mental impairment</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d4d9fa5f-c501-42d6-89e7-9156e0c4f1f3"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/b3b91803-46c6-4398-8030-a8feea3ea9bc"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/6b36ca46-5e87-4637-b6e9-73189ff35f01"/>
    <dc:provenance>https://link.springer.com/article/10.1023/A:1005353530304</dc:provenance>
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/52b1257e-71b0-4f69-8efa-387870c76a3a">
        <rdfs:label>Abnormal visual evoked potentials</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000649</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0000649</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/cd539122-ae66-4ad2-8241-d43b66dbe01f"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19821145</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7ea6484e-617c-4416-b1e8-00a4a43a31b4">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0006958</ddiem:url>
        <dc:identifier>HP:0006958</dc:identifier>
        <rdfs:label>Abnormal brain stem auditory evoked potentials</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/277400">
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/30db8e18-2642-431e-a99f-60bf1cd2658f"/>
        <ddiem:iembaseAccessionNumber>90</ddiem:iembaseAccessionNumber>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>METHYLMALONIC ACIDURIA AND HOMOCYSTINURIA, cblC TYPE; MAHCC</rdfs:label>
        <dc:identifier>https://www.omim.org/entry/277400</dc:identifier>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/90</ddiem:iembaseUrl>
      </ddiem:Disease>
    </obo:RO_0002599>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/86fa8ff3-5481-4a1e-abbd-0b92365521df">
        <rdfs:label>Psychiatric disturbances</rdfs:label>
        <dc:identifier>HP:0000708</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000708</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </obo:DDIEM_0000007>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/df2b4246-bfb9-4aaf-b96a-7577fe340006">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27207470</dc:provenance>
    <rdfs:comment>An experimental study done on a mice with GMNT knocked out. suggesting considering Nicotinamide as atreatment option in patients with GNMT deficiency.  https://www.ncbi.nlm.nih.gov/pubmed/20578266/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19019309</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7cec49d6-6b90-4a5f-8737-6f4b9ae6022e">
        <dc:identifier>HP:0001877*</dc:identifier>
        <rdfs:label>High erythrocyte turnover(Abnormality of erythrocytes)*</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001877</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/5634a50b-fb00-426a-b60d-3c73c68634d7"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17397529</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8301428</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/266130"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/518b6d43-2c86-4354-bcc8-68383fdd91a7">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/a5ae0ff8-b67a-47cf-a570-f8c076c9ea8e"/>
      </rdf:Alt>
    </obo:RO_0000057>
  </obo:OGMS_0000112>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/9541eae5-9e3a-4c70-8169-6189bfa3bce2">
    <ddiem:keggEntryId>K09025</ddiem:keggEntryId>
    <rdfs:label>Apolipoprotein A-V</rdfs:label>
    <ddiem:uniprotId>Q6Q788</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/3e4e3978-435d-44fe-ad62-68b7c8c6790b">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/116519</dc:identifier>
        <rdfs:label>APOA5</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/36d69483-52fe-4198-a072-50d31c529724">
    <ddiem:uniprotId>P05093</ddiem:uniprotId>
    <ddiem:ecNumber>1.14.14.19; 1.14.14.32</ddiem:ecNumber>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/bd9495a2-e183-4ccd-8d20-b04db0268b94">
        <rdfs:label>CYP17A1</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/1586</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K00512</ddiem:keggEntryId>
    <rdfs:label>Steroid 17-alpha-hydroxylase</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/20bd756e-0d2d-4807-801d-57cb669e24a8">
    <ddiem:uniprotId>Q9Y276</ddiem:uniprotId>
    <ddiem:keggEntryId>K08900</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/a2762fd9-c9c7-4f3d-b43f-3942d930c838">
        <rdfs:label>BCS1L</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/617</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>ubiquinol-cytochrome c reductase complex chaperone</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/0e2f7db5-0d9e-4d72-9735-79c530e5dac7">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19249206</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16368216</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/6b36ca46-5e87-4637-b6e9-73189ff35f01"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10723193</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/af72c454-8e59-41e7-ab5e-57c09a2f7a98"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/231680"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/202b2073-9e0f-4323-b4bc-9fcf095b645b"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000012"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e568c6cf-f72e-49b3-bc84-916f94f28aeb">
        <rdfs:label>High serum creatine kinase</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003236</ddiem:url>
        <dc:identifier>HP:0003236</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>Synergism inmproves results</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ed2abaf1-0f46-4129-bbe3-ae60472ececb"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
  </obo:OGMS_0000112>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/b3759d1a-881d-4be9-99c1-4c4f146cff98">
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/19d18d16-d582-4b93-ad73-0788911e9fa8"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/e4fe8128-15d7-4874-b568-8ddad4ec30c7"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000010"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/20f5151c-f0e4-462d-93ee-fd0daabd9784">
        <dc:identifier>HP:0002910</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002910</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Elevated Hepatic transaminases</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <rdfs:comment>Testosterone therapy needs to be carefully considered because of the risk of hepatic adenomas.https://www.ncbi.nlm.nih.gov/pubmed/28160246
Androgen receptors are expressed in the liver, and androgens can stimulate hepatocyte proliferation. Although rare, androgens have been shown in observational studies to induce adenoma development (Giannitrapani et al. 2006). Testosterone levels should be assessed for response 2â3 months after therapy is initiated.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19019309</dc:provenance>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/232700">
        <dc:identifier>https://www.omim.org/entry/232700</dc:identifier>
        <rdfs:label>GLYCOGEN STORAGE DISEASE VI; GSD6</rdfs:label>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/a4ebaa38-8c11-4637-92f5-33ce2e9c4deb"/>
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseAccessionNumber>490</ddiem:iembaseAccessionNumber>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/490</ddiem:iembaseUrl>
      </ddiem:Disease>
    </obo:RO_0002599>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25266922</dc:provenance>
  </obo:OGMS_0000112>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/017976a0-b2a3-4c58-9c77-cf714b2bdb0f">
    <ddiem:uniprotId>P24752</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/20d2dcb3-0c91-49f3-95da-35e1f10a041e">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/38</dc:identifier>
        <rdfs:label>ACAT1</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:ecNumber>2.3.1.9</ddiem:ecNumber>
    <rdfs:label>Acetyl-CoA C-acetyltransferase.</rdfs:label>
    <ddiem:keggEntryId>K00626</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/612932">
    <dc:identifier>https://www.omim.org/entry/612932</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/501</ddiem:iembaseUrl>
    <obo:RO_0004020>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/23ca47d9-9d8d-431c-a628-0a5cd412f1a0">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/2027</dc:identifier>
        <rdfs:label>ENO3</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0004020>
    <ddiem:iembaseAccessionNumber>501</ddiem:iembaseAccessionNumber>
    <rdfs:label>GLYCOGEN STORAGE DISEASE XIII; GSD13</rdfs:label>
  </ddiem:Disease>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/2280d5d6-a35d-43cd-9a1b-bf733d416234">
    <rdfs:label>Alpha-mannosidase</rdfs:label>
    <ddiem:uniprotId>O00754</ddiem:uniprotId>
    <ddiem:ecNumber>3.2.1.24</ddiem:ecNumber>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/175dcd8c-14f5-4713-a31a-4eef94ec3621">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/4125</dc:identifier>
        <rdfs:label>MAN2B1</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K12311</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/0fb3d7b8-2c95-4e57-9d3c-44ab8c247009">
    <ddiem:uniprotId>P42898</ddiem:uniprotId>
    <ddiem:keggEntryId>K00297</ddiem:keggEntryId>
    <ddiem:ecNumber>1.5.1.20</ddiem:ecNumber>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/22b1a9c8-e093-48b4-9085-2521e92bd0c6">
        <rdfs:label>MTHFR</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/4524</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>Methylenetetrahydrofolate reductase</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/230200">
    <obo:RO_0004020>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/7cea3964-f848-47bd-982f-cae7cada1069">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/2584</dc:identifier>
        <rdfs:label>GALK1</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0004020>
    <rdfs:comment></rdfs:comment>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/474</ddiem:iembaseUrl>
    <ddiem:iembaseAccessionNumber>474</ddiem:iembaseAccessionNumber>
    <rdfs:label>GALACTOKINASE DEFICIENCY</rdfs:label>
    <dc:identifier>https://www.omim.org/entry/230200</dc:identifier>
  </ddiem:Disease>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/196a4bc1-808f-4f53-9a85-ff33083e9989">
    <ddiem:uniprotId>O00462</ddiem:uniprotId>
    <ddiem:keggEntryId>K01192</ddiem:keggEntryId>
    <rdfs:label>Beta-mannosidase</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/321831eb-3a94-4deb-abe6-c3ff381d746d">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/4126</dc:identifier>
        <rdfs:label>MANBA</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:ecNumber>3.2.1.25</ddiem:ecNumber>
  </ddiem:ProtienOrEnzyme>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/39382ac2-7a67-4f45-85ef-277e2a7d5b46">
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/76e590fa-f89d-4d64-a7a3-c08485b7023c"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/834144f0-fa47-4662-b309-8f0f1ba7918a"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/6b36ca46-5e87-4637-b6e9-73189ff35f01"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000012"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/39e026c8-3518-488b-950b-ec15df629d6a">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/bedeea09-4dae-481b-a650-ba3b44e0794e"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b4f2b909-9165-4013-a2cb-82c920e8c0c1">
        <dc:identifier>HP:0003678</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003678</ddiem:url>
        <rdfs:label>Disease progression</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <dc:provenance>http://www.ncbi.nlm.nih.gov/pubmed/16368216</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/231670"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
    <rdfs:comment>This combination therapy should be accompained with low lysin diet that is often combined with the use of lysine-free, tryptophan-reduced amino acids (AA) supplements. These supplements are given with the aim of preventing malnutrition by providing essential amino acids and (depending on the product) also minerals, trace elements and vitamins. https://www.ncbi.nlm.nih.gov/pubmed/10630918</rdfs:comment>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ed2abaf1-0f46-4129-bbe3-ae60472ececb"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16368216</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19019309</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17397529</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3335963</dc:provenance>
  </obo:OGMS_0000112>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/770af6a2-c3a3-4d5a-8d5f-5de9ea47aac8">
    <rdfs:label>AMP deaminase</rdfs:label>
    <ddiem:keggEntryId>K01490</ddiem:keggEntryId>
    <ddiem:ecNumber>3.5.4.6</ddiem:ecNumber>
    <ddiem:uniprotId>P23109</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/f4d618c9-7d32-49fa-9cdf-c06cb7b74ef1">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/270</dc:identifier>
        <rdfs:label>AMPD1</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/eaabf967-4587-48e6-82f3-b0ff2250ac18">
    <rdfs:comment>Testosterone therapy needs to be carefully considered because of the risk of hepatic adenomas.https://www.ncbi.nlm.nih.gov/pubmed/28160246
Androgen receptors are expressed in the liver, and androgens can stimulate hepatocyte proliferation. Although rare, androgens have been shown in observational studies to induce adenoma development (Giannitrapani et al. 2006). Testosterone levels should be assessed for response 2â3 months after therapy is initiated.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24613482</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20631546</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25153581</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/72dfe879-ecfc-41e6-8040-c725ceef1c29">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/c68c043c-4105-442c-88ea-27e9f1dcd0ea"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/05d037f8-54d9-4b78-bc06-486b6a60a5ee">
        <dc:identifier>HP:0000939</dc:identifier>
        <rdfs:label>Osteoporosis</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000939</ddiem:url>
        <rdfs:comment>Preventive calcium and vitamin D3 supplementation is also recommended to prevent osteoporosis.</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/53d81324-bc69-4ec5-bd3c-186d552927d4">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/0ded8f3a-dc70-4452-a4d4-d65c42c85341"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.nature.com/articles/gim201069</dc:provenance>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/232400">
        <dc:identifier>https://www.omim.org/entry/232400</dc:identifier>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/487</ddiem:iembaseUrl>
        <ddiem:iembaseAccessionNumber>487</ddiem:iembaseAccessionNumber>
        <rdfs:comment>Managment guidelines for treating GSD3 can be accessed through https://www.ncbi.nlm.nih.gov/pubmed/20631546</rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/8416dd8e-87a3-4132-b85f-991652ee4e85"/>
        <rdfs:label>GLYCOGEN STORAGE DISEASE III; GSD3</rdfs:label>
      </ddiem:Disease>
    </obo:RO_0002599>
  </obo:DDIEM_0000013>
  <obo:DDIEM_0000010 rdf:about="http://ddiem.phenomebrowser.net/4aec4784-ae9f-4722-8106-3d18914af554">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583863</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC324959</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/e4fe8128-15d7-4874-b568-8ddad4ec30c7"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/19d18d16-d582-4b93-ad73-0788911e9fa8"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15726662</dc:provenance>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/306000">
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/48062b3a-490d-4c19-8fb5-a03313826273"/>
        <rdfs:label>GLYCOGEN STORAGE DISEASE IXa1; GSD9A1</rdfs:label>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/492</ddiem:iembaseUrl>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>https://www.omim.org/entry/306000</dc:identifier>
        <ddiem:iembaseAccessionNumber>492</ddiem:iembaseAccessionNumber>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2564511</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25266922</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3306242</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/397a09b3-2d92-4bfa-8ddf-6f103f0e2656">
        <dc:identifier>HP:0002910</dc:identifier>
        <rdfs:label>Elevated hepatic transaminases</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002910</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>Treatment was stopped three days later because of lack of improvement and severe respiratory alkalosis with lactic acidosis (serum lactic acid 70 mg/dl, normal 4â20 mg/dl). https://www.ncbi.nlm.nih.gov/pubmed/12948744</rdfs:comment>
  </obo:DDIEM_0000010>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/c042f43e-5802-446a-89a5-1e55d07101aa">
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/607364">
        <rdfs:label>BARTTER SYNDROME, TYPE 3; BARTS3</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/c06450ee-9a24-4ac2-9aba-5af25939894c"/>
        <dc:identifier>https://www.omim.org/entry/607364</dc:identifier>
      </ddiem:Disease>
    </obo:RO_0002599>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/c8ce86fd-393f-456b-a238-6bfa672e8581">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/e68fb053-4af7-4e91-b463-a709aec705e3"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28288174</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2646391</dc:provenance>
    <rdfs:comment>Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss</rdfs:comment>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/ba4fb4df-0390-4e86-ad94-68cb70436bd1">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/4e98c19f-40fe-4452-94aa-bfc1fbacb78b"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>http://www.neurologyindia.com/article.asp</dc:provenance>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-Bartter.pdf</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/77066bf1-0b44-448f-a183-61007143ccdc">
        <rdfs:label>Short stature</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0004322</ddiem:url>
        <dc:identifier>HP:0004322</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/972c8769-c1f4-4176-af20-b40d2c755c00">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/0a23c2ad-81e2-4e67-849f-4104a9b251ad"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24260777</dc:provenance>
  </obo:DDIEM_0000013>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/5cf731f5-41f8-42a7-a177-ffbaac1ce448">
    <ddiem:ecNumber>2.3.1.51</ddiem:ecNumber>
    <ddiem:keggEntryId>K13699</ddiem:keggEntryId>
    <rdfs:label>adipose triglyceride lipase (ATGL)</rdfs:label>
    <ddiem:uniprotId>Q8WTS1</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/496bfde9-fcaa-4eff-a973-081078d6c088">
        <rdfs:label>ABHD5</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/51099</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/1ff79e7a-d9f9-43c9-96d5-20f88a11123f">
    <ddiem:keggEntryId>K19873</ddiem:keggEntryId>
    <ddiem:uniprotId>Q9H9S5</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/97527ef1-a44a-4202-911a-e73a9fb378c2">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/79147</dc:identifier>
        <rdfs:label>FKRP</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:ecNumber>2.4.2.-</ddiem:ecNumber>
    <rdfs:label>Fukutin-related protein</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/7a50b35e-4252-408c-9233-6203b06b608a">
    <rdfs:label>malonyl-CoA decarboxylase</rdfs:label>
    <ddiem:keggEntryId>K01578</ddiem:keggEntryId>
    <ddiem:uniprotId>O95822</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/163eae28-8265-48f3-84e0-7884bc592240">
        <rdfs:label>MLYCD</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/23417</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:ecNumber>4.1.1.9</ddiem:ecNumber>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/d2439595-ef99-4c34-8434-6ef83d9f20d8">
    <rdfs:label>Ribose-phosphate diphosphokinase</rdfs:label>
    <ddiem:ecNumber>2.7.6.1</ddiem:ecNumber>
    <ddiem:keggEntryId>K00948</ddiem:keggEntryId>
    <ddiem:uniprotId>P60891</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/5d403e2a-eddc-454d-9aeb-0fb1e2174388">
        <rdfs:label>PRPS1</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/5631</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/967c4b5c-f8f2-444d-8581-4ece24940bb9">
    <ddiem:keggEntryId>K18204</ddiem:keggEntryId>
    <ddiem:uniprotId>Q8N465</ddiem:uniprotId>
    <rdfs:label>cytochrome c oxidase assembly factor</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/0cd436db-1bbe-4a1c-8f5c-b9853cde12e9">
        <rdfs:label>D2HGDH</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/728294</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:ecNumber>1.1.99.-</ddiem:ecNumber>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/4116f0db-d87c-464b-a8aa-7598bf6966b9">
    <ddiem:uniprotId>Q9NRA2</ddiem:uniprotId>
    <ddiem:keggEntryId>K12301</ddiem:keggEntryId>
    <rdfs:label>solute carrier family 17 member 5</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/2d4466f8-3528-411e-b533-eae24cc820a6">
        <rdfs:label>SLC17A5</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/26503</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/648a98c4-5a89-4916-870a-cb3e3be8bc19">
    <ddiem:uniprotId>O00142</ddiem:uniprotId>
    <rdfs:label>Thymidine kinase 2, mitochondrial</rdfs:label>
    <ddiem:ecNumber>2.7.1.21</ddiem:ecNumber>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/6f8239fa-1a03-4c85-b2d2-77ab97e55f9f">
        <rdfs:label>TK2</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/7084</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K00857</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/fdf4fd7d-1075-41ed-8244-705ecd98cc09">
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/261515">
        <rdfs:comment>No proven treatments exist to address the underlying biochemical defect in this disorder, although dietary phytanic acid restriction and/or bile acid supplementation may warrant further study.https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3963001/</rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/ca08250a-79e0-468b-9112-87d58949fc5f"/>
        <dc:identifier>https://www.omim.org/entry/261515</dc:identifier>
        <ddiem:iembaseAccessionNumber>274</ddiem:iembaseAccessionNumber>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/274</ddiem:iembaseUrl>
        <rdfs:label>D-BIFUNCTIONAL PROTEIN DEFICIENCY</rdfs:label>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00004442</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/21ba206b-4ec3-4104-9c8a-670f005b9320"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e26cea2e-5830-4510-ad21-203ffcfc0e85">
        <rdfs:label>The study was terminated</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <rdfs:comment>"Oral tocofersolan was more bio available than the water-soluble formulation in children with chronic cholestasis and similarly bio available in CF. This suggests that water-soluble vitamin E may represent an alternative to painful intramuscular vitamin E injections in chronic cholestasis, or other oral formulations in CF. However, the mechanism responsible for fat malabsorption in CRD concerns the absorptive phase as opposed to the digestive phase in CF and cholestatic syndromes. To our knowledge, no specific studies with these new vitamin E preparations have been conducted in CRD." https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/971536</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6206929</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3963001</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11067870</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19622360</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/805548af-9efd-4822-a8b8-b2f38190cf3e"/>
  </obo:OGMS_0000112>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/84fe165f-c6fa-492e-a104-ef036c9ee652">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/ff2ffe57-3296-4857-9577-1da3fd6fbbff">
        <rdfs:label>SPR</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/6697</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:ecNumber>1.14.16.2</ddiem:ecNumber>
    <ddiem:keggEntryId>K01495</ddiem:keggEntryId>
    <ddiem:keggEntryId>K00501</ddiem:keggEntryId>
    <rdfs:label>GTP cyclohydrolase 1/ tyrosine hydroxylase/sepiapterin reductase</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/4cf4f92e-89c7-4c03-9148-85a8fc1567bf">
        <rdfs:label>GCH1</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/2643</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:ecNumber>3.5.4.16</ddiem:ecNumber>
    <ddiem:uniprotId>P30793</ddiem:uniprotId>
    <ddiem:uniprotId>P07101</ddiem:uniprotId>
    <ddiem:uniprotId>P35270</ddiem:uniprotId>
    <ddiem:keggEntryId>K00072</ddiem:keggEntryId>
    <ddiem:ecNumber>1.1.1.153</ddiem:ecNumber>
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/9676fa84-21f6-4244-a68b-4ff450096189"/>
  </ddiem:ProtienOrEnzyme>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/c756f3ed-bbaa-4d91-af50-2600340450d3">
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/db6d42d0-bc1e-458c-9a99-e1e2fe9a00d1"/>
    <rdfs:comment>Synergism inmproves results</rdfs:comment>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/5634a50b-fb00-426a-b60d-3c73c68634d7"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/48f0eae9-c050-47a4-8918-9b66e9cc570d"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/266130"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22830360</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26984560</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25896882</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/2a0058a0-36d4-4702-933b-34629a68d9d7">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/b749fb04-e4f9-4f5c-99a5-5afb15894ba2"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27775558</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
  </obo:DDIEM_0000013>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/285bc809-f362-4ce3-978e-23cfc5ece976">
    <rdfs:label>mitochondrially encoded NADH dehydrogenase 4</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/78de30dc-3662-4faf-a9c7-a25ca2fca939">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/""</dc:identifier>
        <rdfs:label>MT-ND4</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>""</ddiem:keggEntryId>
    <ddiem:uniprotId>""</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/9fa2d03e-73fa-48f7-8383-a055f2090a3f">
    <rdfs:comment>There was no clinical effect, but amild reduction in the plasma level of desmosterol was observed.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22791294</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/3e1fb772-3868-4561-b538-7eabf3c84653"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3389144</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/105650"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/fec0af46-08df-4c06-a764-9441665924ed">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/fa0fb973-0780-4b23-89a0-3a2461eb64ca"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28883274</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2ac8550a-7df9-46e4-af62-86ad68de350b">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Reticulocytopenia</rdfs:label>
        <dc:identifier>HP:0001896</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001896</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000015"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1546717</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/1cbfe780-074e-4883-9c7d-c7b1847865a4"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27329125</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2503027</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10779036</dc:provenance>
  </obo:DDIEM_0000007>
  <owl:Class rdf:about="http://purl.obolibrary.org/obo/activity_modification_of_a_genetically_defective_protein_by_genome_editing">
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000012"/>
    <rdfs:label xml:lang="en">activity modification of a genetically defective protein by genome editing</rdfs:label>
    <obo:IAO_0000115 xml:lang="en">Modulation of the activity or stability of a genetically defective gene through direct modification of one or both endogenous alleles of the gene, using genome editing techniques such as CRISPR/Cas</obo:IAO_0000115>
    <dc:creator>https://orcid.org/0000-0002-5111-7263</dc:creator>
  </owl:Class>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/ed7f6c1b-95d4-4849-97e9-fab870fd6bc0">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1899474</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/6125282b-5f3b-48b7-b234-65a42eaef613">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/bc447ce0-3a80-4b07-998a-504612d2780c"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/387b9aa2-9a28-479d-a7f0-8ecfc6876a9c">
        <dc:identifier>HP:0001250</dc:identifier>
        <rdfs:label>seizures</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001250</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9732974</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8163996</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/9ac596cb-17a1-49f7-901a-f7909ce6b1f1">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/568e015d-ad9b-43a7-8959-f7dd5cfabd7e"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/610768">
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/fa8e587a-df3a-4b92-be5e-10a6b66346fc"/>
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/342</ddiem:iembaseUrl>
        <rdfs:label>CONGENITAL DISORDER OF GLYCOSYLATION, TYPE Im; CDG1M</rdfs:label>
        <ddiem:iembaseAccessionNumber>342</ddiem:iembaseAccessionNumber>
        <dc:identifier>https://www.omim.org/entry/610768</dc:identifier>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12084887</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10590041</dc:provenance>
    <rdfs:comment>There is one case that didn't responed to l- dpa treatmet although of confirmed mutation in TH gene. https://www.ncbi.nlm.nih.gov/pubmed/11196107</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16891685</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23890587</dc:provenance>
  </obo:DDIEM_0000013>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/e5408f85-25de-4587-a864-ec5037196638">
    <rdfs:label>Lysosomal protective protein protein/cathepsin A or PPCA/Î²-galactosidase/ neuraminidase</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/52380bb2-64f0-49fb-9c08-31203c009b30">
        <rdfs:label>CTSA</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/5476</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>P10619</ddiem:uniprotId>
    <ddiem:ecNumber>3.4.16.5</ddiem:ecNumber>
    <ddiem:keggEntryId>K13289</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/9cc39372-02b1-4073-82d6-ff85da0de03d">
    <ddiem:keggEntryId>K15728</ddiem:keggEntryId>
    <rdfs:label>Phosphatidate phosphatase</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/4ffc0403-f326-4bf9-818a-85cfeecb79f9">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/23175</dc:identifier>
        <rdfs:label>LPIN1</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:ecNumber>3.1.3.4</ddiem:ecNumber>
    <ddiem:uniprotId>Q14693</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/b6e7930f-5580-431d-934f-19e8d0f0e074">
    <ddiem:keggEntryId>K00318</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/0be1765a-c186-411b-a731-57a176407569">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/5625</dc:identifier>
        <rdfs:label>PRODH</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:ecNumber>1.5.5.2</ddiem:ecNumber>
    <rdfs:label>proline dehydrogenase 1</rdfs:label>
    <ddiem:uniprotId>O43272</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <obo:DDIEM_0000010 rdf:about="http://ddiem.phenomebrowser.net/7e1321d7-4b51-4775-9bb6-2b65f839cd2d">
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/0449a602-c972-47e0-94b5-36cdaafb335b"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/48188dda-baf1-4346-b92f-d16cebafa6bf">
        <dc:identifier>HP:0002360</dc:identifier>
        <rdfs:label>Sleep disturbance,Poor sleep quality</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002360</ddiem:url>
        <rdfs:comment>The therapy may allow patients with GSD to sleep through the night without awakening for therapy https://www.ncbi.nlm.nih.gov/pubmed/18996862</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29223626</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17514432</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e8e31867-cd3c-41f1-abbc-ed93c5f7de6e"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/232200"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/cd810eea-40f1-4ce9-9186-f3e4bdeb2201"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02054832</dc:provenance>
    <rdfs:comment>Ad vectors, HDAd is completely devoid of all viral protein genes and has been shown to display markedly reduced toxicity in mice.https://www.ncbi.nlm.nih.gov/pubmed/15753292</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18996862</dc:provenance>
  </obo:DDIEM_0000010>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/4ae98374-47c1-4ed5-a9f6-66f7fe047ad0">
    <rdfs:label>lamin B receptor</rdfs:label>
    <ddiem:uniprotId>Q14739</ddiem:uniprotId>
    <ddiem:keggEntryId>K19532</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/c4f672b1-c8ab-4dfb-9da7-bdf2b23b984b">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/3930</dc:identifier>
        <rdfs:label>LBR</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:ecNumber>1.3.1.70</ddiem:ecNumber>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/a29baa5a-3999-4062-9cae-d15f9c138911">
    <ddiem:ecNumber>3.5.1.12</ddiem:ecNumber>
    <rdfs:label>biotinidase</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/0f4dfb61-855b-4a50-80ad-95baf716369e">
        <rdfs:label>BTD</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/686</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K01435</ddiem:keggEntryId>
    <ddiem:uniprotId>P43251</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/614128">
    <rdfs:comment></rdfs:comment>
    <dc:identifier>https://www.omim.org/entry/614128</dc:identifier>
    <ddiem:iembaseAccessionNumber>916</ddiem:iembaseAccessionNumber>
    <rdfs:label>LACTATE DEHYDROGENASE B DEFICIENCY; LDHBD</rdfs:label>
    <obo:RO_0004020>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/e10e2d31-8148-4d11-b3b9-eb63bc89f0fa">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/3945</dc:identifier>
        <rdfs:label>LDHB</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0004020>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/916</ddiem:iembaseUrl>
  </ddiem:Disease>
  <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/74b38671-57f8-4c8d-81f3-6f69fd96a7c3">
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/771666f5-dccc-4d6d-bdd9-8158f1ab0f07"/>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/613153">
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/97527ef1-a44a-4202-911a-e73a9fb378c2"/>
        <dc:identifier>https://www.omim.org/entry/613153</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseAccessionNumber>645</ddiem:iembaseAccessionNumber>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/645</ddiem:iembaseUrl>
        <rdfs:label>MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH BRAIN AND EYE ANOMALIES), TYPE A, 5; MDDGA5</rdfs:label>
      </ddiem:Disease>
    </obo:RO_0002599>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b2e722ac-ef7a-428c-9e80-5a2a05c4a830"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1059131117301243</dc:provenance>
    <dc:provenance>https://www.nature.com/articles/nm1059</dc:provenance>
    <dc:provenance>https://link.springer.com/article/10.1007/s11940-011-0131-z</dc:provenance>
    <rdfs:comment>In a different study IV administration of Glucose wasn't effective.https://www.ncbi.nlm.nih.gov/pubmed/22238410</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/books/NBK1520</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
  </obo:DDIEM_0000007>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/eaeae6e7-ec9b-4170-93fc-84e174f839a7">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/7c8463fa-57bf-4aae-a56c-5e21beb73b73">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/2538</dc:identifier>
        <rdfs:label>G6PC</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>Glucose 6-phophatase</rdfs:label>
    <ddiem:keggEntryId>K01084</ddiem:keggEntryId>
    <ddiem:ecNumber>3.1.3.9</ddiem:ecNumber>
    <ddiem:uniprotId>P35575</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/300868">
    <dc:identifier>https://www.omim.org/entry/300868</dc:identifier>
    <obo:RO_0004020>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/1c8bfdd9-d1ef-4ec3-a89b-0d62b5f15fe4">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/5277</dc:identifier>
        <rdfs:label>PIGA</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0004020>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/1141</ddiem:iembaseUrl>
    <rdfs:label>MULTIPLE CONGENITAL ANOMALIES-HYPOTONIA-SEIZURES SYNDROME 2; MCAHS2</rdfs:label>
    <rdfs:comment>Ketogenic diet - A novel treatment for early epileptic encephalopathy due to PIGA deficiency. https://www.ncbi.nlm.nih.gov/pubmed/27126216</rdfs:comment>
    <ddiem:iembaseAccessionNumber>1141</ddiem:iembaseAccessionNumber>
  </ddiem:Disease>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/730e49ba-219a-486f-8669-5fb95e0b6ed9">
    <ddiem:uniprotId>Q7LG56</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/120ea392-3c9d-4f94-9767-a2cd732df3c3">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/50484</dc:identifier>
        <rdfs:label>RRM2B</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>Ribonucleoside-diphosphate reductase subunit M2 B</rdfs:label>
    <ddiem:ecNumber>1.17.4.1</ddiem:ecNumber>
    <ddiem:keggEntryId>K10808</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/43ea5825-f291-495e-96b7-edf91e7cbf40">
    <ddiem:ecNumber>3.5.2.2</ddiem:ecNumber>
    <ddiem:uniprotId>Q14117</ddiem:uniprotId>
    <rdfs:label>dihydropyrimidinase</rdfs:label>
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/e25c9da5-1972-44c3-9294-ea13388f33bf"/>
    <ddiem:keggEntryId>K01464</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/1f5a025b-fd81-4f03-84ef-80b0d175743e">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/320fc82a-adc3-4a2f-9abd-5388b55b5499">
        <rdfs:label>MT-CO3</rdfs:label>
        <dc:identifier>https://ghr.nlm.nih.gov/gene/MT-CO3</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/003e09d4-d7c6-42cb-a1af-66804d442ef7">
        <rdfs:label>MT-CO1</rdfs:label>
        <dc:identifier>https://ghr.nlm.nih.gov/gene/MT-CO1</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/2423e94c-dce6-4e39-9989-a70f413e4272">
        <rdfs:label>MT-CYB</rdfs:label>
        <dc:identifier>https://ghr.nlm.nih.gov/gene/MT-CYB</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>Cytochrome c oxidase subunit 1/Cytochrome c oxidase subunit 2/Cytochrome c oxidase subunit 3</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/612933">
    <ddiem:iembaseAccessionNumber>499</ddiem:iembaseAccessionNumber>
    <rdfs:label>GLYCOGEN STORAGE DISEASE XI; GSD11</rdfs:label>
    <dc:identifier>https://www.omim.org/entry/612933</dc:identifier>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/499</ddiem:iembaseUrl>
    <obo:RO_0004020>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/5fe216b1-deeb-427c-b92e-956fdc441ba2">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/3939</dc:identifier>
        <rdfs:label>LDHA</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0004020>
    <rdfs:comment></rdfs:comment>
  </ddiem:Disease>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/68604817-dbb0-4c1f-a53a-5432df309ef8">
    <ddiem:keggEntryId>K19331</ddiem:keggEntryId>
    <ddiem:uniprotId>Q8WZ55</ddiem:uniprotId>
    <rdfs:label>barttin</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/12e27cae-6f58-4e84-9e94-6daaca9ef99b">
        <rdfs:label>BSND</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/7809</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/7a926596-2f32-4dd1-954c-859edca55fd8">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/dd4fb71a-d7bd-486a-8773-be5b5dd3a750">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/51604</dc:identifier>
        <rdfs:label>PIGT</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>Q969N2</ddiem:uniprotId>
    <rdfs:label>GPI transamidase component PIG-T</rdfs:label>
    <ddiem:keggEntryId>K05292</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/620d8e09-a7d0-4086-b924-8db92779e963">
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/545000"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/books/NBK1520</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/22ec54bf-0456-419a-9f64-3fca3837df36">
        <rdfs:label>Low quality of life (Constitutional symptoms)*</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/de2f9565-d217-424d-b54d-5a9be0514a37"/>
    <dc:provenance>https://link.springer.com/article/10.1007/s11940-011-0131-z</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1059131117301243</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ec6e911d-5384-4d30-af87-2dcec9be9f3b">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002180</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Myoclonus</rdfs:label>
        <dc:identifier>HP:0002180</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/4556601b-4e58-4413-90b1-df627cd415d1"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28686997</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/6b36ca46-5e87-4637-b6e9-73189ff35f01"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17275787</dc:provenance>
    <rdfs:comment>Clonazepam is a useful adjunct for myoclonus and can be used in combination with lamotrigine to avoid lamotrigineâs myoclonic effects . 
Zonisamide should remain a second-line adjunct in the treatment of JME, owing to the lack of supportive data.
https://link.springer.com/article/10.1007/s11940-011-0131-z</rdfs:comment>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
  </obo:OGMS_0000112>
  <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/f87053fa-c2c6-4850-8125-6baf3e7b7068">
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/236792">
        <rdfs:label>L-2-HYDROXYGLUTARIC ACIDURIA; L2HGA</rdfs:label>
        <ddiem:iembaseAccessionNumber>165</ddiem:iembaseAccessionNumber>
        <rdfs:comment></rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/79b4c332-a20b-40af-b9cc-8691e11899ff"/>
        <dc:identifier>https://www.omim.org/entry/236792</dc:identifier>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/165</ddiem:iembaseUrl>
      </ddiem:Disease>
    </obo:RO_0002599>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/af72c454-8e59-41e7-ab5e-57c09a2f7a98"/>
    <rdfs:comment></rdfs:comment>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/efd3056c-4cdd-4941-ac56-6784d9cee1f8"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26208971</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22840416</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0303846712003952</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000012"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S109037980800010X</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/f966894b-fd2b-49bc-8fe1-94ab7897d487">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/26c5d310-6abb-44d2-841c-6eaa3c176ae1"/>
      </rdf:Alt>
    </obo:RO_0000057>
  </obo:DDIEM_0000007>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/c7e1af85-ea0e-49f9-add8-e0ab1e2e7c59">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1091d5f3-e33b-41be-97aa-690866145c21">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000735</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0000735</dc:identifier>
        <rdfs:label>social interaction defect</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23430827</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/30b4d9e3-1250-4f93-b4cf-fda1a9f13183">
        <dc:identifier>HP:0001433</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001433</ddiem:url>
        <rdfs:label>Hepatosplenomegaly</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/cb5070a3-ac95-4c75-b102-192ca4b450a2"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20301535</dc:provenance>
    <rdfs:comment>The regimen was accomapanied with a protein-restricted diet. https://www.ncbi.nlm.nih.gov/pubmed/27567650</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25859380</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/468d17b6-805f-4eeb-801d-ae43a36a1e58">
        <dc:identifier>HP:0000708</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000708</ddiem:url>
        <rdfs:label>episodic behavioral abnormalities</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/222700"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/674c536e-3ae3-494e-b637-d0053ab7fdc5">
        <dc:identifier>HP:0000817</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>lack eye-eye contact</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000817</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28057010</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27567650</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/6b36ca46-5e87-4637-b6e9-73189ff35f01"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/5c133cff-17b8-488d-8776-72b237b44f8f">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/90ce7754-bb54-479a-8b0c-0a272912540f"/>
      </rdf:Alt>
    </obo:RO_0000057>
  </obo:OGMS_0000112>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/1143d993-a2a8-4b56-92af-2f6e72bd2f1a">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23570448</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/387b9aa2-9a28-479d-a7f0-8ecfc6876a9c"/>
    <rdfs:comment>Î±-Tocopherol should be given with the ascorbic acid(vit. C) as the latter helps The resultant tocopheroxil radical regeneration in getting back to reduced tocopherol .</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/daff0864-0bdd-4eb9-a9a0-16b547b75588">
        <dc:identifier>HP:0010818</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0010818</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Generalized tonic convulsions</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/238700">
        <rdfs:comment>Lysine-restricted diet achieved a mild improvement of some signs but did not reverse cognitive impairment. The moderate decrease of plasma lysine concentrations after dietary treatment in the patients supports the need of increase lysine restriction.https://www.ncbi.nlm.nih.gov/pubmed/23890588</rdfs:comment>
        <rdfs:label>HYPERLYSINEMIA, TYPE I</rdfs:label>
        <dc:identifier>https://www.omim.org/entry/238700</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/24ffba31-ca14-42a6-b088-2ca1e876cb73"/>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24204001</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/c51058f7-1e07-472e-a6a6-adeb625d7b5f">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/ea902e7d-fc84-45eb-be83-2a09e72f2865"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/f5919ed0-0d88-482f-843b-0e629ced7671"/>
  </obo:OGMS_0000112>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/239510">
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/38</ddiem:iembaseUrl>
    <ddiem:iembaseAccessionNumber>38</ddiem:iembaseAccessionNumber>
    <dc:identifier>https://www.omim.org/entry/239510</dc:identifier>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/a1833994-238d-4fb7-9153-db5b4e554840"/>
    <rdfs:label>HYPERPROLINEMIA, TYPE II; HYRPRO2</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Disease>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/99bba3ef-c2bd-41e4-abba-ed0f20464515">
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/cd1e7f1c-8e58-4f11-b0b9-0baf12de5fa4">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/17f4b2f0-3187-4ab0-be92-9f8cea731df1"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/246650">
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/1085</ddiem:iembaseUrl>
        <dc:identifier>https://www.omim.org/entry/246650</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/7f7f4e78-e62a-4510-bb57-8109a959f96b"/>
        <rdfs:label>LIPASE DEFICIENCY, COMBINED</rdfs:label>
        <ddiem:iembaseAccessionNumber>1085</ddiem:iembaseAccessionNumber>
      </ddiem:Disease>
    </obo:RO_0002599>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <rdfs:comment>Because of poor response to fenofibrate treatment, it was replaced with gemfibrozil</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/62f13862-3b92-42cc-9dad-e958eef7c627">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002155</ddiem:url>
        <rdfs:label>Hypertriglyceridemia</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0002155</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/ca8a15d2-036b-48cd-a611-5d7fe2580d56">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/1def790f-b29e-4a10-952a-b5dbd1a33029"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16635485</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9a924c30-17c9-427d-af7a-206667b3e9b2">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003074</ddiem:url>
        <rdfs:label>Hyperglycemia</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0003074</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19820022</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/88046746-7e79-4066-99d3-eb94278a8dc8">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/1ab86914-762f-4adf-8de8-fa2c1f467e69"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17339125</dc:provenance>
    <obo:RO_0003304>W464X</obo:RO_0003304>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
  </obo:OGMS_0000112>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/611209">
    <obo:RO_0004020>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/950a656b-d083-4918-8273-3d13b1b0025b">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/9382</dc:identifier>
        <rdfs:label>COG1</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0004020>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/344</ddiem:iembaseUrl>
    <dc:identifier>https://www.omim.org/entry/611209</dc:identifier>
    <ddiem:iembaseAccessionNumber>344</ddiem:iembaseAccessionNumber>
    <rdfs:label>CONGENITAL DISORDER OF GLYCOSYLATION, TYPE IIg; CDG2G</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Disease>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/a41f02ca-e391-45c5-a2d7-9d147294c754">
    <ddiem:uniprotId>Q16836</ddiem:uniprotId>
    <ddiem:ecNumber>1.1.1.35</ddiem:ecNumber>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/aadf97ab-5b30-4cfc-9387-7a318324e045">
        <rdfs:label>HADH</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/3033</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>3-hydroxylacyl-CoA dehydrogenase</rdfs:label>
    <ddiem:keggEntryId>K00022</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/700ba358-03b3-45d7-b54d-2f4646618b76">
    <ddiem:keggEntryId>K00871</ddiem:keggEntryId>
    <rdfs:label>Phosphorylase b kinase gamma catalytic chain, liver/testis isoform</rdfs:label>
    <ddiem:uniprotId>P15735</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/46196255-026b-400b-a2c4-8153c0600c01">
        <rdfs:label>PHKG2</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/5261</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:ecNumber>2.7.11.19</ddiem:ecNumber>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/64837400-a762-4702-9ef2-e35e117242af">
    <ddiem:keggEntryId>K13511</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/8960ce3b-1097-4658-8972-74bd47229036">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/6901</dc:identifier>
        <rdfs:label>TAZ</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>tafazzin ( Protein)</rdfs:label>
    <ddiem:uniprotId>Q16635</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/e3492c4b-d45a-4d15-955a-19cd4419f6c9">
    <ddiem:uniprotId>Q96RQ3</ddiem:uniprotId>
    <rdfs:label>3 Methylcrotonyl-CoA carboxylase</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/66f7aed7-a93c-4abc-b849-2c406b46e19e">
        <rdfs:label>MCCC1</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/56922</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/362c0606-4acc-42f8-97cf-9bcf5bffe3c2">
        <rdfs:label>MCCC2</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/64087</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:ecNumber>6.4.1.4</ddiem:ecNumber>
    <ddiem:keggEntryId>K01969</ddiem:keggEntryId>
    <ddiem:uniprotId>Q9HCC0</ddiem:uniprotId>
    <ddiem:keggEntryId>K01968</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/3ba6cde9-6a50-4d0f-b4e6-d15066416c09">
    <ddiem:uniprotId>O60930</ddiem:uniprotId>
    <ddiem:ecNumber>3.1.26.4</ddiem:ecNumber>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/c347f37f-e0a5-41a4-966d-df592d11f89a">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/246243</dc:identifier>
        <rdfs:label>RNASEH1</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>Ribonuclease H1</rdfs:label>
    <ddiem:keggEntryId>K03469</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/2ddf5036-94bf-4a48-98a0-bec5b19684f8">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/596b8455-1508-4fed-88c0-a3df0e113c1f">
        <dc:identifier>HP:0002353</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002353</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Isoelectric electroencephalogram</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00028262</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/518b6d43-2c86-4354-bcc8-68383fdd91a7"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b7a7e5a7-ec2e-41fa-af0d-b275243f859c">
        <rdfs:label>granular osmiophilic deposits (GROD)</rdfs:label>
        <dc:identifier>HP:0003657</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003657</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>A combination therapy with cysteamine bitartrate and N-acetylcysteine is associated with delay of isoelectric EEG, depletion of GRODs, and subjective benefits as reported by parents and physicians. https://www.ncbi.nlm.nih.gov/pubmed/24997880</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/256730">
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/305</ddiem:iembaseUrl>
        <ddiem:iembaseAccessionNumber>305</ddiem:iembaseAccessionNumber>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/f4d9db52-0dbf-4469-8156-250211ad425d"/>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>https://www.omim.org/entry/256730</dc:identifier>
        <rdfs:label>CEROID LIPOFUSCINOSIS, NEURONAL, 1; CLN1</rdfs:label>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24997880</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d325e640-b4b9-43ba-9edb-03fd9cc11994">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0000737</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000737</ddiem:url>
        <rdfs:label>irritability</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e48d8ead-99b2-4845-9a9f-bf461b43a4b9">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0004372</ddiem:url>
        <dc:identifier>HP:0004372</dc:identifier>
        <rdfs:label>Defected alertness</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/e2a62d30-8f60-413b-973a-e2141188e8a3">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/f06a23d0-3e6b-481d-8cd7-6b83d7348965"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
  </obo:DDIEM_0000007>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/101c9d71-059f-429d-8445-45c86615476c">
    <rdfs:label>Hormone ( Arginine vasopressin)</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/77bed3eb-ece9-4901-b472-739df6f69bef">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/551</dc:identifier>
        <rdfs:label>AVP</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K05242</ddiem:keggEntryId>
    <ddiem:uniprotId>P01185</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/2499758b-70c3-495e-b726-eebf6613f293">
    <ddiem:uniprotId>P07949</ddiem:uniprotId>
    <ddiem:ecNumber>2.7.10.1</ddiem:ecNumber>
    <rdfs:label>Proto-oncogene tyrosine-protein kinase receptor Ret</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/aa7aed1a-14de-4754-990e-819eb135c235">
        <rdfs:label>RET</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/5979</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K05126</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/2795dd50-4b8c-4806-8f1c-b6d63611a810">
    <dc:provenance>https://globenewswire.com/news-release/2015/03/30/720127/10126746/en/Sigma-Tau-Pharmaceuticals-Inc-Receives-Orphan-Drug-Designation-for-EZN-2279-for-Treatment-of-Adenosine-deaminase-Deficient-Severe-Combined-Immunodeficiency-Disease.html</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/00f06e3b-62f8-4650-b1f5-5e3357d90537">
        <dc:identifier>HP:0001254</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>lethargy</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001254</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/bf7620c2-2110-46d3-a909-8d60319489c0">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012378</ddiem:url>
        <dc:identifier>HP:0012378</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>fatigue</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.sciencedirect.com/science/article/abs/pii/S1386634602003315</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648/#b96-tacg-8-201</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d9054e8c-01a4-4bda-bd2b-78a630c0a2d0">
        <dc:identifier>HP:0001987</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>hyperammonemia</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001987</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e3c8a16d-75c0-49a5-85f8-d22384b8eacc">
        <rdfs:label>Elevated serum pancreatic secretory trypsin inhibitor</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ace8a112-4454-4540-b9d8-37016aef880a">
        <rdfs:label>Poor growth</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0001510</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001510</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18958581</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1e5fec12-ab61-4f5c-89c9-a486c180b74f">
        <rdfs:label>Elevated threonine-to-serine ratio ( Abnormality of amino acid metabolism)*</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0004337</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0004337*</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/8f6287e5-3030-453a-a94d-aa9da3cde6a7"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/books/NBK1181</dc:provenance>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <rdfs:comment>It is suggested that the administration of arginine and sodium pyruvate with low-carbohydrate meals may be an effective therapy in patients with citrin deficiency in order either to prolong metabolic normalcy or to provide a safer and more affordable alternative to liver transplantation. https://www.ncbi.nlm.nih.gov/pubmed/18958581/ https://www.ncbi.nlm.nih.gov/books/NBK1181/</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2733ae33-bd39-4535-bcc5-f77194861507">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002039</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>anorexia</rdfs:label>
        <dc:identifier>HP:0002039</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/eed299ff-ef27-4499-9310-422a01a76278">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/9cba78c5-ea99-4b35-8c70-0123a831e309"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15670720</dc:provenance>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/603471">
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/fda8a6f0-6139-4142-89e5-0ee15677ab49"/>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/18</ddiem:iembaseUrl>
        <dc:identifier>https://www.omim.org/entry/603471</dc:identifier>
        <ddiem:iembaseAccessionNumber>18</ddiem:iembaseAccessionNumber>
        <rdfs:label>CITRULLINEMIA, TYPE II, ADULT-ONSET; CTLN2</rdfs:label>
        <rdfs:comment>Liver transplantation is the only radical treatment for CTLN2 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5783980/</rdfs:comment>
      </ddiem:Disease>
    </obo:RO_0002599>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/edb94e07-1417-44d5-9702-3750aaf0d6ab">
        <rdfs:label>Elevated plasma citrulline level</rdfs:label>
        <dc:identifier>HP:0011966</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0011966</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </obo:OGMS_0000112>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/f3a5bb11-db5e-4b32-bae2-c7746778866d">
    <ddiem:keggEntryId>K00297</ddiem:keggEntryId>
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/22b1a9c8-e093-48b4-9085-2521e92bd0c6"/>
    <rdfs:label>methylenetetrahydrofolate reductase</rdfs:label>
    <ddiem:ecNumber>1.5.1.20</ddiem:ecNumber>
    <ddiem:uniprotId>P42898</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/a462a716-48d4-4119-a579-ad60269e3f67">
    <rdfs:label>2-oxoisovalerate dehydrogenase subunit beta, mitochondrial</rdfs:label>
    <ddiem:keggEntryId>K00167</ddiem:keggEntryId>
    <ddiem:ecNumber>1.2.4.4</ddiem:ecNumber>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/d164a31a-4a5e-4442-bbbf-66c2b58adf2e">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/594</dc:identifier>
        <rdfs:label>BCKDHB</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>P21953</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/e9ebd035-e814-4e18-843e-ee2db519f423">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27551684</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24639006</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19627167</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23887143</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00125190</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/eb5152ff-7294-4a87-a512-7b1cec024750"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/aec43db9-f442-4101-818f-081f49d11b59">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/eff6781c-a268-4cf8-b68b-b98073449da3"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/271245">
        <rdfs:comment>Conventional antiepileptic drugs (phenytoin and phenobarbital) are ineffective in most affected individuals.</rdfs:comment>
        <ddiem:iembaseAccessionNumber>944</ddiem:iembaseAccessionNumber>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/944</ddiem:iembaseUrl>
        <dc:identifier>https://www.omim.org/entry/271245</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/8d52e39b-1eef-42a7-ac2d-bbf9181101e1"/>
        <rdfs:label>MITOCHONDRIAL DNA DEPLETION SYNDROME 7 (HEPATOCEREBRAL TYPE); MTDPS7</rdfs:label>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17192294</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10549306</dc:provenance>
    <rdfs:comment>Valporate has been used in two patients, but it had to be discontinued because of a severe elevation of liver enzymes. since then it hasn't been used in IOSCA. VAlporic acid Should be avoided in those patients.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19304794</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/35b5c64e-9aaa-46fd-84a3-e5d483d4e101">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001250</ddiem:url>
        <dc:identifier>HP:0001250</dc:identifier>
        <rdfs:label>Seizures</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </obo:DDIEM_0000013>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/608799">
    <dc:identifier>https://www.omim.org/entry/608799</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/336</ddiem:iembaseUrl>
    <ddiem:iembaseAccessionNumber>336</ddiem:iembaseAccessionNumber>
    <rdfs:label>CONGENITAL DISORDER OF GLYCOSYLATION, TYPE Ie; CDG1E</rdfs:label>
    <obo:RO_0004020>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/1e9d6e90-c1b4-43a8-b825-58ced970efef">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/8813</dc:identifier>
        <rdfs:label>DPM1</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0004020>
  </ddiem:Disease>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/38ad5c33-56dc-47e6-b69f-4d000e143141">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/a284a51e-e6d2-49f4-b5d9-385e2e78fe08">
        <rdfs:label>DDC</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/1644</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:ecNumber>4.1.1.28</ddiem:ecNumber>
    <ddiem:uniprotId>P20711</ddiem:uniprotId>
    <ddiem:keggEntryId>K01593</ddiem:keggEntryId>
    <rdfs:label>Aromatic-L-amino-acid decarboxylase</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/e82dc900-68fb-4dac-bdf2-cd7c9a27a198">
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/af72c454-8e59-41e7-ab5e-57c09a2f7a98"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12359132</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c7141ddf-a458-4241-a8de-dd8769056bf8">
        <rdfs:label>Growth abnormality</rdfs:label>
        <dc:identifier>HP:0001507</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001507</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16857760</dc:provenance>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/611283">
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/135</ddiem:iembaseUrl>
        <dc:identifier>https://www.omim.org/entry/611283</dc:identifier>
        <ddiem:iembaseAccessionNumber>135</ddiem:iembaseAccessionNumber>
        <rdfs:comment>It is as yet uncertain whether IBD deficiency may cause significant morbidity in affected children and whether treatment is necessary. In view of the limited experience worldwide, careful monitoring of the children is recommended. https://www.ncbi.nlm.nih.gov/pubmed/15505379</rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/dcce1a88-50a5-4ddf-8b98-22f7a2197d38"/>
        <rdfs:label>ISOBUTYRYL-CoA DEHYDROGENASE DEFICIENCY; IBDD</rdfs:label>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19210957</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000009"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9889013</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/6b36ca46-5e87-4637-b6e9-73189ff35f01"/>
    <rdfs:comment>1-Combined therapy with carnitine and glycine has been shown to maximize the total excretion of isovaleryl-CoA conjugates, but the clinical benefit of combined versus single therapy has not been established through controlled studies. 2- The relative merits of the two therapies either singly or together in patients with more severe presentations including recurrent crises remains a matter of debate. (https://www.ncbi.nlm.nih.gov/pubmed/16602101) 3- Combined glycine and L-carnitine therapy maximally increases isovaleryl conjugate excretion during metabolic stress but not under stable conditions. https://www.ncbi.nlm.nih.gov/pubmed/8804338</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
  </obo:OGMS_0000112>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/6b903cb1-54d4-4715-adbe-25335c567852">
    <ddiem:uniprotId>P00439</ddiem:uniprotId>
    <ddiem:ecNumber>1.14.16.1</ddiem:ecNumber>
    <ddiem:keggEntryId>K00500</ddiem:keggEntryId>
    <rdfs:label>PHENYLALANINE HYDROXYLASE</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/2f98de2b-f73b-4124-a601-61feaf959faa">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/5053</dc:identifier>
        <rdfs:label>PAH</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/7dac2ad5-4736-4554-abf3-ccd8c5bf6db3">
    <rdfs:label>myosin heavy chain 2</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/ceec3cbd-af43-4741-afa3-9943eea76d54">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/4620</dc:identifier>
        <rdfs:label>MYH2</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>Q9UKX2</ddiem:uniprotId>
    <ddiem:keggEntryId>K10352</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <owl:Class rdf:about="http://purl.obolibrary.org/obo/procedure_to_mitigate_dominant_effects_of_a_genetically_abnormal_protein">
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000005"/>
    <dc:creator>ORCID: 0000-0002-5111-7263</dc:creator>
    <dc:date>4.10.19</dc:date>
    <obo:IAO_0000115>a procedure to suppress or mitigate the effects of a dominant alteration in a genetically abnormal protein by reducing or suppressing  transcription or translation of the abnormal protein gene or rna, or destabilising or otherwise inhibiting an abnormally increased activity or neoactivity of the abnormal protein.</obo:IAO_0000115>
  </owl:Class>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/b6177465-7a2c-4b29-b105-bfae33a3ef35">
    <rdfs:label>ATM serine/threonine kinase</rdfs:label>
    <ddiem:keggEntryId>K04728</ddiem:keggEntryId>
    <ddiem:ecNumber>2.7.11.1</ddiem:ecNumber>
    <ddiem:uniprotId>Q13315</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/af47ee2e-7c80-4e06-b935-70f3f7d5fefe">
        <rdfs:label>ATM</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/472</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/e08bd9b2-5754-454c-a5f5-ad8ada5c0d86">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19821145</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/e26f58c5-3e77-453b-8c30-5df2c9c700e9"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18848477</dc:provenance>
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/277400"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/cd539122-ae66-4ad2-8241-d43b66dbe01f"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3950820</dc:provenance>
    <dc:provenance>https://link.springer.com/article/10.1023/A:1005353530303</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25511120</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/bb44cafe-7430-411a-abdd-750c3e1e2f55"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/b3b91803-46c6-4398-8030-a8feea3ea9bc"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/6b36ca46-5e87-4637-b6e9-73189ff35f01"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/49851e7a-d8cc-4d78-9ba2-0564cc67e1c3"/>
    <rdfs:comment>Selection of this drug combinstion ""Methylprednisolone sodium succinate +
Immune Globulin "" was based on the presumption that the patient had autoimmune encephalopathy. https://www.ncbi.nlm.nih.gov/pubmed/25511120</rdfs:comment>
  </obo:DDIEM_0000007>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/54a5554f-f0f1-46cc-b4a0-5b30c60398fb">
    <ddiem:uniprotId>P06280</ddiem:uniprotId>
    <ddiem:keggEntryId>K01189</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/f16de7ba-e2b9-4e3d-9c02-29ee34593daf">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/2717</dc:identifier>
        <rdfs:label>GLA</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>alpha-galactosidase A</rdfs:label>
    <ddiem:ecNumber>3.2.1.22</ddiem:ecNumber>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/33ec1a01-2010-4c77-8e2c-a7d3be64c63d">
    <ddiem:keggEntryId>""</ddiem:keggEntryId>
    <rdfs:label>Mitochondrially encoded tRNA lysine</rdfs:label>
    <ddiem:uniprotId>""</ddiem:uniprotId>
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/1abaf40f-2a9b-43e9-9c9c-053c92416972"/>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/20b2e996-c680-404d-a21a-3a073d3687d4">
    <ddiem:ecNumber>1.1.99.-</ddiem:ecNumber>
    <ddiem:uniprotId>Q8N465</ddiem:uniprotId>
    <ddiem:keggEntryId>K18204</ddiem:keggEntryId>
    <rdfs:label>D-2-hydroxyglutarate dehydrogenase</rdfs:label>
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/0cd436db-1bbe-4a1c-8f5c-b9853cde12e9"/>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/4ac4c659-c003-4f0b-8d76-cdfb28cfdf6f">
    <rdfs:label>lamins ( Lamins A and C)</rdfs:label>
    <ddiem:uniprotId>P02545</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/c28ba02c-c555-42e6-819b-3c4cb45b5d63">
        <rdfs:label>LMNA</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/4000</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K12641</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/cedcda61-ed26-4426-a2ae-7b031702a3b3">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/39532e9e-392f-414d-bff4-c38a61df5f4c">
        <rdfs:label>TFR2</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/7036</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>transferrin receptor 2</rdfs:label>
    <ddiem:keggEntryId>""</ddiem:keggEntryId>
    <ddiem:uniprotId>Q9UP52</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/252500">
    <ddiem:iembaseAccessionNumber>299</ddiem:iembaseAccessionNumber>
    <rdfs:label>MUCOLIPIDOSIS II ALPHA/BETA</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/299</ddiem:iembaseUrl>
    <dc:identifier>https://www.omim.org/entry/252500</dc:identifier>
    <obo:RO_0004020>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/c5a0e25a-5679-4e79-8aed-1bdc340f27fa">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/79158</dc:identifier>
        <rdfs:label>GNPTAB</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0004020>
  </ddiem:Disease>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/ad0568cd-55dd-4521-88db-441edf08bd91">
    <rdfs:comment>Alhough therapy with desmopressin cannot be recommended based on the results of a single case, the outcome presented here is intriguing and suggests that larger studies in such patients is warranted to assess the broader application of such an intervention.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12084887</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/c51058f7-1e07-472e-a6a6-adeb625d7b5f"/>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/274270">
        <rdfs:comment></rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/b6508f66-baec-44da-81e9-7cc3aaed210d"/>
        <ddiem:iembaseAccessionNumber>159</ddiem:iembaseAccessionNumber>
        <dc:identifier>https://www.omim.org/entry/274270</dc:identifier>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/159</ddiem:iembaseUrl>
        <rdfs:label>DIHYDROPYRIMIDINE DEHYDROGENASE DEFICIENCY</rdfs:label>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27622829</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30349988</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8163996</dc:provenance>
    <dc:provenance>https://link.springer.com/chapter/10.1007%2F8904_2017_14</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/387b9aa2-9a28-479d-a7f0-8ecfc6876a9c"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16891685</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/f5919ed0-0d88-482f-843b-0e629ced7671"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1899474</dc:provenance>
  </obo:DDIEM_0000013>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/04c88a5f-126c-4da4-b014-bade0b35c0ea">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/48e154c6-3ba5-4b41-9816-f430c69c2ded">
        <rdfs:label>GNMT</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/27232</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>Q14749</ddiem:uniprotId>
    <rdfs:label>glycine N-methyltransferase</rdfs:label>
    <ddiem:ecNumber>2.1.1.20</ddiem:ecNumber>
    <ddiem:keggEntryId>K00552</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/5592f759-8625-402d-9bf6-2fe3732aa55d">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19627167</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17192294</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10549306</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/dfe270f3-f4a5-4625-96bd-bcd64cba6494">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/2ae41b35-b0a5-4b25-a059-52aacf3a4649"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/77066bf1-0b44-448f-a183-61007143ccdc"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27884013</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23887143</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00125190</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24639006</dc:provenance>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/608747">
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/d85cc40f-4f57-4c0c-a7f0-1581acf993bc"/>
        <dc:identifier>https://www.omim.org/entry/608747</dc:identifier>
        <rdfs:label>INSULIN-LIKE GROWTH FACTOR I DEFICIENCY</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Disease>
    </obo:RO_0002599>
    <rdfs:comment>The study is terminated (The study was prematurely terminated due to strategic reasons.)</rdfs:comment>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/study/NCT00572156</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/c3951163-c8e6-466e-8940-5830b567e782">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/87b12b7e-1be7-4fc8-a3d0-ffcb66cefb17"/>
      </rdf:Alt>
    </obo:RO_0000057>
  </obo:OGMS_0000112>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/cffa72cc-e166-4f75-a2cc-c23becd14b64">
    <rdfs:label>component of oligomeric golgi complex 1</rdfs:label>
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/950a656b-d083-4918-8273-3d13b1b0025b"/>
    <ddiem:uniprotId>Q8WTW3</ddiem:uniprotId>
    <ddiem:keggEntryId>K20288</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/f287c913-bd43-4638-8bd6-681747c15116">
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/c3af4cca-0eea-44d8-9c18-121be136d146">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/b6605cf9-8268-46f8-a530-f10bfb4e0d02"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0c9fedf9-ad5d-4c29-bfa1-283b584ff7a0">
        <dc:identifier>HP:0002155</dc:identifier>
        <rdfs:label>hypertriglycernemia</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002155</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00214604</dc:provenance>
    <rdfs:comment>Hubacek et al. 2009 's results suggest that the APOA5 gene variants may play an important role in the pharmacogenetics of statin treatment. https://www.ncbi.nlm.nih.gov/pubmed/19530961/. https://www.ncbi.nlm.nih.gov/pubmed/25900265</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2681858</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/4883477</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29695967</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/bb4f2778-cea9-4a4e-8305-854afc7a5ed5">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/97024237-35c1-4a27-88e6-df46878e676d"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/617347"/>
  </obo:DDIEM_0000013>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/179850">
    <rdfs:label>DOWLING-DEGOS DISEASE 1; DDD1</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>https://www.omim.org/entry/179850</dc:identifier>
    <obo:RO_0004020>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/48ec71b8-fb43-41cb-9a18-693c835f537c">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/56983</dc:identifier>
        <rdfs:label>POGLUT1</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0004020>
  </ddiem:Disease>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/b91d5f50-dbb7-4c25-bc52-d9c9d287b1a4">
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/c06450ee-9a24-4ac2-9aba-5af25939894c"/>
    <rdfs:label>Chloride channel protein ClC-Kb</rdfs:label>
    <ddiem:uniprotId>P51801</ddiem:uniprotId>
    <ddiem:keggEntryId>K05018</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/98c2185e-549c-4309-baa1-12c28f5aabfb">
    <rdfs:label>Excitatory amino acid transporter 3</rdfs:label>
    <ddiem:keggEntryId>K05612</ddiem:keggEntryId>
    <ddiem:uniprotId>P43005</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/51559286-c526-42f0-acf3-97a27d62ed75">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/6505</dc:identifier>
        <rdfs:label>SLC1A1</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/b5975931-75a0-48a3-9ff2-0a7de0eb466e">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15252120</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/a56e1e0d-b228-48b9-a576-b71d3749a598">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/3a81bbdb-ea68-4572-9710-d157c94811f8"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16635485</dc:provenance>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/608896">
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/e446e2b0-18fc-4e9f-89c0-a14c3e96d1bb"/>
        <dc:identifier>https://www.omim.org/entry/608896</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>SARCOGLYCAN, GAMMA; SGCG</rdfs:label>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17339125</dc:provenance>
    <rdfs:comment>Corticosteriods might be beneficial in heterozygous mutations as patients have milder phenotypes.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
  </obo:OGMS_0000112>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/36ec316f-885c-43cb-8c5c-2e8f936c328e">
    <rdfs:label>dihydropyrimidine dehydrogenase</rdfs:label>
    <ddiem:keggEntryId>K00207</ddiem:keggEntryId>
    <ddiem:ecNumber>1.3.1.2</ddiem:ecNumber>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/b6508f66-baec-44da-81e9-7cc3aaed210d">
        <rdfs:label>DPYD</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/1806</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>Q12882</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/248510">
    <rdfs:label>MANNOSIDOSIS, BETA A, LYSOSOMAL; MANSB</rdfs:label>
    <ddiem:iembaseAccessionNumber>261</ddiem:iembaseAccessionNumber>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/261</ddiem:iembaseUrl>
    <rdfs:comment></rdfs:comment>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/321831eb-3a94-4deb-abe6-c3ff381d746d"/>
    <dc:identifier>https://www.omim.org/entry/248510</dc:identifier>
  </ddiem:Disease>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/f0515fc1-8521-4d3e-b357-9a32a0244a5f">
    <ddiem:ecNumber>1.1.1.n12; 4.2.1.107; 4.2.1.119</ddiem:ecNumber>
    <rdfs:label>17Î²-hydroxysteroid dehydrogenase type 4</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/ca08250a-79e0-468b-9112-87d58949fc5f">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/3295</dc:identifier>
        <rdfs:label>HSD17B4</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K12405</ddiem:keggEntryId>
    <ddiem:uniprotId>P51659</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/b9aada6a-d468-4f23-b289-d4f558c0ba7c">
    <ddiem:keggEntryId>K09658</ddiem:keggEntryId>
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/af416c45-b362-445e-80cb-0f249f0d1cb8"/>
    <ddiem:uniprotId>O94777</ddiem:uniprotId>
    <rdfs:label>dolichyl-phosphate mannosyltransferase subunit 2</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/b6e3392d-5c43-4c3c-b65a-c7c9f1cf9a0b">
    <ddiem:keggEntryId>K00728</ddiem:keggEntryId>
    <ddiem:uniprotId>Q9UKY4</ddiem:uniprotId>
    <rdfs:label>Protein O-mannosyl-transferase 2</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/1400970c-a38a-4c1c-951e-d5086e2a6070">
        <rdfs:label>POMT2</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/29954</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:ecNumber>2.4.1.109</ddiem:ecNumber>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/d259d31d-dc0b-4bad-b721-a75ac8474e20">
    <ddiem:uniprotId>Q99714</ddiem:uniprotId>
    <ddiem:ecNumber>1.1.1.35; 1.1.1.51; 1.1.1.178</ddiem:ecNumber>
    <rdfs:label>3-hydroxyacyl-CoA dehydrogenase type II</rdfs:label>
    <ddiem:keggEntryId>K08683</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/8cd9f4af-7ac2-41df-a51c-b70c957d891e">
        <rdfs:label>HSD17B10</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/3028</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/7cdbe191-bac7-4bf3-bea7-ed71b1855174">
    <rdfs:label>Choline/ethanolamine kinase</rdfs:label>
    <ddiem:ecNumber>2.7.1.32; 2.7.1.82</ddiem:ecNumber>
    <ddiem:keggEntryId>K14156</ddiem:keggEntryId>
    <ddiem:uniprotId>Q9Y259</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/02084928-3207-4d92-9248-979b3f858044">
        <rdfs:label>CHKB</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/1120</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/9a7d4b1f-f7b2-4370-a9a1-3e963a99dbc9">
    <rdfs:label>Limit dextrin alpha-1,6-maltotetraose-hydrolase</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/1751e99b-0bfa-4e68-b463-600ff5b70dfc">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/2632</dc:identifier>
        <rdfs:label>GBE1</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K00700</ddiem:keggEntryId>
    <ddiem:ecNumber>2.4.1.18</ddiem:ecNumber>
    <ddiem:uniprotId>Q04446</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/b8663980-6591-4929-bfcc-d42d498d8e37">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/72591caf-750c-474b-a625-5f5936f83163">
        <rdfs:label>AKR1D1</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/6718</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>DELTA(4)-3-OXOSTEROID 5-BETA-REDUCTASE</rdfs:label>
    <ddiem:ecNumber>1.3.1.3</ddiem:ecNumber>
    <ddiem:keggEntryId>K00251</ddiem:keggEntryId>
    <ddiem:uniprotId>P51857</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/444b29ea-339c-432a-ac5d-3a68a3f0efbd">
    <ddiem:uniprotId>Q9UNF1</ddiem:uniprotId>
    <rdfs:label>Melanoma-associated antigen D2</rdfs:label>
    <ddiem:keggEntryId>""</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/fd7a8cac-8831-4599-9ac9-ebd1d434f4cb">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/10916</dc:identifier>
        <rdfs:label>MAGED2</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/291a97e9-9a7c-460c-804a-226952c6c34b">
    <ddiem:uniprotId>P04180</ddiem:uniprotId>
    <rdfs:label>lecithin-cholesterol acyltransferase</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/e38a459a-439a-4b5d-99a1-affdaa58dc23">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/3931</dc:identifier>
        <rdfs:label>LCAT</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K00650</ddiem:keggEntryId>
    <ddiem:ecNumber>2.3.1.43</ddiem:ecNumber>
  </ddiem:ProtienOrEnzyme>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/611722">
    <dc:identifier>https://www.omim.org/entry/611722</dc:identifier>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/292</ddiem:iembaseUrl>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>KRABBE DISEASE, ATYPICAL, DUE TO SAPOSIN A DEFICIENCY</rdfs:label>
    <ddiem:iembaseAccessionNumber>292</ddiem:iembaseAccessionNumber>
    <obo:RO_0004020>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/567920d4-ffcc-445c-a1e0-a9a577b4cfff">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/5660</dc:identifier>
        <rdfs:label>PSAP</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0004020>
  </ddiem:Disease>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/56340380-6e32-4504-895b-6ba0267c93ac">
    <ddiem:keggEntryId>K14425</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/53e6335a-cde6-41ed-9eea-f6e4d879629d">
        <rdfs:label>SLC12A1</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/6557</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>Solute carrier family 12 member 1</rdfs:label>
    <ddiem:uniprotId>Q13621</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/2e97a146-7ff2-4a77-9c30-e54e7a6f477d">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/5d82a9bc-e70b-46d2-ada3-813714e1d179">
        <rdfs:label>DNAJC19</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/131118</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>DnaJ heat shock protein family (Hsp40) member C19</rdfs:label>
    <ddiem:keggEntryId>K09539</ddiem:keggEntryId>
    <ddiem:uniprotId>Q96DA6</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/83da6bde-8575-4b7b-a9d7-e5a75a6e5ebb">
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01212744</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21310276</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/de2f9565-d217-424d-b54d-5a9be0514a37"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/613839"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9c601284-c530-4f64-92b1-8737d01c12cc">
        <rdfs:label>seizure</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001250</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0001250</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26095523</dc:provenance>
    <rdfs:comment>The drug was administered through intravitreal injection.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21310277</dc:provenance>
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/92af90b3-792a-4779-90d5-b71bb9153912">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/188ed29a-5505-459b-b5c7-d61c7a45907e"/>
      </rdf:Alt>
    </obo:RO_0000057>
  </obo:DDIEM_0000013>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/9dc16824-7bb0-4652-b541-98f7ef297f5a">
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/246900">
        <rdfs:label>DIHYDROLIPOAMIDE DEHYDROGENASE DEFICIENCY; DLDD</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/bb5e4251-1843-4446-8a93-d2ecfeccb1bd"/>
        <dc:identifier>https://www.omim.org/entry/246900</dc:identifier>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10448086</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/af72c454-8e59-41e7-ab5e-57c09a2f7a98"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25251739</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/4556601b-4e58-4413-90b1-df627cd415d1"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/76e590fa-f89d-4d64-a7a3-c08485b7023c"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0e8aba64-4078-4fe9-99fe-77566657e5b3">
        <rdfs:label>Repeated vomiting</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002572</ddiem:url>
        <dc:identifier>HP:0002572</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14765544</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1567724914001299</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000012"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/78a9efb5-49a5-4f22-9e54-10549dd3f132">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/9c87e3e5-79be-4b55-83ca-7575cf7ebd05"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:comment>Beneficial effects were initially observed on parkinsonian symptoms. However, dyskinesia and dystonic features re-emerged after three months of treatment.</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/16dd5fc3-69e1-4307-869e-5852b1c5b325">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0003128</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003128</ddiem:url>
        <rdfs:label>Lactic acidosis</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/66aa6980-9d73-4eee-8a52-f80a6ead8bf9"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b95433aa-1311-4974-984b-f38e1d0522c0">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001298</ddiem:url>
        <rdfs:label>Encephalopathy</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0001298</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10970889</dc:provenance>
  </obo:OGMS_0000112>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/f47da191-1d16-4d9b-981e-d8172f31ee86">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/e18298ff-791e-4ef2-adf3-f561615d2cda">
        <rdfs:label>DBH</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/1621</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:ecNumber>1.14.17.1</ddiem:ecNumber>
    <ddiem:uniprotId>P09172</ddiem:uniprotId>
    <rdfs:label>dopamine beta (Î²)-hydroxylase</rdfs:label>
    <ddiem:keggEntryId>K00503</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/621e7309-786c-44ac-979e-87e53aca8160">
    <ddiem:keggEntryId>K00759</ddiem:keggEntryId>
    <ddiem:ecNumber>2.4.2.7</ddiem:ecNumber>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/12e29895-78f0-4367-a22d-a8bf930e2d2c">
        <rdfs:label>APRT</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/353</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>P07741</ddiem:uniprotId>
    <rdfs:label>Adenine phosphoribosyltransferase</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <obo:DDIEM_0000015 rdf:about="http://ddiem.phenomebrowser.net/46c57ac9-71ea-42d9-9182-e36f17585973">
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/308050">
        <rdfs:label>CONGENITAL HEMIDYSPLASIA WITH ICHTHYOSIFORM ERYTHRODERMA AND LIMB DEFECTS</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/194</ddiem:iembaseUrl>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/c068ffc7-956c-4ff4-8e4f-0068e48c9a03"/>
        <ddiem:iembaseAccessionNumber>194</ddiem:iembaseAccessionNumber>
        <dc:identifier>https://www.omim.org/entry/308050</dc:identifier>
      </ddiem:Disease>
    </obo:RO_0002599>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9f061cd7-3eff-42ce-881a-ff04942486fe">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0031517</ddiem:url>
        <rdfs:label>Verruciform plaques(verruciform xanthomas)*</rdfs:label>
        <dc:identifier>HP:0031517*</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29341259</dc:provenance>
    <dc:provenance>an enzyme-replacement therapy</dc:provenance>
    <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
    <rdfs:comment>Drug name: Treatment is under trial.</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1b060e29-c7f6-4524-980a-03d5fc9a7934">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000989</ddiem:url>
        <rdfs:label>Itchy skin</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0000989</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
    <dc:provenance>"ENB-0040</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5909487</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ee9b5128-d837-4f67-9f4e-8401a7835863">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0040189</ddiem:url>
        <rdfs:label>Scaling Skin</rdfs:label>
        <dc:identifier>HP:0040189</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>NCT00744042.)."</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/60fbafaf-1798-4701-88f4-a61537760c31">
        <rdfs:label>VXâlike lesions</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4c461888-fa8a-4c1b-b67d-482882a9de49">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0010783</dc:identifier>
        <rdfs:label>Erythema</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0010783</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5096504</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ce4c08ea-98ad-4c46-83c6-2a5cdbb39661">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0007431</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0007431</dc:identifier>
        <rdfs:label>Ichthyosiform erythroderma</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.researchgate.net/publication/8668575_A_successful_treatment_with_pyridoxal_phosphate_for_West_syndrome_in_hypophosphatasia</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/572fa1a7-378b-43af-af3b-8be975ce6911"/>
    <dc:provenance>was associated with improved findings on skeletal radiographs and improved pulmonary and physical function in infants and young children with life-threatening hypophosphatasia. (Funded by Enobia Pharma and Shriners Hospitals for Children; ClinicalTrials.gov number</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/feee8175-af10-4f42-a7ed-b23be088eb74"/>
  </obo:DDIEM_0000015>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/b5e4bf16-5fe1-4361-8753-7eef16e7c9ac">
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/db6d42d0-bc1e-458c-9a99-e1e2fe9a00d1"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/51d5c67e-91a3-4b97-8d43-220f40f40ed9"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30731125</dc:provenance>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/7e7c2b0f-fdf8-40f3-8f0c-914fcaf5d2a7">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/27308b12-4ba4-492a-a2f3-14cbbcf77a0f"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://ojrd.biomedcentral.com/articles/10.1186/1750-1172-3-20</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e2c08728-5cea-40a5-afe7-bb1ac7b469d3">
        <rdfs:label>Disease progression (Progressive)</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003676</ddiem:url>
        <dc:identifier>HP:0003676</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/200100">
        <dc:identifier>https://www.omim.org/entry/200100</dc:identifier>
        <ddiem:iembaseAccessionNumber>371</ddiem:iembaseAccessionNumber>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/371</ddiem:iembaseUrl>
        <rdfs:label>ABETALIPOPROTEINEMIA; ABL</rdfs:label>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/a16e79a8-5779-485e-b951-c08b7885c06c"/>
        <rdfs:comment>The mainstays of treatment include adherence to a low-fat diet, and supplementation with essential fatty acids and high oral doses of fat soluble vitamins. https://www.ncbi.nlm.nih.gov/pubmed/24288038</rdfs:comment>
      </ddiem:Disease>
    </obo:RO_0002599>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/53d81324-bc69-4ec5-bd3c-186d552927d4"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/c148d200-9479-4b6a-a50f-1e30c7044a3f"/>
    <rdfs:comment>Mixed therapy can markedly attenuate the severe retinal degeneration that is associated with untreated ABL or homozygous HBL. Yet, fundoscopic and functional retinal changes do occur despite early initiation of vitamin treatment. Therefore, the adequacy of the present treatment protocol for ABL and homozygous HBL should be re-evaluated.https://www.ncbi.nlm.nih.gov/pubmed/11767031</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24288038</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25488886</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/887793b3-eacf-454d-9d75-36868d219b9e"/>
  </obo:OGMS_0000112>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/7085c15f-dd35-4e46-b1f9-0d76fcf917db">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b2607cc3-985f-49f8-bef5-b2879a4bb5f2">
        <rdfs:label>Abnormal lymphocyte counts</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0040088</ddiem:url>
        <dc:identifier>HP:0040088</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/a298fcb2-6e04-4335-bdff-d0b444f22cf1"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/36c1fa40-979f-4e77-9931-51df096fd815"/>
    <dc:provenance>https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17586848</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8bd4c7f3-0a11-4f54-8cff-45ace2a76ed5">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Abnormal serum fast ORAC(oxygen reduced absorbance capacity)</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>There is a common note in different reserachs refers to the importance of early managment by Vitamin E supplements since it limits disease progression and it can reverse some of the clinical manifestation (e.x ataxia and the intellectual deficit), if it was interoduced early in life. Therefore, early diagnosis is paramount.</rdfs:comment>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/208900">
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/af47ee2e-7c80-4e06-b935-70f3f7d5fefe"/>
        <rdfs:label>ATAXIA-TELANGIECTASIA; AT</rdfs:label>
        <dc:identifier>https://www.omim.org/entry/208900</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15300460</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27906067</dc:provenance>
  </obo:OGMS_0000112>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/d7321089-d0ae-4d1d-9bf6-30a34b87c38a">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/67ecd1db-f85d-46db-9f9b-c33faf782774">
        <rdfs:label>GLUD1</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/2746</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>Glutamate dehydrogenase, mitochondrial</rdfs:label>
    <ddiem:ecNumber>1.4.1.3</ddiem:ecNumber>
    <ddiem:uniprotId>P00367</ddiem:uniprotId>
    <ddiem:keggEntryId>K00261</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/272200">
    <obo:RO_0004020>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/4c632da2-7632-4ef3-9377-ecc1a22ccbcc">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/285362</dc:identifier>
        <rdfs:label>SUMF1</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0004020>
    <rdfs:label>MULTIPLE SULFATASE DEFICIENCY; MSD</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <ddiem:iembaseAccessionNumber>301</ddiem:iembaseAccessionNumber>
    <dc:identifier>https://www.omim.org/entry/272200</dc:identifier>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/301</ddiem:iembaseUrl>
  </ddiem:Disease>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/10557546-18b8-4fdf-b53a-9259abcbcda5">
    <rdfs:comment>The enteric carbohydrateâfree formula with or without fructose addition seems a very effective and safe measures for the rehydration. https://www.ncbi.nlm.nih.gov/pubmed/10404446. https://www.ncbi.nlm.nih.gov/pubmed/20486940</rdfs:comment>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/19d18d16-d582-4b93-ad73-0788911e9fa8"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/ff02436f-a8a1-4263-9a6d-1f6bd05b62b0">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/0b9f80c8-a9c9-4806-8c4e-50bd20525816"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/606824">
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/d4f0dd53-58be-406b-933e-c7a5496fe51e"/>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/482</ddiem:iembaseUrl>
        <rdfs:comment>Treatment rests with the avoidance of Glucse and galactose dietary sugars.https://www.ncbi.nlm.nih.gov/pubmed/28283348.  https://www.ncbi.nlm.nih.gov/pubmed/28753187</rdfs:comment>
        <rdfs:label>GLUCOSE/GALACTOSE MALABSORPTION; GGM</rdfs:label>
        <ddiem:iembaseAccessionNumber>482</ddiem:iembaseAccessionNumber>
        <dc:identifier>https://www.omim.org/entry/606824</dc:identifier>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10404446</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8ee79ef2-a7fc-43bf-a89b-c63e9a50b29a">
        <rdfs:label>Watery Diarrhea</rdfs:label>
        <dc:identifier>HP:0002014</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002014</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27775558</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/20a492b6-6ad2-498d-ae12-f8ade83a8b6d">
        <dc:identifier>HP:0001944</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001944</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Dehydration</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20486940</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4808885</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28283348</dc:provenance>
  </obo:DDIEM_0000013>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/8cc59fcf-85e5-4bff-957f-795480062388">
    <ddiem:keggEntryId>K12407</ddiem:keggEntryId>
    <rdfs:label>glucokinase-4</rdfs:label>
    <ddiem:uniprotId>P35557</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/0d032c9e-26e2-4931-af66-d117e8507669">
        <rdfs:label>GCK</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/2645</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:ecNumber>2.7.1.1</ddiem:ecNumber>
  </ddiem:ProtienOrEnzyme>
  <owl:Class rdf:about="http://purl.obolibrary.org/obo/activity_modification_of_a_genetically_defective_protein_by_transcriptional_or_translational_modification">
    <dc:date>3.10.19</dc:date>
    <dc:creator>ORCID: 0000-0002-5111-7263</dc:creator>
    <obo:IAO_0000115>modification of the amount or stability of a transcript or the efficiency of translation of a transcript in order to reduce or increase the expression of a  genetically abnormal protein.</obo:IAO_0000115>
    <rdfs:label>activity_modification_of_a_genetically_defective_protein_by_transcriptional_or_translational_modification</rdfs:label>
    <obo:IAO_0000115>any procedure designed to suppress or mitigate the effects of a recessive genetic change in an abnormal protein by modification of its transcription or translation, excluding those strategies which involve epigenetic modification or modification of the germline or somatic genome sequence. For example an abnormal Vmax of reaction, alteration of KM, failure to respond to positive  feedback, acquisition of neofunction.</obo:IAO_0000115>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000012"/>
  </owl:Class>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/79ed7264-7c5f-4d2b-9a8b-0b2b828f7783">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/ba6d4cfa-e461-433e-8cc7-dcca4e5a9d6a">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/2767</dc:identifier>
        <rdfs:label>GNA11</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K04635</ddiem:keggEntryId>
    <rdfs:label>guanine nucleotide-binding proteinÂ (GÎ±11)</rdfs:label>
    <ddiem:uniprotId>P29992</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/d31d4a9b-170e-4cfe-8826-75b1348c29e5">
    <rdfs:label>Succinyl-CoA synthetase ( beta subunit)</rdfs:label>
    <ddiem:uniprotId>Q9P2R7</ddiem:uniprotId>
    <ddiem:keggEntryId>K01900</ddiem:keggEntryId>
    <ddiem:ecNumber>6.2.1.5</ddiem:ecNumber>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/8c841bc4-5de7-4cee-8bd3-eee09b6c2f4a">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/8803</dc:identifier>
        <rdfs:label>SUCLA2</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/52832d77-ef92-4d72-90a3-f4998eb4b385">
    <rdfs:label>GM3 synthase/sialyltransferase-9/Lactosylceramide alpha-2,3-sialyltransferase</rdfs:label>
    <ddiem:ecNumber>2.4.99.9</ddiem:ecNumber>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/6b1ae373-d4e3-4450-9357-069d6e480960">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/8869</dc:identifier>
        <rdfs:label>ST3GAL5</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K03370</ddiem:keggEntryId>
    <ddiem:uniprotId>Q9UNP4</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/dfb838dc-2121-4594-9b7b-b22a2c8208ba">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10453735</dc:provenance>
    <rdfs:comment>Based on their study auhors of"  https://www.ncbi.nlm.nih.gov/pubmed/21354122?dopt=Abstract"  presume that the combination of these drugs may contribute to reduce LDL-C/HDL-C ratio effectively as well as lowering concentrations of serum triglyceride.</rdfs:comment>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/aa52b47a-f9db-4ce7-bb91-26794191e368">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/7156bc29-7673-4120-891d-bea6b8c71ca4"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/eb345fb0-e9f4-4420-9c6d-508b9ea1af0b">
        <rdfs:label>hypoglycemia</rdfs:label>
        <dc:identifier>HP:0001943</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001943</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/54cbae5f-8420-4c77-8464-a68be6276b97">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/9a063cb9-8d23-4cf4-9630-4f9b5ffce7ae"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/606762">
        <ddiem:iembaseAccessionNumber>567</ddiem:iembaseAccessionNumber>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/67ecd1db-f85d-46db-9f9b-c33faf782774"/>
        <dc:identifier>https://www.omim.org/entry/606762</dc:identifier>
        <rdfs:comment>Treatments for hyperammonemia such as dietary protein limitation, arginine, benzoate, carbamoyl synthase activators (carglumic acid), and N-carbamoylglutamate have not been effective in reducing ammonia levels. https://www.ncbi.nlm.nih.gov/pubmed/15050973/</rdfs:comment>
        <rdfs:label>HYPERINSULINEMIC HYPOGLYCEMIA, FAMILIAL, 6; HHF6</rdfs:label>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/567</ddiem:iembaseUrl>
      </ddiem:Disease>
    </obo:RO_0002599>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/65084b83-5349-48d3-b185-b9c2720ab857"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26962538</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25781533</dc:provenance>
  </obo:OGMS_0000112>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/2a3fd1e7-011d-44f3-83c8-0cd1e7c555ba">
    <ddiem:keggEntryId>K03857</ddiem:keggEntryId>
    <ddiem:uniprotId>P37287</ddiem:uniprotId>
    <ddiem:ecNumber>2.4.1.198</ddiem:ecNumber>
    <rdfs:label>Phosphatidylinositol N-acetylglucosaminyltransferase subunit A</rdfs:label>
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/1c8bfdd9-d1ef-4ec3-a89b-0d62b5f15fe4"/>
  </ddiem:ProtienOrEnzyme>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/134c4b70-7e3a-49cc-bd92-db4c95975b73">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/dea92466-3863-472e-96ba-6ad150838f52">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001257</ddiem:url>
        <rdfs:label>Spasticity</rdfs:label>
        <dc:identifier>HP:0001257</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/49851e7a-d8cc-4d78-9ba2-0564cc67e1c3"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/55a88e63-a598-4d98-9275-737fc4cd09dc">
        <dc:identifier>HP:0012211</dc:identifier>
        <rdfs:label>Impaired renal function</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012211</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>Treatment with hydroxycobalamin is effective in many patients when started early, it has minimal side effects, and it is available at negligible costs (US $1/day). https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5368212/ 
Treatment with OHCbl and betaine should be initiated as soon as there is a suspicion for cblC disease, without waiting for confirmatory testing and after determining baseline plasma metabolites and vitamin B12 levels</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/95511ff3-5c25-4e5e-9f11-cdf3f894fd20">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0031258</ddiem:url>
        <rdfs:label>Delirium</rdfs:label>
        <dc:identifier>HP:0031258</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://link.springer.com/article/10.1023/A:1005353530303</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/cd539122-ae66-4ad2-8241-d43b66dbe01f"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/e26f58c5-3e77-453b-8c30-5df2c9c700e9"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5368212</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/fdbac7f3-30d9-4465-bb75-a70a6e4e2eb1">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012213</ddiem:url>
        <rdfs:label>decreased glomerular filtration rate</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0012213</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3950820</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/277400"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c9106990-2dc9-4d0b-8b31-72009b8aa14f">
        <rdfs:label>Fatigue</rdfs:label>
        <dc:identifier>HP:0011025</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0011025</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24210589</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a30c0b8d-bfd6-47ac-ada5-95c68b8a5b25">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001878</ddiem:url>
        <rdfs:label>Haemolysis</rdfs:label>
        <dc:identifier>HP:0001878</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://reader.elsevier.com/reader/sd/pii/S0140673615000768</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/599982ac-3b9f-48ab-a404-2c2888155a87">
        <dc:identifier>HP:0002395</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002395</ddiem:url>
        <rdfs:label>Lower limb hyperreflexia</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/bb44cafe-7430-411a-abdd-750c3e1e2f55"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/b3b91803-46c6-4398-8030-a8feea3ea9bc"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24210590</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9511979</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19821145</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/fb99f9f5-5ea6-454e-a25c-0474bf45d940">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002039</ddiem:url>
        <rdfs:label>Anorexia</rdfs:label>
        <dc:identifier>HP:0002039</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
  </obo:OGMS_0000112>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/940057a0-5631-4d31-bc0f-d8abeb467d0f">
    <ddiem:keggEntryId>K19480</ddiem:keggEntryId>
    <ddiem:uniprotId>Q75V66</ddiem:uniprotId>
    <rdfs:label>anoctamin 5</rdfs:label>
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/803445df-02b0-4340-92b7-8f093d7e85a1"/>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/9452f95c-6e65-40c9-8b09-64add72ac388">
    <ddiem:uniprotId>P05019</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/d85cc40f-4f57-4c0c-a7f0-1581acf993bc">
        <rdfs:label>IGF1</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/3479</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>insulin like growth factor 1</rdfs:label>
    <ddiem:keggEntryId>K05459</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/0103c165-4601-40df-ad9a-1259da5987ae">
    <ddiem:uniprotId>Q14118</ddiem:uniprotId>
    <ddiem:keggEntryId>K06265</ddiem:keggEntryId>
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/928dbda0-de95-46b8-ba1b-7d6ea9e6c93b"/>
    <rdfs:label>Dystroglycan</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/43ea9385-0877-4476-a25d-4e69e7ba51c3">
    <ddiem:uniprotId>Q96A29</ddiem:uniprotId>
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/b7729871-edf8-4c8e-a63f-9ee6501210f6"/>
    <ddiem:keggEntryId>K15279</ddiem:keggEntryId>
    <rdfs:label>guanosine 5'-diphosphate (GDP)-fucose transporter</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/01e6cef0-5ead-4cc1-b2b7-13424ad9afb7">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/099ca942-54a3-4785-9822-416a281ecf6f">
        <rdfs:label>CLN6</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/54982</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>Q9NWW5</ddiem:uniprotId>
    <ddiem:keggEntryId>K12359</ddiem:keggEntryId>
    <rdfs:label>CLN6, transmembrane ER protein</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/36121be3-7df3-4913-9a69-d650cec19ac5">
    <ddiem:uniprotId>Q00266</ddiem:uniprotId>
    <ddiem:keggEntryId>K00789</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/d31e66ca-4b0e-4f18-ad08-69342d8829ea">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/4143</dc:identifier>
        <rdfs:label>MAT1A</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>S-adenosylmethionine synthase isoform type-1</rdfs:label>
    <ddiem:ecNumber>2.5.1.6</ddiem:ecNumber>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/ae339bc6-f531-483b-ad15-d71d3100eff3">
    <ddiem:keggEntryId>K17425</ddiem:keggEntryId>
    <ddiem:uniprotId>Q9H9J2</ddiem:uniprotId>
    <ddiem:ecNumber>3.1.26.-</ddiem:ecNumber>
    <rdfs:label>mitochondrial ribosomal protein L44</rdfs:label>
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/261d8c79-bb84-43fa-9100-61805093b94d"/>
  </ddiem:ProtienOrEnzyme>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/e3c1ccfb-4101-466e-b21c-e2e824ad3ba4">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26170630</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/15f5c359-9976-48fc-b7f4-a7119dd385cd">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>neoplastic growth</rdfs:label>
        <dc:identifier>HP:0002664</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002664</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18381602</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00923247</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/3731c591-6e0e-4860-bd0e-3da7fd769279">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/95a4d5e1-e93a-492f-b40f-38ec041cca0c"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/162300">
        <rdfs:label>MULTIPLE ENDOCRINE NEOPLASIA, TYPE IIB; MEN2B</rdfs:label>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/aa7aed1a-14de-4754-990e-819eb135c235"/>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>https://www.omim.org/entry/162300</dc:identifier>
      </ddiem:Disease>
    </obo:RO_0002599>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <rdfs:comment>Treatment-related risks should be taken into account when considering the use of vandetanib in patients with indolent, asymptomatic, or slowly progressing disease.https://www.ncbi.nlm.nih.gov/pubmed/22665903?dopt=Abstract</rdfs:comment>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/cfd1ccae-d6b6-4dd1-bac2-159fb05b0513">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/da66d84d-0bc6-4d27-b9ac-4b88f7fa62e7"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30297385</dc:provenance>
  </obo:OGMS_0000112>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/5010ecc7-42e3-4559-be5b-b5879f709138">
    <ddiem:uniprotId>P07602</ddiem:uniprotId>
    <ddiem:keggEntryId>K12382</ddiem:keggEntryId>
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/567920d4-ffcc-445c-a1e0-a9a577b4cfff"/>
    <rdfs:label>prosaposin</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/0c73362d-0211-46ba-a024-b73079540e82">
    <ddiem:keggEntryId>K02333</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/3950d2fd-124a-4d5b-81af-7be4152d547a">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/11232</dc:identifier>
        <rdfs:label>POLG2</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>Q9UHN1</ddiem:uniprotId>
    <rdfs:label>DNA polymerase subunit gamma-2, mitochondrial</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/11eddf94-ae5d-4c6a-80fd-b1c524bc05f0">
    <ddiem:keggEntryId>K01204</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/7964fd83-d171-4be1-8de5-d5c99e7a54ef">
        <rdfs:label>NAGA</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/4668</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>P17050</ddiem:uniprotId>
    <rdfs:label>alpha-N-acetylgalactosaminidase</rdfs:label>
    <ddiem:ecNumber>3.2.1.49</ddiem:ecNumber>
  </ddiem:ProtienOrEnzyme>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/d7b1b74a-5ef5-421a-8527-a4605638023a">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7760062</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16891685</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/92af90b3-792a-4779-90d5-b71bb9153912"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8163996</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/c51058f7-1e07-472e-a6a6-adeb625d7b5f"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26817292</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12084887</dc:provenance>
    <rdfs:comment>Alhough therapy with desmopressin cannot be recommended based on the results of a single case, the outcome presented here is intriguing and suggests that larger studies in such patients is warranted to assess the broader application of such an intervention.</rdfs:comment>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/eebe8355-1b7b-472c-a6a6-9b5ee94e56bb"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1899474</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18425437</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/261630"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18060820</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b94edf1f-09ea-4426-8f3a-982a40f19cf4">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001285</ddiem:url>
        <dc:identifier>HP:0001285</dc:identifier>
        <rdfs:label>Spastic tetraparesis</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </obo:DDIEM_0000013>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/5c4d5de1-1761-4a43-b4ee-78e797d88b3c">
    <ddiem:ecNumber>2.7.1.31</ddiem:ecNumber>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/36b08a81-3a30-46db-a232-b027870336f5">
        <rdfs:label>GLYCTK</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/132158</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>Q8IVS8</ddiem:uniprotId>
    <rdfs:label>d-glycerateÂ kinase</rdfs:label>
    <ddiem:keggEntryId>K11529</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/0b48820f-f857-40c8-b540-e82177f9f566">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/5fa23e13-a29b-4cd0-9212-9456c164f185">
        <rdfs:label>CTH</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/1491</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>cystathionine gamma-lyase</rdfs:label>
    <ddiem:uniprotId>P32929</ddiem:uniprotId>
    <ddiem:keggEntryId>K01758</ddiem:keggEntryId>
    <ddiem:ecNumber>4.4.1.1</ddiem:ecNumber>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/8a5c49ec-46aa-438d-ae7f-9c3682eeb08c">
    <ddiem:uniprotId>P13647</ddiem:uniprotId>
    <ddiem:keggEntryId>K13667</ddiem:keggEntryId>
    <ddiem:ecNumber>2.4.1.-; 2.4.2.26</ddiem:ecNumber>
    <ddiem:uniprotId>Q8NBL1</ddiem:uniprotId>
    <rdfs:label>keratin 5/protein O-glucosyltransferase</rdfs:label>
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/48ec71b8-fb43-41cb-9a18-693c835f537c"/>
    <ddiem:keggEntryId>K07605</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/0cafb4d9-3720-40f8-b744-5741e196dd39">
        <rdfs:label>KRT5</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/3852</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/0a851ab9-0a15-40ce-ab7a-7ae8f75614be">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/fda8a6f0-6139-4142-89e5-0ee15677ab49">
        <rdfs:label>SLC25A13</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/10165</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>""</ddiem:keggEntryId>
    <ddiem:uniprotId>""</ddiem:uniprotId>
    <rdfs:label>citrin ( protein)</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/9092a65c-3c1a-4f08-9c96-0ac011ae868a">
    <ddiem:ecNumber>2.7.8.17</ddiem:ecNumber>
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/c5a0e25a-5679-4e79-8aed-1bdc340f27fa"/>
    <ddiem:keggEntryId>K08239</ddiem:keggEntryId>
    <ddiem:uniprotId>Q3T906</ddiem:uniprotId>
    <rdfs:label>(Î±) &amp;(Î²)GlcNAc-1-phosphotransferas</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/614202">
    <rdfs:comment></rdfs:comment>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/5bee6dab-88ea-4576-aad2-e9159ce257ae"/>
    <rdfs:label>MENTAL RETARDATION, AUTOSOMAL RECESSIVE 15; MRT15</rdfs:label>
    <ddiem:iembaseAccessionNumber>611</ddiem:iembaseAccessionNumber>
    <dc:identifier>https://www.omim.org/entry/614202</dc:identifier>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/611</ddiem:iembaseUrl>
  </ddiem:Disease>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/9656c5e8-9228-4764-b18f-dae8fe70a5be">
    <ddiem:keggEntryId>K16343</ddiem:keggEntryId>
    <ddiem:ecNumber>3.1.1.4</ddiem:ecNumber>
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/ff8290eb-e268-4f16-8549-1638f8374cf9"/>
    <rdfs:label>85/88 kDa calcium-independent phospholipase A2</rdfs:label>
    <ddiem:uniprotId>O60733</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/e8505d66-7f88-4265-bb70-21563f484408">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/f056ecde-5f49-4310-9b2e-e2f5a1c2c9be">
        <rdfs:label>PCBD1</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/5092</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>P61457</ddiem:uniprotId>
    <ddiem:keggEntryId>K01724</ddiem:keggEntryId>
    <ddiem:ecNumber>4.2.1.96</ddiem:ecNumber>
    <rdfs:label>pterin-4 alpha-carbinolamine dehydratase</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/69c44f67-f564-4e7b-86dc-f09be527c9f4">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/771666f5-dccc-4d6d-bdd9-8158f1ab0f07"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b2e722ac-ef7a-428c-9e80-5a2a05c4a830"/>
    <dc:provenance>https://www.nature.com/articles/nm1059</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1059131117301243</dc:provenance>
    <rdfs:comment>In a different study IV administration of Glucose wasn't effective.https://www.ncbi.nlm.nih.gov/pubmed/22238410</rdfs:comment>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/236670">
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/5af0baac-f914-4666-976d-511135877537"/>
        <dc:identifier>https://www.omim.org/entry/236670</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseAccessionNumber>352</ddiem:iembaseAccessionNumber>
        <rdfs:label>MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH BRAIN AND EYE ANOMALIES), TYPE A, 1; MDDGA1</rdfs:label>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/352</ddiem:iembaseUrl>
      </ddiem:Disease>
    </obo:RO_0002599>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/books/NBK1520</dc:provenance>
    <dc:provenance>https://link.springer.com/article/10.1007/s11940-011-0131-z</dc:provenance>
  </obo:OGMS_0000112>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/d3b96b7e-d165-4de2-b641-e65b575d6240">
    <rdfs:label>Glutamine synthetase</rdfs:label>
    <ddiem:uniprotId>P15104</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/3bb3879a-0617-4739-a549-20de5b0fbe42">
        <rdfs:label>GLUL</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/2752</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K01915</ddiem:keggEntryId>
    <ddiem:ecNumber>6.3.1.2; 2.3.1.225</ddiem:ecNumber>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/e46f9964-5f85-4fb6-8d1c-0ff0e90e8f76">
    <ddiem:keggEntryId>K01476</ddiem:keggEntryId>
    <rdfs:label>Arginase</rdfs:label>
    <ddiem:uniprotId>P05089</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/9020f972-02ef-4b05-b2c3-472aa36bb0c1">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/383</dc:identifier>
        <rdfs:label>ARG1</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:ecNumber>3.5.3.1</ddiem:ecNumber>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/85a01021-f628-4399-8c48-65ba4f747cea">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/b389da03-f43c-4e60-bec9-8a921241668b">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/2517</dc:identifier>
        <rdfs:label>FUCA1</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:ecNumber>3.2.1.51</ddiem:ecNumber>
    <ddiem:uniprotId>P04066</ddiem:uniprotId>
    <ddiem:keggEntryId>K01206</ddiem:keggEntryId>
    <rdfs:label>a-L-fucosidase</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/7546524b-8304-4bf6-ad69-76c894636760">
    <ddiem:ecNumber>1.13.11.5</ddiem:ecNumber>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/681c3341-a684-4037-b28a-0a13963a390f">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/3081</dc:identifier>
        <rdfs:label>HGD</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>Homogentisate 1,2-dioxygenase.</rdfs:label>
    <ddiem:uniprotId>Q93099</ddiem:uniprotId>
    <ddiem:keggEntryId>K00451</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/7311a3f4-1425-47bd-8354-c8fd42e3ca4e">
    <ddiem:keggEntryId>K00760</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/802f69af-881e-468b-b30e-f8b4fb5bd049">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/3251</dc:identifier>
        <rdfs:label>HPRT1</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>hypoxanthine phosphoribosyltransferase 1</rdfs:label>
    <ddiem:uniprotId>P00492</ddiem:uniprotId>
    <ddiem:ecNumber>2.4.2.8</ddiem:ecNumber>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/ff0d3456-de6e-40c6-b8e0-45908e87f76e">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/2ca34841-17b1-4234-a512-4cd3b8afc17c">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/23556</dc:identifier>
        <rdfs:label>PIGN</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>O95427</ddiem:uniprotId>
    <rdfs:label>GPI ethanolamine phosphate transferase 1</rdfs:label>
    <ddiem:keggEntryId>K05285</ddiem:keggEntryId>
    <ddiem:ecNumber>2.-.-.-</ddiem:ecNumber>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/ef6ed4d0-3569-47c3-958c-9f683ced904f">
    <ddiem:uniprotId>Q9H3Z4</ddiem:uniprotId>
    <ddiem:keggEntryId>K09525</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/94da7879-003f-4454-aab9-31fcc61e8c93">
        <rdfs:label>DNAJC5</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/80331</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>DnaJ homolog subfamily C member 5(cysteine string PROTEIN)</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/84638bd3-49df-48c0-99d7-0b20130f7d13">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/d92b5b46-aac4-4c08-8d4a-73dc7dbdf9af">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/2593</dc:identifier>
        <rdfs:label>GAMT</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:ecNumber>2.1.1.2</ddiem:ecNumber>
    <rdfs:label>guanidinoacetate methyltransferase</rdfs:label>
    <ddiem:uniprotId>Q14353</ddiem:uniprotId>
    <ddiem:keggEntryId>K00542</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/c9b0c6dd-7d81-49d5-b179-cf35a490e5aa">
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/1e9d6e90-c1b4-43a8-b825-58ced970efef"/>
    <rdfs:label>dolichol-P-mannose synthase 1</rdfs:label>
    <ddiem:ecNumber>2.4.1.83</ddiem:ecNumber>
    <ddiem:uniprotId>O60762</ddiem:uniprotId>
    <ddiem:keggEntryId>K00721</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/c2edc280-fe9d-454f-8f99-87a2ff2102a6">
    <ddiem:keggEntryId>K13867</ddiem:keggEntryId>
    <ddiem:uniprotId>Q9UM01</ddiem:uniprotId>
    <rdfs:label>Y+L amino acid transporter 1</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/d3304fbc-06ca-4312-b80a-c82ed0a8b0ad">
        <rdfs:label>SLC7A7</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/9056</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/e042dfb1-a509-45d6-8ab8-fe49fcb30197">
    <ddiem:keggEntryId>K09699</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/d3714c99-f33a-4b0b-83b7-280dd2cd59c7">
        <rdfs:label>DBT</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/1629</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>Lipoamide acyltransferase component of branched-chain alpha-keto acid dehydrogenase complex, mitochondrial</rdfs:label>
    <ddiem:uniprotId>P11182</ddiem:uniprotId>
    <ddiem:ecNumber>2.3.1.168</ddiem:ecNumber>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/f96d1849-2f4a-4676-8b02-818ae589dcd9">
    <ddiem:uniprotId>""</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/0a5f4cf4-436f-4a07-b684-6da170ff3e34">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/""</dc:identifier>
        <rdfs:label>ADCK3</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>""</ddiem:keggEntryId>
    <rdfs:label>Atypical kinase COQ8A, mitochondrial</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/8b03ea26-165a-4a67-a8d7-979fe6254fb2">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/98703b2a-0b95-4d82-ac4f-04e36d48089b">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/3145</dc:identifier>
        <rdfs:label>HMBS</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K01749</ddiem:keggEntryId>
    <ddiem:ecNumber>2.5.1.61</ddiem:ecNumber>
    <ddiem:uniprotId>P08397</ddiem:uniprotId>
    <rdfs:label>Hydroxymethylbilane synthase.</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/a9fb23f2-12e5-4cdb-ba8e-d61596b70059">
    <ddiem:uniprotId>P11168</ddiem:uniprotId>
    <ddiem:keggEntryId>K07593</ddiem:keggEntryId>
    <rdfs:label>Solute carrier family 2, facilitated glucose transporter member 2</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/9e79a7ca-b575-4e23-8303-710d96459023">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/6514</dc:identifier>
        <rdfs:label>SLC2A2</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/0a5564c4-7708-49d1-a153-c7bbc03421d7">
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/e10e2d31-8148-4d11-b3b9-eb63bc89f0fa"/>
    <ddiem:keggEntryId>K00016</ddiem:keggEntryId>
    <rdfs:label>lactate dehydrogenase-A, which is one piece (subunit) of the lactate dehydrogenase enzyme</rdfs:label>
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/5fe216b1-deeb-427c-b92e-956fdc441ba2"/>
    <ddiem:uniprotId>P00338</ddiem:uniprotId>
    <ddiem:ecNumber>1.1.1.27</ddiem:ecNumber>
  </ddiem:ProtienOrEnzyme>
  <owl:Class rdf:about="http://purl.obolibrary.org/obo/activity_modification_of_a_genetically_defective_protein_by_epigenetic_manipulation">
    <obo:IAO_0000115 xml:lang="en">Modulation of the level or specificity of expression of a genetically defective gene through modification of an epigenetic mark or process using chemical, biological or genetic means.</obo:IAO_0000115>
    <rdfs:label xml:lang="en">activity modification of a genetically defective protein by epigenetic manipulation</rdfs:label>
    <dc:creator>https://orcid.org/0000-0002-5111-7263</dc:creator>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000012"/>
  </owl:Class>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/6aeb00c2-f70e-4682-b234-0e16d8a2ede6">
    <ddiem:uniprotId>Q9HCJ1</ddiem:uniprotId>
    <rdfs:label>Progressive ankylosis protein homolog</rdfs:label>
    <ddiem:keggEntryId>K22734</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/12f64661-8448-4e7d-9971-2ca66c9cbf2c">
        <rdfs:label>ANKH</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/56172</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/a7647eea-9a84-4d72-a2ab-73199016010b">
    <rdfs:label>Cholestanetriol 26-monooxygenase</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/564cc080-d13b-4ecc-ab74-aa04d1c95735">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/1593</dc:identifier>
        <rdfs:label>CYP27A1</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K00488</ddiem:keggEntryId>
    <ddiem:ecNumber>1.14.15.15</ddiem:ecNumber>
    <ddiem:uniprotId>Q02318</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/b1edceb2-52d5-4734-8ff3-bd7e51ee06fe">
    <rdfs:label>Sodium-dependent neutral amino acid transporter B(0)AT1</rdfs:label>
    <ddiem:uniprotId>Q695T7</ddiem:uniprotId>
    <ddiem:keggEntryId>K05334</ddiem:keggEntryId>
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/f05fd3a8-d8dd-4945-9ed5-9069767ac8dd"/>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/a2d0391a-4f7b-46bf-87bc-7b6a71f8a400">
    <ddiem:keggEntryId>K03841</ddiem:keggEntryId>
    <ddiem:uniprotId>P09467</ddiem:uniprotId>
    <rdfs:label>Fructose-1,6-bisphosphatase 1</rdfs:label>
    <ddiem:ecNumber>3.1.3.11</ddiem:ecNumber>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/5d3237e8-b1fe-4b49-9792-6f16961ca6a4">
        <rdfs:label>FBP1</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/2203</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/f79af07a-231b-4c2a-82c0-d626185fadcc">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/30db8e18-2642-431e-a99f-60bf1cd2658f">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/25974</dc:identifier>
        <rdfs:label>MMACHC</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>Methylmalonic aciduria and homocystinuria type C protein</rdfs:label>
    <ddiem:ecNumber>1.16.1.-</ddiem:ecNumber>
    <ddiem:uniprotId>Q9Y4U1</ddiem:uniprotId>
    <ddiem:keggEntryId>K14618</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/ce715c0f-9a27-4faa-8426-5c4011658d6e">
    <ddiem:uniprotId>Q8NBK3</ddiem:uniprotId>
    <ddiem:ecNumber>1.8.3.7</ddiem:ecNumber>
    <ddiem:keggEntryId>K13444</ddiem:keggEntryId>
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/4c632da2-7632-4ef3-9377-ecc1a22ccbcc"/>
    <rdfs:label>Formylglycine-generating enzyme</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/1315bad3-ea02-4291-b499-830251999555">
    <ddiem:uniprotId>""</ddiem:uniprotId>
    <ddiem:keggEntryId>""</ddiem:keggEntryId>
    <rdfs:label>Adenosine deaminase</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/5f487166-9a02-4384-8321-f913f8a60917">
        <rdfs:label>ADA</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/100</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/614830">
    <ddiem:iembaseAccessionNumber>1120</ddiem:iembaseAccessionNumber>
    <rdfs:label>MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH BRAIN AND EYE ANOMALIES), TYPE A, 8; MDDGA8</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/592ea377-c20c-4a0e-aac2-fb0f7b3db439"/>
    <dc:identifier>https://www.omim.org/entry/614830</dc:identifier>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/1120</ddiem:iembaseUrl>
  </ddiem:Disease>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/155a8e1c-ab74-437e-bd58-03cc2e7fae55">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/d32f3640-0389-49c1-9d27-bcc700dcc924">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/148789</dc:identifier>
        <rdfs:label>B3GALNT2</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>UDP-GalNAc:beta-1,3-N-acetylgalactosaminyltransferase 2</rdfs:label>
    <ddiem:ecNumber>2.4.1.313</ddiem:ecNumber>
    <ddiem:uniprotId>Q8NCR0</ddiem:uniprotId>
    <ddiem:keggEntryId>K09654</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/d24e806f-a8c8-4793-8ad2-756280b96152">
    <ddiem:keggEntryId>K07299</ddiem:keggEntryId>
    <ddiem:uniprotId>P11166</ddiem:uniprotId>
    <rdfs:label>glucose transporter protein type 1 (GLUT1)</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/96e8e882-0a1c-40c4-9c8e-f881e93b8205">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/6513</dc:identifier>
        <rdfs:label>SLC2A1</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/1ebed3c1-50ae-4d8e-b18d-8380777433b6">
    <ddiem:uniprotId>""</ddiem:uniprotId>
    <ddiem:keggEntryId>""</ddiem:keggEntryId>
    <rdfs:label>beta-1,4-galactosyl transferase.</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/c7c23773-e54b-4eb3-aa14-627a8a1c9651">
        <rdfs:label>GALT1</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/""</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/edf4a275-9676-4860-900e-cd0691c76293">
    <rdfs:label>glucosamine (UDP-N-acetyl)-2-epimerase/N-acetylmannosamine kinase</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/a7394c25-fe23-441c-88a7-479838fa3f57">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/10020</dc:identifier>
        <rdfs:label>GNE</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>""</ddiem:keggEntryId>
    <ddiem:uniprotId>""</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/9e565929-d7c4-4273-8125-3be192980f43">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/c6c54f58-04d6-4c81-81e5-704f7f43bdd9">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/5255</dc:identifier>
        <rdfs:label>PHKA1</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K07190</ddiem:keggEntryId>
    <rdfs:label>alpha subunit of muscle phosphorylase kinase</rdfs:label>
    <ddiem:uniprotId>P46020</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/4eff561d-ba9f-45ce-966d-3d2cb26ae615">
    <rdfs:label>apolipoprotein B-48Â + apolipoprotein B-100</rdfs:label>
    <ddiem:uniprotId>P04114</ddiem:uniprotId>
    <ddiem:keggEntryId>K14462</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/5e1f905f-9dac-4915-8e8c-3ceccff2b0d1">
        <rdfs:label>APOB</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/338</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/242600">
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/798</ddiem:iembaseUrl>
    <rdfs:comment></rdfs:comment>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/f05fd3a8-d8dd-4945-9ed5-9069767ac8dd"/>
    <ddiem:iembaseAccessionNumber>798</ddiem:iembaseAccessionNumber>
    <rdfs:label>IMINOGLYCINURIA</rdfs:label>
    <dc:identifier>https://www.omim.org/entry/242600</dc:identifier>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/d59c100d-3095-4947-9485-7e4b8363a993"/>
  </ddiem:Disease>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/b8c1e90f-11e1-45a6-aa0a-bceba0760dd1">
    <ddiem:uniprotId>""</ddiem:uniprotId>
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/c498e3bf-893e-4009-8a65-92d9c3475b15"/>
    <ddiem:keggEntryId>""</ddiem:keggEntryId>
    <rdfs:label>D-ribitol-5-phosphate cytidylyltransferase</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/620a6192-67f8-4ac5-b6b5-a4632eb0687b">
    <ddiem:uniprotId>O60313</ddiem:uniprotId>
    <rdfs:label>mitochondrial dynamin like GTPase</rdfs:label>
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/3483bfdd-bbbf-48ce-b56d-020bcf9c4e58"/>
    <ddiem:keggEntryId>K17079</ddiem:keggEntryId>
    <ddiem:ecNumber>3.6.5.5</ddiem:ecNumber>
  </ddiem:ProtienOrEnzyme>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/162350">
    <dc:identifier>https://www.omim.org/entry/162350</dc:identifier>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/309</ddiem:iembaseUrl>
    <rdfs:label>CEROID LIPOFUSCINOSIS, NEURONAL, 4B, AUTOSOMAL DOMINANT; CLN4B</rdfs:label>
    <ddiem:iembaseAccessionNumber>309</ddiem:iembaseAccessionNumber>
    <rdfs:comment></rdfs:comment>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/94da7879-003f-4454-aab9-31fcc61e8c93"/>
  </ddiem:Disease>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/0028b5b0-c190-4adc-840c-b26e80cac87d">
    <ddiem:ecNumber>1.1.1.-; 1.1.1.181</ddiem:ecNumber>
    <ddiem:uniprotId>Q9H2F3</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/f972158b-0da5-4de1-ad95-478682be2c05">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/80270</dc:identifier>
        <rdfs:label>HSD3B7</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>3-beta-hydroxy-delta-5-C27 steroid oxidoreductase</rdfs:label>
    <ddiem:keggEntryId>K12408</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/3b0423f6-08e4-4393-a4a4-ce3cc0ab72e0">
    <ddiem:uniprotId>Q93100</ddiem:uniprotId>
    <rdfs:label>Phosphorylase b kinase regulatory subunit beta</rdfs:label>
    <ddiem:keggEntryId>K07190</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/3c1788f7-9fa8-4c76-922d-283b4a44b930">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/5257</dc:identifier>
        <rdfs:label>PHKB</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/a094aeef-43d7-42ce-82d6-710eaf97c1fd">
    <ddiem:uniprotId>P04424</ddiem:uniprotId>
    <ddiem:ecNumber>4.3.2.1</ddiem:ecNumber>
    <ddiem:keggEntryId>K01755</ddiem:keggEntryId>
    <rdfs:label>argininosuccinate lyase</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/a10b2f6d-46a3-49d0-8f7a-c2fb76d8dabc">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/435</dc:identifier>
        <rdfs:label>ASL</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/30771d6d-efc4-4225-a92e-7b181d23eea0">
    <ddiem:keggEntryId>K17725</ddiem:keggEntryId>
    <ddiem:ecNumber>1.13.11.18</ddiem:ecNumber>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/8a732a3a-7b73-4305-a9a3-748478f0af92">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/23474</dc:identifier>
        <rdfs:label>ETHE1</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>O95571</ddiem:uniprotId>
    <rdfs:label>persulfide dioxygenase</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/612937">
    <rdfs:label>MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (LIMB-GIRDLE), TYPE C, 15; MDDGC15</rdfs:label>
    <dc:identifier>https://www.omim.org/entry/612937</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/387</ddiem:iembaseUrl>
    <obo:RO_0004020>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/ab495e46-2b45-427e-bf51-9c70cc8b4015">
        <rdfs:label>DPM3</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/54344</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0004020>
    <ddiem:iembaseAccessionNumber>387</ddiem:iembaseAccessionNumber>
  </ddiem:Disease>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/f0257a3b-5c26-4c30-ae4d-304e9a72b623">
    <ddiem:ecNumber>1.5.1.3</ddiem:ecNumber>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/a2ed14b2-bf23-46f1-aeaa-510bd228826b">
        <rdfs:label>DHFR</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/1719</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K00287</ddiem:keggEntryId>
    <ddiem:uniprotId>P00374</ddiem:uniprotId>
    <rdfs:label>Dihydrofolate reductase</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/79e7a2ea-2579-45a0-b113-d25fdc3b6906">
    <rdfs:label>Glutathione hydrolase 1 proenzyme/Gamma-glutamyltranspeptidase</rdfs:label>
    <ddiem:uniprotId>P19440</ddiem:uniprotId>
    <ddiem:keggEntryId>K18592</ddiem:keggEntryId>
    <ddiem:ecNumber>3.4.19.13; 2.3.2.2; 3.4.19.14</ddiem:ecNumber>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/5089cd2c-b43d-4018-a82a-114fd27b208b">
        <rdfs:label>GGT1</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/2678</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/e53b721c-9a7c-403e-a0e7-4e70b0c60dd3">
    <rdfs:label>3-beta-hydroxysterol delta-24-reductase</rdfs:label>
    <ddiem:uniprotId>Q15392</ddiem:uniprotId>
    <ddiem:ecNumber>1.3.1.72</ddiem:ecNumber>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/2d4fb5f9-4762-4039-9348-f5f1f4df96f7">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/1718</dc:identifier>
        <rdfs:label>DHCR24</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K09828</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/222730">
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/49</ddiem:iembaseUrl>
    <dc:identifier>https://www.omim.org/entry/222730</dc:identifier>
    <ddiem:iembaseAccessionNumber>49</ddiem:iembaseAccessionNumber>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>DICARBOXYLIC AMINOACIDURIA; DCBXA</rdfs:label>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/51559286-c526-42f0-acf3-97a27d62ed75"/>
  </ddiem:Disease>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/301f5304-cb3c-4784-b99d-fc051c572335">
    <ddiem:keggEntryId>K22283</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/2faab71c-9bcb-4f99-8bbf-d80daf65a7db">
        <rdfs:label>LIPC</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/3990</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>hepatic lipase</rdfs:label>
    <ddiem:uniprotId>P11150</ddiem:uniprotId>
    <ddiem:ecNumber>3.1.1.3</ddiem:ecNumber>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/cf8adf4f-12ff-4894-95c6-c61bda0f91ec">
    <ddiem:keggEntryId>""</ddiem:keggEntryId>
    <ddiem:uniprotId>""</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/10688ef6-f75f-4ccb-8383-261f7ab2c036">
        <rdfs:label>CTSC</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/1075</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>Dipeptidyl peptidase 1</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/399e69d8-7b86-4bc8-996f-8901a5d5c542">
    <ddiem:uniprotId>Q13825</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/d0ff2775-0e08-4172-b132-b588a2b3a28a">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/549</dc:identifier>
        <rdfs:label>AUH</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:ecNumber>4.2.1.18; 4.2.1.56</ddiem:ecNumber>
    <rdfs:label>Methylglutaconyl-CoA hydratase</rdfs:label>
    <ddiem:keggEntryId>K05607</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/e3c05ff0-dffb-47b2-8d7e-185dd6b452f4">
    <ddiem:uniprotId>Q9UPQ8</ddiem:uniprotId>
    <rdfs:label>dolichol kinase</rdfs:label>
    <ddiem:ecNumber>2.7.1.108</ddiem:ecNumber>
    <ddiem:keggEntryId>K00902</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/fa8e587a-df3a-4b92-be5e-10a6b66346fc">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/22845</dc:identifier>
        <rdfs:label>DOLK</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/ac01f0bf-01a4-41b6-aa32-936821e76cf4">
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/66aa6980-9d73-4eee-8a52-f80a6ead8bf9"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/615156">
        <ddiem:iembaseAccessionNumber>946</ddiem:iembaseAccessionNumber>
        <rdfs:label>PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA WITH MITOCHONDRIAL DNA DELETIONS, AUTOSOMAL DOMINANT 6; PEOA6</rdfs:label>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/946</ddiem:iembaseUrl>
        <dc:identifier>https://www.omim.org/entry/615156</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/2b5d3307-9dd6-42fb-8b09-cf1d89a0caf4"/>
      </ddiem:Disease>
    </obo:RO_0002599>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d4d9fa5f-c501-42d6-89e7-9156e0c4f1f3"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/6b36ca46-5e87-4637-b6e9-73189ff35f01"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/db6d42d0-bc1e-458c-9a99-e1e2fe9a00d1"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12872260</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/a930ecd5-943e-4554-945e-fecf570f510f">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/7aec2470-791a-449b-9860-c41bb133812d"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:comment>Whether in this patient levodopa responsive Parkinsonism is caused bythe co-occurrence of the Twinkle R344Q and POLG G848S mutations remains elusive since brain autopsymaterial for mtDNA analysis was lacking. https://www.ncbi.nlm.nih.gov/pubmed/12872260</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5728770</dc:provenance>
  </obo:OGMS_0000112>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/600627">
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/618</ddiem:iembaseUrl>
    <rdfs:label>HYPERTRYPTOPHANEMIA; HYPTRP</rdfs:label>
    <rdfs:comment>Hypertryptophanemia should be regarded as a benign condition</rdfs:comment>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/954ddf18-17b5-439c-9add-83f5b9907d50"/>
    <ddiem:iembaseAccessionNumber>618</ddiem:iembaseAccessionNumber>
    <dc:identifier>https://www.omim.org/entry/600627</dc:identifier>
  </ddiem:Disease>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/a0f53149-345a-47e4-b40c-cdbc99058109">
    <rdfs:label>Sar1bÂ protein</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/cca27114-b6a4-4a77-ba25-1da0d809da77">
        <rdfs:label>SAR1B</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/51128</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K07953</ddiem:keggEntryId>
    <ddiem:uniprotId>Q9Y6B6</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/fe64f5cd-8611-48da-b68f-c432876b3194">
    <ddiem:keggEntryId>K09666</ddiem:keggEntryId>
    <ddiem:uniprotId>Q8WZA1</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/3ac3ab10-f106-445e-a516-1a2f9bc8295b">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/55624</dc:identifier>
        <rdfs:label>POMGNT1</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:ecNumber>2.4.1.-</ddiem:ecNumber>
    <rdfs:label>Protein O-linked-mannose beta-1,2-N-acetylglucosaminyltransferase 1</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/d87fd27c-bc5e-4c7b-8643-d92e0fac4397">
    <ddiem:ecNumber>1.14.18.-</ddiem:ecNumber>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/c8ad4da2-9032-47df-9e81-fe37ad89d0de">
        <rdfs:label>FA2H</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/79152</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>Q7L5A8</ddiem:uniprotId>
    <ddiem:keggEntryId>K19703</ddiem:keggEntryId>
    <rdfs:label>fatty acid 2-hydroxylase</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/7f09085e-48f6-4a5a-8ea8-6811b9166351">
    <ddiem:keggEntryId>K01556</ddiem:keggEntryId>
    <rdfs:label>kynureninase</rdfs:label>
    <ddiem:ecNumber>3.7.1.3</ddiem:ecNumber>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/cdd2f8a0-3f9b-4556-9d62-2a0a369d9a32">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/8942</dc:identifier>
        <rdfs:label>KYNU</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>Q16719</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/609308">
    <rdfs:label>MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (LIMB-GIRDLE), TYPE C, 1; MDDGC1</rdfs:label>
    <dc:identifier>https://www.omim.org/entry/609308</dc:identifier>
    <obo:RO_0004020>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/5af0baac-f914-4666-976d-511135877537">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/10585</dc:identifier>
        <rdfs:label>POMT1</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0004020>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/352</ddiem:iembaseUrl>
    <ddiem:iembaseAccessionNumber>352</ddiem:iembaseAccessionNumber>
    <rdfs:comment></rdfs:comment>
  </ddiem:Disease>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/b887ffae-e980-4444-a4bd-ea2ff2cdb850">
    <rdfs:label>codanin 1</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/221bdabd-7245-4da5-a894-e98de7ad7a9d">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/146059</dc:identifier>
        <rdfs:label>CDAN1</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>Q8IWY9</ddiem:uniprotId>
    <ddiem:keggEntryId>K19531</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/0e3af879-ee5c-40f0-a93f-edd53e141532">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/9760c659-8c67-492f-b63b-60b1f475b082">
        <rdfs:label>APOE</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/348</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>apolipoprotein E</rdfs:label>
    <ddiem:uniprotId>P02649</ddiem:uniprotId>
    <ddiem:keggEntryId>K04524</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/1d5e50d1-bb25-4056-a353-3d32b296f7ac">
    <rdfs:label>calcium-sensing receptor</rdfs:label>
    <ddiem:uniprotId>P41180</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/ac74bd37-46c0-4164-8c8d-4881a97f33c2">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/846</dc:identifier>
        <rdfs:label>CASR</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K04612</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/78c24512-2c4f-450e-b0e2-47c734ec9de1">
    <rdfs:label>gastric intrinsic factor</rdfs:label>
    <ddiem:uniprotId>""</ddiem:uniprotId>
    <ddiem:keggEntryId>""</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/4d7f5927-b160-4046-bbb5-2a519d859078">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/""</dc:identifier>
        <rdfs:label>GIF</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/2a50611f-7124-4419-a8b6-09b49b02c350">
    <ddiem:ecNumber>4.2.1.75</ddiem:ecNumber>
    <ddiem:keggEntryId>K01719</ddiem:keggEntryId>
    <rdfs:label>uroporphyrinogen III synthase</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/319a24cf-a698-450e-aa28-4ed20c84e282">
        <rdfs:label>UROS</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/7390</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>P10746</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/f6b3769f-4c27-4c65-a2e2-e16b9240ff19">
    <ddiem:uniprotId>Q9P2X0</ddiem:uniprotId>
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/ab495e46-2b45-427e-bf51-9c70cc8b4015"/>
    <rdfs:label>dolichyl-phosphate mannosyltransferase subunit 3</rdfs:label>
    <ddiem:keggEntryId>K09659</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/f6aa12f2-9d4c-4f57-8868-f7cc085e45d9">
    <ddiem:ecNumber>7.6.2.4</ddiem:ecNumber>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/f5a92a25-6b55-46ff-b4ac-600af9f4d3db">
        <rdfs:label>ABCD1</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/215</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K05675</ddiem:keggEntryId>
    <rdfs:label>adrenoleukodystrophy protein</rdfs:label>
    <ddiem:uniprotId>P33897</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/45ee4d54-e663-4add-96aa-ff93901c7773">
    <ddiem:keggEntryId>K14463</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/a16e79a8-5779-485e-b951-c08b7885c06c">
        <rdfs:label>MTTP</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/4547</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>P55157</ddiem:uniprotId>
    <rdfs:label>microsomal triglyceride transfer protein</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/baa23819-749b-43c8-8603-f1a34fe97a60">
    <ddiem:ecNumber>3.2.1.76</ddiem:ecNumber>
    <rdfs:label>alpha-L-iduronidase</rdfs:label>
    <ddiem:uniprotId>P35475</ddiem:uniprotId>
    <ddiem:keggEntryId>K01217</ddiem:keggEntryId>
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/7688167e-f2e2-49c6-81e7-684954b030b6"/>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/f4c4f171-e657-49c4-a8e6-3943e6e90b67">
    <ddiem:keggEntryId>K19523</ddiem:keggEntryId>
    <rdfs:label>carnitine O-palmitoyltransferase 1, muscle isoform</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/fd674c8c-27e7-4fdf-9073-b41c085751d3">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/1375</dc:identifier>
        <rdfs:label>CPT1B</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>Q92523</ddiem:uniprotId>
    <ddiem:ecNumber>2.3.1.21</ddiem:ecNumber>
  </ddiem:ProtienOrEnzyme>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/26c52a54-bb8d-461c-9b62-332b9521ad77">
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/62f13862-3b92-42cc-9dad-e958eef7c627"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16635485</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/cd1e7f1c-8e58-4f11-b0b9-0baf12de5fa4"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/246650"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19820022</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/88046746-7e79-4066-99d3-eb94278a8dc8"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17339125</dc:provenance>
    <rdfs:comment>Because of poor response to fenofibrate treatment, it was replaced with gemfibrozil</rdfs:comment>
  </obo:OGMS_0000112>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/718e20cc-a705-467a-a8ca-de9e50d56669">
    <ddiem:keggEntryId>""</ddiem:keggEntryId>
    <rdfs:label>Methylmalonic aciduria and homocystinuria type D protein, mitochondrial</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/9354cf69-3bab-4ed0-ade6-7877b069c9f3">
        <rdfs:label>MMADHC</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/27249</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>Q9H3L0</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/0ee93767-f353-418c-a40e-fbc75c3857b6">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/f2173f45-1505-4676-9ee8-be970d33771b">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/54658</dc:identifier>
        <rdfs:label>UGT1A1</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K00699</ddiem:keggEntryId>
    <ddiem:uniprotId>P22309</ddiem:uniprotId>
    <rdfs:label>UDP glucuronosyltransferase family 1 member A1</rdfs:label>
    <ddiem:ecNumber>2.4.1.17</ddiem:ecNumber>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/e354c2b2-31f6-4075-a9e1-f4200dd8fbcb">
    <rdfs:label>lysosomal acid lipase</rdfs:label>
    <ddiem:uniprotId>P38571</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/1f6138e2-9d98-4c5b-874c-42bd9382c1fc">
        <rdfs:label>LIPA</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/3988</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:ecNumber>3.1.1.13</ddiem:ecNumber>
    <ddiem:keggEntryId>K01052</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/2839f11c-1474-4816-add4-9a55064cd8b2">
    <rdfs:label>3-BETA-HYDROXY-DELTA-5-C27-STEROID OXIDOREDUCTASE</rdfs:label>
    <ddiem:keggEntryId>K12408</ddiem:keggEntryId>
    <ddiem:ecNumber>1.1.1.-; 1.1.1.181</ddiem:ecNumber>
    <ddiem:uniprotId>Q9H2F3</ddiem:uniprotId>
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/f972158b-0da5-4de1-ad95-478682be2c05"/>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/a2fe42aa-d4c7-4590-a5e1-ce165abc6187">
    <ddiem:keggEntryId>K08573</ddiem:keggEntryId>
    <rdfs:label>calpain 3</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/28777d8e-8ce0-4f05-9eec-bccf9dd423a0">
        <rdfs:label>CAPN3</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/825</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>P20807</ddiem:uniprotId>
    <ddiem:ecNumber>3.4.22.54</ddiem:ecNumber>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/c29c1004-a342-440f-a12b-114aab8068a4">
    <ddiem:keggEntryId>K00849</ddiem:keggEntryId>
    <ddiem:ecNumber>2.7.1.6</ddiem:ecNumber>
    <rdfs:label>galactokinase 1</rdfs:label>
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/7cea3964-f848-47bd-982f-cae7cada1069"/>
    <ddiem:uniprotId>P51570</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/9f702214-37be-4b69-a260-d49ee9d66d69">
    <rdfs:label>Twinkle protein, mitochondrial</rdfs:label>
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/8d52e39b-1eef-42a7-ac2d-bbf9181101e1"/>
    <ddiem:uniprotId>Q96RR1</ddiem:uniprotId>
    <ddiem:ecNumber>3.6.4.12</ddiem:ecNumber>
    <ddiem:keggEntryId>K17680</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/5d937da3-88a9-4281-9aa6-8d0a11747111">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/19af0a65-bf6c-4cce-9946-7f35d87ac006">
        <rdfs:label>AP2S1</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/1175</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>P53680</ddiem:uniprotId>
    <ddiem:keggEntryId>K11827</ddiem:keggEntryId>
    <rdfs:label>adaptor protein-2Â Ï-subunit</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/dcb8d85b-ede0-4a00-8f1a-e6df58cd2076">
    <rdfs:label>arginine:glycine amidinotransferase</rdfs:label>
    <ddiem:ecNumber>2.1.4.1</ddiem:ecNumber>
    <ddiem:uniprotId>P50440</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/a1eb9ee8-f67b-4738-aebf-3a38d55a3892">
        <rdfs:label>GATM</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/2628</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K00613</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/2bbf8e95-663c-40d5-ba14-753c2b3cce79">
    <ddiem:ecNumber>3.1.3.1</ddiem:ecNumber>
    <rdfs:label>tissue-nonspecific alkaline phosphatase (TNSALP)</rdfs:label>
    <ddiem:uniprotId>P05186</ddiem:uniprotId>
    <ddiem:keggEntryId>K01077</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/6ed7d20c-8b72-41a5-ac32-47d4eba88fcc">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/249</dc:identifier>
        <rdfs:label>ALPL</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/7a273ba9-b204-41a0-b18f-e071d678a22e">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15938133</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8ed73252-5fe0-451d-8975-2c7da3be02f8">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002354</ddiem:url>
        <dc:identifier>HP:0002354</dc:identifier>
        <rdfs:label>Memory impairment</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9422aaba-5c89-40f6-b352-f6142bb81334">
        <rdfs:label>Behavioural abnormalites</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000708</ddiem:url>
        <dc:identifier>HP:0000708</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d0f00bb9-3e49-4161-aa81-c0dc6faab42d">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>cognitive imapirment</rdfs:label>
        <dc:identifier>HP:0100543</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0100543</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/246900"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12927581</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/548720cd-8d60-4013-929d-3ae3d5d06aeb">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/0ba5acf4-f36f-41da-91ea-e73d96d9b195"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/48f0eae9-c050-47a4-8918-9b66e9cc570d"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/518b6d43-2c86-4354-bcc8-68383fdd91a7"/>
    <rdfs:comment>There is no clinical role for NaPBA at present; however, ongoing studies are assessing its efficacy https://www.ncbi.nlm.nih.gov/pubmed/28919799 Phenotypes corrected were based on invivo trial on mice not humans.</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d59bd726-a080-437e-82c7-bd824b26cab0">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001328</ddiem:url>
        <dc:identifier>HP:0001328</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Learning impairment</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28919799</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0166432812001830</dc:provenance>
  </obo:OGMS_0000112>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/3b194ce3-6b86-414f-a6aa-dbe570974d7e">
    <ddiem:keggEntryId>K01809</ddiem:keggEntryId>
    <ddiem:ecNumber>5.3.1.8</ddiem:ecNumber>
    <rdfs:label>Mannose-6-phosphate isomerase</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/582aa68a-6fd0-4ab9-8c3b-acf3bf6794f3">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/4351</dc:identifier>
        <rdfs:label>MPI</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>P34949</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/26fdb321-fdfa-4213-acd2-fd6944a1e8d5">
    <ddiem:keggEntryId>K00382</ddiem:keggEntryId>
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/bb5e4251-1843-4446-8a93-d2ecfeccb1bd"/>
    <rdfs:label>dihydrolipoamide dehydrogenase</rdfs:label>
    <ddiem:ecNumber>1.8.1.4</ddiem:ecNumber>
    <ddiem:uniprotId>P09622</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/e3c98a7b-ce1d-4798-93d8-fd1072c83b56">
    <ddiem:uniprotId>P12235</ddiem:uniprotId>
    <ddiem:keggEntryId>K05863</ddiem:keggEntryId>
    <rdfs:label>ADP/ATP translocase 1</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/5f3085ff-bea4-4b9a-b389-306846f61b37">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/291</dc:identifier>
        <rdfs:label>SLC25A4</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/f4f11da2-43de-43df-a892-aff5604f2713">
    <ddiem:uniprotId>Q04656</ddiem:uniprotId>
    <ddiem:keggEntryId>K17686</ddiem:keggEntryId>
    <ddiem:ecNumber>7.2.2.8</ddiem:ecNumber>
    <rdfs:label>Copper-transporting ATPase 1</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/727a1cc2-7ac1-48d1-ba41-e07a8df1eb7d">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/538</dc:identifier>
        <rdfs:label>ATP7A</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/cd5e9702-50c8-4fff-bb75-b6b69e66e7cc">
    <ddiem:keggEntryId>""</ddiem:keggEntryId>
    <ddiem:uniprotId>""</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/36e8d65a-5e4f-4b54-9a90-8d3825658c5b">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/""</dc:identifier>
        <rdfs:label>PTPS</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>6-pyruvoyl-tetrahydropterin synthase</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/333c3abe-7b67-46ed-ba23-9aa0901aabef">
    <ddiem:keggEntryId>K01679</ddiem:keggEntryId>
    <ddiem:uniprotId>P07954</ddiem:uniprotId>
    <ddiem:ecNumber>4.2.1.2</ddiem:ecNumber>
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/81952674-f6c9-4ba7-b718-1db027ade688"/>
    <rdfs:label>Fumarate hydratase, mitochondrial</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/2bc94168-4ad7-4185-b906-3b8e58f53158">
    <rdfs:label>Tricarboxylate transport protein, mitochondrial</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/7bf4f9e9-5e0d-4717-bef1-a24d5114e42d">
        <rdfs:label>SLC25A1</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/6576</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K15100</ddiem:keggEntryId>
    <ddiem:uniprotId>P53007</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/6f791217-3604-45c5-8709-165095300b2d">
    <ddiem:ecNumber>4.99.1.1</ddiem:ecNumber>
    <rdfs:label>ferrochelatase</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/f1a5084f-1886-418f-9a23-adc5d8a3dd95">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/2235</dc:identifier>
        <rdfs:label>FECH</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K01772</ddiem:keggEntryId>
    <ddiem:uniprotId>P22830</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/afc7e793-5b8c-45fc-bdfd-800b83e4439c">
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/5af0baac-f914-4666-976d-511135877537"/>
    <ddiem:uniprotId>""</ddiem:uniprotId>
    <rdfs:label>protein O-mannosyltransferase 1</rdfs:label>
    <ddiem:keggEntryId>""</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/d8625543-7d68-43ea-b8a1-5926e72e32cf">
    <ddiem:ecNumber>4.2.1.11</ddiem:ecNumber>
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/23ca47d9-9d8d-431c-a628-0a5cd412f1a0"/>
    <rdfs:label>enolase 3</rdfs:label>
    <ddiem:keggEntryId>K01689</ddiem:keggEntryId>
    <ddiem:uniprotId>P13929</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/5a6bf305-4a7c-4766-8669-0205c7d101f6">
    <ddiem:ecNumber>2.4.2.-</ddiem:ecNumber>
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/0c3b7789-2618-4531-9ff4-f72ad4a608d1"/>
    <ddiem:uniprotId>O75072</ddiem:uniprotId>
    <rdfs:label>Fukutin</rdfs:label>
    <ddiem:keggEntryId>K19872</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/628b9b7a-cd60-45a9-9389-293ce3a9edd4">
    <rdfs:label>thiamine transporter</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/aeb8ece0-50d0-4bbd-b9ba-618a49582673">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/80704</dc:identifier>
        <rdfs:label>SLC19A3</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>Q9BZV2</ddiem:uniprotId>
    <ddiem:keggEntryId>K14610</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <obo:DDIEM_0000010 rdf:about="http://ddiem.phenomebrowser.net/71c4206d-f9e8-436c-be1d-b39d0cac8adb">
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/cd810eea-40f1-4ce9-9186-f3e4bdeb2201"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02054832</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/0449a602-c972-47e0-94b5-36cdaafb335b"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29223626</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24613482</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17514432</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9357a41d-cd9b-42ff-b10f-a22ddbc4210e">
        <rdfs:label>Sleep disturbance</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002360</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0002360</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/232400"/>
    <rdfs:comment>Testosterone therapy needs to be carefully considered because of the risk of hepatic adenomas.https://www.ncbi.nlm.nih.gov/pubmed/28160246
Androgen receptors are expressed in the liver, and androgens can stimulate hepatocyte proliferation. Although rare, androgens have been shown in observational studies to induce adenoma development (Giannitrapani et al. 2006). Testosterone levels should be assessed for response 2â3 months after therapy is initiated.</rdfs:comment>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
  </obo:DDIEM_0000010>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/5c897f2e-75c8-48a5-96f6-347edbf54d30">
    <rdfs:label>4-hydroxyphenylpyruvate dioxygenase</rdfs:label>
    <ddiem:ecNumber>1.13.11.27</ddiem:ecNumber>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/c774bb3c-9ce8-4026-80e7-e93a912510a1">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/3242</dc:identifier>
        <rdfs:label>HPD</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>P32754</ddiem:uniprotId>
    <ddiem:keggEntryId>K00457</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/429cfa38-02b4-4c1c-b1ce-9c3d534f4c0b">
    <ddiem:uniprotId>Q99707</ddiem:uniprotId>
    <ddiem:keggEntryId>K00548</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/bd43cb52-7e4c-41df-ae27-81887ad1960b">
        <rdfs:label>MTR</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/4548</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:ecNumber>2.1.1.13</ddiem:ecNumber>
    <rdfs:label>Methionine synthase</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/375d5f3c-b345-4159-896c-8fbb473fc2e7">
    <ddiem:ecNumber>1.5.1.34</ddiem:ecNumber>
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/1909b02a-b024-4806-a90a-b956d08bb2d3"/>
    <ddiem:keggEntryId>K00357</ddiem:keggEntryId>
    <ddiem:uniprotId>P09417</ddiem:uniprotId>
    <rdfs:label>Dihydropteridine reductase</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/ea8f4c41-8566-4a53-95ec-f62cbcf4dba5">
    <rdfs:label>apolipoprotein A5</rdfs:label>
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/3e4e3978-435d-44fe-ad62-68b7c8c6790b"/>
    <ddiem:uniprotId>Q6Q788</ddiem:uniprotId>
    <ddiem:keggEntryId>K09025</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/8c59b7b1-8e71-4122-947b-fa7163fb35cf">
    <ddiem:ecNumber>2.4.1.-</ddiem:ecNumber>
    <ddiem:keggEntryId>K05284</ddiem:keggEntryId>
    <rdfs:label>beta-alanine-alpha-ketoglutarate transaminase.</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/ceecbe7b-3d12-4850-8a69-050e5ac8cb06">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/93183</dc:identifier>
        <rdfs:label>PIGM</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>Q9H3S5</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/215140">
    <dc:identifier>https://www.omim.org/entry/215140</dc:identifier>
    <ddiem:iembaseAccessionNumber>197</ddiem:iembaseAccessionNumber>
    <rdfs:comment></rdfs:comment>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/c4f672b1-c8ab-4dfb-9da7-bdf2b23b984b"/>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/197</ddiem:iembaseUrl>
    <rdfs:label>GREENBERG DYSPLASIA; GRBGD</rdfs:label>
  </ddiem:Disease>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/eda19f23-acf1-45c0-b95a-7ed4e0169599">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/5fb18f2f-4e68-44ed-91c4-34685738b771">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/1893</dc:identifier>
        <rdfs:label>ECM1</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>Q16610</ddiem:uniprotId>
    <rdfs:label>extracellular matrix protein 1</rdfs:label>
    <ddiem:keggEntryId>""</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/7389d922-f65b-428e-b716-ef83f170440e">
    <ddiem:uniprotId>""</ddiem:uniprotId>
    <rdfs:label>Aminoadipic semialdehyde synthase, mitochondrial  including Lysine ketoglutarate reductase +Saccharopine dehydrogenase</rdfs:label>
    <ddiem:keggEntryId>""</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/24ffba31-ca14-42a6-b088-2ca1e876cb73">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/10157</dc:identifier>
        <rdfs:label>AASS</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/605637">
    <rdfs:comment></rdfs:comment>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/ceec3cbd-af43-4741-afa3-9943eea76d54"/>
    <rdfs:label>MYOPATHY, PROXIMAL, AND OPHTHALMOPLEGIA</rdfs:label>
    <dc:identifier>https://www.omim.org/entry/605637</dc:identifier>
  </ddiem:Disease>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/79e939d9-782a-43df-a89f-998fc802a037">
    <ddiem:ecNumber>2.8.1.8</ddiem:ecNumber>
    <ddiem:keggEntryId>K03644</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/a4066a40-5cb3-4ced-bd39-92070e4df1e3">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/11019</dc:identifier>
        <rdfs:label>LIAS</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>lipoic acid synthetase</rdfs:label>
    <ddiem:uniprotId>O43766</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <owl:AnnotationProperty rdf:about="http://purl.obolibrary.org/obo/IAO_0000115"/>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/f9c5f70d-96a4-4d8e-8e48-d6a8c0ecc045">
    <ddiem:keggEntryId>K08764</ddiem:keggEntryId>
    <ddiem:ecNumber>2.3.1.176</ddiem:ecNumber>
    <rdfs:label>sterol carrier protein 2</rdfs:label>
    <ddiem:uniprotId>P22307</ddiem:uniprotId>
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/e896dec4-248d-49d0-bcc7-a800f520a633"/>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/1f019b7d-08ad-4f36-9526-2e21480ea723">
    <ddiem:keggEntryId>K13524</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/d1619fbd-39ee-4951-bf88-67bfd7662c11">
        <rdfs:label>ABAT</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/18</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>P80404</ddiem:uniprotId>
    <rdfs:label>GABA-transaminase</rdfs:label>
    <ddiem:ecNumber>2.6.1.19; 2.6.1.22</ddiem:ecNumber>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/dac32654-93bd-4437-8664-417d947dcead">
    <ddiem:uniprotId>P48637</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/99770541-5981-465b-91c3-21df56cf2d3e">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/2937</dc:identifier>
        <rdfs:label>GSS</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:ecNumber>6.3.2.3</ddiem:ecNumber>
    <ddiem:keggEntryId>K21456</ddiem:keggEntryId>
    <rdfs:label>glutathione synthetase</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/76df9ae6-0106-4393-b600-11126b27cd73">
    <ddiem:keggEntryId>""</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/188cc2d2-e6ee-4faa-a419-a3c7bbde1e0c">
        <rdfs:label>NPC2</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/10577</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>NPC intracellular cholesterol transporter 2</rdfs:label>
    <ddiem:uniprotId>""</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/633bcb37-249b-4038-a879-a6a9af2e53a3">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9b7dbd5d-0f1c-4909-8303-bbed922dd481">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Hyperurecemia</rdfs:label>
        <dc:identifier>done</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/done</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02527343</dc:provenance>
    <rdfs:comment>Niacin DB00627 occasionally can be used with Fibrate and omega 3 fatty acid in treating hypertriglyceridiemia. https://www.ncbi.nlm.nih.gov/pubmed/21079616</rdfs:comment>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8842764</dc:provenance>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/162000">
        <ddiem:iembaseAccessionNumber>1405</ddiem:iembaseAccessionNumber>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/1405</ddiem:iembaseUrl>
        <rdfs:label>HYPERURICEMIC NEPHROPATHY, FAMILIAL JUVENILE, 1; HNFJ1</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>https://www.omim.org/entry/162000</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/450d85e7-a3a9-4f99-8295-06295b3b8c5b"/>
      </ddiem:Disease>
    </obo:RO_0002599>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/899af578-4c5a-4b91-801f-90ac92423999">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/eea552eb-c991-4da4-b030-eb0aaf467c53"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5338723</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/e090b3f8-5890-490f-8057-33d9f8be81e4">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/13720715-b575-4503-8922-b1f3f6942235"/>
      </rdf:Alt>
    </obo:RO_0000057>
  </obo:DDIEM_0000013>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/9c39321c-592d-4aba-960d-fd1ad33063b3">
    <ddiem:keggEntryId>K14736</ddiem:keggEntryId>
    <rdfs:label>transferrin</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/713698dc-abe5-452a-ae49-09edc6a7cc19">
        <rdfs:label>TF</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/7018</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>P02787</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/550500">
    <rdfs:label>MYOGLOBINURIA, RECURRENT</rdfs:label>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/320fc82a-adc3-4a2f-9abd-5388b55b5499"/>
    <dc:identifier>https://www.omim.org/entry/550500</dc:identifier>
    <rdfs:comment></rdfs:comment>
  </ddiem:Disease>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/e614a6cb-74dc-437a-8764-d533850e0da6">
    <ddiem:keggEntryId>K01623</ddiem:keggEntryId>
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/186371a3-abf5-4efe-88fd-b60b2daed9d9"/>
    <ddiem:ecNumber>4.1.2.13</ddiem:ecNumber>
    <rdfs:label>aldolase, fructose-bisphosphate A</rdfs:label>
    <ddiem:uniprotId>P04075</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/cf9b1931-5a2f-44dd-be6d-e0c10e99d0fe">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/9753a6f7-da3d-491a-b453-05602d9d69ed">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/3077</dc:identifier>
        <rdfs:label>HFE</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>Hereditary hemochromatosis protein</rdfs:label>
    <ddiem:keggEntryId>""</ddiem:keggEntryId>
    <ddiem:uniprotId>Q30201</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/339ffcbf-1541-4164-a748-70a4165b1b11">
    <rdfs:label>DNA polymerase subunit gamma-2</rdfs:label>
    <ddiem:ecNumber>2.7.7.7</ddiem:ecNumber>
    <ddiem:uniprotId>P54098</ddiem:uniprotId>
    <ddiem:keggEntryId>K02332</ddiem:keggEntryId>
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/42910152-5855-4c4b-bc8a-f9d7f0ec1dba"/>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/5c0b4c49-a505-42cd-8c3d-129d4ffd93a0">
    <rdfs:label>Alkaline phosphatase</rdfs:label>
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/6ed7d20c-8b72-41a5-ac32-47d4eba88fcc"/>
    <ddiem:uniprotId>P05186</ddiem:uniprotId>
    <ddiem:ecNumber>3.1.3.1</ddiem:ecNumber>
    <ddiem:keggEntryId>K01077</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <owl:Class rdf:about="http://purl.obolibrary.org/obo/DDIEM_0000016">
    <obo:IAO_0000115 xml:lang="en">A therapeutic procedure that stimulates a component of the pathway or network in which a genetically defective defective protein is found, compensating for alteration of activity of that protein. [PNS]</obo:IAO_0000115>
    <dc:date rdf:datatype="http://www.w3.org/2001/XMLSchema#dateTime">2019-07-15T18:09:20+00:00</dc:date>
    <rdfs:label xml:lang="en">functional complementation or a defective protein by stimulation</rdfs:label>
    <dc:creator>leechuck</dc:creator>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
  </owl:Class>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/f42ff217-aa96-482d-a408-cfdf2dd03a83">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/ddf24210-fd69-4e0c-949d-7256b7e881cd">
        <rdfs:label>GLB1</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/2720</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:ecNumber>3.2.1.23</ddiem:ecNumber>
    <rdfs:label>beta-galactosidase</rdfs:label>
    <ddiem:keggEntryId>K12309</ddiem:keggEntryId>
    <ddiem:uniprotId>P16278</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/91eca52b-25a5-4957-b546-ed10819e6a36">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/dac9335f-10e1-4e20-b109-1990e641a7d3">
        <rdfs:label>SLC25A20</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/788</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>carnitine-acylcarnitine translocase</rdfs:label>
    <ddiem:uniprotId>O43772</ddiem:uniprotId>
    <ddiem:keggEntryId>K15109</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/2d8a8fca-bf0e-494d-ac53-aa6360a63b27">
    <rdfs:label>succinate-hydroxymethylglutarate coA-transferase</rdfs:label>
    <ddiem:keggEntryId>K18703</ddiem:keggEntryId>
    <ddiem:ecNumber>2.8.3.13</ddiem:ecNumber>
    <ddiem:uniprotId>Q9HAC7</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/edac7fdf-ffca-4fb9-8958-46a62247fdb5">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/79783</dc:identifier>
        <rdfs:label>SUGCT</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/2057a49d-5dc4-4d3d-b712-2ae65d60a43e">
    <ddiem:uniprotId>P51857</ddiem:uniprotId>
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/72591caf-750c-474b-a625-5f5936f83163"/>
    <ddiem:ecNumber>1.3.1.3</ddiem:ecNumber>
    <ddiem:keggEntryId>K00251</ddiem:keggEntryId>
    <rdfs:label>Aldo-keto reductase family 1 member D1</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/166553c7-787b-4dc6-b78d-86f0e37cc627">
    <rdfs:label>Carnitine acetyltransferase</rdfs:label>
    <ddiem:keggEntryId>""</ddiem:keggEntryId>
    <ddiem:uniprotId>P43155</ddiem:uniprotId>
    <ddiem:ecNumber>2.3.1.7</ddiem:ecNumber>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/b2a371f3-1268-414c-809b-3dfe566a4d48">
        <rdfs:label>CRAT</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/1384</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/215720">
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/cca27114-b6a4-4a77-ba25-1da0d809da77"/>
    <rdfs:label>CITRULLINE TRANSPORT DEFECT</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>https://www.omim.org/entry/215720</dc:identifier>
  </ddiem:Disease>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/cf00e0b2-a3dc-492d-bd22-61815d6b0123">
    <rdfs:label>Prosaposin</rdfs:label>
    <ddiem:keggEntryId>K12382</ddiem:keggEntryId>
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/567920d4-ffcc-445c-a1e0-a9a577b4cfff"/>
    <ddiem:uniprotId>P07602</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/daa23b65-3537-4051-a3de-e7fe1f2a0138">
    <ddiem:keggEntryId>K10863</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/ea240189-f99d-44f6-bd66-461e5b58a5f8">
        <rdfs:label>APTX</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/54840</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:ecNumber>3.1.11.7; 3.1.12.2</ddiem:ecNumber>
    <rdfs:label>Aprataxin</rdfs:label>
    <ddiem:uniprotId>Q7Z2E3</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/1c5a8fc3-9666-4dfc-98fc-009cc1df71c1">
    <rdfs:label>uridine diphosphateâglucuronyl transferase</rdfs:label>
    <ddiem:ecNumber>2.4.1.17</ddiem:ecNumber>
    <ddiem:keggEntryId>K00699</ddiem:keggEntryId>
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/f2173f45-1505-4676-9ee8-be970d33771b"/>
    <ddiem:uniprotId>P22309</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/7ab7e10f-319d-4dc5-88b1-646ad5a89cc7">
    <ddiem:keggEntryId>K05626</ddiem:keggEntryId>
    <rdfs:label>atrophin 1</rdfs:label>
    <ddiem:uniprotId>P54259</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/2b47a534-7015-4284-a6ee-74eafe60e58e">
        <rdfs:label>ATN1</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/1822</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/75d59db8-b61b-491e-9ba9-8bb1dcd5ee69">
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/4cf4f92e-89c7-4c03-9148-85a8fc1567bf"/>
    <ddiem:keggEntryId>K01495</ddiem:keggEntryId>
    <ddiem:ecNumber>3.5.4.16</ddiem:ecNumber>
    <ddiem:uniprotId>P30793</ddiem:uniprotId>
    <rdfs:label>GTP cyclohydrolase 1</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <foaf:Person rdf:about="Resource(https://www.pdn.cam.ac.uk)/EuniceMcMurray">
    <rdfs:label>Eunice McMurray</rdfs:label>
    <foaf:mbox rdf:resource="mailto:emm1@cam.ac.uk"/>
  </foaf:Person>
  <owl:AnnotationProperty rdf:about="http://purl.org/dc/elements/1.1/date"/>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/8c0d50d5-3baa-4901-adb8-bbec0c362cb6">
    <rdfs:label>LARGE xylosyl- and glucuronyltransferase 1</rdfs:label>
    <ddiem:keggEntryId>""</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/5cefcd24-5e21-406c-b7e7-a277879685da">
        <rdfs:label>LARGE</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/""</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>""</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/ca3b2f17-35c8-488d-acf7-802f07158d55">
    <ddiem:keggEntryId>K01640</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/58acd2c5-c2be-4bd6-9b94-c96c10a53ae9">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/3155</dc:identifier>
        <rdfs:label>HMGCL</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:ecNumber>4.1.3.4</ddiem:ecNumber>
    <ddiem:uniprotId>P35914</ddiem:uniprotId>
    <rdfs:label>HMG-CoA lyase</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/0c164a2e-bfb1-4361-8908-c9c085f21805">
    <ddiem:keggEntryId>K12565</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/88042d75-cd37-4a91-8d21-1beb89e39ab1">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/6442</dc:identifier>
        <rdfs:label>SGCA</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>Q16586</ddiem:uniprotId>
    <rdfs:label>sarcoglycan alpha</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/616479">
    <rdfs:comment></rdfs:comment>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/c347f37f-e0a5-41a4-966d-df592d11f89a"/>
    <rdfs:label>PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA WITH MITOCHONDRIAL DNA DELETIONS, AUTOSOMAL RECESSIVE 2; PEOB2</rdfs:label>
    <dc:identifier>https://www.omim.org/entry/616479</dc:identifier>
  </ddiem:Disease>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/210fe604-373c-4d5f-b9df-081aa1cd713e">
    <rdfs:label>sarcoglycan gamma</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/e446e2b0-18fc-4e9f-89c0-a14c3e96d1bb">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/6445</dc:identifier>
        <rdfs:label>SGCG</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K12564</ddiem:keggEntryId>
    <ddiem:uniprotId>Q13326</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <owl:AnnotationProperty rdf:about="http://purl.org/dc/elements/1.1/creator"/>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/4e06fb1d-cf23-4ad7-bb13-f720028008de">
    <ddiem:keggEntryId>K14158</ddiem:keggEntryId>
    <rdfs:label>sodium/glucose cotransporter protein called SGLT1</rdfs:label>
    <ddiem:uniprotId>P13866</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/d4f0dd53-58be-406b-933e-c7a5496fe51e">
        <rdfs:label>SLC5A1</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/6523</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/b15e0287-d7a7-4696-82c3-9233b735427e">
    <rdfs:label>GPI mannosyltransferase 1</rdfs:label>
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/ceecbe7b-3d12-4850-8a69-050e5ac8cb06"/>
    <ddiem:uniprotId>Q9H3S5</ddiem:uniprotId>
    <ddiem:ecNumber>2.4.1.-</ddiem:ecNumber>
    <ddiem:keggEntryId>K05284</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/688fae90-c810-45c6-9070-062050ab026a">
    <rdfs:label>uromodulin</rdfs:label>
    <ddiem:uniprotId>P07911</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/450d85e7-a3a9-4f99-8295-06295b3b8c5b">
        <rdfs:label>UMOD</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/7369</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K18274</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/276e8e8a-e43b-4b9a-bd8e-f2ae41dc9177">
    <ddiem:uniprotId>P01009</ddiem:uniprotId>
    <rdfs:label>alpha-1-antitrypsin (major plasma serine protease inhibitor)</rdfs:label>
    <ddiem:keggEntryId>K03984</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/e4e84e27-6327-4739-991c-ae735323b318">
        <rdfs:label>SERPINA1</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/5265</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/67a14b97-741e-4833-b442-dbffe674b93a">
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/97527ef1-a44a-4202-911a-e73a9fb378c2"/>
    <rdfs:label>fukutin-related protein (FKRP)</rdfs:label>
    <ddiem:ecNumber>2.4.2.-</ddiem:ecNumber>
    <ddiem:keggEntryId>K19873</ddiem:keggEntryId>
    <ddiem:uniprotId>Q9H9S5</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <owl:Ontology rdf:about="http://purl.obolibrary.org/obo/">
    <owl:imports rdf:resource="http://purl.obolibrary.org/obo/ogms.owl"/>
  </owl:Ontology>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a6d6b318-f238-4942-8a31-8aba1bfeec22">
    <dc:identifier>HP:0011013</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0011013</ddiem:url>
    <rdfs:label>abnormal carbohydrate metabolism*</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/dd840dd0-64af-4270-b65f-7934b9b29a4f">
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/aed6c48a-f146-4e90-b66c-2d10ac790a96"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:comment>Many studies have reported early responce to l- dopa treatment as mentioned in https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4503963/, and other pointed to " prominent dyskinesia " as side effect to same treatment https://www.ncbi.nlm.nih.gov/pubmed/19087156/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6206929</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8225213</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11067870</dc:provenance>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19622360</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/73ee989c-18fb-4d98-9b01-4fb03004069e">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/50bbf25c-9376-4e3f-879a-ca29d093f0d4"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/607765">
        <rdfs:label>BILE ACID SYNTHESIS DEFECT, CONGENITAL, 1; CBAS1</rdfs:label>
        <dc:identifier>https://www.omim.org/entry/607765</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/f972158b-0da5-4de1-ad95-478682be2c05"/>
      </ddiem:Disease>
    </obo:RO_0002599>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7915305</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20619503</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18570303</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19087156</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4503963</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2072042</dc:provenance>
  </obo:OGMS_0000112>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/a86a0852-1717-4622-ad8b-1d4ed6713355">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4c252287-c3f1-4642-9f64-bb5b8083ebe4">
        <rdfs:label>Elevated Urinary DHA excretion</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/614723">
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/12e29895-78f0-4367-a22d-a8bf930e2d2c"/>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>ADENINE PHOSPHORIBOSYLTRANSFERASE DEFICIENCY; APRTD</rdfs:label>
        <dc:identifier>https://www.omim.org/entry/614723</dc:identifier>
      </ddiem:Disease>
    </obo:RO_0002599>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/51525fc1-fb4c-4f62-8963-2fb8faca1fed">
        <rdfs:label>Dysuria</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0100518</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0100518</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02752633</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6b6d7f5c-f3f6-42c5-8576-73c063d4c053">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000787</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>urolithiasis</rdfs:label>
        <dc:identifier>HP:0000787</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15767622</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/books/NBK100238</dc:provenance>
    <rdfs:comment>There is a study for "Non-viral delivery of the porphobilinogen deaminase cDNA into a mouse model of acute intermittent porphyria{ ECO: 0005542} https://www.ncbi.nlm.nih.gov/pubmed/15110317</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648/#b96-tacg-8-201</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2c4c2145-9d1d-4115-8792-8077248dbf65">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0000112</dc:identifier>
        <rdfs:label>crystalline nephropathy</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000112</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2aace5ae-1cfa-4e52-99f2-c0d7f67918e3">
        <rdfs:label>Kidney stones</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/97ee8e25-18d2-435d-be89-ffb04c9da19d">
        <dc:identifier>HP:0000790</dc:identifier>
        <rdfs:label>Hematuria</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000790</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a2eb141b-8e09-4606-8dff-7c3e899c2629">
        <rdfs:label>Recurrent urinary tract infections</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000010</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0000010</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/aaea9ca7-d37c-4d81-8797-c4a3fcd8d6b9">
        <rdfs:label>Chronic kidney disease</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012622</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0012622</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://academic.oup.com/ckj/article/9/6/800/2709623</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/899af578-4c5a-4b91-801f-90ac92423999"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29241594</dc:provenance>
  </obo:OGMS_0000112>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/a155753b-ac50-4984-acd5-80ae6865850b">
    <rdfs:comment>Uncoooked cornstrach was introduced in small frequent meal and was accomapined with elimination of lactose in diet</rdfs:comment>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02527343</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/412123cc-a734-417a-8ce8-616f310590bc">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0001397</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001397</ddiem:url>
        <rdfs:label>Hepatic steatosis</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT03508687</dc:provenance>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/151660">
        <rdfs:comment>Data regarding TZD therapy and the restoration of adipose tissue in lipoatrophic areas has been conflicting; it appears as though TZDs do not improve lipoatrophy in patients with FPLD2. https://www.ncbi.nlm.nih.gov/pubmed/19040647/</rdfs:comment>
        <rdfs:label>LIPODYSTROPHY, FAMILIAL PARTIAL, TYPE 2; FPLD2</rdfs:label>
        <dc:identifier>https://www.omim.org/entry/151660</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/c28ba02c-c555-42e6-819b-3c4cb45b5d63"/>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5338723</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/62f13862-3b92-42cc-9dad-e958eef7c627"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/7e294e4f-596e-4bed-8838-2a13a74c74a9">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/cb39e50a-d4be-40a7-a2c6-9e575ca1a2b2"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02211209</dc:provenance>
  </obo:OGMS_0000112>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/2e4474c9-8f76-4973-834f-7f1ad06c5c32">
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/ac9e4c34-6622-410a-8b39-d4b71217d40b"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b2f79574-538d-42b1-95dd-b2359901bc44">
        <rdfs:label>High plasma phenylalanine level</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0004923</ddiem:url>
        <dc:identifier>HP:0004923</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ba749995-52d3-4618-adf5-a80bbf1d7c6a">
        <rdfs:label>Receptive language delay</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0010863</ddiem:url>
        <dc:identifier>HP:0010863</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>Alhough therapy with desmopressin cannot be recommended based on the results of a single case, the outcome presented here is intriguing and suggests that larger studies in such patients is warranted to assess the broader application of such an intervention.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27622829</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/c4633604-cb41-4d90-84d5-44841bde9fef"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30349988</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23430801</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8163996</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/78f3d001-4887-4d42-8777-a38dce39096e"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/804ee22e-7659-4fb5-abaf-b520bf18ba46"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/ff5e395d-975f-446c-a5c0-2c6349abf7a5"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/e26f58c5-3e77-453b-8c30-5df2c9c700e9"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1899474</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16891685</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/52e8a2fc-4f09-484c-b760-3256113b017d">
        <rdfs:label>unalertencess</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002329</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0002329*</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12084887</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26817292</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/261630"/>
  </obo:OGMS_0000112>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/1203be3b-8ddd-4b67-91c8-38c96f885bbc">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19323589</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:comment>There is no clinical role for NaPBA at present; however, ongoing studies are assessing its efficacy https://www.ncbi.nlm.nih.gov/pubmed/28919799 Phenotypes corrected were based on invivo trial on mice not humans.</rdfs:comment>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24746802</dc:provenance>
    <dc:provenance>https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/202b2073-9e0f-4323-b4bc-9fcf095b645b"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01212744</dc:provenance>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/520000">
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/409</ddiem:iembaseUrl>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/1abaf40f-2a9b-43e9-9c9c-053c92416972"/>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/27cf12eb-db1f-49f7-ba20-908346f6c667"/>
        <dc:identifier>https://www.omim.org/entry/520000</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>DIABETES AND DEAFNESS, MATERNALLY INHERITED; MIDD</rdfs:label>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/e8fb24f7-308e-4736-836b-f600761996e6"/>
        <ddiem:iembaseAccessionNumber>409</ddiem:iembaseAccessionNumber>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/4556601b-4e58-4413-90b1-df627cd415d1"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
  </obo:OGMS_0000112>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/73316025-17ba-4432-8743-d4268c2c7478">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b1507cea-7e85-4035-9cfa-e6c22fc6cbc5">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001959</ddiem:url>
        <rdfs:label>Polydipsia</rdfs:label>
        <dc:identifier>HP:0001959</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16882283</dc:provenance>
    <rdfs:comment>In individuals with allergies or intolerance to allopurinol, febuxostat may be considered; however, no data on the use of this medication in UMOD-associated kidney disease are available at present.</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/fe852d51-e042-488c-b347-8c128adaec9c">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003165</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0003165</dc:identifier>
        <rdfs:label>Elevated circulating parathyroid hormone level</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17803689</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22142470</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f2be6625-9cca-4a55-9c96-5db910a8adc7">
        <dc:identifier>HP:0003072</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003072</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Hypercalcemia</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b06ea300-4791-4371-9dec-b0ca464121f4">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0004732</ddiem:url>
        <rdfs:label>Impaired renal uric acid clearance</rdfs:label>
        <dc:identifier>HP:0004732</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28459040</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20495831</dc:provenance>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/145980">
        <dc:identifier>https://www.omim.org/entry/145980</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/ac74bd37-46c0-4164-8c8d-4881a97f33c2"/>
        <rdfs:label>HYPOCALCIURIC HYPERCALCEMIA, FAMILIAL, TYPE I; HHC1</rdfs:label>
        <rdfs:comment>In majority of cases, there is no need for treatment until thecalcium level is very high, it becomes necessary to treat FHH.https://www.ncbi.nlm.nih.gov/pubmed/21986511</rdfs:comment>
      </ddiem:Disease>
    </obo:RO_0002599>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000012"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/057054e8-3498-4069-b295-e83a34a3c389">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/6b1e2c3d-796f-4767-8ba4-5cce6cd7e5c2"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21289269</dc:provenance>
  </obo:OGMS_0000112>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/0967de03-d801-46be-aacd-78b8275d71f5">
    <rdfs:comment>A combination therapy with cysteamine bitartrate and N-acetylcysteine is associated with delay of isoelectric EEG, depletion of GRODs, and subjective benefits as reported by parents and physicians. https://www.ncbi.nlm.nih.gov/pubmed/24997880</rdfs:comment>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d516cb33-b62e-4211-803b-1df600eb7047"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/88a76fdd-4215-4f44-872c-9344ac76a05a"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29631617</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00028262</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/256730"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
  </obo:OGMS_0000112>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/63a0f3fe-ac11-418e-805b-3f33485ee494">
    <rdfs:label>Retrovirus-mediated gene transfer of 6-pyruvoyl-tetrahydropterin synthase</rdfs:label>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/89196a73-5b9e-49cc-b5ff-f4a5a1d7c9f4">
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/d6fd6253-32ee-4df5-84f0-f420e3c6fe75"/>
        <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
        <rdfs:comment>It's an investigational therapy where Positive results from using a selective monoamine oxidase (MAO) B inhibitor or non-ergot dopamine agonist pramipexole as an adjunct therapy have been described in the medical literature. This use of such an inhibitor can allow for lower doses of neurotransmitter precursor to be used. However, the long-term safety (e.g. effects on neonatal brain development) and effectiveness of this therapy is unknown and more research is required to determine what role, if any, selective monoamine oxidase B inhibitors play in the treatment of individuals with tetrahydrobiopterin deficiency. https://rarediseases.org/rare-diseases/tetrahydrobiopterin-deficiency/. https://www.researchgate.net/publication/233414693_Deprenyl_in_6-Pyruvoyl_Tetrahydropterin_Synthase_Deficiency. https://www.degruyter.com/downloadpdf/j/pteridines.1995.6.issue-3/pteridines.1995.6.3.144/pteridines.1995.6.3.144.pdf</rdfs:comment>
        <dc:provenance>https://www.researchgate.net/publication/233414693_Deprenyl_in_6-Pyruvoyl_Tetrahydropterin_Synthase_Deficiency</dc:provenance>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/direct_complementation_of_a_genetically_defective_protein_by_gene_therapy"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12003346</dc:provenance>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/9a35c519-df14-4ac7-a536-4ddc9c2d5c1c"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/261640"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8864759</dc:provenance>
        <dc:provenance>https://www.babysfirsttest.org/newborn-screening/conditions/3-methylcrotonyl-coa-carboxylase-deficiency</dc:provenance>
        <dc:provenance>https://rarediseases.org/rare-diseases/tetrahydrobiopterin-deficiency</dc:provenance>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
  </ddiem:Drug>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/39248d5c-a200-4ac3-8761-63d6b01d6f18">
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/397a09b3-2d92-4bfa-8ddf-6f103f0e2656"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25266922</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15726662</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000010"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583863</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300</dc:provenance>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/261750">
        <rdfs:label>GLYCOGEN STORAGE DISEASE IXb; GSD9B</rdfs:label>
        <dc:identifier>https://www.omim.org/entry/261750</dc:identifier>
        <ddiem:iembaseAccessionNumber>1258</ddiem:iembaseAccessionNumber>
        <rdfs:comment></rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/3c1788f7-9fa8-4c76-922d-283b4a44b930"/>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/1258</ddiem:iembaseUrl>
      </ddiem:Disease>
    </obo:RO_0002599>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d99eaa74-e215-4f5f-9546-28e4cc5570be">
        <rdfs:label>Short Stature</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0004322</ddiem:url>
        <dc:identifier>HP:0004322</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC324959</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2564511</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/ed30ad6f-a7a2-4510-9e8f-561fa7e3d666">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/6a52e971-e9dd-45fd-aa8d-74a2b630f0f0"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:comment>Treatment was stopped three days later because of lack of improvement and severe respiratory alkalosis with lactic acidosis (serum lactic acid 70 mg/dl, normal 4â20 mg/dl). https://www.ncbi.nlm.nih.gov/pubmed/12948744</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3306242</dc:provenance>
  </obo:OGMS_0000112>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/227d9c64-4536-4d08-80ca-a4474e0f1ccb">
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/261640">
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/4</ddiem:iembaseUrl>
        <rdfs:comment></rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/36e8d65a-5e4f-4b54-9a90-8d3825658c5b"/>
        <rdfs:label>HYPERPHENYLALANINEMIA, BH4-DEFICIENT, A; HPABH4A</rdfs:label>
        <ddiem:iembaseAccessionNumber>4</ddiem:iembaseAccessionNumber>
        <dc:identifier>https://www.omim.org/entry/261640</dc:identifier>
      </ddiem:Disease>
    </obo:RO_0002599>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/ac9e4c34-6622-410a-8b39-d4b71217d40b"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/defd389a-6020-47ff-b82a-feee9681cf43">
        <dc:identifier>HP:0012759</dc:identifier>
        <rdfs:label>Neurodevelopmental abnormality</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012759</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16601879</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1664324f-694a-4960-bbee-fa39e5a1d7dc">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Intellectual disability</rdfs:label>
        <dc:identifier>HP:0001249</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001249</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/c576bad9-b514-49c9-a2f8-c639d5e8fd3f"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/dee0cb1f-8fe1-4760-a796-dddc3d860532">
        <rdfs:label>Delayed CNS mylinaton</rdfs:label>
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
        <dc:identifier>HP:0002188</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002188</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25304915</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/c4633604-cb41-4d90-84d5-44841bde9fef"/>
    <rdfs:comment>Effect of glycine in treating the condition is variable among literatures.  "Case reports have noted variable results regarding the effect of glycine administration. Some studies have found that supplemental glycine results in increased excretion of 3-methylcrotonyl glycine, while others have not found a persistent effect; no studies have observed clinical improvement of symptoms on treatment and no randomized clinical trials have been published" https://www.sciencedirect.com/science/article/pii/S1096719207005975?via%3Dihub#bib11
https://www.ncbi.nlm.nih.gov/pubmed/8831079
https://www.ncbi.nlm.nih.gov/pubmed/7474896</rdfs:comment>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/749c4e05-a067-4dbf-bfde-b25a6123b0e0"/>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12003346</dc:provenance>
    <dc:provenance>https://www.babysfirsttest.org/newborn-screening/conditions/3-methylcrotonyl-coa-carboxylase-deficiency</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23690520</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6178724</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/78f3d001-4887-4d42-8777-a38dce39096e"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/50b11d07-6d6c-485b-b3af-1f6d0e4d644e"/>
  </obo:OGMS_0000112>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/fdae03cc-8e7b-4bf1-ac5a-b9179cde1d47">
    <dc:identifier>HP:0000164</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000164</ddiem:url>
    <rdfs:label>Dental Defects</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/5d52cd5e-c07e-42de-9182-df20d21e19da">
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/608643">
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/a284a51e-e6d2-49f4-b5d9-385e2e78fe08"/>
        <ddiem:iembaseAccessionNumber>100</ddiem:iembaseAccessionNumber>
        <rdfs:label>AROMATIC L-AMINO ACID DECARBOXYLASE DEFICIENCY</rdfs:label>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/100</ddiem:iembaseUrl>
        <dc:identifier>https://www.omim.org/entry/608643</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Disease>
    </obo:RO_0002599>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/da184cec-d903-494e-a46f-a3dad76d2400">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002421</ddiem:url>
        <dc:identifier>HP:0002421</dc:identifier>
        <rdfs:label>Poor head control</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ad006969-4020-495b-b825-5f95a5d87391">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Oculogyric crisis</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0010553</ddiem:url>
        <dc:identifier>HP:0010553</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6a73c2b1-c147-41b6-a5f9-4604bcac8ae2">
        <rdfs:label>Voluntary movement abnormalities (Abnormality of movement)*</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0100022*</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0100022</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e95bfb09-8ecd-45c4-b80e-72bb7816e68f">
        <dc:identifier>HP:0001290</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001290</ddiem:url>
        <rdfs:label>Hypotonia</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5241937</dc:provenance>
    <dc:provenance>https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23494656</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/621b465a-c3a8-4011-8265-4e3983701096">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/75278c7a-98fe-4bd5-a4a6-8efca1c2cc12"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:comment>In a study done by Mastrandeleo et. al , it was mentioned that Transdermal rotigotine was efficacious in the early stages of AADC of an affected male; however, the treatment was not effective in his older, more impaired brother.</rdfs:comment>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01395641</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3955971</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23390030</dc:provenance>
    <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/74b66f98-6381-4667-b744-1af42f1cb529">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002459</ddiem:url>
        <rdfs:label>Autonomic dysfunction</rdfs:label>
        <dc:identifier>HP:0002459</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </obo:OGMS_0000112>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/607625">
    <rdfs:comment></rdfs:comment>
    <ddiem:iembaseAccessionNumber>304</ddiem:iembaseAccessionNumber>
    <rdfs:label>NIEMANN-PICK DISEASE, TYPE C2; NPC2</rdfs:label>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/304</ddiem:iembaseUrl>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/188cc2d2-e6ee-4faa-a419-a3c7bbde1e0c"/>
    <dc:identifier>https://www.omim.org/entry/607625</dc:identifier>
  </ddiem:Disease>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/12621df5-9e28-4635-a0d6-5ac00ab59261">
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01420627</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29241594</dc:provenance>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/102700">
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/142</ddiem:iembaseUrl>
        <ddiem:iembaseAccessionNumber>142</ddiem:iembaseAccessionNumber>
        <rdfs:label>SEVERE COMBINED IMMUNODEFICIENCY, AUTOSOMAL RECESSIVE, T CELL-NEGATIVE, B CELL-NEGATIVE, NK CELL-NEGATIVE, DUE TO ADENOSINE DEAMINASE DEFICIENCY</rdfs:label>
        <dc:identifier>https://www.omim.org/entry/102700</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/5f487166-9a02-4384-8321-f913f8a60917"/>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://globenewswire.com/news-release/2015/03/30/720127/10126746/en/Sigma-Tau-Pharmaceuticals-Inc-Receives-Orphan-Drug-Designation-for-EZN-2279-for-Treatment-of-Adenosine-deaminase-Deficient-Severe-Combined-Immunodeficiency-Disease.html</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2585601</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/4545c674-c3f0-46ca-9286-b2a815b064de">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/17afc5d6-c85c-41a2-86a1-e14e15a4b30c"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3488882</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648/#b96-tacg-8-201</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/cdec8137-0822-4811-8652-bbe062cd76d5">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Recurrent infection</rdfs:label>
        <dc:identifier>HP:0002719</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002719</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>IG replacement is also indicated in infants with severe combined immunodeficiency (SCID) awaiting transplant and in those in which B cells function is not restored following transplantation. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2585601/</rdfs:comment>
  </obo:DDIEM_0000013>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/278000">
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/302</ddiem:iembaseUrl>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/1f6138e2-9d98-4c5b-874c-42bd9382c1fc"/>
    <rdfs:label>LYSOSOMAL ACID LIPASE DEFICIENCY</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>https://www.omim.org/entry/278000</dc:identifier>
    <ddiem:iembaseAccessionNumber>302</ddiem:iembaseAccessionNumber>
  </ddiem:Disease>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/cb40e28f-cc65-4e8a-ab4f-51e53eac530c">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002719</ddiem:url>
    <dc:identifier>HP:0002719</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>"Frequent, severe infections"</rdfs:label>
  </ddiem:Phenotype>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/cd489235-a91d-4928-bb81-637b2919412b">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3162680</dc:provenance>
    <dc:provenance>https://link.springer.com/article/10.1007%2Fs11883-014-0440-2</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/62f13862-3b92-42cc-9dad-e958eef7c627"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/617347"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25079293</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:comment>clinicians might only switch to combination therapy in FD patients who remain severely hypertriglyceridemic and/or hypercholesterolemic on monotherapy instead of prescribing combined statin-fibrate therapy to all FD patients that do not meet the non-HDL-C target.https://www.ncbi.nlm.nih.gov/pubmed/25768710</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28098593</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/f8712a5b-6773-4e20-b7d8-bb42f873ffcf">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/2555637e-3af5-42d1-ba7c-e3d67489c049"/>
      </rdf:Alt>
    </obo:RO_0000057>
  </obo:OGMS_0000112>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/23c0f345-1598-4dc8-a9e6-6b2b98712dfd">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25832663</dc:provenance>
    <rdfs:comment>Testosterone therapy needs to be carefully considered because of the risk of hepatic adenomas.https://www.ncbi.nlm.nih.gov/pubmed/28160246
Androgen receptors are expressed in the liver, and androgens can stimulate hepatocyte proliferation. Although rare, androgens have been shown in observational studies to induce adenoma development (Giannitrapani et al. 2006). Testosterone levels should be assessed for response 2â3 months after therapy is initiated.</rdfs:comment>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/232400"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17514432</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29223626</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24613482</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2f330e37-5bd8-44a3-ba42-94923b435485">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012211</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0012211</dc:identifier>
        <rdfs:label>exercise intolerance</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/ff02436f-a8a1-4263-9a6d-1f6bd05b62b0"/>
  </obo:OGMS_0000112>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/31ba3c75-9c65-482c-b783-451e11c158a7">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0004324</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0004324</dc:identifier>
    <rdfs:label>weight gain</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/59201c4e-ef95-4492-81f6-233c60073a8d">
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/7ba0ddaf-3653-43e7-bae9-d53b41c895eb">
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/300322"/>
        <dc:provenance>https://rarediseases.org/rare-diseases/lesch-nyhan-syndrome</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27179999</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/2dfbbd8b-c34d-4c46-98d4-e75f66ffc981"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3202309</dc:provenance>
        <rdfs:comment>Treatment with allopurinol was associated with xanthine lithiasis. https://www.ncbi.nlm.nih.gov/pubmed/17065067 
https://www.ncbi.nlm.nih.gov/pubmed/16773422/</rdfs:comment>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24093206</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/5b53f2f0-5ffd-4058-8a71-a8aca22b32e5"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21483849</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29054473</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/fa24eff3-c401-4324-b234-88444910ba26"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22198833</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21126241</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0003304>Spa</obo:RO_0003304>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <rdfs:label>Alprazolam</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00404</ddiem:url>
    <dc:identifier>DB00404</dc:identifier>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/3223c78d-7e37-4e46-ba44-14a8d29275ab">
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/f8e8c458-cdba-4fa4-a0d7-f720749fb9aa">
        <dc:provenance>http://www.neurologyindia.com/article.asp</dc:provenance>
        <rdfs:comment>Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss</rdfs:comment>
        <dc:provenance>https://www.orpha.net/data/patho/GB/uk-Bartter.pdf</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/602522"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/50b13d74-1819-4baf-a663-a65f46baeb91"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/abccd4d6-c26d-43f5-a1bb-09057b22362d"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24260777</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.nejm.org/doi/full/10.1056/NEJM197807132990214</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2646391</dc:provenance>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/ae941678-b12d-4907-9e40-6a71a79a947c">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5045115</dc:provenance>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23432031</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6411330</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/118600"/>
        <rdfs:comment>Effective only in flares. Oral steroids should be preferred when joint involvement is polyarticular; intra-muscular steroids when contraindication to use oral steroids and joint involvement is polyarticular; intra-articular steroids when joint involvement is mono- or oligoarticular.  https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6411330/</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31239752</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/095762a4-b9bf-47c0-918d-9f5ce2a2f67e"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/4f58f104-5672-4762-b3dc-5aa64b45cdc0"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/50b13d74-1819-4baf-a663-a65f46baeb91"/>
        <dc:provenance>https://acrabstracts.org/abstract/anakinra-compared-to-prednisone-on-the-treatment-of-acute-cppd-crystal-arthritis-a-randomized-controlled-double-blind-study</dc:provenance>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <rdfs:label>Naproxen</rdfs:label>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/b5a16603-b96e-4901-b093-9d640792cc3f">
        <rdfs:comment>There is a contraversy about effectivness of methotrexate in treating "Condrocalcinosis 2" .. Details are in https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4223155/ and https://www.ncbi.nlm.nih.gov/pubmed/22832286/</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/50b13d74-1819-4baf-a663-a65f46baeb91"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17541659</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/0b21626b-db68-48a4-b6f7-9a2248bba621"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21102543</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22832289</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4223155</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/118610"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6411330</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6169684</dc:provenance>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <dc:identifier>DB00788</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00788</ddiem:url>
  </ddiem:Drug>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/b63488c0-d0d4-4e1f-9ad0-2f831d21012c">
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <rdfs:comment>If on supplemental bicarbonate or citrate, phosphorus or calcitriol or other vitamin D analog, need kidney function assessment 1 w/blood &amp; urine tests
May need serum vitamin D-25 hydroxy to assess for parent vitamin D deficiency</rdfs:comment>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/309000">
        <ddiem:iembaseAccessionNumber>1061</ddiem:iembaseAccessionNumber>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/1061</ddiem:iembaseUrl>
        <dc:identifier>https://www.omim.org/entry/309000</dc:identifier>
        <rdfs:label>LOWE OCULOCEREBRORENAL SYNDROME; OCRL</rdfs:label>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/011a0fa0-9b10-4853-a0f9-60965261efe0"/>
        <rdfs:comment></rdfs:comment>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://www.paediatricaindonesiana.org/index.php/paediatrica-indonesiana/article/view/59/33</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/b85320e8-bfd6-4cc7-aa0e-16b144f05edb">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/eaa48ea4-c25a-404d-a98c-ae4f6bcc0847"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26251718</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e51d5b33-bc0b-443c-9399-fcebf876c9a6">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0002150</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002150</ddiem:url>
        <rdfs:label>High calcium excretion</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17339125</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
  </obo:OGMS_0000112>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0ab6ea8c-1776-4c82-8789-0bfe82480ecd">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0025142</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0025142*</dc:identifier>
    <rdfs:label>affected functional activity</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f4bcaa8a-92d7-4328-92c3-e4514008f207">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Acute decompensation</rdfs:label>
  </ddiem:Phenotype>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/71513e08-ee54-4066-a806-3d015b05822d">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12801620</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12181212</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3162680</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/457789d6-10dc-4f16-85f5-5b3ed8c11a1f">
        <dc:identifier>HP:0003124</dc:identifier>
        <rdfs:label>High serum total cholesterol</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003124</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>clinicians might only switch to combination therapy in FD patients who remain severely hypertriglyceridemic and/or hypercholesterolemic on monotherapy instead of prescribing combined statin-fibrate therapy to all FD patients that do not meet the non-HDL-C target.https://www.ncbi.nlm.nih.gov/pubmed/25768710</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7490e4be-5f1b-4ec0-ad93-dcb3a2741910">
        <rdfs:label>High remnant-like particle (RLP)-cholesterol</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/617347"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/36097182-3eed-4df8-99cd-08eeff6ce767">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0031798</ddiem:url>
        <dc:identifier>HP:0031798</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Elevated apolipoprotein B level</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8c7db260-d57f-4964-9632-3112478db864">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0002155</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002155</ddiem:url>
        <rdfs:label>High serum triglyceride</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/fee6d538-da4d-4b13-9e0f-526f5277f305"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/77560d5a-d287-467d-946a-3fb25141263c">
        <dc:identifier>HP:0003362</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Elevated VLDL-cholesterol,serum TG ratio</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003362</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2065040</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b75343ed-35c8-497c-bd8f-3300a86a7c9a">
        <rdfs:label>High remnant-like particle (RLP)-TG</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </obo:OGMS_0000112>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/23780b08-fd12-4f13-8a48-864a499b1762">
    <rdfs:label>Retrovirus</rdfs:label>
    <obo:RO_0000056>
      <obo:direct_complementation_of_a_genetically_defective_protein_by_gene_therapy rdf:about="http://ddiem.phenomebrowser.net/84af8e23-ab33-4ea3-a0f7-e95aaa512506">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300</dc:provenance>
        <rdfs:comment>Information about the Study can be ound in https://gmoinfo.jrc.ec.europa.eu/bsnifs-gmo/B-NL-17-001.pdf</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15753292</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3306242</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/162de3ca-5932-410a-8797-34b69655ebad"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9156798</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583863</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15726662</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9457971</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/145434e3-5330-4a0b-a874-7a048b64936a"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/218800"/>
      </obo:direct_complementation_of_a_genetically_defective_protein_by_gene_therapy>
    </obo:RO_0000056>
  </ddiem:Drug>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/a625f425-f2a1-4566-9be5-989c40f316be">
    <rdfs:comment>In this study"https://www.ncbi.nlm.nih.gov/pubmed/10385780?dopt=Abstract" authors claimed that gemfibrozil is more effective in reducing total triglyceride and VLDL lipid levels than simvastatin, and simvastatin is better in reducing LDL cholesterol than gemfibrozil is. IDL and apolipoprotein E levels were reduced similarly with both drugs.</rdfs:comment>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/617347"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/53b3ac96-ba25-4a71-ad79-75588152173d">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003119</ddiem:url>
        <rdfs:label>high non-HDL-C (Abnormality of lipid metabolism)*</rdfs:label>
        <dc:identifier>HP:0003119*</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/866674f7-6686-4955-b72a-3e13de23b98e"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25768710</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28098593</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0021915015001379</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3162680</dc:provenance>
  </obo:OGMS_0000112>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/a8a027e7-1dda-419c-92fc-0915be308ede">
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02014883</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0085253816306020</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1a708dc8-b6f8-4c52-836a-79310a0fbfe0">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0040084</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0040084</ddiem:url>
        <rdfs:label>Abnormal serum renin level</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/be80862b-64dd-4836-b153-fb0a2c5c7494">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0004319</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0004319</dc:identifier>
        <rdfs:label>Abnormally reduced levels of aldosterone</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29624790</dc:provenance>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/263800">
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/889</ddiem:iembaseUrl>
        <rdfs:comment></rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/c06450ee-9a24-4ac2-9aba-5af25939894c"/>
        <rdfs:label>GITELMAN SYNDROME; GTLMNS</rdfs:label>
        <ddiem:iembaseAccessionNumber>889</ddiem:iembaseAccessionNumber>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/23b0fb34-a4db-4681-bc22-999d01cdd3a6"/>
        <dc:identifier>https://www.omim.org/entry/263800</dc:identifier>
      </ddiem:Disease>
    </obo:RO_0002599>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/5187dc8f-11c0-4f2c-a5ae-0ef4ef19e9a4">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/ff688d97-31af-4f2a-8328-264bd82a922d"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12141411</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a615f712-7774-4e29-bf01-0cc4a3fb6fad">
        <rdfs:label>Refractory hypokalemia</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002900</ddiem:url>
        <dc:identifier>HP:0002900*</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02000960</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23196212</dc:provenance>
    <rdfs:comment>The use of the drug is limited by its long-term cardiovascular adverse effects. https://www.ncbi.nlm.nih.gov/pubmed/12141411</rdfs:comment>
  </obo:DDIEM_0000013>
  <obo:DDIEM_0000011 rdf:about="http://ddiem.phenomebrowser.net/29286523-6446-457b-aaab-0d65cc5b0c83">
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/aa52b47a-f9db-4ce7-bb91-26794191e368"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <rdfs:comment>Sodium bicarbonate is not given routinely as any acidosis usually corrects quickly, but sodium bicarbonate may be needed if, after the initial bolus of glucose, the pH remains &lt;7.1 or the pH is deteriorating rapidly. https://www.ncbi.nlm.nih.gov/pubmed/29203193</rdfs:comment>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/229700">
        <rdfs:comment>The therapy is based on avoiding prolonged fasts, glucose infusion, and a specific diet, rich in glucose without fructose intake. https://www.ncbi.nlm.nih.gov/pubmed?Db=pubmed&amp;Cmd=Retrieve&amp;list_uids=29390242&amp;dopt=abstractplus
Fructose, glycerol and oral medicines that may contain sucrose and sorbitol should not be given during acute illness. https://link.springer.com/chapter/10.1007/978-3-642-15720-2_9</rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/5d3237e8-b1fe-4b49-9792-6f16961ca6a4"/>
        <ddiem:iembaseAccessionNumber>483</ddiem:iembaseAccessionNumber>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/483</ddiem:iembaseUrl>
        <dc:identifier>https://www.omim.org/entry/229700</dc:identifier>
        <rdfs:label>FRUCTOSE-1,6-BISPHOSPHATASE DEFICIENCY; FBP1D</rdfs:label>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27491218</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29203193</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29390242</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/345f7321-2b9d-4b63-8db8-6f154976000d"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
  </obo:DDIEM_0000011>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d3373f65-311e-48f4-a0a1-0e381c00021b">
    <rdfs:label>High ganglioside accumulation</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/81b8a935-3ffe-4168-999b-7b8b88ae6253">
    <rdfs:label>Abnormal number of b cells</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0010975</ddiem:url>
    <dc:identifier>HP:0010975</dc:identifier>
  </ddiem:Phenotype>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/b684f820-1cee-44eb-bb7f-d71a8757c972">
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/237400">
        <ddiem:iembaseAccessionNumber>161</ddiem:iembaseAccessionNumber>
        <rdfs:label>HYPER-BETA-ALANINEMIA</rdfs:label>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/ceecbe7b-3d12-4850-8a69-050e5ac8cb06"/>
        <dc:identifier>https://www.omim.org/entry/237400</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/161</ddiem:iembaseUrl>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/6198500</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/387b9aa2-9a28-479d-a7f0-8ecfc6876a9c"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/cb8c1a3c-ea88-42e0-9868-360674391bab">
        <rdfs:label>somnolence</rdfs:label>
        <dc:identifier>HP:0002360</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002360</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26962538</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7936305</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/eb5152ff-7294-4a87-a512-7b1cec024750"/>
    <rdfs:comment>The results of this study suggest that octreotide may aid in the acute or long-term treatment of congenital hyperinsulinism in a limited number of selected cases.https://www.ncbi.nlm.nih.gov/pubmed/8410522/</rdfs:comment>
    <dc:provenance>https://link.springer.com/referenceworkentry/10.1007%2F978-3-540-29676-8_199</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
  </obo:DDIEM_0000013>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/44b64be5-0ae1-4dab-80fd-ba9a7a0a8107">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000708</ddiem:url>
    <rdfs:label>behavior al abnormalities</rdfs:label>
    <dc:identifier>HP:0000708</dc:identifier>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/32664135-6368-4082-8eb4-65fc836514ab">
    <dc:identifier>DB00855</dc:identifier>
    <rdfs:label>Aminolevulinic acid</rdfs:label>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/34b3c884-198d-42ea-bd14-484f193d59f8">
        <rdfs:comment>pyridoxine-responsive patients exhibit higher residual CBS activity in their cultured fibroblasts (typically 1â9%) or in plasma (typically 4â22%) (Fowler et al. 1978; Alcaide et al. 2015).</rdfs:comment>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24355692</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14739681</dc:provenance>
        <ddiem:failedToContributeToCondition>H65R</ddiem:failedToContributeToCondition>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/45a54626-68f5-428b-8f67-24c577b4b444"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30755342</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16619244</dc:provenance>
        <obo:RO_0003304>R266K</obo:RO_0003304>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/8b35eca0-6a41-437d-81e2-1ff6182e89d9"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/236200"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31082797</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31196723</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31211405</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20490928</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/62b6a8f7-d946-4412-a84a-0f47bb5402d8"/>
        <obo:RO_0003304>R125Q</obo:RO_0003304>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00855</ddiem:url>
  </ddiem:Drug>
  <obo:DDIEM_0000011 rdf:about="http://ddiem.phenomebrowser.net/1e1cf724-c0bf-4e15-9d26-fb45d9ca19bd">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9889013</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19210957</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28053874</dc:provenance>
    <rdfs:comment>1-Combined therapy with carnitine and glycine has been shown to maximize the total excretion of isovaleryl-CoA conjugates, but the clinical benefit of combined versus single therapy has not been established through controlled studies. 2- The relative merits of the two therapies either singly or together in patients with more severe presentations including recurrent crises remains a matter of debate. (https://www.ncbi.nlm.nih.gov/pubmed/16602101) 3- Combined glycine and L-carnitine therapy maximally increases isovaleryl conjugate excretion during metabolic stress but not under stable conditions. https://www.ncbi.nlm.nih.gov/pubmed/8804338</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12359132</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/eb318982-8e44-434a-92f2-7148303622aa">
        <rdfs:label>Failure to thrive</rdfs:label>
        <dc:identifier>HP:0001508</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001508</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/611283"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e5eb9536-0736-4a25-8d17-62d77104eed8">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003234</ddiem:url>
        <dc:identifier>HP:0003234</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Carnitine deficiency</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/6b36ca46-5e87-4637-b6e9-73189ff35f01"/>
  </obo:DDIEM_0000011>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/ab4b00ad-e5b6-4d59-a2bd-5d4847ea945d">
    <ddiem:url>https://www.drugbank.ca/drugs/DB04789</ddiem:url>
    <dc:identifier>DB04789</dc:identifier>
    <obo:RO_0000056>
      <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/8bcac904-9764-4fe7-999f-4978e5385ce9">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31196723</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30081189</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/603174"/>
        <rdfs:comment>Retroviral vector carrying the full-length cDNA for alpha-L-iduronidase</rdfs:comment>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/eb5152ff-7294-4a87-a512-7b1cec024750"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31211405</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31082797</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30755342</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/c97ad2d6-e373-4ed4-a68e-39a93d2fc790"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/b3b91803-46c6-4398-8030-a8feea3ea9bc"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f4ef2ff1-df39-4e71-a050-49775bf6ebee"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/cd539122-ae66-4ad2-8241-d43b66dbe01f"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31434105</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11916316</dc:provenance>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00638547</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/697b2dc5-4716-441a-8b7f-4bd51c050758"/>
      </obo:DDIEM_0000013>
    </obo:RO_0000056>
    <rdfs:label>5-methyltetrahydrofolic acid</rdfs:label>
  </ddiem:Drug>
  <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/d123b314-9eb8-4f8c-97a4-1aea96f2a894">
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/aaea9ca7-d37c-4d81-8797-c4a3fcd8d6b9"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648/#b96-tacg-8-201</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/97ee8e25-18d2-435d-be89-ffb04c9da19d"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a2eb141b-8e09-4606-8dff-7c3e899c2629"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/614723"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/4c252287-c3f1-4642-9f64-bb5b8083ebe4"/>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/2c4c2145-9d1d-4115-8792-8077248dbf65"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29241594</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/6b6d7f5c-f3f6-42c5-8576-73c063d4c053"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/51525fc1-fb4c-4f62-8963-2fb8faca1fed"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/984feddc-27a2-42df-99c7-e75ffab932e0">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/f0d5e99a-f1cf-4286-a6bd-92bf5a7af421"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15767622</dc:provenance>
    <rdfs:comment>Febuxostat was, however, significantly more efficacious than allopurinol in reducing DHA excretion in the prescribed doses. This finding, which may translate into improved outcomes of patients with APRT deficiency, should be confirmed in a larger sample. https://www.ncbi.nlm.nih.gov/pubmed/29241594
The XDH inhibitor febuxostat is an alternative option for those allergic to or intolerant of allopurinol. A low purine diet and ample fluid intake are recommended.https://www.ncbi.nlm.nih.gov/books/NBK100238/</rdfs:comment>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02752633</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/books/NBK100238</dc:provenance>
  </obo:DDIEM_0000007>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5a7380bb-31e6-44a5-8716-cdc5239d0ac5">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>tonic seizures ( Focal tonic seizures)</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0011167</ddiem:url>
    <dc:identifier>HP:0011167*</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/bb2a27d2-7d5d-461b-9c21-e6b49265f2a1">
    <dc:identifier>HP:0040006*</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0040006</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Low life span (Mortality)*</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/11e9507e-52cf-4fab-9119-9bfce5929ed1">
    <dc:identifier>DB08883</dc:identifier>
    <obo:RO_0000056>
      <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/979a688d-bffb-41b9-a601-3a746b097d18">
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/125370"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28856097</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/3222f241-12d0-487a-b09e-a398d4d51350"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24816443</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/1cd39339-6a58-41f1-937b-a74f800b5081"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/eb6d66cc-8ce1-4560-a099-984a6c49ce26"/>
        <rdfs:comment>The treatment regimen resulted in neuroleptic malignant syndrome.</rdfs:comment>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/241129d3-62d1-4eb5-95d7-33ff54bd00b6"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29739138</dc:provenance>
      </obo:DDIEM_0000013>
    </obo:RO_0000056>
    <ddiem:url>https://www.drugbank.ca/drugs/DB08883</ddiem:url>
    <rdfs:label>Perampanel</rdfs:label>
  </ddiem:Drug>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/4db6097c-8707-48ca-91d4-0cb0b56e1871">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20975743</dc:provenance>
    <rdfs:comment>Preventive calcium and vitamin D3 supplementation is also recommended to prevent osteoporosis.</rdfs:comment>
    <dc:provenance>https://www.semanticscholar.org/paper/Glycogen-storage-diseases%3A-Diagnosis%2C-treatment-and-Chen-Weinstein/439025d057229db1b3a117cb02b3c7e6f2bd3580</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17514432</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/72dfe879-ecfc-41e6-8040-c725ceef1c29"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/05d037f8-54d9-4b78-bc06-486b6a60a5ee"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/59e7f50a-299e-4511-bf88-53e5209d77eb">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/6711d4e7-07e9-44e7-8dd2-8026fc68a3b2"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/232200"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
  </obo:OGMS_0000112>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7932c6ce-492b-4fc2-b676-294caeb78bf5">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0100851</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Behaviour abnormalities</rdfs:label>
    <dc:identifier>HP:0100851</dc:identifier>
  </ddiem:Phenotype>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/d5d84a94-628a-4330-9ac0-dd81019862c2">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19415691</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24683506</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.semanticscholar.org/paper/The-Incidence-of-Transient-Neonatal-Tyrosinemia-a-Zea-Rey-Cruz-Camino/b66304a0a56304f686380af915a92b2b860e9305</dc:provenance>
    <dc:provenance>http://www.scielo.br/pdf/jiems/v5/2326-4594-jiems-5-e170016.pdf</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27488560</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/c148d200-9479-4b6a-a50f-1e30c7044a3f"/>
    <rdfs:comment>One of the studies that was carried on mice provides useful information for developing the optimal dosage regimen for HPBCD therapy when administered intravenously to NPC patients.https://www.ncbi.nlm.nih.gov/pubmed/26027824</rdfs:comment>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/140350">
        <rdfs:label>HAWKINSINURIA</rdfs:label>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/22</ddiem:iembaseUrl>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/c774bb3c-9ce8-4026-80e7-e93a912510a1"/>
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseAccessionNumber>22</ddiem:iembaseAccessionNumber>
        <dc:identifier>https://www.omim.org/entry/140350</dc:identifier>
      </ddiem:Disease>
    </obo:RO_0002599>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/98414ad8-6944-4731-808f-f54d8771eb35">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001508</ddiem:url>
        <rdfs:label>failure to thrive</rdfs:label>
        <dc:identifier>HP:0001508</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28803710</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/34e33d87-198e-4c78-90a7-bd592a936f0c">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001510</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0001510</dc:identifier>
        <rdfs:label>growth delay</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/34051829-79a9-48bb-9e5d-04a4d7391146">
        <rdfs:label>hemolytic anemia</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0001878</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001878</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6290cc0f-ce36-43ec-9bc2-504943be6238">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>low Î²2 microglobulin,creatinine ratio</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25717099</dc:provenance>
  </obo:DDIEM_0000013>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/3770c3b5-0185-4774-83fe-d075a4007210">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/63fde4ae-6a85-4577-950a-8094b03b7f20">
        <dc:identifier>MP:0009587</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>abnormal sphingosine level(Abnormality of lipid metabolism)*</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/MP_0009587</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>rhLCAT was used in atrial and it has been found to increase the HDL-C and it was safe. https://www.ncbi.nlm.nih.gov/pubmed/24385512</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28275553</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c2e7055f-3143-4c60-870a-f2adec34cc5f">
        <rdfs:label>Abnormal spleen size</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001744</ddiem:url>
        <dc:identifier>HP:0001744</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b569ca88-9cc7-4b10-a4df-62391f6bca65">
        <dc:identifier>HP:0001369</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001369</ddiem:url>
        <rdfs:label>Joint inflammation</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a1d4e021-7c9b-4803-838b-792b01807b4d">
        <rdfs:label>Abnormal tissue lipid profiles(Abnormality of lipid metabolism)*</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003119</ddiem:url>
        <dc:identifier>HP:0003119</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/eadc078a-f923-4256-80af-e13ae0c917e9">
        <dc:identifier>HP:0001510</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Delayed growth</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001510</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5338723</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3fc25a3d-a042-4da4-8c74-15efada35bd0">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>High macrophage infiltration into tissues(Abnormal inflammatory response)*</rdfs:label>
        <dc:identifier>HP:0012647*</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012647</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/368aeed4-a390-4619-86d4-0c3920935a47">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>High intracellular cermaid level</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/MP_0020582</ddiem:url>
        <dc:identifier>MP:0020582*</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/38dce48c-0826-4c84-a526-10e951a4b322">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/729b6afd-7097-4303-a8a1-91dd7dcaf577"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/dfd34eed-6345-4044-b4d5-a34242266b30">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>high plasma MCP-1</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27155573</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/228000">
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/1297</ddiem:iembaseUrl>
        <dc:identifier>https://www.omim.org/entry/228000</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/dc9a15a5-ffb5-4b3b-82b0-2a6b4add5c5f"/>
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseAccessionNumber>1297</ddiem:iembaseAccessionNumber>
        <rdfs:label>FARBER LIPOGRANULOMATOSIS; FRBRL</rdfs:label>
      </ddiem:Disease>
    </obo:RO_0002599>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e1d60d58-e76f-4cac-ade3-fa92e4d472ba">
        <rdfs:label>High cermaide level</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/MP_0020582</ddiem:url>
        <dc:identifier>MP:0020582</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23681708</dc:provenance>
  </obo:OGMS_0000112>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/03f63372-9391-42de-8619-379483fe24e7">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0100022</ddiem:url>
    <rdfs:label>excessive adventitious movements</rdfs:label>
    <dc:identifier>HP:0100022*</dc:identifier>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/c79c34b3-ebe4-40f6-8e39-679990782ff1">
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/25f3ba1d-ea1b-45d6-b6bf-c0e3f9c0eeac">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29390242</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/612319"/>
        <rdfs:comment>rhLCAT was used in atrial and it has been found to increase the HDL-C and it was safe. https://www.ncbi.nlm.nih.gov/pubmed/24385512</rdfs:comment>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/9d63a58f-b943-4558-bc02-12e66500e387"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/32944c9b-a98b-4a97-ace5-bd99bd252fec"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21735565</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27491218</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/3b3baab2-e25e-4336-9531-f1c2b2fe8ab7"/>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01219</ddiem:url>
    <dc:identifier>DB01219</dc:identifier>
    <rdfs:label>Dantrolene</rdfs:label>
  </ddiem:Drug>
  <obo:DDIEM_0000012 rdf:about="http://ddiem.phenomebrowser.net/4744dc6c-9f6e-4b0a-8a82-8e2852bd485b">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583863</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26692114</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3306242</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4841061</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6282099</dc:provenance>
    <rdfs:comment>Controversial benefits https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4158338/</rdfs:comment>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/606785">
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/661</ddiem:iembaseUrl>
        <ddiem:iembaseAccessionNumber>661</ddiem:iembaseAccessionNumber>
        <rdfs:label>CRIGLER-NAJJAR SYNDROME, TYPE II</rdfs:label>
        <dc:identifier>https://www.omim.org/entry/606785</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/f2173f45-1505-4676-9ee8-be970d33771b"/>
        <rdfs:comment>Treatment of CNS type 2 is usually conservative with avoidance of drugs that displace bilirubin from albumin like penicillin, sulphonamides, salicylates, ceftriaxone and furosemide. https://www.ncbi.nlm.nih.gov/pubmed/23162302/
Affected patients should also avoid drugs that displace bilirubin from albumin such as penicillines, sulphonamides, salicylates, ceftriaxone and furosemide.https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300/</rdfs:comment>
      </ddiem:Disease>
    </obo:RO_0002599>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/372922a9-3a97-417a-a958-9bc1fc685c24">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/7d078e77-e174-4a2c-bda7-2f3a0a6fcbeb"/>
      </rdf:Alt>
    </obo:RO_0000057>
  </obo:DDIEM_0000012>
  <obo:DDIEM_0000012 rdf:about="http://ddiem.phenomebrowser.net/482d33af-463d-4788-a40f-7ef69775def3">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/af72c454-8e59-41e7-ab5e-57c09a2f7a98"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10581232</dc:provenance>
    <dc:provenance>http://www.ncbi.nlm.nih.gov/pubmed/16368216</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/231680"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16368216</dc:provenance>
    <rdfs:comment>Synergism inmproves results</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
  </obo:DDIEM_0000012>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/bf3a8e1e-5272-4998-8c1b-1dd583be7df8">
    <rdfs:comment>Preventive calcium and vitamin D3 supplementation is also recommended to prevent osteoporosis.</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/62f13862-3b92-42cc-9dad-e958eef7c627"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b4af2b96-50e1-491b-bf80-ad0e36096c65">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Hyperuricemia</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20357432</dc:provenance>
    <dc:provenance>https://www.semanticscholar.org/paper/Glycogen-storage-diseases%3A-Diagnosis%2C-treatment-and-Chen-Weinstein/439025d057229db1b3a117cb02b3c7e6f2bd3580</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17514432</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/232200"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/c148d200-9479-4b6a-a50f-1e30c7044a3f"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3a796c4b-2a50-46f4-919d-43fc56c0c413">
        <rdfs:label>Growth failure</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0001510</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001510</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20975743</dc:provenance>
  </obo:OGMS_0000112>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/748338ef-6d54-429c-b0de-b2c98a0df421">
    <rdfs:label>Myoclonus jerk</rdfs:label>
    <dc:identifier>HP:0001336</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001336</ddiem:url>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/1f6cc1f4-2d37-48ac-9c28-7dc442364d24">
    <rdfs:comment></rdfs:comment>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/f966894b-fd2b-49bc-8fe1-94ab7897d487"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e159f58c-475d-4a5b-b7fe-ff036d10b960">
        <rdfs:label>defected  L-2-HGDH enzyme activity</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/236792"/>
    <dc:provenance>https://n.neurology.org/content/70/13/1051</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00151710</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22391998</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b13d201e-9e47-48a5-8864-7ee72f817234">
        <rdfs:label>Leukodystrophy</rdfs:label>
        <dc:identifier>HP:0002415</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002415</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2c8aa700-7181-4694-aac4-babba8043d93">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0040144</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>L-2-hydroxyglutaric aciduria</rdfs:label>
        <dc:identifier>HP:0040144</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/efd3056c-4cdd-4941-ac56-6784d9cee1f8"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18362286</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000012"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9d63a58f-b943-4558-bc02-12e66500e387">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001332</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0001332</dc:identifier>
        <rdfs:label>dystonia</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/6b36ca46-5e87-4637-b6e9-73189ff35f01"/>
  </obo:OGMS_0000112>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/245900">
    <rdfs:comment></rdfs:comment>
    <dc:identifier>https://www.omim.org/entry/245900</dc:identifier>
    <ddiem:iembaseAccessionNumber>380</ddiem:iembaseAccessionNumber>
    <rdfs:label>LECITHIN:CHOLESTEROL ACYLTRANSFERASE DEFICIENCY</rdfs:label>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/380</ddiem:iembaseUrl>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/e38a459a-439a-4b5d-99a1-affdaa58dc23"/>
  </ddiem:Disease>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/cdb4bcd2-cafd-4af8-9a38-18e5cf6eb851">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f9277694-636f-4bc6-ac3a-c23145d602c2">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002155</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0002155</dc:identifier>
        <rdfs:label>hypertriglyceridemia</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/144650">
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/1086</ddiem:iembaseUrl>
        <rdfs:comment></rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/3e4e3978-435d-44fe-ad62-68b7c8c6790b"/>
        <dc:identifier>https://www.omim.org/entry/144650</dc:identifier>
        <rdfs:label>HYPERLIPOPROTEINEMIA, TYPE V</rdfs:label>
        <ddiem:iembaseAccessionNumber>1086</ddiem:iembaseAccessionNumber>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18001312</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/5679950</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1894760</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/4883477</dc:provenance>
    <rdfs:comment>Caution against possible exacerbation of the glucose tolerance is necessary in the treatment of diabetic patients with nicotinic acid. Also, as marked weight control in obese patients may induce severe hypertriglyceridemia and acute pancreatitis associated with rebound of the body weight, this risk must be considered. https://www.ncbi.nlm.nih.gov/pubmed/22129523</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3271cc26-e3a9-44a0-b5ff-76a00841ca83">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003233</ddiem:url>
        <dc:identifier>HP:0003233</dc:identifier>
        <rdfs:label>Low HDL-C</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000012"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5863a84b-5778-467a-b3bb-d3c8e9a1002f">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003141</ddiem:url>
        <rdfs:label>Elevated LDL-C level</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0003141</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/f8712a5b-6773-4e20-b7d8-bb42f873ffcf"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c8ee05bd-b510-4dc9-a7d4-fb7576da6665">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003362</ddiem:url>
        <dc:identifier>HP:0003362</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>High VLDL-triglycerides</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b957fbd9-ac97-437a-81e6-c253bae37c24">
        <dc:identifier>HP:0003124</dc:identifier>
        <rdfs:label>High total plasma cholesterol</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003124</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </obo:OGMS_0000112>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/605407">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>SEGAWA SYNDROME, AUTOSOMAL RECESSIVE</rdfs:label>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/9676fa84-21f6-4244-a68b-4ff450096189"/>
    <dc:identifier>https://www.omim.org/entry/605407</dc:identifier>
  </ddiem:Disease>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/995f04a2-db93-47be-afbd-9278effe22a0">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22840416</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0303846712003952</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/6125282b-5f3b-48b7-b234-65a42eaef613"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>http://www.medlink.com/scripts/mpdf/print_friendly.php</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11102558</dc:provenance>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/300438">
        <rdfs:label>HSD10 MITOCHONDRIAL DISEASE; HSD10MD</rdfs:label>
        <dc:identifier>https://www.omim.org/entry/300438</dc:identifier>
        <rdfs:comment>Treatment attempts with isoleucine and protein restriction did not clearly alter or improve the course of the disease despite reduction in the excretion of 2-methyl-3-hydroxybutyrate and tiglylglycine. https://www.ncbi.nlm.nih.gov/pubmed/22132097. https://www.ncbi.nlm.nih.gov/pubmed/11102558</rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/8cd9f4af-7ac2-41df-a51c-b70c957d891e"/>
        <ddiem:iembaseAccessionNumber>64</ddiem:iembaseAccessionNumber>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/64</ddiem:iembaseUrl>
      </ddiem:Disease>
    </obo:RO_0002599>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/387b9aa2-9a28-479d-a7f0-8ecfc6876a9c"/>
    <rdfs:comment></rdfs:comment>
  </obo:DDIEM_0000013>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/081da9b8-3b6f-4ad6-9d5d-9fb8989c54be">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19019309</dc:provenance>
    <rdfs:comment>Testosterone therapy needs to be carefully considered because of the risk of hepatic adenomas.https://www.ncbi.nlm.nih.gov/pubmed/28160246
Androgen receptors are expressed in the liver, and androgens can stimulate hepatocyte proliferation. Although rare, androgens have been shown in observational studies to induce adenoma development (Giannitrapani et al. 2006). Testosterone levels should be assessed for response 2â3 months after therapy is initiated.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24493026</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/eb5152ff-7294-4a87-a512-7b1cec024750"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/94d1a514-656f-4cdb-9a85-309752ada44a">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>abnormal muscle phosphorylase activity</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ab2904fb-dbfe-4d7d-89b6-36ab12b4290e">
        <rdfs:label>insufficient anaerobic glycolysis of skeletal muscle</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17490880</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/232600">
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/a19ce879-c539-4e20-a2ed-68addb2c0d6a"/>
        <rdfs:label>GLYCOGEN STORAGE DISEASE V; GSD5</rdfs:label>
        <dc:identifier>https://www.omim.org/entry/232600</dc:identifier>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/489</ddiem:iembaseUrl>
        <ddiem:iembaseAccessionNumber>489</ddiem:iembaseAccessionNumber>
        <rdfs:comment></rdfs:comment>
      </ddiem:Disease>
    </obo:RO_0002599>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/2f330e37-5bd8-44a3-ba42-94923b435485"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22334182</dc:provenance>
  </obo:DDIEM_0000013>
  <obo:DDIEM_0000010 rdf:about="http://ddiem.phenomebrowser.net/fdbd2f2f-7b8e-4c8b-a377-7157ef48e7f0">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17397529</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16435214</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c1f0c575-de4b-4231-a5c0-a3d4d9b9d968">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001298</ddiem:url>
        <dc:identifier>HP:0001298</dc:identifier>
        <rdfs:label>Brain damage</rdfs:label>
        <rdfs:comment>Initiation of treatment after the onset of symptoms is generally not effective in preventing permanent damage. The combination is suggested to given in presymptomatic patients to prevent brain damage.https://www.ncbi.nlm.nih.gov/pubmed/21431622</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23326493</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/6b36ca46-5e87-4637-b6e9-73189ff35f01"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/834144f0-fa47-4662-b309-8f0f1ba7918a"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0c895282-f25f-4dff-9bee-b494aaf3e6f0">
        <rdfs:label>Cerebral palsy</rdfs:label>
        <dc:identifier>HP:0100021</dc:identifier>
        <rdfs:comment>Early diagnosis can prevent the phenotype, Initiation of treatment after the onset of symptoms is generally not effective in preventing permanent damage. https://www.ncbi.nlm.nih.gov/pubmed/21431622. https://www.ncbi.nlm.nih.gov/pubmed/10630918</rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0100021</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ed2abaf1-0f46-4129-bbe3-ae60472ececb"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/e00cdfc1-dfa5-4614-8e84-c0222d1d489a">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/eaf3c29f-5dcd-474f-8932-fe14bf52f918"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10630918</dc:provenance>
    <rdfs:comment>This combination therapy should be accompained with low lysin diet that is often combined with the use of lysine-free, tryptophan-reduced amino acids (AA) supplements. These supplements are given with the aim of preventing malnutrition by providing essential amino acids and (depending on the product) also minerals, trace elements and vitamins. https://www.ncbi.nlm.nih.gov/pubmed/10630918</rdfs:comment>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/231670"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19019309</dc:provenance>
  </obo:DDIEM_0000010>
  <obo:DDIEM_0000015 rdf:about="http://ddiem.phenomebrowser.net/4830b65d-510f-4fd2-b673-796a63fbfab2">
    <dc:provenance>https://www.researchgate.net/publication/8668575_A_successful_treatment_with_pyridoxal_phosphate_for_West_syndrome_in_hypophosphatasia</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/308050"/>
    <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
    <dc:provenance>an enzyme-replacement therapy</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ea086167-ccbb-4d90-b715-6210ca4e3e9d">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/MP_00011911</ddiem:url>
        <rdfs:label>Cutaneous abnormalities</rdfs:label>
        <dc:identifier>MP:00011911</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>Drug name: Treatment is under trial.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5909487</dc:provenance>
    <dc:provenance>NCT00744042.)."</dc:provenance>
    <dc:provenance>was associated with improved findings on skeletal radiographs and improved pulmonary and physical function in infants and young children with life-threatening hypophosphatasia. (Funded by Enobia Pharma and Shriners Hospitals for Children; ClinicalTrials.gov number</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
    <dc:provenance>"ENB-0040</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5096504</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ce4c08ea-98ad-4c46-83c6-2a5cdbb39661"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/feee8175-af10-4f42-a7ed-b23be088eb74"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/866674f7-6686-4955-b72a-3e13de23b98e"/>
  </obo:DDIEM_0000015>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/01ef47c7-085a-468f-bed3-3bb206f58053">
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/387b9aa2-9a28-479d-a7f0-8ecfc6876a9c"/>
    <rdfs:comment>Drug name: A switch to idebenone treatment resulted in clinical and metabolic worsening, which disappeared with subsequent CoQ10 treatment. https://www.ncbi.nlm.nih.gov/pubmed/15326254/                                       Drug not only failed to improve his condition but also worsened the course of the disease and was therefore discontinued after 7 months. https://www.ncbi.nlm.nih.gov/pubmed/18319072.  In another patient, the myoclonus was aggravated by idebenone. She recovered her previous status after its withdrawal. https://www.ncbi.nlm.nih.gov/pubmed/24164873</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4263309</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28125198</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24164873</dc:provenance>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/612016">
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/0a5f4cf4-436f-4a07-b684-6da170ff3e34"/>
        <dc:identifier>https://www.omim.org/entry/612016</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>COENZYME Q10 DEFICIENCY, PRIMARY, 4; COQ10D4</rdfs:label>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/c51058f7-1e07-472e-a6a6-adeb625d7b5f"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2427298</dc:provenance>
  </obo:OGMS_0000112>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/d75149d3-7e54-442c-84ac-aa83023f1667">
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02930655</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01218659</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7bb56179-2305-4692-837d-0289ab17f7f5">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>High Gb3(globotriaosylceramide) accumulation.</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29982630</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000015"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT03425539</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT03737214</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20495831</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/10886a2b-bcbb-4f38-9868-70f432659168">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/2ebf284e-e31f-41f7-abda-1d6132a32fb7"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:comment>Given the favorable half-life of pegunigalsidase alfa and its low level of inhibition by pre-existing neutralizing antibodies, there is potential for pegunigalsidase alfa to attenuate and/or stabilize renal function in patients who continue to lose renal function while on currently-available enzyme replacement therapy</rdfs:comment>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/301500">
        <rdfs:label>FABRY DISEASE</rdfs:label>
        <dc:identifier>https://www.omim.org/entry/301500</dc:identifier>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/296</ddiem:iembaseUrl>
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseAccessionNumber>296</ddiem:iembaseAccessionNumber>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/f16de7ba-e2b9-4e3d-9c02-29ee34593daf"/>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28088251</dc:provenance>
  </obo:OGMS_0000112>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/bef7a13d-eda9-4945-8a7c-9cae16ec1a64">
    <dc:identifier>HP:0008344</dc:identifier>
    <rdfs:label>High plasma branched chain amino acids</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0008344</ddiem:url>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5a75ae43-ff10-4dd5-9b93-c31167d0efb2">
    <rdfs:label>increased dopamine and serotonin levelsÂ (neurotransmitter levels)</rdfs:label>
    <dc:identifier>HP:0012654</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0012654</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/ef9725c0-f378-4a53-9958-a2d773fb1608">
    <ddiem:url>https://www.drugbank.ca/drugs/DB04075</ddiem:url>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/1d14710a-7440-44a8-bc80-413bc75b452f">
        <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000012"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/13992367</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14213380</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/c9fda279-6846-43e7-852e-e36ca6b91738"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/237300"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31392111</dc:provenance>
        <rdfs:comment>Drug name: Intranasal dDAVP, because of efficacy, long duration of action, and infrequent side effects, is the preferred treatment of neurogenic diabetes insipidus in children and adults.https://www.ncbi.nlm.nih.gov/pubmed/626447</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23649895</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/1815b4f2-d633-4f48-8127-6e84004fd906"/>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <dc:identifier>DB04075</dc:identifier>
    <rdfs:label>N-Acetyl-L-Glutamate</rdfs:label>
  </ddiem:Drug>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/b39fa91c-62db-4030-8494-a38a35efca4a">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24912437</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27155573</dc:provenance>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/227810">
        <dc:identifier>https://www.omim.org/entry/227810</dc:identifier>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/481</ddiem:iembaseUrl>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/9e79a7ca-b575-4e23-8303-710d96459023"/>
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseAccessionNumber>481</ddiem:iembaseAccessionNumber>
        <rdfs:label>FANCONI-BICKEL SYNDROME; FBS</rdfs:label>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5338723</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/77066bf1-0b44-448f-a183-61007143ccdc"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7564233</dc:provenance>
    <rdfs:comment>Uncoooked cornstrach was introduced in small frequent meal and was accomapined with elimination of lactose in diet</rdfs:comment>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/53d81324-bc69-4ec5-bd3c-186d552927d4"/>
  </obo:OGMS_0000112>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e193638f-bdb3-488d-a26d-193805fb8a3c">
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001298</ddiem:url>
    <rdfs:label>encephalopathy</rdfs:label>
    <dc:identifier>HP:0001298</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e15f656c-0a21-4b1c-b1fa-65f91cb3cef0">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001337</ddiem:url>
    <rdfs:label>Tremor</rdfs:label>
    <dc:identifier>HP:0001337</dc:identifier>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/d7ff5fd7-41ba-4307-91b6-77a33f6cf4d9">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ef277a72-cce9-4ec8-9f7e-cfc2700e6701">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003326</ddiem:url>
        <dc:identifier>HP:0003326</dc:identifier>
        <rdfs:label>muscle pain</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648/#b96-tacg-8-201</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/263570">
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/1751e99b-0bfa-4e68-b463-600ff5b70dfc"/>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>POLYGLUCOSAN BODY NEUROPATHY, ADULT FORM; APBN</rdfs:label>
        <dc:identifier>https://www.omim.org/entry/263570</dc:identifier>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10870849</dc:provenance>
    <rdfs:comment>All therapeutic trials conducted so far to modify the inflammatory response did not reveal a relevant clinical benefit from beta interferon, cyclophosphamide, cyclosporin, immunoglobulins, pentoxifylline, and thalidomide. https://www.sciencedirect.com/science/article/pii/S0167488906001881?via%3Dihub</rdfs:comment>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/a5339c14-5cc3-41e8-b345-f78cf77e4e18">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/135c16c6-28e6-4598-ab34-8776b5c49b01"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://globenewswire.com/news-release/2015/03/30/720127/10126746/en/Sigma-Tau-Pharmaceuticals-Inc-Receives-Orphan-Drug-Designation-for-EZN-2279-for-Treatment-of-Adenosine-deaminase-Deficient-Severe-Combined-Immunodeficiency-Disease.html</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1bbf2a8a-7505-4af8-a972-d05825424167">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012378</ddiem:url>
        <rdfs:label>Lack of energy</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0012378</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15670720</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00947960</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d20985f9-7ef9-468e-ac5b-d325f8d17863">
        <dc:identifier>HP:0011025</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0011025</ddiem:url>
        <rdfs:label>defective heart function</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </obo:DDIEM_0000013>
  <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/96d90e61-4ae9-45e5-bf1e-1a06d32cf00c">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20619503</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4503963</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19087156</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/eb318982-8e44-434a-92f2-7148303622aa"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/607765"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11067870</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/94987563-bd7a-4c39-bf4c-1305d041276e">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002630</ddiem:url>
        <rdfs:label>fat soluble vitamin malabsorption(Fat malabsorption)*</rdfs:label>
        <dc:identifier>HP:0002630*</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4280294</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/dc1d1587-a013-4034-bb77-9db84bbc0a94">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/df230097-a316-41a1-9b84-7d1e636fa499"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18570303</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <rdfs:comment>Many studies have reported early responce to l- dopa treatment as mentioned in https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4503963/, and other pointed to " prominent dyskinesia " as side effect to same treatment https://www.ncbi.nlm.nih.gov/pubmed/19087156/</rdfs:comment>
  </obo:DDIEM_0000007>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/34cfec2b-48b4-48d0-8fb2-c2ffb1d7c978">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24746802</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01212744</dc:provenance>
    <dc:provenance>https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/b72d1a91-57bb-4e00-a58c-8a1fb9a0a6c5">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/a7b0b3f3-84c1-42b6-ab43-8b39cf0688db"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
    <rdfs:comment>Effect of those two drugs was short-term response. Disease Name: There are many drugs with known detrimental effect on mitochondrial function. These include antibiotics like tetracycline and chloramphenicol; antiepileptics like valproate, phenytoin, antiretroviral agents and metformin. Overall their effects in patients with MIDD are not known. Statin therapy should be avoided in patients especially with myopathy. HMG Co-A reductase inhibitors can reduce both cholesterol and Co-enzyme Q via mevalonate pathway. These patients may have higher rate of lactic acidosis and intolerance to statins resulting in myalgia and may worsen the symptoms of existing myopathy. https://www.sciencedirect.com/science/article/pii/S1056872714000610?via%3Dihub#bb0115</rdfs:comment>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/520000"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28756474</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4395c662-ed63-44db-a94b-23f8f8e60cc7">
        <dc:identifier>HP:0000819</dc:identifier>
        <rdfs:label>Diabetes</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000819</ddiem:url>
        <rdfs:comment>Mitochondrial diabetes is treated as other forms of diabetes; however, the use of metformin should be avoided due to the increased risk of lactic acidosis. https://www.ncbi.nlm.nih.gov/pubmed/27966441 Cases were treated with metformin at some stage and also received statins which could be harmful in such patients. https://www.ncbi.nlm.nih.gov/pubmed/24746802</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
  </obo:DDIEM_0000013>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2358a2a5-6ed8-4d95-af40-73fd9faa84ee">
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0012378</dc:identifier>
    <rdfs:label>Low energy level(Tiredness)*</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0012378</ddiem:url>
  </ddiem:Phenotype>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/5786e82b-7375-42d4-ad60-71e8af7af152">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25674260</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/77a75623-027a-4786-95d6-224fa276fbbd">
        <dc:identifier>HP:0002015</dc:identifier>
        <rdfs:label>dysphagia</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002015</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01793090</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3950820</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/610131"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8cc1afbd-2ccf-4549-a427-d6ead3cd469a">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0009071</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Inflammatory myopathy</rdfs:label>
        <dc:identifier>HP:0009071</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5cf8ba8d-dc30-4cae-939f-4404a3ae00bf">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0000467</dc:identifier>
        <rdfs:label>neck muscle weakness</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000467</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>The combination of three antiepileptic drugs and LGIT"modified KD" is effective and well tolerated as treatment for severe episodes of POLG-related mitochondrial epilepsy. They suggest as well that combining LGIT to antiepileptic drug treatment should be considered in this potentially life-threatening condition.https://www.ncbi.nlm.nih.gov/pubmed/23248042?dopt=Abstract</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19821145</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f596bc91-e740-4cf2-947e-907a5d4b034d">
        <dc:identifier>HP:0001260</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001260</ddiem:url>
        <rdfs:label>dysarthria</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://link.springer.com/article/10.1023/A:1005353530303</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/1cbfe780-074e-4883-9c7d-c7b1847865a4"/>
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
  </obo:DDIEM_0000013>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/fe693d60-c0d4-47bd-bde9-c776d6b70ab6">
    <dc:identifier>HP:0030953</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>conjunctival irritation</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0030953</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/987baa4e-15ac-44f7-abed-1ea17393b425">
    <rdfs:label>frequent hospital admission</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/d1650547-ce17-4db4-9b01-06d3175afe2c">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3491070</dc:provenance>
    <rdfs:comment>Treatment-related risks should be taken into account when considering the use of vandetanib in patients with indolent, asymptomatic, or slowly progressing disease.https://www.ncbi.nlm.nih.gov/pubmed/22665903?dopt=Abstract</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6dd30681-730f-4bc0-b4b4-f757f5079913">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0031029</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0031029</ddiem:url>
        <rdfs:label>Increased plasma CEA</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/162300"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22665903</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f55903ec-06dd-40a5-a487-26a19febeb31">
        <rdfs:label>Weight loss</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001824</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0001824</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00514046</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6214082</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/51b9f32d-4102-4c93-bd5d-f638c3aa9a26">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Objective response rate (ORR)</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0003304>M918T</obo:RO_0003304>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22025146</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/bf8cb472-5dee-42d2-9aae-77015d030211">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Decreased adipose tissue</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0040063</ddiem:url>
        <dc:identifier>HP:0040063</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9a072f97-a02c-460a-9ea8-d24d2f4c1fe7">
        <dc:identifier>HP:0003528</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Elevated calcitonin</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003528</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/88ec29a7-11a0-4c9d-8d51-1fea2cbb9e43">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012531</ddiem:url>
        <dc:identifier>HP:0012531</dc:identifier>
        <rdfs:label>Pain</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4307225</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f834d6f3-64d7-4659-9f29-60b1bec9dd60">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Short Progression-free survival</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23543666</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27650489</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/118dc3e6-ac06-47f8-be0a-2ea369af9b2c">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002653</ddiem:url>
        <rdfs:label>Bone pain</rdfs:label>
        <dc:identifier>HP:0002653</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/813f6204-9c52-4a00-bd1f-3a7f21d41e93">
        <rdfs:label>disease control rate(  Rapid disease progression)</rdfs:label>
        <dc:identifier>HP:0003678</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003678</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/62b1d0b8-474c-43eb-9bde-02eceb168a66">
        <dc:identifier>HP:0003199</dc:identifier>
        <rdfs:label>Low skeletal muscle mass</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003199</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/3731c591-6e0e-4860-bd0e-3da7fd769279"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23766359</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a0c57930-ae41-4694-b6b8-d7c4bddaf818">
        <rdfs:label>low quality of life ( Constitutional symptom)*</rdfs:label>
        <dc:identifier>HP:0025142*</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0025142</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20371662</dc:provenance>
  </obo:OGMS_0000112>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/4dadb0b6-71d6-4706-bd84-dd525f6ac2ba">
    <rdfs:comment>Testosterone therapy needs to be carefully considered because of the risk of hepatic adenomas.https://www.ncbi.nlm.nih.gov/pubmed/28160246
Androgen receptors are expressed in the liver, and androgens can stimulate hepatocyte proliferation. Although rare, androgens have been shown in observational studies to induce adenoma development (Giannitrapani et al. 2006). Testosterone levels should be assessed for response 2â3 months after therapy is initiated.</rdfs:comment>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/2f330e37-5bd8-44a3-ba42-94923b435485"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/232600"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25391139</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24493026</dc:provenance>
    <dc:provenance>http://www.ncbi.nlm.nih.gov/pubmed/28932990</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17490880</dc:provenance>
    <dc:provenance>https://link.springer.com/content/pdf/10.1016%2Fj.nurt.2008.08.006.pdf</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/66aa6980-9d73-4eee-8a52-f80a6ead8bf9"/>
  </obo:DDIEM_0000013>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/2045cd4d-737d-46fe-a1af-0e2e4bc48e72">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/30e4d0b4-0b04-4269-b3f6-198ef790a271">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000822</ddiem:url>
        <rdfs:label>Hypertension</rdfs:label>
        <dc:identifier>HP:0000822</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/245900"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23391322</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5338723</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/1441dbea-f090-46a5-b7c6-3746d3be46c4">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/2301d2c2-3e5e-4140-9776-22e5d4f0f7f5"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02527343</dc:provenance>
    <dc:provenance>https://www.clinicaltrials.gov/ct2/show/NCT01554800</dc:provenance>
    <rdfs:comment>Niacin DB00627 occasionally can be used with Fibrate and omega 3 fatty acid in treating hypertriglyceridiemia. https://www.ncbi.nlm.nih.gov/pubmed/21079616</rdfs:comment>
  </obo:OGMS_0000112>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ff026e0d-ffdf-4fa8-aa62-206e0173575e">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003281</ddiem:url>
    <dc:identifier>HP:0003281</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>high serum ferritin concentration</rdfs:label>
  </ddiem:Phenotype>
  <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/ded36b62-43d7-4fce-9dda-6fe79e428fbe">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4052756/#S10title</dc:provenance>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/207800">
        <dc:identifier>https://www.omim.org/entry/207800</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/9020f972-02ef-4b05-b2c3-472aa36bb0c1"/>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/16</ddiem:iembaseUrl>
        <ddiem:iembaseAccessionNumber>16</ddiem:iembaseAccessionNumber>
        <rdfs:label>ARGININEMIA</rdfs:label>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11148549</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5508465</dc:provenance>
    <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
    <rdfs:comment>Alternative pathway therapy has limited effectiveness in preventing hyperammonemia and must be combined with effective dietary management. https://www.ncbi.nlm.nih.gov/pubmed/11148549</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4382922</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23494656</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/2ce2a3f0-914c-481a-8b67-1c6a3499311d"/>
    <dc:provenance>https://www.clinicaltrialsregister.eu/ctr-search/search</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/81ef2c4d-b7c6-4946-9915-b9446d90401d"/>
  </obo:DDIEM_0000007>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/5bc9952b-dc92-47b3-abc8-913bf575f22b">
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/7ad84786-d5c7-4cff-9269-0088c28dd551">
        <rdfs:label>Sodium phosphate, dibasic</rdfs:label>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/9848620e-11c5-4572-ab51-a23e5f11d517"/>
        <ddiem:url>https://www.drugbank.ca/drugs/DB14502</ddiem:url>
        <dc:identifier>DB14502</dc:identifier>
      </ddiem:Drug>
    </rdf:li>
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/ebac5ee5-82fc-4e24-a5ed-b90dcd6bad33">
        <dc:identifier>DB09449</dc:identifier>
        <ddiem:url>https://www.drugbank.ca/drugs/DB09449</ddiem:url>
        <rdfs:label>Sodium phosphate, monobasic</rdfs:label>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/9848620e-11c5-4572-ab51-a23e5f11d517"/>
      </ddiem:Drug>
    </rdf:li>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/33ca4976-b103-4d63-beb2-bfdd454e09f0">
    <ddiem:url>https://www.whocc.no/atc_ddd_index/?code=C03D</ddiem:url>
    <rdfs:label>POTASSIUM-SPARING AGENTS</rdfs:label>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/5a5288c4-ac30-4668-ab47-61a07441c82d">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30387909</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <dc:provenance>https://www.orpha.net/data/patho/GB/uk-Bartter.pdf</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/0c02b8bc-236d-4a76-96d8-c4867688fb71"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/4d04e19f-76cb-477e-81fd-bb199a14aa0b"/>
        <dc:provenance>http://www.neurologyindia.com/article.asp</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/96fedb8d-f7a8-40f7-bf8b-b5937ec19260"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/607364"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/fdb284b5-f13e-43f9-a8b5-38696daab465"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24260777</dc:provenance>
        <rdfs:comment>Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss</rdfs:comment>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/3fb47463-aac2-4ed8-8441-421613b22f08"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2646391</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <dc:identifier>C03D</dc:identifier>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2f50914e-701d-491c-b809-3303070fbc5d">
    <dc:identifier>HP:0001941</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001941</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>acidemia</rdfs:label>
  </ddiem:Phenotype>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/f0d77e34-8d80-439f-969f-3404d519f8a7">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c1ba99ab-cc06-4a3f-8f61-65a683c970c2">
        <rdfs:label>Abnormal liver function</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/278000"/>
    <rdfs:comment>Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/efec2f9a-a4e4-4740-995f-09b674867b49">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0003119</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003119</ddiem:url>
        <rdfs:label>Dyslipidemia</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23432031</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02376751</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28804516</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/9a93d88e-4507-4129-a186-3504822cf546">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/9e76f120-24a8-4513-8870-840fcc3af20c"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29773783</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31239752</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1cd5566d-fc34-4527-a356-ab654f1b78c1">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003107</ddiem:url>
        <rdfs:label>High plasma cholesterol level*</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0003107</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27878737</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29374495</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/58b790a1-d590-40df-91a7-1bec934ae767">
        <rdfs:label>hypertriglycemia</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002155</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0002155</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01371825</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
  </obo:OGMS_0000112>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/b54fba15-926e-47f6-bb82-a05bdbd32ced">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15670720</dc:provenance>
    <rdfs:comment>Medium-chain triglyceride (MCT) supplement therapy with a low-carbohydrate formula was effective in CTLN2 to prevent a relapse of hyperammonemic encephalopathy. https://www.ncbi.nlm.nih.gov/pubmed/29651749</rdfs:comment>
    <dc:provenance>https://globenewswire.com/news-release/2015/03/30/720127/10126746/en/Sigma-Tau-Pharmaceuticals-Inc-Receives-Orphan-Drug-Designation-for-EZN-2279-for-Treatment-of-Adenosine-deaminase-Deficient-Severe-Combined-Immunodeficiency-Disease.html</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e91f1b26-2e97-40a8-ae25-c4164e7f8cea">
        <rdfs:label>High plasma citrulline levels</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0011966</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0011966</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29651749</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26427088</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/603471"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10870849</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5892aeea-5be5-497b-bd02-010e8a451564">
        <rdfs:label>low plasma glutamine levels</rdfs:label>
        <dc:identifier>HP:0010903</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0010903</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648/#b96-tacg-8-201</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6077bb9d-4f08-4cbe-b27f-58fc914179e0">
        <dc:identifier>HP:0001298*</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001298</ddiem:url>
        <rdfs:label>Relapse of hyperammonemic encephalopathy</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2c2a09e0-27b0-4716-8ee8-4bfaadf00fbe">
        <dc:identifier>HP:0001987</dc:identifier>
        <rdfs:label>High blood ammonia level</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001987</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/c148d200-9479-4b6a-a50f-1e30c7044a3f"/>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
  </obo:OGMS_0000112>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/3c07775f-5982-40cb-b084-5bb7503b7c8d">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5045115</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/7a1433cb-0900-4284-8365-0a1341ceaf10">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/a40e80e3-8202-4845-b5ae-0a286711a4f4"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/118600">
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/12f64661-8448-4e7d-9971-2ca66c9cbf2c"/>
        <dc:identifier>https://www.omim.org/entry/118600</dc:identifier>
        <rdfs:label>CHONDROCALCINOSIS 2; CCAL2</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31239752</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29374495</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28804516</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0cd08a38-f58b-41c1-b399-150103c7879b">
        <dc:identifier>HP:0001369</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001369</ddiem:url>
        <rdfs:label>Arthritis</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT03128905</dc:provenance>
    <rdfs:comment>Effective in flares when used in combination with NSAIDs. It is also beneficial as prophylaxis for preventing recurrent flares. Oral COL should be preferred over the intravenous form. If contraindications present to use oral COL, then intravenous COL solution should be pre-diluted with 0.9% NaCl prior to infusion.</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23432031</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/095762a4-b9bf-47c0-918d-9f5ce2a2f67e">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0002829</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002829</ddiem:url>
        <rdfs:label>Arthralgia</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </obo:OGMS_0000112>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f9b46fc1-7c71-4f0d-b82d-527a5d9769f1">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Low pancreatic zymogens</rdfs:label>
  </ddiem:Phenotype>
  <obo:DDIEM_0000009 rdf:about="http://ddiem.phenomebrowser.net/5955d8ca-0124-4554-8c7c-e2670ccaa0d9">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1755734</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7254778</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/661bba58-9ffe-44fd-a248-e5fef6420449"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/ee648868-cd6d-4499-8052-dfbd16f58cae">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/445dae4a-bd4d-4446-a14f-729f3519d194"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16601905</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15159649</dc:provenance>
    <rdfs:comment>There was no clinical effect, but amild reduction in the plasma level of desmosterol was observed.</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7356686</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22791294</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28883274</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/660ec100-9b6b-4342-a494-1fd3fcf99457">
        <rdfs:label>High ornithine plasma level</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012026</ddiem:url>
        <dc:identifier>HP:0012026</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/258870"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/07ad221b-edb1-43c5-87af-29c53f34fb2f">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003676</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Disease progresssion</rdfs:label>
        <dc:identifier>HP:0003676</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </obo:DDIEM_0000009>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/c25781dc-0210-4b3f-b45a-ff48affc3ae5">
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT03519646</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1517f03f-f0d6-4a65-9532-e0c51fcb0d90">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Decreased hemoglobin</rdfs:label>
        <dc:identifier>HP:0001903</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001903</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15895716</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30247105</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/93cefd2e-eb26-4c42-87a0-46f170c13cdd">
        <dc:identifier>HP:0001744</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001744</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>High spleen volume</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/b2d7e801-3f9c-4720-821e-746dc2325437">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/1fb174d8-4cc3-41f7-8184-96a9e6d9919b"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:comment>The treatment was done via convection-enhanced delivery</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3b8a7752-a33a-43df-8697-89f32c0f3e9e">
        <dc:identifier>HP:0001873</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001873</ddiem:url>
        <rdfs:label>thrombocytopenia</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29358012</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/results/NCT01685216</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7814809</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1a6f1ab5-eee1-4001-bb13-2c7cb508949d">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002240</ddiem:url>
        <rdfs:label>high liver volume</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0002240</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>http://clinicaltrials.gov/show/NCT00358150</dc:provenance>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/231005">
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/6b58a1f4-ac8c-4ddc-bce7-4e5f6fb332d0"/>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>GAUCHER DISEASE, TYPE IIIC</rdfs:label>
        <dc:identifier>https://www.omim.org/entry/231005</dc:identifier>
      </ddiem:Disease>
    </obo:RO_0002599>
  </obo:OGMS_0000112>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/be1c15d8-7e70-4b08-82c6-3fd7f66edfaa">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16619244</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30755342</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20506325</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/14aa57e8-8de3-473e-94f8-3334e3c2b0a8">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/8a379409-af0b-493f-b5cc-c01f39d6c7ee"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2176d5ef-a37b-4765-afd5-3eb7bf0f264b">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>"The approach is likely unsuccessful due to reactive properties, intrinsic instability, and charged character of SAM."</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14739681</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31211405</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31196723</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24355692</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000012"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31082797</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/236200">
        <dc:identifier>https://www.omim.org/entry/236200</dc:identifier>
        <ddiem:iembaseAccessionNumber>27</ddiem:iembaseAccessionNumber>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/27</ddiem:iembaseUrl>
        <rdfs:comment>Current treatment includes (i) the administration of pyridoxine to putatively stimulate the residual CBSactivity; (ii)restriction of dietary methionine intake to decrease the load in the affected pathway; (iii) supplementation of cystine to correct cysteine deficiency; and (iv)administration of betaine, folic acid and cobalamin to facilitate the remethylationof homocysteine back to methionine.</rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/75fecfc9-fdc1-4e5b-9d87-41fe8c14fc77"/>
        <rdfs:label>HOMOCYSTINURIA DUE TO CYSTATHIONINE BETA-SYNTHASE DEFICIENCY</rdfs:label>
      </ddiem:Disease>
    </obo:RO_0002599>
    <rdfs:comment>pyridoxine-responsive patients exhibit higher residual CBS activity in their cultured fibroblasts (typically 1â9%) or in plasma (typically 4â22%) (Fowler et al. 1978; Alcaide et al. 2015).</rdfs:comment>
  </obo:OGMS_0000112>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/c8a0dad9-3d59-4c42-b83f-ed9d3e4b5ccd">
    <ddiem:url>https://www.drugbank.ca/drugs/DB01115</ddiem:url>
    <obo:RO_0000056>
      <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/53177d49-3c92-43b5-bca1-270f81be9a17">
        <dc:provenance>https://www.semanticscholar.org/paper/The-Incidence-of-Transient-Neonatal-Tyrosinemia-a-Zea-Rey-Cruz-Camino/b66304a0a56304f686380af915a92b2b860e9305</dc:provenance>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00712738</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19415691</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25717099</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/7b1d3826-8e23-4e2d-af1b-dc84c8d8e06f"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14632789</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/604250"/>
        <rdfs:comment>One of the studies that was carried on mice provides useful information for developing the optimal dosage regimen for HPBCD therapy when administered intravenously to NPC patients.https://www.ncbi.nlm.nih.gov/pubmed/26027824</rdfs:comment>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00733811</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a09a00cd-6976-42fb-986d-d6c4653a0a5d"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
      </obo:DDIEM_0000013>
    </obo:RO_0000056>
    <dc:identifier>DB01115</dc:identifier>
    <rdfs:label>Nifedipine</rdfs:label>
  </ddiem:Drug>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/5ec37888-edcb-4d73-b5c1-005bbcc1df06">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11067870</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22149023</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6206929</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19622360</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3963001</dc:provenance>
    <rdfs:comment>"Oral tocofersolan was more bio available than the water-soluble formulation in children with chronic cholestasis and similarly bio available in CF. This suggests that water-soluble vitamin E may represent an alternative to painful intramuscular vitamin E injections in chronic cholestasis, or other oral formulations in CF. However, the mechanism responsible for fat malabsorption in CRD concerns the absorptive phase as opposed to the digestive phase in CF and cholestatic syndromes. To our knowledge, no specific studies with these new vitamin E preparations have been conducted in CRD." https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717/</rdfs:comment>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/220110">
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/937</ddiem:iembaseUrl>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/0cd436db-1bbe-4a1c-8f5c-b9853cde12e9"/>
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseAccessionNumber>937</ddiem:iembaseAccessionNumber>
        <dc:identifier>https://www.omim.org/entry/220110</dc:identifier>
        <rdfs:label>MITOCHONDRIAL COMPLEX IV DEFICIENCY</rdfs:label>
      </ddiem:Disease>
    </obo:RO_0002599>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/35b5c64e-9aaa-46fd-84a3-e5d483d4e101"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/971536</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/23ecce48-b7ae-4193-ad6c-c109e0329680"/>
  </obo:DDIEM_0000013>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/29b4324a-7e77-438a-bfe3-af7d5e02f9aa">
    <dc:identifier>HP:0002180</dc:identifier>
    <rdfs:label>Neuromuscular degeneration</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002180</ddiem:url>
  </ddiem:Phenotype>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/e2f9394c-3abe-476b-be21-4b6640913c43">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24854628</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28225998</dc:provenance>
    <obo:RO_0003304>R219K</obo:RO_0003304>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19770656</dc:provenance>
    <rdfs:comment>Intravenous heparin 10,000 U per day is an effective, simple, and safe method of lowering the triglyceride level in hypertriglyceridemia-induced pancreatitis in pregnancy, However, the reduction of the triglyceride level by heparin is only temporary and long-term use may paradoxically result in an increase in the triglyceride level as a result of depletion of LPL. Heparin can be stopped once the triglyceride level falls below 11 mmol/L.https://www.ncbi.nlm.nih.gov/pubmed/12114919.  https://www.ncbi.nlm.nih.gov/pubmed/1800965</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21289269</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20495831</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d60a9c21-e4b6-4c31-977a-77622430c9a6">
        <dc:identifier>HP:0003233</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003233</ddiem:url>
        <rdfs:label>Low HDL cholesterol concentration</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/604091">
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/379</ddiem:iembaseUrl>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>HYPOALPHALIPOPROTEINEMIA, PRIMARY</rdfs:label>
        <ddiem:iembaseAccessionNumber>379</ddiem:iembaseAccessionNumber>
        <dc:identifier>https://www.omim.org/entry/604091</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/21d9b574-ac72-415a-a794-818b33ec46af"/>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://www.clinicaltrials.gov/ct2/show/NCT00458055</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a68fc244-8add-4818-a3ae-faff3ebba1b2">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>hypoalphalipoproteinemia</rdfs:label>
        <dc:identifier>HP:0003233</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003233</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a1907268-350b-41b9-ad94-c01d173718b8">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Increased low-density lipoprotein cholesterol concentration</rdfs:label>
        <dc:identifier>HP:0003141</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003141</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18993152</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/bb4f2778-cea9-4a4e-8305-854afc7a5ed5"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000012"/>
    <dc:provenance>https://www.clinicaltrials.gov/ct2/show/NCT01942291</dc:provenance>
  </obo:OGMS_0000112>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/04ca9c20-cbb4-4d94-8f6d-41d85d5271d0">
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/125c68b3-de51-4b8f-8fed-2cabe541e53a">
        <rdfs:label>Antisense morpholino oligonucleotides (AMOs)</rdfs:label>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/ad8aa8fe-1f09-41ed-93ee-3e2c45f239ff"/>
      </ddiem:Drug>
    </rdf:li>
  </rdf:Alt>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/2df4e764-821c-4ba3-8e60-20dda5e54205">
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/79468376-a366-477e-8527-7adeee9132f0">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/5ff7116c-2d31-4f50-a207-cf47ffeb5be0"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25488886</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17132287</dc:provenance>
    <rdfs:comment>Investigational "Infertility investigation Abetalipoproteinaemia patients might benefit from progesterone supplementation, and further studies on this and hormonal profiles would benefit this pool of patients. Optimising the nutritional profile and body mass index of female patients will undoubtedly contribute to better chances at conception.:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4265040/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24288038</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/200100"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/07e41902-fb56-43db-9be8-97aed9348d04">
        <dc:identifier>HP:0000821</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000821</ddiem:url>
        <rdfs:label>subclinical hypothyroidism</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <dc:provenance>https://ojrd.biomedcentral.com/articles/10.1186/1750-1172-3-20</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26396722</dc:provenance>
  </obo:DDIEM_0000013>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e3f98a5e-43d9-4016-8682-0271dd425197">
    <dc:identifier>HP:0001928</dc:identifier>
    <rdfs:label>blood coagulation</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001928</ddiem:url>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c5c37929-d201-4022-b86d-866d7c1febc7">
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0012535</ddiem:url>
    <dc:identifier>HP:0012535*</dc:identifier>
    <rdfs:label>Abnormal brain neurochemical levels (Abnormality of neurotransmitter metabolism)*</rdfs:label>
  </ddiem:Phenotype>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/0d9221d8-ef76-45b4-aa1c-95abd8bbdce8">
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/e4f5c16b-731c-4c1f-a354-e45e79ab0cca">
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/34ec616e-ba0d-436a-85e1-8a92697132d4"/>
        <rdfs:label>Prokinetic agents</rdfs:label>
      </ddiem:Drug>
    </rdf:li>
  </rdf:Alt>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/222ea346-1024-42c3-9bc5-92d3ecb249a1">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a55caabb-d7cf-4dec-a6db-2197056018f7">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0011943</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0011943</ddiem:url>
        <rdfs:label>abnormal thiosulfates level</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29526615</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/602473"/>
    <rdfs:comment>Drug used as an aternate therapy with (Metronidazole+Acetylcysteine)</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27830356</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/c0a60657-445a-46b2-bb60-19d308f37cbc">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/9af01061-73f2-4d95-96e6-3b1842e2184c"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0022202X15352507</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/518b6d43-2c86-4354-bcc8-68383fdd91a7"/>
  </obo:OGMS_0000112>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d856e87d-0719-4f09-972b-1c2c5527f853">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003219</ddiem:url>
    <dc:identifier>HP:0003219</dc:identifier>
    <rdfs:label>high EMA levels</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/2ae41b35-b0a5-4b25-a059-52aacf3a4649">
    <ddiem:url>https://www.drugbank.ca/drugs/DB01277</ddiem:url>
    <rdfs:label>Mecasermin</rdfs:label>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/fbdd77de-f98a-4b2d-9cfc-2b84dfe00fcd">
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/492c790e-9d09-4105-9c0d-f6ba519ad0b8"/>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00125190</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10323388</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/608747"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/3bbae410-ef54-490a-a352-cf314d34232c"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/33a05a6e-f046-4b2c-89f2-5db9adf5f018"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/c32db724-11bb-44d8-a299-22cf446e8060"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/61b2fbde-0c18-4d4a-bb94-ddeb670ed0fb"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/28629e44-daca-4eef-91a6-0ae1a2a2d0a8"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/dfe270f3-f4a5-4625-96bd-bcd64cba6494"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10549306</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23887143</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10770174</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d67d2f2d-7b95-4084-b84d-2428758cada7"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d77ccceb-eaa6-413b-8db8-ae63022fc6ea"/>
        <rdfs:comment>The drug has been tested in many clinical trials. However Two studies have been terminated, one is for unacceptable hypoglycemic attacks as a side effect of the treatment and the other time is due to shortage of "increlex " supply.</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24639006</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19627167</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f2e6455d-1896-4cf0-af42-1c98e666fdf8"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/37a34016-80e5-4371-b772-f693eaa18e3e"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17192294</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27884013</dc:provenance>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <dc:identifier>DB01277</dc:identifier>
  </ddiem:Drug>
  <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/a1f83fdd-a903-43d7-9614-fec6065218ae">
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/1ccff58f-0fa7-40bd-8d37-91dfe2eb69c1">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/5a31869e-4f2d-42a9-b854-eaed1512342b"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/62f13862-3b92-42cc-9dad-e958eef7c627"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4b9c4859-164a-4b47-bac9-957b01b41b7b">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001939</ddiem:url>
        <dc:identifier>HP:0001939</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Increased erythrocyte glycogen content</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25266922</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/232700"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/eb318982-8e44-434a-92f2-7148303622aa"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/20f5151c-f0e4-462d-93ee-fd0daabd9784"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3483883</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19019309</dc:provenance>
    <dc:provenance>https://www.nature.com/articles/pr19842087</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b252ecb7-edce-4aee-8b1b-b6f72ab1e86f">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0002240</dc:identifier>
        <rdfs:label>Hepatomeglay</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002240</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>Testosterone therapy needs to be carefully considered because of the risk of hepatic adenomas.https://www.ncbi.nlm.nih.gov/pubmed/28160246
Androgen receptors are expressed in the liver, and androgens can stimulate hepatocyte proliferation. Although rare, androgens have been shown in observational studies to induce adenoma development (Giannitrapani et al. 2006). Testosterone levels should be assessed for response 2â3 months after therapy is initiated.</rdfs:comment>
  </obo:DDIEM_0000007>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/081c0ca0-12b3-45b5-83f7-f4e0e6021c57">
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/2f2e6046-6f97-4db4-b845-bcaa863d2851">
        <dc:identifier>DB05990</dc:identifier>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/b154a2a3-f029-41a8-837d-54e752322595"/>
        <rdfs:label>Obeticholic acid</rdfs:label>
        <ddiem:url>https://www.drugbank.ca/drugs/DB05990</ddiem:url>
      </ddiem:Drug>
    </rdf:li>
  </rdf:Alt>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/b35c4f98-48c3-4d4c-9ce9-125c420c0c5a">
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/ca7be59b-f4b5-4edb-ba4e-bcc4021181b2">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/60343a50-9682-41d0-9a62-9a6da5d5594f"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3249181</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1e109f4d-243f-49a4-ba18-4a04eda27b13">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0005110</ddiem:url>
        <rdfs:label>Atrial fibrillation</rdfs:label>
        <dc:identifier>HP:0005110</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18632498</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/a51ef2d1-a45c-425c-8503-8e5b59941c5b">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/d8acc973-6d08-45d5-80e1-e9dc9ec4af67"/>
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/47374066-e347-449b-9e91-203c27d02efa"/>
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/17bcb986-ac14-4c99-b516-c896eb289d7c"/>
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/a168b583-4467-494e-adf1-d5226dfd5cee"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31239752</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23432031</dc:provenance>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/302060">
        <rdfs:label>BARTH SYNDROME; BTHS</rdfs:label>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/59</ddiem:iembaseUrl>
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseAccessionNumber>59</ddiem:iembaseAccessionNumber>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/8960ce3b-1097-4658-8972-74bd47229036"/>
        <dc:identifier>https://www.omim.org/entry/302060</dc:identifier>
      </ddiem:Disease>
    </obo:RO_0002599>
  </obo:DDIEM_0000013>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/19da86b3-b99e-4dab-9073-218045a8b6db">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30247105</dc:provenance>
    <obo:RO_0003304>CYP2D6</obo:RO_0003304>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/30b4d9e3-1250-4f93-b4cf-fda1a9f13183"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6f0ecdf8-d19d-4ab5-827d-56ef304cce4e">
        <dc:identifier>HP:0003656</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003656</ddiem:url>
        <rdfs:label>abnormal glucocerebroside level</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30264864</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/231005"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4b44c227-2a35-4378-90d7-84c67e42065f">
        <rdfs:label>low mean hemoglobin concentration</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0025547</ddiem:url>
        <dc:identifier>HP:0025547</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/1c9d266e-04cc-433b-a581-750411fdefc9">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/a7f7bc12-b1b9-41aa-abf2-9bb8d0b91eeb"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29358012</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7814809</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <dc:provenance>http://clinicaltrials.gov/show/NCT00358150</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/3b8a7752-a33a-43df-8697-89f32c0f3e9e"/>
    <rdfs:comment>The treatment was done via convection-enhanced delivery</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29680197</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15895716</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28935503</dc:provenance>
  </obo:OGMS_0000112>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/3c84013b-4633-4d36-b436-9a505ffee901">
    <rdfs:label>Nicotinamide riboside</rdfs:label>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/1fba2992-6d5d-4212-80b8-5f64be71ef52">
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00125190</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007764"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24639006</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19627167</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/271245"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17192294</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23887143</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30373890</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19304794</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/cb5d4538-9890-415f-9719-49f7fca28ad2"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/7ec38a70-e4e7-4970-9b42-9ed35bb0fa54"/>
        <rdfs:comment>A potential drug for treatment of IOSCA.https://www.ncbi.nlm.nih.gov/pubmed/30373892</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10549306</dc:provenance>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <dc:identifier>DB14933</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB14933</ddiem:url>
  </ddiem:Drug>
  <obo:DDIEM_0000012 rdf:about="http://ddiem.phenomebrowser.net/3a23962d-5abc-4ca7-94ae-fa61f6317766">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19019309</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16434679</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <rdfs:comment>Testosterone therapy needs to be carefully considered because of the risk of hepatic adenomas.https://www.ncbi.nlm.nih.gov/pubmed/28160246
Androgen receptors are expressed in the liver, and androgens can stimulate hepatocyte proliferation. Although rare, androgens have been shown in observational studies to induce adenoma development (Giannitrapani et al. 2006). Testosterone levels should be assessed for response 2â3 months after therapy is initiated.</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/232600"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/42dc744f-e6f2-4e02-b0a4-8d6b14695840">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/4b3777e7-be02-4e38-8da1-60ea87b48621"/>
      </rdf:Alt>
    </obo:RO_0000057>
  </obo:DDIEM_0000012>
  <obo:DDIEM_0000012 rdf:about="http://ddiem.phenomebrowser.net/fd7d7db2-1649-4379-8d3e-8b944ac170af">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4841061</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/606785"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/92af90b3-792a-4779-90d5-b71bb9153912"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583863</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b7cd6bf5-3321-41b9-979c-b2ed7f6995e3">
        <rdfs:label>high serum bilirubin level</rdfs:label>
        <dc:identifier>HP:0002904</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002904</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <rdfs:comment>Controversial benefits https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4158338/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4788912</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3306242</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23162302</dc:provenance>
  </obo:DDIEM_0000012>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/54f3351b-31bd-470e-a6fb-f76bd3d798ef">
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/b45c17f3-4062-4ad3-b0a2-fd987f3bdf54">
        <dc:identifier>A11E</dc:identifier>
        <ddiem:url>https://www.whocc.no/atc_ddd_index/?code=A11E</ddiem:url>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/5ca8264f-2780-445b-87c4-68488ae4265f"/>
      </ddiem:Drug>
    </rdf:li>
  </rdf:Alt>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/607015">
    <rdfs:label>HURLER-SCHEIE SYNDROME</rdfs:label>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/241</ddiem:iembaseUrl>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>https://www.omim.org/entry/607015</dc:identifier>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/7688167e-f2e2-49c6-81e7-684954b030b6"/>
    <ddiem:iembaseAccessionNumber>241</ddiem:iembaseAccessionNumber>
  </ddiem:Disease>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/2ccbbc1a-a417-4a68-9c23-f6e5e28044f8">
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/201100">
        <ddiem:iembaseAccessionNumber>202</ddiem:iembaseAccessionNumber>
        <dc:identifier>https://www.omim.org/entry/201100</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/806654ec-b935-4282-846c-6599e2af109d"/>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/202</ddiem:iembaseUrl>
        <rdfs:label>ACRODERMATITIS ENTEROPATHICA, ZINC-DEFICIENCY TYPE; AEZ</rdfs:label>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/4929571</dc:provenance>
    <rdfs:comment>Enthusiasm for the use of this antimalarial was tempered by the subsequent recognition that irreversible retinopathy was a predictable complication of diiodoquinoline therapy. https://www.sciencedirect.com/science/article/pii/S0190962206022560#bib39
Unfortunately, the long-term treatment with 8-hydroxyquinoline preparations has serious side effects as it leads to optic nerve atrophy and blindness [13], [14]. Therefore, an alternative treatment was desperately sought. https://www.sciencedirect.com/science/article/pii/S0946672X14001837?via%3Dihub#bib0070</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/13044560</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/542ad725-5a88-4fe0-8a7a-77d817c49f99">
        <rdfs:label>Acrodermatitis (Dermatitis)*</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0011123</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0011123</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/60de0157-fb9f-4e7b-9845-577b1f25b99c">
        <dc:identifier>HP:0001596</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001596</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Alopecia</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1275520</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/df3c5291-85d5-491d-876f-8e614165264c">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0040181</dc:identifier>
        <rdfs:label>Perioral dermatitis</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0040181</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/a1224d85-4f04-42b3-aba1-f5ba7b778863">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/02c0c401-8c22-4028-89cb-c658990a902b"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14354277</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ee36264b-0445-4c6b-9b29-2bf96a526985">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002014</ddiem:url>
        <dc:identifier>HP:0002014</dc:identifier>
        <rdfs:label>Diarrhea</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24288038</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
  </obo:OGMS_0000112>
  <obo:DDIEM_0000010 rdf:about="http://ddiem.phenomebrowser.net/448673b4-3581-4889-85dc-4213d76e645d">
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/232400"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/12e92868-d594-4e15-aee0-5ded13899ac2">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002240</ddiem:url>
        <rdfs:label>Enlarged size of the liver</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0002240</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/fb4ec149-5fba-4f0a-8fe0-7d7cef318824">
        <rdfs:label>hypoglycemic seizures</rdfs:label>
        <dc:identifier>HP:0002173</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002173</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4fea0f3d-7e1f-47d7-805c-b04ccde6d08c">
        <rdfs:label>linear growth velocity(Abnormality of body height)*</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000002</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0000002*</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20631546</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25153581</dc:provenance>
    <rdfs:comment>Testosterone therapy needs to be carefully considered because of the risk of hepatic adenomas.https://www.ncbi.nlm.nih.gov/pubmed/28160246
Androgen receptors are expressed in the liver, and androgens can stimulate hepatocyte proliferation. Although rare, androgens have been shown in observational studies to induce adenoma development (Giannitrapani et al. 2006). Testosterone levels should be assessed for response 2â3 months after therapy is initiated.</rdfs:comment>
    <dc:provenance>https://www.nature.com/articles/gim201069</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24613482</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/e4fe8128-15d7-4874-b568-8ddad4ec30c7"/>
  </obo:DDIEM_0000010>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/32944c9b-a98b-4a97-ace5-bd99bd252fec">
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/eb1be296-fe4f-4129-aa06-2bae726dd211">
        <dc:identifier>DB00697</dc:identifier>
        <ddiem:url>https://www.drugbank.ca/drugs/DB00697</ddiem:url>
        <rdfs:label>Tizanidine</rdfs:label>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/25f3ba1d-ea1b-45d6-b6bf-c0e3f9c0eeac"/>
      </ddiem:Drug>
    </rdf:li>
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/464cd3e6-d8ef-4685-8219-5101ad6522a2">
        <dc:identifier>DB12537</dc:identifier>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/25f3ba1d-ea1b-45d6-b6bf-c0e3f9c0eeac"/>
        <ddiem:url>https://www.drugbank.ca/drugs/DB12537</ddiem:url>
        <rdfs:label>Benzodiazepine</rdfs:label>
      </ddiem:Drug>
    </rdf:li>
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/ac42b5f3-e43a-4af9-b2b8-f445c79c6c28">
        <rdfs:label>Amphetamine</rdfs:label>
        <dc:identifier>DB00182</dc:identifier>
        <ddiem:url>https://www.drugbank.ca/drugs/DB00182</ddiem:url>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/25f3ba1d-ea1b-45d6-b6bf-c0e3f9c0eeac"/>
      </ddiem:Drug>
    </rdf:li>
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/c79c34b3-ebe4-40f6-8e39-679990782ff1"/>
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/a48848d8-0543-4f6c-8cab-9fa5e08cb5e6">
        <rdfs:label>Trihexyphenidyl</rdfs:label>
        <dc:identifier>DB00376</dc:identifier>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/25f3ba1d-ea1b-45d6-b6bf-c0e3f9c0eeac"/>
        <ddiem:url>https://www.drugbank.ca/drugs/DB00376</ddiem:url>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/2850a361-3756-4327-a5c6-8451efb3aa20"/>
      </ddiem:Drug>
    </rdf:li>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/2795b7d5-b30d-45bf-ba20-82524d79f867">
    <ddiem:url>https://www.drugbank.ca/drugs/DB01611</ddiem:url>
    <dc:identifier>DB01611</dc:identifier>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/a81eb411-22ff-4d97-83c3-a02cda7fe5cf">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6411330</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9195122</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/095762a4-b9bf-47c0-918d-9f5ce2a2f67e"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d1d51b11-11b7-42d9-b71a-ef0a5f9c40f6"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/5001be32-bd9d-4986-a0a0-2fb2906aba35"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22832289</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/5394a49d-b739-4b9b-ad02-5c32844dedad"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4223155</dc:provenance>
        <rdfs:comment>There is a contraversy about effectivness of methotrexate in treating "Condrocalcinosis 2" .. Details are in https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4223155/ and https://www.ncbi.nlm.nih.gov/pubmed/22832286/</rdfs:comment>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/118600"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21102543</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6169684</dc:provenance>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <rdfs:label>Hydroxychloroquine</rdfs:label>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4840b1d9-27d1-4d20-864d-940e8be365f2">
    <dc:identifier>HP:0040006*</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0040006</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Reduced life span (Mortality)*</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6896b663-4839-4b89-a768-466860c29f28">
    <dc:identifier>HP:0001324</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Fat malabsorption</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001324</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d24dda5c-0e4f-48be-b573-8c62cfd7948e">
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0002453*</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002453</ddiem:url>
    <rdfs:label>Bilateral abnormal signal intensities in the globus pallidus (Abnormality of the globus pallidus)*</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e5ba0c72-3ade-4897-9641-ef8971981fb8">
    <dc:identifier>HP:0009830*</dc:identifier>
    <rdfs:label>Painful neuropathy(neuropathy)*</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0009830</ddiem:url>
  </ddiem:Phenotype>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/a31c0648-1fd4-4102-aca3-5496408f861a">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16868861</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25335805</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28057010</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/6777479</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22402328</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/fec0af46-08df-4c06-a764-9441665924ed"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25859380</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/cfe00ee2-86e0-4fb8-8a62-61815b56c036">
        <dc:identifier>HP:0000938</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000938</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Osteopenia</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>The role of corticosteroids also remains controversial, due to increase risk of infection. As well as, it's  ineffective against the respiratory symptoms. https://www.ncbi.nlm.nih.gov/pubmed/25335805</rdfs:comment>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/222700"/>
  </obo:DDIEM_0000013>
  <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/e3f77dbb-9f6e-4d46-bc11-4e66bf58d7d8">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7357085</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/87aa509c-ee91-434e-bd47-6c8e972e5588">
        <rdfs:label>Elevated blood homocystine</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0002160</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002160</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3950820</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/77c657d7-e0e3-44ec-a1cb-2836f73f6f15"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b962f88a-a849-4148-ba7a-fa3e9c0cd40e"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/da4089ef-2c16-4409-bb06-04297150f2c7">
        <rdfs:label>Myelopathy</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002196</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0002196</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/277400"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25511120</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17431913</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d7146eda-7f0b-40c7-bc27-4b1f29c00864">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002317</ddiem:url>
        <dc:identifier>HP:0002317</dc:identifier>
        <rdfs:label>Gait instability</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/6749192</dc:provenance>
    <rdfs:comment>Bartholomwe et al. have suggested in their paper in 1988 that daily injections of OH-B12 are not necessary to maintain metabolic control and that orally administered OH-B12 is unlikely to be effective. Betaine appears to act synergistically with OH-B12 and should be part of the treatment regimen. Although there are theoretical reasons for using L-carnitine and folinic acid, we could not document their effectiveness in these two patients. https://www.ncbi.nlm.nih.gov/pubmed/3257264/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19821145</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/b3b91803-46c6-4398-8030-a8feea3ea9bc"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://link.springer.com/article/10.1023/A:1005353530303</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f6ba4552-318f-4a21-ba07-de9840ea3e24">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012120</ddiem:url>
        <dc:identifier>HP:0012120</dc:identifier>
        <rdfs:label>Methylmalonic aciduria</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
  </obo:DDIEM_0000007>
  <obo:direct_complementation_of_a_genetically_defective_protein_by_gene_therapy rdf:about="http://ddiem.phenomebrowser.net/7d66e607-0873-4fd3-afe8-b67b6245cfee">
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/36c5831c-4418-4e9b-997f-0ea097e4ffc5">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/03b8a7f3-07de-41c7-9545-c79f80b1bc2b"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15767622</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02180412</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5f9811e2-ec79-4b18-b131-157e90b07964">
        <dc:identifier>HP:0001939*</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001939</ddiem:url>
        <rdfs:label>Hepatic metabolic abnormalities ( Metabolism abnormality)*</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/176000">
        <dc:identifier>https://www.omim.org/entry/176000</dc:identifier>
        <rdfs:label>PORPHYRIA, ACUTE INTERMITTENT; AIP</rdfs:label>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/112</ddiem:iembaseUrl>
        <ddiem:iembaseAccessionNumber>112</ddiem:iembaseAccessionNumber>
        <rdfs:comment></rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/98703b2a-0b95-4d82-ac4f-04e36d48089b"/>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648/#b96-tacg-8-201</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6358544</dc:provenance>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <rdfs:comment>The rh-HMBS-enzyme replacement therapy, however, had no effect on the patientsâ symptoms during acute attacks mainly due to constantly high plasma ALA levels. The potential development of rh-HMBS-enzyme replacement therapy should be focused on the delivery of an active enzyme into the liver ,the main site of ALA overproduction, restoring the normal HMBS activity and heme biosynthesis. https://www.ncbi.nlm.nih.gov/pubmed/17375984/</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/362bd782-ae97-4cea-bae1-3df20f07bff8">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002333</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Abnormal neuromotor function</rdfs:label>
        <dc:identifier>HP:0002333</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19861948</dc:provenance>
  </obo:direct_complementation_of_a_genetically_defective_protein_by_gene_therapy>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ccbfc81f-ab86-41c7-8cc6-4f2910c606ed">
    <rdfs:label>Neuropathy</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0009830</ddiem:url>
    <dc:identifier>HP:0009830</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/69c7f3d9-22a7-4128-adc2-f6f73618d4c3">
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003117</ddiem:url>
    <rdfs:label>Serotonin deficiency</rdfs:label>
    <dc:identifier>HP:0003117*</dc:identifier>
  </ddiem:Phenotype>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/08de229f-8872-483a-9b95-0c9b0bf67ba9">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6440f217-bff4-4d2a-92e8-44dca7b0ebd9">
        <dc:identifier>HP:0000735</dc:identifier>
        <rdfs:label>Impaired social interaction</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000735</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4727671</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15131757</dc:provenance>
    <rdfs:comment>Drug name: Treatment is under trial.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22734130</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
    <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/9c601284-c530-4f64-92b1-8737d01c12cc"/>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/613068">
        <ddiem:iembaseAccessionNumber>71</ddiem:iembaseAccessionNumber>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/22b1a9c8-e093-48b4-9085-2521e92bd0c6"/>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/71</ddiem:iembaseUrl>
        <dc:identifier>https://www.omim.org/entry/613068</dc:identifier>
        <rdfs:label>NEURODEGENERATION DUE TO CEREBRAL FOLATE TRANSPORT DEFICIENCY</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26153518</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d9d625a0-bd18-495d-bf6b-c1f6b7cc9fe1">
        <rdfs:label>Myoclonic seizures</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002123</ddiem:url>
        <dc:identifier>HP:0002123</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0df943c1-2908-42df-ae97-dcf006d67493">
        <dc:identifier>HP:0100022</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0100022</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Movement disorder</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/e26f58c5-3e77-453b-8c30-5df2c9c700e9"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/fb8dbeb4-51cb-4aa6-bccb-1a60adbf735c">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0010819</dc:identifier>
        <rdfs:label>astatic seizures</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0010819</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20301583</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1316120</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30804055</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28590052</dc:provenance>
  </obo:OGMS_0000112>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/224120">
    <rdfs:label>ANEMIA, CONGENITAL DYSERYTHROPOIETIC, TYPE Ia; CDAN1A</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/221bdabd-7245-4da5-a894-e98de7ad7a9d"/>
    <dc:identifier>https://www.omim.org/entry/224120</dc:identifier>
  </ddiem:Disease>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1a90f43d-b719-49a2-ac58-06dcb7429074">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003077</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0003077</dc:identifier>
    <rdfs:label>Hyperlipidemia</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/37a34016-80e5-4371-b772-f693eaa18e3e">
    <rdfs:label>Abnormal circulating insulin level</rdfs:label>
    <dc:identifier>HP:0040215</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0040215</ddiem:url>
  </ddiem:Phenotype>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/cced0042-f26c-4163-aa50-6d29c1b97b5c">
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0166432812001830</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000012"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:comment>There is no clinical role for NaPBA at present; however, ongoing studies are assessing its efficacy https://www.ncbi.nlm.nih.gov/pubmed/28919799 Phenotypes corrected were based on invivo trial on mice not humans.</rdfs:comment>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/bef7a13d-eda9-4945-8a7c-9cae16ec1a64"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/81ef2c4d-b7c6-4946-9915-b9446d90401d"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f1c4981d-daea-451f-8682-c2b1cb345592">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>High plasma branched chain keto acids</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/248600">
        <ddiem:iembaseAccessionNumber>1252</ddiem:iembaseAccessionNumber>
        <dc:identifier>https://www.omim.org/entry/248600</dc:identifier>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/1252</ddiem:iembaseUrl>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/d3714c99-f33a-4b0b-83b7-280dd2cd59c7"/>
        <rdfs:label>MAPLE SYRUP URINE DISEASE; MSUD</rdfs:label>
        <rdfs:comment>In vitro study in which a discussion about activation of MSUD E1 mutants by TMAO treatment was studied further by titrating the osmolyte concentration. The activation of E1 activity for the three type IA MSUD mutants Y368C- , F364C- , and Y393N- is insignificant below 0.4 M TMAO. Rapid rises in residual E1 activity were obtained at 0.5 M or higher TMAO concentrations. The highest degree of activation occurs at 1 M TMAO concentration for all three MSUD mutants, with Y368C- at 50%, F364C- at 39%, and Y393N- at 17% of the wild type specific activity. At higher than 1 M TMAO concentrations, elevated residual E1 activities decline precipitously.</rdfs:comment>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28919799</dc:provenance>
  </obo:OGMS_0000112>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/f4dfde87-7666-455f-b3f2-2e09da6e9da6">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:comment>Treatment was stopped three days later because of lack of improvement and severe respiratory alkalosis with lactic acidosis (serum lactic acid 70 mg/dl, normal 4â20 mg/dl). https://www.ncbi.nlm.nih.gov/pubmed/12948744</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3306242</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/cb5070a3-ac95-4c75-b102-192ca4b450a2"/>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/608158">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>https://www.omim.org/entry/608158</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/f2173f45-1505-4676-9ee8-be970d33771b"/>
        <rdfs:label>CoQ-RESPONSIVE OXPHOS DEFICIENCY</rdfs:label>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719215300895</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d9054e8c-01a4-4bda-bd2b-78a630c0a2d0"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583863</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9156798</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12948744</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15726662</dc:provenance>
  </obo:OGMS_0000112>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/544127be-192d-475a-a54d-c224d1bd6229">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>CNS damage progression</rdfs:label>
    <dc:identifier>HP:0007367</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0007367</ddiem:url>
  </ddiem:Phenotype>
  <owl:Class rdf:about="http://purl.obolibrary.org/obo/OGMS_0000112"/>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/9a8ef311-71ce-4849-9ecf-45cd8aa3ad6c">
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/6816038a-eab9-4fea-a720-1be4092fe49d">
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/0f0cfd3b-c867-4009-b7d3-b7232b9ebcf5"/>
        <dc:identifier>CHEBI_113373</dc:identifier>
        <ddiem:url>https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI_113373</ddiem:url>
        <rdfs:label>sodium beta-hydroxybutyrate</rdfs:label>
      </ddiem:Drug>
    </rdf:li>
  </rdf:Alt>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/7e03991c-d67f-48a9-b7e0-9a52127ca7ff">
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <rdfs:comment>One of the studies that was carried on mice provides useful information for developing the optimal dosage regimen for HPBCD therapy when administered intravenously to NPC patients.https://www.ncbi.nlm.nih.gov/pubmed/26027824</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25717099</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17124037</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14632789</dc:provenance>
    <dc:provenance>https://www.semanticscholar.org/paper/The-Incidence-of-Transient-Neonatal-Tyrosinemia-a-Zea-Rey-Cruz-Camino/b66304a0a56304f686380af915a92b2b860e9305</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28624580</dc:provenance>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/602390">
        <rdfs:label>HEMOCHROMATOSIS, TYPE 2A; HFE2A</rdfs:label>
        <dc:identifier>https://www.omim.org/entry/602390</dc:identifier>
        <ddiem:iembaseAccessionNumber>581</ddiem:iembaseAccessionNumber>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/367d029c-3614-4e9d-b855-f67d81d73a92"/>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/581</ddiem:iembaseUrl>
        <rdfs:comment></rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/2f4259fc-582d-403d-9e49-213d288ccfc5"/>
      </ddiem:Disease>
    </obo:RO_0002599>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/548720cd-8d60-4013-929d-3ae3d5d06aeb"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a09a00cd-6976-42fb-986d-d6c4653a0a5d">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0011031</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>iron overload(Abnormality of iron homeostasis)*</rdfs:label>
        <dc:identifier>HP:0011031*</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19415691</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28803710</dc:provenance>
  </obo:OGMS_0000112>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/73f62ed2-803e-4da5-baa1-d1f93b759935">
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12003346</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25304915</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16601879</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/186b1cbe-37d0-4e36-84d0-9ed192d5c437">
        <dc:identifier>HP:0003117</dc:identifier>
        <rdfs:label>Abnormality in serotonin turnover (Abnormality of circulating hormone level)</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003117</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/ac9e4c34-6622-410a-8b39-d4b71217d40b"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23690520</dc:provenance>
    <dc:provenance>https://www.babysfirsttest.org/newborn-screening/conditions/3-methylcrotonyl-coa-carboxylase-deficiency</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/50b11d07-6d6c-485b-b3af-1f6d0e4d644e"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/261640"/>
    <rdfs:comment>The patients should receive combination treatment with BH4 and neurotransmitter precursors as soon as possible to reduce neurological deterioration https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
  </obo:OGMS_0000112>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/2bf57f0a-bd09-496a-9846-f61f30ffadbe">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5096481</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10969108</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10453735</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28621098</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/606762"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23295286</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/37e0edf9-e95c-48dd-9cfd-75af7b73eea9">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000842</ddiem:url>
        <dc:identifier>HP:0000842</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Hyperinsulinism</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/65084b83-5349-48d3-b185-b9c2720ab857"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/adeaf2e8-1dff-4abb-85f0-dcf918dfc1a6">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0001250</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001250</ddiem:url>
        <rdfs:label>epileptic seizures</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>Based on their study auhors of"  https://www.ncbi.nlm.nih.gov/pubmed/21354122?dopt=Abstract"  presume that the combination of these drugs may contribute to reduce LDL-C/HDL-C ratio effectively as well as lowering concentrations of serum triglyceride.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25781533</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/eb345fb0-e9f4-4420-9c6d-508b9ea1af0b"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26962538</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20936362</dc:provenance>
  </obo:OGMS_0000112>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/345125e4-7990-480b-8d77-3415fd234a6b">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16544179</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000015"/>
    <obo:RO_0002558>
      <ddiem:Evidence rdf:about="http://ddiem.phenomebrowser.net/ECO:0000305">
        <ddiem:url>http://purl.obolibrary.org/obo/ECO_0000305</ddiem:url>
        <dc:identifier>ECO:0000305</dc:identifier>
      </ddiem:Evidence>
    </obo:RO_0002558>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9732974</dc:provenance>
    <rdfs:comment>Alhough therapy with desmopressin cannot be recommended based on the results of a single case, the outcome presented here is intriguing and suggests that larger studies in such patients is warranted to assess the broader application of such an intervention.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29908244</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f55903ec-06dd-40a5-a487-26a19febeb31"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1899474</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16891685</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/86927110-ebd4-46e2-b5c6-cd446bcbea85">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/9e89e51f-4567-49aa-9d16-9913106f8447"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12084887</dc:provenance>
    <dc:provenance>https://link.springer.com/chapter/10.1007%2F8904_2017_14</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a7640c4c-85aa-46a5-b38c-e44a59e90a93">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0040006</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>mortality</rdfs:label>
        <dc:identifier>HP:0040006</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8163996</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27622829</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/274270"/>
  </obo:OGMS_0000112>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/5bb2229c-a9d1-4207-b16b-3831a00ef961">
    <obo:RO_0000056>
      <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/9aabfd73-7015-41f7-b6d2-d9fa59ccfa16">
        <rdfs:comment>The drug was administered through intravitreal injection.</rdfs:comment>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01212744</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/540000"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26095523</dc:provenance>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00887562</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/9bcd6e8e-7a61-4aba-b55e-d5650fc3b3f0"/>
        <dc:provenance>https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117</dc:provenance>
        <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/7d14658a-4b9d-4e36-848b-28462edf1aa3"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8757046</dc:provenance>
      </obo:DDIEM_0000013>
    </obo:RO_0000056>
    <rdfs:label>Idebenone</rdfs:label>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/400985cb-c009-4ffa-9198-b78406160f7f">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/612016"/>
        <rdfs:comment>Drug name: A switch to idebenone treatment resulted in clinical and metabolic worsening, which disappeared with subsequent CoQ10 treatment. https://www.ncbi.nlm.nih.gov/pubmed/15326254/                                       Drug not only failed to improve his condition but also worsened the course of the disease and was therefore discontinued after 7 months. https://www.ncbi.nlm.nih.gov/pubmed/18319072.  In another patient, the myoclonus was aggravated by idebenone. She recovered her previous status after its withdrawal. https://www.ncbi.nlm.nih.gov/pubmed/24164873</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28125198</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24164873</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/7d14658a-4b9d-4e36-848b-28462edf1aa3"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4263309</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15326254</dc:provenance>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <dc:identifier>DB09081</dc:identifier>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/8744bc96-7796-4542-aac4-cf52ae11461f">
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11723211</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3202309</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17573650</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11001192</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f6b28bb6-b5c7-4ba6-b75c-2978e8b741a9"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/28ffadde-9675-423a-bde8-f4c58e28f595"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01495715</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21788663</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21810891</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/535000"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ce8b5819-cb2d-4a37-bc4e-6a870f02a0c8"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b123f4a7-4b1c-41db-b28f-deef7db8017f"/>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02771379</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00747487</dc:provenance>
        <obo:RO_0003304>"m.3460G&gt;A, m.11778G&gt;A, and m.14484T&gt;C"</obo:RO_0003304>
        <rdfs:comment>Author: "The therapeutic potential of idebenone therapy is likely to have the highest impact if therapy is initiated early in the disease at a time when retinal ganglion cell loss is still minimal.https://www.ncbi.nlm.nih.gov/pubmed/21810891/</rdfs:comment>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e652b778-e20e-4611-b3ad-455d936fa919"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29054473</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21483849</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/7d14658a-4b9d-4e36-848b-28462edf1aa3"/>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <ddiem:url>https://www.drugbank.ca/drugs/DB09081</ddiem:url>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/a9b011d9-e86d-4377-b209-e354fa663c73">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17826341</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12069112</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f4f41d47-6c09-46fa-861f-5ca2030e515b"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12771265</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/7d14658a-4b9d-4e36-848b-28462edf1aa3"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/229300"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/bf015380-56f8-4899-9caf-e4cc2494b777"/>
        <rdfs:comment>There is controversy about idebenone effect on LVM index ; although there were some studies suggested its effect on reducing LVM index and neurological problems, there are some that documented its faiure in acheiving this result. https://www.ncbi.nlm.nih.gov/pubmed/21392622
https://www.ncbi.nlm.nih.gov/pubmed/20697044</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11907009</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/5b73731e-9140-4985-b706-30fe1e677197"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12368988</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12771264</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/605328df-3f16-47f1-9315-f97e00fcba14"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/953aefcd-fbaa-4081-88aa-3ad90fe2ec5b"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/749c4e05-a067-4dbf-bfde-b25a6123b0e0"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18234531</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/2279eec2-ec3a-4a24-81cb-e4082f1f688a"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/12860d8a-7844-4608-a964-071cd16777c3"/>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
  </ddiem:Drug>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/8aa4ff89-6380-4d93-a886-0033497a871e">
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d9054e8c-01a4-4bda-bd2b-78a630c0a2d0"/>
    <rdfs:comment>Treatment was stopped three days later because of lack of improvement and severe respiratory alkalosis with lactic acidosis (serum lactic acid 70 mg/dl, normal 4â20 mg/dl). https://www.ncbi.nlm.nih.gov/pubmed/12948744</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15726662</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12948744</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9156798</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583863</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/da32e11a-3af1-4374-9d44-962336a3dc17">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/8538656a-d1c6-411f-9202-dc0839c05076"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3306242</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/608158"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719215300895</dc:provenance>
  </obo:DDIEM_0000013>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/f5f35b83-e99d-43d4-b469-f03c9d6fd66d">
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/14aa237f-cc5c-441f-a462-2833c71bc098">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4902399</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3415789</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a3578176-5857-4639-9400-801bf27a0c6d"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/60de0157-fb9f-4e7b-9845-577b1f25b99c"/>
        <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/3b9a70fe-52ce-4915-947d-c851c73fed31"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/201100"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ce0d460b-91a7-4e2a-add5-e5af4c177c46"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
        <rdfs:comment>Investigational "Infertility investigation Abetalipoproteinaemia patients might benefit from progesterone supplementation, and further studies on this and hormonal profiles would benefit this pool of patients. Optimising the nutritional profile and body mass index of female patients will undoubtedly contribute to better chances at conception.:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4265040/</rdfs:comment>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d325e640-b4b9-43ba-9edb-03fd9cc11994"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/f9d2b6d7-6963-4934-8fb4-ad8ba989ed43"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24718477</dc:provenance>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24288038</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12044538</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/eee992ce-4b7e-440c-980f-19aa12ced069"/>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01593</ddiem:url>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/7a9014bc-ff09-41a2-ad6e-b5c945330886">
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/177000"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/c9c8acb8-94f5-4915-9298-e25ad3912769"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19656325</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19744342</dc:provenance>
        <rdfs:comment>https://www.ncbi.nlm.nih.gov/pubmed/8370580</rdfs:comment>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23884489</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22092997</dc:provenance>
        <dc:provenance>http://www.ncbi.nlm.nih.gov/pubmed/22092997</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26979527</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/f9d2b6d7-6963-4934-8fb4-ad8ba989ed43"/>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <dc:identifier>DB01593</dc:identifier>
    <rdfs:label>Zinc</rdfs:label>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/b09b5d00-a6f3-406b-9391-4c63eafd3f00">
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/c3d4e686-e448-4225-b11e-4feb6e6be685"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/books/NBK1493</dc:provenance>
        <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/df9bf4f4-e55d-48c9-b2dd-1e583b245dde"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3415789</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/02264d42-2607-4e15-9bc4-44e3dadef4e2"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/f9d2b6d7-6963-4934-8fb4-ad8ba989ed43"/>
        <rdfs:comment>Investigational "Infertility investigation Abetalipoproteinaemia patients might benefit from progesterone supplementation, and further studies on this and hormonal profiles would benefit this pool of patients. Optimising the nutritional profile and body mass index of female patients will undoubtedly contribute to better chances at conception.:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4265040/</rdfs:comment>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/604290"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12044538</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24288038</dc:provenance>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/db6d42d0-bc1e-458c-9a99-e1e2fe9a00d1"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
  </ddiem:Drug>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/128230">
    <rdfs:label>DYSTONIA, DOPA-RESPONSIVE; DRD</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/ff2ffe57-3296-4857-9577-1da3fd6fbbff"/>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/4cf4f92e-89c7-4c03-9148-85a8fc1567bf"/>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/9676fa84-21f6-4244-a68b-4ff450096189"/>
    <dc:identifier>https://www.omim.org/entry/128230</dc:identifier>
  </ddiem:Disease>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/161d5461-ddf5-45da-aeb5-a55f94f2997f">
    <rdfs:label>Vitamin E</rdfs:label>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/557718cf-9ab4-4268-88e0-c1805a212090">
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/bc3e4180-e592-4ef1-b398-404c1a884ea8"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/544127be-192d-475a-a54d-c224d1bd6229"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/db6d42d0-bc1e-458c-9a99-e1e2fe9a00d1"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7375069</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/266130"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/9b160f79-146d-473c-a4b9-f388490534a4"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17206463</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e193387f-b9ef-4913-877f-8cbff03660de"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17397529</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29340523</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/1e7b5e33-54bf-43fc-a4c9-de6e00ad2200"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/62919f45-f522-4bd1-938e-d05ceb788c1d"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19019309</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d5308c60-31df-436b-897e-73d3f8e5a72f"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <rdfs:comment>An experimental study done on a mice with GMNT knocked out. suggesting considering Nicotinamide as atreatment option in patients with GNMT deficiency.  https://www.ncbi.nlm.nih.gov/pubmed/20578266/</rdfs:comment>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00163</ddiem:url>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/d13e4430-5415-43ee-92f1-025acf67882e">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25717099</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19415691</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/4744026</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/48f0eae9-c050-47a4-8918-9b66e9cc570d"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/dae370ea-0daf-4d21-918e-6f8825d721bb"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/9fff14ac-e607-4faf-9a06-f8fb3b58cf9a"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/615558"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24288038</dc:provenance>
        <rdfs:comment>These inconsistent results have suggested that the response might depend on the specific gene mutations
 As the response was not sustained and serum ALP and PLP and urine PEA returned to baseline between 8 and 13 months of treatment 
In N461L mutation which led to complete disappearance of the bone isoenzyme, disease was not modified by PTH treatment.  

https://www.ncbi.nlm.nih.gov/pubmed/22218563?dopt=Abstract
https://www.ncbi.nlm.nih.gov/pubmed/20089612?dopt=Abstract (Lack of sustained response to teriparatide in a patient with adult hypophosphatasia_</rdfs:comment>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/29b4324a-7e77-438a-bfe3-af7d5e02f9aa"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24751931</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9110486</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/db6d42d0-bc1e-458c-9a99-e1e2fe9a00d1"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/cec6807d-8ad6-4b23-9641-ec2acb30c053"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26086616</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18308659</dc:provenance>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/3a483178-73bd-4de3-96f8-38cb1c161057">
        <dc:provenance>was associated with improved findings on skeletal radiographs and improved pulmonary and physical function in infants and young children with life-threatening hypophosphatasia. (Funded by Enobia Pharma and Shriners Hospitals for Children; ClinicalTrials.gov number</dc:provenance>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/275630"/>
        <rdfs:comment>Drug name: Treatment is under trial.</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
        <dc:provenance>NCT00744042.)."</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/fa261bcd-57e6-4381-9754-2ef89b790ac7"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/db6d42d0-bc1e-458c-9a99-e1e2fe9a00d1"/>
        <dc:provenance>"ENB-0040</dc:provenance>
        <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
        <dc:provenance>an enzyme-replacement therapy</dc:provenance>
        <dc:provenance>https://onlinelibrary.wiley.com/doi/abs/10.1111/pde.12170</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.researchgate.net/publication/8668575_A_successful_treatment_with_pyridoxal_phosphate_for_West_syndrome_in_hypophosphatasia</dc:provenance>
      </obo:DDIEM_0000013>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/6d879e6d-21c9-4190-ba33-f6670c938eb7">
        <dc:provenance>https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813</dc:provenance>
        <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/9999cc2a-1c33-4f75-b50c-c9ab9732afa3"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20301419</dc:provenance>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01797055</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/5048010f-10dc-4624-8720-aa3b9e6d66f0"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15300460</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/277460"/>
        <rdfs:comment>There is a common note in different reserachs refers to the importance of early managment by Vitamin E supplements since it limits disease progression and it can reverse some of the clinical manifestation (e.x ataxia and the intellectual deficit), if it was interoduced early in life. Therefore, early diagnosis is paramount.</rdfs:comment>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d8418cdd-4a30-4d86-8794-a8944db1bb1e"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9931538</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27906067</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17586848</dc:provenance>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11554913</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/db6d42d0-bc1e-458c-9a99-e1e2fe9a00d1"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/bf015380-56f8-4899-9caf-e4cc2494b777"/>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/d380c5e5-d048-466a-bbb1-c78040e26c06">
        <dc:provenance>https://clinicaltrials.gov/ct2/show/study/NCT00840112</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/bbbd85ae-fe26-4da6-b289-a0780482f63e"/>
        <dc:provenance>https://www.jci.org/articles/view/11948</dc:provenance>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16835865</dc:provenance>
        <dc:provenance>https://www.babysfirsttest.org/newborn-screening/conditions/3-methylcrotonyl-coa-carboxylase-deficiency</dc:provenance>
        <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ccbfc81f-ab86-41c7-8cc6-4f2910c606ed"/>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/231530"/>
        <rdfs:comment>Effect of glycine in treating the condition is variable among literatures.  "Case reports have noted variable results regarding the effect of glycine administration. Some studies have found that supplemental glycine results in increased excretion of 3-methylcrotonyl glycine, while others have not found a persistent effect; no studies have observed clinical improvement of symptoms on treatment and no randomized clinical trials have been published" https://www.sciencedirect.com/science/article/pii/S1096719207005975?via%3Dihub#bib11
https://www.ncbi.nlm.nih.gov/pubmed/8831079
https://www.ncbi.nlm.nih.gov/pubmed/7474896</rdfs:comment>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/db6d42d0-bc1e-458c-9a99-e1e2fe9a00d1"/>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/39c54bfb-4712-4fa0-b0fb-64ff73ffa456">
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b7c17761-3831-457e-9e7c-e4b77150a029"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/cb40e28f-cc65-4e8a-ab4f-51e53eac530c"/>
        <rdfs:comment>To exclude a lack of uridine as a limiting factor, uridine was added for the
 last 9 weeks of treatment.</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19066956</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/db6d42d0-bc1e-458c-9a99-e1e2fe9a00d1"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/232220"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17514432</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18996862</dc:provenance>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <obo:DDIEM_0000011 rdf:about="http://ddiem.phenomebrowser.net/3fe0af18-964b-47f9-8b3e-569f4fe835d3">
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/00cca270-d6c2-4087-b579-30b342a595c4"/>
        <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/200100"/>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
        <rdfs:comment>It's an investigational therapy where Positive results from using a selective monoamine oxidase (MAO) B inhibitor or non-ergot dopamine agonist pramipexole as an adjunct therapy have been described in the medical literature. This use of such an inhibitor can allow for lower doses of neurotransmitter precursor to be used. However, the long-term safety (e.g. effects on neonatal brain development) and effectiveness of this therapy is unknown and more research is required to determine what role, if any, selective monoamine oxidase B inhibitors play in the treatment of individuals with tetrahydrobiopterin deficiency. https://rarediseases.org/rare-diseases/tetrahydrobiopterin-deficiency/. https://www.researchgate.net/publication/233414693_Deprenyl_in_6-Pyruvoyl_Tetrahydropterin_Synthase_Deficiency. https://www.degruyter.com/downloadpdf/j/pteridines.1995.6.issue-3/pteridines.1995.6.3.144/pteridines.1995.6.3.144.pdf</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26086616</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d71d717f-c80f-418b-9945-36bca70ad305"/>
        <dc:provenance>https://ojrd.biomedcentral.com/articles/10.1186/1750-1172-3-20</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30358967</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/db6d42d0-bc1e-458c-9a99-e1e2fe9a00d1"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24288038</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3954973</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/fbeede9d-4d57-4d82-a798-23b4be82825f"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25488886</dc:provenance>
      </obo:DDIEM_0000011>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/06190342-0114-4996-8ca5-5755a9d00322">
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/735e0035-3c60-49bc-b830-69074947b261"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/db6d42d0-bc1e-458c-9a99-e1e2fe9a00d1"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/246700"/>
        <dc:provenance>https://rarediseases.info.nih.gov/diseases/9683/chylomicron-retention-disease</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4223155</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23329770</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22832289</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6169684</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21102543</dc:provenance>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5915691</dc:provenance>
        <rdfs:comment>There is a contraversy about effectivness of methotrexate in treating "Condrocalcinosis 2" .. Details are in https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4223155/ and https://www.ncbi.nlm.nih.gov/pubmed/22832286/</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <dc:identifier>DB00163</dc:identifier>
  </ddiem:Drug>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/c8ed1994-7ecc-4d57-aefe-69678e728b46">
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/261750"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/ce1a08af-5cab-4d43-9e48-9a05e939b37a">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/c23cf81d-b12a-4d91-aec2-09b105f5a452"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC324959</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/397a09b3-2d92-4bfa-8ddf-6f103f0e2656"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583863</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2564511</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25266922</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15726662</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:comment>Treatment was stopped three days later because of lack of improvement and severe respiratory alkalosis with lactic acidosis (serum lactic acid 70 mg/dl, normal 4â20 mg/dl). https://www.ncbi.nlm.nih.gov/pubmed/12948744</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3306242</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000010"/>
  </obo:OGMS_0000112>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/9c40de2d-53f8-4fcb-be5b-e3f0e38783fc">
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/233910">
        <dc:identifier>https://www.omim.org/entry/233910</dc:identifier>
        <ddiem:iembaseAccessionNumber>3</ddiem:iembaseAccessionNumber>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>HYPERPHENYLALANINEMIA, BH4-DEFICIENT, B; HPABH4B</rdfs:label>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/3</ddiem:iembaseUrl>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/4cf4f92e-89c7-4c03-9148-85a8fc1567bf"/>
      </ddiem:Disease>
    </obo:RO_0002599>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719208000048</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20818608</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19234759</dc:provenance>
    <rdfs:comment>Sodium phenylbutyrate lowers the resynthesis of arginine from ornithine via the urea cycle.https://www.ncbi.nlm.nih.gov/pubmed/24268530</rdfs:comment>
    <dc:provenance>https://link.springer.com/referenceworkentry/10.1007%2F978-3-540-29676-8_1729</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/5509192c-926c-4aea-b6a8-36e0a2b2911c">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/7c4c7350-096d-4a7d-842b-e9c429f466c3"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/9357a41d-cd9b-42ff-b10f-a22ddbc4210e"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d085d8b8-d983-42e9-9c26-3dc1db45c4bc">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Defected neurotransmitter homeostasis in the CNS</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012535</ddiem:url>
        <dc:identifier>HP:0012535</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22729819</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12003346</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3b3baab2-e25e-4336-9531-f1c2b2fe8ab7">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>spasticity</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001257</ddiem:url>
        <dc:identifier>HP:0001257</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/636f2382-d55e-4dc2-9bd2-b65b0c2f1e42">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0001270</dc:identifier>
        <rdfs:label>abnormal motor development</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001270</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10078749</dc:provenance>
  </obo:OGMS_0000112>
  <obo:DDIEM_0000012 rdf:about="http://ddiem.phenomebrowser.net/704a84f0-21bd-4ce7-9c3c-77250cd6307c">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/69cc42e0-f905-45cb-8164-997ea7a82367">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001712</ddiem:url>
        <dc:identifier>HP:0001712</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Left ventricular hypertrophy</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01218659</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/301500"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30723321</dc:provenance>
    <rdfs:comment>The drug was more effective in some mutations than others, so if the results are analysed according to the mutation there is an advantage for migalastat.https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6370600/
 Miglustat stabilises specific mutant (amenable) forms of Î±-Gal to facilitate normal lysosomal trafficking. https://www.ncbi.nlm.nih.gov/pubmed/27834756/</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3ce25676-2b63-4b58-b0b8-996aa8948653">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>High mean number of GL-3 inclusions,kidney interstitial capillary(KIC)</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.nature.com/articles/s41436-019-0451-z</dc:provenance>
    <obo:RO_0003304>"p.D33G/p.L36W (n=2)/p.D55V/p.Q57L /p.G85D/p.R112H/G144V/p.I253T (n=4)/p.G258R (n=2) ,.A156T (n=3)                             p.P293T (n=2) /p.C174R                                                                                                           p.F295C                                                                  p.G183D (n=2)                                    p.L300P                                                                      p.M187I                                                                             p.R301Q   (n=3)                                                                           p.P205T (n=2)                                p.I317T                                                                  p.Y216C (n=3) /                             p.D322E (n=2)                                                    33p.L243F                                                                              p.G325R (n=2)/p.G373S / p.D244N/ p.R356W"</obo:RO_0003304>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a6563de7-dea8-4468-b4b8-a308c766ffd5">
        <rdfs:label>High plasma lyso-globotriaosylsphingosine level</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/cd742dcc-22c6-425f-ad6d-b4ef0452aa6e">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/13589aab-a04f-4985-b232-346074e51c74"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01458119</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
    <ddiem:failedToContributeToCondition>"E48K, R49P, S65I, I117S, G183V, G261D, G271S, S276G, R342Q (n=8), L414S"</ddiem:failedToContributeToCondition>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00925301</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30875019</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27834756</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27509102</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30765910</dc:provenance>
  </obo:DDIEM_0000012>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/7c72f493-fa32-4bf8-94c8-184384960efd">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9605e0fa-41fb-4c12-afc1-04fdb0d230ca">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002917</ddiem:url>
        <dc:identifier>HP:0002917</dc:identifier>
        <rdfs:label>hypomagnesemia</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/241200">
        <rdfs:label>BARTTER SYNDROME, TYPE 2, ANTENATAL; BARTS2</rdfs:label>
        <dc:identifier>https://www.omim.org/entry/241200</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/dda24f3e-5352-4e05-99e8-ecabf70d0a83"/>
        <rdfs:comment></rdfs:comment>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2646391</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/7d16d8d9-8d19-4337-8bd3-2d28a85e4f23">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/c2ecf1f2-a499-4466-8f17-4173e2736f35"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-Bartter.pdf</dc:provenance>
    <dc:provenance>http://www.neurologyindia.com/article.asp</dc:provenance>
    <rdfs:comment>Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24260777</dc:provenance>
  </obo:OGMS_0000112>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/5beb0a2b-4689-48d9-9bc6-5694dd831ea4">
    <ddiem:url>https://www.drugbank.ca/drugs/DB14507</ddiem:url>
    <rdfs:label>Lithium citrate</rdfs:label>
    <obo:RO_0000056>
      <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/7f2e2c71-611f-4891-a69d-a91c60f0fad3">
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/239500"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28202261</dc:provenance>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28285122</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/778ed03e-3afa-486e-916a-68611d1fa0d8"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/4121c319-d513-4227-9c2c-d300d5664f61"/>
        <rdfs:comment>These inconsistent results have suggested that the response might depend on the specific gene mutations
 As the response was not sustained and serum ALP and PLP and urine PEA returned to baseline between 8 and 13 months of treatment 
In N461L mutation which led to complete disappearance of the bone isoenzyme, disease was not modified by PTH treatment.  

https://www.ncbi.nlm.nih.gov/pubmed/22218563?dopt=Abstract
https://www.ncbi.nlm.nih.gov/pubmed/20089612?dopt=Abstract (Lack of sustained response to teriparatide in a patient with adult hypophosphatasia_</rdfs:comment>
      </obo:DDIEM_0000013>
    </obo:RO_0000056>
    <dc:identifier>DB14507</dc:identifier>
  </ddiem:Drug>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/2873ee75-25f8-4718-ae5c-11065fa86552">
    <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15131757</dc:provenance>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/213700">
        <rdfs:comment></rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/564cc080-d13b-4ecc-ab74-aa04d1c95735"/>
        <rdfs:label>CEREBROTENDINOUS XANTHOMATOSIS; CTX</rdfs:label>
        <ddiem:iembaseAccessionNumber>183</ddiem:iembaseAccessionNumber>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/183</ddiem:iembaseUrl>
        <dc:identifier>https://www.omim.org/entry/213700</dc:identifier>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28590052</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26153518</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1316120</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0498e405-6b18-4f5b-8ead-39d2aa6b46f4">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001324</ddiem:url>
        <rdfs:label>muscle weakness</rdfs:label>
        <dc:identifier>HP:0001324</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>Drug name: Treatment is under trial.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30804055</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20301583</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/4556601b-4e58-4413-90b1-df627cd415d1"/>
  </obo:OGMS_0000112>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/fc7cfe0d-08c8-4ad4-bbca-e5fca9a43456">
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/02b1f9fd-6e2f-4a2e-acd8-d2d727c4fb43">
        <rdfs:comment>Phenobarbital, clonazepam, valproate, and midazolam could not completely control seizures. https://www.ncbi.nlm.nih.gov/pubmed/20052547/</rdfs:comment>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26537923</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/230000"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/9897b42a-c20a-48c2-b814-56fe0dade2b4"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/0cd08a38-f58b-41c1-b399-150103c7879b"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27491218</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6649943</dc:provenance>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/082c4a03-8f05-4551-b691-a107fbff5efd">
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/1ef5ca6c-acc0-4137-bc95-14577650f3d9"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/88ec29a7-11a0-4c9d-8d51-1fea2cbb9e43"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/af919467-55e5-4c67-8978-a38be6a20fd3"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25173351</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30225156</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/260920"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26962538</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24561416</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/404c382f-7439-4041-b8fd-bad9d82109c5"/>
        <rdfs:comment>The results of this study suggest that octreotide may aid in the acute or long-term treatment of congenital hyperinsulinism in a limited number of selected cases.https://www.ncbi.nlm.nih.gov/pubmed/8410522/</rdfs:comment>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/9897b42a-c20a-48c2-b814-56fe0dade2b4"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26516243</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/c9106990-2dc9-4d0b-8b31-72009b8aa14f"/>
      </obo:DDIEM_0000013>
    </obo:RO_0000056>
    <dc:identifier>DB06273</dc:identifier>
    <rdfs:label>Tocilizumab</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB06273</ddiem:url>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6e5decf5-1b99-47d5-b5e3-b142df429eb7">
    <rdfs:label>Abnormal Awake EEG</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002353</ddiem:url>
    <dc:identifier>HP:0002353</dc:identifier>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/f2925ecf-5485-44c7-b23d-ee99839bffd5">
    <dc:identifier>DB00808</dc:identifier>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/7764d447-ba83-4d5b-baa4-f0b46fd6539b">
        <rdfs:comment>Some patients could only be fully controlled by the combination of chlorpropamide and hydrochlorothiazide.</rdfs:comment>
        <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12016800</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15131757</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/125700"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/08249b8c-9cf8-42f2-afc7-c6a363010f34"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26153518</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30804055</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10510995</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/4610bccc-ba63-4ff6-b73c-fd7909dd9a0d"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/88352e00-abe7-4b89-a7cc-ce1be42b7c1b"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b2e4f205-7ff4-4c00-ab70-a6470c2b131f"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28590052</dc:provenance>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <rdfs:label>Indapamide</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00808</ddiem:url>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b5d9691e-2e2d-4de4-9280-b51463031e55">
    <dc:identifier>HP:0002155*</dc:identifier>
    <rdfs:label>Abnormal fasting triglycerides</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002155</ddiem:url>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/74166c99-82ed-4fa7-8022-ab10061b6a9b">
    <ddiem:url>https://www.drugbank.ca/drugs/DB00476</ddiem:url>
    <dc:identifier>DB00476</dc:identifier>
    <rdfs:label>Duloxetine</rdfs:label>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/af03c20e-709c-47c9-a18f-2925c56c9b9b">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29596118</dc:provenance>
        <rdfs:comment>The drug was administered through intravitreal injection.</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26095523</dc:provenance>
        <dc:provenance>http://ichgcp.net/clinical-trials-registry/NCT03432871</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/d6753414-6547-47da-af01-5b9310596be6"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/540000"/>
        <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <dc:provenance>https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/8b8142a8-4b90-4d8d-99fa-e7646f88aff9"/>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01212744</dc:provenance>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/db1f93d8-1515-4d18-8a3c-e8dce06f2612">
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0000707</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000707</ddiem:url>
    <rdfs:label>Neurological abnormalties</rdfs:label>
  </ddiem:Phenotype>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/60348b12-7b29-4426-8d7a-fc853762a897">
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/53abf5f6-3d88-45d2-86cb-0e9a650fc313">
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/94e3f1cd-5570-4a65-871f-f982b29c12fe"/>
        <ddiem:url>https://www.drugbank.ca/drugs/DB14476</ddiem:url>
        <rdfs:label>DL-alpha-Tocopherol</rdfs:label>
        <dc:identifier>DB14476</dc:identifier>
      </ddiem:Drug>
    </rdf:li>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/edace8ef-6023-46de-b03a-89ca8401b022">
    <rdfs:label>Taurine</rdfs:label>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/803b0aa2-1288-4fef-b0b7-f6659c7fc408">
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7936305</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26962538</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/874d1dda-4066-4783-ad21-5e5ac8eaf174"/>
        <rdfs:comment>The results of this study suggest that octreotide may aid in the acute or long-term treatment of congenital hyperinsulinism in a limited number of selected cases.https://www.ncbi.nlm.nih.gov/pubmed/8410522/</rdfs:comment>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/237400"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27023909</dc:provenance>
        <dc:provenance>https://link.springer.com/article/10.1007%2Fs00726-017-2462-x</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/1ec53405-6dc6-4c8b-a9f9-346b194ba998"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <dc:identifier>DB01956</dc:identifier>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/f688edec-20c7-41f3-88b6-e4712b37b394">
        <dc:provenance>http://ichgcp.net/clinical-trials-registry/NCT03432871</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/17f4178b-4525-4283-8ed7-569eae8e79cc"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29596118</dc:provenance>
        <rdfs:comment>The drug was administered through intravitreal injection.</rdfs:comment>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26095523</dc:provenance>
        <dc:provenance>https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/48f0eae9-c050-47a4-8918-9b66e9cc570d"/>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01212744</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/540000"/>
        <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/1ec53405-6dc6-4c8b-a9f9-346b194ba998"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01956</ddiem:url>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4830e73a-2ac3-44c6-8ad5-c12948c22932">
    <rdfs:label>Personality disorder</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0012075</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0012075</ddiem:url>
  </ddiem:Phenotype>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/5821bf5b-2c57-4fa9-b6bd-abd65d5546c5">
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18425437</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8163996</dc:provenance>
    <rdfs:comment>Alhough therapy with desmopressin cannot be recommended based on the results of a single case, the outcome presented here is intriguing and suggests that larger studies in such patients is warranted to assess the broader application of such an intervention.</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/de2f9565-d217-424d-b54d-5a9be0514a37"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12084887</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/261630"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7760062</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16891685</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1899474</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25667865</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/387b9aa2-9a28-479d-a7f0-8ecfc6876a9c"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26817292</dc:provenance>
  </obo:DDIEM_0000013>
  <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/0485ceb0-da17-47fb-af36-06d5d13d2d40">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19821145</dc:provenance>
    <dc:provenance>https://link.springer.com/article/10.1023/A:1005353530303</dc:provenance>
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/b3b91803-46c6-4398-8030-a8feea3ea9bc"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/236270">
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/8b7778d7-bbe1-43c4-ab00-0f7a9d613a6c"/>
        <dc:identifier>https://www.omim.org/entry/236270</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/31</ddiem:iembaseUrl>
        <rdfs:label>HOMOCYSTINURIA-MEGALOBLASTIC ANEMIA, cblE COMPLEMENTATION TYPE; HMAE</rdfs:label>
        <ddiem:iembaseAccessionNumber>31</ddiem:iembaseAccessionNumber>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01793090</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28210839</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3950820</dc:provenance>
    <rdfs:comment>Selection of this drug combinstion ""Methylprednisolone sodium succinate +
Immune Globulin "" was based on the presumption that the patient had autoimmune encephalopathy. https://www.ncbi.nlm.nih.gov/pubmed/25511120</rdfs:comment>
  </obo:DDIEM_0000007>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/ed83bf45-456e-4147-89a7-42c07d77dd28">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/abfe65ad-0e26-4efa-8aad-0e9049766dbb">
        <rdfs:label>High biliary cholesterol saturation index</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/237500">
        <dc:identifier>https://www.omim.org/entry/237500</dc:identifier>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/554</ddiem:iembaseUrl>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/e35ecfa0-efdd-4788-af0e-4fc1c9e10675"/>
        <ddiem:iembaseAccessionNumber>554</ddiem:iembaseAccessionNumber>
        <rdfs:label>DUBIN-JOHNSON SYNDROME; DJS</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16952291</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26264947</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/73ee989c-18fb-4d98-9b01-4fb03004069e"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16083704</dc:provenance>
    <rdfs:comment>Rifampicin and ursodeoxycholic acid (UDCA) therapy have beneficial effects in chronic cholestatic diseases. These may result, in part, from the induction of MRP2 expression in the liver and kidney. However, neither an indication nor a general role for these agents in Dubin-Johnson syndrome has been defined.https://www.ncbi.nlm.nih.gov/pubmed/12012642
These drugs, in fact, should be used with caution in patients with Dubin-Johnson syndrome. Reporting on a patient with the disease who had a novel 974CâG nonsense mutation of the MRP2gene, Corpechot et al found a rise in conjugated bilirubinemia following the chronic administration of rifampicin, as well as a sharp increase in serum bile acid concentration following the concomitant chronic administration of rifampicin and UDCA. These adverse effects may result from an increased expression of MRP3at the basolateral membrane of hepatocytes as a direct consequence of drug induction.https://www.ncbi.nlm.nih.gov/pubmed/16952291 https://emedicine.medscape.com/article/173517-treatment</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/05fa56e4-c04d-4111-a5f8-870005801870">
        <rdfs:label>hyperbilirunbinemia</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0002904</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002904</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ac341809-0511-4e2b-990b-f29f5730decc">
        <rdfs:label>pruritus</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000989</ddiem:url>
        <dc:identifier>HP:0000989</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1fb57b96-ddbb-4dc5-9e46-71df2655ef3c">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012202</ddiem:url>
        <dc:identifier>HP:0012202</dc:identifier>
        <rdfs:label>elevated serum concentrations of bile acids</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12012642</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/3f7a98ed-1d69-47d7-8fc0-342d40305dd9">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/056cd8cc-9967-4f9f-b425-f97ec923aae6"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2056fdbc-a0a3-4cb8-8c08-e95c42757171">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0003155</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003155</ddiem:url>
        <rdfs:label>high serum alkaline phosphatase</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </obo:OGMS_0000112>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6499bf4e-1966-42b9-baa3-5dac87a818c9">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Elevated prostaglandin E2</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003566</ddiem:url>
    <dc:identifier>HP:0003566</dc:identifier>
  </ddiem:Phenotype>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/0ce63990-ac48-4e4f-998f-c7dfa67d5e37">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2637faa2-167f-4bda-bfb7-4b8b16ab3637">
        <rdfs:label>Parkinsonism</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2b94d7b2-4310-4fdc-a3f9-24483194dd90">
        <rdfs:label>Axial dystonia</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002530</ddiem:url>
        <dc:identifier>HP:0002530</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30838265</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24943079</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e15f656c-0a21-4b1c-b1fa-65f91cb3cef0"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30941926</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19821145</dc:provenance>
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/78f3d001-4887-4d42-8777-a38dce39096e"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f6e4cdff-dd69-4a5c-a89c-877c1320d930">
        <rdfs:label>Rigidity</rdfs:label>
        <dc:identifier>HP:0002063</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002063</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ff1f5283-8e7f-44f3-adf7-58cf8fe1291f"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/00b0e5c9-8db3-4e1b-a9df-6f7add93e36f">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Limb dystonia</rdfs:label>
        <dc:identifier>HP:0001332</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001332</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ef745b45-6525-49f5-9b6c-9447c376f31f">
        <rdfs:label>Gait abnormality</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0001288</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001288</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>Selection of this drug combinstion ""Methylprednisolone sodium succinate +
Immune Globulin "" was based on the presumption that the patient had autoimmune encephalopathy. https://www.ncbi.nlm.nih.gov/pubmed/25511120</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3950820</dc:provenance>
    <dc:provenance>https://link.springer.com/article/10.1023/A:1005353530303</dc:provenance>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/157640">
        <ddiem:iembaseAccessionNumber>418</ddiem:iembaseAccessionNumber>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/42910152-5855-4c4b-bc8a-f9d7f0ec1dba"/>
        <dc:identifier>https://www.omim.org/entry/157640</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA WITH MITOCHONDRIAL DNA DELETIONS, AUTOSOMAL DOMINANT 1; PEOA1</rdfs:label>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/418</ddiem:iembaseUrl>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01793090</dc:provenance>
  </obo:DDIEM_0000013>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/d2907c91-b72d-4078-9040-5d7f2a32a43b">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/939a34da-3c57-420f-a671-f45a905eb358">
        <rdfs:comment>Overall survival (OS), was found to be statistically insignificant. Despite being insignificant, patients receiving cabozantinib had a median OS of 26.6 months vs. a median OS of just 21.1 months for placebo patients (HR 0.85; 95% CI 0.64 to1.12; p = 0.24), resulting in an actual difference of 5.5 months. This provides patients treated with cabozantinib a 20.68% longer survival period compared to the placebo group. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6214082/</rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/MP_    ....</ddiem:url>
        <dc:identifier>MP:    ....</dc:identifier>
        <rdfs:label>overall survival( premature death)</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/a60d0182-086b-497e-8f85-26e0752728d8">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/4053765f-ff27-4433-bc2f-ad605a3f92a0"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2cfeade5-f060-4834-aeec-49b6c7695afe">
        <rdfs:comment>The estimated tumor response rate for cabozantinib and placebo is 28% and 0%, respectively, with results varying independently on RET-status, thus making it a promising treatment option. https://www.ncbi.nlm.nih.gov/pubmed/24002501</rdfs:comment>
        <rdfs:label>Low tumor response rate</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00923247</dc:provenance>
    <rdfs:comment>Treatment-related risks should be taken into account when considering the use of vandetanib in patients with indolent, asymptomatic, or slowly progressing disease.https://www.ncbi.nlm.nih.gov/pubmed/22665903?dopt=Abstract</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f834d6f3-64d7-4659-9f29-60b1bec9dd60"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00704730</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00215605</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c6aeb611-bcf8-431a-84ad-d375639c005a">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>phospholylation of RET</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/162300"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/9a072f97-a02c-460a-9ea8-d24d2f4c1fe7"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30297385</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21606412</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24002501</dc:provenance>
  </obo:OGMS_0000112>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/e643648c-e4ac-4141-86e1-d57f70bdf43f">
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/4fd50135-003a-4a38-9d9f-c4d2f89f96f7">
        <ddiem:url>https://www.drugbank.ca/drugs/DB00695</ddiem:url>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/b353bd62-b699-4a54-9d65-f3fcd11f7002"/>
        <dc:identifier>DB00695</dc:identifier>
        <rdfs:label>Furosemide</rdfs:label>
      </ddiem:Drug>
    </rdf:li>
  </rdf:Alt>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/e8cae7a0-41da-45c1-9244-84b1af478b35">
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/74c1331b-75c0-4ed1-ae65-1a3b0cf065db">
        <ddiem:url>https://www.drugbank.ca/drugs/DB15146</ddiem:url>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/7cbd8e92-8adc-49c9-a4cd-696ee64413ee"/>
        <rdfs:label>Adrabetadex</rdfs:label>
        <dc:identifier>DB15146</dc:identifier>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/ba2c130d-aa7a-427c-ac4b-d30e89105814"/>
      </ddiem:Drug>
    </rdf:li>
  </rdf:Alt>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/55254497-e925-4d37-9d26-eea6c7d3437f">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9110486</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/88ec29a7-11a0-4c9d-8d51-1fea2cbb9e43"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/93892661-9301-4b99-9e67-4661b376a265">
        <dc:identifier>HP:0001376</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>mobility problems</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001376</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/38bd590b-ad95-49dd-a227-3ff84f8b3aa9">
        <rdfs:label>High urine phosphoethanolamine</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003239</ddiem:url>
        <dc:identifier>HP:0003239</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20739387</dc:provenance>
    <obo:RO_0003304>compound heterozygotes for a p.G339R and p.E191KÂ ALPLÂ mutation</obo:RO_0003304>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/4f1ecdd0-cb85-48cd-815d-f30671eb6edf">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/0cc64ccb-926e-40c8-bda2-57daea182809"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/929b7c3f-8691-4faf-93b2-7d1ece8e9f53">
        <rdfs:label>High serum pyridoxal 5'-phosphate</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d53499d1-384e-468d-8de8-96968502d5be">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003260</ddiem:url>
        <dc:identifier>HP:0003260*</dc:identifier>
        <rdfs:label>High bone turnover markers</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17213282</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25717099</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/42badaa4-f215-40db-b0d0-1213e82dfa90">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001832</ddiem:url>
        <rdfs:label>metatarsal stress fractures</rdfs:label>
        <dc:identifier>HP:0001832</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2671b291-c8e4-43ec-ab5c-72e08d72b784">
        <dc:identifier>HP:0006462</dc:identifier>
        <rdfs:label>defect in skeletal mineralization</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0006462</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000012"/>
    <ddiem:failedToContributeToCondition>N461L</ddiem:failedToContributeToCondition>
    <obo:RO_0003304>Ala176Thr/Val423Ala/Val522Ala</obo:RO_0003304>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27042741</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22218563</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20089612</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/94fd58f4-1cd9-430a-9708-005e38596aa6">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002756</ddiem:url>
        <rdfs:label>stress fractures(Pathologic fracture)*</rdfs:label>
        <dc:identifier>HP:0002756*</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f13644d6-d185-43d6-8197-8942a2405ee7">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>proximal femur pseudofractures</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0100036</ddiem:url>
        <dc:identifier>HP:0100036</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0003304>D378V /G339R/E191K/A176T/V423A</obo:RO_0003304>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18308659</dc:provenance>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/241500">
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/6ed7d20c-8b72-41a5-ac32-47d4eba88fcc"/>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/561</ddiem:iembaseUrl>
        <ddiem:iembaseAccessionNumber>561</ddiem:iembaseAccessionNumber>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>https://www.omim.org/entry/241500</dc:identifier>
        <rdfs:label>HYPOPHOSPHATASIA, INFANTILE</rdfs:label>
      </ddiem:Disease>
    </obo:RO_0002599>
    <rdfs:comment>These inconsistent results have suggested that the response might depend on the specific gene mutations
 As the response was not sustained and serum ALP and PLP and urine PEA returned to baseline between 8 and 13 months of treatment 
In N461L mutation which led to complete disappearance of the bone isoenzyme, disease was not modified by PTH treatment.  

https://www.ncbi.nlm.nih.gov/pubmed/22218563?dopt=Abstract
https://www.ncbi.nlm.nih.gov/pubmed/20089612?dopt=Abstract (Lack of sustained response to teriparatide in a patient with adult hypophosphatasia_</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19415691</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/4744026</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26245849</dc:provenance>
  </obo:OGMS_0000112>
  <obo:DDIEM_0000010 rdf:about="http://ddiem.phenomebrowser.net/d0203dab-cbbf-4efd-a5bb-d28a7e2c36b5">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/202b2073-9e0f-4323-b4bc-9fcf095b645b"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16763896</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12122118</dc:provenance>
    <rdfs:comment>Dietry treatment supplementation</rdfs:comment>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/a5339c14-5cc3-41e8-b345-f78cf77e4e18"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4efed0da-fb5f-4b6f-8a7a-16fb9a750cdd">
        <dc:identifier>HP:0003201</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003201</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Rhabdomyolysis</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/600890">
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/178</ddiem:iembaseUrl>
        <ddiem:iembaseAccessionNumber>178</ddiem:iembaseAccessionNumber>
        <dc:identifier>https://www.omim.org/entry/600890</dc:identifier>
        <rdfs:label>HYDROXYACYL-CoA DEHYDROGENASE/3-KETOACYL-CoA THIOLASE/ENOYL-CoA HYDRATASE, ALPHA SUBUNIT; HADHA</rdfs:label>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/7d431472-f90d-4587-a235-42204a097e12"/>
      </ddiem:Disease>
    </obo:RO_0002599>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/67594906-a387-4d45-ae37-7b7fe19369aa">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0025142</ddiem:url>
        <rdfs:label>Low quality of life</rdfs:label>
        <dc:identifier>HP:0025142</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ecbcf6ab-69ab-4901-8e24-f37aa276dffb">
        <dc:identifier>HP:0001638</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001638</ddiem:url>
        <rdfs:label>Cardiomyopathy</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </obo:DDIEM_0000010>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/121270">
    <rdfs:label>COPPER DEFICIENCY, FAMILIAL BENIGN</rdfs:label>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/f2173f45-1505-4676-9ee8-be970d33771b"/>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>https://www.omim.org/entry/121270</dc:identifier>
  </ddiem:Disease>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/42ad7b50-a3a0-4ca2-b250-b9157ec53a75">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1bc1f9e1-c2f7-427f-908c-4152ef8ccc40">
        <rdfs:label>Lower extremity weakness</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0007340</ddiem:url>
        <dc:identifier>HP:0007340</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d7146eda-7f0b-40c7-bc27-4b1f29c00864"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/86fa8ff3-5481-4a1e-abbd-0b92365521df"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6391119</dc:provenance>
    <rdfs:comment>All patients received OHCbl (intramuscular injection; 0.5â1 mg/week) and betaine (oral administration; 1â3 g/day). Some patients also took oral administration of folic acid (10â30 mg/day) and compound vitamin B (20â60 mg/day)</rdfs:comment>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/b3b91803-46c6-4398-8030-a8feea3ea9bc"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3950820</dc:provenance>
    <dc:provenance>https://link.springer.com/article/10.1023/A:1005353530303</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/e26f58c5-3e77-453b-8c30-5df2c9c700e9"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/deb15b2b-baeb-44f9-bc87-fb6acd8b998b">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/385e274a-0b58-4975-b44b-4569424e049e"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19821145</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/277400"/>
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
    <dc:provenance>https://reader.elsevier.com/reader/sd/pii/S0140673615000768</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/cd539122-ae66-4ad2-8241-d43b66dbe01f"/>
  </obo:OGMS_0000112>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/d7678ddc-3824-46d7-a328-3b216d294a50">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3412ec7a-98b8-49f5-a690-433f8ff3e452">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001943</ddiem:url>
        <dc:identifier>HP:0001943</dc:identifier>
        <rdfs:label>Mild asymptomatic hypoglycemia</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/280544</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2564511</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/261750"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15726662</dc:provenance>
    <rdfs:comment>Treatment was stopped three days later because of lack of improvement and severe respiratory alkalosis with lactic acidosis (serum lactic acid 70 mg/dl, normal 4â20 mg/dl). https://www.ncbi.nlm.nih.gov/pubmed/12948744</rdfs:comment>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/397a09b3-2d92-4bfa-8ddf-6f103f0e2656"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3306242</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/1ccff58f-0fa7-40bd-8d37-91dfe2eb69c1"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/64482499-b03b-44a4-8ed9-0c916e569b8d">
        <rdfs:label>Hepatomegaly</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/62f13862-3b92-42cc-9dad-e958eef7c627"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC324959</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583863</dc:provenance>
  </obo:DDIEM_0000013>
  <obo:DDIEM_0000012 rdf:about="http://ddiem.phenomebrowser.net/43aa786f-e798-438b-b392-a1906bbaf93c">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000305"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7294dca7-14d3-49c7-81b8-43169d57aa8e">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Abnormality of circulating enzyme level</rdfs:label>
        <dc:identifier>HP:0011021</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0011021</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5454877</dc:provenance>
    <rdfs:comment>rhLCAT was used in atrial and it has been found to increase the HDL-C and it was safe. https://www.ncbi.nlm.nih.gov/pubmed/24385512</rdfs:comment>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/4a62d032-e020-4347-bf60-a485890cf6d7">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/8f2fac9e-079d-442e-b3fa-da52ed3ba548"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27491218</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29390242</dc:provenance>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/612319">
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/c8ad4da2-9032-47df-9e81-fe37ad89d0de"/>
        <rdfs:label>SPASTIC PARAPLEGIA 35, AUTOSOMAL RECESSIVE; SPG35</rdfs:label>
        <dc:identifier>https://www.omim.org/entry/612319</dc:identifier>
        <ddiem:iembaseAccessionNumber>1054</ddiem:iembaseAccessionNumber>
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/1054</ddiem:iembaseUrl>
      </ddiem:Disease>
    </obo:RO_0002599>
  </obo:DDIEM_0000012>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/74bccc9a-9611-4a56-b539-bc7e0e6fdb6f">
    <rdfs:label>Low enzyme activity</rdfs:label>
    <dc:identifier>HP:0012379</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0012379</ddiem:url>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/28c17f6d-492b-482e-98fc-920d29b2ee7d">
    <rdfs:label>Calcium makes phototherapy more efficient</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ef01e254-1edc-4c01-a474-b4159931037b">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001019</ddiem:url>
    <dc:identifier>HP:0001019</dc:identifier>
    <rdfs:label>Erythroderma</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/cd63f195-cf20-460f-bef8-95473bfecb22">
    <dc:identifier>HP:0011506</dc:identifier>
    <rdfs:label>choroidal neovascularization</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0011506</ddiem:url>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/abccd4d6-c26d-43f5-a1bb-09057b22362d">
    <dc:identifier>HP:0002900</dc:identifier>
    <rdfs:label>hypokalemia</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002900</ddiem:url>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/7b17e3cd-6da9-4687-80cb-45b834826e2b">
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/601678">
        <dc:identifier>https://www.omim.org/entry/601678</dc:identifier>
        <rdfs:label>BARTTER SYNDROME, TYPE 1, ANTENATAL; BARTS1</rdfs:label>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/53e6335a-cde6-41ed-9eea-f6e4d879629d"/>
        <rdfs:comment></rdfs:comment>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2646391</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/972c8769-c1f4-4176-af20-b40d2c755c00"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b70ccb4c-a98b-4ca8-a509-73e13da4e4d3">
        <dc:identifier>HP:0003111</dc:identifier>
        <rdfs:label>electrolyte disturbances</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003111</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>http://www.neurologyindia.com/article.asp</dc:provenance>
    <rdfs:comment>Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss</rdfs:comment>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/6f590a0a-8844-4f61-9b83-3d9582f6c765">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/d8acc973-6d08-45d5-80e1-e9dc9ec4af67"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6233707</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/c8ce86fd-393f-456b-a238-6bfa672e8581"/>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-Bartter.pdf</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24260777</dc:provenance>
  </obo:DDIEM_0000013>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/97da4084-237f-48bc-9355-8561d05e3676">
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27710244</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02211209</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/151660"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5338723</dc:provenance>
    <rdfs:comment>Niacin DB00627 occasionally can be used with Fibrate and omega 3 fatty acid in treating hypertriglyceridiemia. https://www.ncbi.nlm.nih.gov/pubmed/21079616</rdfs:comment>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/cd1e7f1c-8e58-4f11-b0b9-0baf12de5fa4"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/21636aca-11ac-467e-aa7f-80153e6d0a3f"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02527343</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/62f13862-3b92-42cc-9dad-e958eef7c627"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
  </obo:OGMS_0000112>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/5ff7116c-2d31-4f50-a207-cf47ffeb5be0">
    <ddiem:url>https://www.drugbank.ca/drugs/DB00451</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/2df4e764-821c-4ba3-8e60-20dda5e54205"/>
    <rdfs:label>Levothyroxine</rdfs:label>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/73917aba-7703-4e08-a8ff-ec2fb84a0882">
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/79468376-a366-477e-8527-7adeee9132f0"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4841061</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8444253</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/7a73f54d-09e8-4425-8e2e-9e85119166de"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <rdfs:comment>Controversial benefits https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4158338/</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4158338</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3505515</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19622360</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/219800"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3016220</dc:provenance>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <dc:identifier>DB00451</dc:identifier>
  </ddiem:Drug>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/e250bbf3-9b95-43ab-9c19-21c7c9fcdaaf">
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26962538</dc:provenance>
    <rdfs:comment>The results of this study suggest that octreotide may aid in the acute or long-term treatment of congenital hyperinsulinism in a limited number of selected cases.https://www.ncbi.nlm.nih.gov/pubmed/8410522/</rdfs:comment>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/260920">
        <dc:identifier>https://www.omim.org/entry/260920</dc:identifier>
        <rdfs:label>HYPER-IgD SYNDROME; HIDS</rdfs:label>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/78e53042-3518-49c0-aedc-e7f2981c0b86"/>
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/191</ddiem:iembaseUrl>
        <ddiem:iembaseAccessionNumber>191</ddiem:iembaseAccessionNumber>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://link.springer.com/referenceworkentry/10.1007%2F978-3-540-29676-8_199</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25758134</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/095762a4-b9bf-47c0-918d-9f5ce2a2f67e"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20712835</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/05b945a1-29b9-4cd2-9987-8e9ba4183898">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/d5e5e5f4-af62-4267-8a57-b59bc814746f"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e0e05872-e83f-4087-9af2-a26a7d75115d">
        <dc:identifier>HP:0001386</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>joint swelling</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001386</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </obo:OGMS_0000112>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f1c6f6c8-e3c7-4edc-aa68-a8454edffeb5">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001250</ddiem:url>
    <rdfs:label>epilepsy</rdfs:label>
    <dc:identifier>HP:0001250</dc:identifier>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/75a8e592-13c4-4465-9546-45b5da1da0e5">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/afc0915e-8be6-4cc7-a662-5ffbc52f1a69">
        <rdfs:label>Abnormal lecithin:cholesterol acyltransferase activity</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/MP_0011598</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>MP:0011598</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/15c0b180-d450-4a60-872e-91c58360566c">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003119</ddiem:url>
        <dc:identifier>HP:0003119</dc:identifier>
        <rdfs:label>abnormal plasma lipids levels</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5338723</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/245900"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/013daa1b-2cfa-4a59-a187-05d2aaff85f3">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003233</ddiem:url>
        <rdfs:label>low HDL level</rdfs:label>
        <dc:identifier>HP:0003233</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d5577b48-a3aa-4487-b1a6-0eda41fab055">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001903</ddiem:url>
        <rdfs:label>anemia</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0001903</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f47b0595-c3dc-4c80-a8c3-1ead78d36c33">
        <dc:identifier>HP:0000093</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000093</ddiem:url>
        <rdfs:label>proteinuria</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.clinicaltrials.gov/ct2/show/NCT01554800</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e40738dc-c433-43a1-b21e-f5fe5c02e6b0">
        <rdfs:label>low APO A level</rdfs:label>
        <dc:identifier>HP:0025201*</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0025201</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c9c04221-793c-44df-9560-a6d7d4ef1383">
        <dc:identifier>HP:0003233</dc:identifier>
        <rdfs:label>low HDL-C level</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003233</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>Niacin DB00627 occasionally can be used with Fibrate and omega 3 fatty acid in treating hypertriglyceridiemia. https://www.ncbi.nlm.nih.gov/pubmed/21079616</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/12659056-5564-4870-bb72-dbbb4691e49e">
        <dc:identifier>MP:0003193</dc:identifier>
        <rdfs:label>Abnormal cholesterol efflux from cells</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/MP_0003193</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4826469</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/052e9c01-f490-4cb2-8ce6-45d27565aecd">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>dyslipidemia</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/MP_0003949</ddiem:url>
        <dc:identifier>MP:0003949</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/f30b62cb-39e6-4b5c-b873-30e905ac3ee1">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/22c021ab-1d82-4720-91df-555fbdf1a827"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c4424854-9232-4d2e-a155-149f563f7e8f">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0025201</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0025201*</dc:identifier>
        <rdfs:label>Low Apo B protein level</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02527343</dc:provenance>
  </obo:OGMS_0000112>
  <obo:DDIEM_0000011 rdf:about="http://ddiem.phenomebrowser.net/1b216d69-4807-4a05-a2d6-3df42f85efb9">
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719211006093#bb0025</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/585b2de2-3665-4459-aab4-63124c2d92e7">
        <rdfs:label>Hyperreflexia</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0001347</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001347</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>Pharmaceutical studies are needed to reduce the adverse enteral effects.https://www.ncbi.nlm.nih.gov/pubmed/30127521</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27671894</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/67719bd8-b5ad-47e1-a846-0ec5f9e74f9b">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001508</ddiem:url>
        <dc:identifier>HP:0001508</dc:identifier>
        <rdfs:label>Poor weight gain</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/6e5decf5-1b99-47d5-b5e3-b142df429eb7"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27671893</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4545930</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19585268</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27671896</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b506c187-bcd0-4cfb-86d5-4faf26ab5fec">
        <rdfs:label>Delayed development</rdfs:label>
        <dc:identifier>HP:0001263</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001263</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27671892</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9511979</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/405c407e-4189-4c58-862f-e161d5f1ae4e">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012759</ddiem:url>
        <rdfs:label>Neurodevelopmental abnormalities</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0012759</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/defd389a-6020-47ff-b82a-feee9681cf43"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c91d2a3d-3cf8-4887-92e2-bce6f2e9df19">
        <dc:identifier>HP:0004396</dc:identifier>
        <rdfs:label>Poor appetite</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0004396</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e81afc5d-929c-4381-b0f7-9916e6346410">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001249</ddiem:url>
        <dc:identifier>HP:0001249</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Low IQ</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/014067369192373A</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c3022a16-04a6-4598-a7ed-acb6287afdba">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001270</ddiem:url>
        <dc:identifier>HP:0001270</dc:identifier>
        <rdfs:label>Delayed motor milestone</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27671891</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f53dc592-d9d1-4dc7-967b-e6d9091a9644">
        <rdfs:label>Behavioural abnormalities</rdfs:label>
        <dc:identifier>HP:0000708</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000708</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/db6ae9f3-4649-49ce-9309-1f7f8bddb430">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0011448</dc:identifier>
        <rdfs:label>Foot clouns</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0011448</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/dcbc8dfc-1067-4652-a1d2-7ff1e801b26b">
        <rdfs:label>Poor traction response</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5e5f22ba-bcec-48a5-b6b1-c36f47a9228d">
        <rdfs:label>Irritability</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000737</ddiem:url>
        <dc:identifier>HP:0000737</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/98694bd2-87ef-4939-99c5-411f458798b0">
        <rdfs:label>Poor traction response (Poor muscle tone)*</rdfs:label>
        <dc:identifier>HP:0001290</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001290</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30384011</dc:provenance>
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6f2e0b43-5db9-4725-9982-dcc1db779ce1">
        <rdfs:label>Restricted diffusion in the corpus callosum in MRI(Abnormality of the nervous system)*</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000707</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0000707</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6cacd237-bf50-4036-9096-355c2d944a66">
        <dc:identifier>HP:0000707</dc:identifier>
        <rdfs:label>Restricted diffusion in the corpus callosum in MRI (Abnormality of the nervous system)*</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000707</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a81520a5-f9ba-4a67-be7c-9d245e7880e6">
        <rdfs:label>Delayed mylination</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012449</ddiem:url>
        <dc:identifier>HP:0012449</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27671895</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/933190ef-9948-4d8e-8848-f9929222e83c">
        <dc:identifier>HP:0007266</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Brain demylination</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0007266</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/250850">
        <ddiem:iembaseAccessionNumber>1283</ddiem:iembaseAccessionNumber>
        <dc:identifier>https://www.omim.org/entry/250850</dc:identifier>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/1283</ddiem:iembaseUrl>
        <rdfs:comment>Recommendation and guidlines in treating this disease and other inherited methylation disorders can be found in this link: https://www.ncbi.nlm.nih.gov/pubmed/27671891</rdfs:comment>
        <rdfs:label>METHIONINE ADENOSYLTRANSFERASE I/III DEFICIENCY</rdfs:label>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/d31e66ca-4b0e-4f18-ad08-69342d8829ea"/>
      </ddiem:Disease>
    </obo:RO_0002599>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30389272</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/14aa57e8-8de3-473e-94f8-3334e3c2b0a8"/>
  </obo:DDIEM_0000011>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/b17feafd-d8a2-42ff-8d1b-019fdbb79410">
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/102700"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648/#b96-tacg-8-201</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/376b91ac-2f25-4c77-a1a5-44d10591c398">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0010978</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Abnormal immune function</rdfs:label>
        <dc:identifier>HP:0010978</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/cb40e28f-cc65-4e8a-ab4f-51e53eac530c"/>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/7d637952-aef1-4ba0-a60c-5a18cbeb811a">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/b7dc0bbb-b1d1-42ac-ab75-af2168fcc0b3"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29241594</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/cdec8137-0822-4811-8652-bbe062cd76d5"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/81b8a935-3ffe-4168-999b-7b8b88ae6253"/>
    <dc:provenance>https://globenewswire.com/news-release/2015/03/30/720127/10126746/en/Sigma-Tau-Pharmaceuticals-Inc-Receives-Orphan-Drug-Designation-for-EZN-2279-for-Treatment-of-Adenosine-deaminase-Deficient-Severe-Combined-Immunodeficiency-Disease.html</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3488882</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2726071</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b2607cc3-985f-49f8-bef5-b2879a4bb5f2"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01420627</dc:provenance>
    <rdfs:comment>Further data gathering is necessary to determine overall outcome of patients on long-term therapy "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2726071/</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
  </obo:OGMS_0000112>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/32f0dabc-b2ad-42b5-a592-11479540ed61">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/408da46a-9db8-4152-9516-7c18501f1382">
        <rdfs:label>High Î±-ketoisocaproate level</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:comment>Drugs has decreased rhe frequency of the tonic seizuress</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2668944</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b95433aa-1311-4974-984b-f38e1d0522c0"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/248600"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/68af7c93-e764-400d-9b08-7a73f163d29f">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/bb9470e1-f07f-4939-bc9e-aee21ea40d71"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/fcd05121-2ca5-4e56-b836-b200ebf0c0de">
        <rdfs:label>Branched-chain amino acid accumulation</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0008344</ddiem:url>
        <rdfs:comment>Study ws done in pups: Administering norleucine to heterozygous mothers of classic maple syrup urine disease pups reduced branched-chain amino acid accumulation in milk as well as blood and brain of these pups to enhance survival.</rdfs:comment>
        <dc:identifier>HP:0008344</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </obo:OGMS_0000112>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/29761c75-aac7-458e-91a8-5046d97bfee0">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30384011</dc:provenance>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/309400">
        <rdfs:comment></rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/727a1cc2-7ac1-48d1-ba41-e07a8df1eb7d"/>
        <rdfs:label>MENKES DISEASE</rdfs:label>
        <dc:identifier>https://www.omim.org/entry/309400</dc:identifier>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/199</ddiem:iembaseUrl>
        <ddiem:iembaseAccessionNumber>199</ddiem:iembaseAccessionNumber>
      </ddiem:Disease>
    </obo:RO_0002599>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/bfb85bc6-fa05-4576-b03f-b3762727a4f3">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/f14eae07-de43-4384-ab54-270750e177d1"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22815746</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/508ba241-d7a4-4fdd-a9f3-f98ad0a0935d">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/a25ea26d-5b4b-4d09-b1ed-cd8e752a02c9"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/ebe73625-e52a-47e1-97c8-f4d4d12cffd6">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/bc430260-22a3-4ec3-b844-89f245186339"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/fada5d5c-f11c-45ee-8265-2a6beb4cced0">
        <rdfs:label>Copper accumulation in kidney(Abnormal copper levels)*</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0010836*</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0010836</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9511979</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f37bd9c3-ecd3-440e-938f-00a1f540aa0c">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0010836</ddiem:url>
        <rdfs:label>Low Brain Copper (Abnormal copper levels)*</rdfs:label>
        <dc:identifier>HP:0010836*</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>However, to the knowledge of the authors Horn et al. 2019 https://www.ncbi.nlm.nih.gov/pubmed/30384011, clinical evaluation of the copper-thiocarbamate complexes as well as of the copper-thiosemicarbazone remains to be done.</rdfs:comment>
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
  </obo:OGMS_0000112>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b56b3632-77d0-4eb1-ae8d-bab8bcce9d93">
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0001939</dc:identifier>
    <rdfs:label>Metabolism abnormality</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001939</ddiem:url>
  </ddiem:Phenotype>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/c9411aa6-0eee-4e70-98d3-6f818ac466a0">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9686828</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11749046</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000009"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719212002971</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000015"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/85ce8119-1e09-46a3-a820-d08b8f8e92d0"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8813986</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719213003661</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29506905</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719213003107</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/612736"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d24dda5c-0e4f-48be-b573-8c62cfd7948e"/>
    <rdfs:comment>A competitive inhibition of AGAT activity via high-dose l-ornithine supplementation</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/aed7ba50-b644-4a74-9f68-0cf5e295c71c">
        <rdfs:label>Slow background activity in the EEG(EEG abnormality)*</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002353</ddiem:url>
        <dc:identifier>HP:0002353*</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9f48f112-9d40-4441-a756-9510e547240a">
        <dc:identifier>HP:0001250</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001250</ddiem:url>
        <rdfs:label>Epileptic seizures</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </obo:OGMS_0000112>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/3a81bbdb-ea68-4572-9710-d157c94811f8">
    <obo:RO_0000056>
      <obo:direct_complementation_of_a_genetically_defective_protein_by_gene_therapy rdf:about="http://ddiem.phenomebrowser.net/e85efbde-1eef-4dc0-bdf2-b987a4fc2d67">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/a56e1e0d-b228-48b9-a576-b71d3749a598"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17339125</dc:provenance>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/608099"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/dcf61289-0c08-45ed-b0c6-390829910eea"/>
        <rdfs:comment>Corticosteriods might be beneficial in heterozygous mutations as patients have milder phenotypes.</rdfs:comment>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
      </obo:direct_complementation_of_a_genetically_defective_protein_by_gene_therapy>
    </obo:RO_0000056>
    <rdfs:label>AAV2/1-MCK-Sgca</rdfs:label>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0eb299a1-a7b1-452c-bfee-754a7a8bb327">
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000924</ddiem:url>
    <rdfs:label>pathology in many somatic tissues</rdfs:label>
    <dc:identifier>HP:0000924*</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/245010">
    <rdfs:comment></rdfs:comment>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/1110</ddiem:iembaseUrl>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/10688ef6-f75f-4ccb-8383-261f7ab2c036"/>
    <rdfs:label>HAIM-MUNK SYNDROME; HMS</rdfs:label>
    <ddiem:iembaseAccessionNumber>1110</ddiem:iembaseAccessionNumber>
    <dc:identifier>https://www.omim.org/entry/245010</dc:identifier>
  </ddiem:Disease>
  <obo:direct_complementation_of_a_genetically_defective_protein_by_gene_therapy rdf:about="http://ddiem.phenomebrowser.net/a3ac990b-3cd4-445c-9a2e-4445ed7e50f1">
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29624790</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02014883</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d733efa9-3872-48ad-9a47-98355a5f0ab0">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0004302</dc:identifier>
        <rdfs:label>Abnormal motor function</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0004302</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3cd60a12-1654-4b23-b4a3-9f4d6e8cb911">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0007166</ddiem:url>
        <rdfs:label>Paroxysmal exertion-induced dyskinesia (Paroxysmal dyskinesia)</rdfs:label>
        <dc:identifier>HP:0007166</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29303961</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/da1e4416-49a0-4795-9505-b487ad66afdd">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/b46f82cf-aa1c-4cb4-b80f-154c70d7658b"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23196212</dc:provenance>
    <rdfs:comment>The enteric carbohydrateâfree formula with or without fructose addition seems a very effective and safe measures for the rehydration. https://www.ncbi.nlm.nih.gov/pubmed/10404446. https://www.ncbi.nlm.nih.gov/pubmed/20486940</rdfs:comment>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/606777">
        <rdfs:label>GLUT1 DEFICIENCY SYNDROME 1; GLUT1DS1</rdfs:label>
        <dc:identifier>https://www.omim.org/entry/606777</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/96e8e882-0a1c-40c4-9c8e-f881e93b8205"/>
        <ddiem:iembaseAccessionNumber>480</ddiem:iembaseAccessionNumber>
        <rdfs:comment>The currently established or investigated precision medicine treatments include the ketogenic diet in patients with GLUT1 deficiency. https://www.ncbi.nlm.nih.gov/pubmed/27781560/ https://www.ncbi.nlm.nih.gov/pubmed/22812641/ https://www.ncbi.nlm.nih.gov/pubmed/12029447?dopt=Abstract
Clinical exacerbation in Glut 1 DS could happen with certain AEDs based on their mechanism of action or effects on the Glut 1 transporter. Common AEDs known to inhibit the Glut 1 transporter in vitro, for example, 1) phenobarbital https://www.ncbi.nlm.nih.gov/pubmed/12029447?dopt=Abstract , 2) Valporate https://www.ncbi.nlm.nih.gov/pubmed/16149077?dopt=Abstract 3) Benzodiazepines https://www.ncbi.nlm.nih.gov/pubmed/12029447?dopt=Abstract are relatively contraindicated in Glut 1 DS. https://www.ncbi.nlm.nih.gov/pubmed/22812641/
In addition, combination therapy of KD and carbonic anhydrase inhibitorsâfor example, topiramate, zonisamide, and acetazolamideâmay increase risk of nonâanion gap metabolic acidosis and urolithiasis, and should be avoided if possible https://www.ncbi.nlm.nih.gov/pubmed/20466520?dopt=Abstract</rdfs:comment>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/480</ddiem:iembaseUrl>
      </ddiem:Disease>
    </obo:RO_0002599>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d5543a0a-f28a-4d1f-953b-72509719f73c">
        <dc:identifier>HP:0031884</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0031884</ddiem:url>
        <rdfs:label>Abnormal CSF glucose levels</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22812641</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02000960</dc:provenance>
  </obo:direct_complementation_of_a_genetically_defective_protein_by_gene_therapy>
  <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/c0215cda-323a-4d31-8b11-a37cd7faa483">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/21c874b6-6f6e-4047-bb8e-0a59501d571b">
        <rdfs:label>Low mean hemoglobin level</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001903</ddiem:url>
        <dc:identifier>HP:0001903</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20439622</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27499018</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/results/NCT00376168</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21503667</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00962260</dc:provenance>
    <rdfs:comment>Indomethacin was the most effective but can cause gastrointestinal intolerance and decreased eGFR. Amiloride and eplerenone have similar but lower efficacies and increase sodium depletion. The benefit/risk ratio of each drug should be carefully evaluated for each patient.          https://www.ncbi.nlm.nih.gov/pubmed/25012174
Despite a documented effect on hypokalemia, indomethacin and other nonsteroidal anti-inflammatory drugs should be used with caution due to their short- and long-term gastrointestinal side effects and nephrotoxicity.https://www.ncbi.nlm.nih.gov/pubmed/28003083</rdfs:comment>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01074944</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/1c9d266e-04cc-433b-a581-750411fdefc9"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28381550</dc:provenance>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/230800">
        <ddiem:iembaseAccessionNumber>288</ddiem:iembaseAccessionNumber>
        <rdfs:label>GAUCHER DISEASE, TYPE I</rdfs:label>
        <dc:identifier>https://www.omim.org/entry/230800</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/288</ddiem:iembaseUrl>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/6b58a1f4-ac8c-4ddc-bce7-4e5f6fb332d0"/>
      </ddiem:Disease>
    </obo:RO_0002599>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
  </obo:DDIEM_0000007>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/c85ea16f-6b04-4d05-bec5-58b18a6930f3">
    <dc:identifier>DB00869</dc:identifier>
    <rdfs:label>Dorzolamide</rdfs:label>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/aeffddda-3166-493b-b0d6-9a6c666b81c9">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26669244</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/e7a14bec-cbbe-4f50-81cf-23f0a4cc0357"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29395598</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/266130"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/7d16d8d9-8d19-4337-8bd3-2d28a85e4f23"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17397529</dc:provenance>
        <rdfs:comment>An experimental study done on a mice with GMNT knocked out. suggesting considering Nicotinamide as atreatment option in patients with GNMT deficiency.  https://www.ncbi.nlm.nih.gov/pubmed/20578266/</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19019309</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a449a7c4-4d81-439e-992b-180400fb2ba8"/>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00869</ddiem:url>
  </ddiem:Drug>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/24f4695f-cb83-4e74-acd9-eab279a88b0d">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24816443</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ec6e911d-5384-4d30-af87-2dcec9be9f3b"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/125370">
        <rdfs:label>DENTATORUBRAL-PALLIDOLUYSIAN ATROPHY; DRPLA</rdfs:label>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/2b47a534-7015-4284-a6ee-74eafe60e58e"/>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>https://www.omim.org/entry/125370</dc:identifier>
      </ddiem:Disease>
    </obo:RO_0002599>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/de2f9565-d217-424d-b54d-5a9be0514a37"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/c91d2a3d-3cf8-4887-92e2-bce6f2e9df19"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8ecb30dc-b2e9-455d-8387-52fdb71ca0d0">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002069</ddiem:url>
        <dc:identifier>HP:0002069</dc:identifier>
        <rdfs:label>Tonic-clonic seizures</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25558587</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/67594906-a387-4d45-ae37-7b7fe19369aa"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e316f32c-fb26-4111-ab29-5738cff667f1">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002353</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>EEG abnormality</rdfs:label>
        <dc:identifier>HP:0002353</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/9f48f112-9d40-4441-a756-9510e547240a"/>
    <rdfs:comment>Use of dichloroacetate to activate the pyruvate dehydrogenase complex led to a significant decline in lactate levels, but this was also transient.https://www.ncbi.nlm.nih.gov/pubmed/8652022</rdfs:comment>
  </obo:DDIEM_0000013>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/01267a92-1124-4e3b-adb8-f40b53ac7344">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e193387f-b9ef-4913-877f-8cbff03660de">
        <dc:identifier>HP:0001875</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Neutropenia</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001875</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/62796528-e345-4e70-ab89-6eadbde48658">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001263</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>atypical psychomotor development</rdfs:label>
        <dc:identifier>HP:0001263*</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8163996</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12084887</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/532f8488-56d7-42f2-a4ec-cf6fb38143fc">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>abnormal expression of E- and P-selectin ligands</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>Drug name: Treatment is under trial.</rdfs:comment>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/266265">
        <ddiem:iembaseAccessionNumber>341</ddiem:iembaseAccessionNumber>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>CONGENITAL DISORDER OF GLYCOSYLATION, TYPE IIc; CDG2C</rdfs:label>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/b7729871-edf8-4c8e-a63f-9ee6501210f6"/>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/341</ddiem:iembaseUrl>
        <dc:identifier>https://www.omim.org/entry/266265</dc:identifier>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://pdfs.semanticscholar.org/7753/abad26acee41547592d5a3a65b0483eff767.pdf</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16891685</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2d3c7769-a3c6-4e97-8e92-6f5eaf5bc39a">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0010977</dc:identifier>
        <rdfs:label>defected phagocytic function</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0010977</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9732974</dc:provenance>
    <dc:provenance>http://www.bloodjournal.org/content/94/12/3976.abstract</dc:provenance>
    <dc:provenance>the patient showed significant psychomotor improvement while on fucose therapy."</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17276979</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <dc:provenance>http://www.jbc.org/content/282/14/10762.long#ref-14</dc:provenance>
    <dc:provenance>correction of the delayed psychomotor development was expected to be more difficult to achieve. However</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29702557</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e9b468e5-c423-4e66-9db6-ca7e0174b9a7">
        <rdfs:label>Abnormal fucosylation state of glycoconjugates.</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1899474</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d9d3a783-108b-4b38-8e65-356241ff75d3">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002719</ddiem:url>
        <rdfs:label>recurrent infection</rdfs:label>
        <dc:identifier>HP:0002719</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/810ce452-f5c9-452b-892d-1570cc41fe27">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Abnormal selectin ligand function</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10590041</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12756558</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/5500440d-31d0-4436-bea4-edc0e28fa677">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/46252de6-1c27-4993-9d9d-9e6630124c08"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/807ddff7-26ce-49b9-ae62-984d6dc443de">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0001875</dc:identifier>
        <rdfs:label>low neutrophil count</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001875</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4263309</dc:provenance>
    <dc:provenance>"espite the successful correction of immunodeficiency-related defects in CDG IIc (LAD II)</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d08c0c5c-1b99-4d57-aca5-338136db7ed6">
        <rdfs:label>Abnormal Golgi located fucosylation</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </obo:OGMS_0000112>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a37a2378-3cd3-4d5a-bf9a-7f59622d264c">
    <dc:identifier>HP:0000518</dc:identifier>
    <rdfs:label>Cataract</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000518</ddiem:url>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <obo:DDIEM_0000011 rdf:about="http://ddiem.phenomebrowser.net/c62f313d-da26-478e-825e-a4a20e9017cc">
    <rdfs:comment>Drug has no difference in terms of prognosis.</rdfs:comment>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28057010</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/222700"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25859380</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/e0c5c12a-82c4-41b5-a1bf-b7ecbf88e50b">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/3a808368-bf1f-459a-9380-806271f4f98b"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20301535</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27567650</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4e01b027-6933-4213-ba72-a6cf9d0a185a">
        <rdfs:label>hypolysinemia</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </obo:DDIEM_0000011>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/b5ec7393-9c9a-4eae-8f27-be52d68952cc">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29374495</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/c1ba99ab-cc06-4a3f-8f61-65a683c970c2"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1521691810001101</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/efec2f9a-a4e4-4740-995f-09b674867b49"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23432031</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/12ebbe36-2a52-4466-b4c4-4c0d6cc96ac0">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/deab5bfe-615f-4f9e-bf66-96f67c839755"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28804516</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <rdfs:comment>Treatment success with statins has been mixed.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31239752</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/278000"/>
  </obo:OGMS_0000112>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/0515fb9d-e9ee-4d3f-91de-2e63156e7b22">
    <ddiem:url>https://www.drugbank.ca/drugs/DB00915</ddiem:url>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/bcf11eff-12aa-4767-9a18-9eadf1354339">
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/c28390ad-02a9-4015-9b24-ef838bc92501"/>
        <rdfs:comment>The mechanisms of its effects in movement disorders are not well understood but probably reflect an increase in synthesis and release of dopamine, with perhaps some inhibition of dopamine uptake.</rdfs:comment>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/233910"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/14516f12-619a-4962-8b81-f9af9648684b"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18276179</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20818608</dc:provenance>
        <dc:provenance>https://link.springer.com/referenceworkentry/10.1007%2F978-3-540-29676-8_1729</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19234759</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15389992</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10078749</dc:provenance>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719208000048</dc:provenance>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/c4c1434b-67de-4720-9c10-5aa9b141f15c">
        <rdfs:comment>There is a common note in different reserachs refers to the importance of early managment by Vitamin E supplements since it limits disease progression and it can reverse some of the clinical manifestation (e.x ataxia and the intellectual deficit), if it was interoduced early in life. Therefore, early diagnosis is paramount.</rdfs:comment>
        <dc:provenance>https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22550086</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/0866fbe4-a4b2-4d29-bee8-18df8eb8fd02"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/c28390ad-02a9-4015-9b24-ef838bc92501"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27906067</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/208900"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15300460</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17586848</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/fbe442f1-71f3-4160-be72-d58df5fe426f"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/bf015380-56f8-4899-9caf-e4cc2494b777"/>
        <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
      </obo:DDIEM_0000013>
    </obo:RO_0000056>
    <rdfs:label>Amantadine</rdfs:label>
    <dc:identifier>DB00915</dc:identifier>
  </ddiem:Drug>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/c993d639-43fd-4972-a973-28de88950889">
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27775558</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/c65ab82f-fd66-4207-9b23-79940d950674">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/03cd91e6-acaa-4034-83f1-86495fb4e3f3"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/266130"/>
    <rdfs:comment>Synergism inmproves results</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26984560</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/c9290508-0a2b-4206-a2f7-6788c0fa965f">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/817ea5b8-c59c-41a7-948f-1454e84f0b05"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/76e590fa-f89d-4d64-a7a3-c08485b7023c"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22830360</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/b0568ff3-8170-4e53-bcb4-8a44ed08af35">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/f633c9b2-bafb-4221-bd9a-351b2b26a5f5"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25896882</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
  </obo:OGMS_0000112>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/647abb1a-1232-4443-a8ca-045b3c38a563">
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/535000"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <rdfs:comment>Dietry treatment supplementation</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/741463af-be8e-40c2-bbb5-2ad297ba0c74">
        <dc:identifier>HP:0000648</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000648</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Optic atrophy</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30107658</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30208599</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/92d9e8e1-52f9-4f5a-98d1-1fced44c863a">
        <dc:identifier>HP:0025464</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Low ATP synthesis</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0025464</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ce8b5819-cb2d-4a37-bc4e-6a870f02a0c8">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0030532</ddiem:url>
        <dc:identifier>HP:0030532</dc:identifier>
        <rdfs:label>Abnormal visual acuity</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/direct_complementation_of_a_genetically_defective_protein_by_gene_therapy"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT03153293</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/1f490e8c-dced-4547-b6e8-e1cf2d23f79e">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/5e136d21-8aa6-4476-aa6e-7e2633b9d956"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0003304>G11778A</obo:RO_0003304>
  </obo:OGMS_0000112>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/0a6c54ac-a248-40b7-b0ea-db5d0cc373c3">
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/71a194c6-39ae-4796-a741-98b8f1756a81">
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/9874c736-0338-478b-9c63-135cdcccb01a"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15978931</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/56ad9674-86c0-401f-b038-cae5cfe6cbd1"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/4d770aea-2a7f-4592-881e-1c574d4ea434"/>
        <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
        <rdfs:comment>The approach is (RNA interference-based, liver-targeted therapeutic), however this trial has been terminated.</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30477028</dc:provenance>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02900183</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5508465</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/cdec8137-0822-4811-8652-bbe062cd76d5"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/613490"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30049652</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6361470</dc:provenance>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <rdfs:label>Recombinant alpha 1-antitrypsin</rdfs:label>
    <dc:identifier>DB05481</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB05481</ddiem:url>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/9312e84c-087d-415d-9fb1-c60a60180d32">
    <rdfs:label>Hydrochlorothiazide</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00999</ddiem:url>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/b5006e23-c677-42b4-9fef-0ce082a17841">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15131757</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28590052</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b2e4f205-7ff4-4c00-ab70-a6470c2b131f"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/125700"/>
        <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/2e9d005a-65d7-4710-9b3b-37ce9b8fefa7"/>
        <rdfs:comment>Some patients could only be fully controlled by the combination of chlorpropamide and hydrochlorothiazide.</rdfs:comment>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/855cf5b9-8721-485c-8070-7a064dba8967"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1220254</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26153518</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30804055</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1316120</dc:provenance>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <dc:identifier>DB00999</dc:identifier>
  </ddiem:Drug>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/af049001-e6d9-45c9-aaab-202a3b3d1814">
    <rdfs:comment>While is probably the drug of choic in treating this disease, There is an urge to take cautions in using it in patients with high plasma concentration of chenodeoxycholic acid (and thus we would not use it in a patient with secondary 5p-reductase deficiency). The reason for this is that,if the plasma concentration of chenodeoxycholic acid is increased,it is probable that the hepatocyte concentration is also increased and hydrophobic dihydroxy bile acids such as chenodeoxycholic acid are thought to contribute to the liver cell damage that occurs in cholestasis. https://www.ncbi.nlm.nih.gov/pubmed/8707100</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20619503</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28697823</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11067870</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18570303</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/21ba206b-4ec3-4104-9c8a-670f005b9320"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/39aa5faf-4243-40de-af65-f72d13eccf26">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002910</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>abnormal liver function</rdfs:label>
        <dc:identifier>HP:0002910</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/235555"/>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4503963</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8225213</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19087156</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/c1ba99ab-cc06-4a3f-8f61-65a683c970c2"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/61628279-7f77-4b6f-b80d-ed6990d6a00c">
        <rdfs:label>hepatomegaly</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0002240</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002240</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6206929</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/64482499-b03b-44a4-8ed9-0c916e569b8d"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19622360</dc:provenance>
  </obo:OGMS_0000112>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a73f51bb-4fc8-4a9f-9358-09a1ade56488">
    <rdfs:label>Neurological abnormalities.</rdfs:label>
    <dc:identifier>HP:0000707</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000707</ddiem:url>
  </ddiem:Phenotype>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/a3b84acb-5f1f-4d5e-9a39-9bb7708f86f6">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24639006</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19627167</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ee149108-f23f-4219-9591-29438940e615">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Complex partial seizure</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23887143</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00125190</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7b9b2ab4-bdfb-46e5-8e3a-1ac8ec6a5992">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Generalized convulsion</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/d2ac0f76-1c45-4962-9846-fbdbf6e5771b">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/982a81c2-937e-4a52-9c00-eb7c934eccf6"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3b9a70fe-52ce-4915-947d-c851c73fed31">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000713</ddiem:url>
        <rdfs:label>Agitation</rdfs:label>
        <dc:identifier>HP:0000713</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/cb1ae896-014a-4fc5-b114-2a8fc115ebb2">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0000718</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000718</ddiem:url>
        <rdfs:label>Aggressive behavior</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/271245"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17192294</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/3580d7a6-00c7-40dd-ad0b-525b8b4366d8">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/9a1641b5-7d88-44d1-af58-0e5d79278094"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10549306</dc:provenance>
    <rdfs:comment>Valporate has been used in two patients, but it had to be discontinued because of a severe elevation of liver enzymes. since then it hasn't been used in IOSCA. VAlporic acid Should be avoided in those patients.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19304794</dc:provenance>
  </obo:DDIEM_0000013>
  <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/ddaeac03-5dcb-46bd-b708-bc83928632af">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28804516</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a242091d-4333-4b8e-9bdb-c3df13afec97">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002155</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0002155</dc:identifier>
        <rdfs:label>Increased plasma triglycerides</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23432031</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01371825</dc:provenance>
    <rdfs:comment>Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4930475</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/278000"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29374495</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31239752</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/843e0dd5-c3ca-48a1-b0b0-a1d50ad2009e">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/8d67848c-4420-47df-a7e7-522d788db26e"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
  </obo:DDIEM_0000007>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/7214f0e0-a52d-4a9f-9c31-02d4504f4f51">
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e8e31867-cd3c-41f1-abbc-ed93c5f7de6e"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/b6a1b1b9-186f-44ab-90ea-10b9c31d08b9">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/c0ca5200-1b24-4fdb-a8e6-f874136a34df"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16803637</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/241500"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9110486</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25717099</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/4744026</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c8db1c74-ff97-4bc8-b2e1-664bbfa56d1b">
        <rdfs:label>Lower limb pain</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012514</ddiem:url>
        <dc:identifier>HP:0012514</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19415691</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10574582</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/202b2073-9e0f-4323-b4bc-9fcf095b645b"/>
    <rdfs:comment>Vitamin D should be given to target the lower limit of the normal range for 25-OH-vitamin D (about 20 ng/mL).</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c8490521-1111-4f5e-be3e-77e565ea5026">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0011023</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Abnormal prostaglandin level</rdfs:label>
        <dc:identifier>HP:0011023</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/21802679-d67b-437f-b5b0-09ab0fe7f601">
        <rdfs:label>Abnormal walking distance</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </obo:DDIEM_0000013>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/860a4c9a-77da-4ea8-b8f6-d1d5eeb333a1">
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/dd932009-660d-4438-9386-870a9ab86d88">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/4e9ec317-55ba-4ef0-9a72-c0be9f3e53d5"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6206929</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/224120"/>
    <dc:provenance>http://www.ncbi.nlm.nih.gov/pubmed/15804998</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19622360</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11067870</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <rdfs:comment>"Oral tocofersolan was more bio available than the water-soluble formulation in children with chronic cholestasis and similarly bio available in CF. This suggests that water-soluble vitamin E may represent an alternative to painful intramuscular vitamin E injections in chronic cholestasis, or other oral formulations in CF. However, the mechanism responsible for fat malabsorption in CRD concerns the absorptive phase as opposed to the digestive phase in CF and cholestatic syndromes. To our knowledge, no specific studies with these new vitamin E preparations have been conducted in CRD." https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717/</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3477eeac-419a-4a7b-8c20-da3326ab1bd2">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Abnormal upregulated enteral iron uptake (Abnormality of iron homeostasis)*</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0011031</ddiem:url>
        <dc:identifier>HP:0011031*</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16141353</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1702c11c-d538-4f3f-ab08-92bc251de4a7">
        <rdfs:label>low hemoglobin concentration</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001931</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0001931</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </obo:DDIEM_0000013>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8ee13c9b-e59d-463f-bde3-2bd87a8c1faf">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Decreased beta-galactosidase activity</rdfs:label>
    <dc:identifier>HP:0008166</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0008166</ddiem:url>
  </ddiem:Phenotype>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/281c851d-beed-4f31-8759-d7016456e4b3">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/85ce138a-16dc-40c9-9eda-341dcb523a31">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000708</ddiem:url>
        <rdfs:label>Behavioral abnormality</rdfs:label>
        <dc:identifier>HP:0000708</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3421fd32-4b6a-4855-b053-489542f5cfbc">
        <dc:identifier>HP:0010836*</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0010836</ddiem:url>
        <rdfs:label>Low brain copper levels (Abnormal copper levels)*</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/c5c37929-d201-4022-b86d-866d7c1febc7"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a96cb469-7656-4d48-a2f7-bf6e5c4ba656">
        <dc:identifier>HP:0001507</dc:identifier>
        <rdfs:label>Abnormal growth</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001507</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/abs/pii/088789949190052M</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9511979</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <rdfs:comment>Pharmaceutical studies are needed to reduce the adverse enteral effects.https://www.ncbi.nlm.nih.gov/pubmed/30127521</rdfs:comment>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/d7bd96b4-19dc-454b-a31b-d13b79afee85">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/c80ee7ca-5d28-4c6e-9341-0bcacadb1df0"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/direct_complementation_of_a_genetically_defective_protein_by_gene_therapy"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/db1f93d8-1515-4d18-8a3c-e8dce06f2612"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/309400"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2287bc9c-212f-4943-a125-e03436701b1e">
        <dc:identifier>HP:0003287*</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003287</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Brain mitochondrial abnormalities (Mitochondrial dysfunction)</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30090842</dc:provenance>
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30384011</dc:provenance>
  </obo:OGMS_0000112>
  <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/fac05802-fe1d-4052-aae0-7cb65537c2f8">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/158ad3d6-ae49-4cae-9168-cd8a9ea29c77">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0100022</ddiem:url>
        <rdfs:label>Abnormal movement</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0100022</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/98a69309-00f5-4c38-8570-cacb7e2c44b1"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/387b9aa2-9a28-479d-a7f0-8ecfc6876a9c"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/c7568be9-e6b5-4e41-9ee1-202e43e5338f"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e146bb54-c52b-4b95-ac66-48544fd465cc">
        <rdfs:label>signal abnormality of the cortex</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0030178</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0030178</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31061755</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24260777</dc:provenance>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/607483">
        <rdfs:label>THIAMINE METABOLISM DYSFUNCTION SYNDROME 2 (BIOTIN- OR THIAMINE-RESPONSIVE TYPE); THMD2</rdfs:label>
        <dc:identifier>https://www.omim.org/entry/607483</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/aeb8ece0-50d0-4bbd-b9ba-618a49582673"/>
        <rdfs:comment></rdfs:comment>
      </ddiem:Disease>
    </obo:RO_0002599>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/67121d1d-9b99-4c95-9ab2-02d425f60509">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001347</ddiem:url>
        <rdfs:label>Abnormal reflexes</rdfs:label>
        <dc:identifier>HP:0001347</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27749535</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/78a9efb5-49a5-4f22-9e54-10549dd3f132"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>http://www.neurologyindia.com/article.asp</dc:provenance>
    <rdfs:comment>Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss</rdfs:comment>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e193638f-bdb3-488d-a26d-193805fb8a3c"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26577040</dc:provenance>
  </obo:DDIEM_0000007>
  <obo:DDIEM_0000010 rdf:about="http://ddiem.phenomebrowser.net/5d4524d1-e130-470d-93ef-338b3552adab">
    <rdfs:comment>Testosterone therapy needs to be carefully considered because of the risk of hepatic adenomas.https://www.ncbi.nlm.nih.gov/pubmed/28160246
Androgen receptors are expressed in the liver, and androgens can stimulate hepatocyte proliferation. Although rare, androgens have been shown in observational studies to induce adenoma development (Giannitrapani et al. 2006). Testosterone levels should be assessed for response 2â3 months after therapy is initiated.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/e4fe8128-15d7-4874-b568-8ddad4ec30c7"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/40ca2771-d030-4a37-9d1f-23d44cda1091">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0011015</ddiem:url>
        <dc:identifier>HP:0011015</dc:identifier>
        <rdfs:label>Abnormal blood glucose concentration</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/232700"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25266922</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b3b6e59f-81cb-470d-b827-c474752c4e3f">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0004322</ddiem:url>
        <rdfs:label>short stature</rdfs:label>
        <dc:identifier>HP:0004322</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19019309</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/2358a2a5-6ed8-4d95-af40-73fd9faa84ee"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20301760</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/20f5151c-f0e4-462d-93ee-fd0daabd9784"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/eb318982-8e44-434a-92f2-7148303622aa"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16434679</dc:provenance>
  </obo:DDIEM_0000010>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/250940">
    <ddiem:iembaseAccessionNumber>30</ddiem:iembaseAccessionNumber>
    <dc:identifier>https://www.omim.org/entry/250940</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>HOMOCYSTINURIA-MEGALOBLASTIC ANEMIA, cblG COMPLEMENTATION TYPE; HMAG</rdfs:label>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/bd43cb52-7e4c-41df-ae27-81887ad1960b"/>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/30</ddiem:iembaseUrl>
  </ddiem:Disease>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/269920">
    <rdfs:label>INFANTILE SIALIC ACID STORAGE DISEASE; ISSD</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <ddiem:iembaseAccessionNumber>267</ddiem:iembaseAccessionNumber>
    <dc:identifier>https://www.omim.org/entry/269920</dc:identifier>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/267</ddiem:iembaseUrl>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/2d4466f8-3528-411e-b533-eae24cc820a6"/>
  </ddiem:Disease>
  <obo:DDIEM_0000012 rdf:about="http://ddiem.phenomebrowser.net/8d2a5f35-d4c6-460e-af7b-13b7f2ca28ec">
    <dc:provenance>https://www.semanticscholar.org/paper/The-Incidence-of-Transient-Neonatal-Tyrosinemia-a-Zea-Rey-Cruz-Camino/b66304a0a56304f686380af915a92b2b860e9305</dc:provenance>
    <dc:provenance>http://www.scielo.br/pdf/jiems/v5/2326-4594-jiems-5-e170016.pdf</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28803710</dc:provenance>
    <rdfs:comment>One of the studies that was carried on mice provides useful information for developing the optimal dosage regimen for HPBCD therapy when administered intravenously to NPC patients.https://www.ncbi.nlm.nih.gov/pubmed/26027824</rdfs:comment>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/5634a50b-fb00-426a-b60d-3c73c68634d7"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14206878</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26226126</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25717099</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19415691</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ba0e70c3-e0f3-4002-b838-786cf3eef6ed">
        <rdfs:label>Low activity of the immature 4-HPPD enzyme</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/140350"/>
  </obo:DDIEM_0000012>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c62ad3d7-4f4c-45df-81f3-33b7c597c929">
    <dc:identifier>HP:0001396</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001396</ddiem:url>
    <rdfs:label>Defected bile flow</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/5f00e19d-b990-44e6-a76a-4aec412d5b56">
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/76e590fa-f89d-4d64-a7a3-c08485b7023c"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26669244</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/7b517ff3-fc9a-449b-a7f3-1355c1eb4688"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17397529</dc:provenance>
    <rdfs:comment>An experimental study done on a mice with GMNT knocked out. suggesting considering Nicotinamide as atreatment option in patients with GNMT deficiency.  https://www.ncbi.nlm.nih.gov/pubmed/20578266/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29340523</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/266130"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19019309</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
  </obo:DDIEM_0000013>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8bf9b165-a172-44b3-914a-a365374959cc">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Abnormal levels of urine total alkanes</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/220111">
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/425</ddiem:iembaseUrl>
    <ddiem:iembaseAccessionNumber>425</ddiem:iembaseAccessionNumber>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/22f08369-976f-410c-8981-79d7b997fbe5"/>
    <dc:identifier>https://www.omim.org/entry/220111</dc:identifier>
    <rdfs:comment>Antioxidants (idebenone, N-acetyl cysteine, resveratrol) exacerbate palmitate plus lactate-induced cell death. Collectively, our results raise some concerns about the potential negative impact of a high-fat diet and of antioxidant treatments in LSFC patients.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4383560/</rdfs:comment>
    <rdfs:label>LEIGH SYNDROME, FRENCH CANADIAN TYPE; LSFC</rdfs:label>
  </ddiem:Disease>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/203500">
    <ddiem:iembaseAccessionNumber>23</ddiem:iembaseAccessionNumber>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/23</ddiem:iembaseUrl>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>https://www.omim.org/entry/203500</dc:identifier>
    <rdfs:label>ALKAPTONURIA; AKU</rdfs:label>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/681c3341-a684-4037-b28a-0a13963a390f"/>
  </ddiem:Disease>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/261100">
    <ddiem:iembaseAccessionNumber>83</ddiem:iembaseAccessionNumber>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/83</ddiem:iembaseUrl>
    <dc:identifier>https://www.omim.org/entry/261100</dc:identifier>
    <rdfs:label>MEGALOBLASTIC ANEMIA 1</rdfs:label>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/7209539c-a72b-47df-8072-3dbde7cea8d7"/>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/b0cf640e-9847-4799-9630-a4f50ac0f2ad"/>
    <rdfs:comment></rdfs:comment>
  </ddiem:Disease>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/fbbbef9b-4812-487c-a159-45f751afa222">
    <ddiem:url>https://www.whocc.no/atc_ddd_index/?code=A11EB</ddiem:url>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/53cf3b24-0cc5-4dbb-ae5b-ccfe329bdba1">
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/520000"/>
        <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/4556601b-4e58-4413-90b1-df627cd415d1"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/d205d39b-6523-40eb-a352-c903ebd7a86e"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24746802</dc:provenance>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/17f4178b-4525-4283-8ed7-569eae8e79cc"/>
        <rdfs:comment>The drug was administered through intravitreal injection.</rdfs:comment>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01212744</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/732d4b93-2f5f-4339-a594-0d7d90e9ad2d"/>
        <dc:provenance>https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/6b36ca46-5e87-4637-b6e9-73189ff35f01"/>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23806424</dc:provenance>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <rdfs:label>Vitamin B-complex with vitamin C</rdfs:label>
    <dc:identifier>A11EB</dc:identifier>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/24544a47-9da8-40f2-9d20-abd9e73478c5">
    <obo:RO_0000056>
      <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/ff0cc9c3-8522-4a9d-b2b1-fe5dbe719eef">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30731125</dc:provenance>
        <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25488886</dc:provenance>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24288038</dc:provenance>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/200100"/>
        <rdfs:comment>Investigational "Infertility investigation Abetalipoproteinaemia patients might benefit from progesterone supplementation, and further studies on this and hormonal profiles would benefit this pool of patients. Optimising the nutritional profile and body mass index of female patients will undoubtedly contribute to better chances at conception.:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4265040/</rdfs:comment>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/c659dc72-db4f-4b3c-867a-2d655336fcdb"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/1e563444-127e-40f7-8c83-93768b346275"/>
        <dc:provenance>https://ojrd.biomedcentral.com/articles/10.1186/1750-1172-3-20</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/585fba8b-3b07-4be4-a3be-5c7a78786a57"/>
      </obo:DDIEM_0000013>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <obo:DDIEM_0000011 rdf:about="http://ddiem.phenomebrowser.net/9671adc1-17ff-4ceb-91b4-8a98ace6c343">
        <rdfs:comment>The standardized treatment consists of weekly to monthly intramuscular injections of vitamin B12. Hydroxocobalamin injections are preferred over cyanocobalamin as the latter may cause muscular pain and have ophthalmo-neurological side effects. Oral vitamin B12 supplementation may be ineffective and not recommended.

https://www.orpha.net/consor/cgi-bin/OC_Exp.php?Expert=332

Cyanocobalamin, a pharmacologic preparation requiring conversion to metabolically active cobalamins, is the form commonly available in the United States, whereas hydroxocobalamin, which requires less frequent injections,1,15 is preferred in parts of Europe. Methylcobalamin, a light-sensitive form, is rarely used.
https://www.ncbi.nlm.nih.gov/pubmed/6019807/</rdfs:comment>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/261000"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/37781719-d0f1-4a44-a381-4843ff83d638"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24424200</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/4024886d-ee0a-41d3-bd11-0989827e2078"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/8f47d233-951e-46e2-ba52-9c03ec5da17e"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d31e1db3-58b2-440c-a9ff-03d08ccba8bd"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9694707</dc:provenance>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25308559</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/6823973</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/1e563444-127e-40f7-8c83-93768b346275"/>
      </obo:DDIEM_0000011>
    </obo:RO_0000056>
    <rdfs:label>Cyanocobalamin</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00115</ddiem:url>
    <dc:identifier>DB00115</dc:identifier>
  </ddiem:Drug>
  <obo:DDIEM_0000012 rdf:about="http://ddiem.phenomebrowser.net/3771ef67-c02d-4686-8074-f41e171a3a1f">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1954161f-90e2-41d8-a62f-b2dae3f7ecbc">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0000407</dc:identifier>
        <rdfs:label>Sensorineural hearing impairment</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000407</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/05e7f55b-2b6c-41b1-ab80-d392719246d8">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Mislocalization of R8L</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24189473</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-Bartter.pdf</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/94670f11-3c4b-4add-bb25-0278edeca1e1">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Low plasma membrane expression of R8Lin kidney</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>http://www.neurologyindia.com/article.asp</dc:provenance>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/602522">
        <rdfs:comment></rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/12e27cae-6f58-4e84-9e94-6daaca9ef99b"/>
        <rdfs:label>BARTTER SYNDROME, TYPE 4A, NEONATAL, WITH SENSORINEURAL DEAFNESS; BARTS4A</rdfs:label>
        <dc:identifier>https://www.omim.org/entry/602522</dc:identifier>
      </ddiem:Disease>
    </obo:RO_0002599>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/35edbd24-3651-4cd4-ad2b-385a12b4ffb3">
        <dc:identifier>HP:0200114</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0200114</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Metabolic alkalosis</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2646391</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1b46dab3-5fe4-45fd-992c-5b0a34faf3f6">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>ER-associated degradation of R8L</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4f8c5fb9-f813-4852-8017-a5f808513f9b">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Hypokalemia</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002900</ddiem:url>
        <dc:identifier>HP:0002900</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/7a2540e3-c893-4982-b524-031f713e028e">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/5e321172-22c1-4884-b776-f64294828a6d"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24260777</dc:provenance>
    <rdfs:comment>Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss</rdfs:comment>
  </obo:DDIEM_0000012>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e0c0eedf-910f-4246-afdf-131a2dafbe8a">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002748</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Renal rickets</rdfs:label>
    <dc:identifier>HP:0002748</dc:identifier>
  </ddiem:Phenotype>
  <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/a7a5d6a5-b826-45c2-98f5-cbb86b0923a2">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28883274</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d4864e65-04b3-45a0-8cc9-5f8381829431">
        <rdfs:label>Pathological apoptosis</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/84583dc6-6694-434b-9307-77ba1dd96176">
        <rdfs:label>low hb level</rdfs:label>
        <dc:identifier>HP:0001903</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001903</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26305041</dc:provenance>
    <dc:provenance>http://www.ncbi.nlm.nih.gov/pubmed/26758319</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/1cbfe780-074e-4883-9c7d-c7b1847865a4"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9f2a897e-a2ed-4e01-b850-635bf15e198b">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0025142*</dc:identifier>
        <rdfs:label>low quality of ife</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0025142</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:comment>There was no clinical effect, but amild reduction in the plasma level of desmosterol was observed.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22791294</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/105650"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b03d781c-e2d6-43e8-b2b0-43e55f03f079">
        <rdfs:label>erythroid progenitor depletion</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0025034</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0025034*</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/97bcd1be-816c-481b-b40a-bfbd56e665cd">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012130</ddiem:url>
        <rdfs:label>premature differentiation of erythroid cells</rdfs:label>
        <dc:identifier>HP:0012130*</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27329125</dc:provenance>
    <dc:provenance>http://www.ncbi.nlm.nih.gov/pubmed/26305041</dc:provenance>
  </obo:DDIEM_0000007>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/71be84df-584f-45ef-8a49-f350b1768e70">
    <rdfs:label>Methylcobalamin</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB03614</ddiem:url>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/28b31036-4714-4ba0-b5a7-f5c72fa6efab">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27942180</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/2d4db577-7053-4a23-b269-de343a037157"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29572946</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/fd6538e5-b940-4e4e-a987-aa77472afe99"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/51d5c67e-91a3-4b97-8d43-220f40f40ed9"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26958680</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d592cd72-87e3-4596-97dd-f86880e0856e"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/2ce2a3f0-914c-481a-8b67-1c6a3499311d"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24222293</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14593474</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23364648</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26040326</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/8590b2f3-154e-4501-a7ea-0a25f700a3e4"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/261100"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/fb34fc8a-25c6-476c-821d-911cbddff26b"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18768530</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/4eff29ed-3869-48d7-b55a-0a52e49b0633"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22219566</dc:provenance>
        <rdfs:comment>In the clinical trial: The trial is not enrolling by invitation, no results have been posted yet. update by Oct.7th 2019
Authors have stated that "The data indicate that the retromer and sphingolipid metabolism play a critical role in PLA2G6-associated diseases. These observations may be relevant to Parkinson disease (PD) given that loss of vps35 or gain of Î±-Syn also affects retromer function and causes ceramide accumulation." https://www.ncbi.nlm.nih.gov/pubmed/29909971</rdfs:comment>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ce41cb95-464e-4f83-bfd4-b9b72b0d0fde"/>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <dc:identifier>DB03614</dc:identifier>
  </ddiem:Drug>
  <obo:DDIEM_0000008 rdf:about="http://ddiem.phenomebrowser.net/953eee1a-1c2a-4665-aae3-89e5f25c2eb0">
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/248360">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>MALONYL-CoA DECARBOXYLASE DEFICIENCY</rdfs:label>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/177</ddiem:iembaseUrl>
        <ddiem:iembaseAccessionNumber>177</ddiem:iembaseAccessionNumber>
        <dc:identifier>https://www.omim.org/entry/248360</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/163eae28-8265-48f3-84e0-7884bc592240"/>
      </ddiem:Disease>
    </obo:RO_0002599>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/6b36ca46-5e87-4637-b6e9-73189ff35f01"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28649527</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24613099</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28781843</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25859380</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24886114</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26858006</dc:provenance>
    <rdfs:comment>The regimen was accomapanied with a protein-restricted diet. https://www.ncbi.nlm.nih.gov/pubmed/27567650</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7275c795-9773-4776-a1d5-57a6a30c67da">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0012120</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012120</ddiem:url>
        <rdfs:label>High urinary malonic acid</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </obo:DDIEM_0000008>
  <owl:Class rdf:about="http://purl.obolibrary.org/obo/DDIEM_0000008">
    <dc:date rdf:datatype="http://www.w3.org/2001/XMLSchema#dateTime">2019-07-15T18:03:52+00:00</dc:date>
    <dc:creator>leechuck</dc:creator>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000005"/>
    <obo:IAO_0000115 xml:lang="en">A therapeutic procedure in which the diet is supplemented with or depleted in molecules  closely related to the products or end processes of a genetically defective protein which occur as natural products in the diet. [PNS]</obo:IAO_0000115>
    <rdfs:label xml:lang="en">dietary regime modification</rdfs:label>
  </owl:Class>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/492690f9-8192-419c-9e5d-975da201ff63">
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0030098</ddiem:url>
    <dc:identifier>HP:0030098</dc:identifier>
    <rdfs:label>Abnormal fukutin mRNA expression</rdfs:label>
  </ddiem:Phenotype>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/787fe4ca-2069-4fc7-80f7-a7b38c947603">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26766614</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/e112d14f-d3f5-4d99-87da-df3c3abf9bc2">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/10987cc8-b8de-47dd-860a-680d24d8bc7a"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.tandfonline.com/doi/full/10.3109/0886022X.2014.900422</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000012"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/18cac209-bc0b-43d4-920d-f10272168572">
        <rdfs:label>Brain pathology</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001298</ddiem:url>
        <dc:identifier>HP:0001298</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/230600">
        <rdfs:label>GM1-GANGLIOSIDOSIS, TYPE II</rdfs:label>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/ddf24210-fd69-4e0c-949d-7256b7e881cd"/>
        <dc:identifier>https://www.omim.org/entry/230600</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23337983</dc:provenance>
    <rdfs:comment>The mechanisms of its effects in movement disorders are not well understood but probably reflect an increase in synthesis and release of dopamine, with perhaps some inhibition of dopamine uptake.</rdfs:comment>
  </obo:OGMS_0000112>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/f1361a87-87ba-4fbe-98da-71c071f3db0e">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b352c55e-c159-4e88-a292-5843245509c2">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0004396</ddiem:url>
        <rdfs:label>decreased appetite</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0004396</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <rdfs:comment>One of the studies that was carried on mice provides useful information for developing the optimal dosage regimen for HPBCD therapy when administered intravenously to NPC patients.https://www.ncbi.nlm.nih.gov/pubmed/26027824</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c88d25ce-d2de-4c70-ac25-b60a224f7936">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001942</ddiem:url>
        <dc:identifier>HP:0001942</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>metabolic acidosis</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>http://www.scielo.br/pdf/jiems/v5/2326-4594-jiems-5-e170016.pdf</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25717099</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/518b6d43-2c86-4354-bcc8-68383fdd91a7"/>
    <dc:provenance>https://www.semanticscholar.org/paper/The-Incidence-of-Transient-Neonatal-Tyrosinemia-a-Zea-Rey-Cruz-Camino/b66304a0a56304f686380af915a92b2b860e9305</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24683506</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19415691</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28803710</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2bd23973-8887-41fd-9207-032a1f69b754">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>pyroglutamic aciduria(Organic aciduria)*</rdfs:label>
        <dc:identifier>HP:0001992*</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001992</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/140350"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27488560</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4898e0f4-2175-46ba-823b-b4320288f8e3">
        <dc:identifier>HP:0001939*</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001939</ddiem:url>
        <rdfs:label>secondary glutathione deficiency(Abnormality of metabolism,homeostasis)*</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </obo:OGMS_0000112>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/75278c7a-98fe-4bd5-a4a6-8efca1c2cc12">
    <obo:RO_0000056>
      <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/d507eb65-d3a9-482b-aad6-ffd5bc49a009">
        <rdfs:comment>It was withdrawn from the U.S. and Canadian markets in 2007 due to an increased risk of cardiac valve dysfunction.</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15670720</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648/#b96-tacg-8-201</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24613933</dc:provenance>
        <dc:provenance>https://globenewswire.com/news-release/2015/03/30/720127/10126746/en/Sigma-Tau-Pharmaceuticals-Inc-Receives-Orphan-Drug-Designation-for-EZN-2279-for-Treatment-of-Adenosine-deaminase-Deficient-Severe-Combined-Immunodeficiency-Disease.html</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/0866fbe4-a4b2-4d29-bee8-18df8eb8fd02"/>
        <dc:provenance>https://www.sciencedirect.com/science/article/abs/pii/S1386634602003315</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/books/NBK1181</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/612953"/>
        <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/621b465a-c3a8-4011-8265-4e3983701096"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
      </obo:DDIEM_0000013>
    </obo:RO_0000056>
    <rdfs:label>Pergolide</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/5d52cd5e-c07e-42de-9182-df20d21e19da"/>
    <dc:identifier>DB01186</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01186</ddiem:url>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/56b2619d-1085-4d2c-a38a-6144bb9f360e">
    <dc:identifier>MP:0001845</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/MP_0001845</ddiem:url>
    <rdfs:label>inflammation</rdfs:label>
  </ddiem:Phenotype>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/7ae6200d-7c74-416a-a95e-c3e278dc336b">
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4841061</dc:provenance>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/219800">
        <dc:identifier>https://www.omim.org/entry/219800</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/8237daba-9339-4e48-8926-93512a872681"/>
        <rdfs:label>CYSTINOSIS, NEPHROPATHIC; CTNS</rdfs:label>
        <ddiem:iembaseAccessionNumber>525</ddiem:iembaseAccessionNumber>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/525</ddiem:iembaseUrl>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3016220</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3505515</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9d7bdd6b-2787-4788-827f-2592df032b27">
        <dc:identifier>HP:004017</dc:identifier>
        <rdfs:label>Low serum testosterone levels</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_004017</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19622360</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8444253</dc:provenance>
    <rdfs:comment>Controversial benefits https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4158338/</rdfs:comment>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/9e7506ea-fc46-4874-bd48-54800293684c">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/0539cb0c-7dad-44dc-8419-170411b23f9e"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19217094</dc:provenance>
  </obo:OGMS_0000112>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/07470974-abc5-43ff-ad64-fc6a62044b32">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28202261</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/406fd0a7-51a9-4fb8-a284-8edd2f7834aa">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/2cdad9eb-2251-47b0-9b23-d918d3be13c5"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28285122</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:comment>These inconsistent results have suggested that the response might depend on the specific gene mutations
 As the response was not sustained and serum ALP and PLP and urine PEA returned to baseline between 8 and 13 months of treatment 
In N461L mutation which led to complete disappearance of the bone isoenzyme, disease was not modified by PTH treatment.  

https://www.ncbi.nlm.nih.gov/pubmed/22218563?dopt=Abstract
https://www.ncbi.nlm.nih.gov/pubmed/20089612?dopt=Abstract (Lack of sustained response to teriparatide in a patient with adult hypophosphatasia_</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/11bc3f6b-5ee4-4f8a-9b6c-82e054856953">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000708</ddiem:url>
        <rdfs:label>behavioural disturbance</rdfs:label>
        <dc:identifier>HP:0000708</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/239500">
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/0be1765a-c186-411b-a731-57a176407569"/>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/40</ddiem:iembaseUrl>
        <rdfs:label>HYPERPROLINEMIA, TYPE I; HYRPRO1</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseAccessionNumber>40</ddiem:iembaseAccessionNumber>
        <dc:identifier>https://www.omim.org/entry/239500</dc:identifier>
      </ddiem:Disease>
    </obo:RO_0002599>
  </obo:DDIEM_0000013>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/dd25e73c-ca54-47fa-9e12-d5c3c4e2d769">
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000012"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/5586569</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/72703028-0152-4c11-a949-9a8334366c2c">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/86709fee-3ee6-4b98-8eb4-3771dfce1f6f"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/236800">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>https://www.omim.org/entry/236800</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/cdd2f8a0-3f9b-4556-9d62-2a0a369d9a32"/>
        <rdfs:label>HYDROXYKYNURENINURIA</rdfs:label>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24561416</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26962538</dc:provenance>
    <rdfs:comment>The results of this study suggest that octreotide may aid in the acute or long-term treatment of congenital hyperinsulinism in a limited number of selected cases.https://www.ncbi.nlm.nih.gov/pubmed/8410522/</rdfs:comment>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/74bccc9a-9611-4a56-b539-bc7e0e6fdb6f"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26516243</dc:provenance>
  </obo:OGMS_0000112>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7c405dcc-c5f8-4d0a-82b2-927f7097882e">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001288</ddiem:url>
    <dc:identifier>HP:0001288</dc:identifier>
    <rdfs:label>gait abnormality</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/703aa365-5f46-428f-8e28-f3458a64b507">
    <dc:provenance>http://www.ncbi.nlm.nih.gov/pubmed/28317891</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/232200"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17514432</dc:provenance>
    <rdfs:comment>Ad vectors, HDAd is completely devoid of all viral protein genes and has been shown to display markedly reduced toxicity in mice.https://www.ncbi.nlm.nih.gov/pubmed/15753292</rdfs:comment>
    <dc:provenance>https://www.nature.com/articles/srep44408</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18996862</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/6b36ca46-5e87-4637-b6e9-73189ff35f01"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7fcd0daf-ac7c-4207-be8c-aa5c8354ca26">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>mitochondrial dysfunction</rdfs:label>
        <dc:identifier>HP:0003287</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003287</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007764"/>
  </obo:DDIEM_0000013>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f6b28bb6-b5c7-4ba6-b75c-2978e8b741a9">
    <rdfs:label>Gliosis</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002171</ddiem:url>
    <dc:identifier>HP:0002171</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2327783f-39d7-4fc2-9776-290d77526dba">
    <rdfs:label>Extrapyramidal movement disorders</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002071</ddiem:url>
    <dc:identifier>HP:0002071</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b0b5334f-0c55-45f8-b685-49a63efa7894">
    <dc:identifier>HP:0002069</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002069</ddiem:url>
    <rdfs:label>Generalized tonicâclonic seizure</rdfs:label>
  </ddiem:Phenotype>
  <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/50b9861b-7b98-43ae-8490-6adc7d06c617">
    <rdfs:comment>Poor compliance to the treatment was noticed</rdfs:comment>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/75edfa97-8ab4-43a1-a165-73be3f3fdcb2">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/5c23f823-6244-46e7-8fd2-e2b17545110e"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19820022</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/62f13862-3b92-42cc-9dad-e958eef7c627"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/cd1e7f1c-8e58-4f11-b0b9-0baf12de5fa4"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16635485</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/843e0dd5-c3ca-48a1-b0b0-a1d50ad2009e"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/03faf248-0736-42d9-91a3-f28e0be81ca3">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/2f253b2d-afa5-4357-aab2-32c395b11f0c"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/246650"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17339125</dc:provenance>
  </obo:DDIEM_0000007>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/66d8b2cf-7763-4b38-a198-ef809d72d35f">
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/6b36ca46-5e87-4637-b6e9-73189ff35f01"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00125190</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007764"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24639006</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19627167</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/271245"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17192294</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23887143</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19304794</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/236e1fc3-b207-4961-9e95-32fdf11b672e">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Abnormal circulating creatinine level</rdfs:label>
        <dc:identifier>HP:0012100</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012100</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30373890</dc:provenance>
    <rdfs:comment>The increased creatine/creatinine ratio in adult IOSCA patients, as well as in the IOSCA child patient who is motorically as active as her ageâmates, suggests an important role of creatine metabolism in the disease pathogenesis. Creatine synthesis is a major methyl group user, utilizing the same 1C/methyl pool as transsulfuration cycle, and thus, the creatine supplementation in IOSCA and IBM should be studied thus creatine is considered as a potential drug for treatment of IOSCA.https://www.ncbi.nlm.nih.gov/pubmed/30373890</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10549306</dc:provenance>
  </obo:OGMS_0000112>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/86d39558-b732-4b95-b113-850aab706b81">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28813744</dc:provenance>
    <dc:provenance>https://www.clinicaltrialsregister.eu/ctr-search/search</dc:provenance>
    <rdfs:comment>Nitisonone, a triketone herbicide and high-dose vitamin C (ascorbic acid) have been prescribed, but their efficacy has not been proven , A recent study in Oct. 2018 https://www.ncbi.nlm.nih.gov/pubmed/30449931 #It should be noted that despite its potential beneficial effects, nitisinone causes a large increase in circulating tyrosine. https://www.ncbi.nlm.nih.gov/pubmed/26891864. #There are more cinical studies running about Alkaptnuria "for more information please check http://www.developakure.eu/index.html</rdfs:comment>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/518b6d43-2c86-4354-bcc8-68383fdd91a7"/>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/203500"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5508465</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30477028</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30049652</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0f52e972-3b13-4bc0-a345-65a3c6c1f17c">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>apoptosis induced in chondrocytes</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01828463</dc:provenance>
  </obo:OGMS_0000112>
  <obo:DDIEM_0000015 rdf:about="http://ddiem.phenomebrowser.net/41b6f1f4-5afd-426f-9a62-99b753d09542">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3335288</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26979527</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23016163</dc:provenance>
    <rdfs:comment>Some references are aganist activated charcoal as treatment for Erthropoietic Protoporphyria. https://www.ncbi.nlm.nih.gov/pubmed/8127352?dopt=Abstract</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7758200</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22092997</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23884489</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4784ab6a-beb9-4240-8ac7-070bba1ba3c0">
        <dc:identifier>HP:0010472*</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0010472</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Hepatic prophyria(Abnormality of the heme biosynthetic pathway)*</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/ae499126-d971-47fd-9896-1129369bfadc">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/79242f64-8513-41aa-a569-c865b581c7ae"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/177000">
        <ddiem:iembaseAccessionNumber>107</ddiem:iembaseAccessionNumber>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/107</ddiem:iembaseUrl>
        <rdfs:label>PROTOPORPHYRIA, ERYTHROPOIETIC, 1; EPP1</rdfs:label>
        <dc:identifier>https://www.omim.org/entry/177000</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/f1a5084f-1886-418f-9a23-adc5d8a3dd95"/>
      </ddiem:Disease>
    </obo:RO_0002599>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
  </obo:DDIEM_0000015>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3222f241-12d0-487a-b09e-a398d4d51350">
    <rdfs:label>myoclonic seizures</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002123</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0002123</dc:identifier>
  </ddiem:Phenotype>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/976a3d86-ed87-4a9b-bb1e-32542d3aacdd">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26962538</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/991f369d-5064-4ca5-bd3d-2e99aaf92f02">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0001954</dc:identifier>
        <rdfs:label>periodic fever</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001954</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>The results of this study suggest that octreotide may aid in the acute or long-term treatment of congenital hyperinsulinism in a limited number of selected cases.https://www.ncbi.nlm.nih.gov/pubmed/8410522/</rdfs:comment>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/2b99444a-29ec-4198-83fd-19ccecad77d9">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/9cefedc4-c24c-49db-b23f-071fd0448346"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/6198500</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24935455</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/260920"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/2ce812c4-bafa-4417-9564-38303dba2f7c">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/241ba9f8-91b0-43e1-8a4d-d22ad535e893"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/662f72e1-385d-4424-8fcf-20209b1674bf">
        <dc:identifier>HP:0010978</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Abnormality of immune system physiology</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0010978</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://link.springer.com/referenceworkentry/10.1007%2F978-3-540-29676-8_199</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
  </obo:DDIEM_0000013>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6db05be7-670b-423a-b3c2-b20539ad5d6f">
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0000982</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000982</ddiem:url>
    <rdfs:label>Palmoplantar keratoderma</rdfs:label>
  </ddiem:Phenotype>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/48d12dec-4fcc-45d7-ac7d-4174e4a2d132">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15159649</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7254778</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/ec47b7d5-88fa-479a-a630-f7ccafa7969f">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/22cf93ec-99c7-4769-8fdd-1f6319557374"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:comment>There was no clinical effect, but amild reduction in the plasma level of desmosterol was observed.</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1392b718-9832-4360-9e1a-97ebd172660e">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000504</ddiem:url>
        <rdfs:label>abnormal central vision</rdfs:label>
        <dc:identifier>HP:0000504</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1755734</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28560651</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/cd63f195-cf20-460f-bef8-95473bfecb22"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28883274</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7356686</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22791294</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/099c2239-019c-4085-9d03-864587fcf94f">
        <dc:identifier>HP:0007663</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0007663</ddiem:url>
        <rdfs:label>decreased visual acuity</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/258870"/>
  </obo:DDIEM_0000013>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/0a19657b-11c8-4e4e-b80e-edbbd3cab970">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18996862</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/232220"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17514432</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/c148d200-9479-4b6a-a50f-1e30c7044a3f"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000010"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/3a796c4b-2a50-46f4-919d-43fc56c0c413"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/62f13862-3b92-42cc-9dad-e958eef7c627"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20357432</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/9b7dbd5d-0f1c-4909-8303-bbed922dd481"/>
    <rdfs:comment>Testosterone therapy needs to be carefully considered because of the risk of hepatic adenomas.https://www.ncbi.nlm.nih.gov/pubmed/28160246
Androgen receptors are expressed in the liver, and androgens can stimulate hepatocyte proliferation. Although rare, androgens have been shown in observational studies to induce adenoma development (Giannitrapani et al. 2006). Testosterone levels should be assessed for response 2â3 months after therapy is initiated.</rdfs:comment>
  </obo:OGMS_0000112>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f65c70c2-493e-40e6-85d9-f3178b19b17a">
    <dc:identifier>HP:0012465</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0012465</ddiem:url>
    <rdfs:label>Increased liver iron level</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/71d96d1c-1bc5-4c0e-8a52-17bbfd68648a">
    <rdfs:label>Nocturnal hypopnea</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002877</ddiem:url>
    <dc:identifier>HP:0002877</dc:identifier>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/26d49ef3-1505-425f-b05e-53ded1abf58f">
    <rdfs:label>low proximal tubular reabsorption of bicarbonates</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0004910</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0004910*</dc:identifier>
  </ddiem:Phenotype>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/435dddf2-91eb-4c81-abaf-3c7ae0e19585">
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/9acf166d-8a25-4838-af1e-e30c4567dd03">
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/9d6de3fb-8983-4133-9c79-695f33a7eeca"/>
        <rdfs:label>Laronidase</rdfs:label>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/333f9d06-e4ac-424d-86fa-8cb04c7a44e0"/>
        <dc:identifier>DB00090</dc:identifier>
        <ddiem:url>https://www.drugbank.ca/drugs/DB00090</ddiem:url>
      </ddiem:Drug>
    </rdf:li>
  </rdf:Alt>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/928b1463-099d-4a92-80ea-d44cfbe2b6f2">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/452d33b0-eda6-4036-b2c4-ec40913689b6">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0008373</ddiem:url>
        <dc:identifier>HP:0008373</dc:identifier>
        <rdfs:label>Puberty and gonadal disorders</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment></rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18458702</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26161337#</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18458702#</dc:provenance>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/202110">
        <dc:identifier>https://www.omim.org/entry/202110</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/bd9495a2-e183-4ccd-8d20-b04db0268b94"/>
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/125</ddiem:iembaseUrl>
        <rdfs:label>ADRENAL HYPERPLASIA, CONGENITAL, DUE TO 17-ALPHA-HYDROXYLASE DEFICIENCY</rdfs:label>
        <ddiem:iembaseAccessionNumber>125</ddiem:iembaseAccessionNumber>
      </ddiem:Disease>
    </obo:RO_0002599>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/9e7506ea-fc46-4874-bd48-54800293684c"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
  </obo:OGMS_0000112>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/d5011663-f751-441d-a9f5-b7c795dfe51f">
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/615511">
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/f4d618c9-7d32-49fa-9cdf-c06cb7b74ef1"/>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>MYOPATHY DUE TO MYOADENYLATE DEAMINASE DEFICIENCY; MMDD</rdfs:label>
        <dc:identifier>https://www.omim.org/entry/615511</dc:identifier>
      </ddiem:Disease>
    </obo:RO_0002599>
    <rdfs:comment>IG replacement is also indicated in infants with severe combined immunodeficiency (SCID) awaiting transplant and in those in which B cells function is not restored following transplantation. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2585601/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3488882</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d821e4c6-27ae-4ebe-ba23-f06d94bc628e">
        <rdfs:label>Exercise-induced myalgia</rdfs:label>
        <dc:identifier>HP:0003738</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003738</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://pdfs.semanticscholar.org/99dc/08fa85d5728e08f29b8c13177aac3206f4ec.pdf</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3503f6e6-91c2-407a-89fc-0a92aa3c23e4">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003394</ddiem:url>
        <dc:identifier>HP:0003394</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Muscle cramps</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648/#b96-tacg-8-201</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01420627</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/50345b3a-7459-4853-ba1e-a85f3f1e34bd">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/b503ae74-604c-4a0c-b3b1-58ba923e0293"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7385dd32-755e-43a2-9a39-92afac215eed">
        <rdfs:label>Exercise-induced muscle fatigue</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0009020</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0009020</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://globenewswire.com/news-release/2015/03/30/720127/10126746/en/Sigma-Tau-Pharmaceuticals-Inc-Receives-Orphan-Drug-Designation-for-EZN-2279-for-Treatment-of-Adenosine-deaminase-Deficient-Severe-Combined-Immunodeficiency-Disease.html</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e0a97a94-066c-4d31-8faa-6e9b4ba82ca1">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Limb muscle weakness</rdfs:label>
        <dc:identifier>HP:0003690</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003690</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29241594</dc:provenance>
  </obo:OGMS_0000112>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/c5957b38-4ef2-4c4f-a9a6-67c8e3bb6727">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/482d33af-463d-4788-a40f-7ef69775def3"/>
    <dc:identifier>DB00140</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00140</ddiem:url>
    <obo:RO_0000056>
      <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/bdcc77d4-602f-498e-805a-9f04c6414794">
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a4a51327-9207-48cb-bc0e-54fe83c8682d"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1059131117301243</dc:provenance>
        <dc:provenance>https://link.springer.com/article/10.1007/s11940-011-0131-z</dc:provenance>
        <rdfs:comment>In a different study IV administration of Glucose wasn't effective.https://www.ncbi.nlm.nih.gov/pubmed/22238410</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26006750</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/books/NBK1520</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/602541"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/af72c454-8e59-41e7-ab5e-57c09a2f7a98"/>
      </obo:DDIEM_0000007>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/0f7d2cd5-0b56-46fb-bfd4-746730b23de3">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/223f7b5d-3382-414e-99b7-2e2e458e68c3"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28766179</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/30306d09-ae88-4171-8e36-18a895108902"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
        <rdfs:comment>Synergism inmproves results</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16368216</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/231690"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/af72c454-8e59-41e7-ab5e-57c09a2f7a98"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:00007121"/>
        <dc:provenance>http://www.ncbi.nlm.nih.gov/pubmed/16368216</dc:provenance>
      </obo:DDIEM_0000007>
    </obo:RO_0000056>
    <rdfs:label>Riboflavin</rdfs:label>
    <obo:RO_0000056>
      <obo:DDIEM_0000012 rdf:about="http://ddiem.phenomebrowser.net/e2075159-d241-4b64-8100-ea2dd24e489a">
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/af72c454-8e59-41e7-ab5e-57c09a2f7a98"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24321868</dc:provenance>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00151710</dc:provenance>
        <rdfs:comment></rdfs:comment>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22391998</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/1cd3bef8-faf4-49ff-bb7c-b872015f26f3"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/236792"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19755409</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/2c8aa700-7181-4694-aac4-babba8043d93"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e90a4831-ed94-4573-9f28-00b04e1a4b36"/>
      </obo:DDIEM_0000012>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <obo:DDIEM_0000012 rdf:about="http://ddiem.phenomebrowser.net/5bbb9b18-0710-4c72-9d8c-ff400f1e2d84">
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1567724914001299</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12927581</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10970889</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/246900"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/af72c454-8e59-41e7-ab5e-57c09a2f7a98"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ac66b840-eeb4-44fd-b593-8f8bb668da8d"/>
        <rdfs:comment>Beneficial effects were initially observed on parkinsonian symptoms. However, dyskinesia and dystonic features re-emerged after three months of treatment.</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25251739</dc:provenance>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/61c6e3d4-2575-4537-9df3-fc8a7920ad59"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/70484379-4972-47a1-9b19-8363d46a21c7"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/16dd5fc3-69e1-4307-869e-5852b1c5b325"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/72f059a6-3bac-48bf-94b5-4c9d231090d7"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
      </obo:DDIEM_0000012>
    </obo:RO_0000056>
  </ddiem:Drug>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/613027">
    <rdfs:comment></rdfs:comment>
    <ddiem:iembaseAccessionNumber>1259</ddiem:iembaseAccessionNumber>
    <dc:identifier>https://www.omim.org/entry/613027</dc:identifier>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/1259</ddiem:iembaseUrl>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/46196255-026b-400b-a2c4-8153c0600c01"/>
    <rdfs:label>GLYCOGEN STORAGE DISEASE IXc; GSD9C</rdfs:label>
  </ddiem:Disease>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/3e051ecf-74f6-42e1-afca-52c032f0c662">
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/e48d3cf1-ad38-47fa-bccb-6d54464e513f">
        <ddiem:url>https://www.drugbank.ca/drugs/DB06210</ddiem:url>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/60a13a7f-ce7b-4392-9953-33827cfa8f52"/>
        <rdfs:label>Eltrombopag</rdfs:label>
        <dc:identifier>DB06210</dc:identifier>
      </ddiem:Drug>
    </rdf:li>
  </rdf:Alt>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/f5d80de6-d928-430d-8875-2421d716f081">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31239752</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30788385</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/17f4178b-4525-4283-8ed7-569eae8e79cc">
        <rdfs:label>Mitochondrial dysfunction</rdfs:label>
        <dc:identifier>HP:0003287</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003287</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/302060"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/3e10073b-048c-4a2c-b9c0-ef420e96d549">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/59774fa1-be7d-4e44-b3e8-a5f2306f3c83"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18632498</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e923f55a-4b00-47dd-9ee4-a05d18911c67">
        <rdfs:label>Abnormal cardiac protein (TAZ) expression</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30070157</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a2136919-d75c-4f97-a6a0-55d812c2f9ec">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001324</ddiem:url>
        <rdfs:label>Mueculoskeletal dysfunction</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0001324</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3249181</dc:provenance>
    <rdfs:comment>Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23432031</dc:provenance>
  </obo:OGMS_0000112>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/dd902a9f-5bd6-425b-9c6d-d0fa954c2068">
    <obo:RO_0000056>
      <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/a6378f6b-e494-40b7-946c-0b14878fb682">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19821145</dc:provenance>
        <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/258450"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12872260</dc:provenance>
        <rdfs:comment>Whether in this patient levodopa responsive Parkinsonism is caused bythe co-occurrence of the Twinkle R344Q and POLG G848S mutations remains elusive since brain autopsymaterial for mtDNA analysis was lacking.  https://www.ncbi.nlm.nih.gov/pubmed/12872260</rdfs:comment>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01793090</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/78f3d001-4887-4d42-8777-a38dce39096e"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/2637faa2-167f-4bda-bfb7-4b8b16ab3637"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3950820</dc:provenance>
        <dc:provenance>https://link.springer.com/article/10.1023/A:1005353530303</dc:provenance>
      </obo:DDIEM_0000013>
    </obo:RO_0000056>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/0ce63990-ac48-4e4f-998f-c7dfa67d5e37"/>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/70cc0203-f854-4594-8de8-0cbce63f7ec8">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12872260</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/617069"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/78f3d001-4887-4d42-8777-a38dce39096e"/>
        <rdfs:comment>Whether in this patient levodopa responsive Parkinsonism is caused bythe co-occurrence of the Twinkle R344Q and POLG G848S mutations remains elusive since brain autopsymaterial for mtDNA analysis was lacking. https://www.ncbi.nlm.nih.gov/pubmed/12872260</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24076137</dc:provenance>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <obo:DDIEM_0000011 rdf:about="http://ddiem.phenomebrowser.net/61b2b140-920e-474b-84f3-aa40fbe1407a">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20818608</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19234759</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/233910"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/9d63a58f-b943-4558-bc02-12e66500e387"/>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719208000048</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12003346</dc:provenance>
        <dc:provenance>https://link.springer.com/referenceworkentry/10.1007%2F978-3-540-29676-8_1729</dc:provenance>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10078749</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12391354</dc:provenance>
        <rdfs:comment>Sodium phenylbutyrate lowers the resynthesis of arginine from ornithine via the urea cycle.https://www.ncbi.nlm.nih.gov/pubmed/24268530</rdfs:comment>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/78f3d001-4887-4d42-8777-a38dce39096e"/>
      </obo:DDIEM_0000011>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/b25fab32-4e5f-4a1a-87e6-20d00e98d8ba">
        <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/607483"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24260777</dc:provenance>
        <dc:provenance>Abstract</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
        <rdfs:comment>Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss</rdfs:comment>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/9d63a58f-b943-4558-bc02-12e66500e387"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/78f3d001-4887-4d42-8777-a38dce39096e"/>
        <dc:provenance>http://www.neurologyindia.com/article.asp</dc:provenance>
      </obo:DDIEM_0000013>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/d0c31d05-e1e9-4855-947c-b38f60176d5a">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30013934</dc:provenance>
        <rdfs:comment></rdfs:comment>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/9d63a58f-b943-4558-bc02-12e66500e387"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/78f3d001-4887-4d42-8777-a38dce39096e"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0303846712003952</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22840416</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11102558</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/300438"/>
      </obo:DDIEM_0000013>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/3b5c5a00-09b8-4ad8-aeba-a47f4b8b4c63">
        <rdfs:comment>Whether in this patient levodopa responsive Parkinsonism is caused bythe co-occurrence of the Twinkle R344Q and POLG G848S mutations remains elusive since brain autopsymaterial for mtDNA analysis was lacking. https://www.ncbi.nlm.nih.gov/pubmed/12872260</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12872260</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24076137</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/613077"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/78f3d001-4887-4d42-8777-a38dce39096e"/>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <dc:identifier>DB01235</dc:identifier>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/fbd00446-2589-4cd5-a8ad-b74d3b347527">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18570303</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/612953"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19087156</dc:provenance>
        <rdfs:comment>Many studies have reported early responce to l- dopa treatment as mentioned in https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4503963/, and other pointed to " prominent dyskinesia " as side effect to same treatment https://www.ncbi.nlm.nih.gov/pubmed/19087156/</rdfs:comment>
        <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4503963</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20619503</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/0866fbe4-a4b2-4d29-bee8-18df8eb8fd02"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20938027</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/78f3d001-4887-4d42-8777-a38dce39096e"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25660576</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <obo:DDIEM_0000011 rdf:about="http://ddiem.phenomebrowser.net/2381b3a4-d7e5-417b-a52b-73c7db884954">
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/953aefcd-fbaa-4081-88aa-3ad90fe2ec5b"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11346370</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/98a69309-00f5-4c38-8570-cacb7e2c44b1"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/128230"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9886460</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/45b7e735-b77b-4e79-8c6b-7d55d881884d"/>
        <rdfs:comment>Topical retinoic acids, topical steroids, hydroquinone, tretinoin, and systemic retinoids have been used without success. https://www.ncbi.nlm.nih.gov/pubmed/2350982
https://www.ncbi.nlm.nih.gov/pubmed/3679816 https://www.ncbi.nlm.nih.gov/pubmed/29797344

Combination of Q-switched Nd: YAG and Fractional Carbon Dioxide Laser could be a promising therapy to pigmentation of Dowling-Degos diseaseÂ  https://www.ncbi.nlm.nih.gov/pubmed/28529428</rdfs:comment>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8163996</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/c9106990-2dc9-4d0b-8b31-72009b8aa14f"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12084887</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16908750</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16891685</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/2637faa2-167f-4bda-bfb7-4b8b16ab3637"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1899474</dc:provenance>
      </obo:DDIEM_0000011>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/ea672281-9cdd-42f8-882c-9ecfdf65331a">
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/617070"/>
        <rdfs:comment>Whether in this patient levodopa responsive Parkinsonism is caused bythe co-occurrence of the Twinkle R344Q and POLG G848S mutations remains elusive since brain autopsymaterial for mtDNA analysis was lacking. https://www.ncbi.nlm.nih.gov/pubmed/12872260</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24076137</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/78f3d001-4887-4d42-8777-a38dce39096e"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12872260</dc:provenance>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01235</ddiem:url>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/41adf57b-77a2-447d-b634-3089162b27bc">
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/78f3d001-4887-4d42-8777-a38dce39096e"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/618098"/>
        <rdfs:comment>Whether in this patient levodopa responsive Parkinsonism is caused bythe co-occurrence of the Twinkle R344Q and POLG G848S mutations remains elusive since brain autopsymaterial for mtDNA analysis was lacking. https://www.ncbi.nlm.nih.gov/pubmed/12872260</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24076137</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12872260</dc:provenance>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/499468ca-5c2b-4544-b6cb-1ea5d4d3023e">
        <rdfs:comment>Whether in this patient levodopa responsive Parkinsonism is caused bythe co-occurrence of the Twinkle R344Q and POLG G848S mutations remains elusive since brain autopsymaterial for mtDNA analysis was lacking.  https://www.ncbi.nlm.nih.gov/pubmed/12872260</rdfs:comment>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01793090</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/78f3d001-4887-4d42-8777-a38dce39096e"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3950820</dc:provenance>
        <dc:provenance>https://link.springer.com/article/10.1023/A:1005353530303</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19821145</dc:provenance>
        <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/609283"/>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12872260</dc:provenance>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/a7cab2a0-ae88-4f01-bed6-136ae5eff6ed">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24076137</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12872260</dc:provenance>
        <rdfs:comment>Whether in this patient levodopa responsive Parkinsonism is caused bythe co-occurrence of the Twinkle R344Q and POLG G848S mutations remains elusive since brain autopsymaterial for mtDNA analysis was lacking. https://www.ncbi.nlm.nih.gov/pubmed/12872260</rdfs:comment>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/78f3d001-4887-4d42-8777-a38dce39096e"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/609286"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/2637faa2-167f-4bda-bfb7-4b8b16ab3637"/>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <obo:DDIEM_0000011 rdf:about="http://ddiem.phenomebrowser.net/3993a968-6059-4c66-8122-808e2c5976a7">
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25304915</dc:provenance>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b1cc2163-3a0c-4c32-976b-29a7aca7cd10"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/0df943c1-2908-42df-ae97-dcf006d67493"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/78f3d001-4887-4d42-8777-a38dce39096e"/>
        <dc:provenance>https://www.babysfirsttest.org/newborn-screening/conditions/3-methylcrotonyl-coa-carboxylase-deficiency</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16601879</dc:provenance>
        <rdfs:comment>The patients should receive combination treatment with BH4 and neurotransmitter precursors as soon as possible to reduce neurological deterioration. https://www.ncbi.nlm.nih.gov/pubmed/16601879
In general, lâdopa is used with DCIs like as carbidopa or benserazide to block the peripheral conversion to dopamine. This coadministration not only increases bioavailability but also reduces peripheral side effects. 
Clinicians should be cautious, because Levodopa-Induced Dyskinesia " LIDs can occur commonly in patients with DRDâplus, especially because of SR, TH, and PTPS deficiencies. The current study showed that LIDs were reported in  44.4% of patients who had PTPS deficiencies. In such patients, a very low starting dose of lâdopa with from 0.5 to 1 mg/kg daily divided into 4 to 6 doses is recommended https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6178724/</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12003346</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/50b11d07-6d6c-485b-b3af-1f6d0e4d644e"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/261640"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23690520</dc:provenance>
        <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
      </obo:DDIEM_0000011>
    </obo:RO_0000056>
    <rdfs:label>Levodopa</rdfs:label>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/b66bd6b0-8224-4b84-a86d-37aa659e1e27">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30723321</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/books/NBK6803</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.nature.com/articles/s41436-019-0451-z</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f3f9a6a8-94d8-44d0-91b8-89d6241b686a"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19666145</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/78f3d001-4887-4d42-8777-a38dce39096e"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/612073"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/4391b4d9-a461-4cf9-b43a-5b23e0a6ea20"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01458119</dc:provenance>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01218659</dc:provenance>
        <rdfs:comment>The drug has been used in two patients; in one patient it resulted in a tempoary improvment for 6 months, in the other it resulted in adverse effects and irritability with involuntary movements, and the treatment was discontinued.</rdfs:comment>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00925301</dc:provenance>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
  </ddiem:Drug>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/e7d13feb-ebd0-481c-838b-22210bd30be8">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12794686</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3306242</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000010"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2564511</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29223626</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d1b65947-08fe-478f-80a6-a81b79b82bd1">
        <rdfs:label>Ketosis</rdfs:label>
        <dc:identifier>HP:0001946</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001946</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/240600">
        <ddiem:iembaseAccessionNumber>497</ddiem:iembaseAccessionNumber>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/497</ddiem:iembaseUrl>
        <rdfs:label>GLYCOGEN STORAGE DISEASE 0, LIVER; GSD0A</rdfs:label>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/d515eb90-ae73-4803-b380-7787227e81fb"/>
        <rdfs:comment>GS deficiency has a good long term prognosis: it is usually associated with a normal intellectual outcome, symptoms can be prevented if the condition is recognized and treated by avoidance of prolonged fasting and tolerance to fasting improves with age. https://www.ncbi.nlm.nih.gov/pubmed/12794686
Patients are treated with a diet high in protein with complex, low glycemic index carbohydrates. Since gluconeogenesis is intact, protein supplementation provides gluconeogenic precursors that can be used for endogenous glucose production. In turn, there is also less dependence upon fatty acid oxidation, and accumulation of free fatty acids and ketones is prevented. This not only reduces systemic acidosis, but prevention of hyperketonemia also enhances gluconeogenesis since more alanine can be released from skeletal muscle. https://www.ncbi.nlm.nih.gov/pubmed/106027
Simple carbohydrates should be limited since they can increase blood lactate concentrations. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1474809/</rdfs:comment>
        <dc:identifier>https://www.omim.org/entry/240600</dc:identifier>
      </ddiem:Disease>
    </obo:RO_0002599>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/dd77b874-3cc1-4afb-851d-3100f81f2db9">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012051</ddiem:url>
        <dc:identifier>HP:0012051</dc:identifier>
        <rdfs:label>MorningHypoglycemia (Hypoglycemia)*</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>Uncooked Cornstarch usually is administered at bedtime, and every 6 hours during illness, to prevent morning hypoglycemia and ketosis. In children who are particularly active, a dose of cornstarch in the morning or 1 hour before strenuous or prolonged physical activity can improve stamina. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1474809/</rdfs:comment>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/e4fe8128-15d7-4874-b568-8ddad4ec30c7"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583863</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15726662</dc:provenance>
  </obo:OGMS_0000112>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f318b1c4-247b-4f0c-9079-47b47a2998fe">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Corneal scar</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000559</ddiem:url>
    <dc:identifier>HP:0000559</dc:identifier>
  </ddiem:Phenotype>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/63f05662-6086-401e-83b6-b28786016f79">
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25488886</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24288038</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26396722</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/200100"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26086616</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/7e7c2b0f-fdf8-40f3-8f0c-914fcaf5d2a7"/>
    <rdfs:comment>It's an investigational therapy where Positive results from using a selective monoamine oxidase (MAO) B inhibitor or non-ergot dopamine agonist pramipexole as an adjunct therapy have been described in the medical literature. This use of such an inhibitor can allow for lower doses of neurotransmitter precursor to be used. However, the long-term safety (e.g. effects on neonatal brain development) and effectiveness of this therapy is unknown and more research is required to determine what role, if any, selective monoamine oxidase B inhibitors play in the treatment of individuals with tetrahydrobiopterin deficiency. https://rarediseases.org/rare-diseases/tetrahydrobiopterin-deficiency/. https://www.researchgate.net/publication/233414693_Deprenyl_in_6-Pyruvoyl_Tetrahydropterin_Synthase_Deficiency. https://www.degruyter.com/downloadpdf/j/pteridines.1995.6.issue-3/pteridines.1995.6.3.144/pteridines.1995.6.3.144.pdf</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/31e4ed31-beee-4874-8e55-d0713ab6ab06">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002630</ddiem:url>
        <rdfs:label>Malabsorption of lipid-soluble vitamins (Fat malabsorption)*</rdfs:label>
        <dc:identifier>HP:0002630</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://ojrd.biomedcentral.com/articles/10.1186/1750-1172-3-20</dc:provenance>
  </obo:OGMS_0000112>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/81f520eb-74e5-4cac-8040-b53e9eacb0f0">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007764"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17446099</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d4d9fa5f-c501-42d6-89e7-9156e0c4f1f3"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <rdfs:comment>Corticosteriods might be beneficial in heterozygous mutations as patients have milder phenotypes.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28107841</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28931339</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0bbe452a-4761-4f1e-acf4-525fc01bce3a">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0011804</ddiem:url>
        <rdfs:label>Abnormal muscle function</rdfs:label>
        <dc:identifier>HP:0011804</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/57eb8e3b-cbcf-4667-ad66-35d73d48e527">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0040081</ddiem:url>
        <dc:identifier>HP:0040081</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Abnormal serum creatine kinase</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/202b2073-9e0f-4323-b4bc-9fcf095b645b"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/bfc1292c-e134-4fd6-bbc5-ebe405132736">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0100614</ddiem:url>
        <rdfs:label>Myositis</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0100614</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25048216</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9e04273c-0292-4e71-af93-f2d35fff7945">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003678</ddiem:url>
        <rdfs:label>Rapid progression</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0003678</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23817215</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28334834</dc:provenance>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/607155">
        <rdfs:label>MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (LIMB-GIRDLE), TYPE C, 5; MDDGC5</rdfs:label>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/97527ef1-a44a-4202-911a-e73a9fb378c2"/>
        <dc:identifier>https://www.omim.org/entry/607155</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28480302</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/c7bbce4e-bbe2-4090-8287-ee48481c6418"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b2e722ac-ef7a-428c-9e80-5a2a05c4a830"/>
  </obo:DDIEM_0000013>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/32e0aee6-43c4-4274-8b86-57d6195ee842">
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/4556601b-4e58-4413-90b1-df627cd415d1"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22990144</dc:provenance>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/609056">
        <rdfs:label>SALT AND PEPPER DEVELOPMENTAL REGRESSION SYNDROME; SPDRS</rdfs:label>
        <ddiem:iembaseAccessionNumber>360</ddiem:iembaseAccessionNumber>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/6b1ae373-d4e3-4450-9357-069d6e480960"/>
        <dc:identifier>https://www.omim.org/entry/609056</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/360</ddiem:iembaseUrl>
      </ddiem:Disease>
    </obo:RO_0002599>
    <rdfs:comment>The mechanisms of its effects in movement disorders are not well understood but probably reflect an increase in synthesis and release of dopamine, with perhaps some inhibition of dopamine uptake.</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e09fb4b7-ebdf-4c5f-a34b-f02a0345d897">
        <dc:identifier>HP:0000817</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000817</ddiem:url>
        <rdfs:label>Poor eye contect</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d64477e7-e1bf-4b19-95a4-c1753c4aaa58">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>abnormal interactivity</rdfs:label>
        <dc:identifier>HP:0012433</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012433</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.tandfonline.com/doi/full/10.3109/0886022X.2014.900422</dc:provenance>
  </obo:OGMS_0000112>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/00cca270-d6c2-4087-b579-30b342a595c4">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000488</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Retinopathy</rdfs:label>
    <dc:identifier>HP:0000488</dc:identifier>
  </ddiem:Phenotype>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/ed2710dc-5fa6-473b-8152-c32981c0112f">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17514432</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18996862</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/232220"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b5a96ee0-de0b-4c93-a35a-8555fa2d65e2">
        <rdfs:comment>In this study, the amount of oral galactose and uridine sufficient to correct PGM1-deficiency, 322 could not improve the hypoglycosylation of neutrophils in a GSD-Ib patient.https://www.ncbi.nlm.nih.gov/pubmed/28126686?dopt=Abstract</rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0011990</ddiem:url>
        <dc:identifier>HP:0011990</dc:identifier>
        <rdfs:label>Partial correction of neutrophil dysfunction</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/dd7b2ce6-aa8d-4c83-b498-b3a83bb3453a">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/8badbb2a-2bd8-4dfb-8de3-f660cd927058"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/d8e93da5-10ea-4de8-be71-ac3e907d0c30">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/0c9b864d-5111-4161-a145-1e5e677fde9d"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>http://www.ncbi.nlm.nih.gov/pubmed/28126686</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <rdfs:comment>To exclude a lack of uridine as a limiting factor, uridine was added for the
 last 9 weeks of treatment.</rdfs:comment>
  </obo:DDIEM_0000013>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/735e0035-3c60-49bc-b830-69074947b261">
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0000707</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000707</ddiem:url>
    <rdfs:label>neurological abnormalities</rdfs:label>
  </ddiem:Phenotype>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/561941a1-2fa1-495a-8256-ef74af9761a9">
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/3b199d0d-9de8-4614-864b-659dca3865ab">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/ea902e7d-fc84-45eb-be83-2a09e72f2865"/>
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/568e015d-ad9b-43a7-8959-f7dd5cfabd7e"/>
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/188ed29a-5505-459b-b5c7-d61c7a45907e"/>
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/8e66fe3e-2d3d-4aa4-aa4b-714f7e983001"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/35b5c64e-9aaa-46fd-84a3-e5d483d4e101"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15895716</dc:provenance>
    <rdfs:comment>Phenobarbital, clonazepam, valproate, and midazolam could not completely control seizures. https://www.ncbi.nlm.nih.gov/pubmed/20052547/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/5707897</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29358012</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29480352</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19428278</dc:provenance>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/613163">
        <dc:identifier>https://www.omim.org/entry/613163</dc:identifier>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/36</ddiem:iembaseUrl>
        <ddiem:iembaseAccessionNumber>36</ddiem:iembaseAccessionNumber>
        <rdfs:label>GABA-TRANSAMINASE DEFICIENCY</rdfs:label>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/d1619fbd-39ee-4951-bf88-67bfd7662c11"/>
        <rdfs:comment></rdfs:comment>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7814809</dc:provenance>
  </obo:DDIEM_0000013>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2bb0f639-2813-43ec-9ab9-1b4af5cdc966">
    <rdfs:label>Low serum HDL-cholesterol</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003233</ddiem:url>
    <dc:identifier>HP:0003233</dc:identifier>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/ac5af18a-3c15-4d21-8690-f4752a5a3300">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19019309</dc:provenance>
    <dc:provenance>http://www.ncbi.nlm.nih.gov/pubmed/16435214</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/c659dc72-db4f-4b3c-867a-2d655336fcdb">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/d9ca7f8c-bc0c-4b1e-83c3-efb3019fae77"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:comment>An experimental study done on a mice with GMNT knocked out. suggesting considering Nicotinamide as atreatment option in patients with GNMT deficiency.  https://www.ncbi.nlm.nih.gov/pubmed/20578266/</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/eb5152ff-7294-4a87-a512-7b1cec024750"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/266130"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/79d44480-aca4-4c37-8b4e-b20a0d413380"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/129453a0-45bd-46a5-86db-c8c8fa6fffbc">
        <rdfs:label>anaemia</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001903</ddiem:url>
        <dc:identifier>HP:0001903</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16435214</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17397529</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/29cfed37-b05a-4dcc-a638-4727a54f5439">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/d40cb3ee-5b8d-4a8a-8918-77f5b1207acc"/>
      </rdf:Alt>
    </obo:RO_0000057>
  </obo:DDIEM_0000013>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/bcfc1c50-19ac-431f-b31a-2729cd6a3514">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/70b5636a-c94d-4bfc-a021-b7ad343fb317">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0007010</dc:identifier>
        <rdfs:label>Impaired fine motor skillls</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0007010</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e15f656c-0a21-4b1c-b1fa-65f91cb3cef0"/>
    <rdfs:comment>The treatment was done via convection-enhanced delivery</rdfs:comment>
    <dc:provenance>http://www.ncbi.nlm.nih.gov/pubmed/20584029</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7814809</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e316f32c-fb26-4111-ab29-5738cff667f1"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19428278</dc:provenance>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/219500">
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/28</ddiem:iembaseUrl>
        <rdfs:comment>Cystathioninuria not associated with vitamin B6 dependency is an evidence of genetic heterogeneity in primary cystathioninuria. https://www.ncbi.nlm.nih.gov/pubmed/417288        https://www.ncbi.nlm.nih.gov/pubmed/5707897</rdfs:comment>
        <ddiem:iembaseAccessionNumber>28</ddiem:iembaseAccessionNumber>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/5fa23e13-a29b-4cd0-9212-9456c164f185"/>
        <rdfs:label>CYSTATHIONINURIA</rdfs:label>
        <dc:identifier>https://www.omim.org/entry/219500</dc:identifier>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15895716</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29358012</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8f71b11b-e0b4-420d-8424-f54d48aec2ff">
        <rdfs:label>High total homocysteine level</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0010919</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0010919</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8c3734f7-9b93-40da-a152-bd01686239fb">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0003153</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003153</ddiem:url>
        <rdfs:label>Cystathioninuria</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000012"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/eb5152ff-7294-4a87-a512-7b1cec024750"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/5707897</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/417288</dc:provenance>
  </obo:OGMS_0000112>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/0ccbbff2-7f2f-46c4-940e-520d356f70c1">
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/ba4fb4df-0390-4e86-ad94-68cb70436bd1"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3505515</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b84f06b0-1aa6-4fb8-8271-58f9c83b8f6d">
        <rdfs:label>proximal tubule salt lossesÂ (Proximal tubular defect)</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000114</ddiem:url>
        <dc:identifier>HP:0000114</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3550461</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/cf94d8f5-1918-402b-8f92-6cb884eed702">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000127</ddiem:url>
        <rdfs:label>renal salt wasting</rdfs:label>
        <dc:identifier>HP:0000127</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/219800"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5d3c4042-f396-408f-a8e5-6b8655479d83">
        <rdfs:label>polyuria</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000103</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0000103</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19622360</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/31ba3c75-9c65-482c-b783-451e11c158a7"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4158338</dc:provenance>
    <rdfs:comment>Controversial benefits https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4158338/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8444253</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3016220</dc:provenance>
  </obo:DDIEM_0000013>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/56f94b6a-f805-457a-aa19-2473ad045def">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0004295</ddiem:url>
    <dc:identifier>HP:0004295</dc:identifier>
    <rdfs:label>Gastric mucosal atrophy(Abnormality of gastric mucosa)*</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/5d4ceb3c-8221-47ee-8d75-3d5d442f8857">
    <rdfs:comment>In a different study IV administration of Glucose wasn't effective.https://www.ncbi.nlm.nih.gov/pubmed/22238410</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2897261</dc:provenance>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/151800">
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/1abaf40f-2a9b-43e9-9c9c-053c92416972"/>
        <dc:identifier>https://www.omim.org/entry/151800</dc:identifier>
        <rdfs:comment>The surgical management  is the only effective treatment for the case. Patients are usually instructed to stop alcohol consumption. https://www.ncbi.nlm.nih.gov/pubmed/1696085/ https://www.ncbi.nlm.nih.gov/pubmed/8210195/</rdfs:comment>
        <rdfs:label>LIPOMATOSIS, MULTIPLE SYMMETRIC; MSL</rdfs:label>
      </ddiem:Disease>
    </obo:RO_0002599>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/37f2eae9-543b-46f1-8f91-7f2d4c550bf4">
        <dc:identifier>HP:0009124*</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0009124</ddiem:url>
        <rdfs:label>Rapid progression in body fat mass( Abnormality of adipose tissue* )</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/e443cff5-8a73-4c19-be44-c1fa86ec316b">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/e8997369-b875-4041-996a-b250b58f2832"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/76e7f4ac-a0e2-41e8-bc2e-79bdf3482c03">
        <dc:identifier>HP:0008993</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0008993</ddiem:url>
        <rdfs:label>Increased intraabdominal fat</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b4f2b909-9165-4013-a2cb-82c920e8c0c1"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
  </obo:OGMS_0000112>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/f51da089-d6fc-40e5-a28c-2cbf21dbded7">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28919799</dc:provenance>
    <rdfs:comment>There is no clinical role for NaPBA at present; however, ongoing studies are assessing its efficacy https://www.ncbi.nlm.nih.gov/pubmed/28919799 Phenotypes corrected were based on invivo trial on mice not humans.</rdfs:comment>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/c7568be9-e6b5-4e41-9ee1-202e43e5338f"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/bef7a13d-eda9-4945-8a7c-9cae16ec1a64"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/248600"/>
  </obo:OGMS_0000112>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/19fb6344-0f70-4a55-9b6e-4cfdf79fc9e6">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003281</ddiem:url>
    <dc:identifier>HP:0003281</dc:identifier>
    <rdfs:label>Elevated serum ferritin concentrations</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/f93250a7-0a00-46b9-99dc-9ffbe57104f4">
    <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5508465</dc:provenance>
    <rdfs:comment>The drug is used as a maintenance therapy https://www.ncbi.nlm.nih.gov/books/NBK476305/ https://www.tandfonline.com/doi/abs/10.1080/21678707.2017.1405807</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d2855038-dccc-4161-8382-6f0ddec62925">
        <dc:identifier>HP:0010909*</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0010909</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Elevated blood arginine levels( Abnorality in arginie metabolism)*</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4382922</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26358771</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT03378531</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/207800"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/510f9d89-5215-4011-9b66-ec31fab60f43">
        <dc:identifier>HP:0000707*</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000707</ddiem:url>
        <rdfs:label>Unstable neurological function (Abnormality of the nervous system)*</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5048010f-10dc-4624-8720-aa3b9e6d66f0">
        <rdfs:label>Disease progression (Rapidly progressive)*</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003678</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0003678*</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.clinicaltrialsregister.eu/ctr-search/search</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23494656</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/d08c5c0c-f1a2-448b-8412-ab7544c9eb46">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/64b0d449-8916-49d3-b2e6-76b4033e5324"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
  </obo:OGMS_0000112>
  <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/d404eb57-79fa-4adc-a01a-6f071d3c2751">
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/309400"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9511979</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/d95856a9-6b04-4b97-a14a-ddb2484a1cbe">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/a021ad3d-e98c-4fad-ae7c-5214335bde9c"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.sciencedirect.com/science/article/abs/pii/088789949190052M</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30384011</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/bb2a27d2-7d5d-461b-9c21-e6b49265f2a1"/>
    <rdfs:comment>Pharmaceutical studies are needed to reduce the adverse enteral effects.https://www.ncbi.nlm.nih.gov/pubmed/30127521</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30127521</dc:provenance>
    <dc:provenance>https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
  </obo:DDIEM_0000007>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/d36e5949-8122-4617-b716-e6404f3a0a88">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10549306</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24639006</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19627167</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/271245"/>
    <rdfs:comment>The drug is occasionally effective especially when started early in status epilepticus.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20301746</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00125190</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/35b5c64e-9aaa-46fd-84a3-e5d483d4e101"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/23ecce48-b7ae-4193-ad6c-c109e0329680"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17192294</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27884013</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23887143</dc:provenance>
  </obo:DDIEM_0000013>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/6ff879d2-b80a-49d6-a766-24aebc2ea938">
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/cb4cd4be-0ee2-4763-b602-d4c41579d808">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/9167cea4-da4f-4112-9c5f-bc483f444fe7"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:comment>"Oral tocofersolan was more bio available than the water-soluble formulation in children with chronic cholestasis and similarly bio available in CF. This suggests that water-soluble vitamin E may represent an alternative to painful intramuscular vitamin E injections in chronic cholestasis, or other oral formulations in CF. However, the mechanism responsible for fat malabsorption in CRD concerns the absorptive phase as opposed to the digestive phase in CF and cholestatic syndromes. To our knowledge, no specific studies with these new vitamin E preparations have been conducted in CRD." https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717/</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/57a2e036-c451-4232-95f9-f550ed11077f">
        <rdfs:label>low physical capacity</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012378</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0012378</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/615395">
        <dc:identifier>https://www.omim.org/entry/615395</dc:identifier>
        <ddiem:iembaseAccessionNumber>961</ddiem:iembaseAccessionNumber>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/261d8c79-bb84-43fa-9100-61805093b94d"/>
        <rdfs:label>COMBINED OXIDATIVE PHOSPHORYLATION DEFICIENCY 16; COXPD16</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/961</ddiem:iembaseUrl>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25797485</dc:provenance>
    <dc:provenance>https://link.springer.com/article/10.1007%2Fs10048-015-0444-2</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/6b36ca46-5e87-4637-b6e9-73189ff35f01"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
  </obo:DDIEM_0000013>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/88adc4f3-fcd3-48a9-a808-c6949da8ea66">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8444253</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/b1a20169-7783-41c0-a7cc-a90e67ac66ca">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/44e9353a-2df9-4e73-bbc5-7bae176d7bbe"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4158338</dc:provenance>
    <rdfs:comment>Controversial benefits https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4158338/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3505515</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/53e9f3ea-097d-48d4-b1f6-818e9793fe5f">
        <dc:identifier>HP:0001941</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001941</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>acidosis</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19622360</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3550461</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3016220</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/219800"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/7b517ff3-fc9a-449b-a7f3-1355c1eb4688"/>
  </obo:DDIEM_0000013>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/7a350ec8-bb3e-4e7c-87e0-2a7eebf6f08d">
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/c71945d9-e156-470c-ba70-ac1e4b666c51">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/db95ffb7-1fff-4344-8468-e7a3060cd676"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2427298</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e3f98a5e-43d9-4016-8682-0271dd425197"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12756558</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/634eed25-4fde-4f69-8f0b-fa17f1c09f44">
        <rdfs:label>urinary tract infection</rdfs:label>
        <dc:identifier>HP:0000010</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000010</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10484808</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/69ecf7b5-3ca1-4ee9-aaf1-4d0c3f4d1edd">
        <dc:identifier>MP:0005567</dc:identifier>
        <rdfs:label>hypoproteinemia</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/MP_0005567</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/602579">
        <dc:identifier>https://www.omim.org/entry/602579</dc:identifier>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/322</ddiem:iembaseUrl>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/582aa68a-6fd0-4ab9-8c3b-acf3bf6794f3"/>
        <ddiem:iembaseAccessionNumber>322</ddiem:iembaseAccessionNumber>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>CONGENITAL DISORDER OF GLYCOSYLATION, TYPE Ib; CDG1B</rdfs:label>
      </ddiem:Disease>
    </obo:RO_0002599>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/52866145-a549-417f-b141-e91b256864c4">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Hypoglycosylation of serum glycoproteins</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4263309</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9525984</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1a6aadf2-6528-4761-9de6-62bf5a2d59d4">
        <rdfs:label>hypoglycaemia</rdfs:label>
        <dc:identifier>HP:0001943</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001943</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>Drug name: Treatment is under trial.</rdfs:comment>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b56b3632-77d0-4eb1-ae8d-bab8bcce9d93"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/684f9583-81f9-4138-92f2-018168c75c41">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0002243</dc:identifier>
        <rdfs:label>protein-losing enteropathy</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002243</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <dc:provenance>https://pdfs.semanticscholar.org/7753/abad26acee41547592d5a3a65b0483eff767.pdf</dc:provenance>
  </obo:OGMS_0000112>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/cd476638-fa93-4ed6-82bb-607675598ef0">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/1203be3b-8ddd-4b67-91c8-38c96f885bbc"/>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/bc51741d-8261-419a-a08e-740fffc6587a">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10601810</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26823911</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ac66b840-eeb4-44fd-b593-8f8bb668da8d"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5625994</dc:provenance>
        <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29596118</dc:provenance>
        <rdfs:comment>The drug was administered through intravitreal injection.</rdfs:comment>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
        <dc:provenance>https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ee3816ba-6d5c-4944-a831-dc8f54588617"/>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01212744</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/540000"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/4556601b-4e58-4413-90b1-df627cd415d1"/>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <dc:identifier>DB09270</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB09270</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/2873ee75-25f8-4718-ae5c-11065fa86552"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/32e0aee6-43c4-4274-8b86-57d6195ee842"/>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/8e175776-de3c-421d-bb80-cd78a2ed6bd4">
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/530000"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27709644</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/4556601b-4e58-4413-90b1-df627cd415d1"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26884075</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/0d590fb5-4997-45f8-bf70-93f923e2063f"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26118651</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/48f0eae9-c050-47a4-8918-9b66e9cc570d"/>
        <rdfs:comment>MCT should be at least 70% of the total fat content of the diet.</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27442316</dc:provenance>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/b9ea2503-75cf-4d03-8c13-ad511fa1e0bf">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/608158"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/4556601b-4e58-4413-90b1-df627cd415d1"/>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719215300895</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3306242</dc:provenance>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
        <rdfs:comment>Treatment was stopped three days later because of lack of improvement and severe respiratory alkalosis with lactic acidosis (serum lactic acid 70 mg/dl, normal 4â20 mg/dl). https://www.ncbi.nlm.nih.gov/pubmed/12948744</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12948744</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9156798</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15726662</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583863</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/c1ba99ab-cc06-4a3f-8f61-65a683c970c2"/>
      </obo:DDIEM_0000007>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/9a6721aa-deb3-4a2b-99cc-69055f8e6d78">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28277561</dc:provenance>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/387b9aa2-9a28-479d-a7f0-8ecfc6876a9c"/>
        <rdfs:comment>There is a common note in different reserachs refers to the importance of early managment by Vitamin E supplements since it limits disease progression and it can reverse some of the clinical manifestation (e.x ataxia and the intellectual deficit), if it was interoduced early in life. Therefore, early diagnosis is paramount.</rdfs:comment>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/c262357b-72d5-48da-928e-e13cd4b62fb4"/>
        <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
        <dc:provenance>https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27906067</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/4556601b-4e58-4413-90b1-df627cd415d1"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15300460</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/208920"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17586848</dc:provenance>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <rdfs:label>Ubidecarenone</rdfs:label>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/40935077-2817-416a-8f5c-05b0189ecae8">
        <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3950820</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19821145</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/4556601b-4e58-4413-90b1-df627cd415d1"/>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01793090</dc:provenance>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
        <dc:provenance>https://link.springer.com/article/10.1023/A:1005353530303</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/78ecd39d-7157-41bf-ac78-ab63a8603a54"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/610131"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e1ab1408-3f0b-412a-9df4-30ad7a784975"/>
        <rdfs:comment>The combination of three antiepileptic drugs and LGIT"modified KD" is effective and well tolerated as treatment for severe episodes of POLG-related mitochondrial epilepsy. They suggest as well that combining LGIT to antiepileptic drug treatment should be considered in this potentially life-threatening condition.https://www.ncbi.nlm.nih.gov/pubmed/23248042?dopt=Abstract</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27442316</dc:provenance>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/a1ebff7e-b7f4-4ce3-a0e4-005385097716">
        <obo:RO_0003304>Homozygous deletion (c.1511_1512delCT) that leads to a premature truncation of the protein (p. Ala504fs)</obo:RO_0003304>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/246387c5-4a08-4db9-8134-ea1389cefe0a"/>
        <obo:RO_0003304>homozygous frameshift mutation (c.1844_1845insG) in the C-terminus of mitochondrial atypical kinase COQ8A</obo:RO_0003304>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b5f1c85c-c10f-4784-8074-331163733442"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/4556601b-4e58-4413-90b1-df627cd415d1"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4263309</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2427193</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28125198</dc:provenance>
        <obo:RO_0003304>comp. htz c.1523 T &gt; C exon13 + del exons 3 to 15 p.Phe508Ser</obo:RO_0003304>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/2f330e37-5bd8-44a3-ba42-94923b435485"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29159460</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ec6e911d-5384-4d30-af87-2dcec9be9f3b"/>
        <rdfs:comment>A combination therapy of Î´-tocopherol and HPBCD further improved the effect compared to that of either drug used as a single therapy.</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15326254</dc:provenance>
        <obo:RO_0003304>Hetero c.[1541AâG] + [1750_1752 delACC]</obo:RO_0003304>
        <obo:RO_0003304>comp. htz c.[895C &gt; T] + [1358delT] exons 7 and 11 p.[Arg299Trp] + [ Leu453Argfs*24]</obo:RO_0003304>
        <obo:RO_0003304>G272D https://www.ncbi.nlm.nih.gov/pubmed/18319072</obo:RO_0003304>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/98a69309-00f5-4c38-8570-cacb7e2c44b1"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/27ecf745-ac09-4ec2-bb9b-8a5f47caba15"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18319074</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26818466</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/612016"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ef745b45-6525-49f5-9b6c-9447c376f31f"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b6f8dc53-22dd-4e4f-a8eb-af0a1b6edf9e"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/393ded8e-5aec-4d99-8233-5ac8509e4432"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/c9106990-2dc9-4d0b-8b31-72009b8aa14f"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ab8c3b9a-8e04-42fd-8a51-dcda6a931f21"/>
        <obo:RO_0003304>Homozygous deletion (c.504del_CT)</obo:RO_0003304>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/48f32ce4-16cf-4278-9b03-79e206da83cd"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e8aa9f47-a95b-4ab5-b52b-395f8167324e"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/878bf718-3e50-4307-90f4-0a896944c6e3"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3843540</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24164873</dc:provenance>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/84d51e9f-21f5-490f-bcb2-89cd3e22c4cd">
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <rdfs:comment>An experimental study done on a mice with GMNT knocked out. suggesting considering Nicotinamide as atreatment option in patients with GNMT deficiency.  https://www.ncbi.nlm.nih.gov/pubmed/20578266/</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17397529</dc:provenance>
        <dc:provenance>http://www.ncbi.nlm.nih.gov/pubmed/26669244</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/813a597f-f721-495e-83ef-685cb1c5df10"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19019309</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/4556601b-4e58-4413-90b1-df627cd415d1"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/266130"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26669244</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/c1234c40-29ff-4bef-acf5-458f9098fc69">
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/4c5a6ef6-0902-4999-8706-563954c68dde">
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/82154b2f-5714-4a2f-8e32-d29def2ade30"/>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/b98f2dbc-5c19-472a-9075-db4857f0afd6"/>
        <rdfs:label>Eculizumab</rdfs:label>
        <ddiem:url>https://www.drugbank.ca/drugs/DB01257</ddiem:url>
        <dc:identifier>DB01257</dc:identifier>
      </ddiem:Drug>
    </rdf:li>
  </rdf:Alt>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/5ca8264f-2780-445b-87c4-68488ae4265f">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0303846712003952</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22840416</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/300438"/>
    <dc:provenance>https://www.semanticscholar.org/paper/Clinical-Diagnosis-and-Treatment-of-Dehydrogenase-A-Cui-Wang/f6e88d647f2e2c7df2897e939ec33f9d86899b37</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11102558</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/54f3351b-31bd-470e-a6fb-f76bd3d798ef"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2753603b-2fa6-4bfc-bd22-ecf80bf6a1a1">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Abnormality of the nervous system</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000707</ddiem:url>
        <dc:identifier>HP:0000707</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment></rdfs:comment>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
  </obo:OGMS_0000112>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/9036677d-0ab3-4044-a63d-964624078335">
    <dc:provenance>https://onlinelibrary.wiley.com/doi/abs/10.1111/pde.12170</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
    <dc:provenance>was associated with improved findings on skeletal radiographs and improved pulmonary and physical function in infants and young children with life-threatening hypophosphatasia. (Funded by Enobia Pharma and Shriners Hospitals for Children; ClinicalTrials.gov number</dc:provenance>
    <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/fa261bcd-57e6-4381-9754-2ef89b790ac7">
        <dc:identifier>HP:0001397</dc:identifier>
        <rdfs:label>steatohepatitis</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001397</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/73ee989c-18fb-4d98-9b01-4fb03004069e"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/275630">
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseAccessionNumber>753</ddiem:iembaseAccessionNumber>
        <dc:identifier>https://www.omim.org/entry/275630</dc:identifier>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/753</ddiem:iembaseUrl>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/496bfde9-fcaa-4eff-a973-081078d6c088"/>
        <rdfs:label>CHANARIN-DORFMAN SYNDROME; CDS</rdfs:label>
      </ddiem:Disease>
    </obo:RO_0002599>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>"ENB-0040</dc:provenance>
    <dc:provenance>NCT00744042.)."</dc:provenance>
    <dc:provenance>https://www.researchgate.net/publication/8668575_A_successful_treatment_with_pyridoxal_phosphate_for_West_syndrome_in_hypophosphatasia</dc:provenance>
    <rdfs:comment>Drug name: Treatment is under trial.</rdfs:comment>
    <dc:provenance>an enzyme-replacement therapy</dc:provenance>
  </obo:OGMS_0000112>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/96e6a2b5-a45d-4c1b-9eeb-982ff64d5070">
    <dc:provenance>https://emedicine.medscape.com/article/942055-treatment</dc:provenance>
    <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25638506</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/dea92466-3863-472e-96ba-6ad150838f52"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/9d63a58f-b943-4558-bc02-12e66500e387"/>
    <rdfs:comment>Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28649539</dc:provenance>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/253260">
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/0f4dfb61-855b-4a50-80ad-95baf716369e"/>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/93</ddiem:iembaseUrl>
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseAccessionNumber>93</ddiem:iembaseAccessionNumber>
        <dc:identifier>https://www.omim.org/entry/253260</dc:identifier>
        <rdfs:label>BIOTINIDASE DEFICIENCY</rdfs:label>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26577040</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/39e026c8-3518-488b-950b-ec15df629d6a"/>
  </obo:DDIEM_0000013>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/7ce84530-4b65-4812-9be7-caf4f77515ff">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24093206</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3202309</dc:provenance>
    <obo:RO_0003304>A354V</obo:RO_0003304>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0a7e1ecd-1cde-4954-94da-7e105178f1be">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001941</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>acidotic crises</rdfs:label>
        <dc:identifier>HP:0001941*</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/c9d2579f-f5aa-49a0-92ab-83e99695c249">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/ceac9bcd-9659-44c1-a5a5-5897a8716e30"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0003304>A354V and C12775STOP</obo:RO_0003304>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29054473</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22202226</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02805790</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/468dc4a2-3cec-4f1c-be72-9ced6c58cf39">
        <rdfs:label>Low COX content and activity</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21600768</dc:provenance>
    <rdfs:comment>The cyclosporine trial (taken immediately upon visual loss in the first eye) is in progress in Leber's optic atrophy to prevent involvement of the fellow eye.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21483849</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02176733</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/220111"/>
  </obo:OGMS_0000112>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1982031f-5771-4c22-8e7f-f7ef25833e5e">
    <dc:identifier>HP:0008936</dc:identifier>
    <rdfs:label>axial hypotonia</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0008936</ddiem:url>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/e66babb0-fc35-4389-9324-52c85654d6f3">
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/530000">
        <ddiem:iembaseAccessionNumber>398</ddiem:iembaseAccessionNumber>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>KEARNS-SAYRE SYNDROME; KSS</rdfs:label>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/567920d4-ffcc-445c-a1e0-a9a577b4cfff"/>
        <dc:identifier>https://www.omim.org/entry/530000</dc:identifier>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/398</ddiem:iembaseUrl>
      </ddiem:Disease>
    </obo:RO_0002599>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/013e6db9-a0b1-4a55-bddb-f94b89496292">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/83a811e7-ba27-47f4-967e-7d91423294bb"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2fed0422-4f7f-4b78-9984-a269339960f3">
        <dc:identifier>HP:0001635</dc:identifier>
        <rdfs:label>acute congestive heart failure</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001635</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/7020c096-0241-42a7-a7ce-8e756ce3826e">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/e907c231-979c-4358-97a9-3902b925b2f6"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26884075</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/685c289a-e63e-48e4-b7ea-b0acdc9e981f">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/c36ad0d6-2c27-42e4-9bd7-9cf9d08f7f7d"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27709644</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/54fcc65f-b73b-4e44-a4aa-4ae2f7924c31">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/78cdf15b-1f28-4e18-9c47-41a91d9f8cf2"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:comment>MCT should be at least 70% of the total fat content of the diet.</rdfs:comment>
  </obo:OGMS_0000112>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/6b1e7436-7f5c-40a1-bec8-009f6ed8839e">
    <obo:RO_0000056>
      <obo:direct_complementation_of_a_genetically_defective_protein_by_gene_therapy rdf:about="http://ddiem.phenomebrowser.net/4fa983e7-bbc1-429f-9f3d-9acb4bdbb8b0">
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17192294</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/605820"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19627167</dc:provenance>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01517880</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20030229</dc:provenance>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00125190</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/0525ffae-8cdc-4e24-87b4-7c7777bf2de5"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10549306</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/e6938ced-9c66-43eb-b30b-8be0c174fcbc"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21517694</dc:provenance>
        <rdfs:comment>In the clinical trial: The trial is not enrolling by invitation, no results have been posted yet. update by Oct.7th 2019
Authors have stated that "The data indicate that the retromer and sphingolipid metabolism play a critical role in PLA2G6-associated diseases. These observations may be relevant to Parkinson disease (PD) given that loss of vps35 or gain of Î±-Syn also affects retromer function and causes ceramide accumulation." https://www.ncbi.nlm.nih.gov/pubmed/29909971</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26546927</dc:provenance>
      </obo:direct_complementation_of_a_genetically_defective_protein_by_gene_therapy>
    </obo:RO_0000056>
    <rdfs:label>GNE gene lipoplex</rdfs:label>
  </ddiem:Drug>
  <obo:DDIEM_0000011 rdf:about="http://ddiem.phenomebrowser.net/5bdd0642-37f4-4713-b29e-42dbafe1e713">
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30373615</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19087156</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6206929</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b5748a09-0ff1-41dc-9c08-e0ea71eb001b">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0500014</ddiem:url>
        <dc:identifier>HP:0500014</dc:identifier>
        <rdfs:label>Histologic abnormalities in liver (Abnormal test result)*</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/805548af-9efd-4822-a8b8-b2f38190cf3e"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/10e1bf67-51f2-4196-9385-52321601abc4">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003678</ddiem:url>
        <rdfs:label>progression of the disease (Rapidly progressive)*</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0003678*</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ac0a4a8c-196f-4e5e-845d-e8dab07253c6">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001396</ddiem:url>
        <rdfs:label>Bile flow defect</rdfs:label>
        <dc:identifier>HP:0001396</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20619503</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9d7b39fc-c853-4a54-9820-4390db000016">
        <dc:identifier>HP:0001394</dc:identifier>
        <rdfs:label>Cirrhosis</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001394</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19622360</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4a3685cf-0600-4997-8969-a1f174a04b26">
        <dc:identifier>HP:0001939*</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001939</ddiem:url>
        <rdfs:label>production of toxic intermediates</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/c62ad3d7-4f4c-45df-81f3-33b7c597c929"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20938027</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18570303</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/94987563-bd7a-4c39-bf4c-1305d041276e"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16819396</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ac523342-45e6-4195-b67d-f3fb0a7f3440">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>synthesisÂ of atypicalÂ bileÂ acids</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7d23b8ad-84ee-453a-bcae-870f17b96d93">
        <rdfs:label>Atypical bile acids</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://rarediseases.info.nih.gov/diseases/9813/congenital-bile-acid-synthesis-defect-type-2</dc:provenance>
    <rdfs:comment>Many studies have reported early responce to l- dopa treatment as mentioned in https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4503963/, and other pointed to " prominent dyskinesia " as side effect to same treatment https://www.ncbi.nlm.nih.gov/pubmed/19087156/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11067870</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://rarediseases.info.nih.gov/diseases/9813/congenital-bile-acid-synthesis-defect-type-1</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e039c55a-a545-4f91-880d-acee005cf8aa">
        <rdfs:label>Hepatic Biochemical abnormalities (Laboratory abnormality)*</rdfs:label>
        <dc:identifier>HP:0001939*</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001939</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/607765"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4503963</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8225213</dc:provenance>
  </obo:DDIEM_0000011>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/608099">
    <rdfs:label>MUSCULAR DYSTROPHY, LIMB-GIRDLE, AUTOSOMAL RECESSIVE 3; LGMDR3</rdfs:label>
    <dc:identifier>https://www.omim.org/entry/608099</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/88042d75-cd37-4a91-8d21-1beb89e39ab1"/>
  </ddiem:Disease>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/b9bbd298-85b8-498d-90ed-31d45276866b">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25717099</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12547874</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19415691</dc:provenance>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/151670">
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/2faab71c-9bcb-4f99-8bbf-d80daf65a7db"/>
        <rdfs:label>LIPASE, HEPATIC; LIPC</rdfs:label>
        <dc:identifier>https://www.omim.org/entry/151670</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22798447</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8a6f3b33-4f02-4a46-bd32-09f021b9601f">
        <rdfs:label>High atherogenic lipoprotein(Abnormality of lipid metabolism)*</rdfs:label>
        <dc:identifier>HP:0003119*</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003119</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26194979</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f51a69bb-3263-45e1-9b92-5ebc52c777f1">
        <dc:identifier>HP:0003119*</dc:identifier>
        <rdfs:label>High Apolipoprotein B (ApoB)(Abnormality of lipid metabolism)*</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003119</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/c3af4cca-0eea-44d8-9c18-121be136d146"/>
    <rdfs:comment>Rosuvastatin therapy (20 mg per day) could be used as a preventive therapy.https://www.ncbi.nlm.nih.gov/pubmed/22798447</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/232cba24-1918-40c2-abb5-f626ab15af0b">
        <rdfs:label>High low-density lipoprotein (LDL)-C(Abnormality of lipid metabolism)*</rdfs:label>
        <dc:identifier>HP:0003119*</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003119</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00733811</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14632789</dc:provenance>
  </obo:OGMS_0000112>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/e3bd99d8-e18d-4c49-8e39-aa4439ac45a3">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22410442</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21483849</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29054473</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26448041</dc:provenance>
    <rdfs:comment>Author: "The therapeutic potential of idebenone therapy is likely to have the highest impact if therapy is initiated early in the disease at a time when retinal ganglion cell loss is still minimal.https://www.ncbi.nlm.nih.gov/pubmed/21810891/</rdfs:comment>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/6fc54827-731b-4f29-af16-69f7389dcc25">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/fb062757-de94-4052-b65b-0a3757c278e0"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3744a9ee-b31d-46ed-a8e4-6312289330df">
        <rdfs:label>Retinal ganglion loss</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000479</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0000479</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/5048010f-10dc-4624-8720-aa3b9e6d66f0"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02300753</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/138a78ff-ef3d-4fb2-88a3-41da42b4f77b">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Visual loss</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000572</ddiem:url>
        <dc:identifier>HP:0000572</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/535000"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21600768</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3202309</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ce8b5819-cb2d-4a37-bc4e-6a870f02a0c8"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24093206</dc:provenance>
  </obo:OGMS_0000112>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/2301d2c2-3e5e-4140-9776-22e5d4f0f7f5">
    <dc:identifier>DB01197</dc:identifier>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/b353bd62-b699-4a54-9d65-f3fcd11f7002">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18632498</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/1441dbea-f090-46a5-b7c6-3746d3be46c4"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/3777dea7-eaa5-4e11-a748-466065fb774a"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e9cdf487-2c29-4164-8ff0-37f7364fcb63"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/302060"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/66a62fbe-a604-41f7-8f0b-7161dd56326f"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20981509</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31239752</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3249181</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23432031</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/93fc5614-e6b3-44b3-bf6f-0dc09d0e21d5"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30070157</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/e643648c-e4ac-4141-86e1-d57f70bdf43f"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/e3a59696-57ee-47c9-98cc-341bc54f1e1d"/>
        <rdfs:comment>Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss</rdfs:comment>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/2045cd4d-737d-46fe-a1af-0e2e4bc48e72"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01197</ddiem:url>
    <rdfs:label>Captopril</rdfs:label>
  </ddiem:Drug>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/613077">
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/120ea392-3c9d-4f94-9767-a2cd732df3c3"/>
    <dc:identifier>https://www.omim.org/entry/613077</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA WITH MITOCHONDRIAL DNA DELETIONS, AUTOSOMAL DOMINANT 5; PEOA5</rdfs:label>
  </ddiem:Disease>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/75d0767b-42ad-40da-9d02-989a91b4e497">
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/f0a7d6e1-7421-4c17-bf58-3a7ee3ffa341">
        <dc:provenance>http://ichgcp.net/clinical-trials-registry/NCT03432871</dc:provenance>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26095523</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/19722b60-4092-407f-8f30-f4965e74968f"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/1009cd0f-b0d9-4ba6-8d42-18d63b35caeb"/>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT03432871</dc:provenance>
        <dc:provenance>https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117</dc:provenance>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
        <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/540000"/>
        <rdfs:comment>The drug was administered through intravitreal injection.</rdfs:comment>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01212744</dc:provenance>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <dc:identifier>DB03227</dc:identifier>
    <rdfs:label>Nicotinamide Mononucleotide</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB03227</ddiem:url>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d4be491a-166d-46a8-ba7d-6f5c96f15c06">
    <rdfs:label>Diffuse scaling(Skin Scaling)*</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0040189*</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0040189</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d31e1db3-58b2-440c-a9ff-03d08ccba8bd">
    <rdfs:label>Abnormal reticulocyte count</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0004312</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0004312</ddiem:url>
  </ddiem:Phenotype>
  <obo:DDIEM_0000006 rdf:about="http://ddiem.phenomebrowser.net/e10a3dea-8d2d-4628-938a-dfc9f9b7d90a">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6d989658-5b5e-4911-b532-6acf9fd05b86">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003281</ddiem:url>
        <rdfs:label>High ferritin level</rdfs:label>
        <dc:identifier>HP:0003281</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>There is controversy about idebenone effect on LVM index ; although there were some studies suggested its effect on reducing LVM index and neurological problems, there are some that documented its faiure in acheiving this result. https://www.ncbi.nlm.nih.gov/pubmed/21392622
https://www.ncbi.nlm.nih.gov/pubmed/20697044</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3dd2c288-af0f-447c-9ba1-5602e10805c7">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Low Frataxin expression level</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16269021</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/29cfed37-b05a-4dcc-a638-4727a54f5439"/>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/229300">
        <ddiem:iembaseAccessionNumber>1241</ddiem:iembaseAccessionNumber>
        <rdfs:label>FRIEDREICH ATAXIA 1; FRDA</rdfs:label>
        <dc:identifier>https://www.omim.org/entry/229300</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/0fc0465f-a7f0-4412-bde9-2b577c2b01f2"/>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/1241</ddiem:iembaseUrl>
      </ddiem:Disease>
    </obo:RO_0002599>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/48f0eae9-c050-47a4-8918-9b66e9cc570d"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/43b47f7d-d161-40f7-aa88-01c271e16ca0">
        <dc:identifier>HP:0003254</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003254</ddiem:url>
        <rdfs:label>High urinary 8-hydroxydeoxyguanosine level(Abnormality of DNA repair)*</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18759345</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17702040</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21597884</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1524cb5c-416b-4233-9245-43d655ea6677">
        <dc:identifier>HP:0003287</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003287</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Low NADH,NAD ratio(Mitochondrial dysfunction)</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/efd3056c-4cdd-4941-ac56-6784d9cee1f8"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2a5bc6a2-e5c1-45b9-a1d8-9ef93e59a5da">
        <dc:identifier>HP:0012378</dc:identifier>
        <rdfs:label>Tiredness</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012378</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </obo:DDIEM_0000006>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/b6dbcbad-d4cd-4e5e-8688-be82ca39795c">
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/c8b801e8-ea74-4d6c-bfd6-0413d2c63439">
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/7cd8f8f6-01ba-458e-b3d6-c085fa9af27e"/>
        <rdfs:label>OTZÂ (L-2-oxothiazoline-4-carboxylic acid</rdfs:label>
      </ddiem:Drug>
    </rdf:li>
  </rdf:Alt>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/00f5c594-d628-46c9-8acb-6914443d39ae">
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02922413</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/176000"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/04d88d9b-6f23-4732-87e6-602e54592955">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0100543</ddiem:url>
        <rdfs:label>abnormal mental status</rdfs:label>
        <dc:identifier>HP:0100543</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648/#b96-tacg-8-201</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02180412</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/ae499126-d971-47fd-9896-1129369bfadc"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15767622</dc:provenance>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/96b793a7-3f44-4684-8e4e-270c97c660a7">
        <dc:identifier>HP:0012531</dc:identifier>
        <rdfs:label>pain</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012531</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/724050e5-5af2-4093-a5f3-8d026db730a8">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0011009</ddiem:url>
        <dc:identifier>HP:0011009</dc:identifier>
        <rdfs:label>Acute attack</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6358544</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/70a2df43-3542-4dd3-bb09-95aa4eb3211b">
        <rdfs:label>tachycardia</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001649</ddiem:url>
        <dc:identifier>HP:0001649</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>Currently, the use of glucose is limited only to mild attacks (ie, mild pain, no paresis, seizures, or hyponatremia) according to the guidelines for the treatment of an acute attack in the USA and South Africa, or if heme arginate or hematin are not available locally. https://www.ncbi.nlm.nih.gov/pubmed/15643299/ https://www.ncbi.nlm.nih.gov/pubmed/15767622/
Intravenous glucose in water solutions, such as dextrose 5% or 10%, should be avoided as they may aggravate hyponatraemia. https://www.ncbi.nlm.nih.gov/pubmed/22783787</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9b019a1a-e8c3-45f5-ab16-32b11896eee9">
        <dc:identifier>HP:0000822</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000822</ddiem:url>
        <rdfs:label>hypertension</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </obo:OGMS_0000112>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d592cd72-87e3-4596-97dd-f86880e0856e">
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0012120</ddiem:url>
    <dc:identifier>HP:0012120</dc:identifier>
    <rdfs:label>Abnormal methylmalonic acid level.</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5b34a762-f302-4074-8d69-04b9d32726e2">
    <rdfs:label>Hyponatremia</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002902</ddiem:url>
    <dc:identifier>HP:0002902</dc:identifier>
  </ddiem:Phenotype>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/68c0f69e-a7af-4741-b049-35be43597d2c">
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/e22f339d-9b4c-4244-bd1d-925ebbf20c20">
        <rdfs:label>Protoporphyrin</rdfs:label>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/49324341-6d6f-40e9-b87f-1aea5e56d846"/>
        <ddiem:url>https://www.drugbank.ca/drugs/DB02285</ddiem:url>
        <dc:identifier>DB02285</dc:identifier>
      </ddiem:Drug>
    </rdf:li>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/25968082-87b6-4f3c-b39c-b264615da92c">
    <rdfs:label>Dihydrexidine</rdfs:label>
    <dc:identifier>DB12890</dc:identifier>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/f0fe7c73-b1a9-4a6d-b82b-45a4865d91ee">
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01395641</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3955971</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
        <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/d85aaa45-4f49-49b2-b267-3c8ccf5f064b"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/608643"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/74b66f98-6381-4667-b744-1af42f1cb529"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/da184cec-d903-494e-a46f-a3dad76d2400"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3073162</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e95bfb09-8ecd-45c4-b80e-72bb7816e68f"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ad006969-4020-495b-b825-5f95a5d87391"/>
        <dc:provenance>https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23494656</dc:provenance>
        <rdfs:comment>Consider trial if pyridoxine gives too many side effects or is not effective. Chronic use in high dose can cause severe sensorimotor polyneuropathy. https://www.ncbi.nlm.nih.gov/pubmed/25001633/</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5241937</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/5137e1c4-c9c3-4a62-a26e-a86c20f4d54e"/>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <ddiem:url>https://www.drugbank.ca/drugs/DB12890</ddiem:url>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/22a94e91-2bbf-4989-b3db-f05af0e6a0a5">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0011025</ddiem:url>
    <rdfs:label>Abnormal cardiac function</rdfs:label>
    <dc:identifier>HP:0011025</dc:identifier>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/6432703a-595f-4b25-8db8-024a899dc48c">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b1fa11b5-6a99-4131-a313-20fd0d1a1884">
        <dc:identifier>HP:0000707</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000707</ddiem:url>
        <rdfs:label>neurological damage</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/c148d200-9479-4b6a-a50f-1e30c7044a3f"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15131757</dc:provenance>
    <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28590052</dc:provenance>
    <rdfs:comment>Drug name: Intranasal dDAVP, because of efficacy, long duration of action, and infrequent side effects, is the preferred treatment of neurogenic diabetes insipidus in children and adults.https://www.ncbi.nlm.nih.gov/pubmed/626447</rdfs:comment>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/eb345fb0-e9f4-4420-9c6d-508b9ea1af0b"/>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/601987">
        <rdfs:label>CARNITINE PALMITOYLTRANSFERASE I, MUSCLE; CPT1B</rdfs:label>
        <dc:identifier>https://www.omim.org/entry/601987</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/fd674c8c-27e7-4fdf-9073-b41c085751d3"/>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://rarediseases.info.nih.gov/diseases/10325/carnitine-palmitoyltransferase-i-deficiency-muscle</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19452263</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30804055</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26153518</dc:provenance>
  </obo:DDIEM_0000007>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/223360">
    <dc:identifier>https://www.omim.org/entry/223360</dc:identifier>
    <rdfs:label>ORTHOSTATIC HYPOTENSION 1; ORTHYP1</rdfs:label>
    <ddiem:iembaseAccessionNumber>101</ddiem:iembaseAccessionNumber>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/101</ddiem:iembaseUrl>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/e18298ff-791e-4ef2-adf3-f561615d2cda"/>
    <rdfs:comment></rdfs:comment>
  </ddiem:Disease>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/41ddfa5a-ab90-4f54-8ddd-832c7f8f5018">
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/856f6008-ee51-41b6-8a82-012383114596">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002160</ddiem:url>
        <dc:identifier>HP:0002160</dc:identifier>
        <rdfs:label>Elevated plasma homocysteine concentration</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/77c657d7-e0e3-44ec-a1cb-2836f73f6f15"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/749c4e05-a067-4dbf-bfde-b25a6123b0e0"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/5361854f-7f31-45a0-9196-7a2a5e838318"/>
    <rdfs:comment>Selection of this drug combinstion ""Methylprednisolone sodium succinate +
Immune Globulin "" was based on the presumption that the patient had autoimmune encephalopathy. https://www.ncbi.nlm.nih.gov/pubmed/25511120</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3950820</dc:provenance>
    <dc:provenance>https://link.springer.com/article/10.1023/A:1005353530303</dc:provenance>
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5fda68fe-bd9c-42de-a9cf-e27e73d1fe81">
        <rdfs:label>Granulocytopenia</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001913</ddiem:url>
        <dc:identifier>HP:0001913</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28210839</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/250940"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000012"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01793090</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/b3b91803-46c6-4398-8030-a8feea3ea9bc"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/16ccf1e2-b510-47fb-939b-7c8be34c450b">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001873</ddiem:url>
        <dc:identifier>HP:0001873</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Thrombocytopenia</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19821145</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/bbf39077-cad5-403a-8ff4-fc532b31ddf7">
        <dc:identifier>HP:0002907</dc:identifier>
        <rdfs:label>Microhematuria</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002907</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </obo:OGMS_0000112>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/58b82c4c-b4f4-4cfd-b855-3f84e7938ef6">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/45809f76-b3cb-473b-a1f1-403d1c23fe91">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002149</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0002149</dc:identifier>
        <rdfs:label>hyperuricemia</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/63e7edcc-0dc4-4106-9e8d-b98ee2e2f0ee">
        <dc:identifier>HP:0003077</dc:identifier>
        <rdfs:label>hyperlipidemia</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003077</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17514432</dc:provenance>
    <rdfs:comment>Anti-inflammatory medications, including derivatives of 5-aminosalicylic acid (5-ASA), might be a helpful adjunct for treating gastrointestinal complaints in GSD Ib patients, if renal function is carefully monitored . https://www.ncbi.nlm.nih.gov/pubmed/12373585</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/17bd6593-dbe8-4b90-9432-d748ba483340">
        <dc:identifier>HP:0000855*</dc:identifier>
        <rdfs:label>age-related insulin resistance(Insulin resistance)*</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000855</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18996862</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/5dce09b3-24a8-4cc1-b890-13a151edaef4">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/13e1a867-614d-46ac-9d99-e6e4c61f9431"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2a7fca2e-01a7-4152-b72c-45ef227e7622">
        <dc:identifier>HP:0001513</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001513</ddiem:url>
        <rdfs:label>obesity</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/direct_complementation_of_a_genetically_defective_protein_by_gene_therapy"/>
    <dc:provenance>http://www.ncbi.nlm.nih.gov/pubmed/28973635</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9d238f43-d7e4-44a5-b6e7-2cc0d83972a2">
        <rdfs:label>lactic acidemia</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003128</ddiem:url>
        <dc:identifier>HP:0003128</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/eb345fb0-e9f4-4420-9c6d-508b9ea1af0b"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/232220"/>
  </obo:OGMS_0000112>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/64e75e0d-bd7c-4fc6-9cdd-2cfd6721c9c3">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2681858</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7be338ef-d2c8-4c75-8de4-f4e57fc7036d">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Study was terminated due to lack of safety</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/4883477</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/d4c98967-e0bf-46ea-bdd0-832fa326539b">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/a491cfe0-7651-4e28-9024-a9858f09bec6"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/fee6d538-da4d-4b13-9e0f-526f5277f305"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29695967</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00145431</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/617347"/>
    <rdfs:comment>Study was terminated due to safety issues.</rdfs:comment>
  </obo:DDIEM_0000013>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/457d96e1-6a3d-4c84-acba-6aca3a1b0e7c">
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0003165</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003165</ddiem:url>
    <rdfs:label>abnormal parathyroid hormone level</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/a9630580-c9df-44e2-9626-1870a8b4bdae">
    <rdfs:label>Sodium acetate</rdfs:label>
    <obo:RO_0000056>
      <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/b25f0f29-5792-49ec-95f0-e9b22fc8b8cc">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
        <dc:provenance>https://www.orpha.net/data/patho/GB/uk-Bartter.pdf</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
        <dc:provenance>http://www.neurologyindia.com/article.asp</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/04bcdc35-6bd5-4dfe-92e6-456151791f87"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17185149</dc:provenance>
        <rdfs:comment>Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss</rdfs:comment>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/5b34a762-f302-4074-8d69-04b9d32726e2"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24260777</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2646391</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/607364"/>
      </obo:DDIEM_0000013>
    </obo:RO_0000056>
    <dc:identifier>DB09395</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB09395</ddiem:url>
  </ddiem:Drug>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/57351e14-3467-4c43-956e-b5ea18576fdf">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25717099</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19415691</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20677779</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/140350"/>
    <dc:provenance>https://www.semanticscholar.org/paper/The-Incidence-of-Transient-Neonatal-Tyrosinemia-a-Zea-Rey-Cruz-Camino/b66304a0a56304f686380af915a92b2b860e9305</dc:provenance>
    <dc:provenance>http://www.scielo.br/pdf/jiems/v5/2326-4594-jiems-5-e170016.pdf</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24683506</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e164c21b-99f9-4cea-8864-dba3ca721620">
        <rdfs:label>Extreme frailty (Fatigue)*</rdfs:label>
        <dc:identifier>HP:0012378*</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012378</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28803710</dc:provenance>
    <rdfs:comment>One of the studies that was carried on mice provides useful information for developing the optimal dosage regimen for HPBCD therapy when administered intravenously to NPC patients.https://www.ncbi.nlm.nih.gov/pubmed/26027824</rdfs:comment>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/89c2524f-61fa-421d-8d5e-d50530c1c476">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/560ac420-cd02-4239-847e-6a03bbf0090c"/>
      </rdf:Alt>
    </obo:RO_0000057>
  </obo:OGMS_0000112>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/1bea97c1-9392-4fb3-9dd8-d3f8caf82d17">
    <dc:identifier>DB01200</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01200</ddiem:url>
    <obo:RO_0000056>
      <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/ce1ae6ce-3fd0-400c-b460-5cd4ad0c46bd">
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/9d63a58f-b943-4558-bc02-12e66500e387"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/74b66f98-6381-4667-b744-1af42f1cb529"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5241937</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23494656</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/096c2299-8ddb-45f7-bbd3-98235f7a2765"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3073162</dc:provenance>
        <rdfs:comment>Alternative pathway therapy has limited effectiveness in preventing hyperammonemia and must be combined with effective dietary management. https://www.ncbi.nlm.nih.gov/pubmed/11148549</rdfs:comment>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/a0ad4968-b2f4-4c46-9602-76b8d9450348"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a0f4c13b-5f5c-4a17-bc0b-2dd0fab0a2c8"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/0f4943b0-36d1-411a-9dda-c2bebcd5168b"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/c184d5a2-3421-4a16-8dad-13864d5ffd5e"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/1982031f-5771-4c22-8e7f-f7ef25833e5e"/>
        <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a76b6ab4-7b49-4a86-86e3-b4f12d901624"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/da184cec-d903-494e-a46f-a3dad76d2400"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3955971</dc:provenance>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01395641</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/608643"/>
      </obo:DDIEM_0000007>
    </obo:RO_0000056>
    <rdfs:label>Bromocriptine</rdfs:label>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/50ce9ba3-1032-49e1-a2b6-db0b1cdf164e">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>deteriorating pulmonary function</rdfs:label>
    <dc:identifier>HP:0005952</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0005952</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9d096e60-6642-4e91-9bb3-9e3930aed3fc">
    <dc:identifier>HP:0000992</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>skin photosensitivity</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000992</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f1330ea5-29c1-47d4-95b5-cab8823e4b15">
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002718</ddiem:url>
    <rdfs:label>Recurrent bacterial infection</rdfs:label>
    <dc:identifier>HP:0002718</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/255120">
    <rdfs:comment></rdfs:comment>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/228</ddiem:iembaseUrl>
    <ddiem:iembaseAccessionNumber>228</ddiem:iembaseAccessionNumber>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/86db9b47-29e8-4e38-be01-5e205caa32e8"/>
    <dc:identifier>https://www.omim.org/entry/255120</dc:identifier>
    <rdfs:label>CARNITINE PALMITOYLTRANSFERASE I DEFICIENCY</rdfs:label>
  </ddiem:Disease>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/a63a711a-9838-4a14-a486-e4bad808de53">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31196723</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2f5c4a3f-b419-46c0-b65d-31fc1533a7aa">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012279</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Low plasma serine levels</rdfs:label>
        <dc:identifier>HP:0012279</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/cf72b905-8f01-424b-a0e0-04456c9db7f3">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0010918</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0010918</ddiem:url>
        <rdfs:label>High total cysteine levels</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31211405</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/60dda08c-0ded-49e9-ac2f-f68bd2484f5c">
        <dc:identifier>HP:0002160</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002160</ddiem:url>
        <rdfs:label>High total homocysteine levels</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/236200"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31082797</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30755342</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16619244</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24355692</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d84dda4e-d142-440b-918c-996becdb20db">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>high blood S -adenosylhomocysteine level</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14739681</dc:provenance>
    <rdfs:comment>Current treatment includes (i) the administration of pyridoxine to putatively stimulate the residual CBSactivity; (ii)restriction of dietary methionine intake to decrease the load in the affected pathway; (iii) supplementation of cystine to correct cysteine deficiency; and (iv)administration of betaine, folic acid and cobalamin to facilitate the remethylationof homocysteine back to methionine.</rdfs:comment>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000012"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/8b06ecde-61db-4db7-a656-960b7b30b2d1">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/2d078c1d-a418-4550-8d95-46ef5ff4a27d"/>
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/cd994311-f58f-471c-8778-fdf7c002e669"/>
      </rdf:Alt>
    </obo:RO_0000057>
  </obo:OGMS_0000112>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a7a047a0-cbcb-48dd-a447-103ec14fe040">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001336</ddiem:url>
    <dc:identifier>HP:0001336</dc:identifier>
    <rdfs:label>myoclonuic Jerk</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <owl:Class rdf:about="http://purl.obolibrary.org/obo/DDIEM_0000015">
    <obo:IAO_0000115 xml:lang="en">A therapeutic procedure that inhibits  a component of the pathway or network in which a genetically defective protein is found, compensating for alteration of activity of that protein.[PNS]</obo:IAO_0000115>
    <dc:creator>leechuck</dc:creator>
    <rdfs:label xml:lang="en">functional complementation of a defective protein by inhibition</rdfs:label>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <dc:date rdf:datatype="http://www.w3.org/2001/XMLSchema#dateTime">2019-07-15T18:08:56+00:00</dc:date>
  </owl:Class>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/f6322a80-aaab-4553-a6ea-da66ad561586">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b6b95930-1f50-4600-9ad8-cc06fb233121">
        <rdfs:label>polydipsia</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/MP_0001426</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>MP:0001426</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/d7d631c4-cdd5-4041-af99-ca57a8a64424">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/7195c20d-7a1a-40c7-9b6e-06992fba3413"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28590052</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/125700"/>
    <dc:provenance>https://academic.oup.com/jcem/article/98/10/3958/2833930</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15131757</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26153518</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/68651a86-8558-4772-94bd-a2e2f4e27210">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001959</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0001959</dc:identifier>
        <rdfs:label>thirst</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
    <rdfs:comment>Drug name: Treatment is under trial.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1316120</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30804055</dc:provenance>
    <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
  </obo:OGMS_0000112>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/a4f7199a-cae5-4eb8-8912-de25de6f3717">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d42c519f-5479-477f-9716-8fd51f26e655">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000114</ddiem:url>
        <dc:identifier>HP:0000114</dc:identifier>
        <rdfs:label>Proximal tubular dysfunction</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/7b517ff3-fc9a-449b-a7f3-1355c1eb4688"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12937245</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.paediatricaindonesiana.org/index.php/paediatrica-indonesiana/article/view/59/33</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17339125</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/309000"/>
    <rdfs:comment>If on supplemental bicarbonate or citrate, phosphorus or calcitriol or other vitamin D analog, need kidney function assessment 1 w/blood &amp; urine tests
May need serum vitamin D-25 hydroxy to assess for parent vitamin D deficiency</rdfs:comment>
  </obo:DDIEM_0000013>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/27308b12-4ba4-492a-a2f3-14cbbcf77a0f">
    <dc:identifier>CHEBI_28384</dc:identifier>
    <ddiem:url>https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI_28384</ddiem:url>
    <rdfs:label>vitamine K</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/63f05662-6086-401e-83b6-b28786016f79"/>
  </ddiem:Drug>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/298154c2-7729-4435-bee9-302ed5ffca85">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/4744026</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19415691</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25717099</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18308659</dc:provenance>
    <rdfs:comment>These inconsistent results have suggested that the response might depend on the specific gene mutations
 As the response was not sustained and serum ALP and PLP and urine PEA returned to baseline between 8 and 13 months of treatment 
In N461L mutation which led to complete disappearance of the bone isoenzyme, disease was not modified by PTH treatment.  

https://www.ncbi.nlm.nih.gov/pubmed/22218563?dopt=Abstract
https://www.ncbi.nlm.nih.gov/pubmed/20089612?dopt=Abstract (Lack of sustained response to teriparatide in a patient with adult hypophosphatasia_</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17395561</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20739387</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/241500"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9110486</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9a645a24-bd59-44fb-96dd-75f97c1caac8">
        <rdfs:label>Seizure</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0001250</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001250</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/eb5152ff-7294-4a87-a512-7b1cec024750"/>
  </obo:OGMS_0000112>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/20e803af-f797-446b-bd27-f3e84d13a4f0">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0005180</ddiem:url>
    <dc:identifier>HP:0005180</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>tricuspid regurgitation</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7530ea8f-f9fd-41cf-bbb5-0f1e70c1a7f8">
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0002135</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002135</ddiem:url>
    <rdfs:label>Progressive basal ganglia calcification</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b67b56de-6d98-4bfa-8b0f-b99e3f441cd5">
    <rdfs:label>Low Î²-gal activity (Abnormal enzyme,coenzyme activity )*</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d1d51b11-11b7-42d9-b71a-ef0a5f9c40f6">
    <dc:identifier>HP:0001386</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>swollen joint</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001386</ddiem:url>
  </ddiem:Phenotype>
  <obo:DDIEM_0000011 rdf:about="http://ddiem.phenomebrowser.net/d01b15a5-689c-41ff-b47e-07f937050b8e">
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/236800"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2a711059-e324-4698-b4d4-fb615a7533ea">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002014</ddiem:url>
        <rdfs:label>diarrhoea</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0002014</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10540864</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26516243</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/69bfe5c7-0308-4ee2-a358-13a675736394">
        <dc:identifier>HP:0011123</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>dermatitis</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0011123</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17334708</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <rdfs:comment>The results of this study suggest that octreotide may aid in the acute or long-term treatment of congenital hyperinsulinism in a limited number of selected cases.https://www.ncbi.nlm.nih.gov/pubmed/8410522/</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14169454</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24561416</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26962538</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c83e3350-47bc-464d-8791-867ad0b56f67">
        <rdfs:label>dementia</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000726</ddiem:url>
        <dc:identifier>HP:0000726</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/f8712a5b-6773-4e20-b7d8-bb42f873ffcf"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ecf217d0-14b4-42dd-9c37-ecd580c18fec">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>sensitivity to sunlight</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000992</ddiem:url>
        <dc:identifier>HP:0000992</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </obo:DDIEM_0000011>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/02f3615f-cc8f-4c0c-8b7e-30c95714ea35">
    <rdfs:label>AAV2CUhCLN2</rdfs:label>
    <obo:RO_0000056>
      <obo:direct_complementation_of_a_genetically_defective_protein_by_gene_therapy rdf:about="http://ddiem.phenomebrowser.net/b166b56a-0116-4321-a93f-b6e29bb0b478">
        <rdfs:comment>A combination therapy of Î´-tocopherol and HPBCD further improved the effect compared to that of either drug used as a single therapy.</rdfs:comment>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01907087</dc:provenance>
        <dc:provenance>https://emedicine.medscape.com/article/1178391-treatment</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28589525</dc:provenance>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/b3a9bc45-182d-4528-8449-039d11c72c40"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/204500"/>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00151216</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24938720</dc:provenance>
      </obo:direct_complementation_of_a_genetically_defective_protein_by_gene_therapy>
    </obo:RO_0000056>
  </ddiem:Drug>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/23b28ce0-8a30-437c-8bd1-9fa02752e27f">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28967191</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15342551</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10657992</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20607610</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27906067</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/09be1f8f-102e-4f79-b2c1-9a57cbd44e25">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001939</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0001939*</dc:identifier>
        <rdfs:label>High amount of Man2GlcNAc2-Asn in in nonneuronal tissues ( Metabolism abnormality)*</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/f1f7d8c9-a78b-4b6d-a968-d6a5982e6c84">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/bdbf1fa3-7b52-426f-aa22-297cd770126e"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/0eb299a1-a7b1-452c-bfee-754a7a8bb327"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/60da5c73-051b-458e-bd32-bb3095f7313a">
        <rdfs:label>High amount of aspartylglucosamine in brain tissue (( Metabolism abnormality)*)</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0001939*</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001939</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>There is a combined evidence demonstrates that a high dose ERT with AGA in newborn AGU mice is up to twofold more effective in reducing the amount of the accumulated storage material from the brain tissue than ERT in adult AGU animals, indicating the importance of early detection and treatment of the disease. https://www.ncbi.nlm.nih.gov/pubmed/20607610</rdfs:comment>
    <dc:provenance>https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6ec5ca5b-7afa-4063-9ad5-c3a81d0858e8">
        <rdfs:label>accumulating substance aspartylglucosamine from ( Metaboic abnormality)*</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0001939*</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001939</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/208400">
        <rdfs:label>ASPARTYLGLUCOSAMINURIA; AGU</rdfs:label>
        <dc:identifier>https://www.omim.org/entry/208400</dc:identifier>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/258</ddiem:iembaseUrl>
        <rdfs:comment>As by 2016 Banning et al. mentioned "Currently, no treatment for AGU is available, although several preclinical studies aiming at enzyme replacement (ERT) or gene therapy have been published. Neither of these treatment options is expected to be available within the next few years</rdfs:comment>
        <ddiem:iembaseAccessionNumber>258</ddiem:iembaseAccessionNumber>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/3f3cedb6-1df7-414c-88c3-1e0249caa279"/>
      </ddiem:Disease>
    </obo:RO_0002599>
  </obo:OGMS_0000112>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/6a52e971-e9dd-45fd-aa8d-74a2b630f0f0">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/39248d5c-a200-4ac3-8761-63d6b01d6f18"/>
    <rdfs:label>Complex Carbohydrates</rdfs:label>
  </ddiem:Drug>
  <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/0b83f6d6-8e7b-4833-a02c-d3f1dd68e459">
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/fe7e81c0-fdb4-40cb-8776-3305412724f5"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25614308</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28590052</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15131757</dc:provenance>
    <rdfs:comment>Drug name: Intranasal dDAVP, because of efficacy, long duration of action, and infrequent side effects, is the preferred treatment of neurogenic diabetes insipidus in children and adults.https://www.ncbi.nlm.nih.gov/pubmed/626447</rdfs:comment>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/212138"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30804055</dc:provenance>
    <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19452263</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26153518</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/6b36ca46-5e87-4637-b6e9-73189ff35f01"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
  </obo:DDIEM_0000007>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/46cb02cd-4e31-4b65-a7eb-1b26764cfae2">
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3950820</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01793090</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19821145</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/48f0eae9-c050-47a4-8918-9b66e9cc570d"/>
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/6fc54827-731b-4f29-af16-69f7389dcc25"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5884027</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/277400"/>
    <dc:provenance>https://link.springer.com/article/10.1023/A:1005353530303</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <rdfs:comment>Selection of this drug combinstion ""Methylprednisolone sodium succinate +
Immune Globulin "" was based on the presumption that the patient had autoimmune encephalopathy. https://www.ncbi.nlm.nih.gov/pubmed/25511120</rdfs:comment>
  </obo:DDIEM_0000013>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/203750">
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/65</ddiem:iembaseUrl>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/20d2dcb3-0c91-49f3-95da-35e1f10a041e"/>
    <dc:identifier>https://www.omim.org/entry/203750</dc:identifier>
    <rdfs:label>ALPHA-METHYLACETOACETIC ACIDURIA</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <ddiem:iembaseAccessionNumber>65</ddiem:iembaseAccessionNumber>
  </ddiem:Disease>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b280332e-7198-436f-8b73-15dbc52c8664">
    <rdfs:label>liver fibrosis progression</rdfs:label>
    <dc:identifier>HP:0001395</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001395</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/872c060a-e1b7-4d19-a52f-8abbd65edb62">
    <dc:identifier>HP:0100543</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>cognitive dysfunction</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0100543</ddiem:url>
  </ddiem:Phenotype>
  <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/bcf92d20-f9e3-4f9b-a583-2ee31adcaeb4">
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01907087</dc:provenance>
    <dc:provenance>https://emedicine.medscape.com/article/1178391-treatment</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4263309</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f5a42017-cba1-4edb-913f-d75d2dc3a56e">
        <rdfs:label>cognitive deficits</rdfs:label>
        <dc:identifier>HP:0100543</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0100543</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29631617</dc:provenance>
    <rdfs:comment>A combination therapy of Î´-tocopherol and HPBCD further improved the effect compared to that of either drug used as a single therapy.</rdfs:comment>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/204500"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28589525</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/0b724f28-e827-4297-a715-fd5a37d544e8">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/9d36cb46-ef35-4fbe-b892-9fcb1a8e78e9"/>
      </rdf:Alt>
    </obo:RO_0000057>
  </obo:DDIEM_0000007>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/ff144509-5e7b-430b-9424-11af05afc4b9">
    <rdfs:comment>If on supplemental bicarbonate or citrate, phosphorus or calcitriol or other vitamin D analog, need kidney function assessment 1 w/blood &amp; urine tests
May need serum vitamin D-25 hydroxy to assess for parent vitamin D deficiency</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5b45651d-9f28-4857-b620-ceb6c5e7099a">
        <dc:identifier>HP:0004918</dc:identifier>
        <rdfs:label>Metabolic acidosis (Hyperchloremic metabolic acidosis)</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0004918</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20301653</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/c9290508-0a2b-4206-a2f7-6788c0fa965f"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/309000"/>
    <dc:provenance>https://www.paediatricaindonesiana.org/index.php/paediatrica-indonesiana/article/view/59/33</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/4f8c5fb9-f813-4852-8017-a5f808513f9b"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17339125</dc:provenance>
  </obo:OGMS_0000112>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/1a4a6fdf-50a9-4ca6-8ced-5c9cd89a675d">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8842764</dc:provenance>
    <rdfs:comment>Niacin DB00627 occasionally can be used with Fibrate and omega 3 fatty acid in treating hypertriglyceridiemia. https://www.ncbi.nlm.nih.gov/pubmed/21079616</rdfs:comment>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02527343</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/9b7dbd5d-0f1c-4909-8303-bbed922dd481"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/e090b3f8-5890-490f-8057-33d9f8be81e4"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5338723</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20301530</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/162000"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
  </obo:OGMS_0000112>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/d0f3d490-75cb-4b0a-b18c-c8ea6fcb7b35">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9b9f44cb-8687-4f3f-ba4d-e791a7f90403">
        <rdfs:label>Defect in protein synthesis (Abnormality of circulating protein level)*</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0010876*</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0010876</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10959439</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22791294</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/63a584e2-0699-4288-9783-e312dee417a9">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012133</ddiem:url>
        <dc:identifier>HP:0012133*</dc:identifier>
        <rdfs:label>Decreased red blood cell production</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25098371</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22734070</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/84ac02b0-896b-472b-ab20-fc4303fa15f2">
        <dc:identifier>HP:0001903</dc:identifier>
        <rdfs:label>low heamoglobin leval</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001903</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17562599</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/0e39ff91-f98c-4409-a49d-915ee619ca24">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/33c18466-3423-48e5-9cdd-a226d34b2604"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:comment>There was no clinical effect, but amild reduction in the plasma level of desmosterol was observed.</rdfs:comment>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02386267</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/105650"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01362595</dc:provenance>
  </obo:OGMS_0000112>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/f564969c-7ca8-4afd-a01a-02c40ea0f659">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/93163c18-d22a-4cf1-a8d3-80fa0a7f8d31">
        <dc:identifier>HP:0002027, HP:0002017</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>"(abdominal pain, nausea, vomiting)"</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002027, HP_0002017</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1275520</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648/#b96-tacg-8-201</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/176000"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/1272f181-4d3e-4c37-962d-f5af1e907617"/>
    <rdfs:comment>Currently, the use of glucose is limited only to mild attacks (ie, mild pain, no paresis, seizures, or hyponatremia) according to the guidelines for the treatment of an acute attack in the USA and South Africa, or if heme arginate or hematin are not available locally. https://www.ncbi.nlm.nih.gov/pubmed/15643299/ https://www.ncbi.nlm.nih.gov/pubmed/15767622/
Intravenous glucose in water solutions, such as dextrose 5% or 10%, should be avoided as they may aggravate hyponatraemia. https://www.ncbi.nlm.nih.gov/pubmed/22783787</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1be88aad-e85c-428d-886d-05e9286cf27a">
        <rdfs:label>Excretion of heme precursors(Abnormality of the heme biosynthetic pathway)*</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0010472</ddiem:url>
        <dc:identifier>HP:0010472</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02180412</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4ecc699c-d036-4256-b887-c8fcc58585ad">
        <rdfs:label>Mild attack</rdfs:label>
        <dc:identifier>HP:0012825</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012825</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23605132</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24288038</dc:provenance>
  </obo:OGMS_0000112>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/87572a80-fabb-42d6-ae60-29677222be1f">
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/164c87bf-5a07-423b-a457-d4a49c757660">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/203cdf74-876f-4478-9f4a-ddc684815990"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/4359fd49-c128-4118-8b96-b9368bcb6de5"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02520934</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <rdfs:comment>The treatment was done via convection-enhanced delivery</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c141d119-f2ae-4c66-8db0-eb5183ba2aa4">
        <rdfs:label>speech impairment</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0002167</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002167</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/973004b4-666e-4736-8081-7dd0f1302286">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002069</ddiem:url>
        <rdfs:label>generalized tonic-clonic seizures</rdfs:label>
        <dc:identifier>HP:0002069</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15895716</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7814809</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18952590</dc:provenance>
    <dc:provenance>https://link.springer.com/article/10.1007%2Fs11011-018-0236-1</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/317a019d-c5bc-4cf5-81f7-f86bab9981c7">
        <rdfs:label>neuropathy</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0009830</ddiem:url>
        <dc:identifier>HP:0009830</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17433057</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/231005"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24441827</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
  </obo:OGMS_0000112>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/aa266118-fd36-47f2-ab86-e961ee16fe24">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0012217</ddiem:url>
    <dc:identifier>HP:0012217</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Accumulated  urine porphobilinogen</rdfs:label>
  </ddiem:Phenotype>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/ad3dd7b8-b21c-4099-abfc-9dd598848621">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28098593</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0021915015001379</dc:provenance>
    <rdfs:comment>In this study"https://www.ncbi.nlm.nih.gov/pubmed/10385780?dopt=Abstract" authors claimed that gemfibrozil is more effective in reducing total triglyceride and VLDL lipid levels than simvastatin, and simvastatin is better in reducing LDL cholesterol than gemfibrozil is. IDL and apolipoprotein E levels were reduced similarly with both drugs.</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/baf3b39f-20e6-4e6f-9fc8-151ac633e074">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>High VLDL triglycerides</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25768710</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10385780</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/572fa1a7-378b-43af-af3b-8be975ce6911"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/617347"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/53b3ac96-ba25-4a71-ad79-75588152173d"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
  </obo:DDIEM_0000013>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/a58cd49f-a2e2-419e-8f18-4381e016f383">
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/277460">
        <rdfs:label>VITAMIN E, FAMILIAL ISOLATED DEFICIENCY OF; VED</rdfs:label>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/a94295fc-0062-44ea-abad-71c95893feb7"/>
        <dc:identifier>https://www.omim.org/entry/277460</dc:identifier>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/658</ddiem:iembaseUrl>
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseAccessionNumber>658</ddiem:iembaseAccessionNumber>
      </ddiem:Disease>
    </obo:RO_0002599>
    <rdfs:comment>There is a common note in different reserachs refers to the importance of early managment by Vitamin E supplements since it limits disease progression and it can reverse some of the clinical manifestation (e.x ataxia and the intellectual deficit), if it was interoduced early in life. Therefore, early diagnosis is paramount.</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15300460</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0022347699704245</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27906067</dc:provenance>
    <dc:provenance>https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/a93a73a1-92cf-47f6-a606-0c9a9d3d5199">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/337febda-56f7-43af-922e-bfc888891d84"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17586848</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c6fc1978-0f62-49ee-b257-940793734318">
        <rdfs:label>High urinary LTE4 excretion (Abnormality of leukotriene metabolism)*</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0030390</ddiem:url>
        <dc:identifier>HP:0030390*</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/caf95084-0aa7-402f-8686-5e8c44763759">
        <rdfs:label>Abnormal H50 (The erythrocyte resistance to oxidative stress)</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
    <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
  </obo:OGMS_0000112>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/62919f45-f522-4bd1-938e-d05ceb788c1d">
    <rdfs:label>abnormal polymorphonuclear leukocyte function</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0001874</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001874</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/f7c463a4-e4bf-423f-b387-c3c11b9a2c4d">
    <ddiem:url>https://www.drugbank.ca/drugs/DB14992</ddiem:url>
    <rdfs:label>Pegunigalsidase alfa</rdfs:label>
    <dc:identifier>DB14992</dc:identifier>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/1429ffe7-91f2-4df9-9fe3-2493ae41b04b">
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01678898</dc:provenance>
        <rdfs:comment>Given the favorable half-life of pegunigalsidase alfa and its low level of inhibition by pre-existing neutralizing antibodies, there is potential for pegunigalsidase alfa to attenuate and/or stabilize renal function in patients who continue to lose renal function while on currently-available enzyme replacement therapy</rdfs:comment>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/7c200429-0109-4440-a775-d43f27a7e6a5"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20495831</dc:provenance>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT03180840</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/047ae803-f6e6-4970-8bc1-c71d6d8c93cb"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21289269</dc:provenance>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01981720</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01769001</dc:provenance>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01218659</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/301500"/>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/799e9cb8-ae4f-4130-b161-09585a1a47f9">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20495831</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25561459</dc:provenance>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/study/NCT02795676</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/301500"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25885911</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/047ae803-f6e6-4970-8bc1-c71d6d8c93cb"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21289269</dc:provenance>
        <dc:provenance>https://www.clinicaltrials.gov/ct2/show/NCT02697136</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/227ed6ae-0b24-4d17-a7df-24692b4c883c"/>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01218659</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
        <rdfs:comment>Drugs were used sequentially for 8 weeks, after 4 weeks washout. in the clinical trial. Atorvastatin or fenofibrate had little effect on HDL cholesterol; atorvastatin decreased the total cholesterol/HDL cholesterol ratio by 26%. Fenofibrate did not change HDL cholesterol levels and caused an increase in LDL cholesterol. Niacin was the only effective drug to increase HDL cholesterol. https://www.ncbi.nlm.nih.gov/pubmed/18993152</rdfs:comment>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/7c200429-0109-4440-a775-d43f27a7e6a5"/>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
  </ddiem:Drug>
  <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/019c1890-a005-434d-937a-ca6f4baf3a1a">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23390030</dc:provenance>
    <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e95bfb09-8ecd-45c4-b80e-72bb7816e68f"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/da184cec-d903-494e-a46f-a3dad76d2400"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/6a73c2b1-c147-41b6-a5f9-4604bcac8ae2"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ad006969-4020-495b-b825-5f95a5d87391"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/74b66f98-6381-4667-b744-1af42f1cb529"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5241937</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23494656</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3955971</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01395641</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/608643"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/ee4a9b6a-7a61-40be-9922-9241a030e98b"/>
    <dc:provenance>https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813</dc:provenance>
    <rdfs:comment>In a study done by Mastrandeleo et. al , it was mentioned that Transdermal rotigotine was efficacious in the early stages of AADC of an affected male; however, the treatment was not effective in his older, more impaired brother.</rdfs:comment>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
  </obo:DDIEM_0000007>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/83a811e7-ba27-47f4-967e-7d91423294bb">
    <rdfs:label>Methyclothiazide</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/e66babb0-fc35-4389-9324-52c85654d6f3"/>
    <dc:identifier>DB00232</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00232</ddiem:url>
  </ddiem:Drug>
  <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/22f9df78-5708-4c04-9421-429251395c83">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <rdfs:comment>An experimental study done on a mice with GMNT knocked out. suggesting considering Nicotinamide as atreatment option in patients with GNMT deficiency.  https://www.ncbi.nlm.nih.gov/pubmed/20578266/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20578266</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19019309</dc:provenance>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/606664">
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/48e154c6-3ba5-4b41-9816-f430c69c2ded"/>
        <rdfs:label>GLYCINE N-METHYLTRANSFERASE DEFICIENCY</rdfs:label>
        <ddiem:iembaseAccessionNumber>25</ddiem:iembaseAccessionNumber>
        <dc:identifier>https://www.omim.org/entry/606664</dc:identifier>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/25</ddiem:iembaseUrl>
        <rdfs:comment>Treatment recommendations could be regular monitoring and low-methionine diet if symptoms appear or if methionine is very high. https://www.ncbi.nlm.nih.gov/pubmed/27207470.                                                                                                                                                                                                                                                                                            The necessity for treatment of this asymptomatic seemingly benign disorder is presently questionable, careful follow-up being the main parameter for optimal care. https://www.ncbi.nlm.nih.gov/pubmed/27671891. No treatment needed in most cases.</rdfs:comment>
      </ddiem:Disease>
    </obo:RO_0002599>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/16251498-c67e-4e73-b139-c3eca7cb9c25">
        <dc:identifier>HP:0001395</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001395</ddiem:url>
        <rdfs:label>Liver fibrosis</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27207470</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/82d6503a-1d21-4fc9-ae62-1f66b0778ba4">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0001397</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001397</ddiem:url>
        <rdfs:label>Liver steatosis</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/09be099b-d15e-46ec-a6ca-012c4fdcf329">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001397</ddiem:url>
        <dc:identifier>HP:0001397</dc:identifier>
        <rdfs:label>Fatty liver</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19585268</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/36c1fa40-979f-4e77-9931-51df096fd815"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a80fdac1-7f14-4203-aeb1-82b6dfdef814">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>DNA hypermethylation</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </obo:DDIEM_0000007>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/9e56f56b-c10f-4f4a-bd65-ba04d3077231">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27709644</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e1d68b97-5799-48ca-b473-17bb70a15c8e">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000819</ddiem:url>
        <dc:identifier>HP:0000819</dc:identifier>
        <rdfs:label>Diabetes mellitus</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>MCT should be at least 70% of the total fat content of the diet.</rdfs:comment>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/b72d1a91-57bb-4e00-a58c-8a1fb9a0a6c5"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/530000"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25092642</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26884075</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
  </obo:OGMS_0000112>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/12450700-608b-4313-8ac8-542ef8e93ea1">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29757052</dc:provenance>
    <rdfs:comment>There was no clinical effect, but amild reduction in the plasma level of desmosterol was observed.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28883274</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24082780</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/eb5152ff-7294-4a87-a512-7b1cec024750"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/258870"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7028650</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/68d9b737-b8cd-4839-9920-055e689a3fe9">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012026</ddiem:url>
        <dc:identifier>HP:0012026</dc:identifier>
        <rdfs:label>high ornithine level</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22791294</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000012"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17565677</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29654911</dc:provenance>
  </obo:OGMS_0000112>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/8d67848c-4420-47df-a7e7-522d788db26e">
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/e2df5afc-0c82-4904-bc3b-057488b276f7">
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/606785"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19752526</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/843e0dd5-c3ca-48a1-b0b0-a1d50ad2009e"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e375431f-3965-4b53-b6a2-acbe377157fa"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26692114</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3306242</dc:provenance>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000012"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583863</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6282099</dc:provenance>
        <rdfs:comment>Coupling AAV-mediated promoterless gene targeting to SaCas9 nuclease to efficiently correct liver metabolic diseases</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16830281</dc:provenance>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/b6dee06f-1ec0-49ed-8239-8146e7fe51b9">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21289269</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/145750"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <rdfs:comment>In individuals with allergies or intolerance to allopurinol, febuxostat may be considered; however, no data on the use of this medication in UMOD-associated kidney disease are available at present.</rdfs:comment>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000012"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/62f13862-3b92-42cc-9dad-e958eef7c627"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20495831</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25993639</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22142470</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24524914</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/843e0dd5-c3ca-48a1-b0b0-a1d50ad2009e"/>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <rdfs:label>Fenofibrate</rdfs:label>
    <dc:identifier>DB01039</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/ddaeac03-5dcb-46bd-b708-bc83928632af"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01039</ddiem:url>
  </ddiem:Drug>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/ec2f62de-c72f-4603-8dd9-f1ae0a22123f">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/357fdd36-d597-4ca6-bf19-4dd4db6b63df">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>High level of very low-density lipoprotein</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003362</ddiem:url>
        <dc:identifier>HP:0003362</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5cfb12ae-a8de-4dbb-aa2e-513a9815217c">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003233</ddiem:url>
        <rdfs:label>Low HDL-cholesterol</rdfs:label>
        <dc:identifier>HP:0003233</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/27c31550-9d48-4ec0-a005-d6dc8fc89c76"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23633496</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3d8af215-4dec-4f37-b192-4a2d6afeed11">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003124</ddiem:url>
        <rdfs:label>High total cholesterol</rdfs:label>
        <dc:identifier>HP:0003124</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f9277694-636f-4bc6-ac3a-c23145d602c2"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12709436</dc:provenance>
    <obo:RO_0002558>
      <ddiem:Evidence rdf:about="http://ddiem.phenomebrowser.net/ECO:00007121">
        <dc:identifier>ECO:00007121</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/ECO_00007121</ddiem:url>
      </ddiem:Evidence>
    </obo:RO_0002558>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2653622</dc:provenance>
    <rdfs:comment>The drug was accompanied with lysin restricted diet</rdfs:comment>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/144650"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22129523</dc:provenance>
  </obo:OGMS_0000112>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/6e02a1ec-4fab-4072-9c59-43b0d895616b">
    <dc:provenance>https://link.springer.com/article/10.1007%2Fs11011-018-0236-1</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/8ef44a5f-00f5-478b-9397-572155b57824">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/60fbebfd-e179-4b97-a8ad-ba77e43a20e5"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/230900">
        <rdfs:label>GAUCHER DISEASE, TYPE II</rdfs:label>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/6b58a1f4-ac8c-4ddc-bce7-4e5f6fb332d0"/>
        <dc:identifier>https://www.omim.org/entry/230900</dc:identifier>
        <rdfs:comment>By Knocking out RIPK3, we show that modulating the receptor-interacting protein kinase-3 (Ripk3) pathway markedly improves neurological and systemic disease in a mouse model of GD. https://www.ncbi.nlm.nih.gov/pubmed/24441827
Notably, Ripk3 deficiency substantially improved the clinical course of GD mice, with increased survival and motor coordination and salutary effects on cerebral as well as hepatic injury.</rdfs:comment>
      </ddiem:Disease>
    </obo:RO_0002599>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00244582</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24441827</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/47357431-5fc7-4df3-abcf-dcfdf69fe431">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>No result is  added</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23085429</dc:provenance>
    <rdfs:comment>The treatment was done via convection-enhanced delivery</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15895716</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7814809</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18952590</dc:provenance>
  </obo:OGMS_0000112>
  <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/24676602-e5fa-43d9-8ba1-4c1908093dce">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24260777</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <ddiem:failedToContributeToCondition>G167A / F213A</ddiem:failedToContributeToCondition>
    <obo:RO_0003304>L155/ G345/ A349</obo:RO_0003304>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-Bartter.pdf</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/fc93d0f1-bf9e-4bd3-b319-5f7e38eab94a">
        <rdfs:label>Abnormal ClC-Ka function</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0003304>"L155A, G345S and A349E"</obo:RO_0003304>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20649569</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/602522"/>
    <rdfs:comment>Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss</rdfs:comment>
    <dc:provenance>http://www.neurologyindia.com/article.asp</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/3de49c14-7443-4cd0-b441-e94d679850d3">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/ba84977f-9f90-4112-8534-8ef4bbdcfda8"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2646391</dc:provenance>
  </obo:DDIEM_0000007>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/131e1564-ae29-4565-848a-78788230e643">
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0003234</dc:identifier>
    <rdfs:label>secondary carnitine deficiency (Carnitine deficiency)*</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003234</ddiem:url>
  </ddiem:Phenotype>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/f06fc014-e20c-47b7-bb6f-836b13e054d4">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16891685</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/0ab6ea8c-1776-4c82-8789-0bfe82480ecd"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1899474</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16544179</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/5d3c4042-f396-408f-a8e5-6b8655479d83"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9732974</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8163996</dc:provenance>
    <rdfs:comment>Alhough therapy with desmopressin cannot be recommended based on the results of a single case, the outcome presented here is intriguing and suggests that larger studies in such patients is warranted to assess the broader application of such an intervention.</rdfs:comment>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/610768"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23890587</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/b40ef143-f25c-4c7d-92a2-548b5e2f94d8">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/a6f1970f-d085-4bd2-a613-eb0e5592e411"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12084887</dc:provenance>
  </obo:OGMS_0000112>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/c03074f5-1fe2-4ebd-99ae-fd33a76ed96f">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
    <dc:provenance>https://www.researchgate.net/publication/8668575_A_successful_treatment_with_pyridoxal_phosphate_for_West_syndrome_in_hypophosphatasia</dc:provenance>
    <dc:provenance>NCT00744042.)."</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>"ENB-0040</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/275630"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28636073</dc:provenance>
    <dc:provenance>https://onlinelibrary.wiley.com/doi/abs/10.1111/pde.12170</dc:provenance>
    <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
    <dc:provenance>an enzyme-replacement therapy</dc:provenance>
    <dc:provenance>was associated with improved findings on skeletal radiographs and improved pulmonary and physical function in infants and young children with life-threatening hypophosphatasia. (Funded by Enobia Pharma and Shriners Hospitals for Children; ClinicalTrials.gov number</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/474f6478-2870-4afc-97f0-32a8fa5d90bb">
        <rdfs:label>scaling</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0040189</ddiem:url>
        <dc:identifier>HP:0040189</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>Drug name: Treatment is under trial.</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5fa1a9a3-005e-4582-a174-845310c0aa55">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0010783</ddiem:url>
        <rdfs:label>erythema</rdfs:label>
        <dc:identifier>HP:0010783</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9b96bd0a-a2d5-437b-9970-24d9815345ae">
        <rdfs:label>Ichthyosis</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0008064</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0008064</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0d9b919c-8703-4f4d-a948-adc1ba4175e3">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000989</ddiem:url>
        <rdfs:label>Pruritis</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0000989</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/b86cdfcc-609e-44c1-b7c5-483868c7ef9a">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/025c1012-5b89-4794-911f-22655ff93abe"/>
      </rdf:Alt>
    </obo:RO_0000057>
  </obo:DDIEM_0000013>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/aef5487f-25d9-4e3e-8518-e8e67a677226">
    <rdfs:label>Increased total cholesterol</rdfs:label>
    <dc:identifier>HP:0003124</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003124</ddiem:url>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/55bc9bd2-8784-4f12-9cbd-be0f558e1c6a">
    <dc:identifier>DB09210</dc:identifier>
    <rdfs:label>Piracetam</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB09210</ddiem:url>
    <obo:RO_0000056>
      <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/6ce09f33-6c9b-4fbd-bb49-182d34c540d5">
        <rdfs:comment>Clonazepam is a useful adjunct for myoclonus and can be used in combination with lamotrigine to avoid lamotrigineâs myoclonic effects . 
Zonisamide should remain a second-line adjunct in the treatment of JME, owing to the lack of supportive data.
https://link.springer.com/article/10.1007/s11940-011-0131-z</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28717435</dc:provenance>
        <obo:RO_0003304>m.8344A &gt; G</obo:RO_0003304>
        <dc:provenance>https://link.springer.com/article/10.1007/s11940-011-0131-z</dc:provenance>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/books/NBK1520</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1059131117301243</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/06f2a5b6-c0b3-422b-82b6-50857ca84b57"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d9d625a0-bd18-495d-bf6b-c1f6b7cc9fe1"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/545000"/>
      </obo:DDIEM_0000007>
    </obo:RO_0000056>
  </ddiem:Drug>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/cfadd4f8-81ec-44d7-bce4-564183cdd002">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10189233</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/0d9b919c-8703-4f4d-a948-adc1ba4175e3"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/906d8942-638a-4bb9-a064-919d5c0cf0df">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Hepatotoxicity</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/85e1aa3b-e715-423e-a2d7-0911f59ec316">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/9f882a81-b6f9-4e86-9754-9dcc8291fa82"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22092997</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/15f36f12-cd8f-4caa-839e-6552fd6fc7c4">
        <dc:identifier>HP:0002910</dc:identifier>
        <rdfs:label>Abnormal liver function test</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002910</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/fe663d82-1b4d-4bfc-b3d7-dd1c34f8081c">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0000969</dc:identifier>
        <rdfs:label>Fluid retention</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000969</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20375647</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ea64b30c-6eef-48d1-a95d-3b07c1d2772c">
        <rdfs:label>Abdominal pain</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0002027</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002027</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19656325</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7758200</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3335288</dc:provenance>
    <rdfs:comment>Some references are aganist activated charcoal as treatment for Erthropoietic Protoporphyria. https://www.ncbi.nlm.nih.gov/pubmed/8127352?dopt=Abstract</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23884489</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/177000"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26979527</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8a567073-5e58-4a90-8c78-55d52877793b">
        <rdfs:label>Photosenstivity</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000992</ddiem:url>
        <dc:identifier>HP:0000992</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
  </obo:DDIEM_0000013>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/a0a73ff8-68e7-4e98-9adb-1ec7dd6ffa7b">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28318733</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/530000"/>
    <rdfs:comment>MCT should be at least 70% of the total fat content of the diet.</rdfs:comment>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d99eaa74-e215-4f5f-9546-28e4cc5570be"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27718492</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/c3951163-c8e6-466e-8940-5830b567e782"/>
  </obo:OGMS_0000112>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/5ce7f4a3-fc46-48d8-8e23-8665010c19d3">
    <obo:RO_0000056>
      <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/ecd847d9-4bb5-42c0-8920-90e8fc777ac7">
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28285122</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/35b5c64e-9aaa-46fd-84a3-e5d483d4e101"/>
        <rdfs:comment>These inconsistent results have suggested that the response might depend on the specific gene mutations
 As the response was not sustained and serum ALP and PLP and urine PEA returned to baseline between 8 and 13 months of treatment 
In N461L mutation which led to complete disappearance of the bone isoenzyme, disease was not modified by PTH treatment.  

https://www.ncbi.nlm.nih.gov/pubmed/22218563?dopt=Abstract
https://www.ncbi.nlm.nih.gov/pubmed/20089612?dopt=Abstract (Lack of sustained response to teriparatide in a patient with adult hypophosphatasia_</rdfs:comment>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/0fb835fb-b796-4f5c-bcbd-5e24b59fe9a7"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/239500"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24173411</dc:provenance>
      </obo:DDIEM_0000013>
    </obo:RO_0000056>
    <dc:identifier>DB02209</dc:identifier>
    <rdfs:label>Pyridoxine phosphate</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB02209</ddiem:url>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/0a65c7bf-ba73-4e38-8f89-10ddf07e5b40">
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/04ab13ad-6093-4704-9085-534a523dc8eb">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15208740</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6358544</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/176000"/>
        <rdfs:comment>The rh-HMBS-enzyme replacement therapy, however, had no effect on the patientsâ symptoms during acute attacks mainly due to constantly high plasma ALA levels. The potential development of rh-HMBS-enzyme replacement therapy should be focused on the delivery of an active enzyme into the liver ,the main site of ALA overproduction, restoring the normal HMBS activity and heme biosynthesis. https://www.ncbi.nlm.nih.gov/pubmed/17375984/</rdfs:comment>
        <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/5e6f6120-18c5-49ed-ad8f-043d0c0bafba"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648/#b96-tacg-8-201</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15767622</dc:provenance>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02180412</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/938ab7e3-7316-43dc-97e5-cc71d53c6feb"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <rdfs:label>rhPBGD</rdfs:label>
  </ddiem:Drug>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/84a78c3d-4157-4355-852c-db0ffd5d2a66">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20301643</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17192294</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10549306</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/35b5c64e-9aaa-46fd-84a3-e5d483d4e101"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23887143</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/92af90b3-792a-4779-90d5-b71bb9153912"/>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/604369">
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/1369</ddiem:iembaseUrl>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/2d4466f8-3528-411e-b533-eae24cc820a6"/>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>https://www.omim.org/entry/604369</dc:identifier>
        <rdfs:label>SALLA DISEASE; SD</rdfs:label>
        <ddiem:iembaseAccessionNumber>1369</ddiem:iembaseAccessionNumber>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00125190</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12794688</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19627167</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <rdfs:comment>In the clinical trial: The trial is not enrolling by invitation, no results have been posted yet. update by Oct.7th 2019
Authors have stated that "The data indicate that the retromer and sphingolipid metabolism play a critical role in PLA2G6-associated diseases. These observations may be relevant to Parkinson disease (PD) given that loss of vps35 or gain of Î±-Syn also affects retromer function and causes ceramide accumulation." https://www.ncbi.nlm.nih.gov/pubmed/29909971</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24639006</dc:provenance>
  </obo:DDIEM_0000013>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/d8cc9f2c-6151-4112-a6b7-bc7a15cc5cb3">
    <rdfs:comment>One of the studies that was carried on mice provides useful information for developing the optimal dosage regimen for HPBCD therapy when administered intravenously to NPC patients.https://www.ncbi.nlm.nih.gov/pubmed/26027824</rdfs:comment>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/50a8422f-ef16-4deb-bbca-e6f452304164">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/d833f998-6293-4be6-b311-7d772f121821"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28803710</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/aa572610-4c4f-4972-941d-94a1cad6fa20">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/aae70f10-b4b9-4f59-9742-21ed07e2b569"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11787939</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19750228</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/dab69f8f-ccd3-47dd-9287-5a82e5e16c3e">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0000972</dc:identifier>
        <rdfs:label>Palmoplantar hyperkeratosis</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000972</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/245010"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19415691</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25717099</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2897870</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02534844</dc:provenance>
  </obo:DDIEM_0000013>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f08a585f-1c07-4ddc-aba4-55c1f7471273">
    <rdfs:label>High plasma level of very-long-chain fatty acids</rdfs:label>
    <dc:identifier>HP:0003455</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003455</ddiem:url>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/5fca1ada-bb06-4b29-a3ad-7ab80da61769">
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01212744</dc:provenance>
    <dc:provenance>https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/0b9dc28e-020e-436c-87ac-df22a56d12b2">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/c63644d0-ba07-4a20-9b80-48b6e7672c86"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
    <rdfs:comment>There is no clinical role for NaPBA at present; however, ongoing studies are assessing its efficacy https://www.ncbi.nlm.nih.gov/pubmed/28919799 Phenotypes corrected were based on invivo trial on mice not humans.</rdfs:comment>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1525001605000845</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1c0b2d85-87bb-4cee-a4e8-be440e52bd37">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0004923</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0004923</dc:identifier>
        <rdfs:label>Abnormal blood Phenylalanine levels</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/261600">
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/1</ddiem:iembaseUrl>
        <dc:identifier>https://www.omim.org/entry/261600</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/2f98de2b-f73b-4124-a601-61feaf959faa"/>
        <rdfs:comment>Dietary treatment has proved to be very effective in preventing the devastating consequences of PAH deficiency when started early in lifeDrug name: Tetrahydrobiopterin stimulates phenylalanine hydroxylase activity in about 20% of patients, and in those patients serves as a useful adjunct to the phenylalanine-restricted diet because it increases phenylalanine tolerance and allows some dietary freedom.. A striking normalisation (within 8 h) in phenylalanine concentrations after drug administartion indicates BH4 deficiency whereas very little or no reduction in phenylalanine indicates BH4-non-responsive phenylketonuria. https://www.sciencedirect.com/science/article/pii/S0140673610609610?via%3Dihub</rdfs:comment>
        <rdfs:label>PHENYLKETONURIA; PKU</rdfs:label>
        <ddiem:iembaseAccessionNumber>1</ddiem:iembaseAccessionNumber>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719218300210</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
  </obo:DDIEM_0000007>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/703325b0-e30a-4217-8c51-859c54d64d18">
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01212744</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a6bad8c1-50e3-4da9-97a9-89872d08b306">
        <rdfs:label>Increased lateral ventricular lactate level</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
    <dc:provenance>http://ichgcp.net/clinical-trials-registry/NCT03432871</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/540000"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26095523</dc:provenance>
    <dc:provenance>https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6aaa6529-f253-4775-9ccb-3c606450b0fd">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>High serum GDF15 level</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30738201</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/eed299ff-ef27-4499-9310-422a01a76278"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e0d04841-3a30-48a3-827f-cbe4ec436ada">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>High lactate ,pyruvate ratio</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
    <rdfs:comment>The drug was administered through intravitreal injection.</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3e75e7d3-5d65-419c-872f-c10284859178">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002151</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Elevated serum lactate level</rdfs:label>
        <dc:identifier>HP:0002151</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </obo:DDIEM_0000013>
  <obo:DDIEM_0000015 rdf:about="http://ddiem.phenomebrowser.net/7cbd8e92-8adc-49c9-a4cd-696ee64413ee">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26766614</dc:provenance>
    <rdfs:comment>The mechanisms of its effects in movement disorders are not well understood but probably reflect an increase in synthesis and release of dopamine, with perhaps some inhibition of dopamine uptake.</rdfs:comment>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/e8cae7a0-41da-45c1-9244-84b1af478b35"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5d157d70-8bcc-47e0-b5a3-e1d44893a384">
        <dc:identifier>HP:0003107*</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Elevated intraneuronal cholesterol (Abnormality of cholesterol metabolism)*</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003107</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.intechopen.com/books/cyclodextrin-a-versatile-ingredient/use-of-2-hydroxypropyl-beta-cyclodextrin-for-niemann-pick-type-c-disease</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/607625"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.tandfonline.com/doi/full/10.3109/0886022X.2014.900422</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4829f67c-b32b-4786-aa18-ed79deb1ec13">
        <dc:identifier>HP:0003119*</dc:identifier>
        <rdfs:label>Increased free sphingosine accumulation(Abnormality of lipid metabolism)*</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003119</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e61017fe-c929-4827-a269-14a945e9dfa6">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>High intraneuronal GSL storage</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </obo:DDIEM_0000015>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d2e8f06e-ec85-40db-a71d-44d4fe0b369f">
    <rdfs:label>Aggressive periodontitis(Sever periodontitis)</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0000166</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000166</ddiem:url>
  </ddiem:Phenotype>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/d18ac453-207e-469d-8993-6d9650904796">
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/145750">
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/3e4e3978-435d-44fe-ad62-68b7c8c6790b"/>
        <dc:identifier>https://www.omim.org/entry/145750</dc:identifier>
        <rdfs:label>HYPERTRIGLYCERIDEMIA, FAMILIAL</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15251700</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21289269</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22142470</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20495831</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25993639</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/62f13862-3b92-42cc-9dad-e958eef7c627"/>
    <rdfs:comment>In individuals with allergies or intolerance to allopurinol, febuxostat may be considered; however, no data on the use of this medication in UMOD-associated kidney disease are available at present.</rdfs:comment>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/88046746-7e79-4066-99d3-eb94278a8dc8"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
  </obo:OGMS_0000112>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/8797b3f3-24e7-4963-9370-dd14e661cbcf">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21503667</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/230800"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/64482499-b03b-44a4-8ed9-0c916e569b8d"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3b8746dd-251f-4904-ae4d-e4c9674d135a">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0001744</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001744</ddiem:url>
        <rdfs:label>Splenomegly</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/585fba8b-3b07-4be4-a3be-5c7a78786a57">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Anemia</rdfs:label>
        <dc:identifier>HP:0001903</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001903</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00391625</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15895716</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000012"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02574286</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15505381</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11227045</dc:provenance>
    <rdfs:comment>The drug was used in a pilot study.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23085429</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12064906</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25801797</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/eb32fe0a-3e9c-450d-8e27-443b1cf6cb0c">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/c8036f60-2aff-47df-83f5-a6575c761301"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01463215</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16199246</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28381550</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/58250b72-3547-4fc5-9ce4-6143de5e8f5d"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8d337db4-9036-4b5a-a6a4-7040b1aa4c9e">
        <rdfs:label>High chitotriosidase level</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16285070</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6ea02c60-6f7a-43f9-a120-34aff7087995">
        <rdfs:label>Thrombocytpenia</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0001873</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001873</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8aed56d4-0e79-40e8-942d-9328e522c114">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0002240</dc:identifier>
        <rdfs:label>hepatomegly</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002240</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </obo:OGMS_0000112>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/0c776f5d-bb37-426d-96a9-2cfc234d16f4">
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/26836c73-9c3c-4ba7-8b71-75424a2c5c92">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/068a5a16-3193-49f1-8f7a-0fa9fdb7a5ee"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:comment>Effect of those two drugs was short-term response. Disease Name: There are many drugs with known detrimental effect on mitochondrial function. These include antibiotics like tetracycline and chloramphenicol; antiepileptics like valproate, phenytoin, antiretroviral agents and metformin. Overall their effects in patients with MIDD are not known. Statin therapy should be avoided in patients especially with myopathy. HMG Co-A reductase inhibitors can reduce both cholesterol and Co-enzyme Q via mevalonate pathway. These patients may have higher rate of lactic acidosis and intolerance to statins resulting in myalgia and may worsen the symptoms of existing myopathy. https://www.sciencedirect.com/science/article/pii/S1056872714000610?via%3Dihub#bb0115</rdfs:comment>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/520000"/>
    <dc:provenance>https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28766015</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01212744</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1131f45c-8979-41ec-bf26-fb803112b45e">
        <dc:identifier>HP:0010832*</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0010832</ddiem:url>
        <rdfs:label>Neuropathic pain(Abnormality of pain sensation)*</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24746802</dc:provenance>
  </obo:DDIEM_0000013>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/94d482af-3bba-4b51-9c93-8745358cd8a1">
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19019309</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17397529</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/266130"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/5634a50b-fb00-426a-b60d-3c73c68634d7"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27207470</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8301428</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f328a9f6-49d0-4637-9a72-57ec8c3c1e65">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>oxidative stress</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0025464</ddiem:url>
        <dc:identifier>HP:0025464</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>An experimental study done on a mice with GMNT knocked out. suggesting considering Nicotinamide as atreatment option in patients with GNMT deficiency.  https://www.ncbi.nlm.nih.gov/pubmed/20578266/</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
  </obo:OGMS_0000112>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8d176e2b-da50-45f9-ba69-2a7194967007">
    <dc:identifier>HP:0011018</dc:identifier>
    <rdfs:label>extended G1 interval</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0011018</ddiem:url>
  </ddiem:Phenotype>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/b98f2dbc-5c19-472a-9075-db4857f0afd6">
    <dc:provenance>https://link.springer.com/article/10.1023/A:1005353530303</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28210839</dc:provenance>
    <rdfs:comment>Selection of this drug combinstion ""Methylprednisolone sodium succinate +
Immune Globulin "" was based on the presumption that the patient had autoimmune encephalopathy. https://www.ncbi.nlm.nih.gov/pubmed/25511120</rdfs:comment>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/250940"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3950820</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/16ccf1e2-b510-47fb-939b-7c8be34c450b"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/585fba8b-3b07-4be4-a3be-5c7a78786a57"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01793090</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/c1234c40-29ff-4bef-acf5-458f9098fc69"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/bbf39077-cad5-403a-8ff4-fc532b31ddf7"/>
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9a22be94-7b60-457c-90d5-862e999240c2">
        <dc:identifier>HP:0012594</dc:identifier>
        <rdfs:label>Microalbuminura</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012594</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19821145</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/68ae4b6d-ec64-42e4-a2d2-847a9c0bed32">
        <rdfs:label>Thrombotic microangiopathy</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </obo:OGMS_0000112>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/6593ee5e-80cb-4fa7-bc52-a6f9467a3fbf">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3073162</dc:provenance>
    <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
    <dc:provenance>https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23494656</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000012"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5241937</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/608643"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ab059969-ff51-4629-9190-443b1616eb8f">
        <rdfs:label>boost residual AADC activity with a cofactor excess</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>Alternative pathway therapy has limited effectiveness in preventing hyperammonemia and must be combined with effective dietary management. https://www.ncbi.nlm.nih.gov/pubmed/11148549</rdfs:comment>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01395641</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3955971</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/eb5152ff-7294-4a87-a512-7b1cec024750"/>
  </obo:OGMS_0000112>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/f1771b30-6187-4248-b24b-b63626f1afbc">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ae228e3c-023f-410d-8f0f-3f7da2bc934d">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Muscular hypotonia</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001252</ddiem:url>
        <dc:identifier>HP:0001252</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22729819</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/3a796c4b-2a50-46f4-919d-43fc56c0c413"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/98a69309-00f5-4c38-8570-cacb7e2c44b1"/>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/264070">
        <rdfs:comment>Protein and phenylalanine restriction should be maintained in order to avoid disease progression.</rdfs:comment>
        <dc:identifier>https://www.omim.org/entry/264070</dc:identifier>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/6</ddiem:iembaseUrl>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/f056ecde-5f49-4310-9b2e-e2f5a1c2c9be"/>
        <rdfs:label>HYPERPHENYLALANINEMIA, BH4-DEFICIENT, D; HPABH4D</rdfs:label>
        <ddiem:iembaseAccessionNumber>6</ddiem:iembaseAccessionNumber>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9585615</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24204001</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/c576bad9-b514-49c9-a2f8-c639d5e8fd3f"/>
    <rdfs:comment>Î±-Tocopherol should be given with the ascorbic acid(vit. C) as the latter helps The resultant tocopheroxil radical regeneration in getting back to reduced tocopherol .</rdfs:comment>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/c4633604-cb41-4d90-84d5-44841bde9fef"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9760199</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3dbf1aef-d465-4241-b744-0702e64df2a0">
        <rdfs:label>High urinary levels of primapterin (7-biopterin)</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
  </obo:OGMS_0000112>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9bf54cf6-724e-4c73-8949-7b1bea28a0ae">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003678</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0003678*</dc:identifier>
    <rdfs:label>Kidney disease progression ( Progressive disorder)*</rdfs:label>
  </ddiem:Phenotype>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/d4ada489-7dc6-415e-a7fa-30194e8af9ce">
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/095762a4-b9bf-47c0-918d-9f5ce2a2f67e"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/118600"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d1d51b11-11b7-42d9-b71a-ef0a5f9c40f6"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4223155</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29675606</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6169684</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22832289</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/cc200f02-4580-4632-975c-27b28dd48d0a">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/5650ffd5-d485-42a0-bd0e-cbece89b01e8"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25315665</dc:provenance>
    <rdfs:comment>There is a contraversy about effectivness of methotrexate in treating "Condrocalcinosis 2" .. Details are in https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4223155/ and https://www.ncbi.nlm.nih.gov/pubmed/22832286/</rdfs:comment>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4379613</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21102543</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
  </obo:DDIEM_0000013>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/927c92a7-893e-4036-a001-75293ca412bb">
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/268200">
        <dc:identifier>https://www.omim.org/entry/268200</dc:identifier>
        <ddiem:iembaseAccessionNumber>750</ddiem:iembaseAccessionNumber>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/4ffc0403-f326-4bf9-818a-85cfeecb79f9"/>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/750</ddiem:iembaseUrl>
        <rdfs:label>MYOGLOBINURIA, ACUTE RECURRENT, AUTOSOMAL RECESSIVE</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1886403</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5530714b-7ff2-427d-9abb-199835a5d0ca">
        <rdfs:label>Increased muscle lipid droplets</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0012240</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012240</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/0498e405-6b18-4f5b-8ead-39d2aa6b46f4"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220407</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <rdfs:comment>The mainstays of treatment are moderate protein (leucine) restriction and avoidance of prolonged fasting and of excessive dietary fat intake, both of which increase fatty acid oxidation; these measures are generally effective in preventing acute decompensations.https://www.ncbi.nlm.nih.gov/pubmed/3128690</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26997609</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30420558</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/80de3df6-5b08-4e5d-9390-d588abc05dae">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>ER (endoplasmic reticulum) stress</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/2b5c1ff4-b31b-4a97-a59a-90e2f0c132a4">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/8df72417-da07-4b70-bf14-ec23750e72b4"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ac66b840-eeb4-44fd-b593-8f8bb668da8d">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0003198</dc:identifier>
        <rdfs:label>Myopathy</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003198</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2443756</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/61fe6c6e-360e-4c1e-820d-475d59fe0337">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003713</ddiem:url>
        <dc:identifier>HP:0003713</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>fiber necrosis</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </obo:OGMS_0000112>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/3e366340-3aa0-46da-8123-2f5c9717c356">
    <dc:provenance>http://www.neurologyindia.com/article.asp</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
    <dc:provenance>Abstract</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24260777</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d1b65947-08fe-478f-80a6-a81b79b82bd1"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <rdfs:comment>Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss</rdfs:comment>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/1272f181-4d3e-4c37-962d-f5af1e907617"/>
    <dc:provenance>https://onlinelibrary.wiley.com/doi/pdf/10.1111/j.1552-6569.2012.00772.x</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/203750"/>
  </obo:OGMS_0000112>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/fa4b02ca-8fcd-4715-8109-5541b8167dbf">
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/872c060a-e1b7-4d19-a52f-8abbd65edb62"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0fd25bbc-4cfd-49cf-a36f-b973c377fb2f">
        <dc:identifier>HP:0000707</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000707</ddiem:url>
        <rdfs:label>neurological disease</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/204500"/>
    <dc:provenance>https://emedicine.medscape.com/article/1178391-treatment</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/69d95f70-717c-4df4-92b1-fec2e712374b">
        <dc:identifier>HP:0000707</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>neurologic deficits</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000707</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/d313d7b8-4375-4cab-9e53-5d50832fa2a3">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/1197949f-ed27-4438-bd4f-2626e7b3f8db"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28589525</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29688815</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24938720</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
    <rdfs:comment>A combination therapy of Î´-tocopherol and HPBCD further improved the effect compared to that of either drug used as a single therapy.</rdfs:comment>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d516cb33-b62e-4211-803b-1df600eb7047"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/08a7ebab-3cd1-4cb0-82c4-4f78495aba49">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002540</ddiem:url>
        <dc:identifier>HP:0002540</dc:identifier>
        <rdfs:label>loss of ambulation</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4263309</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01907087</dc:provenance>
  </obo:OGMS_0000112>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0d590fb5-4997-45f8-bf70-93f923e2063f">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0012040</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Corneal Oedema</rdfs:label>
    <dc:identifier>HP:0012040</dc:identifier>
  </ddiem:Phenotype>
  <obo:DDIEM_0000010 rdf:about="http://ddiem.phenomebrowser.net/552f4b3f-f4d6-4d25-b402-5ea5ce0cfe28">
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/397a09b3-2d92-4bfa-8ddf-6f103f0e2656"/>
    <rdfs:comment>Treatment was stopped three days later because of lack of improvement and severe respiratory alkalosis with lactic acidosis (serum lactic acid 70 mg/dl, normal 4â20 mg/dl). https://www.ncbi.nlm.nih.gov/pubmed/12948744</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583863</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC324959</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2564511</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/306000"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/f2d98618-243b-41cc-80f7-7491547e5cce">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/bda33a97-8ee2-47ee-a072-c0849fe7f38b"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3306242</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15726662</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25266922</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
  </obo:DDIEM_0000010>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/f777a5a7-2350-4379-bc34-845e14b670fa">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17586848</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/208900"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3970bf46-b290-4d26-8fbc-ebdef451b6de">
        <rdfs:label>Neuronal death</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002529</ddiem:url>
        <dc:identifier>HP:0002529</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
    <rdfs:comment>There is a common note in different reserachs refers to the importance of early managment by Vitamin E supplements since it limits disease progression and it can reverse some of the clinical manifestation (e.x ataxia and the intellectual deficit), if it was interoduced early in life. Therefore, early diagnosis is paramount.</rdfs:comment>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/a298fcb2-6e04-4335-bdff-d0b444f22cf1"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/48f0eae9-c050-47a4-8918-9b66e9cc570d"/>
    <dc:provenance>https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27906067</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15300460</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
  </obo:DDIEM_0000013>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/250950">
    <dc:identifier>https://www.omim.org/entry/250950</dc:identifier>
    <ddiem:iembaseAccessionNumber>58</ddiem:iembaseAccessionNumber>
    <rdfs:label>3-METHYLGLUTACONIC ACIDURIA, TYPE I; MGCA1</rdfs:label>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/58</ddiem:iembaseUrl>
    <rdfs:comment></rdfs:comment>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/d0ff2775-0e08-4172-b132-b588a2b3a28a"/>
  </ddiem:Disease>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/f1cb2ea6-408a-4ea5-9590-f4d46f2ae098">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27207470</dc:provenance>
    <rdfs:comment>An experimental study done on a mice with GMNT knocked out. suggesting considering Nicotinamide as atreatment option in patients with GNMT deficiency.  https://www.ncbi.nlm.nih.gov/pubmed/20578266/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19019309</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17397529</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/2a0058a0-36d4-4702-933b-34629a68d9d7"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f328a9f6-49d0-4637-9a72-57ec8c3c1e65"/>
    <dc:provenance>http://www.ncbi.nlm.nih.gov/pubmed/26984560</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/266130"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
  </obo:DDIEM_0000013>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/9fc7f902-2a88-42ce-b4dd-e0597a191642">
    <obo:RO_0000056>
      <obo:DDIEM_0000015 rdf:about="http://ddiem.phenomebrowser.net/96dd3f5d-9a7f-4296-b62f-f1ee7e3f5950">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15895716</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/613163"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/6d8d1fbb-ae08-4c88-9451-d15672f5fcd2"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/5361854f-7f31-45a0-9196-7a2a5e838318"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29480352</dc:provenance>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/5707897</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e316f32c-fb26-4111-ab29-5738cff667f1"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/4391b4d9-a461-4cf9-b43a-5b23e0a6ea20"/>
        <rdfs:comment>The treatment was done via convection-enhanced delivery</rdfs:comment>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/7fd9216d-b011-474d-84fd-f2f90de09ab0"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7814809</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>http://www.ncbi.nlm.nih.gov/pubmed/28411234</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19428278</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29358012</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b3165e18-388a-433f-942e-4c688e0064fe"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/03f63372-9391-42de-8619-379483fe24e7"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/259c3c7a-bfb5-46a6-9550-cebb62ced455"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
      </obo:DDIEM_0000015>
    </obo:RO_0000056>
    <dc:identifier>DB01205</dc:identifier>
    <rdfs:label>Flumazenil</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01205</ddiem:url>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/637d9771-4d1a-4965-8581-d339b0b8b2ba">
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/551e794e-f55b-42b0-b827-73b14bbda09f">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30373890</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17192294</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10549306</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19627167</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/35b5c64e-9aaa-46fd-84a3-e5d483d4e101"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23887143</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/48f0eae9-c050-47a4-8918-9b66e9cc570d"/>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00125190</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/271245"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/12f5dbc6-5253-4e3d-a6f7-d406147f769b"/>
        <rdfs:comment>Glutathione depletion indicates decreased potential for antioxidant capacity in IOSCA. Additionally, we analysed a blood sample of an IOSCA child patient who showed high creatine/creatinine ratio and low taurine and kynurenate. The significant depletion of kynurenate and the significant depletion of niacinamide are both consistent with depletion of NAD+thus both Clutathione and Nicotinamide riboside are considered as potential drugs for treatment of IOSCA.https://www.ncbi.nlm.nih.gov/pubmed/30373891</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24639006</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19304794</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007764"/>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00143</ddiem:url>
    <dc:identifier>DB00143</dc:identifier>
    <rdfs:label>Glutathione</rdfs:label>
  </ddiem:Drug>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/1c7c7814-6dbc-4553-8006-1ee75cc31a4c">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7f189e5b-6a49-4607-9151-babee9feec0c">
        <dc:identifier>HP:0003713</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Muscle necrosis</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003713</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/253800">
        <dc:identifier>https://www.omim.org/entry/253800</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/0c3b7789-2618-4531-9ff4-f72ad4a608d1"/>
        <ddiem:iembaseAccessionNumber>642</ddiem:iembaseAccessionNumber>
        <rdfs:label>MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH BRAIN AND EYE ANOMALIES), TYPE A, 4; MDDGA4</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/642</ddiem:iembaseUrl>
      </ddiem:Disease>
    </obo:RO_0002599>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21726969</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5226641f-b70c-461b-9edd-a079e45ffb79">
        <rdfs:label>Muscle inflammation</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0100614</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0100614</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>Phenobarbital, clonazepam, valproate, and midazolam could not completely control seizures. https://www.ncbi.nlm.nih.gov/pubmed/20052547/</rdfs:comment>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/202b2073-9e0f-4323-b4bc-9fcf095b645b"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27421908</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/49152949-b69a-489e-be08-286538ca7b8c">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/6a0265c0-e375-4ad6-9d5f-9ad89aef19f5"/>
      </rdf:Alt>
    </obo:RO_0000057>
  </obo:OGMS_0000112>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/237300">
    <dc:identifier>https://www.omim.org/entry/237300</dc:identifier>
    <ddiem:iembaseAccessionNumber>11</ddiem:iembaseAccessionNumber>
    <rdfs:label>CARBAMOYL PHOSPHATE SYNTHETASE I DEFICIENCY, HYPERAMMONEMIA DUE TO</rdfs:label>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/3f093a92-a356-4d97-96da-c328be153824"/>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/11</ddiem:iembaseUrl>
    <rdfs:comment></rdfs:comment>
  </ddiem:Disease>
  <obo:DDIEM_0000015 rdf:about="http://ddiem.phenomebrowser.net/35be1cbf-9813-4fd3-b019-e2aec432dbb6">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/177000"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26979527</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22092997</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/bd5d7622-c416-47db-8610-98d5fa14affb">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Study was Terminated (Interim analysis demonstrated the treatment was not effective)</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/0bb630a6-1838-46b4-bd41-455818820a32">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/1308e75b-8c6c-40f0-bdea-ff8d8cfe0405"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31395332</dc:provenance>
    <rdfs:comment>The drug resulted in significant reduction of  both plasma PPIX and hepatic PPIX in a murine animal model but no effect in humans during clinical trial. thus, These results demonstrate that while INH can lower PPIX in an animal model of EPP, the standard dose used to treat TB is insufficient to affect levels in humans. https://www.ncbi.nlm.nih.gov/pubmed/31395332</rdfs:comment>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00004940</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23884489</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01550705</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
  </obo:DDIEM_0000015>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/a91afdeb-e22e-486b-b02d-d44de165d1a4">
    <rdfs:label>Alpha-Aminoisobutyric Acid</rdfs:label>
    <obo:RO_0000056>
      <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/25b99742-1d7d-4c51-a08d-554bba1440a4">
        <rdfs:comment>There was no clinical effect, but amild reduction in the plasma level of desmosterol was observed.</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28883274</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/660ec100-9b6b-4342-a494-1fd3fcf99457"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/258870"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/ce191990-c6b3-4fe3-92b8-bdae0025b829"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1755734</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7356686</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7254778</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22791294</dc:provenance>
      </obo:DDIEM_0000013>
    </obo:RO_0000056>
    <dc:identifier>DB02952</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB02952</ddiem:url>
  </ddiem:Drug>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/069994f7-dfc3-4ec4-8386-8d864f386472">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f7815e75-1e0d-407e-8eb3-9a9cb0a26ecd">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001892</ddiem:url>
        <rdfs:label>Bleeding tendency</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0001892</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21102543</dc:provenance>
    <rdfs:comment>"Oral tocofersolan was more bio available than the water-soluble formulation in children with chronic cholestasis and similarly bio available in CF. This suggests that water-soluble vitamin E may represent an alternative to painful intramuscular vitamin E injections in chronic cholestasis, or other oral formulations in CF. However, the mechanism responsible for fat malabsorption in CRD concerns the absorptive phase as opposed to the digestive phase in CF and cholestatic syndromes. To our knowledge, no specific studies with these new vitamin E preparations have been conducted in CRD." https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22832289</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6169684</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/246700"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23329770</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/64c2d03b-1002-44aa-8bcb-6162d508dd34">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/b6fdd131-13af-4866-ab68-56bc4992c9be"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4223155</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1620a676-69ea-466a-a55f-4c7cf634eb3e">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Vitamin K insufficiency</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
  </obo:DDIEM_0000013>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b3165e18-388a-433f-942e-4c688e0064fe">
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0100786</dc:identifier>
    <rdfs:label>hypersomnolence</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0100786</ddiem:url>
  </ddiem:Phenotype>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/5b003d50-8f7e-4a77-8197-2f398d8abe93">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:comment>The drug was accompained by mild protein restriction (1.5â2.0 g/kg/day)</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22840416</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22132097</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0303846712003952</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/6b36ca46-5e87-4637-b6e9-73189ff35f01"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e3294401-3943-4027-b383-ae73eed707db">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0011804</ddiem:url>
        <dc:identifier>HP:0011804</dc:identifier>
        <rdfs:label>Abnormal muscle physiology</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/300438"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11102558</dc:provenance>
  </obo:OGMS_0000112>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/e31b9160-7c05-437e-b3f4-a02ffa53907d">
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00461799</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a6534dbd-7c6e-40b9-aea2-344c4854e2d7">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002570</ddiem:url>
        <rdfs:label>increased fecal fat excretion</rdfs:label>
        <dc:identifier>HP:0002570</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4841061</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583863</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/be7761b2-3447-48dc-bf4e-6a2bc71a33e4">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0008282</ddiem:url>
        <rdfs:label>low fecal excretion of unconjugated bilirubin (Unconjugated hyperbilirubinemia)*</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0008282*</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/606785"/>
    <rdfs:comment>Controversial benefits https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4158338/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4788912</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3306242</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0d795729-cd52-46a1-9df5-444a03c263c3">
        <rdfs:label>high plasma level of unconjugated bilirubin concentration</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0008282</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0008282</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/962d9867-8a82-476b-993a-3c85ab32e8ce">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/4ab240b8-315a-4c76-82d5-2adb708ae883"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
  </obo:OGMS_0000112>
  <obo:DDIEM_0000011 rdf:about="http://ddiem.phenomebrowser.net/5f074480-64dc-4b79-a96c-16ead706c46a">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f7d82219-ae1e-4c27-8f01-2e95df3285f6">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0030980</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Low brain glutamine concentration</rdfs:label>
        <dc:identifier>HP:0030980</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25896882</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d2b802d8-4af7-4ff5-9b65-759a1b60ec94">
        <rdfs:label>Abnormal plasma glutamine levels</rdfs:label>
        <dc:identifier>HP:0010903</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0010903</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/266130"/>
    <rdfs:comment>Synergism inmproves results</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27775558</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7fd9216d-b011-474d-84fd-f2f90de09ab0">
        <dc:identifier>HP:0002329</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002329</ddiem:url>
        <rdfs:label>unalertness</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>http://www.ncbi.nlm.nih.gov/pubmed/16368216</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/834144f0-fa47-4662-b309-8f0f1ba7918a"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22830360</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3d29d822-e058-4559-8957-e0cad8f0d7a6">
        <dc:identifier>HP:0002353</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002353</ddiem:url>
        <rdfs:label>Abnormal EEG results</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/fa59250f-7621-4f30-9098-26ea1d3848e3">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0030213</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0030213</ddiem:url>
        <rdfs:label>Lack of emotional expressions</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ade859b6-7b17-43b2-ac70-b8f3f1c8e252">
        <dc:identifier>HP:0030980*</dc:identifier>
        <rdfs:label>Low CSF glutamine level</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0030980</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2bcc5c84-3370-4a95-a714-73f8dd07f160">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Secondary NAD+ deficiencyÂ in leucocytes</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
  </obo:DDIEM_0000011>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8a9318a8-6c5b-4a39-bf92-abcccacff65e">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Acidosis</rdfs:label>
    <dc:identifier>HP:0001941</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001941</ddiem:url>
  </ddiem:Phenotype>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/a5f80368-a5ab-4e33-bd31-c1d6be08bf49">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4263309</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24164873</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02955264</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
    <rdfs:comment>Drug name: Treatment is under trial.</rdfs:comment>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/dd7b2ce6-aa8d-4c83-b498-b3a83bb3453a"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2427298</dc:provenance>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/607091">
        <dc:identifier>https://www.omim.org/entry/607091</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/338</ddiem:iembaseUrl>
        <rdfs:label>CONGENITAL DISORDER OF GLYCOSYLATION, TYPE IId; CDG2D</rdfs:label>
        <ddiem:iembaseAccessionNumber>338</ddiem:iembaseAccessionNumber>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/c7c23773-e54b-4eb3-aa14-627a8a1c9651"/>
      </ddiem:Disease>
    </obo:RO_0002599>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000010"/>
  </obo:OGMS_0000112>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/809aeb0f-b818-4ab4-badf-75a03e334500">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>disability(Functional motor problems)*</rdfs:label>
    <dc:identifier>HP:0004302*</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0004302</ddiem:url>
  </ddiem:Phenotype>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/b73a6897-19fd-47af-a6d6-4fc481d840bb">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22832289</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21102543</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4223155</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/246700"/>
    <rdfs:comment>"Oral tocofersolan was more bio available than the water-soluble formulation in children with chronic cholestasis and similarly bio available in CF. This suggests that water-soluble vitamin E may represent an alternative to painful intramuscular vitamin E injections in chronic cholestasis, or other oral formulations in CF. However, the mechanism responsible for fat malabsorption in CRD concerns the absorptive phase as opposed to the digestive phase in CF and cholestatic syndromes. To our knowledge, no specific studies with these new vitamin E preparations have been conducted in CRD." https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717/</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a706e830-0807-4e67-9479-d284f097b8c3">
        <rdfs:label>No Studies were done on this drug.</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6169684</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27520363</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/97bf2a32-8c38-44ac-8e12-a508f87c0085">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/b2f4cdb6-e447-4d1c-af84-0f1ddc36b66e"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23329770</dc:provenance>
  </obo:DDIEM_0000013>
  <obo:DDIEM_0000011 rdf:about="http://ddiem.phenomebrowser.net/5e5c88d0-8916-4fd3-8530-8d2b7f8d362d">
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/949ac949-7e55-4927-bb7a-db8a712cc8f9">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/3b11bc13-be0f-4578-9dc3-7a6b7e2008e9"/>
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/ef64aef2-384b-4689-92ec-10462ab2a3b5"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/0498e405-6b18-4f5b-8ead-39d2aa6b46f4"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20625172</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30755342</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22386973</dc:provenance>
    <rdfs:comment>There was no studies, but since there is an observation of low plasma serine conc. in untreated CBS-deficient patients that merits further exploration since supplementation with serine might be a novel and safe component of treatment of homocystinuria.</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ebeb4085-7d4b-4bc0-a2b8-207b33005f52">
        <dc:identifier>HP:0001249</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001249</ddiem:url>
        <rdfs:label>Low IQ score</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/60e7425f-a1ab-476e-9eaa-a71c3b177e71">
        <rdfs:label>METABOLIC ENCEPHALOMYOPATHY</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0287de77-2f13-4620-9a8e-9e409c061e83">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012758</ddiem:url>
        <dc:identifier>HP:0012758</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>neurodevelopmental delay</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a905388e-d444-4968-b69b-5828c5c63e5a">
        <dc:identifier>HP:0001263</dc:identifier>
        <rdfs:label>psychomotor retardation</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001263</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/44b64be5-0ae1-4dab-80fd-ba9a7a0a8107"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23770102</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31196723</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2b5e5e0d-fbdd-4efc-80af-a03d8299844f">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0002474*</dc:identifier>
        <rdfs:label>communicative skills abnormalities</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002474</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31211405</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3a48f2a6-758a-404d-afce-d14b54ede9d6">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002463</ddiem:url>
        <dc:identifier>HP:0002463</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>language impairment</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/602360">
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/a1eb9ee8-f67b-4738-aebf-3a38d55a3892"/>
        <dc:identifier>https://www.omim.org/entry/602360</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>L-ARGININE:GLYCINE AMIDINOTRANSFERASE; GATM</rdfs:label>
      </ddiem:Disease>
    </obo:RO_0002599>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/872c060a-e1b7-4d19-a52f-8abbd65edb62"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/75f831a8-8ae9-4736-a79b-125a2cf91b53">
        <rdfs:label>Low developmental score</rdfs:label>
        <dc:identifier>HP:0012759*</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012759</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31082797</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24355692</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9ce29ac7-85f3-4b43-a8e6-8ce54e8f2633">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012113</ddiem:url>
        <dc:identifier>HP:0012113*</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Low cerebral creatine content</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20682460</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14739681</dc:provenance>
  </obo:DDIEM_0000011>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/20509ec1-bb30-49b4-a8ab-6b091544aadd">
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/4545c674-c3f0-46ca-9286-b2a815b064de"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/991f369d-5064-4ca5-bd3d-2e99aaf92f02"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18839211</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0003304>compound V377I and I126T mutations</obo:RO_0003304>
    <rdfs:comment>The results of this study suggest that octreotide may aid in the acute or long-term treatment of congenital hyperinsulinism in a limited number of selected cases.https://www.ncbi.nlm.nih.gov/pubmed/8410522/</rdfs:comment>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/260920"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22740624</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26962538</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/c7bbce4e-bbe2-4090-8287-ee48481c6418"/>
    <dc:provenance>https://link.springer.com/referenceworkentry/10.1007%2F978-3-540-29676-8_199</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/fe677961-c0b0-4bff-9414-4510de13c516">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/a1f3236c-cc8a-43d5-91bb-9d7df012bdca"/>
      </rdf:Alt>
    </obo:RO_0000057>
  </obo:DDIEM_0000013>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0f9cdbdc-59eb-455a-96af-c40c6ecc3988">
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001290</ddiem:url>
    <rdfs:label>Low muscular tone</rdfs:label>
    <dc:identifier>HP:0001290</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b72ba78c-27d6-4a5e-8db6-7e0d3fceb7c7">
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0002354</dc:identifier>
    <rdfs:label>working spatial memoryÂ impairment*</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002354</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/924066a0-311a-4887-b870-d9df2522cb22">
    <dc:identifier>HP:0001635</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001635</ddiem:url>
    <rdfs:label>Congestive heart failure</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c706c6c6-d626-4e01-987e-48db4fd2aa4d">
    <rdfs:label>Vitamin D insufficiency</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/8a1e0d96-8f8c-44af-aea4-eb960c300e6d">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24746802</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01212744</dc:provenance>
    <dc:provenance>https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/5463a639-ce8e-48a7-a403-fa9cd5732f59">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/499d67b6-f538-4bbd-8045-1b48cfc2e5e2"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/520000"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/732dff93-80b6-436f-bb35-dd701bcb6919">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0004395</ddiem:url>
        <rdfs:label>Malnutrition</rdfs:label>
        <dc:identifier>HP:0004395</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23806424</dc:provenance>
    <rdfs:comment>The drug was administered through intravitreal injection.</rdfs:comment>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
  </obo:DDIEM_0000013>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/226a1444-8929-417a-846f-5efc57b02ab7">
    <rdfs:comment>Indomethacin was the most effective but can cause gastrointestinal intolerance and decreased eGFR. Amiloride and eplerenone have similar but lower efficacies and increase sodium depletion. The benefit/risk ratio of each drug should be carefully evaluated for each patient.          https://www.ncbi.nlm.nih.gov/pubmed/25012174
Despite a documented effect on hypokalemia, indomethacin and other nonsteroidal anti-inflammatory drugs should be used with caution due to their short- and long-term gastrointestinal side effects and nephrotoxicity.https://www.ncbi.nlm.nih.gov/pubmed/28003083</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28381550</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/263800"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25012174</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01146197</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5507263</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/379babc0-b14e-4f80-beba-b581bb9a9a9e">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/4813d17c-f655-4b23-9362-bd373f8fef16"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23196212</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/b21b580f-fbc4-4b3b-8319-91051142ccee">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/d4440823-9f31-4cd0-93f0-960b4cbc8a41"/>
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/fc197a75-67d2-4434-b0fa-c860a229e3d6"/>
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/db15474a-93e2-47aa-9514-1067be82c80d"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a615f712-7774-4e29-bf01-0cc4a3fb6fad"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21503667</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
  </obo:OGMS_0000112>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/2af1f93f-b53a-4db9-9420-4d84dfabd82a">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23494656</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/direct_complementation_of_a_genetically_defective_protein_by_gene_therapy"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/cd98e30b-a8d7-49ba-8d3a-d7f9f93b9eaa">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/becd1919-f003-4f5a-ad3f-c3309585bb59"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25474440</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4052756/#S10title</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23388701</dc:provenance>
    <dc:provenance>https://www.clinicaltrialsregister.eu/ctr-search/search</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/872c060a-e1b7-4d19-a52f-8abbd65edb62"/>
    <rdfs:comment>Alternative pathway therapy has limited effectiveness in preventing hyperammonemia and must be combined with effective dietary management. https://www.ncbi.nlm.nih.gov/pubmed/11148549</rdfs:comment>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/735e0035-3c60-49bc-b830-69074947b261"/>
    <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/207800"/>
    <dc:provenance>https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/03f7c9ce-3f4a-4e42-a162-e998f2a5047d">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>neurotoxicity</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </obo:OGMS_0000112>
  <obo:DDIEM_0000008 rdf:about="http://ddiem.phenomebrowser.net/46def950-dcac-4479-9cac-ac007d92e730">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4302571</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20631546</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/833d3406-f3a5-4807-ab6e-45999e6ba64d">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0011025</ddiem:url>
        <rdfs:label>low energetic state of heart(Abnormality of cardiovascular system physiology)*</rdfs:label>
        <dc:identifier>HP:0011025*</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24613482</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d727855f-2944-47f5-8ca3-e41332f229f4">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003236</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0003236</dc:identifier>
        <rdfs:label>Increased creatine kinase activity</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>Testosterone therapy needs to be carefully considered because of the risk of hepatic adenomas.https://www.ncbi.nlm.nih.gov/pubmed/28160246
Androgen receptors are expressed in the liver, and androgens can stimulate hepatocyte proliferation. Although rare, androgens have been shown in observational studies to induce adenoma development (Giannitrapani et al. 2006). Testosterone levels should be assessed for response 2â3 months after therapy is initiated.</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5fd786ba-7661-4287-b9be-391388e5ac7c">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003236</ddiem:url>
        <rdfs:label>high creatine kinase</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0003236</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/74ff3119-4268-4366-a2f8-09e7c8b971a9">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0004359</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Abnormal blood levels of  fatty acids</rdfs:label>
        <dc:identifier>HP:0004359</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/14606524-8023-4f2b-b71d-1e06b511ab5c">
        <rdfs:label>cardiomyopathy</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001638</ddiem:url>
        <dc:identifier>HP:0001638</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/1e7a3086-7b7c-48f8-81f8-18af07464963">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/c3cad2b7-54ab-4d62-8adf-1793dfe62029"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c85b6039-04f6-43c3-9a8c-c0c4f4886757">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001939</ddiem:url>
        <dc:identifier>HP:0001939</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>abnormal blood levels of ketone bodies</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17514432</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/32323216-3ed7-479f-880a-27e2babd4d9a">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0011804</ddiem:url>
        <rdfs:label>low energetic state of skeletal muscle</rdfs:label>
        <dc:identifier>HP:0011804</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/232400"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
  </obo:DDIEM_0000008>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/168bb830-63cf-4a6b-9a8f-c2638081c8b5">
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/219800"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19622360</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3016220</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14690254</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f8783ea7-0efb-44c1-9613-6988993e420c">
        <rdfs:label>Albuminuria</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012592</ddiem:url>
        <dc:identifier>HP:0012592</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>Controversial benefits https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4158338/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3505515</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4841061</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/c43c51ab-2724-4c83-b564-0fc420fdcdcd">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/37d111b3-8fb7-4c7b-8ade-89aaf159641b"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a5b3ccf7-5677-4eef-bff3-9f30bfd99beb">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000100</ddiem:url>
        <dc:identifier>HP:0000100</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>glomerular proteinuria</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8444253</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4158338</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
  </obo:OGMS_0000112>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/4c73028d-a140-4d88-923b-7e0c52f45224">
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01074944</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27499018</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a3ceb7cd-d833-4763-b441-1723d1184132">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Low lumbar spine bone mineral density(bnormality of bone mineral density)*</rdfs:label>
        <dc:identifier>HP:0004348</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0004348</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/16ccf1e2-b510-47fb-939b-7c8be34c450b"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21503667</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00962260</dc:provenance>
    <rdfs:comment>Indomethacin was the most effective but can cause gastrointestinal intolerance and decreased eGFR. Amiloride and eplerenone have similar but lower efficacies and increase sodium depletion. The benefit/risk ratio of each drug should be carefully evaluated for each patient.          https://www.ncbi.nlm.nih.gov/pubmed/25012174
Despite a documented effect on hypokalemia, indomethacin and other nonsteroidal anti-inflammatory drugs should be used with caution due to their short- and long-term gastrointestinal side effects and nephrotoxicity.https://www.ncbi.nlm.nih.gov/pubmed/28003083</rdfs:comment>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/1c9d266e-04cc-433b-a581-750411fdefc9"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28381550</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20439622</dc:provenance>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/608013">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>GAUCHER DISEASE, PERINATAL LETHAL</rdfs:label>
        <dc:identifier>https://www.omim.org/entry/608013</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/6b58a1f4-ac8c-4ddc-bce7-4e5f6fb332d0"/>
      </ddiem:Disease>
    </obo:RO_0002599>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/64482499-b03b-44a4-8ed9-0c916e569b8d"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/results/NCT00376168</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/58250b72-3547-4fc5-9ce4-6143de5e8f5d"/>
  </obo:OGMS_0000112>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/c36ad0d6-2c27-42e4-9bd7-9cf9d08f7f7d">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/e66babb0-fc35-4389-9324-52c85654d6f3"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00235</ddiem:url>
    <rdfs:label>Milrinone</rdfs:label>
    <dc:identifier>DB00235</dc:identifier>
  </ddiem:Drug>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/5064d8a9-a718-4458-ac47-0cad1ba4b20a">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1899474</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000015"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16361586</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11346370</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8163996</dc:provenance>
    <rdfs:comment>Topical retinoic acids, topical steroids, hydroquinone, tretinoin, and systemic retinoids have been used without success. https://www.ncbi.nlm.nih.gov/pubmed/2350982
https://www.ncbi.nlm.nih.gov/pubmed/3679816 https://www.ncbi.nlm.nih.gov/pubmed/29797344

Combination of Q-switched Nd: YAG and Fractional Carbon Dioxide Laser could be a promising therapy to pigmentation of Dowling-Degos diseaseÂ  https://www.ncbi.nlm.nih.gov/pubmed/28529428</rdfs:comment>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/69c7f3d9-22a7-4128-adc2-f6f73618d4c3"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12084887</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8b8142a8-4b90-4d8d-99fa-e7646f88aff9">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Depression</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000716</ddiem:url>
        <dc:identifier>HP:0000716</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/128230"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16891685</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/ac9e4c34-6622-410a-8b39-d4b71217d40b"/>
  </obo:OGMS_0000112>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/2243874d-50d6-4070-a74c-ac838c71fe13">
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/67e7e836-ecba-4d79-a35d-ea8a7916d735">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18458702</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26161337</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/ff1cb1db-7fb7-436f-b430-14e30e2cac47"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/30e4d0b4-0b04-4269-b3f6-198ef790a271"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/3685857e-2079-42cf-9817-f2f4104a8291"/>
        <rdfs:comment></rdfs:comment>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/3dff1795-dd8a-4336-ba60-51a3ff83c667"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b73b20fb-ced5-418b-94e2-15846e8ed820"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/202110"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <dc:identifier>DB00741</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00741</ddiem:url>
    <rdfs:label>Hydrocortisone</rdfs:label>
  </ddiem:Drug>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/c9199baa-6af2-4c45-a6bc-244c7726b13b">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5338723</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/227810"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7564233</dc:provenance>
    <rdfs:comment>Uncoooked cornstrach was introduced in small frequent meal and was accomapined with elimination of lactose in diet</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/055c5dec-dfd9-48c4-9e64-48ac2c77a0c1">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002748</ddiem:url>
        <dc:identifier>HP:0002748</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Rickets</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24912437</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/dd84b1e1-499a-4396-b27a-2d8c967648b9">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/164bc286-561d-4819-b234-75cb6d8ff1ef"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27155573</dc:provenance>
  </obo:DDIEM_0000013>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/4c526a1d-82b8-4711-86a3-5ea76e113c8a">
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000012"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9493705</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19770656</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <rdfs:comment>Intravenous heparin 10,000 U per day is an effective, simple, and safe method of lowering the triglyceride level in hypertriglyceridemia-induced pancreatitis in pregnancy, However, the reduction of the triglyceride level by heparin is only temporary and long-term use may paradoxically result in an increase in the triglyceride level as a result of depletion of LPL. Heparin can be stopped once the triglyceride level falls below 11 mmol/L.https://www.ncbi.nlm.nih.gov/pubmed/12114919.  https://www.ncbi.nlm.nih.gov/pubmed/1800965</rdfs:comment>
    <dc:provenance>https://www.clinicaltrials.gov/ct2/show/NCT01942291</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20495831</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d60a9c21-e4b6-4c31-977a-77622430c9a6"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/88046746-7e79-4066-99d3-eb94278a8dc8"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21289269</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28225998</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/604091"/>
  </obo:OGMS_0000112>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/0f3272bc-fb15-41f4-8eac-71e965f83cdc">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6a780665-67a7-47a3-8428-9d9095f45823">
        <dc:identifier>HP:0002748</dc:identifier>
        <rdfs:label>rickets</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002748</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6e9e79cd-b82c-4490-a5cc-e68b05984fa4">
        <dc:identifier>HP:0006462</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0006462</ddiem:url>
        <rdfs:label>poor skeletal mineralization</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30811537</dc:provenance>
    <dc:provenance>https://cdn.intechopen.com/pdfs/56869.pdf</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/899ef1a5-e64b-4f89-9e4d-926cf760d293">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/543ff07e-c42c-49b1-b540-885acf72b1eb"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/477a25b5-9299-4885-b375-a510b6c16d47">
        <dc:identifier>HP:0007015</dc:identifier>
        <rdfs:label>gross motor dysfunction</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0007015</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29405935</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30083035</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/4744026</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/409df4e0-05a1-495f-921b-1c2eae88c9bb">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002093</ddiem:url>
        <dc:identifier>HP:0002093</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>respiratory insufficiency</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19415691</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25717099</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a0d79f4c-bb56-489c-b981-a3a8b21b39fb">
        <dc:identifier>HP:0007010</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0007010</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>fine motor dysfunction</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26744272</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/34e33d87-198e-4c78-90a7-bd592a936f0c"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0e1b9731-a1d5-4f26-9e2b-742d594a4582">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>cognitive impairment</rdfs:label>
        <dc:identifier>HP:0100543</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0100543</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0929693X18300174</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9110486</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/241500"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/bf7620c2-2110-46d3-a909-8d60319489c0"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/79b70f8e-bb68-4f88-925a-8a9f76d130b7">
        <dc:identifier>HP:0004348</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0004348</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Defect of bone mineralisation</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/0498e405-6b18-4f5b-8ead-39d2aa6b46f4"/>
    <rdfs:comment>The rationale and mechanism of action of chloroquine /hydroxychloroquine are not established, their use for this indication is off-label, suitable dosage forms are not available, tablets are not scored for division, and it is not established how treatment should be monitored and when it should be stopped. Potential hepatotoxicity and retinal damage with prolonged use and hemolysis particularly in patients with glucose-6- phosphate dehydrogenase (G6PD) deficiency are also concerns.</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/473d7efb-b6e6-413f-b21a-78401f83f4d4">
        <rdfs:label>delayed growth(stature)</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000002</ddiem:url>
        <dc:identifier>HP:0000002</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
  </obo:OGMS_0000112>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/0fd9f588-0f30-4cef-aec2-ee5286cfc053">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/study/NCT00229619</dc:provenance>
    <rdfs:comment>There was no clinical effect, but amild reduction in the plasma level of desmosterol was observed.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15813920</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22791294</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25098371</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/fcd214b1-eac0-4141-a6f4-a1534aaf2ab4">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0001877</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001877</ddiem:url>
        <rdfs:label>low RBC count</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/8a5727f7-7c13-4c91-94b9-657d9b281f51">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/d99a8de9-c48d-4bbc-a946-3b6835c8a0c0"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22734070</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17562599</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/105650"/>
  </obo:OGMS_0000112>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b3e102e2-09d6-4d91-b282-2882f9c8ac66">
    <rdfs:label>fasting ketogenesis</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001946,HP_0025212</ddiem:url>
    <dc:identifier>HP:0001946,HP:0025212</dc:identifier>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/87a7f8be-f7fc-4caf-b37f-fa2211000aab">
    <dc:provenance>https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/cdec8137-0822-4811-8652-bbe062cd76d5"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23190330</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20380929</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/97837c33-2946-41d7-b6ef-fbf3550f83af">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0004369</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0004369</dc:identifier>
        <rdfs:label>low levels of purines</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/301835">
        <rdfs:comment></rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/5d403e2a-eddc-454d-9aeb-0fb1e2174388"/>
        <rdfs:label>ARTS SYNDROME; ARTS</rdfs:label>
        <dc:identifier>https://www.omim.org/entry/301835</dc:identifier>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28967191</dc:provenance>
    <rdfs:comment>From the biochemical viewpoint there is strong recommendation for giving patients with AADCD a trial of MAO inhibitors, although there is little evidence of clinical benefit. All patients had co-treatment with dopamine agonists and/ or pyridoxine https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5241937/</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e4cd5322-74ae-40ba-8f45-43da1554d4da">
        <dc:identifier>HP:0003678*</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Hearing impairment progression(Rapid progression)*</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003678</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/14aa57e8-8de3-473e-94f8-3334e3c2b0a8"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17701896</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ec2cb7c5-81bc-47b9-bc88-5d7bcb42abb7">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0003678*</dc:identifier>
        <rdfs:label>Progression of retinal degeneration ( Rapidly Progressive)*</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003678</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/987baa4e-15ac-44f7-abed-1ea17393b425"/>
    <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0002929707613470</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8d7a7f11-2467-4dd3-a476-a70097ac9dc5">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0002098</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002098</ddiem:url>
        <rdfs:label>Noctornal difficulty breathing</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2850427</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2d3275a9-6af4-4142-bb44-6b7dea606949">
        <rdfs:label>Ataxia Progression(Rapid progression)</rdfs:label>
        <dc:identifier>HP:0002719</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002719</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </obo:DDIEM_0000007>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/715cc5a1-c438-44d5-a296-477df061e963">
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11068651</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02527343</dc:provenance>
    <rdfs:comment>In individuals with allergies or intolerance to allopurinol, febuxostat may be considered; however, no data on the use of this medication in UMOD-associated kidney disease are available at present.</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2f24c83a-ea15-4963-bb24-78bea2820941">
        <rdfs:label>Mortality</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0040006</ddiem:url>
        <dc:identifier>HP:0040006</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ce40723a-b31f-41af-9f0a-f05e7f0f6f0b">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Disaess progression(Progressive)*</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003676</ddiem:url>
        <dc:identifier>HP:0003676</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/899af578-4c5a-4b91-801f-90ac92423999"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/162000"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5338723</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/9b7dbd5d-0f1c-4909-8303-bbed922dd481"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12205338</dc:provenance>
  </obo:DDIEM_0000013>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/ba2c130d-aa7a-427c-ac4b-d30e89105814">
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e90a4831-ed94-4573-9f28-00b04e1a4b36"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25717099</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e61017fe-c929-4827-a269-14a945e9dfa6"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8bd58640-f32e-4c02-9293-090af875ea0b">
        <rdfs:label>Poor swallowing</rdfs:label>
        <dc:identifier>HP:0002015</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002015</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/4829f67c-b32b-4786-aa18-ed79deb1ec13"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19750228</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/e8cae7a0-41da-45c1-9244-84b1af478b35"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/9e04273c-0292-4e71-af93-f2d35fff7945"/>
    <rdfs:comment>One of the studies that was carried on mice provides useful information for developing the optimal dosage regimen for HPBCD therapy when administered intravenously to NPC patients.https://www.ncbi.nlm.nih.gov/pubmed/26027824</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11787939</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/688c2d42-f99c-4736-b0ae-21827fd43b87">
        <dc:identifier>HP:0002180</dc:identifier>
        <rdfs:label>Neurodegeneration</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002180</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29429782</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/257220"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/4840b1d9-27d1-4d20-864d-940e8be365f2"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1f98d35b-2234-4cd4-82f9-28b11ebe343d">
        <dc:identifier>HP:0001392</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Liver injury</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001392</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7a116cae-a4e0-4c67-a0f1-768a152c2f4c">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003107</ddiem:url>
        <dc:identifier>HP:0003107*</dc:identifier>
        <rdfs:label>Cholesterol sequestration (Abnormality of cholesterol metabolism)*</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02534844</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/856f154b-8131-4d35-b84a-42d65abbfc66">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0007010</ddiem:url>
        <rdfs:label>Fine motor impairment</rdfs:label>
        <dc:identifier>HP:0007010</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28803710</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19415691</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26027824</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000015"/>
  </obo:OGMS_0000112>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/acc4b65c-96fe-4ff5-9d9f-3d2fb3a3fdd6">
    <dc:identifier>HP:0002910</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002910</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Abnormal AST level (Abnormal liver enzymes)*</rdfs:label>
  </ddiem:Phenotype>
  <obo:DDIEM_0000011 rdf:about="http://ddiem.phenomebrowser.net/4339cd54-a844-457b-aadf-ae96a3f965db">
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/605820">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>https://www.omim.org/entry/605820</dc:identifier>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/1299</ddiem:iembaseUrl>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/a7394c25-fe23-441c-88a7-479838fa3f57"/>
        <rdfs:label>NONAKA MYOPATHY; NM</rdfs:label>
        <ddiem:iembaseAccessionNumber>1299</ddiem:iembaseAccessionNumber>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17192294</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26546927</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10549306</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00125190</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20030229</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19627167</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/fefb524d-97ea-4cb9-aa35-a21ac15d1327">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/53f38532-7575-4d09-8bbb-7f69f487e5ff"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/202b2073-9e0f-4323-b4bc-9fcf095b645b"/>
    <rdfs:comment>In the clinical trial: The trial is not enrolling by invitation, no results have been posted yet. update by Oct.7th 2019
Authors have stated that "The data indicate that the retromer and sphingolipid metabolism play a critical role in PLA2G6-associated diseases. These observations may be relevant to Parkinson disease (PD) given that loss of vps35 or gain of Î±-Syn also affects retromer function and causes ceramide accumulation." https://www.ncbi.nlm.nih.gov/pubmed/29909971</rdfs:comment>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21517694</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01517880</dc:provenance>
  </obo:DDIEM_0000011>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/bd1cb0d2-f088-4186-9d1e-e5e56f7d7b1a">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8cde5235-2b13-44f6-962d-19c856bc8895">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0030872</ddiem:url>
        <rdfs:label>Left ventricle dysfunction</rdfs:label>
        <dc:identifier>HP:0030872</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3593b31c-8ed7-49a5-85fc-a6219d84096a">
        <rdfs:label>cardiac dilation, Heart enlargment, cardimegaly</rdfs:label>
        <dc:identifier>HP:0001640</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001640</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8700879</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/32dbc22a-8644-4a32-8308-475d4e5bab59">
        <dc:identifier>HP:0006670*</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0006670</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>left ventricularc contractility abnormalities</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0088629b-4c10-4c44-8375-7710e089e0c9">
        <dc:identifier>HP:0001714</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>ventricular hypertrophy</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001714</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31082797</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00638547</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31434105</dc:provenance>
    <rdfs:comment>Retroviral vector carrying the full-length cDNA for alpha-L-iduronidase</rdfs:comment>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/607014">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>https://www.omim.org/entry/607014</dc:identifier>
        <ddiem:iembaseAccessionNumber>241</ddiem:iembaseAccessionNumber>
        <rdfs:label>HURLER SYNDROME</rdfs:label>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/7688167e-f2e2-49c6-81e7-684954b030b6"/>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/241</ddiem:iembaseUrl>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30081189</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31196723</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31211405</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/direct_complementation_of_a_genetically_defective_protein_by_gene_therapy"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/53c74396-5933-45e7-8095-6f53a23026f5">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/4a271ff0-afec-4cbe-8842-16d73920e19c"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30170069</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4d034bc2-e2f8-4cd3-a75c-867ecfe6d672">
        <rdfs:label>Lysosomal storage abnormalities(Abnormality of lysosomal metabolism)*</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0004356</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0004356</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30755342</dc:provenance>
  </obo:OGMS_0000112>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/062de990-8c83-4416-b23d-27905a90acaf">
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0303846712003952</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20803213</dc:provenance>
    <rdfs:comment></rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/93c1ad5b-7b12-459d-b659-ff21d8ec184d">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Status epilepticus</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/203700">
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/411</ddiem:iembaseUrl>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/42910152-5855-4c4b-bc8a-f9d7f0ec1dba"/>
        <rdfs:label>MITOCHONDRIAL DNA DEPLETION SYNDROME 4A (ALPERS TYPE); MTDPS4A</rdfs:label>
        <dc:identifier>https://www.omim.org/entry/203700</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseAccessionNumber>411</ddiem:iembaseAccessionNumber>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S109037980800010X</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/c09bdf57-4493-41d8-8a84-c5dc4407a7a9">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/1dc8b4c6-4603-4113-acee-63aad42a845a"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22840416</dc:provenance>
  </obo:DDIEM_0000013>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/73f9876c-f8d3-485d-8ef0-afefebc47c68">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a49873a5-44af-4992-b861-80cd45221381">
        <dc:identifier>HP:0001945*</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001945</ddiem:url>
        <rdfs:label>hyperpyrexia in case of acute encephalopathic crises(Fever)*</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>This combination therapy should be accompained with low lysin diet that is often combined with the use of lysine-free, tryptophan-reduced amino acids (AA) supplements. These supplements are given with the aim of preventing malnutrition by providing essential amino acids and (depending on the product) also minerals, trace elements and vitamins. https://www.ncbi.nlm.nih.gov/pubmed/10630918</rdfs:comment>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17397529</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16368216</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/59a7fc29-fb40-4b80-8d28-a4fa17511c0d">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/fdd06c3c-85e9-443a-95f1-920d6181e2fd"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <dc:provenance>http://www.ncbi.nlm.nih.gov/pubmed/16368216</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10222465</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/231670"/>
  </obo:DDIEM_0000013>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/08293dea-0a75-4c17-8626-a3f045673225">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21102543</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6169684</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22832289</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/735e0035-3c60-49bc-b830-69074947b261"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2f50a32a-79e4-407e-862f-eb74a7cda331">
        <rdfs:label>Abnormal Adipose tissue tocopherol level.</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5915691</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/0b724f28-e827-4297-a715-fd5a37d544e8"/>
    <rdfs:comment>There is a contraversy about effectivness of methotrexate in treating "Condrocalcinosis 2" .. Details are in https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4223155/ and https://www.ncbi.nlm.nih.gov/pubmed/22832286/</rdfs:comment>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/246700"/>
    <dc:provenance>https://rarediseases.info.nih.gov/diseases/9683/chylomicron-retention-disease</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4223155</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4982212</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23329770</dc:provenance>
  </obo:DDIEM_0000013>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/77aa0a68-9d24-43ed-ad1d-803db94a609b">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002446</ddiem:url>
    <rdfs:label>AstrocytosisÂ inÂ cerebral cortex</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0002446</dc:identifier>
  </ddiem:Phenotype>
  <obo:DDIEM_0000011 rdf:about="http://ddiem.phenomebrowser.net/c64e8b92-df5e-4d34-86c4-0157affa78a5">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/aa6eb3de-1312-4ec7-9d14-a29d9210b831">
        <rdfs:label>Decreased sialylation of muscle glycans</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012350</ddiem:url>
        <dc:identifier>HP:0012350</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10549306</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/f604812d-07fe-449e-a1dc-243ff066afa4">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/c732e704-38a0-4883-9cab-a69af92ec036"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02346461</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21517694</dc:provenance>
    <rdfs:comment>In the clinical trial: The trial is not enrolling by invitation, no results have been posted yet. update by Oct.7th 2019
Authors have stated that "The data indicate that the retromer and sphingolipid metabolism play a critical role in PLA2G6-associated diseases. These observations may be relevant to Parkinson disease (PD) given that loss of vps35 or gain of Î±-Syn also affects retromer function and causes ceramide accumulation." https://www.ncbi.nlm.nih.gov/pubmed/29909971</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26546927</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17192294</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/605820"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28641925</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00125190</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4aab3d89-7713-43f5-859a-fc60fabd268f">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012363</ddiem:url>
        <dc:identifier>HP:0012363</dc:identifier>
        <rdfs:label>Low circulating levels of free sialic acids</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19627167</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/81176e89-92ca-4c49-82ae-ac6d23644e9e">
        <dc:identifier>HP:0003216*</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003216</ddiem:url>
        <rdfs:label>Amyloid deposition</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b3698b79-49fb-47f1-9b27-8f6272c8fe19">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003805</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0003805</dc:identifier>
        <rdfs:label>Rimmed vacuoles</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23887143</dc:provenance>
  </obo:DDIEM_0000011>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/c800e3c9-1b06-44e2-8a71-d10ff97668a4">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220407</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/00f1ebac-1754-422d-991e-c03a29e3f5e4">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003234</ddiem:url>
        <dc:identifier>HP:0003234</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Decreased plasma carnitine</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2443756</dc:provenance>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/246450">
        <rdfs:label>3-HYDROXY-3-METHYLGLUTARYL-CoA LYASE DEFICIENCY; HMGCLD</rdfs:label>
        <ddiem:iembaseAccessionNumber>62</ddiem:iembaseAccessionNumber>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/62</ddiem:iembaseUrl>
        <dc:identifier>https://www.omim.org/entry/246450</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/58acd2c5-c2be-4bd6-9b94-c96c10a53ae9"/>
        <rdfs:comment></rdfs:comment>
      </ddiem:Disease>
    </obo:RO_0002599>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b4f2b909-9165-4013-a2cb-82c920e8c0c1"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1886403</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <rdfs:comment>In the clinical trial: The trial is not enrolling by invitation, no results have been posted yet. update by Oct.7th 2019
Authors have stated that "The data indicate that the retromer and sphingolipid metabolism play a critical role in PLA2G6-associated diseases. These observations may be relevant to Parkinson disease (PD) given that loss of vps35 or gain of Î±-Syn also affects retromer function and causes ceramide accumulation." https://www.ncbi.nlm.nih.gov/pubmed/29909971</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29565174</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/6b36ca46-5e87-4637-b6e9-73189ff35f01"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000008"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26997609</dc:provenance>
  </obo:OGMS_0000112>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/33c4171d-3892-49b2-a5a5-9c66b26603d2">
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/ba4fb4df-0390-4e86-ad94-68cb70436bd1"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/804ee22e-7659-4fb5-abaf-b520bf18ba46"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25852896</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23196212</dc:provenance>
    <rdfs:comment>Indomethacin was the most effective but can cause gastrointestinal intolerance and decreased eGFR. Amiloride and eplerenone have similar but lower efficacies and increase sodium depletion. The benefit/risk ratio of each drug should be carefully evaluated for each patient.          https://www.ncbi.nlm.nih.gov/pubmed/25012174
Despite a documented effect on hypokalemia, indomethacin and other nonsteroidal anti-inflammatory drugs should be used with caution due to their short- and long-term gastrointestinal side effects and nephrotoxicity.https://www.ncbi.nlm.nih.gov/pubmed/28003083</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25012174</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21503667</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28381550</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/263800"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5507263</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/be80862b-64dd-4836-b153-fb0a2c5c7494"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/1a708dc8-b6f8-4c52-836a-79310a0fbfe0"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/bd3d56c1-781c-434f-9149-8b1124c3b9db">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000847</ddiem:url>
        <rdfs:label>high plasma RAAS activity</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0000847*</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </obo:DDIEM_0000013>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1914597b-986e-4b14-852a-dca9d8654604">
    <rdfs:label>low intracellular cysteine*</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0010918</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0010918</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4ce0dd72-9a12-4760-9585-86e11efe406a">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0011804</ddiem:url>
    <dc:identifier>HP:0011804</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>abnormal muscle function</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/2555637e-3af5-42d1-ba7c-e3d67489c049">
    <dc:identifier>DB00627</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/d01b15a5-689c-41ff-b47e-07f937050b8e"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/cd489235-a91d-4928-bb81-637b2919412b"/>
    <rdfs:label>Niacin</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00627</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/cdb4bcd2-cafd-4af8-9a38-18e5cf6eb851"/>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/597a2e09-1cb7-4674-abec-009691d96665">
        <dc:provenance>https://www.clinicaltrials.gov/ct2/show/NCT01942291</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20495831</dc:provenance>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000012"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/604091"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21289269</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/f8712a5b-6773-4e20-b7d8-bb42f873ffcf"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a68fc244-8add-4818-a3ae-faff3ebba1b2"/>
        <rdfs:comment>Intravenous heparin 10,000 U per day is an effective, simple, and safe method of lowering the triglyceride level in hypertriglyceridemia-induced pancreatitis in pregnancy, However, the reduction of the triglyceride level by heparin is only temporary and long-term use may paradoxically result in an increase in the triglyceride level as a result of depletion of LPL. Heparin can be stopped once the triglyceride level falls below 11 mmol/L.https://www.ncbi.nlm.nih.gov/pubmed/12114919.  https://www.ncbi.nlm.nih.gov/pubmed/1800965</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18993152</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d60a9c21-e4b6-4c31-977a-77622430c9a6"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2988622</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28225998</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19770656</dc:provenance>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/e63deaf8-0e33-4e75-b681-da414f0c9815">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25526748</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19415691</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28803710</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f9b2227e-9132-42b6-8a45-18e2fb98c1b7"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/490e25b1-b763-4344-a256-b6035e150a12"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/234500"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19750228</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/f8712a5b-6773-4e20-b7d8-bb42f873ffcf"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/025b758b-4f35-4ceb-af73-650f5889b0eb"/>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02534844</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11787939</dc:provenance>
        <rdfs:comment>One of the studies that was carried on mice provides useful information for developing the optimal dosage regimen for HPBCD therapy when administered intravenously to NPC patients.https://www.ncbi.nlm.nih.gov/pubmed/26027824</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25717099</dc:provenance>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d1d89ef4-0a03-4492-b451-2a6565d3c3f0">
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0002900</dc:identifier>
    <rdfs:label>Hypokalemia Metabolic Alkalosis</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002900</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/00cd9fb4-c7f1-4443-9269-0292bc35ee38">
    <rdfs:label>Chronic constipation</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0012450</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0012450</dc:identifier>
  </ddiem:Phenotype>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/f2fb72be-0adc-48ac-a062-fc27029db697">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25455802</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/232600"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4302571</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d4d9fa5f-c501-42d6-89e7-9156e0c4f1f3"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT03112889</dc:provenance>
    <rdfs:comment>Testosterone therapy needs to be carefully considered because of the risk of hepatic adenomas.https://www.ncbi.nlm.nih.gov/pubmed/28160246
Androgen receptors are expressed in the liver, and androgens can stimulate hepatocyte proliferation. Although rare, androgens have been shown in observational studies to induce adenoma development (Giannitrapani et al. 2006). Testosterone levels should be assessed for response 2â3 months after therapy is initiated.</rdfs:comment>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/c51058f7-1e07-472e-a6a6-adeb625d7b5f"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25762569</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
  </obo:OGMS_0000112>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/26836019-e54b-4483-9790-601c42abce1e">
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/261640"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ae463dc5-7eba-47a7-9e00-c681e71d3805">
        <dc:identifier>HP:0012656</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012656</ddiem:url>
        <rdfs:label>Low dopamine level</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>It's an investigational therapy where Positive results from using a selective monoamine oxidase (MAO) B inhibitor or non-ergot dopamine agonist pramipexole as an adjunct therapy have been described in the medical literature. This use of such an inhibitor can allow for lower doses of neurotransmitter precursor to be used. However, the long-term safety (e.g. effects on neonatal brain development) and effectiveness of this therapy is unknown and more research is required to determine what role, if any, selective monoamine oxidase B inhibitors play in the treatment of individuals with tetrahydrobiopterin deficiency. https://rarediseases.org/rare-diseases/tetrahydrobiopterin-deficiency/. https://www.researchgate.net/publication/233414693_Deprenyl_in_6-Pyruvoyl_Tetrahydropterin_Synthase_Deficiency. https://www.degruyter.com/downloadpdf/j/pteridines.1995.6.issue-3/pteridines.1995.6.3.144/pteridines.1995.6.3.144.pdf</rdfs:comment>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <dc:provenance>https://www.researchgate.net/publication/233414693_Deprenyl_in_6-Pyruvoyl_Tetrahydropterin_Synthase_Deficiency</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12003346</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/b805862b-923c-42df-a1a6-ccadd30704e9">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/8ca9b146-5a58-4e7a-af60-ba0a8f8deab6"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <dc:provenance>https://rarediseases.org/rare-diseases/tetrahydrobiopterin-deficiency</dc:provenance>
    <dc:provenance>https://www.babysfirsttest.org/newborn-screening/conditions/3-methylcrotonyl-coa-carboxylase-deficiency</dc:provenance>
    <dc:provenance>https://www.degruyter.com/downloadpdf/j/pteridines.1995.6.issue-3/pteridines.1995.6.3.144/pteridines.1995.6.3.144.pdf</dc:provenance>
  </obo:OGMS_0000112>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/decc676b-2824-4cb3-97b5-0128c2a6f590">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>splenomegaly</rdfs:label>
    <dc:identifier>HP:0001744</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001744</ddiem:url>
  </ddiem:Phenotype>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/9d6de3fb-8983-4133-9c79-695f33a7eeca">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31082797</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/435dddf2-91eb-4c81-abaf-3c7ae0e19585"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/71d96d1c-1bc5-4c0e-8a52-17bbfd68648a"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11172140</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31434105</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0ad89904-b652-4ef6-8301-75c9b0c510f4">
        <dc:identifier>HP:0012763</dc:identifier>
        <rdfs:label>dyspnea at rest</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012763</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a3f205be-3080-486a-82b0-2a32970a80e5">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0010444</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0010444</dc:identifier>
        <rdfs:label>pulmonary regurgitation</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/57f26730-ce09-491f-8314-ae16ac95fdf6">
        <rdfs:label>low quality of sleep</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002360</ddiem:url>
        <dc:identifier>HP:0002360</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f8d81542-28c3-433d-92e9-dce561d59fbf">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0007663</ddiem:url>
        <rdfs:label>impaired Visual acuity</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0007663</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/479ef275-21c6-4f01-81fc-e8103cdc0c9b">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000969</ddiem:url>
        <rdfs:label>pitting edema</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0000969</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b2607f24-92cd-4615-9eaf-ce3ec5b8f214">
        <dc:identifier>HP:0002500</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002500</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>brain MRI abnormalities</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30755342</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4ef1602a-abbe-4ba6-959a-f685bd61e155">
        <rdfs:label>Abnormal apneaâhypopnea index</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f989c425-c59f-45a2-a11a-2dad27820b8a">
        <dc:identifier>HP:0010535</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0010535</ddiem:url>
        <rdfs:label>Sleep apnea</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>GNeo-IDUA and IDUA injected intravenously resulted in reduced hepatic glycosaminoglycan accumulation but had no effect in the brain due to fast clearance from the circulation. In contrast, intranasally administered GNeo-IDUA entered the brain rapidly. Repetitive intranasal treatment with GNeo-IDUA reduced glycosaminoglycan storage, lysosome size and number, and neurodegenerative astrogliosis in the olfactory bulb and primary somatosensory cortex, whereas IDUA was less effective. The enhanced efficacy of GNeo-IDUA was not the result of increased nose-to-brain delivery or enzyme stability, but rather due to more efficient uptake into neurons and astrocytes. https://www.ncbi.nlm.nih.gov/pubmed/28958576</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/76149764-454d-4e1e-8387-720910f0a3b8">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>photophobia</rdfs:label>
        <dc:identifier>HP:0000613</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000613</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/bcfff910-1e24-45d0-945b-a038fb48aa7f">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>white matter abnormalities</rdfs:label>
        <dc:identifier>HP:0002500</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002500</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3581de33-be76-4ff9-847f-c75647d61cb3">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>low exercise endurance</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31196723</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/607014"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31211405</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/fe693d60-c0d4-47bd-bde9-c776d6b70ab6"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19748810</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f558402e-35d3-49b7-a23a-d3e497caf3fc">
        <rdfs:label>brain ventricular dilatation</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002119</ddiem:url>
        <dc:identifier>HP:0002119</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/be7aee27-0bd6-49a7-b96a-3a9b82e13fda">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002189</ddiem:url>
        <dc:identifier>HP:0002189</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Daytime somnolence</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00638547</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/efcae25d-dd9a-40dc-9042-a1d22f9d2a13">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0011729</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Abnormality of joint mobility</rdfs:label>
        <dc:identifier>HP:0011729</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/30b4d9e3-1250-4f93-b4cf-fda1a9f13183"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31630958</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6d920948-e85f-4ea6-8a73-ee4080129736">
        <dc:identifier>HP:0003541</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003541</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Urinary glycosaminoglycan excretion</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/20e803af-f797-446b-bd27-f3e84d13a4f0"/>
  </obo:OGMS_0000112>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/b2f4cdb6-e447-4d1c-af84-0f1ddc36b66e">
    <ddiem:url>https://www.drugbank.ca/drugs/DB11635</ddiem:url>
    <dc:identifier>DB11635</dc:identifier>
    <rdfs:label>Tocofersolan</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/b73a6897-19fd-47af-a6d6-4fc481d840bb"/>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1d28af6e-8a7e-40ab-867c-dbef0964b7a2">
    <rdfs:label>High serum ferritin</rdfs:label>
    <dc:identifier>HP:0003281</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003281</ddiem:url>
  </ddiem:Phenotype>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/13c48602-969d-4207-9b39-e606b646c90a">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21483849</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29054473</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/dea92466-3863-472e-96ba-6ad150838f52"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/300322"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22198833</dc:provenance>
    <dc:provenance>https://rarediseases.org/rare-diseases/lesch-nyhan-syndrome</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27179999</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/39e026c8-3518-488b-950b-ec15df629d6a"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3202309</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <rdfs:comment>Treatment with allopurinol was associated with xanthine lithiasis. https://www.ncbi.nlm.nih.gov/pubmed/17065067 
https://www.ncbi.nlm.nih.gov/pubmed/16773422/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16549399</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24093206</dc:provenance>
  </obo:OGMS_0000112>
  <obo:DDIEM_0000011 rdf:about="http://ddiem.phenomebrowser.net/7b538f8f-852e-47bc-911d-27bcbe45d276">
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/2c8aa700-7181-4694-aac4-babba8043d93"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1f2f0bd5-9415-4161-88a8-95c9f3e369cc">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>low urinary excretion of TCA cycle intermediates malate and succinate</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22840416</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/c9290508-0a2b-4206-a2f7-6788c0fa965f"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0303846712003952</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/387b9aa2-9a28-479d-a7f0-8ecfc6876a9c"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7e2df378-18c9-4682-a72d-335b2a209e2f">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0012321</dc:identifier>
        <rdfs:label>D-2-hydroxyglutaric aciduria</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012321</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S109037980800010X</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0727a4dd-6b67-409c-9291-5691196dd9e9">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012405</ddiem:url>
        <dc:identifier>HP:0012405</dc:identifier>
        <rdfs:label>Hypocitraturia</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment></rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24687295</dc:provenance>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/615182">
        <ddiem:iembaseAccessionNumber>924</ddiem:iembaseAccessionNumber>
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/924</ddiem:iembaseUrl>
        <rdfs:label>COMBINED D-2- AND L-2-HYDROXYGLUTARIC ACIDURIA; D2L2AD</rdfs:label>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/7bf4f9e9-5e0d-4717-bef1-a24d5114e42d"/>
        <dc:identifier>https://www.omim.org/entry/615182</dc:identifier>
      </ddiem:Disease>
    </obo:RO_0002599>
  </obo:DDIEM_0000011>
  <obo:DDIEM_0000011 rdf:about="http://ddiem.phenomebrowser.net/0b3ceace-f52f-4d5c-92c3-c335d960f17c">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26153518</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/bc9d8cda-8154-466c-afd5-ccfff8a1651d">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>MP:0001665</dc:identifier>
        <rdfs:label>chronic diarrhoea</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/MP_0001665</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1316120</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/90bcfdb2-62a7-4945-8106-041cac6fa0d7">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0040129</dc:identifier>
        <rdfs:label>Abnormal nerve conduction velocity</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0040129</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e7416954-e68f-4859-9872-89a477de114b">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000707</ddiem:url>
        <rdfs:label>neurological dysfunctions</rdfs:label>
        <dc:identifier>HP:0000707</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/0df943c1-2908-42df-ae97-dcf006d67493"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31115677</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ac39eeed-f535-40f4-8fd0-593fff2bf11a">
        <rdfs:label>Xanthoma</rdfs:label>
        <dc:identifier>HP:0001114</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001114</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25424010</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2a5d5526-c8a9-416c-b0ab-4570fc44a987">
        <rdfs:label>Incoordination</rdfs:label>
        <dc:identifier>HP:0002311</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002311</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ea21dfae-c1dd-4440-b63e-8b15f145cf98">
        <dc:identifier>HP:0000518</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000518</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>cataracts</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30804055</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/213700"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28590052</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1ad3c62e-1381-40c8-850d-b626ad244723">
        <dc:identifier>HP:0003124</dc:identifier>
        <rdfs:label>Elevated serum cholesterol</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003124</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29260356</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0721717e-a22f-4944-a413-f33e16da9358">
        <rdfs:label>EEG abnormalities</rdfs:label>
        <dc:identifier>HP:0002353</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002353</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>Drug name: Treatment is under trial.</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a67a82de-71a0-4220-82b9-6ed1fbd3322b">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001288</ddiem:url>
        <dc:identifier>HP:0001288</dc:identifier>
        <rdfs:label>abnormal gait</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e90a4831-ed94-4573-9f28-00b04e1a4b36"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/21ba206b-4ec3-4104-9c8a-670f005b9320"/>
    <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28980151</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15131757</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/9c601284-c530-4f64-92b1-8737d01c12cc"/>
  </obo:DDIEM_0000011>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1e9f4dcf-871e-4d53-84e3-ef1e040f5359">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0100022</ddiem:url>
    <dc:identifier>HP:0100022</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>deambulation</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/df9bf4f4-e55d-48c9-b2dd-1e583b245dde">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001738</ddiem:url>
    <rdfs:label>pancreatic dysfunction</rdfs:label>
    <dc:identifier>HP:0001738</dc:identifier>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/eefb88dd-4a16-4447-9edd-e7d3f847a3a9">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31239752</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/866674f7-6686-4955-b72a-3e13de23b98e"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/278000"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01371825</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c3a52554-b64d-4c65-ac67-119c5fe2cb73">
        <rdfs:label>Elevated urine mevalonate levels</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/df9850d4-e33f-4abf-b0ba-12ba98a4ef8d">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003141</ddiem:url>
        <dc:identifier>HP:0003141</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Increased LDL cholesterol</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/aef5487f-25d9-4e3e-8518-e8e67a677226"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC442441</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28804516</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23432031</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a242091d-4333-4b8e-9bdb-c3df13afec97"/>
    <rdfs:comment>Treatment success with statins has been mixed.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29374495</dc:provenance>
  </obo:OGMS_0000112>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/87adf1e7-97c5-4143-a2cd-03d8b7fad426">
    <obo:RO_0000056>
      <obo:direct_complementation_of_a_genetically_defective_protein_by_gene_therapy rdf:about="http://ddiem.phenomebrowser.net/da3dcb34-8474-4bd5-9bb7-4d38c23a0a05">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23494656</dc:provenance>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02998879</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/609458"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/863c211f-57c5-401c-9a9b-3e3a77a77154"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
        <rdfs:comment>The approach is (RNA interference-based, liver-targeted therapeutic), however this trial has been terminated.</rdfs:comment>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5508465</dc:provenance>
        <dc:provenance>https://www.clinicaltrialsregister.eu/ctr-search/search</dc:provenance>
        <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/51d5c67e-91a3-4b97-8d43-220f40f40ed9"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26827607</dc:provenance>
      </obo:direct_complementation_of_a_genetically_defective_protein_by_gene_therapy>
    </obo:RO_0000056>
    <rdfs:label>AAV1vector expressing Î±-Mannosidase</rdfs:label>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ce41cb95-464e-4f83-bfd4-b9b72b0d0fde">
    <rdfs:label>Low level of serum B12</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0040126</ddiem:url>
    <dc:identifier>HP:0040126</dc:identifier>
  </ddiem:Phenotype>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/68c36854-f1e2-4c4f-b335-59d8ec5ec50b">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/db52afba-4429-4ca5-8182-d338bc66335b">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0006517</ddiem:url>
        <dc:identifier>HP:0006517</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Pulmonary Alveolar Proteinosis</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000012"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25335805</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29058386</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2b9ef1e9-2177-46ff-9309-63fff08ba2a3">
        <rdfs:label>Low pulmonary function</rdfs:label>
        <dc:identifier>HP:0005952</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0005952</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/2c5d1869-70e4-4a21-9ce0-1f028a9f7b45">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/8d8642d0-8ae6-4f18-93e0-efd5ccd12176"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:comment>The regimen was accomapanied with a protein-restricted diet. https://www.ncbi.nlm.nih.gov/pubmed/27567650</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25859380</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/222700"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21110863</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27783330</dc:provenance>
  </obo:OGMS_0000112>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/63140549-5214-4490-9fb3-f9b70b2be068">
    <rdfs:label>lack of eye contact</rdfs:label>
    <dc:identifier>HP:0000817</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000817</ddiem:url>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/1ab86914-762f-4adf-8de8-fa2c1f467e69">
    <ddiem:url>https://www.drugbank.ca/drugs/DB01241</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/d18ac453-207e-469d-8993-6d9650904796"/>
    <dc:identifier>DB01241</dc:identifier>
    <rdfs:label>Gemfibrozil</rdfs:label>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/3df3a4f2-91cf-4b5f-a8ee-860e053105c8">
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2681858</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/88046746-7e79-4066-99d3-eb94278a8dc8"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/4cea6455-678d-4f14-816e-92d028e3c76f"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/c8ee05bd-b510-4dc9-a7d4-fb7576da6665"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/4883477</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/144650"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/3271cc26-e3a9-44a0-b5ff-76a00841ca83"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29695967</dc:provenance>
        <rdfs:comment>Hubacek et al. 2009 's results suggest that the APOA5 gene variants may play an important role in the pharmacogenetics of statin treatment. https://www.ncbi.nlm.nih.gov/pubmed/19530961/. https://www.ncbi.nlm.nih.gov/pubmed/25900265</rdfs:comment>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/fdc00c01-f727-4087-8068-242c2486bf89"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/5863a84b-5778-467a-b3bb-d3c8e9a1002f"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2702860</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/83308d11-c117-4f8d-9b7f-c0bb0a8882d6"/>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/f038d9a1-5106-4596-9fcc-60b9e0dc0e11">
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000012"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/53b3ac96-ba25-4a71-ad79-75588152173d"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/617347"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10385780</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25768710</dc:provenance>
        <rdfs:comment>In this study"https://www.ncbi.nlm.nih.gov/pubmed/10385780?dopt=Abstract" authors claimed that gemfibrozil is more effective in reducing total triglyceride and VLDL lipid levels than simvastatin, and simvastatin is better in reducing LDL cholesterol than gemfibrozil is. IDL and apolipoprotein E levels were reduced similarly with both drugs.</rdfs:comment>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/baf3b39f-20e6-4e6f-9fc8-151ac633e074"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/88046746-7e79-4066-99d3-eb94278a8dc8"/>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0021915015001379</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28098593</dc:provenance>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/4c526a1d-82b8-4711-86a3-5ea76e113c8a"/>
  </ddiem:Drug>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/74c6f833-4c9c-439c-afef-6c80b2ba96c7">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29054473</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21600768</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/29f5464e-5f27-4e80-b510-75f5026ff55b">
        <dc:identifier>HP:0025464</dc:identifier>
        <rdfs:label>Increased reactive oxygen species production</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0025464</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24093206</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6104515</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/92d9e8e1-52f9-4f5a-98d1-1fced44c863a"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <rdfs:comment>Author: "The therapeutic potential of idebenone therapy is likely to have the highest impact if therapy is initiated early in the disease at a time when retinal ganglion cell loss is still minimal.https://www.ncbi.nlm.nih.gov/pubmed/21810891/</rdfs:comment>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/535000"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3202309</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21483849</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/e3f8ef83-a890-423a-8dbd-a852b10c8f19">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/e1cf19aa-20db-4f3e-864d-5fdf059fac8d"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02693119</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000012"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02805790</dc:provenance>
  </obo:OGMS_0000112>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6bb785ef-18d5-4569-a35b-4bb92a45e59e">
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0012664</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0012664</ddiem:url>
    <rdfs:label>Low ejection fraction</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8a97cf5f-ce12-41b2-8f91-84e8681b489e">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0012379</ddiem:url>
    <rdfs:label>Low IDUA activity(Abnormal enzyme activity)*</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0012379</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/71f1fd93-f9d6-4cd8-9fee-0fa289113825">
    <rdfs:label>Protein oxidation</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/a9f948f7-a921-4ae1-a6b1-337eac3a15a5">
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/492690f9-8192-419c-9e5d-975da201ff63"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/ee5d78bb-0d63-472e-82d4-3e02c1b9a367">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/c2bc6126-9297-47ac-b94e-f87be32732c0"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27421908</dc:provenance>
    <dc:provenance>https://www.nature.com/articles/nature10456</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/253800"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1774833f-bdce-4faf-ae87-a47ef395c390">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>pathogenic exon trapping</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <rdfs:comment>Phenobarbital, clonazepam, valproate, and midazolam could not completely control seizures. https://www.ncbi.nlm.nih.gov/pubmed/20052547/</rdfs:comment>
  </obo:OGMS_0000112>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/a46230d8-b198-4fdf-9e77-f0c43e776003">
    <obo:RO_0000056>
      <obo:DDIEM_0000015 rdf:about="http://ddiem.phenomebrowser.net/45bcedc0-e093-480d-90ee-28020b3d3d58">
        <dc:provenance>was associated with improved findings on skeletal radiographs and improved pulmonary and physical function in infants and young children with life-threatening hypophosphatasia. (Funded by Enobia Pharma and Shriners Hospitals for Children; ClinicalTrials.gov number</dc:provenance>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
        <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
        <dc:provenance>an enzyme-replacement therapy</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/572fa1a7-378b-43af-af3b-8be975ce6911"/>
        <rdfs:comment>Drug name: Treatment is under trial.</rdfs:comment>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/56b2619d-1085-4d2c-a38a-6144bb9f360e"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d775e028-28b4-423c-86cc-ade0a57ad28e"/>
        <dc:provenance>NCT00744042.)."</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b836c8fd-4c66-4b0f-ad45-b2e51d44349f"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5909487</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
        <dc:provenance>"ENB-0040</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5096504</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/308050"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/9cab0efd-6217-4d52-b269-32c3345c0f68"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/7eef4b38-b505-44b8-8185-5fd377d86a86"/>
        <dc:provenance>https://www.researchgate.net/publication/8668575_A_successful_treatment_with_pyridoxal_phosphate_for_West_syndrome_in_hypophosphatasia</dc:provenance>
      </obo:DDIEM_0000015>
    </obo:RO_0000056>
    <rdfs:label>Simvastatin</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/ad3dd7b8-b21c-4099-abfc-9dd598848621"/>
    <obo:RO_0000056>
      <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/5486934f-6895-462c-a55d-c98cd362ca18">
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d73da1be-4e31-4139-961d-d01bc7298b7b"/>
        <dc:provenance>https://link.springer.com/referenceworkentry/10.1007%2F978-3-540-29676-8_199</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/260920"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26962538</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22740624</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19011501</dc:provenance>
        <rdfs:comment>The results of this study suggest that octreotide may aid in the acute or long-term treatment of congenital hyperinsulinism in a limited number of selected cases.https://www.ncbi.nlm.nih.gov/pubmed/8410522/</rdfs:comment>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/572fa1a7-378b-43af-af3b-8be975ce6911"/>
      </obo:DDIEM_0000013>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <obo:DDIEM_0000015 rdf:about="http://ddiem.phenomebrowser.net/e2be69b0-c0f3-4e7f-b36a-29d269538210">
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/5361854f-7f31-45a0-9196-7a2a5e838318"/>
        <ddiem:failedToContributeToCondition>c.479C&gt;G p.(Pro160Arg) and c.630C&gt;A p.(Asp210Glu)</ddiem:failedToContributeToCondition>
        <obo:RO_0003304>p.K148E and p.D210E</obo:RO_0003304>
        <rdfs:comment>The drug has been reported to be unbeneficial in one patient . https://www.ncbi.nlm.nih.gov/pubmed/30097991</rdfs:comment>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/362cfa6f-3abb-4811-9d7d-4050cfb6c53a"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/572fa1a7-378b-43af-af3b-8be975ce6911"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/72c43a87-f6e8-4f8f-a543-147632aabb51"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/607330"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24142275</dc:provenance>
      </obo:DDIEM_0000015>
    </obo:RO_0000056>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00641</ddiem:url>
    <dc:identifier>DB00641</dc:identifier>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/153f11c4-be0d-47b0-a44d-a08667d0ea09">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28804516</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/278000"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/1a90f43d-b719-49a2-ac58-06dcb7429074"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23432031</dc:provenance>
        <rdfs:comment>Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss</rdfs:comment>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01371825</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29374495</dc:provenance>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31239752</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16848116</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/572fa1a7-378b-43af-af3b-8be975ce6911"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
  </ddiem:Drug>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/1bbb2414-97d9-47ab-bfa1-6b06ce60bf36">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22149023</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/220110"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11067870</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6206929</dc:provenance>
    <rdfs:comment>"Oral tocofersolan was more bio available than the water-soluble formulation in children with chronic cholestasis and similarly bio available in CF. This suggests that water-soluble vitamin E may represent an alternative to painful intramuscular vitamin E injections in chronic cholestasis, or other oral formulations in CF. However, the mechanism responsible for fat malabsorption in CRD concerns the absorptive phase as opposed to the digestive phase in CF and cholestatic syndromes. To our knowledge, no specific studies with these new vitamin E preparations have been conducted in CRD." https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/971536</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/35b5c64e-9aaa-46fd-84a3-e5d483d4e101"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19622360</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/92af90b3-792a-4779-90d5-b71bb9153912"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3963001</dc:provenance>
  </obo:OGMS_0000112>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/3ecab22e-86c3-429b-988c-b6611799c46d">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28590052</dc:provenance>
    <rdfs:comment>Drug name: Treatment is under trial.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/626447</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1316120</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8fdd4a3e-236c-4a1d-88e9-ba9d4cbf6c6d">
        <rdfs:label>Increased urine output</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0000103</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000103</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30804055</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26153518</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01280188</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/5d3c4042-f396-408f-a8e5-6b8655479d83"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/b40ef143-f25c-4c7d-92a2-548b5e2f94d8"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/125700"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15131757</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12016800</dc:provenance>
    <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
  </obo:OGMS_0000112>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/766262d8-cb3e-48d4-9cdb-751f40d1da52">
    <rdfs:label>high serum phenylalanine</rdfs:label>
    <dc:identifier>HP:0004923</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0004923</ddiem:url>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/cb989c15-d6bb-4a67-b6a8-413330e99b6b">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>High serum iron</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003452</ddiem:url>
    <dc:identifier>HP:0003452</dc:identifier>
  </ddiem:Phenotype>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/ad8aa8fe-1f09-41ed-93ee-3e2c45f239ff">
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/04ca9c20-cbb4-4d94-8f6d-41d85d5271d0"/>
    <dc:provenance>https://www.babysfirsttest.org/newborn-screening/conditions/3-methylcrotonyl-coa-carboxylase-deficiency</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/05698700-e7b9-4ec7-8ff1-f6a580b92c0f">
        <rdfs:label>pseudoexon activation</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0003304>"c.84â322A&gt;T, c.163 + 695_163 + 751del57, or c.164â712A&gt;T"</obo:RO_0003304>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/261640"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21542064</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23690520</dc:provenance>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12003346</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22832064</dc:provenance>
    <rdfs:comment>Effect of glycine in treating the condition is variable among literatures.  "Case reports have noted variable results regarding the effect of glycine administration. Some studies have found that supplemental glycine results in increased excretion of 3-methylcrotonyl glycine, while others have not found a persistent effect; no studies have observed clinical improvement of symptoms on treatment and no randomized clinical trials have been published" https://www.sciencedirect.com/science/article/pii/S1096719207005975?via%3Dihub#bib11
https://www.ncbi.nlm.nih.gov/pubmed/8831079
https://www.ncbi.nlm.nih.gov/pubmed/7474896</rdfs:comment>
  </obo:OGMS_0000112>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/37b821ea-70ce-470f-ac6b-60b7909bceaf">
    <rdfs:comment>"Oral tocofersolan was more bio available than the water-soluble formulation in children with chronic cholestasis and similarly bio available in CF. This suggests that water-soluble vitamin E may represent an alternative to painful intramuscular vitamin E injections in chronic cholestasis, or other oral formulations in CF. However, the mechanism responsible for fat malabsorption in CRD concerns the absorptive phase as opposed to the digestive phase in CF and cholestatic syndromes. To our knowledge, no specific studies with these new vitamin E preparations have been conducted in CRD." https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717/</rdfs:comment>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/35b5c64e-9aaa-46fd-84a3-e5d483d4e101"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22149023</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/c51058f7-1e07-472e-a6a6-adeb625d7b5f"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/220110"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6206929</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/971536</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19622360</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3963001</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11067870</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
  </obo:DDIEM_0000013>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/b1a106ee-bd29-4d21-8c14-9d5263c1751e">
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/613490">
        <rdfs:label>ALPHA-1-ANTITRYPSIN DEFICIENCY; A1ATD</rdfs:label>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/e4e84e27-6327-4739-991c-ae735323b318"/>
        <dc:identifier>https://www.omim.org/entry/613490</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Disease>
    </obo:RO_0002599>
    <rdfs:comment>The approach is (RNA interference-based, liver-targeted therapeutic), however this trial has been terminated.</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/30b1929a-4d18-4b54-85f6-a6fe26f65156">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Lung inflammation (Abnormality of respiratory system)</rdfs:label>
        <dc:identifier>HP:0002086</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002086</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5508465</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/401e3899-3505-4f02-9fee-0cce0e2be265">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002098</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0002098</dc:identifier>
        <rdfs:label>Difficulty breathing</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30477028</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22282548</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15978931</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30049652</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/8b653e41-dcd5-4de9-8833-2fa36d2e052b">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/9f08ac5f-d2e5-4ae9-8e23-1d6cd2d8cdbc"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02900183</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0dd15836-5165-48e0-afee-6b1b86f39ce8">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0006530</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0006530</ddiem:url>
        <rdfs:label>Alveoli damage ( interstitial pulmonary abnormality)*</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
  </obo:OGMS_0000112>
  <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/d4e3c435-2a1d-427e-923f-0841d481dec9">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27567650</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/6777479</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22402328</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/5c133cff-17b8-488d-8776-72b237b44f8f"/>
    <rdfs:comment>Citrulline should be given in "Low-dose" as of 100 mg/kg/d.  https://www.ncbi.nlm.nih.gov/pubmed/21308987/.  
Adjusting l-citrulline dosage may be crucial, as excessive citrulline may worsen intracellular arginine accumulation  leading to harmful effects. https://www.ncbi.nlm.nih.gov/pubmed/22402328/ https://www.ncbi.nlm.nih.gov/pubmed/27567650</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25335805</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25859380</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/222700"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/2ce2a3f0-914c-481a-8b67-1c6a3499311d"/>
  </obo:DDIEM_0000007>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/be019600-352d-427c-8235-085854043c0d">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20495831</dc:provenance>
    <rdfs:comment>Intravenous heparin 10,000 U per day is an effective, simple, and safe method of lowering the triglyceride level in hypertriglyceridemia-induced pancreatitis in pregnancy, However, the reduction of the triglyceride level by heparin is only temporary and long-term use may paradoxically result in an increase in the triglyceride level as a result of depletion of LPL. Heparin can be stopped once the triglyceride level falls below 11 mmol/L.https://www.ncbi.nlm.nih.gov/pubmed/12114919.  https://www.ncbi.nlm.nih.gov/pubmed/1800965</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12114919</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28225998</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23323877</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/62f13862-3b92-42cc-9dad-e958eef7c627"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21289269</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19770656</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/c3af4cca-0eea-44d8-9c18-121be136d146"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/52f8bd48-691f-495f-8e00-ade205c145ba">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003141</ddiem:url>
        <rdfs:label>High LDL level</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0003141</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/145750"/>
  </obo:OGMS_0000112>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/0f46a7ea-e156-4b53-8b66-868e3d7281dc">
    <rdfs:comment>The rationale and mechanism of action of chloroquine /hydroxychloroquine are not established, their use for this indication is off-label, suitable dosage forms are not available, tablets are not scored for division, and it is not established how treatment should be monitored and when it should be stopped. Potential hepatotoxicity and retinal damage with prolonged use and hemolysis particularly in patients with glucose-6- phosphate dehydrogenase (G6PD) deficiency are also concerns.</rdfs:comment>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/72047e7b-6315-4e3b-8d89-ca58c59503b3">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/5ce34dc9-4a8a-4d27-8ab6-1973175f870b"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/6173993</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0022202X15441491</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25717099</dc:provenance>
    <ddiem:failedToContributeToCondition>C282Y/H63D  heterozygosity or compound heterozygosity /C282Y(Homozygous mutation)</ddiem:failedToContributeToCondition>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14632789</dc:provenance>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/176100">
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/7efebd51-4cdf-42e8-8366-05c293bc7eb7"/>
        <dc:identifier>https://www.omim.org/entry/176100</dc:identifier>
        <rdfs:label>PORPHYRIA CUTANEA TARDA</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseAccessionNumber>114</ddiem:iembaseAccessionNumber>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/114</ddiem:iembaseUrl>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/8be7ae64-4310-4ba7-8788-f8ebd25b7baa"/>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/4811840</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/c1ba99ab-cc06-4a3f-8f61-65a683c970c2"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22985607</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9110486</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7324107</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/5080345</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/fd72f3b1-299a-4247-906c-4fdfacbc789b">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Increased serum ferritin</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003281</ddiem:url>
        <dc:identifier>HP:0003281</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/4744026</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19415691</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f7ba69df-b9cc-48a0-9f7f-631f38e9cf4e">
        <dc:identifier>HP:0012463</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Elevated transferrin saturation</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012463</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/de802a56-6551-4a3a-9040-d6f7770d7bbd">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0010472</ddiem:url>
        <rdfs:label>Increased liver protoporphyrin concentration (Abnormality of the heme biosynthetic pathway)*</rdfs:label>
        <dc:identifier>HP:0010472*</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/378f833b-a94d-49c0-89c2-674f68edb9ba">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003452</ddiem:url>
        <dc:identifier>HP:0003452</dc:identifier>
        <rdfs:label>Increased serum iron</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/4739135</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f65c70c2-493e-40e6-85d9-f3178b19b17a"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12622622</dc:provenance>
  </obo:DDIEM_0000013>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/20cd649c-b2c3-4f4a-8fa0-2440c045a70a">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26884075</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/be66178f-5b6d-4cac-b42c-5decfa4b4b3a">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Decreased cellular ATP level</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0011925</ddiem:url>
        <dc:identifier>HP:0011925*</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26118651</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/5fc38d66-c569-473f-b914-4fb19be0435b">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/8309fc89-d7d4-4be6-ac49-188ae08c8211"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:comment>MCT should be at least 70% of the total fat content of the diet.</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/530000"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/17f4178b-4525-4283-8ed7-569eae8e79cc"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27709644</dc:provenance>
  </obo:OGMS_0000112>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/fcb2cc0c-fac7-498b-9164-96cd0d2a49fd">
    <rdfs:label>Ecopipam</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB12273</ddiem:url>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/23110bae-425d-4dd6-a8fc-f50ab69a4406">
        <dc:provenance>https://clinicaltrials.gov/ct2/show/results/NCT01751802</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26922636</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27179999</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3202309</dc:provenance>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24093206</dc:provenance>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/results/NCT01065558</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/e0bb620c-e9f5-4141-bc7d-240944dc3513"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21483849</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29054473</dc:provenance>
        <rdfs:comment>The cyclosporine trial (taken immediately upon visual loss in the first eye) is in progress in Leber's optic atrophy to prevent involvement of the fellow eye.</rdfs:comment>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/300322"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e5e9da4c-e295-4408-8694-fe8876b00d89"/>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <dc:identifier>DB12273</dc:identifier>
  </ddiem:Drug>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/a78b0d6e-4018-4246-a3a8-6f076e273cb7">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/fcda5768-bb13-4470-87c0-e573f3cc73cb">
        <dc:identifier>HP:0004325</dc:identifier>
        <rdfs:label>Low weight</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0004325</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f40d696f-5d8f-4640-acae-29df4cd8da64">
        <dc:identifier>HP:0001433</dc:identifier>
        <rdfs:label>hepatosplenomegaly</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001433</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a6da042b-cebb-4cc9-afa1-78f199602191">
        <rdfs:label>Elevated liver enzyme levels</rdfs:label>
        <dc:identifier>HP:0002910</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002910</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648/#b96-tacg-8-201</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3488882</dc:provenance>
    <dc:provenance>https://www.asgct.org/education/disease-treatments/inherited-immunodeficiencies</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f4893a3a-021b-4cb3-92fb-f8c93457dc62">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001879</ddiem:url>
        <rdfs:label>Abnormal eosinophil counts</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0001879</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1182205</dc:provenance>
    <rdfs:comment>Febuxostat was, however, significantly more efficacious than allopurinol in reducing DHA excretion in the prescribed doses. This finding, which may translate into improved outcomes of patients with APRT deficiency, should be confirmed in a larger sample. https://www.ncbi.nlm.nih.gov/pubmed/29241594
The XDH inhibitor febuxostat is an alternative option for those allergic to or intolerant of allopurinol. A low purine diet and ample fluid intake are recommended.https://www.ncbi.nlm.nih.gov/books/NBK100238/</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/37e2686e-f98e-45a9-b5bc-1ebc58bea463">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001878</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Hemolysis</rdfs:label>
        <dc:identifier>HP:0001878</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15767622</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29241594</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/49fcc2c8-716e-4688-ba17-1e459a3309fb">
        <dc:identifier>HP:0001888</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001888</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>lymphopenia</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01420627</dc:provenance>
    <dc:provenance>https://globenewswire.com/news-release/2015/03/30/720127/10126746/en/Sigma-Tau-Pharmaceuticals-Inc-Receives-Orphan-Drug-Designation-for-EZN-2279-for-Treatment-of-Adenosine-deaminase-Deficient-Severe-Combined-Immunodeficiency-Disease.html</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/102700"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/14784cfa-6c46-4117-a910-6584cbcdc5ab">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/f5d85262-0ab8-48cc-9938-7a9ba4c6ed4d"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/69bfe5c7-0308-4ee2-a358-13a675736394"/>
    <dc:provenance>https://adisinsight.springer.com/trials/700243447</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/37889b3d-a576-43d6-a2cb-0b6c85a21336">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0002960</dc:identifier>
        <rdfs:label>Thyroid antibodies (autoimmunity)*</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002960</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/376b91ac-2f25-4c77-a1a5-44d10591c398"/>
  </obo:OGMS_0000112>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/94fc1775-e96b-4212-97f9-5907805447a7">
    <rdfs:label>Abnormal aPTT level</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003645</ddiem:url>
    <dc:identifier>HP:0003645</dc:identifier>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/4cf4cfc6-2f57-404c-9d02-ec1a2ae8177e">
    <dc:identifier>D07A</dc:identifier>
    <ddiem:url>https://www.whocc.no/atc_ddd_index/?code=D07A</ddiem:url>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/e156d470-de15-4f31-bb06-2499516e29ce">
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/3f8a89eb-cfac-4298-97ef-6391b5e82b26"/>
        <rdfs:comment>In a different study IV administration of Glucose wasn't effective.https://www.ncbi.nlm.nih.gov/pubmed/22238410</rdfs:comment>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1059131117301243</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/books/NBK1520</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/ad990414-5b73-475b-a876-47cc32abc214"/>
        <dc:provenance>https://link.springer.com/article/10.1007/s11940-011-0131-z</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4830701</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/602541"/>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <rdfs:label>CORTICOSTEROIDS, PLAIN</rdfs:label>
  </ddiem:Drug>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/c5ed9d76-d38f-43d3-9d59-ab120571f5df">
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/218800"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8900123</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/40bfc99d-40c9-40f6-9d12-c8e5000a0877">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/8391be2e-5a2d-49ba-ab16-1275141e4056"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3306242</dc:provenance>
    <rdfs:comment>Information about the Study can be ound in https://gmoinfo.jrc.ec.europa.eu/bsnifs-gmo/B-NL-17-001.pdf</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15753292</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583863</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/145434e3-5330-4a0b-a874-7a048b64936a">
        <dc:identifier>HP:0002904</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Hyperbilirubinemia</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002904</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/direct_complementation_of_a_genetically_defective_protein_by_gene_therapy"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15726662</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9156798</dc:provenance>
  </obo:OGMS_0000112>
  <obo:direct_complementation_of_a_genetically_defective_protein_by_gene_therapy rdf:about="http://ddiem.phenomebrowser.net/e1df26dc-d9f9-4019-a4e6-9ffa77f8ab55">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9930336</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16518877</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/3c19fde5-49ca-4c2b-94b0-6d52fc0f22d4">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/bd620ab2-51a0-408b-b8ec-ad1515fb6b11"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/208400"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/40262075-3535-45b1-93e7-1084c782209f">
        <rdfs:label>Liver lysosomal storage abnormality</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20607610</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <rdfs:comment>The  injections  of  recombinant  viruses in vivo into  theAGU  mouse  brain  showed  no  inflammation  peak  orgliosis related to the viral injection, but mild periventricu-lar  microglial  activation  persisted  throughout  the  wholefollow-up  time.  The  AGA  immunostaining  prevailed  inthe  ependymal  cells  lining  the  ventricles  and  expressedAGA  was  also  found  in  the  surrounding  brain  areas.
Other reports of adenovirus-mediated gene expression inthe brain have indicated inflammation during the first 2weeks   after  injection 

https://www.sciencedirect.com/science/article/pii/030645229500068T 
https://www.ncbi.nlm.nih.gov/pubmed/9930336</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27906067</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/dd0491bd-64dc-427b-8dd3-2cd15d8060f1">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Brain lysosomal storage disease</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28967191</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15342551</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/111623cc-aecb-4d9b-87ad-282707ffd6aa">
        <rdfs:label>ipsilateral brain neuronal storage abnormalities</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/42741e00-0dad-4e18-99f7-4803d78f5b92">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Low expression of AGA enzyme</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </obo:direct_complementation_of_a_genetically_defective_protein_by_gene_therapy>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/8006073f-4b36-4903-b56c-bda9ff8c0d7e">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24718477</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24288038</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/b97c7b01-07a5-4d6b-9b8a-bcdaeecc0d22">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/a83d37f1-7679-47a7-8dd4-7319c09fc2a3"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2779298</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3415789</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/f9d2b6d7-6963-4934-8fb4-ad8ba989ed43">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/f5f35b83-e99d-43d4-b469-f03c9d6fd66d"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12044538</dc:provenance>
    <rdfs:comment>Investigational "Infertility investigation Abetalipoproteinaemia patients might benefit from progesterone supplementation, and further studies on this and hormonal profiles would benefit this pool of patients. Optimising the nutritional profile and body mass index of female patients will undoubtedly contribute to better chances at conception.:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4265040/</rdfs:comment>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/201100"/>
  </obo:DDIEM_0000013>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/0f3c959c-7845-4aa4-891c-483c0c0c562f">
    <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/615eec77-9894-4b4f-9dae-dd98bf04145a">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001931</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>hypochromic anemia</rdfs:label>
        <dc:identifier>HP:0001931</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8317485</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01797055</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17586848</dc:provenance>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/209300">
        <ddiem:iembaseAccessionNumber>206</ddiem:iembaseAccessionNumber>
        <rdfs:label>ATRANSFERRINEMIA</rdfs:label>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/206</ddiem:iembaseUrl>
        <dc:identifier>https://www.omim.org/entry/209300</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/713698dc-abe5-452a-ae49-09edc6a7cc19"/>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15300460</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/3615198b-5f3c-4d9a-ad69-d573af03bccc">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/23c2b1cc-9dd5-4e89-b0bf-949fdd721453"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:comment>There is a common note in different reserachs refers to the importance of early managment by Vitamin E supplements since it limits disease progression and it can reverse some of the clinical manifestation (e.x ataxia and the intellectual deficit), if it was interoduced early in life. Therefore, early diagnosis is paramount.</rdfs:comment>
  </obo:OGMS_0000112>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/a330d0cc-3d0e-4fb8-947e-de6a1fcba5e3">
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/48e3b1d9-481b-45a3-934c-dd0c1cf6385e">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/1db5ab2f-74fa-447a-adb1-d9292dd7ca8e"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d73ad6b2-16b0-4ad8-bdd3-4b6439b8019e">
        <rdfs:label>Microgliosis</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0100708</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0100708</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/811d2430-4b20-41bd-85be-a76fd0ad37ef">
        <rdfs:label>Hypomyelination</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/MP_0013438</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>MP:0013438</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/77aa0a68-9d24-43ed-ad1d-803db94a609b"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d99de04e-c6e7-4c80-aaff-10d5f76ce76e">
        <rdfs:label>Abnormal lysosomal membrane associated protein-1 (LAMP-1) gene expression</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9a0c02e4-e533-4113-adad-647cd8e8339a">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>High level of fucosyl-linked oligosaccharide accumulation</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1b7a884a-d281-4bbe-95f5-0016bd7b92ca">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/MP_0000880</ddiem:url>
        <dc:identifier>MP:0000880</dc:identifier>
        <rdfs:label>Purkinji cells apoptosis</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/25c5855a-3828-40f4-aeb5-10655de61dcf">
        <rdfs:label>OligodendrocyteÂ loss</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0100709</ddiem:url>
        <dc:identifier>HP:0100709</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26537923</dc:provenance>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/230000">
        <dc:identifier>https://www.omim.org/entry/230000</dc:identifier>
        <ddiem:iembaseAccessionNumber>259</ddiem:iembaseAccessionNumber>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/259</ddiem:iembaseUrl>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>FUCOSIDOSIS</rdfs:label>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/b389da03-f43c-4e60-bec9-8a921241668b"/>
      </ddiem:Disease>
    </obo:RO_0002599>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6fa88fb0-5aa5-413b-9ce3-60ff20cb54ef">
        <dc:identifier>HP:0002062*</dc:identifier>
        <rdfs:label>PyramidalÂ neuronÂ loss</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002062</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d2dffdb1-d415-4808-8dff-ef7892e36d90">
        <rdfs:label>Neuronal vacuolation</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/54d96679-925a-4610-94ec-2fefc1f9d632">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>LysosomalÂ expansion inÂ neuronsÂ of deep cortex</rdfs:label>
        <dc:identifier>HP:0004356*</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0004356</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>Phenobarbital, clonazepam, valproate, and midazolam could not completely control seizures. https://www.ncbi.nlm.nih.gov/pubmed/20052547/</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21575633</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6b4a190b-e88b-41f3-862e-ce326258797c">
        <dc:identifier>HP:0000707</dc:identifier>
        <rdfs:label>Abnormal neurololgical function</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000707</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27491218</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/963b4ade-790f-4af1-a0f9-2ac62e0bb492">
        <rdfs:label>Astrocytosis</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/MP_0003354</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>MP:0003354</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </obo:OGMS_0000112>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/035a8a90-663c-468e-8ac4-4e97dc0dbfea">
    <dc:identifier>HP:0000704</dc:identifier>
    <rdfs:label>Periodontitis</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000704</ddiem:url>
  </ddiem:Phenotype>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/e49115f5-4e58-4b05-8dee-d9556826def2">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/70484379-4972-47a1-9b19-8363d46a21c7">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003546</ddiem:url>
        <rdfs:label>Exercise intolerance</rdfs:label>
        <dc:identifier>HP:0003546</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/302060"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/2b5c1ff4-b31b-4a97-a59a-90e2f0c132a4"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3249181</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28279226</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31239752</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18632498</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29695963</dc:provenance>
    <rdfs:comment>Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23432031</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9c36cacc-0a81-4a79-98a0-f313658e406d">
        <dc:identifier>HP:0001635</dc:identifier>
        <rdfs:label>Cardiac dysfunction</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001635</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </obo:OGMS_0000112>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/1318da9f-1bbf-4051-8b6f-748861789bdc">
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/253260"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26577040</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT03269045</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25638506</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/9c601284-c530-4f64-92b1-8737d01c12cc"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <rdfs:comment>Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss</rdfs:comment>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/78a9efb5-49a5-4f22-9e54-10549dd3f132"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28649539</dc:provenance>
  </obo:OGMS_0000112>
  <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/b74773b2-06fe-48e2-9f59-bf2599c059a3">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15131757</dc:provenance>
    <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19452263</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/c148d200-9479-4b6a-a50f-1e30c7044a3f"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26153518</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30804055</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25614308</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28590052</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/804ee22e-7659-4fb5-abaf-b520bf18ba46"/>
    <rdfs:comment>Drug name: Intranasal dDAVP, because of efficacy, long duration of action, and infrequent side effects, is the preferred treatment of neurogenic diabetes insipidus in children and adults.https://www.ncbi.nlm.nih.gov/pubmed/626447</rdfs:comment>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/212138"/>
  </obo:DDIEM_0000007>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0f1e365a-2943-445b-9072-b0e12dcdac34">
    <dc:identifier>HP:0001508</dc:identifier>
    <rdfs:label>failure-to-thrive</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001508</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/df230097-a316-41a1-9b84-7d1e636fa499">
    <rdfs:label>Glycocholic acid</rdfs:label>
    <dc:identifier>DB02691</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/96d90e61-4ae9-45e5-bf1e-1a06d32cf00c"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB02691</ddiem:url>
  </ddiem:Drug>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/612953">
    <rdfs:label>PARKINSON DISEASE 14, AUTOSOMAL RECESSIVE; PARK14</rdfs:label>
    <dc:identifier>https://www.omim.org/entry/612953</dc:identifier>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/ff8290eb-e268-4f16-8549-1638f8374cf9"/>
    <rdfs:comment></rdfs:comment>
  </ddiem:Disease>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/9c0a10a4-979b-44c4-b46e-1b7b419baa1a">
    <dc:provenance>http://www.neurologyindia.com/article.asp</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30387909</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/607364"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2646391</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24260777</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/eb318982-8e44-434a-92f2-7148303622aa"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/77066bf1-0b44-448f-a183-61007143ccdc"/>
    <rdfs:comment>Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss</rdfs:comment>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-Bartter.pdf</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/c3951163-c8e6-466e-8940-5830b567e782"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7709f573-ebc9-44eb-b112-8f3b58e2349f">
        <rdfs:label>Decreased serum IGFâ1</rdfs:label>
        <dc:identifier>HP:0030353</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0030353</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </obo:OGMS_0000112>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/dd0b036a-9adb-4001-bf30-c180aeb395f3">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>abnormal Biotinidase activity in plasma</rdfs:label>
  </ddiem:Phenotype>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/630766ca-42fc-4280-90ec-7feb9c89590a">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/770206a4-7c24-44c8-b25e-5b02255ae4e9">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001263</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Delayed mental development</rdfs:label>
        <dc:identifier>HP:0001263</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>Topical retinoic acids, topical steroids, hydroquinone, tretinoin, and systemic retinoids have been used without success. https://www.ncbi.nlm.nih.gov/pubmed/2350982
https://www.ncbi.nlm.nih.gov/pubmed/3679816 https://www.ncbi.nlm.nih.gov/pubmed/29797344

Combination of Q-switched Nd: YAG and Fractional Carbon Dioxide Laser could be a promising therapy to pigmentation of Dowling-Degos diseaseÂ  https://www.ncbi.nlm.nih.gov/pubmed/28529428</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12084887</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22815559</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16891685</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1899474</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10585338</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/910b5622-25b2-444e-877a-347d33f6639a">
        <rdfs:label>Decreased CSF homovanillic acid</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0003785</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003785</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10407773</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11241071</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8817341</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/78f3d001-4887-4d42-8777-a38dce39096e"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9732974</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/035c76c1-6daa-40f4-9fce-11bc9786802e"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/262aff8c-4c68-4c16-ad37-3e94a2a0e2fe">
        <dc:identifier>HP:0002194</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002194</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>lack of gross motor function</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b72d1cb7-932a-42f9-a4ec-caa99c868a66">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002375</ddiem:url>
        <dc:identifier>HP:0002375</dc:identifier>
        <rdfs:label>Hypokinesia</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8163996</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/605407"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c81a901a-0ce7-4114-8213-b17e705dcbda">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002194</ddiem:url>
        <rdfs:label>Delayed motor skills</rdfs:label>
        <dc:identifier>HP:0002194</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/63140549-5214-4490-9fb3-f9b70b2be068"/>
    <ddiem:failedToContributeToCondition>(926T&gt;C</ddiem:failedToContributeToCondition>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/da184cec-d903-494e-a46f-a3dad76d2400"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20399390</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f77c2814-1a9b-4b7b-ae19-f5193af8bc5e">
        <rdfs:label>Abnormal epinephrine,norepinephrin ratio</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/748338ef-6d54-429c-b0de-b2c98a0df421"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10753262</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/98a69309-00f5-4c38-8570-cacb7e2c44b1"/>
  </obo:OGMS_0000112>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a9bb0bb5-60c8-45af-a18b-220995490e3e">
    <dc:identifier>HP:0000992</dc:identifier>
    <rdfs:label>intolerance to sunlight</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000992</ddiem:url>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/ea902e7d-fc84-45eb-be83-2a09e72f2865">
    <rdfs:label>Valproic Acid</rdfs:label>
    <dc:identifier>DB00313</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/561941a1-2fa1-495a-8256-ef74af9761a9"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00313</ddiem:url>
    <obo:RO_0000056>
      <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/702ceb2e-af9c-46e0-bb89-c584e6123f6e">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1899474</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/274270"/>
        <dc:provenance>https://link.springer.com/chapter/10.1007%2F8904_2017_14</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/c51058f7-1e07-472e-a6a6-adeb625d7b5f"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28275972</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ec071e40-a9de-42ba-9a0d-7ca4df468351"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16891685</dc:provenance>
        <dc:provenance>HP:0000750</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/6d2b5557-7b18-4300-aa41-73dcc0f17c44"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/84ef5cc2-fde1-430e-83fc-fa699c3fbac1"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27622829</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/65bf1bc3-d9a6-42a6-a8a1-e78c384ff6cb"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8163996</dc:provenance>
        <rdfs:comment>Alhough therapy with desmopressin cannot be recommended based on the results of a single case, the outcome presented here is intriguing and suggests that larger studies in such patients is warranted to assess the broader application of such an intervention.</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12084887</dc:provenance>
      </obo:DDIEM_0000013>
    </obo:RO_0000056>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/01ef47c7-085a-468f-bed3-3bb206f58053"/>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/634f5e8a-8e49-4199-8692-347bc2811491">
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/014067369192373A</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/c8e04232-ea28-4fe2-be77-1f4a12d2f1b7"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4545930</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/250850"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19585268</dc:provenance>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
        <dc:provenance>https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117</dc:provenance>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9511979</dc:provenance>
        <rdfs:comment>Pharmaceutical studies are needed to reduce the adverse enteral effects.https://www.ncbi.nlm.nih.gov/pubmed/30127521</rdfs:comment>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/c51058f7-1e07-472e-a6a6-adeb625d7b5f"/>
        <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/dc08ebff-280a-4872-acd2-0fafc38315ae">
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <rdfs:comment>Valporate has been used in two patients, but it had to be discontinued because of a severe elevation of liver enzymes. since then it hasn't been used in IOSCA. VAlporic acid Should be avoided in those patients.</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19304794</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23887143</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/35b5c64e-9aaa-46fd-84a3-e5d483d4e101"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17192294</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19627167</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/271245"/>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00125190</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/c51058f7-1e07-472e-a6a6-adeb625d7b5f"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27551684</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24639006</dc:provenance>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10549306</dc:provenance>
      </obo:DDIEM_0000013>
    </obo:RO_0000056>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/37b821ea-70ce-470f-ac6b-60b7909bceaf"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/f2fb72be-0adc-48ac-a062-fc27029db697"/>
    <obo:RO_0000056>
      <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/66807533-e129-40f2-847e-4b604e1037a1">
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/c51058f7-1e07-472e-a6a6-adeb625d7b5f"/>
        <rdfs:comment>The drug was accompanied with lysin restricted diet</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24204001</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/387b9aa2-9a28-479d-a7f0-8ecfc6876a9c"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23570448</dc:provenance>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000009"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/238700"/>
      </obo:DDIEM_0000013>
    </obo:RO_0000056>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/1308e75b-8c6c-40f0-bdea-ff8d8cfe0405">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/35be1cbf-9813-4fd3-b019-e2aec432dbb6"/>
    <dc:identifier>DB00951</dc:identifier>
    <rdfs:label>Isoniazid</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00951</ddiem:url>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/a168b583-4467-494e-adf1-d5226dfd5cee">
    <obo:RO_0000056>
      <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/f1fb8155-361e-4d81-97b2-90e1417cb412">
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://link.springer.com/article/10.1007/s11940-011-0131-z</dc:provenance>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1059131117301243</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26067811</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ecbcf6ab-69ab-4901-8e24-f37aa276dffb"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/602541"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/3fbdd6dc-ab64-4c45-8cdb-af53eadb93d1"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/b6440918-b260-473b-b8c6-f589e9af695b"/>
        <rdfs:comment>In a different study IV administration of Glucose wasn't effective.https://www.ncbi.nlm.nih.gov/pubmed/22238410</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/books/NBK1520</dc:provenance>
      </obo:DDIEM_0000013>
    </obo:RO_0000056>
    <ddiem:url>https://www.whocc.no/atc_ddd_index/?code=C07</ddiem:url>
    <obo:RO_0000056>
      <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/acac8c6f-cb7a-4997-a332-e8ecee2f6927">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31239752</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/302060"/>
        <rdfs:comment>Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23432031</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a1b7a961-3493-4a87-8f04-5d719892c297"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3249181</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/945a1f69-a783-40b5-94e6-6bdae2e9666a"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18632498</dc:provenance>
      </obo:DDIEM_0000013>
    </obo:RO_0000056>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/b35c4f98-48c3-4d4c-9ce9-125c420c0c5a"/>
    <rdfs:label>BETA BLOCKING AGENTS</rdfs:label>
    <dc:identifier>C07</dc:identifier>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/72335a61-7f79-462c-87be-fe5a1ccb8243">
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/9bcde9b7-3bfc-4c4e-8dde-cb76fa171616">
        <ddiem:url>https://www.drugbank.ca/drugs/DB00734</ddiem:url>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/6bc4517c-156d-487b-8660-49bbff144493"/>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/3623de04-06af-425a-a4e4-879d011f3d99"/>
        <dc:identifier>DB00734</dc:identifier>
        <rdfs:label>Risperidone</rdfs:label>
      </ddiem:Drug>
    </rdf:li>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/a7b0b3f3-84c1-42b6-ab43-8b39cf0688db">
    <dc:identifier>DB00030</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/9e56f56b-c10f-4f4a-bd65-ba04d3077231"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00030</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/34cfec2b-48b4-48d0-8fb2-c2ffb1d7c978"/>
    <obo:RO_0000056>
      <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/ac7a6f74-6a7f-4e6b-b297-11cc593fcdc1">
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e1d68b97-5799-48ca-b473-17bb70a15c8e"/>
        <rdfs:comment>Uncoooked cornstrach was introduced in small frequent meal and was accomapined with elimination of lactose in diet</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5338723</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/227810"/>
        <dc:provenance>http://www.ncbi.nlm.nih.gov/pubmed/29116606</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27155573</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/b72d1a91-57bb-4e00-a58c-8a1fb9a0a6c5"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23456528</dc:provenance>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
      </obo:DDIEM_0000013>
    </obo:RO_0000056>
    <rdfs:label>Insulin Human</rdfs:label>
  </ddiem:Drug>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/6986a6d4-c93c-4e19-afa3-f237fb45e577">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22149023</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/93a86584-22b7-4516-86d1-edef4e9f9a88">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/a1213c99-08f3-4506-96d2-0a61a5d1586a"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/35b5c64e-9aaa-46fd-84a3-e5d483d4e101"/>
    <rdfs:comment>"Oral tocofersolan was more bio available than the water-soluble formulation in children with chronic cholestasis and similarly bio available in CF. This suggests that water-soluble vitamin E may represent an alternative to painful intramuscular vitamin E injections in chronic cholestasis, or other oral formulations in CF. However, the mechanism responsible for fat malabsorption in CRD concerns the absorptive phase as opposed to the digestive phase in CF and cholestatic syndromes. To our knowledge, no specific studies with these new vitamin E preparations have been conducted in CRD." https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717/</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/220110"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19622360</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11067870</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3963001</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6206929</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/971536</dc:provenance>
  </obo:OGMS_0000112>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/f65ed097-57c8-40f4-92dc-10a4cd7db0f5">
    <rdfs:comment></rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0303846712003952</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22132097</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22840416</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/f5919ed0-0d88-482f-843b-0e629ced7671"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/387b9aa2-9a28-479d-a7f0-8ecfc6876a9c"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/300438"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11102558</dc:provenance>
  </obo:OGMS_0000112>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/e23d89a9-20ce-446b-9cce-8eeb6dcb83e2">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25717099</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27488560</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/7b517ff3-fc9a-449b-a7f3-1355c1eb4688"/>
    <rdfs:comment>One of the studies that was carried on mice provides useful information for developing the optimal dosage regimen for HPBCD therapy when administered intravenously to NPC patients.https://www.ncbi.nlm.nih.gov/pubmed/26027824</rdfs:comment>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/140350"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/c88d25ce-d2de-4c70-ac25-b60a224f7936"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28803710</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19415691</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24683506</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.semanticscholar.org/paper/The-Incidence-of-Transient-Neonatal-Tyrosinemia-a-Zea-Rey-Cruz-Camino/b66304a0a56304f686380af915a92b2b860e9305</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>http://www.scielo.br/pdf/jiems/v5/2326-4594-jiems-5-e170016.pdf</dc:provenance>
  </obo:DDIEM_0000013>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1a792c3c-c553-4730-84ba-907404091b6c">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Oedema</rdfs:label>
    <dc:identifier>HP:0000969</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000969</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/79f2b593-fd23-49cb-a100-2fcf406dc6a8">
    <rdfs:label>Benzbromarone</rdfs:label>
    <obo:RO_0000056>
      <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/01bdd849-55ca-427e-ab75-d31897ec49e7">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11068651</dc:provenance>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02527343</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/9b7dbd5d-0f1c-4909-8303-bbed922dd481"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/162000"/>
        <rdfs:comment>In individuals with allergies or intolerance to allopurinol, febuxostat may be considered; however, no data on the use of this medication in UMOD-associated kidney disease are available at present.</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9678437</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/43698ab0-afd0-4ca5-a1ee-dae492cfa56e"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5338723</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/899af578-4c5a-4b91-801f-90ac92423999"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
      </obo:DDIEM_0000013>
    </obo:RO_0000056>
    <ddiem:url>https://www.drugbank.ca/drugs/DB12319</ddiem:url>
    <dc:identifier>DB12319</dc:identifier>
  </ddiem:Drug>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/5d7719e6-7144-4f65-b30f-5fb38b572808">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4886552</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00923247</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30297385</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/35b5c64e-9aaa-46fd-84a3-e5d483d4e101"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/aec43db9-f442-4101-818f-081f49d11b59"/>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/614080">
        <dc:identifier>https://www.omim.org/entry/614080</dc:identifier>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/1145</ddiem:iembaseUrl>
        <ddiem:iembaseAccessionNumber>1145</ddiem:iembaseAccessionNumber>
        <rdfs:label>MULTIPLE CONGENITAL ANOMALIES-HYPOTONIA-SEIZURES SYNDROME 1; MCAHS1</rdfs:label>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/2ca34841-17b1-4234-a512-4cd3b8afc17c"/>
        <rdfs:comment></rdfs:comment>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00704730</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <rdfs:comment>Patient continued to have daily seizures on oxcarbazepine, topiramate and levetiracetam</rdfs:comment>
  </obo:OGMS_0000112>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a501c4d9-c7be-4ce9-be35-515371f6d3e7">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0100529</ddiem:url>
    <rdfs:label>Abnormality of phosphate homeostasis</rdfs:label>
    <dc:identifier>HP:0100529</dc:identifier>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/0ef1d372-c166-4d8e-b153-4b027dd785ce">
    <rdfs:label>Cholic Acid</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB02659</ddiem:url>
    <dc:identifier>DB02659</dc:identifier>
    <obo:RO_0000056>
      <obo:DDIEM_0000011 rdf:about="http://ddiem.phenomebrowser.net/314e5841-bfc8-4fde-98ef-5bcec93a588f">
        <rdfs:comment>Many studies have reported early responce to l- dopa treatment as mentioned in https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4503963/, and other pointed to " prominent dyskinesia " as side effect to same treatment https://www.ncbi.nlm.nih.gov/pubmed/19087156/</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19622360</dc:provenance>
        <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18570303</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8225213</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ac0a4a8c-196f-4e5e-845d-e8dab07253c6"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/235555"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/7c3dc3a0-a898-4e31-b438-6fa587720a72"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/5048010f-10dc-4624-8720-aa3b9e6d66f0"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/35f486d8-eee3-429e-bda3-31bff1a41d4e"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/6911f58c-1e35-4b43-b3c9-b78987f02ebe"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/7b1a34a3-4d87-4e9e-a5fa-17af70e20bce"/>
        <dc:provenance>https://rarediseases.info.nih.gov/diseases/10045/congenital-bile-acid-synthesis-defect-type-2</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11067870</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/805548af-9efd-4822-a8b8-b2f38190cf3e"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ac523342-45e6-4195-b67d-f3fb0a7f3440"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6206929</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20619503</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19087156</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/03408d8b-7d44-412f-8409-63be720e1df9"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/1c607842-cdc7-4aa6-ade9-fe73ef7ad88e"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4503963</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ea816f1e-27b7-4b8d-a28d-1ca7085d73d4"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/2d18b821-1e47-46ed-84ee-326484f2b08b"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/33e09300-c93e-4566-b3d2-7d1d1ee239e1"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/177f0e08-67e7-40f9-a95f-550a786c0af9"/>
      </obo:DDIEM_0000011>
    </obo:RO_0000056>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/5bdd0642-37f4-4713-b29e-42dbafe1e713"/>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a1cad489-6469-40a3-b75a-2e13b4f71a5a">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>No phenotypes were mentioned in the study. In vitro Study.</rdfs:label>
  </ddiem:Phenotype>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/3051ea53-afa8-4e57-8f18-e90651baa0b5">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/145750"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/62f13862-3b92-42cc-9dad-e958eef7c627"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16390715</dc:provenance>
    <rdfs:comment>In individuals with allergies or intolerance to allopurinol, febuxostat may be considered; however, no data on the use of this medication in UMOD-associated kidney disease are available at present.</rdfs:comment>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21289269</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22142470</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/fe35dd1b-3430-4b40-ab6a-49a02cadf457">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/0f107f09-8101-4951-88e4-487c1b79e6a4"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25993639</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20495831</dc:provenance>
  </obo:OGMS_0000112>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/7ca71b67-1b55-4cb6-9d4e-faaa6a44174f">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4a2cd2e3-6d2e-4077-a216-95c43af057bc">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012649</ddiem:url>
        <dc:identifier>HP:0012649</dc:identifier>
        <rdfs:label>Inflammation</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a5f62219-be2b-4caa-a2bf-797c84fefc6f">
        <rdfs:label>concentration of myo-inositol in brain</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0025460</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0025460</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <rdfs:comment>Indomethacin was the most effective but can cause gastrointestinal intolerance and decreased eGFR. Amiloride and eplerenone have similar but lower efficacies and increase sodium depletion. The benefit/risk ratio of each drug should be carefully evaluated for each patient.          https://www.ncbi.nlm.nih.gov/pubmed/25012174
Despite a documented effect on hypokalemia, indomethacin and other nonsteroidal anti-inflammatory drugs should be used with caution due to their short- and long-term gastrointestinal side effects and nephrotoxicity.https://www.ncbi.nlm.nih.gov/pubmed/28003083</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/df87ed35-7b23-4478-91ec-02c237d5b2a1">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0011118</ddiem:url>
        <rdfs:label>concentration of TNF-alpha in plasma</rdfs:label>
        <dc:identifier>HP:0011118*</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00962260</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/518b6d43-2c86-4354-bcc8-68383fdd91a7"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27499018</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/48f0eae9-c050-47a4-8918-9b66e9cc570d"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01427517</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02583672</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23860343</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21503667</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/230800"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28381550</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b3b2bb37-3d0c-4ca5-9f6a-a25fdf74f66a">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Low blood glutathione redox ratios</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/MP_0012604</ddiem:url>
        <dc:identifier>MP:0012604*</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </obo:OGMS_0000112>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/9c87e3e5-79be-4b55-83ca-7575cf7ebd05">
    <dc:identifier>DB00121</dc:identifier>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/308d5d08-5815-4f70-b43b-abc6e3470964">
        <obo:RO_0003304>MCCA-R385S(heterozygote mutation)</obo:RO_0003304>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a9a90466-9689-4c04-81e6-d52039771562"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16773504</dc:provenance>
        <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
        <ddiem:failedToContributeToCondition>MCCB-(IVS16Ã¾1G&gt;A)/ MCCB-missense mutation E99Q Homozygous mutation</ddiem:failedToContributeToCondition>
        <obo:RO_0003304>"heterozygote missense mutation, MCCA-R385S"</obo:RO_0003304>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4470948</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/387b9aa2-9a28-479d-a7f0-8ecfc6876a9c"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000012"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/6015addb-cdd5-4f53-9355-4829d71058ab"/>
        <rdfs:comment>Drug works for heterozygot mutations rather than homozygous ones.
It is possible that biotin treatment might falsely normalize the results of the lymphocyte enzyme assay in biotin-responsive individuals, thus a biotin trial would best be considered after enzyme assay. There is no data suggesting continuing biotin is helpful in nonresponders. https://www.ncbi.nlm.nih.gov/pubmed/18155630</rdfs:comment>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e316f32c-fb26-4111-ab29-5738cff667f1"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1182108</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/210200"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15877210</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18155630</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/78a9efb5-49a5-4f22-9e54-10549dd3f132"/>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00121</ddiem:url>
    <rdfs:label>Biotin</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/1318da9f-1bbf-4051-8b6f-748861789bdc"/>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4cea6455-678d-4f14-816e-92d028e3c76f">
    <dc:identifier>HP:0001013*</dc:identifier>
    <rdfs:comment>The phenotype was controlled with diet, withdrawal from ethanol use, and the fibric acid derivative gemfibrozil.https://www.ncbi.nlm.nih.gov/pubmed/2702860</rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001013</ddiem:url>
    <rdfs:label>Tuberoeruptive xanthomas</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/f06a23d0-3e6b-481d-8cd7-6b83d7348965">
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/5da82627-8c73-451c-9fc7-b0720c16b64e">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3755542</dc:provenance>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/43180bde-f3e5-45b4-8750-5f4d8e3d8747"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/e2a62d30-8f60-413b-973a-e2141188e8a3"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00028262</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/256730"/>
        <rdfs:comment>Overall no significant clinical positive effect of Cystagon was seen in the current study involving four patients. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3755542/</rdfs:comment>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/8170d01c-fda5-4cbc-9d59-700aea255da9">
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/219750"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19622360</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3963001</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12488257</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1929112</dc:provenance>
        <dc:provenance>http://www.ncbi.nlm.nih.gov/pubmed/21897743</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/64d584f0-ba24-49c2-a2c6-efaeab4691be"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12370309</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/e2a62d30-8f60-413b-973a-e2141188e8a3"/>
        <rdfs:comment>"Oral tocofersolan was more bio available than the water-soluble formulation in children with chronic cholestasis and similarly bio available in CF. This suggests that water-soluble vitamin E may represent an alternative to painful intramuscular vitamin E injections in chronic cholestasis, or other oral formulations in CF. However, the mechanism responsible for fat malabsorption in CRD concerns the absorptive phase as opposed to the digestive phase in CF and cholestatic syndromes. To our knowledge, no specific studies with these new vitamin E preparations have been conducted in CRD." https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717/</rdfs:comment>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/e6a80f8f-ee6c-4ca7-b575-4340f2a6fdda">
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11001803</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4158338</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d9a65178-e629-415d-8696-678aa37ba82a"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/9bf54cf6-724e-4c73-8949-7b1bea28a0ae"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3550461</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/65e4b303-5c3d-4abd-b46f-fae588d029d5"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/219800"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/c2d60072-04c0-47f8-9777-ab6a06113853"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/64d584f0-ba24-49c2-a2c6-efaeab4691be"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9758713</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3505515</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8444253</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19622360</dc:provenance>
        <rdfs:comment>Non-compliance is frequent and is secondary to the acrid sulfur body and breath smell, gastrointestinal upset and tight administration schedules (every 6 h) [49]. Strategies to reduce foul odor include oral supplements of vitamin B2 (riboflavin) or the use of chlorophyll tablets to mask the odor produced by dimethyl sulfide, the culprit metabolite of cysteamine that causes bad smell. However, the benefits of these compounds have not been proved and are particularly difficult to monitor in the clinical practice; therefore, their use is purely based on subjective assessment from patients. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4158338/ Cysteamine currently represents the mainstay of therapy, allowing depletion of lysosomal cystine in most tissues. It should be initiated as early as possible and continued lifelong. Although cysteamine does not cure the disease, it dramatically improves the overall prognosis https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4158338/ Phenotypes improved: Because systemic cysteamine treatment has no effect on corneal cystine crystals, topical 0.5 % cysteamine eye drops are indicated. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3016220/</rdfs:comment>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/e2a62d30-8f60-413b-973a-e2141188e8a3"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/eadc078a-f923-4256-80af-e13ae0c917e9"/>
        <dc:provenance>http://www.ncbi.nlm.nih.gov/pubmed/21897743</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/0bcb89bc-df90-4229-9021-71a188057e6f"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23416144</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a495b198-7c73-4e46-a59c-ab9805502b87"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d1eeec89-5531-457a-8e21-771e03895cc1"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/86d114c9-1172-42ff-a7c9-a4ba82a71ca2"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3016220</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/7a73f54d-09e8-4425-8e2e-9e85119166de"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/40f0bb66-20b6-4d0d-a45e-8a2eb01a7ed3"/>
      </obo:DDIEM_0000007>
    </obo:RO_0000056>
    <dc:identifier>DB00847</dc:identifier>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/24337e50-83f5-4efa-bb0c-a851fe5d5fce">
        <rdfs:comment>MCT should be at least 70% of the total fat content of the diet.</rdfs:comment>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02023866</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26884075</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/e2a62d30-8f60-413b-973a-e2141188e8a3"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/8963e454-ea8f-4ca5-8ebb-59ed11987c54"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/530000"/>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02473445</dc:provenance>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00847</ddiem:url>
    <rdfs:label>Cysteamine</rdfs:label>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/b2720941-fbd3-4bab-854d-7936df4f8ede">
    <rdfs:label>Lorazepam</rdfs:label>
    <dc:identifier>DB00186</dc:identifier>
    <obo:RO_0000056>
      <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/cd7d59ba-14f5-44f9-8222-6cc16d478201">
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
        <dc:provenance>https://link.springer.com/article/10.1023/A:1005353530303</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/277400"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25511120</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/4c56e2fe-60b3-4ebd-aa93-32527bd55148"/>
        <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3950820</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/d0542023-4c46-4cb6-a410-d2b442fab8af"/>
        <rdfs:comment>Bartholomwe et al. have suggested in their paper in 1988 that daily injections of OH-B12 are not necessary to maintain metabolic control and that orally administered OH-B12 is unlikely to be effective. Betaine appears to act synergistically with OH-B12 and should be part of the treatment regimen. Although there are theoretical reasons for using L-carnitine and folinic acid, we could not document their effectiveness in these two patients. https://www.ncbi.nlm.nih.gov/pubmed/3257264/</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19821145</dc:provenance>
      </obo:DDIEM_0000013>
    </obo:RO_0000056>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00186</ddiem:url>
  </ddiem:Drug>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/d0d26044-d250-44ef-8ea9-c09cbeb2859f">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31434105</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00638547</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30755342</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25024447</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/aec43db9-f442-4101-818f-081f49d11b59"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/387b9aa2-9a28-479d-a7f0-8ecfc6876a9c"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:comment>The responce to treatment reported to be poor in two patients, may be due to delayed start of treatment and the coexistence of 2 very harmful mutations, which, together with the p.A222V polymorphism, are known to reduce MTHFR enzyme activity. https://www.ncbi.nlm.nih.gov/pubmed/12673793?dopt=Abstract</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31082797</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31211405</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31196723</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/603174"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30081189</dc:provenance>
  </obo:OGMS_0000112>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/acf41c04-7e4c-4c28-a90f-4f87c3f38c0b">
    <rdfs:comment>Controversial benefits https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4158338/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4158338</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4841061</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/05680789-08bb-4f9e-ad6f-d01999cfa14b">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001510</ddiem:url>
        <rdfs:label>retarded growth</rdfs:label>
        <dc:identifier>HP:0001510</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3016220</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/219800"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19622360</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e83fb17a-14ef-480f-bde2-bd02b1552c09">
        <rdfs:label>low phosphate reabsorption</rdfs:label>
        <dc:identifier>HP:0000117</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000117</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3505515</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8444253</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/c3951163-c8e6-466e-8940-5830b567e782"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
  </obo:DDIEM_0000013>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/ef2d0057-c1f4-411b-b885-139b904e529d">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31239752</dc:provenance>
    <rdfs:comment>Effective only in flares. Oral steroids should be preferred when joint involvement is polyarticular; intra-muscular steroids when contraindication to use oral steroids and joint involvement is polyarticular; intra-articular steroids when joint involvement is mono- or oligoarticular.  https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6411330/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23432031</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27790033</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT03128905</dc:provenance>
    <dc:provenance>https://acrabstracts.org/abstract/anakinra-compared-to-prednisone-on-the-treatment-of-acute-cppd-crystal-arthritis-a-randomized-controlled-double-blind-study</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/118600"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5045115</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/0cd08a38-f58b-41c1-b399-150103c7879b"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/1cbfe780-074e-4883-9c7d-c7b1847865a4"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
  </obo:OGMS_0000112>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/223f7b5d-3382-414e-99b7-2e2e458e68c3">
    <rdfs:label>Bacterial glutric acid production</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/813a597f-f721-495e-83ef-685cb1c5df10">
    <dc:identifier>HP:0001941*</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001941</ddiem:url>
    <rdfs:label>high-anion gap acidosis</rdfs:label>
  </ddiem:Phenotype>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/e8841053-2798-47f5-a587-d7b560c95265">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6206929</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/999586bb-12ed-48e6-9349-b9c89094245c">
        <rdfs:label>lipid peroxidation</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/539d8219-5943-49ed-b30c-ff082cab1b53">
        <dc:identifier>HP:0003254*</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003254</ddiem:url>
        <rdfs:label>DNA damage (Abnormality of DNA repair)*</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3963001</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19622360</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/10bca590-03b5-4f46-8098-f05b3acd0614">
        <dc:identifier>HP:0025463</dc:identifier>
        <rdfs:label>oxidative injury*</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0025463</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11067870</dc:provenance>
    <rdfs:comment>"Oral tocofersolan was more bio available than the water-soluble formulation in children with chronic cholestasis and similarly bio available in CF. This suggests that water-soluble vitamin E may represent an alternative to painful intramuscular vitamin E injections in chronic cholestasis, or other oral formulations in CF. However, the mechanism responsible for fat malabsorption in CRD concerns the absorptive phase as opposed to the digestive phase in CF and cholestatic syndromes. To our knowledge, no specific studies with these new vitamin E preparations have been conducted in CRD." https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717/</rdfs:comment>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/71f1fd93-f9d6-4cd8-9fee-0fa289113825"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28396261</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/600721">
        <ddiem:iembaseAccessionNumber>166</ddiem:iembaseAccessionNumber>
        <dc:identifier>https://www.omim.org/entry/600721</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>D-2-HYDROXYGLUTARIC ACIDURIA 1; D2HGA1</rdfs:label>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/166</ddiem:iembaseUrl>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/0cd436db-1bbe-4a1c-8f5c-b9853cde12e9"/>
      </ddiem:Disease>
    </obo:RO_0002599>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/6b36ca46-5e87-4637-b6e9-73189ff35f01"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/971536</dc:provenance>
  </obo:DDIEM_0000013>
  <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/fe436429-2571-4a8b-8a15-bb8957167380">
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/4950cec4-3077-4589-bfcc-25e5be8e6589">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/5e44101a-c1fd-434f-8470-59cc5e8446a6"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17330087</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f1345f6f-6358-4287-9417-8fbc920c2e00">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001324</ddiem:url>
        <dc:identifier>HP:0001324</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>abnormal muscle strenght</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <rdfs:comment>Corticosteriods might be beneficial in heterozygous mutations as patients have milder phenotypes.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17339125</dc:provenance>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/253600">
        <dc:identifier>https://www.omim.org/entry/253600</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/28777d8e-8ce0-4f05-9eec-bccf9dd423a0"/>
        <rdfs:label>MUSCULAR DYSTROPHY, LIMB-GIRDLE, AUTOSOMAL RECESSIVE 1; LGMDR1</rdfs:label>
      </ddiem:Disease>
    </obo:RO_0002599>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2ffb3de3-808b-4366-9dca-1593644f6001">
        <rdfs:label>Muscle atrophy</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0003797</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003797</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
  </obo:DDIEM_0000007>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d4c8cf22-896f-4f54-84d8-ddb0c1d85fba">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0006670</ddiem:url>
    <dc:identifier>HP:0006670</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Impaired myocardial contractility</rdfs:label>
  </ddiem:Phenotype>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/4f55fa5d-5fc2-403f-a8b3-77b6c6824db2">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3306242</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000012"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24145442</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28334762</dc:provenance>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/263700">
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/319a24cf-a698-450e-aa28-4ed20c84e282"/>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/111</ddiem:iembaseUrl>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>PORPHYRIA, CONGENITAL ERYTHROPOIETIC; CEP</rdfs:label>
        <dc:identifier>https://www.omim.org/entry/263700</dc:identifier>
        <ddiem:iembaseAccessionNumber>111</ddiem:iembaseAccessionNumber>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15726662</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3831495</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/cfd1ccae-d6b6-4dd1-bac2-159fb05b0513"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/fed4de23-40c5-49e1-9c59-6d54e18376d2">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0010473</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>abnormal porphyrin accumulation in urine</rdfs:label>
        <dc:identifier>HP:0010473</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/9d096e60-6642-4e91-9bb3-9e3930aed3fc"/>
    <rdfs:comment>Treatment was stopped three days later because of lack of improvement and severe respiratory alkalosis with lactic acidosis (serum lactic acid 70 mg/dl, normal 4â20 mg/dl). https://www.ncbi.nlm.nih.gov/pubmed/12948744</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583863</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7a3c4661-568b-40a7-90ec-3834fc229dbd">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>premature degradation of misfolded UROS mutants</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719215300895</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c63ba464-9a8b-44df-b097-b8654b9b4acf">
        <dc:identifier>HP:0012187</dc:identifier>
        <rdfs:label>high porphyrin accumulation in circulating RBCs</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012187</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </obo:OGMS_0000112>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/138ccbaa-daf0-44d8-87f7-ac2d4b340d99">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0012030</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0012030</dc:identifier>
    <rdfs:label>Abnormal urinary steroid level</rdfs:label>
  </ddiem:Phenotype>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/471b5c95-6070-43c6-8b98-36cb242656a5">
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/bd80cdbf-3d5c-4fe6-b1e2-1984154bcac1">
        <rdfs:label>Droxidopa</rdfs:label>
        <ddiem:url>https://www.drugbank.ca/drugs/DB06262</ddiem:url>
        <dc:identifier>DB06262</dc:identifier>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/abdb1309-11aa-4fa1-a8d6-0ecebce089d0"/>
      </ddiem:Drug>
    </rdf:li>
  </rdf:Alt>
  <obo:DDIEM_0000011 rdf:about="http://ddiem.phenomebrowser.net/1762f74f-3028-435e-95c8-147b1419a61d">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/202110"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27853336</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/f02981c0-c7df-43c3-b1ca-d1df6b41908d">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/99cee34e-f0df-4e6c-a1f2-34bd50e87092"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26161337#</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18458702#</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/452d33b0-eda6-4036-b2c4-ec40913689b6"/>
    <rdfs:comment></rdfs:comment>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
  </obo:DDIEM_0000011>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/21a46f47-c236-4521-abc9-f0e7a415b765">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001947</ddiem:url>
    <rdfs:label>Renal tubular acidosis</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0001947</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/f5d85262-0ab8-48cc-9938-7a9ba4c6ed4d">
    <dc:identifier>DB14712</dc:identifier>
    <rdfs:label>Elapegademase</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB14712</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/a78b0d6e-4018-4246-a3a8-6f076e273cb7"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/2079daf5-3d71-478d-b8cd-d89d19d3aa07">
    <dc:identifier>DB00162</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00162</ddiem:url>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/36eed733-02b2-40a3-bedf-44ac8552f54b">
        <rdfs:comment>Mixed therapy can markedly attenuate the severe retinal degeneration that is associated with untreated ABL or homozygous HBL. Yet, fundoscopic and functional retinal changes do occur despite early initiation of vitamin treatment. Therefore, the adequacy of the present treatment protocol for ABL and homozygous HBL should be re-evaluated.https://www.ncbi.nlm.nih.gov/pubmed/11767031</rdfs:comment>
        <dc:provenance>https://ojrd.biomedcentral.com/articles/10.1186/1750-1172-3-20</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/887793b3-eacf-454d-9d75-36868d219b9e"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/db6d42d0-bc1e-458c-9a99-e1e2fe9a00d1"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30731125</dc:provenance>
        <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24288038</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14749227</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/200100"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25488886</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/dae370ea-0daf-4d21-918e-6f8825d721bb"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11767031</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/48f0eae9-c050-47a4-8918-9b66e9cc570d"/>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <rdfs:label>Vitamin A</rdfs:label>
    <obo:RO_0000056>
      <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/f59c0080-a82d-41e7-ab0b-e07e14f984f5">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26086616</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/50d7ec9d-44c4-472e-9516-11c0255e17e2"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/1d362dce-e6e6-47b7-b112-2c542f81a603"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19415691</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/887793b3-eacf-454d-9d75-36868d219b9e"/>
        <rdfs:comment>These inconsistent results have suggested that the response might depend on the specific gene mutations
 As the response was not sustained and serum ALP and PLP and urine PEA returned to baseline between 8 and 13 months of treatment 
In N461L mutation which led to complete disappearance of the bone isoenzyme, disease was not modified by PTH treatment.  

https://www.ncbi.nlm.nih.gov/pubmed/22218563?dopt=Abstract
https://www.ncbi.nlm.nih.gov/pubmed/20089612?dopt=Abstract (Lack of sustained response to teriparatide in a patient with adult hypophosphatasia_</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24288038</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24751931</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/de269ab9-3502-4721-82c7-9e5c0891c8b5"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18308659</dc:provenance>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/615558"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9110486</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25717099</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/4744026</dc:provenance>
      </obo:DDIEM_0000013>
    </obo:RO_0000056>
  </ddiem:Drug>
  <obo:direct_complementation_of_a_genetically_defective_protein_by_gene_therapy rdf:about="http://ddiem.phenomebrowser.net/69c52cfa-07d3-4f71-9102-d5526f8712fa">
    <rdfs:comment>Uncooked Cornstarch usually is administered at bedtime, and every 6 hours during illness, to prevent morning hypoglycemia and ketosis. In children who are particularly active, a dose of cornstarch in the morning or 1 hour before strenuous or prolonged physical activity can improve stamina. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1474809/</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0c02b8bc-236d-4a76-96d8-c4867688fb71">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001510</ddiem:url>
        <dc:identifier>HP:0001510</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Growth retardation</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b4af2b96-50e1-491b-bf80-ad0e36096c65"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/1dd18a4d-6ec6-4127-81af-17a27d831c19">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/d592df82-5707-4b00-a919-1af9f54f6b4e"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/345f7321-2b9d-4b63-8db8-6f154976000d"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/73987107-10e4-4fbb-bb6e-006265ced16a">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000105</ddiem:url>
        <rdfs:label>Enlarged kidney</rdfs:label>
        <dc:identifier>HP:0000105</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/64482499-b03b-44a4-8ed9-0c916e569b8d"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/232200"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20163245</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10625614</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/1a90f43d-b719-49a2-ac58-06dcb7429074"/>
  </obo:direct_complementation_of_a_genetically_defective_protein_by_gene_therapy>
  <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/d81a647b-dd6f-4997-bd22-a2e066a76ae7">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27567650</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26865117</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20301535</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/81ef2c4d-b7c6-4946-9915-b9446d90401d"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28057010</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/222700"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25859380</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d9054e8c-01a4-4bda-bd2b-78a630c0a2d0"/>
    <rdfs:comment>Drug has no difference in terms of prognosis.</rdfs:comment>
  </obo:DDIEM_0000007>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/0f0cfd3b-c867-4009-b7d3-b7232b9ebcf5">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>http://www.ncbi.nlm.nih.gov/pubmed/16368216</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/89f8f535-e456-4ce5-a851-69acd4196834">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003470</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0003470</dc:identifier>
        <rdfs:label>paralysis</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16368216</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/231680"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/14606524-8023-4f2b-b71d-1e06b511ab5c"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/cce6f9b9-3b47-4a48-8f8e-f2cffbd01b62">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>progressive leukodystrophy</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002415</ddiem:url>
        <dc:identifier>HP:0002415</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/9a8ef311-71ce-4849-9ecf-45cd8aa3ad6c"/>
    <rdfs:comment>Synergism inmproves results</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12727399</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d4c8cf22-896f-4f54-84d8-ddb0c1d85fba"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
  </obo:OGMS_0000112>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/7b979497-be15-4f04-879b-dbbf2ca9fbf8">
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/207900"/>
    <dc:provenance>https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S109671921200265X</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22541557</dc:provenance>
    <rdfs:comment>Alternative pathway therapy has limited effectiveness in preventing hyperammonemia and must be combined with effective dietary management. https://www.ncbi.nlm.nih.gov/pubmed/11148549</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e13f7525-a835-4fc3-85e5-a0ccc4f8c100">
        <rdfs:label>absence of flow-mediated dilatation of brachial artery</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4052756/#S10title</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/e514fbfc-2ebc-4d27-98c2-c9e7bca18270">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/0d6f3fa7-b278-4f82-9564-c16d36937da9"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ea67615b-ec63-4086-8683-350e5190957d">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Cardiac hypertrophy</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/9b019a1a-e8c3-45f5-ab16-32b11896eee9"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ac22d869-ad51-4a48-8478-59b98441ea50">
        <rdfs:label>endothelial dysfunction</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
    <dc:provenance>https://www.clinicaltrialsregister.eu/ctr-search/search</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23494656</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
  </obo:OGMS_0000112>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/7c4c7350-096d-4a7d-842b-e9c429f466c3">
    <rdfs:label>Beta-Hydroxytryptophane</rdfs:label>
    <dc:identifier>DB04159</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/9c40de2d-53f8-4fcb-be5b-e3f0e38783fc"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB04159</ddiem:url>
  </ddiem:Drug>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/300818">
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/1c8bfdd9-d1ef-4ec3-a89b-0d62b5f15fe4"/>
    <rdfs:comment>PNH is caused by somatic mutations in PIGA https://www.ncbi.nlm.nih.gov/pubmed/28516949</rdfs:comment>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/1141</ddiem:iembaseUrl>
    <ddiem:iembaseAccessionNumber>1141</ddiem:iembaseAccessionNumber>
    <dc:identifier>https://www.omim.org/entry/300818</dc:identifier>
    <rdfs:label>PAROXYSMAL NOCTURNAL HEMOGLOBINURIA 1; PNH1</rdfs:label>
  </ddiem:Disease>
  <owl:Class rdf:about="http://purl.obolibrary.org/obo/DDIEM_0000007">
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000002"/>
    <dc:date rdf:datatype="http://www.w3.org/2001/XMLSchema#dateTime">2019-07-15T18:03:22+00:00</dc:date>
    <dc:creator>leechuck</dc:creator>
    <rdfs:label xml:lang="en">functional complementation of a genetically defective protein</rdfs:label>
    <obo:IAO_0000115 xml:lang="en">A therapeutic procedure in which the composition or metabolic activity of the pathway or network in which the defective protein is found is modified, compensating for alteration of activity of that protein. [PNS]</obo:IAO_0000115>
  </owl:Class>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/7e844da0-0572-4d9d-939b-4f70ab3af4ec">
    <rdfs:label>L-Cysteine</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00151</ddiem:url>
    <dc:identifier>DB00151</dc:identifier>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/301da415-8103-47c1-bcd6-3ec5a56089bb">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22092997</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/7c727f93-656f-47e3-ac58-a3d4c1af8dc8"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12535027</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/177000"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d8305c91-39b5-4893-b88c-0a664ab3b871"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23884489</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26979527</dc:provenance>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00004940</dc:provenance>
        <rdfs:comment>Some references are aganist activated charcoal as treatment for Erthropoietic Protoporphyria. https://www.ncbi.nlm.nih.gov/pubmed/8127352?dopt=Abstract</rdfs:comment>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00004831</dc:provenance>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
  </ddiem:Drug>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/300100">
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/280</ddiem:iembaseUrl>
    <dc:identifier>https://www.omim.org/entry/300100</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>ADRENOLEUKODYSTROPHY; ALD</rdfs:label>
    <ddiem:iembaseAccessionNumber>280</ddiem:iembaseAccessionNumber>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/f5a92a25-6b55-46ff-b4ac-600af9f4d3db"/>
  </ddiem:Disease>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/8b05f86c-86f4-44cc-8f62-bdb8d6f02387">
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/235200">
        <ddiem:iembaseAccessionNumber>203</ddiem:iembaseAccessionNumber>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/203</ddiem:iembaseUrl>
        <rdfs:comment></rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/9753a6f7-da3d-491a-b453-05602d9d69ed"/>
        <dc:identifier>https://www.omim.org/entry/235200</dc:identifier>
        <rdfs:label>HEMOCHROMATOSIS, TYPE 1; HFE1</rdfs:label>
      </ddiem:Disease>
    </obo:RO_0002599>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <rdfs:comment>One of the studies that was carried on mice provides useful information for developing the optimal dosage regimen for HPBCD therapy when administered intravenously to NPC patients.https://www.ncbi.nlm.nih.gov/pubmed/26027824</rdfs:comment>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/1d28af6e-8a7e-40ab-867c-dbef0964b7a2"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01524757</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25717099</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/0298da84-bc59-4182-b0f9-3034bcb4e969">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/50c136bb-55e9-46e6-90e0-2aeb7904961c"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28624580</dc:provenance>
    <dc:provenance>https://www.semanticscholar.org/paper/The-Incidence-of-Transient-Neonatal-Tyrosinemia-a-Zea-Rey-Cruz-Camino/b66304a0a56304f686380af915a92b2b860e9305</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28803710</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24683506</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19415691</dc:provenance>
  </obo:DDIEM_0000013>
  <obo:DDIEM_0000010 rdf:about="http://ddiem.phenomebrowser.net/2f3e1777-1d5b-46cc-ac1f-505d6eeee66c">
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/76e590fa-f89d-4d64-a7a3-c08485b7023c"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16040264</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4c87fe3b-e66b-4704-95b1-af63cd43869a">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Disease progression(Retinopathy)</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003676</ddiem:url>
        <dc:identifier>HP:0003676</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/600890"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/75edfa97-8ab4-43a1-a165-73be3f3fdcb2"/>
    <rdfs:comment>Dietry treatment supplementation</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9733ccfb-8af7-4979-ba8d-0955f1cbcccb">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0007663</ddiem:url>
        <dc:identifier>HP:0007663</dc:identifier>
        <rdfs:label>Reduced visual acuity</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </obo:DDIEM_0000010>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/8a976b2c-e088-45f1-b9a1-b0b8d7181535">
    <ddiem:url>https://www.drugbank.ca/drugs/DB00125</ddiem:url>
    <dc:identifier>DB00125</dc:identifier>
    <obo:RO_0000056>
      <obo:DDIEM_0000011 rdf:about="http://ddiem.phenomebrowser.net/1ca85044-cff9-4a42-939f-b9e51b2cdac2">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23494656</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/160f4bd8-666a-4563-a190-b38d862bf5fa"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3073162</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/8f6287e5-3030-453a-a94d-aa9da3cde6a7"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19585269</dc:provenance>
        <rdfs:comment>Alternative pathway therapy has limited effectiveness in preventing hyperammonemia and must be combined with effective dietary management. https://www.ncbi.nlm.nih.gov/pubmed/11148549</rdfs:comment>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/207900"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f9f4b6f6-542c-41af-8894-52a46f046852"/>
        <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23040521</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/dfd10d54-aae4-4804-9f08-f915a2c39e38"/>
        <dc:provenance>https://www.clinicaltrialsregister.eu/ctr-search/search</dc:provenance>
      </obo:DDIEM_0000011>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/8c20e031-682d-4685-a5f4-4325d104985b">
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e5ba0c72-3ade-4897-9641-ef8971981fb8"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/540000"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26954033</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26095523</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/181b6c6e-38ce-4bf0-8220-56a3525eb815"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/8f6287e5-3030-453a-a94d-aa9da3cde6a7"/>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01212744</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <rdfs:comment>The drug was administered through intravitreal injection.</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15728297</dc:provenance>
        <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
        <dc:provenance>https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/924066a0-311a-4887-b870-d9df2522cb22"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/c85c50cd-f5e2-4670-8106-eeaca985537f"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
      </obo:DDIEM_0000013>
    </obo:RO_0000056>
    <rdfs:label>L-Arginine</rdfs:label>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/bad451f8-bece-48a2-9998-f323b88c76c0">
        <dc:provenance>https://www.jstage.jst.go.jp/article/kanzo1960/43/11/43_11_492/_article</dc:provenance>
        <rdfs:comment>Medium-chain triglyceride (MCT) supplement therapy with a low-carbohydrate formula was effective in CTLN2 to prevent a relapse of hyperammonemic encephalopathy. https://www.ncbi.nlm.nih.gov/pubmed/29651749</rdfs:comment>
        <dc:provenance>https://www.sciencedirect.com/science/article/abs/pii/S1386634602003315</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b95433aa-1311-4974-984b-f38e1d0522c0"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5783980</dc:provenance>
        <dc:provenance>https://globenewswire.com/news-release/2015/03/30/720127/10126746/en/Sigma-Tau-Pharmaceuticals-Inc-Receives-Orphan-Drug-Designation-for-EZN-2279-for-Treatment-of-Adenosine-deaminase-Deficient-Severe-Combined-Immunodeficiency-Disease.html</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/5048010f-10dc-4624-8720-aa3b9e6d66f0"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15670720</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/603471"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d9054e8c-01a4-4bda-bd2b-78a630c0a2d0"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/8f6287e5-3030-453a-a94d-aa9da3cde6a7"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648/#b96-tacg-8-201</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18958581</dc:provenance>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/3754ae1b-ee8c-4c0b-a2a1-3af0afb66885">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27567650</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/5980f93c-9e16-40af-9af9-bf41cf24c4bd"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/222700"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25859380</dc:provenance>
        <rdfs:comment>Although  there are resaerchs that have documented the correlation between LPI and GHD because of the known interaction between the amino acids (AA) arginine, ornithine, and lysine and GH secretion https://www.ncbi.nlm.nih.gov/pubmed/2903866/ https://www.ncbi.nlm.nih.gov/pubmed/14328387/ ,https://www.ncbi.nlm.nih.gov/pubmed/18029456/, https://www.ncbi.nlm.nih.gov/pubmed/6790230/ 
Other reasearchs find these supplements have neither obvious benefit nor difference in terms of prognosis. Arginine supplementation is unhelpful as oral arginine is not absorbed from intestinal mucosa.  https://www.ncbi.nlm.nih.gov/pubmed/27567650</rdfs:comment>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25614305</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/4aa70da5-451c-4b0e-8bb3-ad548d768ce3"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20301535</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/e54eea82-68ab-4047-a96b-4d89602cf451"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/3336b039-d083-4cb4-b7ef-a6c56a8d0c68"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/4e01b027-6933-4213-ba72-a6cf9d0a185a"/>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/37279a5e-07fe-402b-a7ab-de64c5f77043">
    <rdfs:label>High CSF MAN2-oligosaccharides</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/68b01051-be3b-43b2-b333-eec9a9c015c4">
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0012446</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0012446</ddiem:url>
    <rdfs:label>Low 5-MTHF level</rdfs:label>
  </ddiem:Phenotype>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/4687d680-bca2-4dc0-b8bc-183d8e3b750b">
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/309400"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <obo:RO_0003304>G666R</obo:RO_0003304>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/35b5c64e-9aaa-46fd-84a3-e5d483d4e101"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9511979</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/results/NCT00001262</dc:provenance>
    <obo:RO_0003304>N1304S</obo:RO_0003304>
    <rdfs:comment>The response to early copper treatment depends on the ATP7A genotype and that optimal outcomes occur only in patients with mutations that permit some residual copper transport . https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3477514/ Parenteral copper supplementation has been used as a potential disease-modifying treatment of Menkes disease for decades. However, recent evidence suggests its efficacy only when treatment is started within days after birth, which also has important implications related to the techniques that enable early diagnosis. https://www.ncbi.nlm.nih.gov/pubmed/30594472 They proposed a 3-year treatment period on the basis of the expected nephrotoxicity of the study drug and the knowledge that brain myelination is typically completed by 24 months of age. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3477514/ A great guidline on treatment is available @ https://www.sciencedirect.com/science/article/pii/S1096719218304104?via%3Dihub 
Cu therapy in milder MD needs close monitoring to avoid systemic Cu accumulation; important to closely follow connective tissue problems
- Administration may be adjusted in relation to new knowledge about nurture of the brain
- Functional classification of mutations may facilitate patient specific therapy
- Cu-HIS therapy may ameliorate, but never cure. https://www.ncbi.nlm.nih.gov/pubmed/30384011</rdfs:comment>
    <ddiem:failedToContributeToCondition>Q1385X</ddiem:failedToContributeToCondition>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/89a26e29-48b8-4364-bfd4-8e21b901ca8b">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012759</ddiem:url>
        <rdfs:label>Socio-cognitive abnormality(Neurodevelopmental abnormality)*</rdfs:label>
        <dc:identifier>HP:0012759*</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10401004</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8223785</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/0944c6fc-f906-4cbb-bcd4-c79f632d1428">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/f891cd7f-935c-4d11-9e6f-0c3bcc589e62"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <ddiem:failedToContributeToCondition>2757delAG</ddiem:failedToContributeToCondition>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/67719bd8-b5ad-47e1-a846-0ec5f9e74f9b"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20652413</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/caf0561b-3a4b-4441-9239-307557a13247">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003678</ddiem:url>
        <rdfs:label>Rapid disease progression</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0003678</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01212744</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3477514</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ef6fd7dc-4291-436b-8013-9946bd064e26">
        <rdfs:label>Eplieptic discharge (Interictal EEG abnormality)*</rdfs:label>
        <dc:identifier>HP:0025373</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0025373</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a73f51bb-4fc8-4a9f-9358-09a1ade56488"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/553e4ee5-3ad4-4cc5-a05a-861e6047da08">
        <dc:identifier>HP:0002224</dc:identifier>
        <rdfs:label>Woolly hair</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002224</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1e62781a-dcbb-430d-965b-62bb18ebcb72">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0012389</dc:identifier>
        <rdfs:label>Appendicular hyoptonia</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012389</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0003304>"IVS9,DS,+6TâG"</obo:RO_0003304>
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30384011</dc:provenance>
    <ddiem:failedToContributeToCondition>Del ex20â23</ddiem:failedToContributeToCondition>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/0f9cdbdc-59eb-455a-96af-c40c6ecc3988"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/50a6f2c4-ff63-4471-9505-5784c37d7830">
        <dc:identifier>HP:0002344</dc:identifier>
        <rdfs:label>Neurologic burden</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002344</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4de59864-9389-4a1c-857b-28dd719628cf">
        <dc:identifier>HP:0002353</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002353</ddiem:url>
        <rdfs:label>Abnormal brain electrical activity</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5341272</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/27724603-0009-4650-a25f-f5403be27659">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0001010</dc:identifier>
        <rdfs:label>Hypopigmented skin</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001010</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </obo:OGMS_0000112>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c1025b64-d3a9-4576-877c-822dbcfef47b">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001271</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0001271</dc:identifier>
    <rdfs:label>Diabetic polyneuropathy</rdfs:label>
  </ddiem:Phenotype>
  <obo:DDIEM_0000011 rdf:about="http://ddiem.phenomebrowser.net/63e8e915-be88-4a94-8cfa-e479295a9d17">
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c01d999a-8d2a-4615-9eac-27c8805d9d85">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0004923</ddiem:url>
        <rdfs:label>Elevated Phe level in blood</rdfs:label>
        <dc:identifier>HP:0004923</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>It's an investigational therapy where Positive results from using a selective monoamine oxidase (MAO) B inhibitor or non-ergot dopamine agonist pramipexole as an adjunct therapy have been described in the medical literature. This use of such an inhibitor can allow for lower doses of neurotransmitter precursor to be used. However, the long-term safety (e.g. effects on neonatal brain development) and effectiveness of this therapy is unknown and more research is required to determine what role, if any, selective monoamine oxidase B inhibitors play in the treatment of individuals with tetrahydrobiopterin deficiency. https://rarediseases.org/rare-diseases/tetrahydrobiopterin-deficiency/. https://www.researchgate.net/publication/233414693_Deprenyl_in_6-Pyruvoyl_Tetrahydropterin_Synthase_Deficiency. https://www.degruyter.com/downloadpdf/j/pteridines.1995.6.issue-3/pteridines.1995.6.3.144/pteridines.1995.6.3.144.pdf</rdfs:comment>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/261630"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8433887</dc:provenance>
    <dc:provenance>https://www.babysfirsttest.org/newborn-screening/conditions/3-methylcrotonyl-coa-carboxylase-deficiency</dc:provenance>
    <dc:provenance>https://rarediseases.org/rare-diseases/tetrahydrobiopterin-deficiency</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7110811</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12003346</dc:provenance>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/c4633604-cb41-4d90-84d5-44841bde9fef"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/749c4e05-a067-4dbf-bfde-b25a6123b0e0"/>
  </obo:DDIEM_0000011>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/1ea8d660-3b1e-4bc5-8924-dffbfe5da7ab">
    <rdfs:comment>Drug works for heterozygot mutations rather than homozygous ones.
It is possible that biotin treatment might falsely normalize the results of the lymphocyte enzyme assay in biotin-responsive individuals, thus a biotin trial would best be considered after enzyme assay. There is no data suggesting continuing biotin is helpful in nonresponders. https://www.ncbi.nlm.nih.gov/pubmed/18155630</rdfs:comment>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/dd0b036a-9adb-4001-bf30-c180aeb395f3"/>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4470948</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/6125282b-5f3b-48b7-b234-65a42eaef613"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/210200"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18155630</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16773504</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/312e268d-80cd-42d2-83b5-4243d95b0a64">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Increased 3-hydroxyisovaleric acid excretion</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1f915365-13e5-49e1-aaed-460b1dee7602">
        <rdfs:label>Increased 3-methylcrotonylglycine excretion</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e316f32c-fb26-4111-ab29-5738cff667f1"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/387b9aa2-9a28-479d-a7f0-8ecfc6876a9c"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15877210</dc:provenance>
  </obo:DDIEM_0000013>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/ea662ce5-b3ac-4462-bf22-9a1b42fdfd8e">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28590052</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b2e4f205-7ff4-4c00-ab70-a6470c2b131f">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Ployuria</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000103</ddiem:url>
        <dc:identifier>HP:0000103</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23884783</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/125700"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30804055</dc:provenance>
    <rdfs:comment>Some patients could only be fully controlled by the combination of chlorpropamide and hydrochlorothiazide.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1316120</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26153518</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15131757</dc:provenance>
    <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/21636aca-11ac-467e-aa7f-80153e6d0a3f"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ded50ab3-55ea-4bdb-9472-e89dc6353a17">
        <dc:identifier>HP:0003158</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Hyposthenuria</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003158</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </obo:DDIEM_0000013>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/99a209f5-1ac8-4a30-b68d-ca33684e9a97">
    <dc:identifier>HP:0003343</dc:identifier>
    <rdfs:label>GSH deficiency</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003343</ddiem:url>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/bb6253e4-3ea8-4ada-9df2-83481c922779">
    <dc:provenance>https://www.tandfonline.com/doi/full/10.3109/0886022X.2014.900422</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/20703861-b3f1-4a97-ab56-6dde385e305a">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001263</ddiem:url>
        <rdfs:label>Delayed Develoment</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0001263</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02234024</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
    <obo:RO_0002558>
      <ddiem:Evidence rdf:about="http://ddiem.phenomebrowser.net/EC0:0007121">
        <ddiem:url>http://purl.obolibrary.org/obo/EC0_0007121</ddiem:url>
        <dc:identifier>EC0:0007121</dc:identifier>
      </ddiem:Evidence>
    </obo:RO_0002558>
    <rdfs:comment>The mechanisms of its effects in movement disorders are not well understood but probably reflect an increase in synthesis and release of dopamine, with perhaps some inhibition of dopamine uptake.</rdfs:comment>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/609056"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/686cfc66-5714-480f-9c6f-98c2e8411b06">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/32c6d22b-6b9c-47b3-b4e9-6558beb3ef79"/>
      </rdf:Alt>
    </obo:RO_0000057>
  </obo:OGMS_0000112>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/cd994311-f58f-471c-8778-fdf7c002e669">
    <ddiem:url>https://www.drugbank.ca/drugs/DB06756</ddiem:url>
    <obo:RO_0000056>
      <obo:DDIEM_0000012 rdf:about="http://ddiem.phenomebrowser.net/09c068fb-76f9-4aca-915e-4420559e6048">
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d3f96075-1275-416d-968f-4339da6a7e99"/>
        <dc:provenance>https://www.nature.com/articles/srep37583/figures/5</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29247835</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
        <rdfs:comment>The trial was done on cell culture not model animals, authors of this paper " https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5120323/" have mentioned that " Since betaine has already been used for pediatric patients, plenty of safety and dosage data are available, which will facilitate the therapeutic trial for AGU. However, it is not quite clear how efficiently betaine penetrates the blood-brain barrier, and it is unclear if it exerts an effect on the central nervous system".</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28967191</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2850427</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/0d297136-dbde-489d-b8d2-222bb6b7a502"/>
        <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/cd539122-ae66-4ad2-8241-d43b66dbe01f"/>
        <dc:provenance>https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/87dc720b-201b-42f6-9941-23efd491ab26"/>
        <obo:RO_0003304>T122K</obo:RO_0003304>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/208400"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ddb09534-bac9-4589-b31d-246c741bc1ce"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5120323</dc:provenance>
      </obo:DDIEM_0000012>
    </obo:RO_0000056>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/a63a711a-9838-4a14-a486-e4bad808de53"/>
    <rdfs:label>Glycine betaine</rdfs:label>
    <dc:identifier>DB06756</dc:identifier>
  </ddiem:Drug>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/a1ae3ffe-16cd-49b4-9ecf-be377d244822">
    <obo:RO_0002558>
      <ddiem:Evidence rdf:about="http://ddiem.phenomebrowser.net/ECO:00055442">
        <dc:identifier>ECO:00055442</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/ECO_00055442</ddiem:url>
      </ddiem:Evidence>
    </obo:RO_0002558>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/604091"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ded2c9ea-d81f-45e0-903c-8ae5b7b7c9fc">
        <dc:identifier>HP:0002621</dc:identifier>
        <rdfs:label>Arterial pluque</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002621</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4c2e6951-6cfe-40f3-9276-ca78ba30ffe6">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0031799</ddiem:url>
        <rdfs:label>Decreased apolipoprotein AI level</rdfs:label>
        <dc:identifier>HP:0031799</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20495831</dc:provenance>
    <rdfs:comment>Drugs were used sequentially for 8 weeks, after 4 weeks washout. in the clinical trial. Atorvastatin or fenofibrate had little effect on HDL cholesterol; atorvastatin decreased the total cholesterol/HDL cholesterol ratio by 26%. Fenofibrate did not change HDL cholesterol levels and caused an increase in LDL cholesterol. Niacin was the only effective drug to increase HDL cholesterol. https://www.ncbi.nlm.nih.gov/pubmed/18993152</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18993152</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21289269</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28213743</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0c716a4d-9b78-4cb0-b0d9-1c647987a70b">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003233</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0003233</dc:identifier>
        <rdfs:label>Decreased plasma HDL-c levels</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25561459</dc:provenance>
    <dc:provenance>https://www.clinicaltrials.gov/ct2/show/NCT02697136</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8f9d2d6d-85ff-4a43-8613-3f49a0c4d966">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002633</ddiem:url>
        <rdfs:label>Vasculitis</rdfs:label>
        <dc:identifier>HP:0002633</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/517182e7-4461-4c51-93d5-80f18bfc5fb7">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/c001d060-fe78-4d0a-9972-76ad77abba0e"/>
      </rdf:Alt>
    </obo:RO_0000057>
  </obo:OGMS_0000112>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/35e244ee-9573-4ccf-9467-bd765a7178f6">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Pain in the skin</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0025280</ddiem:url>
    <dc:identifier>HP:0025280*</dc:identifier>
  </ddiem:Phenotype>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/0313a104-6ef0-410c-b652-3e2ac46f3ace">
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/1a7d683a-005a-4409-aa0b-32eec00008fe">
        <rdfs:label>AAV-treatedÂ Î²gal</rdfs:label>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/0cb7b8fa-56b5-475a-86d3-fdcc145b5632"/>
      </ddiem:Drug>
    </rdf:li>
  </rdf:Alt>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c3d4e686-e448-4225-b11e-4feb6e6be685">
    <rdfs:label>Liver dysfunction</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001410</ddiem:url>
    <dc:identifier>HP:0001410</dc:identifier>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/90560b29-8bec-488e-936f-a743d0b383d7">
    <dc:identifier>HP:0001976</dc:identifier>
    <rdfs:label>Abnormal Antithrombin-III levels</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001976</ddiem:url>
  </ddiem:Phenotype>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/71ebea66-2f22-4e9b-b87b-976e3a069b56">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4538c2da-4900-4384-bc9c-a3444b58fcc8">
        <rdfs:label>edematous</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0000969</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000969</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/256540">
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/52380bb2-64f0-49fb-9c08-31203c009b30"/>
        <dc:identifier>https://www.omim.org/entry/256540</dc:identifier>
        <ddiem:iembaseAccessionNumber>319</ddiem:iembaseAccessionNumber>
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/319</ddiem:iembaseUrl>
        <rdfs:label>GALACTOSIALIDOSIS; GSL</rdfs:label>
      </ddiem:Disease>
    </obo:RO_0002599>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6e3c5d55-856b-4766-9b79-d262d5320a5b">
        <rdfs:label>incoordination</rdfs:label>
        <dc:identifier>HP:0002311</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002311</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15895716</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5461780</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25485164</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <rdfs:comment>Phenobarbital, clonazepam, valproate, and midazolam could not completely control seizures. https://www.ncbi.nlm.nih.gov/pubmed/20052547/</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a4fa6ab8-fcc9-4ac7-9cd1-a7b3a881918d">
        <rdfs:label>infertility</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000789</ddiem:url>
        <dc:identifier>HP:0000789</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22008912</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7814809</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29358012</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/7c405dcc-c5f8-4d0a-82b2-927f7097882e"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/8b1bc8cf-d562-458c-bc76-b939a37722aa">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/bfca260a-87a6-4b7e-b709-7ecd501a9af6"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15084520</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
  </obo:OGMS_0000112>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e662c40c-ee73-496d-8467-681602293075">
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003236</ddiem:url>
    <rdfs:label>Elevation of creatine kinase</rdfs:label>
    <dc:identifier>HP:0003236</dc:identifier>
  </ddiem:Phenotype>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/2e5b82f7-d1a9-48ce-a8f6-359b9be6c412">
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000015"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/4359fd49-c128-4118-8b96-b9368bcb6de5"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/257220"/>
    <rdfs:comment>The mechanisms of its effects in movement disorders are not well understood but probably reflect an increase in synthesis and release of dopamine, with perhaps some inhibition of dopamine uptake.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19750228</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11227045</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
    <dc:provenance>https://www.intechopen.com/books/cyclodextrin-a-versatile-ingredient/use-of-2-hydroxypropyl-beta-cyclodextrin-for-niemann-pick-type-c-disease</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/d046be7f-8385-48c8-aefe-91fd23ce0110"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ee986848-58ec-4f5c-87ab-17494f1335bc">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003107</ddiem:url>
        <rdfs:label>elevated intraneuronal cholesterol(Abnormality of cholesterol metabolism)*</rdfs:label>
        <dc:identifier>HP:0003107*</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
  </obo:OGMS_0000112>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/c97ad2d6-e373-4ed4-a68e-39a93d2fc790">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/ab4b00ad-e5b6-4d59-a2bd-5d4847ea945d"/>
  </rdf:Alt>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7ec38a70-e4e7-4970-9b42-9ed35bb0fa54">
    <rdfs:label>Decreased niacinamide level</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a6c54fee-ebd7-419f-9ad1-27a1c494ae64">
    <dc:identifier>HP:0012187</dc:identifier>
    <rdfs:label>high erythrocyte protoporphyrin levels</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0012187</ddiem:url>
  </ddiem:Phenotype>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/be2ef431-3d1e-43d0-b7f9-e487f823ba4a">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22791294</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10896280</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11486915</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28883274</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29654911</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/e0c5c12a-82c4-41b5-a1bf-b7ecbf88e50b"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5396c7bf-a3e6-45d1-aabb-4d789888612c">
        <rdfs:label>high ornithine level		HP:0012026</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://link.springer.com/content/pdf/10.1023%2FA%3A1010545811361.pdf</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/258870"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24082780</dc:provenance>
    <rdfs:comment>There was no clinical effect, but amild reduction in the plasma level of desmosterol was observed.</rdfs:comment>
  </obo:DDIEM_0000013>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/2950fb95-de9d-4907-bd00-c5446322db59">
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/77c657d7-e0e3-44ec-a1cb-2836f73f6f15"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/e26f58c5-3e77-453b-8c30-5df2c9c700e9"/>
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/89a50ae1-0a1d-4898-8485-e08b60c50b52">
        <rdfs:label>Low total RBC folate level</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0040087</ddiem:url>
        <dc:identifier>HP:0040087</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01212744</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e4a43b17-61e9-432d-9138-d9f0001ccfb5">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Abnormal CSF folate level</rdfs:label>
        <dc:identifier>HP:0012446</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012446</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8757046</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/68b01051-be3b-43b2-b333-eec9a9c015c4"/>
    <rdfs:comment>The drug was administered through intravitreal injection.</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7d2323f2-6eea-4628-8dfe-663aca59ba50">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0025454</ddiem:url>
        <dc:identifier>HP:0025454*</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Abscent 5-MTHF(Abnormal CSF metabolite level)*</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21310277</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21310276</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d12096ce-d4ea-4099-b359-9c9a1f38a31d">
        <rdfs:label>Bone marrow megaloblastic changes</rdfs:label>
        <dc:identifier>HP:0001980</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001980</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/613839"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26095523</dc:provenance>
  </obo:OGMS_0000112>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/231530">
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/aadf97ab-5b30-4cfc-9387-7a318324e045"/>
    <dc:identifier>https://www.omim.org/entry/231530</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>3-HYDROXYACYL-CoA DEHYDROGENASE DEFICIENCY</rdfs:label>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/236</ddiem:iembaseUrl>
    <ddiem:iembaseAccessionNumber>236</ddiem:iembaseAccessionNumber>
  </ddiem:Disease>
  <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/19232490-fa0b-448a-8fd8-fcb126bfdedc">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/fdf038bd-2922-4c15-8d4c-28e49b18e98e">
        <dc:identifier>HP:0003645</dc:identifier>
        <rdfs:label>abnormal activated partial thromboplastin time</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003645</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8163996</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24499211</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12084887</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/dbfcc8d5-72f7-4e31-86b6-6a02b49c576f">
        <dc:identifier>HP:0002910</dc:identifier>
        <rdfs:label>Abnormal ALT level(Abnormal liver enzymes)*</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002910</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b25037de-115d-4e48-8873-23e7e4691fed">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002910</ddiem:url>
        <dc:identifier>HP:0002910</dc:identifier>
        <rdfs:label>"abnormal alanine transaminase,"</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>Drug name: Treatment is under trial.</rdfs:comment>
    <dc:provenance>https://pdfs.semanticscholar.org/7753/abad26acee41547592d5a3a65b0483eff767.pdf</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16891685</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1899474</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/90560b29-8bec-488e-936f-a743d0b383d7"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/94fc1775-e96b-4212-97f9-5907805447a7"/>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/614921">
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/600</ddiem:iembaseUrl>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/737ee446-9735-41b2-b94f-9d80dd3f7155"/>
        <ddiem:iembaseAccessionNumber>600</ddiem:iembaseAccessionNumber>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>https://www.omim.org/entry/614921</dc:identifier>
        <rdfs:label>CONGENITAL DISORDER OF GLYCOSYLATION, TYPE It; CDG1T</rdfs:label>
      </ddiem:Disease>
    </obo:RO_0002599>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/130573d0-a1bc-4406-af2e-0538d53e5d22">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>abnormal nucleotide sugars</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/eb2745ae-443e-4a09-80b6-bb7055bc0cda">
        <rdfs:label>abnormal aspartate transaminase</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002910</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0002910</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9732974</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02955264</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12756558</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4263309</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/63765e0b-953f-4548-9f6b-846ac6d61be9">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001976</ddiem:url>
        <rdfs:label>abnormal Antithrombin-III levels</rdfs:label>
        <dc:identifier>HP:0001976</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28617415</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/acc4b65c-96fe-4ff5-9d9f-3d2fb3a3fdd6"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/dd7b2ce6-aa8d-4c83-b498-b3a83bb3453a"/>
  </obo:DDIEM_0000007>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/c52b008a-3d56-476f-b7ca-e59090b7dd64">
    <rdfs:comment>Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17185149</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-Bartter.pdf</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/96fedb8d-f7a8-40f7-bf8b-b5937ec19260">
        <rdfs:label>Deleterious prognosis</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30387909</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/fdb284b5-f13e-43f9-a8b5-38696daab465">
        <rdfs:label>Salt wasting</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000127</ddiem:url>
        <dc:identifier>HP:0000127</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/ba4fb4df-0390-4e86-ad94-68cb70436bd1"/>
    <dc:provenance>http://www.neurologyindia.com/article.asp</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/607364"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5db95002-243f-4fc7-848b-81f03034f787">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Decreased life expectancy (Mortality)*</rdfs:label>
        <dc:identifier>HP:0040006*</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0040006</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2646391</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24260777</dc:provenance>
  </obo:OGMS_0000112>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/2f253b2d-afa5-4357-aab2-32c395b11f0c">
    <dc:identifier>DB00159</dc:identifier>
    <rdfs:label>Icosapent</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/50b9861b-7b98-43ae-8490-6adc7d06c617"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00159</ddiem:url>
  </ddiem:Drug>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/0e1776ae-9638-4224-80a0-d34fbb52a9c2">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/cbb2adde-3346-4273-8062-e0cd9da35ad7">
        <rdfs:label>Abnormal renal function</rdfs:label>
        <dc:identifier>HP:0012211</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012211</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18996862</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e11fb57b-1a9c-4af5-be8c-70a3386c27db">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0003676*</dc:identifier>
        <rdfs:label>Renal disease progression( Progressive disorder)*</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003676</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20195241</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/553a0521-9aea-4bab-9d16-7c12f577a082"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/232200"/>
    <rdfs:comment>Ad vectors, HDAd is completely devoid of all viral protein genes and has been shown to display markedly reduced toxicity in mice.https://www.ncbi.nlm.nih.gov/pubmed/15753292</rdfs:comment>
    <obo:RO_0002558>
      <ddiem:Evidence rdf:about="http://ddiem.phenomebrowser.net/ECO:0005242">
        <dc:identifier>ECO:0005242</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/ECO_0005242</ddiem:url>
      </ddiem:Evidence>
    </obo:RO_0002558>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17514432</dc:provenance>
    <dc:provenance>https://www.nature.com/articles/srep44408</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/71596f73-e035-4075-8dde-e92136c484bd"/>
  </obo:DDIEM_0000013>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a22176ac-403e-49db-bfef-e41ce97b9cb4">
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0011122</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0011122</ddiem:url>
    <rdfs:label>Skin lesion</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/0c17e08a-9934-4738-8459-a790e2525b99">
    <obo:RO_0000056>
      <obo:DDIEM_0000011 rdf:about="http://ddiem.phenomebrowser.net/cf0a95e0-3736-4875-8ef6-1cea3b477333">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1899474</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/78f3d001-4887-4d42-8777-a38dce39096e"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25667865</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/261630"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7760062</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16891685</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/ac9e4c34-6622-410a-8b39-d4b71217d40b"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26817292</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b036786b-4b44-4acf-8163-38ca61c36fe9"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/c4633604-cb41-4d90-84d5-44841bde9fef"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18425437</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8163996</dc:provenance>
        <rdfs:comment>Alhough therapy with desmopressin cannot be recommended based on the results of a single case, the outcome presented here is intriguing and suggests that larger studies in such patients is warranted to assess the broader application of such an intervention.</rdfs:comment>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/9603ac77-75ca-4a7c-afc3-2d3d527ae515"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12084887</dc:provenance>
      </obo:DDIEM_0000011>
    </obo:RO_0000056>
    <rdfs:label>Entacapone</rdfs:label>
    <dc:identifier>DB00494</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00494</ddiem:url>
  </ddiem:Drug>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/10b75bc7-4534-449b-b6ea-2eca3f42f0eb">
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/220110"/>
    <rdfs:comment>"Oral tocofersolan was more bio available than the water-soluble formulation in children with chronic cholestasis and similarly bio available in CF. This suggests that water-soluble vitamin E may represent an alternative to painful intramuscular vitamin E injections in chronic cholestasis, or other oral formulations in CF. However, the mechanism responsible for fat malabsorption in CRD concerns the absorptive phase as opposed to the digestive phase in CF and cholestatic syndromes. To our knowledge, no specific studies with these new vitamin E preparations have been conducted in CRD." https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717/</rdfs:comment>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/6125282b-5f3b-48b7-b234-65a42eaef613"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/35b5c64e-9aaa-46fd-84a3-e5d483d4e101"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3963001</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22149023</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19622360</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/971536</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6206929</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11067870</dc:provenance>
  </obo:DDIEM_0000013>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/293bd9b6-3ded-49a0-a1d5-8f4b07c0929a">
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/2f1e6dfb-57db-4ca8-9592-fe629a28c757">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/64ab1e0d-dd13-4b2a-85be-6d5f44770bf2"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/238700"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23570448</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24204001</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:comment>Î±-Tocopherol should be given with the ascorbic acid(vit. C) as the latter helps The resultant tocopheroxil radical regeneration in getting back to reduced tocopherol .</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d93d8a8a-d370-4043-a214-3672dbb82b43">
        <rdfs:label>Delayed motor development</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0001270</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001270</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
  </obo:OGMS_0000112>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/45a0c078-9109-4c43-ac94-6b6422acf06d">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220407</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/202b2073-9e0f-4323-b4bc-9fcf095b645b"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30420558</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2443756</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1886403</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/268200"/>
    <rdfs:comment>The mainstays of treatment are moderate protein (leucine) restriction and avoidance of prolonged fasting and of excessive dietary fat intake, both of which increase fatty acid oxidation; these measures are generally effective in preventing acute decompensations.https://www.ncbi.nlm.nih.gov/pubmed/3128690</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/fae4bb69-a39e-4fad-ad13-1314da3e30f1">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/46e2bd6a-fb4e-4833-8ddc-e9b4c169e97a"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6b58a313-3ed2-4996-b075-003b1fd5b3d4">
        <rdfs:label>High triglyceride levels</rdfs:label>
        <dc:identifier>HP:0002155</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002155</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/80de3df6-5b08-4e5d-9390-d588abc05dae"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26997609</dc:provenance>
  </obo:OGMS_0000112>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/253280">
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/3ac3ab10-f106-445e-a516-1a2f9bc8295b"/>
    <dc:identifier>https://www.omim.org/entry/253280</dc:identifier>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/354</ddiem:iembaseUrl>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH BRAIN AND EYE ANOMALIES), TYPE A, 3; MDDGA3</rdfs:label>
    <ddiem:iembaseAccessionNumber>354</ddiem:iembaseAccessionNumber>
  </ddiem:Disease>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/63569027-a160-491e-ac6a-27e46f038469">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25098371</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22791294</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/results/NCT00001962</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17562599</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/fcd214b1-eac0-4141-a6f4-a1534aaf2ab4"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22734070</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/105650"/>
    <rdfs:comment>There was no clinical effect, but amild reduction in the plasma level of desmosterol was observed.</rdfs:comment>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/a18caec9-824f-4789-85b6-1f91e473d00b">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/7cc88ce2-482d-4c14-bde0-bc78b38b66fc"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15813920</dc:provenance>
  </obo:OGMS_0000112>
  <obo:DDIEM_0000015 rdf:about="http://ddiem.phenomebrowser.net/f6ca8c2c-805a-446c-9d11-fa51a3068c70">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30726693</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/bbefe97e-2df7-487a-a970-bad7fba2f8c4">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/2c4a9be6-09bb-46a4-807d-cdc0e81041b9"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02452372</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15767622</dc:provenance>
    <rdfs:comment>There is a study for "Non-viral delivery of the porphobilinogen deaminase cDNA into a mouse model of acute intermittent porphyria{ ECO: 0005542} https://www.ncbi.nlm.nih.gov/pubmed/15110317</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24821812</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/176000"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/82d3105c-7feb-47dc-938a-698abb806253">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Abnormal circulating porphyrin concentration</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0010472</ddiem:url>
        <dc:identifier>HP:0010472</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30766957</dc:provenance>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648/#b96-tacg-8-201</dc:provenance>
  </obo:DDIEM_0000015>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/82bd2ac4-659b-483a-a601-943f8c64f612">
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001510</ddiem:url>
    <rdfs:label>Delayed Growth</rdfs:label>
    <dc:identifier>HP:0001510</dc:identifier>
  </ddiem:Phenotype>
  <obo:DDIEM_0000011 rdf:about="http://ddiem.phenomebrowser.net/a42fb22b-0839-4075-99c6-48d453862fe2">
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <dc:provenance>https://ojrd.biomedcentral.com/articles/10.1186/1750-1172-3-20</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b0e97c4f-c6e2-4613-a8d5-db7ba691101a">
        <dc:identifier>HP:0008897</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0008897</ddiem:url>
        <rdfs:label>Growth impairment</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25488886</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26086616</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:comment>It's an investigational therapy where Positive results from using a selective monoamine oxidase (MAO) B inhibitor or non-ergot dopamine agonist pramipexole as an adjunct therapy have been described in the medical literature. This use of such an inhibitor can allow for lower doses of neurotransmitter precursor to be used. However, the long-term safety (e.g. effects on neonatal brain development) and effectiveness of this therapy is unknown and more research is required to determine what role, if any, selective monoamine oxidase B inhibitors play in the treatment of individuals with tetrahydrobiopterin deficiency. https://rarediseases.org/rare-diseases/tetrahydrobiopterin-deficiency/. https://www.researchgate.net/publication/233414693_Deprenyl_in_6-Pyruvoyl_Tetrahydropterin_Synthase_Deficiency. https://www.degruyter.com/downloadpdf/j/pteridines.1995.6.issue-3/pteridines.1995.6.3.144/pteridines.1995.6.3.144.pdf</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3954973</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/200100"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24288038</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/c148d200-9479-4b6a-a50f-1e30c7044a3f"/>
  </obo:DDIEM_0000011>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/0539cb0c-7dad-44dc-8419-170411b23f9e">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/928b1463-099d-4a92-80ea-d44cfbe2b6f2"/>
    <rdfs:label>Testosterone</rdfs:label>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/aa365131-d6fb-4e41-bdb0-c3c272dbf6e8">
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b40f8b8f-4bb8-4c27-847f-53fdc4ac6b14"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/9e7506ea-fc46-4874-bd48-54800293684c"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/232220"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/4d1fe024-ca8a-40d1-b8ed-47652b3bacb5"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/755d96ad-dc48-4266-bc82-d181d22b9e6f"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17514432</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28160246</dc:provenance>
        <rdfs:comment>Testosterone therapy needs to be carefully considered because of the risk of hepatic adenomas.https://www.ncbi.nlm.nih.gov/pubmed/28160246
Androgen receptors are expressed in the liver, and androgens can stimulate hepatocyte proliferation. Although rare, androgens have been shown in observational studies to induce adenoma development (Giannitrapani et al. 2006). Testosterone levels should be assessed for response 2â3 months after therapy is initiated.</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18996862</dc:provenance>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00624</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/7ae6200d-7c74-416a-a95e-c3e278dc336b"/>
    <dc:identifier>DB00624</dc:identifier>
  </ddiem:Drug>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/02a923b3-8e05-42fb-b1eb-13d0d8a020d5">
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/9c601284-c530-4f64-92b1-8737d01c12cc"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6dff7abf-98dc-4940-83d5-f36b63dac00c">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001939</ddiem:url>
        <dc:identifier>HP:0001939*</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Defective argininosuccinic acid excretion</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/207900"/>
    <dc:provenance>https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S109671921200265X</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/47bb0321-d127-4e26-ad98-91862bbfe734">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/9ec00ca6-95f3-491c-ae38-7869891deab7"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/668730</dc:provenance>
    <rdfs:comment>Alternative pathway therapy has limited effectiveness in preventing hyperammonemia and must be combined with effective dietary management. https://www.ncbi.nlm.nih.gov/pubmed/11148549</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4052756/#S10title</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f5f3def5-2b3b-4041-808c-457f4ac6cedd">
        <rdfs:label>High blood ammonia levels</rdfs:label>
        <dc:identifier>HP:0001987</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001987</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
    <dc:provenance>https://www.clinicaltrialsregister.eu/ctr-search/search</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23494656</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
  </obo:OGMS_0000112>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/219750">
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/525</ddiem:iembaseUrl>
    <rdfs:label>CYSTINOSIS, ADULT NONNEPHROPATHIC</rdfs:label>
    <ddiem:iembaseAccessionNumber>525</ddiem:iembaseAccessionNumber>
    <rdfs:comment></rdfs:comment>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/8237daba-9339-4e48-8926-93512a872681"/>
    <dc:identifier>https://www.omim.org/entry/219750</dc:identifier>
  </ddiem:Disease>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/256600">
    <dc:identifier>https://www.omim.org/entry/256600</dc:identifier>
    <ddiem:iembaseAccessionNumber>760</ddiem:iembaseAccessionNumber>
    <rdfs:label>NEURODEGENERATION WITH BRAIN IRON ACCUMULATION 2A; NBIA2A</rdfs:label>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/760</ddiem:iembaseUrl>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/ff8290eb-e268-4f16-8549-1638f8374cf9"/>
    <rdfs:comment></rdfs:comment>
  </ddiem:Disease>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/dae370ea-0daf-4d21-918e-6f8825d721bb">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000546</ddiem:url>
    <dc:identifier>HP:0000546</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Retinal degeneration</rdfs:label>
  </ddiem:Phenotype>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/bf3d253a-f4c4-43ab-bb10-3f99bbafd3cd">
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/88ec29a7-11a0-4c9d-8d51-1fea2cbb9e43"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1706c16c-5989-4e6e-8510-7b4c34e4c5e3">
        <dc:identifier>HP:0000989</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Pruritus</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000989</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>https://www.ncbi.nlm.nih.gov/pubmed/8370580</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23884489</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19656325</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25402764</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/177000"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27139922</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/49152949-b69a-489e-be08-286538ca7b8c"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19744342</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26979527</dc:provenance>
  </obo:DDIEM_0000013>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/18f9ae75-b5d5-4cde-aafb-4c2a35ee400a">
    <rdfs:label>Probucol</rdfs:label>
    <dc:identifier>DB01599</dc:identifier>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/ec6b5ce7-d269-4c37-bc57-ab6462961971">
        <rdfs:comment>Probucol is a non-Statin cholesterol-lowering drug and a potent inducer of apolipoprotein E (apoE) production in peripheral circulation. https://www.ncbi.nlm.nih.gov/pubmed/12946703</rdfs:comment>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/617347"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/c5b8d892-6014-439b-9f47-5ff1aef1ecdf"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000012"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12181212</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3162680</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/6bbe19d7-d890-46c7-ad26-77a2f07e3fc0"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2065040</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9185508</dc:provenance>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01599</ddiem:url>
  </ddiem:Drug>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/0a8e1c17-5584-43a8-99f4-0354704da621">
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/277400"/>
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3950820</dc:provenance>
    <rdfs:comment>Bartholomwe et al. have suggested in their paper in 1988 that daily injections of OH-B12 are not necessary to maintain metabolic control and that orally administered OH-B12 is unlikely to be effective. Betaine appears to act synergistically with OH-B12 and should be part of the treatment regimen. Although there are theoretical reasons for using L-carnitine and folinic acid, we could not document their effectiveness in these two patients. https://www.ncbi.nlm.nih.gov/pubmed/3257264/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19821145</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ee3d99f8-af23-4e73-9ac6-8f24e26a176d">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Deep venous thrombosis</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002625</ddiem:url>
        <dc:identifier>HP:0002625</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/ad9e3a91-2390-4d60-afd2-260f4e34df87">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/f9fafe5f-a6f7-4abb-9dab-c422051f999d"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://link.springer.com/article/10.1023/A:1005353530303</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11320193</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25511120</dc:provenance>
  </obo:OGMS_0000112>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/602541">
    <ddiem:iembaseAccessionNumber>1047</ddiem:iembaseAccessionNumber>
    <dc:identifier>https://www.omim.org/entry/602541</dc:identifier>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/1047</ddiem:iembaseUrl>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/02084928-3207-4d92-9248-979b3f858044"/>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>MUSCULAR DYSTROPHY, CONGENITAL, MEGACONIAL TYPE; MDCMC</rdfs:label>
  </ddiem:Disease>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a9a90466-9689-4c04-81e6-d52039771562">
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001992</ddiem:url>
    <rdfs:label>Organic aciduria</rdfs:label>
    <dc:identifier>HP:0001992</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3f8a89eb-cfac-4298-97ef-6391b5e82b26">
    <rdfs:label>Nummular eczema (Eczema)*</rdfs:label>
    <dc:identifier>HP:0000964*</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000964</ddiem:url>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/729b6afd-7097-4303-a8a1-91dd7dcaf577">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/3770c3b5-0185-4774-83fe-d075a4007210"/>
    <rdfs:label>human recombinantÂ acidÂ ceramidase/human ACDase-encoding lentivector</rdfs:label>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/525b07c9-fc63-4fbc-ba39-c86cee1ed4b4">
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/ee5a7966-5c54-410f-8b1c-c5bffcf1dcee">
        <ddiem:url>https://www.drugbank.ca/drugs/DB12783</ddiem:url>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/9f416c86-ef43-4ebb-9d22-5dd14bf71a89"/>
        <dc:identifier>DB12783</dc:identifier>
        <rdfs:label>Benserazide</rdfs:label>
      </ddiem:Drug>
    </rdf:li>
  </rdf:Alt>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/25db1469-b177-45d8-bf6f-7c99f50ef59d">
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/01b9cd35-4553-4407-8b4b-65db0928b8db">
        <ddiem:url>https://www.drugbank.ca/drugs/DB01124</ddiem:url>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/5ebd87c6-80cd-477d-b65f-6b04828064a6"/>
        <dc:identifier>DB01124</dc:identifier>
        <rdfs:label>Tolbutamide</rdfs:label>
      </ddiem:Drug>
    </rdf:li>
  </rdf:Alt>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/eabeb264-e565-44bd-bf6f-d98c7be41c0a">
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a449a7c4-4d81-439e-992b-180400fb2ba8"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7254778</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22791294</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1755734</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15159649</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7356686</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28708224</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/427d05ff-3cba-498e-92a0-3744fc92ac3e">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/a056a20b-318d-4a47-abbb-120f75ccf738"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/258870"/>
    <rdfs:comment>There was no clinical effect, but amild reduction in the plasma level of desmosterol was observed.</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/f45c8c02-ff8e-4dda-8366-c95762a05da1">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/b4b6762d-3909-458d-96a4-75a0632f69be"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28883274</dc:provenance>
  </obo:OGMS_0000112>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/355e1d36-e0fb-4fa8-afc6-ee67c65359c7">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
    <dc:provenance>was associated with improved findings on skeletal radiographs and improved pulmonary and physical function in infants and young children with life-threatening hypophosphatasia. (Funded by Enobia Pharma and Shriners Hospitals for Children; ClinicalTrials.gov number</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7ea75030-2e2e-412d-a171-e8ce5ef75a3f">
        <rdfs:label>Decreased physical function</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0025142</ddiem:url>
        <dc:identifier>HP:0025142</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4824800</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3144124</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/899ef1a5-e64b-4f89-9e4d-926cf760d293"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22397652</dc:provenance>
    <dc:provenance>an enzyme-replacement therapy</dc:provenance>
    <dc:provenance>"ENB-0040</dc:provenance>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/241510">
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/6ed7d20c-8b72-41a5-ac32-47d4eba88fcc"/>
        <rdfs:label>HYPOPHOSPHATASIA, CHILDHOOD</rdfs:label>
        <dc:identifier>https://www.omim.org/entry/241510</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/50ce9ba3-1032-49e1-a2b6-db0b1cdf164e"/>
    <dc:provenance>NCT00744042.)."</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/0f1e365a-2943-445b-9072-b0e12dcdac34"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e46ef1f5-ecda-4ab2-ad72-581ab9952287">
        <dc:identifier>HP:0012759</dc:identifier>
        <rdfs:label>Abnormal developmental milestones</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012759</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/fdae03cc-8e7b-4bf1-ac5a-b9179cde1d47"/>
    <rdfs:comment>Drug name: Treatment is under trial.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12756558</dc:provenance>
  </obo:OGMS_0000112>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/970e29f1-a848-445d-9804-571716e71f81">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-Bartter.pdf</dc:provenance>
    <dc:provenance>http://www.neurologyindia.com/article.asp</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24260777</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
    <rdfs:comment>Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss</rdfs:comment>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/c09bdf57-4493-41d8-8a84-c5dc4407a7a9"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2646391</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/84e18d7d-9eae-45da-baa9-0723162b6693">
        <dc:identifier>HP:0002917</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002917</ddiem:url>
        <rdfs:label>Hypomagnesemia</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/abs/pii/S0002962915356895</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/607364"/>
  </obo:OGMS_0000112>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9b160f79-146d-473c-a4b9-f388490534a4">
    <dc:identifier>HP:0001877*</dc:identifier>
    <rdfs:label>Short erythrocyte survival (Abnormality of erythrocytes)*</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001877</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/5e321172-22c1-4884-b776-f64294828a6d">
    <ddiem:url>https://www.drugbank.ca/drugs/DB05134</ddiem:url>
    <dc:identifier>DB05134</dc:identifier>
    <rdfs:label>Tanespimycin</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/3771ef67-c02d-4686-8074-f41e171a3a1f"/>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d8418cdd-4a30-4d86-8794-a8944db1bb1e">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0100513</ddiem:url>
    <dc:identifier>HP:0100513*</dc:identifier>
    <rdfs:label>Abnormal vitamin E level(Vitamin E deficiency)*</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/732d4b93-2f5f-4339-a594-0d7d90e9ad2d">
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/c1456a0b-5c97-47a7-956c-58010c75ee7c">
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/53cf3b24-0cc5-4dbb-ae5b-ccfe329bdba1"/>
        <rdfs:label>Vitamin K</rdfs:label>
        <ddiem:url>https://www.whocc.no/atc_ddd_index/?code=B02BA</ddiem:url>
        <dc:identifier>B02BA</dc:identifier>
      </ddiem:Drug>
    </rdf:li>
  </rdf:Alt>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/99cd5214-3e53-41d3-8acd-d6d99a20746c">
    <rdfs:comment>The drug is used as a maintenance therapy https://www.ncbi.nlm.nih.gov/books/NBK476305/ https://www.tandfonline.com/doi/abs/10.1080/21678707.2017.1405807</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4382922</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c5109be1-f11e-4817-b564-8cdba6210499">
        <rdfs:label>low quality of life(Constitutional symptom )*</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0025142</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0025142*</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23494656</dc:provenance>
    <dc:provenance>https://www.tandfonline.com/doi/abs/10.1080/21678707.2017.1405807</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/6e52c6e3-c960-41b9-8758-bbf133e1fd16">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/ecb8e3c3-1f5f-4379-af17-3a5725fe77e7"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
    <dc:provenance>https://www.clinicaltrialsregister.eu/ctr-search/search</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4017326</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5508465</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/207800"/>
  </obo:OGMS_0000112>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/220120">
    <rdfs:label>D-GLYCERIC ACIDURIA</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>https://www.omim.org/entry/220120</dc:identifier>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/36b08a81-3a30-46db-a232-b027870336f5"/>
  </ddiem:Disease>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c32db724-11bb-44d8-a299-22cf446e8060">
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0004322</ddiem:url>
    <dc:identifier>HP:0004322</dc:identifier>
    <rdfs:label>Low height velocity</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/d40cb3ee-5b8d-4a8a-8918-77f5b1207acc">
    <rdfs:label>Erythropoietin</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/e10a3dea-8d2d-4628-938a-dfc9f9b7d90a"/>
    <dc:identifier>DB00016</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00016</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/ac5af18a-3c15-4d21-8690-f4752a5a3300"/>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c11d560a-4217-4cb7-9e8e-cb3ad286f095">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Imapired muscle function</rdfs:label>
    <dc:identifier>HP:0011804</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0011804</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/1197949f-ed27-4438-bd4f-2626e7b3f8db">
    <rdfs:label>Cerliponase alfa</rdfs:label>
    <dc:identifier>DB13173</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB13173</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/fa4b02ca-8fcd-4715-8109-5541b8167dbf"/>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0f4943b0-36d1-411a-9dda-c2bebcd5168b">
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0100022*</dc:identifier>
    <rdfs:label>Abnormalitilty in voluntary movements(Abnormality of movement)*</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0100022</ddiem:url>
  </ddiem:Phenotype>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/956d4c70-e38d-4edb-9cef-f8b18c8e0a07">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20619503</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7a952ce5-600b-40da-81d1-49f1676afc48">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012029</ddiem:url>
        <dc:identifier>HP:0012029</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Abnormal urinary steroids levels(Abnormality of urine hormone level)*</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6206929</dc:provenance>
    <rdfs:comment>Many studies have reported early responce to l- dopa treatment as mentioned in https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4503963/, and other pointed to " prominent dyskinesia " as side effect to same treatment https://www.ncbi.nlm.nih.gov/pubmed/19087156/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19622360</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d93e4b7b-3402-4b5a-85c2-1b1dfb5b50cc">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0025142</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0025142*</dc:identifier>
        <rdfs:label>Ill-being (Constitutional symptoms)*</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/21ba206b-4ec3-4104-9c8a-670f005b9320"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4503963</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/aed6c48a-f146-4e90-b66c-2d10ac790a96"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/138ccbaa-daf0-44d8-87f7-ac2d4b340d99"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19087156</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8225213</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18570303</dc:provenance>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11067870</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/607765"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2072042</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/1706c16c-5989-4e6e-8510-7b4c34e4c5e3"/>
  </obo:OGMS_0000112>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b1ffa798-38ac-48d4-a3ac-71b8b6debae6">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Intraretinal cystoid spaces (Retinal disease)*</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000479</ddiem:url>
    <dc:identifier>HP:0000479*</dc:identifier>
  </ddiem:Phenotype>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/2880ac2e-1ada-423f-9688-6b79cf903ea2">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/375935</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/13044560</dc:provenance>
    <rdfs:comment>Enthusiasm for the use of this antimalarial was tempered by the subsequent recognition that irreversible retinopathy was a predictable complication of diiodoquinoline therapy. https://www.sciencedirect.com/science/article/pii/S0190962206022560#bib39
Unfortunately, the long-term treatment with 8-hydroxyquinoline preparations has serious side effects as it leads to optic nerve atrophy and blindness [13], [14]. Therefore, an alternative treatment was desperately sought. https://www.sciencedirect.com/science/article/pii/S0946672X14001837?via%3Dihub#bib0070</rdfs:comment>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/201100"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/414be650-5629-4f03-88ce-4fb227783824">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0011123</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Dermatitis</rdfs:label>
        <dc:identifier>HP:0011123</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24288038</dc:provenance>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/af8c2e55-dfcd-47a1-8583-faace127c1dc">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/3dfdb754-349e-49b4-af5d-9edbde0f22ce"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/4929571</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30669644</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1275520</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
  </obo:OGMS_0000112>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/ea4b43b9-ccea-4c59-ad6c-29375776fa70">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21744491</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/books/NBK1520</dc:provenance>
    <rdfs:comment>Clonazepam is a useful adjunct for myoclonus and can be used in combination with lamotrigine to avoid lamotrigineâs myoclonic effects . 
Zonisamide should remain a second-line adjunct in the treatment of JME, owing to the lack of supportive data.
https://link.springer.com/article/10.1007/s11940-011-0131-z</rdfs:comment>
    <dc:provenance>https://link.springer.com/article/10.1007/s11940-011-0131-z</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1059131117301243</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/c09bdf57-4493-41d8-8a84-c5dc4407a7a9"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a9751c40-9bb4-4313-8c46-f8dc368019ec">
        <dc:identifier>HP:0002019</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002019</ddiem:url>
        <rdfs:label>constipation</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/601776">
        <ddiem:iembaseAccessionNumber>1130</ddiem:iembaseAccessionNumber>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/7a5784c8-3014-455f-9008-e3beda930d2b"/>
        <rdfs:label>EHLERS-DANLOS SYNDROME, MUSCULOCONTRACTURAL TYPE, 1; EDSMC1</rdfs:label>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/1130</ddiem:iembaseUrl>
        <dc:identifier>https://www.omim.org/entry/601776</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Disease>
    </obo:RO_0002599>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
  </obo:OGMS_0000112>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9cab0efd-6217-4d52-b269-32c3345c0f68">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001939</ddiem:url>
    <dc:identifier>HP:0001939*</dc:identifier>
    <rdfs:label>Accumulation of toxic metabolites in cholesterol biosynthetic pathway</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/c8a7afad-7fe6-48db-9f58-607150dfc611">
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/bfb85bc6-fa05-4576-b03f-b3762727a4f3"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/da57b93b-0021-4143-b810-aec8664e6cad">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0040006</ddiem:url>
        <rdfs:label>Low survival rate (Mortality)*</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0040006*</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
    <dc:provenance>https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/309400"/>
    <rdfs:comment>However, to the knowledge of the authors Horn et al. 2019 https://www.ncbi.nlm.nih.gov/pubmed/30384011, clinical evaluation of the copper-thiocarbamate complexes as well as of the copper-thiosemicarbazone remains to be done.</rdfs:comment>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9511979</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/bffc5fb4-aa07-4fc9-bce3-64698d8ddf9b">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/b1b91b65-287d-4159-85a9-41494ae0656a"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30384011</dc:provenance>
  </obo:OGMS_0000112>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/ea289878-9ccf-4df1-8e48-1b29406c435f">
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/53d81324-bc69-4ec5-bd3c-186d552927d4"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24787057</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8e2d58d6-8c27-469a-a2cb-49ccf9dc8f4c">
        <rdfs:comment>The findings reported here support the possibility that supplementation might reduce symptoms or augment recovery of patients with schizophrenia, particularly targeting those with elevated proline, who may represent over one quarter of the schizophrenia population.</rdfs:comment>
        <rdfs:label>schizophrenia</rdfs:label>
        <dc:identifier>HP:0100753</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0100753</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/239500"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24980685</dc:provenance>
    <rdfs:comment>These inconsistent results have suggested that the response might depend on the specific gene mutations
 As the response was not sustained and serum ALP and PLP and urine PEA returned to baseline between 8 and 13 months of treatment 
In N461L mutation which led to complete disappearance of the bone isoenzyme, disease was not modified by PTH treatment.  

https://www.ncbi.nlm.nih.gov/pubmed/22218563?dopt=Abstract
https://www.ncbi.nlm.nih.gov/pubmed/20089612?dopt=Abstract (Lack of sustained response to teriparatide in a patient with adult hypophosphatasia_</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
  </obo:OGMS_0000112>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/1dc8b4c6-4603-4113-acee-63aad42a845a">
    <dc:identifier>DB14513</dc:identifier>
    <rdfs:label>Magnesium</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/ea4b43b9-ccea-4c59-ad6c-29375776fa70"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/970e29f1-a848-445d-9804-571716e71f81"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/062de990-8c83-4416-b23d-27905a90acaf"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB14513</ddiem:url>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/9415c9a0-6f40-4a82-9d0f-af9a262053fc">
        <rdfs:comment>Indomethacin was the most effective but can cause gastrointestinal intolerance and decreased eGFR. Amiloride and eplerenone have similar but lower efficacies and increase sodium depletion. The benefit/risk ratio of each drug should be carefully evaluated for each patient.          https://www.ncbi.nlm.nih.gov/pubmed/25012174
Despite a documented effect on hypokalemia, indomethacin and other nonsteroidal anti-inflammatory drugs should be used with caution due to their short- and long-term gastrointestinal side effects and nephrotoxicity.https://www.ncbi.nlm.nih.gov/pubmed/28003083</rdfs:comment>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5507263</dc:provenance>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/c09bdf57-4493-41d8-8a84-c5dc4407a7a9"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25012174</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28381550</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21503667</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/9605e0fa-41fb-4c12-afc1-04fdb0d230ca"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/7cf5eabc-4037-4e73-811e-e9c98e038fe3"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23196212</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2518128</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/263800"/>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
  </ddiem:Drug>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/4bbcfe79-8115-452b-809e-847ed6b16d89">
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/606785"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/28c17f6d-492b-482e-98fc-920d29b2ee7d"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6282099</dc:provenance>
    <rdfs:comment>Coupling AAV-mediated promoterless gene targeting to SaCas9 nuclease to efficiently correct liver metabolic diseases</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19752526</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10603107</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583863</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/72dfe879-ecfc-41e6-8040-c725ceef1c29"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26692114</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3306242</dc:provenance>
  </obo:OGMS_0000112>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/b88e7307-3738-460f-9691-2585fc859af9">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5508465</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/5634a50b-fb00-426a-b60d-3c73c68634d7"/>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <rdfs:comment>Controversial effectivness of AA  in an old study they have demonesterated that AA didn't have much effect in treating patients https://link.springer.com/content/pdf/10.1007%2Fs004310050956.pdf, In a more recent Study , It was noted that AA 's  mild antioxidant nature , helps retard the process of conversion of homogentisate to the polymeric material that is deposited in cartilaginous tissues. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5508465/</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/eebcd764-c115-4293-856a-90f435adced6">
        <rdfs:label>Abnormal chondrocyte growth</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28813744</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/5048010f-10dc-4624-8720-aa3b9e6d66f0"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9718357</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30049652</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7f3bd7e4-92b0-4c2a-a90d-434ed7a1d5a6">
        <rdfs:label>abnormality of proteoglycan metabolism</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0004355</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0004355</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/203500"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30477028</dc:provenance>
  </obo:DDIEM_0000013>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b836c8fd-4c66-4b0f-ad45-b2e51d44349f">
    <rdfs:label>waxy scaling plaques</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0040189*</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0040189</ddiem:url>
  </ddiem:Phenotype>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/161c603a-7011-40f9-b330-df8ee711a4c9">
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <rdfs:comment>The drug has beeen weaned when patient developed visual hallucinatuion before his presentation with a status epilepticus attack. https://www.ncbi.nlm.nih.gov/pubmed/25511120</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19821145</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3950820</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/7b2414e5-89bd-428d-8c06-916ebcc5641a">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/6adbdbc8-1dc2-4104-8ec6-9d3913be420f"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/231d316b-c053-4e7c-9284-e6ee83096b2e">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002360</ddiem:url>
        <dc:identifier>HP:0002360</dc:identifier>
        <rdfs:label>sleep cycle disturbance</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25511120</dc:provenance>
    <dc:provenance>https://link.springer.com/article/10.1023/A:1005353530303</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/277400"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
  </obo:OGMS_0000112>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/dd5b5d4a-f382-487f-b736-8e265fc675ae">
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8163996</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b0b5334f-0c55-45f8-b685-49a63efa7894"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23890587</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12084887</dc:provenance>
    <rdfs:comment>There is one case that didn't responed to l- dpa treatmet although of confirmed mutation in TH gene. https://www.ncbi.nlm.nih.gov/pubmed/11196107</rdfs:comment>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/610768"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16891685</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1899474</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/387b9aa2-9a28-479d-a7f0-8ecfc6876a9c"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10590041</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9732974</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/536b1069-45e8-4e5e-b136-81fc59752297">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0007359</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0007359</dc:identifier>
        <rdfs:label>Focal seizures</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/6125282b-5f3b-48b7-b234-65a42eaef613"/>
  </obo:DDIEM_0000013>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/94ea5744-6403-47db-9924-75fde9114dc8">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/258870"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/direct_complementation_of_a_genetically_defective_protein_by_gene_therapy"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/6201f712-e65f-4c46-8f97-152200072c4c">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/c63a4a34-e965-4817-936d-bcd898fabd05"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/70e705da-6571-4f16-ab98-e3d370735ede">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012379</ddiem:url>
        <dc:identifier>HP:0012379</dc:identifier>
        <rdfs:label>Abnormal enzyme,coenzyme activity</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28883274</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7254778</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22791294</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00001735</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7356686</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9414260</dc:provenance>
    <rdfs:comment>There was no clinical effect, but amild reduction in the plasma level of desmosterol was observed.</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
  </obo:OGMS_0000112>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4aa70da5-451c-4b0e-8bb3-ad548d768ce3">
    <rdfs:label>intracellular defect of arginine</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0005961</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0005961</ddiem:url>
  </ddiem:Phenotype>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/ce58bc70-89f0-410c-87cc-246e17a2cda9">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25717099</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11787939</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02534844</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b4af5594-023b-412b-9401-4ada633894c8">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000982</ddiem:url>
        <rdfs:label>Keratoderma</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0000982</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>One of the studies that was carried on mice provides useful information for developing the optimal dosage regimen for HPBCD therapy when administered intravenously to NPC patients.https://www.ncbi.nlm.nih.gov/pubmed/26027824</rdfs:comment>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/245010"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28803710</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19415691</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10738634</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/9e94d11a-8bf7-4c5b-a7f1-13ae3ca469dc">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/e48c1312-ca63-4280-90e1-dd3a5fda59f4"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d2e8f06e-ec85-40db-a71d-44d4fe0b369f"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19750228</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
  </obo:DDIEM_0000013>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/7d078e77-e174-4a2c-bda7-2f3a0a6fcbeb">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/4744dc6c-9f6e-4b0a-8a82-8e2852bd485b"/>
    <rdfs:label>St. John&amp;apos;s Wort</rdfs:label>
    <dc:identifier>DB01323</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01323</ddiem:url>
  </ddiem:Drug>
  <obo:DDIEM_0000011 rdf:about="http://ddiem.phenomebrowser.net/475bd8f9-ac7f-46fa-90a5-775acbb973f6">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24175354</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/176100"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/02d7dfcd-beb3-4a82-8a2b-1c8d268425f0">
        <dc:identifier>HP:0002574</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002574</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Acute episodic abdominal pain</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>Rosuvastatin therapy (20 mg per day) could be used as a preventive therapy.https://www.ncbi.nlm.nih.gov/pubmed/22798447</rdfs:comment>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00733811</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f9b46fc1-7c71-4f0d-b82d-527a5d9769f1"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/ae499126-d971-47fd-9896-1129369bfadc"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25717099</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14632789</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24652768</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12547874</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19415691</dc:provenance>
  </obo:DDIEM_0000011>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/24956bb3-4333-45e5-bf91-a05325926e64">
    <ddiem:url>https://www.drugbank.ca/drugs/DB00065</ddiem:url>
    <obo:RO_0000056>
      <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/c6d1a097-011a-46dd-b5b3-d40d1dd63141">
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/1c9ea95a-c417-49ce-a9fc-30ce8afa0401"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/260920"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19656398</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22740624</dc:provenance>
        <dc:provenance>https://link.springer.com/referenceworkentry/10.1007%2F978-3-540-29676-8_199</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/bcfc5f9b-3741-4029-a55e-240fb426ac26"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/d82b8cdd-3a56-4922-a399-3eb49f821bbd"/>
        <rdfs:comment>The results of this study suggest that octreotide may aid in the acute or long-term treatment of congenital hyperinsulinism in a limited number of selected cases.https://www.ncbi.nlm.nih.gov/pubmed/8410522/</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26962538</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f318b1c4-247b-4f0c-9079-47b47a2998fe"/>
      </obo:DDIEM_0000013>
    </obo:RO_0000056>
    <dc:identifier>DB00065</dc:identifier>
    <rdfs:label>Infliximab</rdfs:label>
  </ddiem:Drug>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/f154052e-2ba3-478a-8366-6aa4e7337260">
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/105650"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12351372</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10779036</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22791294</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:comment>There was no clinical effect, but amild reduction in the plasma level of desmosterol was observed.</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d9befcc7-677b-450d-b63b-bd9580fcaf63">
        <rdfs:label>Reduced hematocrit</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0031851</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0031851</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24744655</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28883274</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15795909</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/2b4f3e8f-5986-49cf-943f-48e013660d88"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17921858</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/3e1fb772-3868-4561-b538-7eabf3c84653"/>
  </obo:OGMS_0000112>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/9f66e4f9-3dfa-4270-95c2-64124288be06">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3162680</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/21636aca-11ac-467e-aa7f-80153e6d0a3f"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000012"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25768710</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28098593</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/53b3ac96-ba25-4a71-ad79-75588152173d"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/617347"/>
    <rdfs:comment>In this study"https://www.ncbi.nlm.nih.gov/pubmed/10385780?dopt=Abstract" authors claimed that gemfibrozil is more effective in reducing total triglyceride and VLDL lipid levels than simvastatin, and simvastatin is better in reducing LDL cholesterol than gemfibrozil is. IDL and apolipoprotein E levels were reduced similarly with both drugs.</rdfs:comment>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0021915015001379</dc:provenance>
  </obo:OGMS_0000112>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/0a23c2ad-81e2-4e67-849f-4104a9b251ad">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/7b17e3cd-6da9-4687-80cb-45b834826e2b"/>
    <rdfs:label>Potassium</rdfs:label>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/9ca8654a-6bea-47f9-be22-662fd31c7780">
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/972c8769-c1f4-4176-af20-b40d2c755c00"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2646391</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17185149</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/607364"/>
        <dc:provenance>http://www.neurologyindia.com/article.asp</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24260777</dc:provenance>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <rdfs:comment>Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss</rdfs:comment>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/4f8c5fb9-f813-4852-8017-a5f808513f9b"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
        <dc:provenance>https://www.orpha.net/data/patho/GB/uk-Bartter.pdf</dc:provenance>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <ddiem:url>https://www.drugbank.ca/drugs/DB14500</ddiem:url>
    <dc:identifier>DB14500</dc:identifier>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f4ef2ff1-df39-4e71-a050-49775bf6ebee">
    <rdfs:label>Abnormal Folate level</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0040087</ddiem:url>
    <dc:identifier>HP:0040087</dc:identifier>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/d8acc973-6d08-45d5-80e1-e9dc9ec4af67">
    <dc:identifier>C09A</dc:identifier>
    <rdfs:label>ACE INHIBITORS, PLAIN</rdfs:label>
    <ddiem:url>https://www.whocc.no/atc_ddd_index/?code=C09A</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/b35c4f98-48c3-4d4c-9ce9-125c420c0c5a"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/7b17e3cd-6da9-4687-80cb-45b834826e2b"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/acac8c6f-cb7a-4997-a332-e8ecee2f6927"/>
  </ddiem:Drug>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/e10ea1b1-88e2-4e0e-8fad-40491a569860">
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/27c31550-9d48-4ec0-a005-d6dc8fc89c76"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28098593</dc:provenance>
    <dc:provenance>https://link.springer.com/article/10.1007%2Fs11883-014-0440-2</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000012"/>
    <rdfs:comment>clinicians might only switch to combination therapy in FD patients who remain severely hypertriglyceridemic and/or hypercholesterolemic on monotherapy instead of prescribing combined statin-fibrate therapy to all FD patients that do not meet the non-HDL-C target.https://www.ncbi.nlm.nih.gov/pubmed/25768710</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3162680</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/617347"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/62f13862-3b92-42cc-9dad-e958eef7c627"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25079293</dc:provenance>
  </obo:OGMS_0000112>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/eea552eb-c991-4da4-b030-eb0aaf467c53">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/a86a0852-1717-4622-ad8b-1d4ed6713355"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00437</ddiem:url>
    <dc:identifier>DB00437</dc:identifier>
    <obo:RO_0000056>
      <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/bbfbdd13-7041-41b7-86ad-e12f67287a2c">
        <rdfs:comment>Ad vectors, HDAd is completely devoid of all viral protein genes and has been shown to display markedly reduced toxicity in mice.https://www.ncbi.nlm.nih.gov/pubmed/15753292</rdfs:comment>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/232200"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20975743</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17514432</dc:provenance>
        <dc:provenance>https://www.semanticscholar.org/paper/Glycogen-storage-diseases%3A-Diagnosis%2C-treatment-and-Chen-Weinstein/439025d057229db1b3a117cb02b3c7e6f2bd3580</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26835382</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/93c85b1d-5bb3-4695-aba6-b6fd5b92721e"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/899af578-4c5a-4b91-801f-90ac92423999"/>
      </obo:DDIEM_0000013>
    </obo:RO_0000056>
    <rdfs:label>Allopurinol</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/715cc5a1-c438-44d5-a296-477df061e963"/>
    <obo:RO_0000056>
      <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/ea1c00fc-99ad-4460-8e3f-d4811e682fdd">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17065067</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21483849</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/300322"/>
        <rdfs:comment>Treatment with allopurinol was associated with xanthine lithiasis. https://www.ncbi.nlm.nih.gov/pubmed/17065067 
https://www.ncbi.nlm.nih.gov/pubmed/16773422/</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22198833</dc:provenance>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
        <dc:provenance>https://rarediseases.org/rare-diseases/lesch-nyhan-syndrome</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3202309</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27179999</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/899af578-4c5a-4b91-801f-90ac92423999"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/45809f76-b3cb-473b-a1f1-403d1c23fe91"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24093206</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/162ba303-ba46-441f-9dc7-04381fa1a886"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29054473</dc:provenance>
      </obo:DDIEM_0000013>
    </obo:RO_0000056>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1c476a4d-15a8-481d-9c26-2bbe9a04823d">
    <rdfs:label>hemophagocytic-lymphohistiocytosis (Abnormality of immune system physiology)*</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0010978</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0010978</ddiem:url>
  </ddiem:Phenotype>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/4d94d14a-54a8-41da-8824-b653cc661089">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29923092</dc:provenance>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/204200">
        <ddiem:iembaseAccessionNumber>307</ddiem:iembaseAccessionNumber>
        <rdfs:comment></rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/6b977732-edfc-4777-81cf-7a0d949196bf"/>
        <dc:identifier>https://www.omim.org/entry/204200</dc:identifier>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/307</ddiem:iembaseUrl>
        <rdfs:label>CEROID LIPOFUSCINOSIS, NEURONAL, 3; CLN3</rdfs:label>
      </ddiem:Disease>
    </obo:RO_0002599>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/86e570a4-cdba-4d73-8baf-a7638b33eb00"/>
    <rdfs:comment>A combination therapy of Î´-tocopherol and HPBCD further improved the effect compared to that of either drug used as a single therapy.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29631617</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/results/NCT01399047</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/65fc5cee-5ba3-4d27-bc59-36ac5c68e10a">
        <rdfs:label>The primary outcome of the study was to check tolaribilty to treatment. The drug was well tolarated</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01399047</dc:provenance>
  </obo:OGMS_0000112>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/291630fc-7f05-4e92-8b0d-11766b1469ca">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23494656</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/cb5070a3-ac95-4c75-b102-192ca4b450a2"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4052756/#S10title</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11148549</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/207800"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5508465</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/2ce2a3f0-914c-481a-8b67-1c6a3499311d"/>
    <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
    <dc:provenance>https://www.clinicaltrialsregister.eu/ctr-search/search</dc:provenance>
    <rdfs:comment>Alternative pathway therapy has limited effectiveness in preventing hyperammonemia and must be combined with effective dietary management. https://www.ncbi.nlm.nih.gov/pubmed/11148549</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4382922</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
  </obo:OGMS_0000112>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/3f91c4b6-1a5c-4f12-9966-c81850c29755">
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29506905</dc:provenance>
    <rdfs:comment>Sodium phenylbutyrate lowers the resynthesis of arginine from ornithine via the urea cycle.https://www.ncbi.nlm.nih.gov/pubmed/24268530</rdfs:comment>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205003057</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8813986</dc:provenance>
    <dc:provenance>https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-005394-35/ES</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12003346</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719212002971</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/233910"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/c4633604-cb41-4d90-84d5-44841bde9fef"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9667588</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/766262d8-cb3e-48d4-9cdb-751f40d1da52"/>
  </obo:OGMS_0000112>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/9efd382a-66f2-4fbb-841f-aa12ab2a9ed3">
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/6896b663-4839-4b89-a768-466860c29f28"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6169684</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/246700"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4223155</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2596948</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/45dd3944-1d14-4af2-a30e-a078b9e84402">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/4e7c72a6-363b-4d24-9f5d-3b6f268f425d"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22832289</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21102543</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23329770</dc:provenance>
    <rdfs:comment>"Oral tocofersolan was more bio available than the water-soluble formulation in children with chronic cholestasis and similarly bio available in CF. This suggests that water-soluble vitamin E may represent an alternative to painful intramuscular vitamin E injections in chronic cholestasis, or other oral formulations in CF. However, the mechanism responsible for fat malabsorption in CRD concerns the absorptive phase as opposed to the digestive phase in CF and cholestatic syndromes. To our knowledge, no specific studies with these new vitamin E preparations have been conducted in CRD." https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717/</rdfs:comment>
  </obo:OGMS_0000112>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/8df72417-da07-4b70-bf14-ec23750e72b4">
    <rdfs:label>Bezafibrate</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01393</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/e49115f5-4e58-4b05-8dee-d9556826def2"/>
    <obo:RO_0000056>
      <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/a82b315c-8702-41da-8137-cd4a4b073685">
        <rdfs:comment>Based on their study auhors of"  https://www.ncbi.nlm.nih.gov/pubmed/21354122?dopt=Abstract"  presume that the combination of these drugs may contribute to reduce LDL-C/HDL-C ratio effectively as well as lowering concentrations of serum triglyceride.</rdfs:comment>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/5ef47c3a-a81d-41f9-9c6f-b0643e63a592"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000012"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12181212</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/617347"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/5243e4c3-330c-4c93-83c3-af49314aa5c1"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2065040</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21354122</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3162680</dc:provenance>
      </obo:DDIEM_0000013>
    </obo:RO_0000056>
    <dc:identifier>DB01393</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/927c92a7-893e-4036-a001-75293ca412bb"/>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/851532a7-a2c9-4a07-9206-5c6f34ecd206">
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/600890"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/af32c57f-9aa2-4697-8ff1-4ccd3cecc042"/>
        <obo:RO_0003304>c. 1393_1479del-Del exon</obo:RO_0003304>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000012"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
        <obo:RO_0003304>c.1528Gâ&gt;âC</obo:RO_0003304>
        <obo:RO_0003304>c.180â+â3Aâ&gt;âG</obo:RO_0003304>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/7184cc40-6dde-4532-9e3a-a61406e563d8"/>
        <ddiem:failedToContributeToCondition>c.1528Gâ&gt;âC</ddiem:failedToContributeToCondition>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
        <rdfs:comment>Dietry treatment supplementation</rdfs:comment>
        <obo:RO_0003304>c.914Â Tâ&gt;âA</obo:RO_0003304>
        <obo:RO_0003304>c.982Gâ&gt;âA and c.1072Câ&gt;âA</obo:RO_0003304>
        <obo:RO_0003304>C2129-2Aâ&gt;âC</obo:RO_0003304>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/2b5c1ff4-b31b-4a97-a59a-90e2f0c132a4"/>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/a96b845e-f3a9-4996-9d56-c9b0ffc6a41c">
    <ddiem:url>https://www.drugbank.ca/drugs/DB00742</ddiem:url>
    <dc:identifier>DB00742</dc:identifier>
    <rdfs:label>Mannitol</rdfs:label>
    <obo:RO_0000056>
      <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/0be8fde1-093e-40b1-881a-d7ce59deda41">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/books/NBK1181</dc:provenance>
        <rdfs:comment>According to a retrospective study, 11 of 12 patients who received Glyceol died, whereas both of 2 patients who received D-mannitol survived.https://www.ncbi.nlm.nih.gov/pubmed/15050970 
D-mannitol is unlikely to affect cytosolic NADH production even in citrin de ciency. Therefore, it is highly recommended to administer D-mannitol but not Glyceol to treat brain edema in patients with CTLN2. https://www.ncbi.nlm.nih.gov/pubmed/16449956</rdfs:comment>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/b877cfaf-9375-4780-80f3-ae09f2f6ae59"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/603471"/>
        <dc:provenance>https://globenewswire.com/news-release/2015/03/30/720127/10126746/en/Sigma-Tau-Pharmaceuticals-Inc-Receives-Orphan-Drug-Designation-for-EZN-2279-for-Treatment-of-Adenosine-deaminase-Deficient-Severe-Combined-Immunodeficiency-Disease.html</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15670720</dc:provenance>
        <dc:provenance>https://www.sciencedirect.com/science/article/abs/pii/S1386634602003315</dc:provenance>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648/#b96-tacg-8-201</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/07542199-282a-4339-aa09-274957d35e9c"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16449956</dc:provenance>
      </obo:DDIEM_0000013>
    </obo:RO_0000056>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ab8c3b9a-8e04-42fd-8a51-dcda6a931f21">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Neurological abormalities</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000707</ddiem:url>
    <dc:identifier>HP:0000707</dc:identifier>
  </ddiem:Phenotype>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/03e103d6-1737-467d-b750-17ec586d84fe">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11067870</dc:provenance>
    <rdfs:comment>"Oral tocofersolan was more bio available than the water-soluble formulation in children with chronic cholestasis and similarly bio available in CF. This suggests that water-soluble vitamin E may represent an alternative to painful intramuscular vitamin E injections in chronic cholestasis, or other oral formulations in CF. However, the mechanism responsible for fat malabsorption in CRD concerns the absorptive phase as opposed to the digestive phase in CF and cholestatic syndromes. To our knowledge, no specific studies with these new vitamin E preparations have been conducted in CRD." https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717/</rdfs:comment>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/35b5c64e-9aaa-46fd-84a3-e5d483d4e101"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/971536</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/220110"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6206929</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/e44d719c-72fa-49ee-8a1d-3b73d9ef19c9"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22149023</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3963001</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19622360</dc:provenance>
  </obo:DDIEM_0000013>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/261000">
    <rdfs:comment></rdfs:comment>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/4d7f5927-b160-4046-bbb5-2a519d859078"/>
    <dc:identifier>https://www.omim.org/entry/261000</dc:identifier>
    <ddiem:iembaseAccessionNumber>80</ddiem:iembaseAccessionNumber>
    <rdfs:label>INTRINSIC FACTOR DEFICIENCY; IFD</rdfs:label>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/80</ddiem:iembaseUrl>
  </ddiem:Disease>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/333f9d06-e4ac-424d-86fa-8cb04c7a44e0">
    <dc:provenance>https://clinicaltrials.gov/ct2/show/results/NCT00912925</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31211405</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/607015"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c3c9f4e1-66bb-4f7e-ae0a-f931bd80ff7f">
        <dc:identifier>HP:0005952</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Decreased pulmonary function</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0005952</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0cfa4a10-e7b0-4874-a1d9-a13dcec64fff">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Six Minute Walk Test</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/435dddf2-91eb-4c81-abaf-3c7ae0e19585"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c66c34ac-e8b7-495b-a9fd-816a6c19eec6">
        <rdfs:label>High Apnea,Hypopnea Index(sleep apnea)*</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0010535*</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0010535</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31082797</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f83a0765-a42f-461f-b43a-5f0593a9f0bd">
        <rdfs:label>Low Forced Vital Capacity</rdfs:label>
        <dc:identifier>HP:0002111</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002111</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>The results of this study suggest that octreotide may aid in the acute or long-term treatment of congenital hyperinsulinism in a limited number of selected cases.https://www.ncbi.nlm.nih.gov/pubmed/8410522/</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31434105</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/64482499-b03b-44a4-8ed9-0c916e569b8d"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6e96ebe6-c521-46e9-ba1f-87010c235478">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001376</ddiem:url>
        <dc:identifier>HP:0001376</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Limitation of the Joint range of motion</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31196723</dc:provenance>
  </obo:OGMS_0000112>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/a5ae0ff8-b67a-47cf-a570-f8c076c9ea8e">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/86d39558-b732-4b95-b113-850aab706b81"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/7ca71b67-1b55-4cb6-9d4e-faaa6a44174f"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB06151</ddiem:url>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/ef58bb9b-6d93-481e-b8d2-35e45578be8f">
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27830356</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29526615</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/518b6d43-2c86-4354-bcc8-68383fdd91a7"/>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0022202X15352507</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16376514</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/8c3518e1-0d7b-4d48-9398-efe2e9615f68"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/602473"/>
        <rdfs:comment>The drug resulted in significant reduction of  both plasma PPIX and hepatic PPIX in a murine animal model but no effect in humans during clinical trial. thus, These results demonstrate that while INH can lower PPIX in an animal model of EPP, the standard dose used to treat TB is insufficient to affect levels in humans. https://www.ncbi.nlm.nih.gov/pubmed/31395332</rdfs:comment>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <dc:identifier>DB06151</dc:identifier>
    <rdfs:label>Acetylcysteine</rdfs:label>
    <obo:RO_0000056>
      <obo:DDIEM_0000011 rdf:about="http://ddiem.phenomebrowser.net/5ca78d52-ca63-427a-9f8b-5fdca000ec30">
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/eadc078a-f923-4256-80af-e13ae0c917e9"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19019309</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20868666</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11089562</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a37a2378-3cd3-4d5a-bf9a-7f59622d264c"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/bde99d42-21e2-477b-9cac-efa8d7f203d6"/>
        <rdfs:comment>An experimental study done on a mice with GMNT knocked out. suggesting considering Nicotinamide as atreatment option in patients with GNMT deficiency.  https://www.ncbi.nlm.nih.gov/pubmed/20578266/</rdfs:comment>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/231950"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC38850</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27207470</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/518b6d43-2c86-4354-bcc8-68383fdd91a7"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11095909</dc:provenance>
      </obo:DDIEM_0000011>
    </obo:RO_0000056>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/f1361a87-87ba-4fbe-98da-71c071f3db0e"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/0add3a4c-60fe-493e-97a8-037666cfcbb9">
    <obo:RO_0000056>
      <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/60a3f77f-c9fd-411f-97b5-29a7db245e84">
        <rdfs:comment>Uncoooked cornstrach was introduced in small frequent meal and was accomapined with elimination of lactose in diet</rdfs:comment>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT03514420</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5338723</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27155573</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/151660"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/72ca8f73-e2fb-4cfc-b715-49e5def05917"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/4077cef1-24e3-4ea7-b2ac-6ba6073bfc1e"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23456528</dc:provenance>
      </obo:DDIEM_0000013>
    </obo:RO_0000056>
    <rdfs:label>ISIS 703802 (AKCEA-ANGPTL3-LRx)</rdfs:label>
  </ddiem:Drug>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/234500">
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/50</ddiem:iembaseUrl>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/f05fd3a8-d8dd-4945-9ed5-9069767ac8dd"/>
    <ddiem:iembaseAccessionNumber>50</ddiem:iembaseAccessionNumber>
    <dc:identifier>https://www.omim.org/entry/234500</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>HARTNUP DISORDER; HND</rdfs:label>
  </ddiem:Disease>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/0ded8f3a-dc70-4452-a4d4-d65c42c85341">
    <rdfs:label>Vitamin D</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/ea289878-9ccf-4df1-8e48-1b29406c435f"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/b39fa91c-62db-4030-8494-a38a35efca4a"/>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/3b440772-61c6-4adb-8e65-ee5aba117792">
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
        <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
        <dc:provenance>https://ojrd.biomedcentral.com/articles/10.1186/1750-1172-3-20</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26396722</dc:provenance>
        <rdfs:comment>It's an investigational therapy where Positive results from using a selective monoamine oxidase (MAO) B inhibitor or non-ergot dopamine agonist pramipexole as an adjunct therapy have been described in the medical literature. This use of such an inhibitor can allow for lower doses of neurotransmitter precursor to be used. However, the long-term safety (e.g. effects on neonatal brain development) and effectiveness of this therapy is unknown and more research is required to determine what role, if any, selective monoamine oxidase B inhibitors play in the treatment of individuals with tetrahydrobiopterin deficiency. https://rarediseases.org/rare-diseases/tetrahydrobiopterin-deficiency/. https://www.researchgate.net/publication/233414693_Deprenyl_in_6-Pyruvoyl_Tetrahydropterin_Synthase_Deficiency. https://www.degruyter.com/downloadpdf/j/pteridines.1995.6.issue-3/pteridines.1995.6.3.144/pteridines.1995.6.3.144.pdf</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25488886</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26086616</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/53d81324-bc69-4ec5-bd3c-186d552927d4"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/31e4ed31-beee-4874-8e55-d0713ab6ab06"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24288038</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/200100"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <dc:identifier>DB11094</dc:identifier>
    <obo:RO_0000056>
      <obo:DDIEM_0000012 rdf:about="http://ddiem.phenomebrowser.net/11187a00-4205-4183-a611-1826b7e25498">
        <dc:provenance>https://www.semanticscholar.org/paper/Hypophosphatasia%3A-A-Systemic-Skeletal-Disorder-by-Orimo/5d135fbc68735a3e95d3b313fc0636f10215b300</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/53d81324-bc69-4ec5-bd3c-186d552927d4"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25717099</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30811537</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9110486</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/4744026</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26744272</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/241500"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
        <rdfs:comment>Vitamin D should be given to target the lower limit of the normal range for 25-OH-vitamin D (about 20 ng/mL).</rdfs:comment>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/df9628ff-0639-4dd4-88b2-9d9be7cf7a3c"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19415691</dc:provenance>
      </obo:DDIEM_0000012>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/ed09be92-ddb4-4c19-9d76-1346e99e2122">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22832289</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/695c65b7-9e50-49f8-97c2-6689e760ea7b"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23329770</dc:provenance>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6169684</dc:provenance>
        <rdfs:comment>"Oral tocofersolan was more bio available than the water-soluble formulation in children with chronic cholestasis and similarly bio available in CF. This suggests that water-soluble vitamin E may represent an alternative to painful intramuscular vitamin E injections in chronic cholestasis, or other oral formulations in CF. However, the mechanism responsible for fat malabsorption in CRD concerns the absorptive phase as opposed to the digestive phase in CF and cholestatic syndromes. To our knowledge, no specific studies with these new vitamin E preparations have been conducted in CRD." https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717/</rdfs:comment>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/53d81324-bc69-4ec5-bd3c-186d552927d4"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/246700"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4223155</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/c706c6c6-d626-4e01-987e-48db4fd2aa4d"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21102543</dc:provenance>
      </obo:DDIEM_0000013>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/327909f5-1d87-4d44-a6d9-1f6c71449097">
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/9a3fef61-43d9-455a-86b5-c613837079b4"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/177000"/>
        <rdfs:comment>https://www.ncbi.nlm.nih.gov/pubmed/8370580</rdfs:comment>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/53d81324-bc69-4ec5-bd3c-186d552927d4"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24137761</dc:provenance>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <ddiem:url>https://www.drugbank.ca/drugs/DB11094</ddiem:url>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f9e5e429-b751-4b0c-a45a-d7a875de6b14">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000708</ddiem:url>
    <dc:identifier>HP:0000708</dc:identifier>
    <rdfs:label>behavioral abnormalities</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/98aa10ce-d6bb-4987-8fd5-68ffdebdefc8">
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02527343</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/151660"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02211209</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02300233</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5338723</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/47cbaf88-c5da-431b-9ab7-69504f655d98">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/a2e4dc0c-ff00-4df8-bbed-ee4353396f84"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b5d9691e-2e2d-4de4-9280-b51463031e55"/>
    <rdfs:comment>Uncoooked cornstrach was introduced in small frequent meal and was accomapined with elimination of lactose in diet</rdfs:comment>
  </obo:OGMS_0000112>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/3d07024e-09c5-488c-a015-f2cafb51e35c">
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1059131117301243</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/253280"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ce17471b-9400-4bec-ae27-7322205746ec">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000486</ddiem:url>
        <dc:identifier>HP:0000486</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>strabismus</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29555514</dc:provenance>
    <rdfs:comment>In a different study IV administration of Glucose wasn't effective.https://www.ncbi.nlm.nih.gov/pubmed/22238410</rdfs:comment>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/2f1e6dfb-57db-4ca8-9592-fe629a28c757"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8d22c6d6-e2f4-403c-9cca-873fd0ba0175">
        <rdfs:label>esotropia</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000565</ddiem:url>
        <dc:identifier>HP:0000565</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://link.springer.com/article/10.1007/s11940-011-0131-z</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/books/NBK1520</dc:provenance>
  </obo:OGMS_0000112>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/95f2afa4-cdae-4066-b51c-abd28a71181b">
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/308050"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/feee8175-af10-4f42-a7ed-b23be088eb74"/>
    <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
    <dc:provenance>an enzyme-replacement therapy</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/866674f7-6686-4955-b72a-3e13de23b98e"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/2acc2b52-21fb-4489-9289-0416c2ecbfee">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/05d3b8ca-0254-45d5-a239-61ba97888e45"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29392821</dc:provenance>
    <dc:provenance>https://www.researchgate.net/publication/8668575_A_successful_treatment_with_pyridoxal_phosphate_for_West_syndrome_in_hypophosphatasia</dc:provenance>
    <dc:provenance>was associated with improved findings on skeletal radiographs and improved pulmonary and physical function in infants and young children with life-threatening hypophosphatasia. (Funded by Enobia Pharma and Shriners Hospitals for Children; ClinicalTrials.gov number</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5096504</dc:provenance>
    <rdfs:comment>Drug name: Treatment is under trial.</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e6a547a2-9a9e-42f7-967a-a2c8891a4e3c">
        <rdfs:label>verruciform xanthomas</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0031517</ddiem:url>
        <dc:identifier>HP:0031517</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>"ENB-0040</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
    <dc:provenance>NCT00744042.)."</dc:provenance>
  </obo:OGMS_0000112>
  <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/489246cd-381b-44d8-80ba-73c440d34508">
    <dc:provenance>"ENB-0040</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/e4067132-439b-4516-9bd7-43a4b5e54fe4">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/46f45806-9161-48b1-a91c-cb0d90cafd4f"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5909487</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5096504</dc:provenance>
    <dc:provenance>was associated with improved findings on skeletal radiographs and improved pulmonary and physical function in infants and young children with life-threatening hypophosphatasia. (Funded by Enobia Pharma and Shriners Hospitals for Children; ClinicalTrials.gov number</dc:provenance>
    <dc:provenance>https://www.researchgate.net/publication/8668575_A_successful_treatment_with_pyridoxal_phosphate_for_West_syndrome_in_hypophosphatasia</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/308050"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ea086167-ccbb-4d90-b715-6210ca4e3e9d"/>
    <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
    <dc:provenance>an enzyme-replacement therapy</dc:provenance>
    <rdfs:comment>Drug name: Treatment is under trial.</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>NCT00744042.)."</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
  </obo:DDIEM_0000007>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/d8dc90b5-7887-42e8-8454-2bd82c8b4414">
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/481b6db4-d2b7-40e5-9fd5-d3e734322724">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/ebce90cb-ac79-4453-95db-0381632f9143"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31196723</dc:provenance>
    <obo:RO_0003304>S466L /I278T</obo:RO_0003304>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31211405</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/45a54626-68f5-428b-8f67-24c577b4b444">
        <dc:identifier>HP:0002156</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002156</ddiem:url>
        <rdfs:label>Homocystinuria</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/236200"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31082797</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30755342</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16619244</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24355692</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4818a5da-22b8-4059-9c44-1a9f45c945cd">
        <dc:identifier>HP:0010919*</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Abnormal Hcy level</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0010919</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14739681</dc:provenance>
    <rdfs:comment>These data provide strong preclinical evidence that proteasome inhibitors should be considered as potentially useful in treatment of misfolding diseases caused by a missense mutation, such as HCU</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23592311</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000012"/>
  </obo:OGMS_0000112>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/74c6cf6b-ea38-4bc1-b02e-ddb84f408dae">
    <rdfs:label>Glycosade</rdfs:label>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/1376631a-1896-4243-bd59-90ce0a578da3">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29223626</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ca2edda0-57e5-42f4-b076-fbff004f56f1"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2564511</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3306242</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/240600"/>
        <rdfs:comment>Treatment was stopped three days later because of lack of improvement and severe respiratory alkalosis with lactic acidosis (serum lactic acid 70 mg/dl, normal 4â20 mg/dl). https://www.ncbi.nlm.nih.gov/pubmed/12948744</rdfs:comment>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/0449a602-c972-47e0-94b5-36cdaafb335b"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583863</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/fca28bfd-f73e-46d5-9b61-30eae9d1577c"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15726662</dc:provenance>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02054832</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000010"/>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3336b039-d083-4cb4-b7ef-a6c56a8d0c68">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003218</ddiem:url>
    <rdfs:label>orotic aciduria</rdfs:label>
    <rdfs:comment>The drug works through preventing the aciduria and the hyperammonemia rather than treating it.</rdfs:comment>
    <dc:identifier>HP:0003218</dc:identifier>
  </ddiem:Phenotype>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/2dc61d48-f4f1-47db-8266-a3a5441ff2ea">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24746802</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117</dc:provenance>
    <rdfs:comment>The drug was administered through intravitreal injection.</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/419e059b-400d-4433-8405-cdca012bbdf3">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0008028</dc:identifier>
        <rdfs:label>Macular cystoid changes</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0008028</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5568973</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/520000"/>
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/3e7769a7-3186-408c-b713-7bb6935f6bd2">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/dc38e1f2-d1b2-48ad-a0da-2805dbc5fba3"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ce8b5819-cb2d-4a37-bc4e-6a870f02a0c8"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b1ffa798-38ac-48d4-a3ac-71b8b6debae6"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01212744</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
  </obo:OGMS_0000112>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/83fdf574-72bc-4616-809a-501f32b32881">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/0b3ceace-f52f-4d5c-92c3-c335d960f17c"/>
    <obo:RO_0000056>
      <obo:DDIEM_0000015 rdf:about="http://ddiem.phenomebrowser.net/f8651559-896c-4f69-a0f9-865e38c75ece">
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/62f13862-3b92-42cc-9dad-e958eef7c627"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12114919</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/145750"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19770656</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/21ba206b-4ec3-4104-9c8a-670f005b9320"/>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00465751</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20495831</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
        <rdfs:comment>Intravenous heparin 10,000 U per day is an effective, simple, and safe method of lowering the triglyceride level in hypertriglyceridemia-induced pancreatitis in pregnancy, However, the reduction of the triglyceride level by heparin is only temporary and long-term use may paradoxically result in an increase in the triglyceride level as a result of depletion of LPL. Heparin can be stopped once the triglyceride level falls below 11 mmol/L.https://www.ncbi.nlm.nih.gov/pubmed/12114919.  https://www.ncbi.nlm.nih.gov/pubmed/1800965</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28225998</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21289269</dc:provenance>
      </obo:DDIEM_0000015>
    </obo:RO_0000056>
    <ddiem:url>https://www.drugbank.ca/drugs/DB06777</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/956d4c70-e38d-4edb-9cef-f8b18c8e0a07"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/af049001-e6d9-45c9-aaab-202a3b3d1814"/>
    <dc:identifier>DB06777</dc:identifier>
    <rdfs:label>Chenodeoxycholic acid</rdfs:label>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/30c76492-8dfb-4373-ab9f-89285d1fd417">
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/dca3adf0-7645-4e3b-a83c-46a5b21dd3dc">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26692114</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583863</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/21636aca-11ac-467e-aa7f-80153e6d0a3f"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000012"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/405afb44-d7a3-4f8d-abd4-18478b52c5e2"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19752526</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6282099</dc:provenance>
        <rdfs:comment>Coupling AAV-mediated promoterless gene targeting to SaCas9 nuclease to efficiently correct liver metabolic diseases</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7483726</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/606785"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3306242</dc:provenance>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/9f66e4f9-3dfa-4270-95c2-64124288be06"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00636</ddiem:url>
    <dc:identifier>DB00636</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/ea662ce5-b3ac-4462-bf22-9a1b42fdfd8e"/>
    <rdfs:label>Clofibrate</rdfs:label>
  </ddiem:Drug>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/b0c9486a-d200-4e8d-815a-af6ada04370d">
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/e26f58c5-3e77-453b-8c30-5df2c9c700e9"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3955971</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01395641</dc:provenance>
    <rdfs:comment>In a study done by Mastrandeleo et. al , it was mentioned that Transdermal rotigotine was efficacious in the early stages of AADC of an affected male; however, the treatment was not effective in his older, more impaired brother.</rdfs:comment>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/608643"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25001633</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23494656</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23390030</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7385abe6-cb97-4252-8efe-08a4299465ad">
        <rdfs:label>cerebral folate depletion</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012446</ddiem:url>
        <dc:identifier>HP:0012446</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </obo:DDIEM_0000013>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/bbbd85ae-fe26-4da6-b289-a0780482f63e">
    <rdfs:label>Abnormality of peripheral nerves</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0045010</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0045010</dc:identifier>
  </ddiem:Phenotype>
  <obo:DDIEM_0000012 rdf:about="http://ddiem.phenomebrowser.net/43354398-6b69-46ec-a3d3-afc3e3995a46">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23045655</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/db5acca2-5b2c-4072-9b1e-434e92c7d101">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Abnormal enzyme activity</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558>
      <ddiem:Evidence rdf:about="http://ddiem.phenomebrowser.net/EC0:0005542">
        <dc:identifier>EC0:0005542</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/EC0_0005542</ddiem:url>
      </ddiem:Evidence>
    </obo:RO_0002558>
    <rdfs:comment>A clinical candidate for drug repuropsing. DGJNAc contains an N-acetyl group that sterically precludes it from binding to Î±-GAL A and GLB1, so it has improved selectivity for Î±-NAGAL and makes it superior to DGJ.</rdfs:comment>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02473445</dc:provenance>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/609242">
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/263</ddiem:iembaseUrl>
        <rdfs:label>KANZAKI DISEASE</rdfs:label>
        <dc:identifier>https://www.omim.org/entry/609242</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/7964fd83-d171-4be1-8de5-d5c99e7a54ef"/>
        <ddiem:iembaseAccessionNumber>263</ddiem:iembaseAccessionNumber>
      </ddiem:Disease>
    </obo:RO_0002599>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/ac42e564-5ae3-4387-b307-fe7e6742557d">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/66a81dc6-3063-43ca-8e1e-0397cdd7d364"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26884075</dc:provenance>
  </obo:DDIEM_0000012>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/b69f4667-a152-4ad8-8021-7648b066e7a4">
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/866674f7-6686-4955-b72a-3e13de23b98e"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648/#b96-tacg-8-201</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10870849</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/300100"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4197f292-dbfc-4940-a983-279c1143a1ef">
        <rdfs:label>High plasma levels of hexacosanoic acid</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20089986</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15670720</dc:provenance>
    <dc:provenance>https://globenewswire.com/news-release/2015/03/30/720127/10126746/en/Sigma-Tau-Pharmaceuticals-Inc-Receives-Orphan-Drug-Designation-for-EZN-2279-for-Treatment-of-Adenosine-deaminase-Deficient-Severe-Combined-Immunodeficiency-Disease.html</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16949688</dc:provenance>
    <rdfs:comment>The ability of these agents to affect VLCFA levels in a mammalian model was not explored. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5460829/</rdfs:comment>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f08a585f-1c07-4ddc-aba4-55c1f7471273"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
  </obo:OGMS_0000112>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/64d584f0-ba24-49c2-a2c6-efaeab4691be">
    <rdfs:label>corneal crystals</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0000531</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000531</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/553bc278-12d2-4cbe-b284-0c5980a34765">
    <dc:identifier>HP:0002904</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002904</ddiem:url>
    <rdfs:label>High serum bilirubin level</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/bedeea09-4dae-481b-a650-ba3b44e0794e">
    <rdfs:label>Baclofen</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00181</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/13c48602-969d-4207-9b39-e606b646c90a"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/96e6a2b5-a45d-4c1b-9eeb-982ff64d5070"/>
    <dc:identifier>DB00181</dc:identifier>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/920d917d-eff9-4b61-b242-9c59f90d4996">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002149</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0002149</dc:identifier>
    <rdfs:label>hyperuricaemia</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/c2ecf1f2-a499-4466-8f17-4173e2736f35">
    <dc:identifier>DB00819</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/7c72f493-fa32-4bf8-94c8-184384960efd"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00819</ddiem:url>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/0ebe18bc-65cd-450a-9618-55b202bd063b">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24260777</dc:provenance>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/EC:0007121"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2646391</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/35edbd24-3651-4cd4-ad2b-385a12b4ffb3"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d1d89ef4-0a03-4492-b451-2a6565d3c3f0"/>
        <dc:provenance>https://clinicaltrials.gov/ct2/results</dc:provenance>
        <dc:provenance>http://www.neurologyindia.com/article.asp</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/7d16d8d9-8d19-4337-8bd3-2d28a85e4f23"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/601678"/>
        <dc:provenance>https://www.orpha.net/data/patho/GB/uk-Bartter.pdf</dc:provenance>
        <rdfs:comment>Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss</rdfs:comment>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <rdfs:label>Acetazolamide</rdfs:label>
    <obo:RO_0000056>
      <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/3b9117b8-2345-4a9f-b069-c8be30e5eb9d">
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/611105"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21749991</dc:provenance>
        <rdfs:comment>Treatment with allopurinol was associated with xanthine lithiasis. https://www.ncbi.nlm.nih.gov/pubmed/17065067 
https://www.ncbi.nlm.nih.gov/pubmed/16773422/</rdfs:comment>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/35b5c64e-9aaa-46fd-84a3-e5d483d4e101"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a349c290-e541-4978-99b5-7fc1cff3485c"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/7d16d8d9-8d19-4337-8bd3-2d28a85e4f23"/>
      </obo:DDIEM_0000013>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/7ed8ef1b-5171-4a23-bcbf-d44f2898ee60">
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/615398"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/609ad081-cd8b-4e0a-a0a3-854be8e88831"/>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0387760417301742</dc:provenance>
        <rdfs:comment>Drugs has decreased rhe frequency of the tonic seizuress</rdfs:comment>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/7d16d8d9-8d19-4337-8bd3-2d28a85e4f23"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
  </ddiem:Drug>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/6e659e6e-9814-4447-a640-046e49861cf5">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/62b6a8f7-d946-4412-a84a-0f47bb5402d8">
        <rdfs:label>Misfolding of cystathionine Î²-synthase(Abnormal enzyme activity)*</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012379</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0012379*</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31082797</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14739681</dc:provenance>
    <obo:RO_0003304>I278T</obo:RO_0003304>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30755342</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24355692</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16619244</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23592311</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/236200"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000012"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31196723</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31211405</dc:provenance>
    <rdfs:comment>These data provide strong preclinical evidence that proteasome inhibitors should be considered as potentially useful in treatment of misfolding diseases caused by a missense mutation, such as HCU</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/cfd1ccae-d6b6-4dd1-bac2-159fb05b0513"/>
  </obo:OGMS_0000112>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/27f10747-7fa5-4fca-97f6-85cc7e1a736d">
    <rdfs:label>low calcium urine excretion</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003127</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0003127</dc:identifier>
  </ddiem:Phenotype>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/2850a361-3756-4327-a5c6-8451efb3aa20">
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/9d63a58f-b943-4558-bc02-12e66500e387"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0303846712003952</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S109037980800010X</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b6f8dc53-22dd-4e4f-a8eb-af0a1b6edf9e">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001337</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>tremor</rdfs:label>
        <dc:identifier>HP:0001337</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/a9a25133-2bad-4cc8-9f19-43a36e03e896">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/a48848d8-0543-4f6c-8cab-9fa5e08cb5e6"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/300438"/>
    <rdfs:comment></rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22840416</dc:provenance>
  </obo:DDIEM_0000013>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/43180bde-f3e5-45b4-8750-5f4d8e3d8747">
    <rdfs:label>progression of neurodegeneration</rdfs:label>
    <dc:identifier>HP:0002344</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002344</ddiem:url>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9999cc2a-1c33-4f75-b50c-c9ab9732afa3">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Neurological abnormalitis</rdfs:label>
    <dc:identifier>HP:0000707</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000707</ddiem:url>
  </ddiem:Phenotype>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/4ea1c800-ae38-4ea3-a559-595e7f9634ec">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26979527</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23884489</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22092997</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/177000"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22791288</dc:provenance>
    <rdfs:comment>Recent studies, however, have suggested inverse associations between carotenoids and lung cancer mainly in smokers.
https://www.ncbi.nlm.nih.gov/pubmed/18689373/ https://www.ncbi.nlm.nih.gov/pubmed/19254833/</rdfs:comment>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a9bb0bb5-60c8-45af-a18b-220995490e3e"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/b73e088e-ff84-4627-b62b-f557f82c8040">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/d8fd2091-587e-4d5a-80e6-e178cc32c9cf"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/35e244ee-9573-4ccf-9467-bd765a7178f6"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19656325</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/341955</dc:provenance>
  </obo:OGMS_0000112>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/cd79cc74-6a3c-48e8-8df9-5a5e2ff7d990">
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/0b02b048-d5a8-46c9-b5ff-c634611edac7">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/6adbdbc8-1dc2-4104-8ec6-9d3913be420f"/>
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/e9d9b4d9-29be-4f65-a32d-a59a787defac"/>
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/568e015d-ad9b-43a7-8959-f7dd5cfabd7e"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:comment>Clonazepam is a useful adjunct for myoclonus and can be used in combination with lamotrigine to avoid lamotrigineâs myoclonic effects . 
Zonisamide should remain a second-line adjunct in the treatment of JME, owing to the lack of supportive data.
https://link.springer.com/article/10.1007/s11940-011-0131-z</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/545000"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14981187</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1059131117301243</dc:provenance>
    <dc:provenance>https://link.springer.com/article/10.1007/s11940-011-0131-z</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/63cd1cce-d328-48bb-97b4-3d96e6f8042c">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002123</ddiem:url>
        <rdfs:label>Myoclonic epliepsy</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0002123</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/books/NBK1520</dc:provenance>
  </obo:DDIEM_0000013>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/b1b91b65-287d-4159-85a9-41494ae0656a">
    <ddiem:url>https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI_25548</ddiem:url>
    <rdfs:label>nitrilotriacetate</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/c8a7afad-7fe6-48db-9f58-607150dfc611"/>
    <dc:identifier>CHEBI_25548</dc:identifier>
  </ddiem:Drug>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/ece9f5e0-41d1-45d8-a7f9-2b3d420359d1">
    <dc:provenance>https://www.clinicaltrials.gov/ct2/show/NCT02697136</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25885911</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/57593ccd-7c55-4278-925f-58554283aaf2">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>low renal glomerular filtration rate</rdfs:label>
        <dc:identifier>HP:0012213</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012213</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/96b793a7-3f44-4684-8e4e-270c97c660a7"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9250ed09-7895-466a-a197-7340c6b694d7">
        <dc:identifier>HP:0001640</dc:identifier>
        <rdfs:label>cardiomegaly</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001640</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT03018730</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/227ed6ae-0b24-4d17-a7df-24692b4c883c">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/96b83758-081b-4bdc-89db-301c7493dadc"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20495831</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01218659</dc:provenance>
    <rdfs:comment>Drugs were used sequentially for 8 weeks, after 4 weeks washout. in the clinical trial. Atorvastatin or fenofibrate had little effect on HDL cholesterol; atorvastatin decreased the total cholesterol/HDL cholesterol ratio by 26%. Fenofibrate did not change HDL cholesterol levels and caused an increase in LDL cholesterol. Niacin was the only effective drug to increase HDL cholesterol. https://www.ncbi.nlm.nih.gov/pubmed/18993152</rdfs:comment>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/301500"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21289269</dc:provenance>
  </obo:OGMS_0000112>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/788a5e5e-9461-4ed1-8e84-45705866e03e">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18570303</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/51136465-c584-4ee7-9d6c-a586391a6c57">
        <rdfs:label>Low physical capacity (Constitutional symptom)*</rdfs:label>
        <dc:identifier>HP:0025142</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0025142</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20938027</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/615395"/>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4503963</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20619503</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19087156</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/66aa6980-9d73-4eee-8a52-f80a6ead8bf9"/>
    <rdfs:comment>Many studies have reported early responce to l- dopa treatment as mentioned in https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4503963/, and other pointed to " prominent dyskinesia " as side effect to same treatment https://www.ncbi.nlm.nih.gov/pubmed/19087156/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25797485</dc:provenance>
  </obo:OGMS_0000112>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/eeaff26f-8a24-4819-80f8-bd78eaea0903">
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/0659eaa6-731b-414a-9212-88a007b39765">
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/071aacb5-5257-437c-a404-abfd462b8f77"/>
        <ddiem:url>https://www.drugbank.ca/drugs/DB01234</ddiem:url>
        <rdfs:label>Dexamethasone</rdfs:label>
        <dc:identifier>DB01234</dc:identifier>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/6afae260-d8aa-41c1-9bfa-6e2fb7319265"/>
      </ddiem:Drug>
    </rdf:li>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/a28a95b0-e791-4012-b97f-998450eb09c5">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/e8841053-2798-47f5-a587-d7b560c95265"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/703aa365-5f46-428f-8e28-f3458a64b507"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00583</ddiem:url>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/da86ab29-f768-40c9-a03e-38b7cae9f42b">
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/6b36ca46-5e87-4637-b6e9-73189ff35f01"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/309000"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/131e1564-ae29-4565-848a-78788230e643"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://pdfs.semanticscholar.org/3a8e/bd8dda73113f384215ca26d7df0fe61441a1.pdf</dc:provenance>
        <rdfs:comment>If on supplemental bicarbonate or citrate, phosphorus or calcitriol or other vitamin D analog, need kidney function assessment 1 w/blood &amp; urine tests
May need serum vitamin D-25 hydroxy to assess for parent vitamin D deficiency</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17339125</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/books/NBK1480</dc:provenance>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/0ea21213-cf2b-4c01-82d7-c39fd89a1d2e">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26884075</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/6b36ca46-5e87-4637-b6e9-73189ff35f01"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19891905</dc:provenance>
        <rdfs:comment>MCT should be at least 70% of the total fat content of the diet.</rdfs:comment>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ac66b840-eeb4-44fd-b593-8f8bb668da8d"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/530000"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27709644</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/7570198b-b602-4525-995b-a1791144f637"/>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/5b003d50-8f7e-4a77-8197-2f398d8abe93"/>
    <obo:RO_0000056>
      <obo:DDIEM_0000011 rdf:about="http://ddiem.phenomebrowser.net/c1e3bc64-5375-4304-80ee-fe18f3cea767">
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/3b12e910-9473-4fae-9294-fe5161e721bf"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3415789</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/books/NBK1493</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/0e1b9731-a1d5-4f26-9e2b-742d594a4582"/>
        <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/6b36ca46-5e87-4637-b6e9-73189ff35f01"/>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/eadc078a-f923-4256-80af-e13ae0c917e9"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24288038</dc:provenance>
        <rdfs:comment>Investigational "Infertility investigation Abetalipoproteinaemia patients might benefit from progesterone supplementation, and further studies on this and hormonal profiles would benefit this pool of patients. Optimising the nutritional profile and body mass index of female patients will undoubtedly contribute to better chances at conception.:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4265040/</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12044538</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/606175"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b3e102e2-09d6-4d91-b282-2882f9c8ac66"/>
      </obo:DDIEM_0000011>
    </obo:RO_0000056>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/0b83f6d6-8e7b-4833-a02c-d3f1dd68e459"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/953eee1a-1c2a-4665-aae3-89e5f25c2eb0"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/c800e3c9-1b06-44e2-8a71-d10ff97668a4"/>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/e4fabd09-9038-45ad-86d9-88b1dbc16da6">
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/236795"/>
        <dc:provenance>http://eknygos.lsmuni.lt/springer/365/81-92.pdf</dc:provenance>
        <dc:provenance>https://www.jci.org/articles/view/11948</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16835865</dc:provenance>
        <dc:provenance>https://www.babysfirsttest.org/newborn-screening/conditions/3-methylcrotonyl-coa-carboxylase-deficiency</dc:provenance>
        <rdfs:comment>Effect of glycine in treating the condition is variable among literatures.  "Case reports have noted variable results regarding the effect of glycine administration. Some studies have found that supplemental glycine results in increased excretion of 3-methylcrotonyl glycine, while others have not found a persistent effect; no studies have observed clinical improvement of symptoms on treatment and no randomized clinical trials have been published" https://www.sciencedirect.com/science/article/pii/S1096719207005975?via%3Dihub#bib11
https://www.ncbi.nlm.nih.gov/pubmed/8831079
https://www.ncbi.nlm.nih.gov/pubmed/7474896</rdfs:comment>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/6b36ca46-5e87-4637-b6e9-73189ff35f01"/>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/088789949400109F</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/2f50914e-701d-491c-b809-3303070fbc5d"/>
        <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <dc:identifier>DB00583</dc:identifier>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/210492c2-2d07-449e-8ab4-b3fd43d2a208">
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f20a37e0-f929-4af5-93a7-3349dbb12776"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/250950"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5358122</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
        <dc:provenance>https://www.jci.org/articles/view/11948</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/0f051b76-9e98-4ff3-bc3a-45a526c66b84"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11400757</dc:provenance>
        <dc:provenance>https://www.babysfirsttest.org/newborn-screening/conditions/3-methylcrotonyl-coa-carboxylase-deficiency</dc:provenance>
        <rdfs:comment>Effect of glycine in treating the condition is variable among literatures.  "Case reports have noted variable results regarding the effect of glycine administration. Some studies have found that supplemental glycine results in increased excretion of 3-methylcrotonyl glycine, while others have not found a persistent effect; no studies have observed clinical improvement of symptoms on treatment and no randomized clinical trials have been published" https://www.sciencedirect.com/science/article/pii/S1096719207005975?via%3Dihub#bib11
https://www.ncbi.nlm.nih.gov/pubmed/8831079
https://www.ncbi.nlm.nih.gov/pubmed/7474896</rdfs:comment>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/202b2073-9e0f-4323-b4bc-9fcf095b645b"/>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
        <dc:provenance>https://www.researchgate.net/publication/46821474_The_3-methylglutaconic_acidurias_What%27s_new</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/82bd2ac4-659b-483a-a601-943f8c64f612"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/6b36ca46-5e87-4637-b6e9-73189ff35f01"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16835865</dc:provenance>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/1f6cc1f4-2d37-48ac-9c28-7dc442364d24"/>
    <obo:RO_0000056>
      <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/e1c26bd5-48a7-4052-b736-f499534de769">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25859380</dc:provenance>
        <rdfs:comment>Although  there are resaerchs that have documented the correlation between LPI and GHD because of the known interaction between the amino acids (AA) arginine, ornithine, and lysine and GH secretion https://www.ncbi.nlm.nih.gov/pubmed/2903866/ https://www.ncbi.nlm.nih.gov/pubmed/14328387/ ,https://www.ncbi.nlm.nih.gov/pubmed/18029456/, https://www.ncbi.nlm.nih.gov/pubmed/6790230/ 
Other reasearchs find these supplements have neither obvious benefit nor difference in terms of prognosis. Arginine supplementation is unhelpful as oral arginine is not absorbed from intestinal mucosa.  https://www.ncbi.nlm.nih.gov/pubmed/27567650</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23430827</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/2ce2a3f0-914c-481a-8b67-1c6a3499311d"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/6b36ca46-5e87-4637-b6e9-73189ff35f01"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28057010</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20301535</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/222700"/>
      </obo:DDIEM_0000007>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/2822f074-79e1-4f4a-a08e-2d4eb63e305d">
        <dc:provenance>https://link.springer.com/article/10.1007/s11940-011-0131-z</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/books/NBK1520</dc:provenance>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26006750</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/6b36ca46-5e87-4637-b6e9-73189ff35f01"/>
        <rdfs:comment>In a different study IV administration of Glucose wasn't effective.https://www.ncbi.nlm.nih.gov/pubmed/22238410</rdfs:comment>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1059131117301243</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a4a51327-9207-48cb-bc0e-54fe83c8682d"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/602541"/>
      </obo:DDIEM_0000007>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <obo:DDIEM_0000009 rdf:about="http://ddiem.phenomebrowser.net/b28b55d5-c04c-40a7-a7b3-b1a43ba9dd78">
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/8f550abf-822b-4d32-8ea0-305414162fbe"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <rdfs:comment>The drug was accompained by mild protein restriction (1.5â2.0 g/kg/day)</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12837870</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/2b6e16eb-1d7e-4840-aa42-f0a5e3328249"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11102558</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/610006"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22840416</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/6b36ca46-5e87-4637-b6e9-73189ff35f01"/>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0303846712003952</dc:provenance>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
      </obo:DDIEM_0000009>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/8e22781d-6bcd-4db6-ac3b-9c31098ce5da">
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/6b36ca46-5e87-4637-b6e9-73189ff35f01"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a9a90466-9689-4c04-81e6-d52039771562"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
        <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1110863016300763</dc:provenance>
        <dc:provenance>Abstract</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/203750"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24260777</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
        <rdfs:comment>Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss</rdfs:comment>
        <dc:provenance>http://www.neurologyindia.com/article.asp</dc:provenance>
      </obo:DDIEM_0000007>
    </obo:RO_0000056>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/66d8b2cf-7763-4b38-a198-ef809d72d35f"/>
    <obo:RO_0000056>
      <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/2f9c2252-1a70-4265-a498-2342fd30235f">
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ed8e0af1-38f7-483a-a7b8-ef9ae8094f42"/>
        <rdfs:comment>The cyclosporine trial (taken immediately upon visual loss in the first eye) is in progress in Leber's optic atrophy to prevent involvement of the fellow eye.</rdfs:comment>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02176733</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/6b36ca46-5e87-4637-b6e9-73189ff35f01"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3202309</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21600768</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25835550</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29054473</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21483849</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24093206</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/220111"/>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02805790</dc:provenance>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
      </obo:DDIEM_0000013>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/f5c4b964-7b00-4c64-bdcd-cd3452e19573">
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/2dc2eaee-14fc-4715-94c9-6e4d02b067d9"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/8d831179-238a-40d7-9a5e-2aeed3ea4777"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/6b36ca46-5e87-4637-b6e9-73189ff35f01"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16835865</dc:provenance>
        <rdfs:comment>Effect of glycine in treating the condition is variable among literatures.  "Case reports have noted variable results regarding the effect of glycine administration. Some studies have found that supplemental glycine results in increased excretion of 3-methylcrotonyl glycine, while others have not found a persistent effect; no studies have observed clinical improvement of symptoms on treatment and no randomized clinical trials have been published" https://www.sciencedirect.com/science/article/pii/S1096719207005975?via%3Dihub#bib11
https://www.ncbi.nlm.nih.gov/pubmed/8831079
https://www.ncbi.nlm.nih.gov/pubmed/7474896</rdfs:comment>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/231530"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5388644</dc:provenance>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/202b2073-9e0f-4323-b4bc-9fcf095b645b"/>
        <dc:provenance>https://www.jci.org/articles/view/11948</dc:provenance>
        <dc:provenance>https://www.babysfirsttest.org/newborn-screening/conditions/3-methylcrotonyl-coa-carboxylase-deficiency</dc:provenance>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
        <dc:provenance>https://link.springer.com/article/10.1023%2FA%3A1024031714659</dc:provenance>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/3754ae1b-ee8c-4c0b-a2a1-3af0afb66885"/>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/fb8049ce-b6c0-43ec-befc-992bc2f9facc">
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/923ed828-4868-4006-bb14-6f80988f91c0"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/2dc2eaee-14fc-4715-94c9-6e4d02b067d9"/>
        <rdfs:comment>Drug works for heterozygot mutations rather than homozygous ones.
It is possible that biotin treatment might falsely normalize the results of the lymphocyte enzyme assay in biotin-responsive individuals, thus a biotin trial would best be considered after enzyme assay. There is no data suggesting continuing biotin is helpful in nonresponders. https://www.ncbi.nlm.nih.gov/pubmed/18155630</rdfs:comment>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/6b36ca46-5e87-4637-b6e9-73189ff35f01"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/2b6e16eb-1d7e-4840-aa42-f0a5e3328249"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16835865</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/210200"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18155631</dc:provenance>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
        <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
        <dc:provenance>https://www.babysfirsttest.org/newborn-screening/conditions/3-methylcrotonyl-coa-carboxylase-deficiency</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17968484</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8831079</dc:provenance>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10485305</dc:provenance>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/1e1cf724-c0bf-4e15-9d26-fb45d9ca19bd"/>
    <rdfs:label>Levocarnitine</rdfs:label>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/2e9d005a-65d7-4710-9b3b-37ce9b8fefa7">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/9312e84c-087d-415d-9fb1-c60a60180d32"/>
  </rdf:Alt>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/3568ee74-1d10-4246-bbeb-24b29d73c247">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7833193</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ddc7ff06-e6df-4c96-86d7-51088c5529e6">
        <rdfs:label>Low myocardial function</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001638</ddiem:url>
        <dc:identifier>HP:0001638</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3249181</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23432031</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e193387f-b9ef-4913-877f-8cbff03660de"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8fcdfd05-ae2b-4d29-a396-b674cd68eda9">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003146</ddiem:url>
        <dc:identifier>HP:0003146</dc:identifier>
        <rdfs:label>hypocholesterolaemia</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/302060"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31239752</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18632498</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/f85f18a2-c533-43a9-a86f-870802041e67">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/885bff2e-4e95-4955-beed-a07e9203a8c0"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/82bd2ac4-659b-483a-a601-943f8c64f612"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/682c1af3-3deb-48d0-a4fb-9e2fcb0efdb2">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0005135</ddiem:url>
        <rdfs:label>T wave abnormalities</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0005135</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/920d917d-eff9-4b61-b242-9c59f90d4996"/>
  </obo:OGMS_0000112>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/47374066-e347-449b-9e91-203c27d02efa">
    <ddiem:url>https://www.whocc.no/atc_ddd_index/?code=C04</ddiem:url>
    <rdfs:label>PERIPHERAL VASODILATORS</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/b35c4f98-48c3-4d4c-9ce9-125c420c0c5a"/>
    <dc:identifier>C04</dc:identifier>
  </ddiem:Drug>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/5e7ec1d0-889d-4ed4-9c24-85adef85f206">
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/7b517ff3-fc9a-449b-a7f3-1355c1eb4688"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e95bfb09-8ecd-45c4-b80e-72bb7816e68f"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25851806</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7375069</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/6b36ca46-5e87-4637-b6e9-73189ff35f01"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/48dfb020-3526-4162-8560-0baeff5f440b">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/453e32d7-4f2e-4ce4-9e9e-eb250bd9b6b7"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19019309</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/db6d42d0-bc1e-458c-9a99-e1e2fe9a00d1"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e5eb9536-0736-4a25-8d17-62d77104eed8"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/266130"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17397529</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/c7568be9-e6b5-4e41-9ee1-202e43e5338f"/>
    <rdfs:comment>An experimental study done on a mice with GMNT knocked out. suggesting considering Nicotinamide as atreatment option in patients with GNMT deficiency.  https://www.ncbi.nlm.nih.gov/pubmed/20578266/</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ef550087-59d0-4a86-911d-ea564e4fa2be">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0100786</ddiem:url>
        <rdfs:label>Hypersomnia</rdfs:label>
        <dc:identifier>HP:0100786</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/25307f83-5436-4a08-ac20-d01631ad3fe3">
        <dc:identifier>HP:0000952</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000952</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Jaundice</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
  </obo:OGMS_0000112>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/181b6c6e-38ce-4bf0-8220-56a3525eb815">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002401</ddiem:url>
    <dc:identifier>HP:0002401</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Stroke-like episodes</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2217ac19-bc29-478a-8c68-099b409d7ae6">
    <rdfs:label>Recurrent vomiting</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0002572</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002572</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/0cc64ccb-926e-40c8-bda2-57daea182809">
    <ddiem:url>https://www.drugbank.ca/drugs/DB06285</ddiem:url>
    <dc:identifier>DB06285</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/55254497-e925-4d37-9d26-eea6c7d3437f"/>
    <rdfs:label>Teriparatide</rdfs:label>
  </ddiem:Drug>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/834ba610-4902-4dd7-9187-f7c1c0344c72">
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/300438"/>
    <dc:provenance>https://www.semanticscholar.org/paper/Clinical-Diagnosis-and-Treatment-of-Dehydrogenase-A-Cui-Wang/f6e88d647f2e2c7df2897e939ec33f9d86899b37</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11102558</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <rdfs:comment></rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/f94f6380-fb89-4fb4-bc06-34c07d3bb943">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/437b18d0-ebde-49cb-a62f-0d7a1b1e9116"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22840416</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/404c382f-7439-4041-b8fd-bad9d82109c5">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012647</ddiem:url>
        <rdfs:label>Abnormal inflammatory response</rdfs:label>
        <dc:identifier>HP:0012647</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0303846712003952</dc:provenance>
  </obo:OGMS_0000112>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/a296977b-49ef-40c2-acb4-81e412680ead">
    <dc:identifier>DB00413</dc:identifier>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/231aec6a-f2d1-4068-9132-dd0cb9461cf3">
        <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/8682b3f2-bb5b-41c6-8ed1-0b9195cb0d13"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a1fb420a-d6cf-449b-a8c4-1aa3226131de"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e294f01c-8b2b-4446-9395-7b5b3282e0ef"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/78f3d001-4887-4d42-8777-a38dce39096e"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16601879</dc:provenance>
        <dc:provenance>https://www.babysfirsttest.org/newborn-screening/conditions/3-methylcrotonyl-coa-carboxylase-deficiency</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12003346</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/98a20e14-0e9f-470f-9ffc-fee3dfd2b355"/>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19704083</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/43c23ec3-0d77-4aef-9916-0389c3b6aca8"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/261640"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23690520</dc:provenance>
        <rdfs:comment>The addition of pramipexole to the treatment of 6-pyruvoyl tetrahydropterin synthase deficiency improves the results of l-3,4 dihydroxyphenylalanine therapy.https://www.ncbi.nlm.nih.gov/pubmed/19704083</rdfs:comment>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00413</ddiem:url>
    <obo:RO_0000056>
      <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/23b57650-676a-40ac-b944-9587c6c0d530">
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/7178af06-55cd-4314-b898-c4ec7482bc7a"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/9c657128-2cd0-473e-a63f-5ed2bd58c719"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/261630"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/fffbf06a-fff9-4d59-9e4b-560ffd8434e2"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25707872</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8163996</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16891685</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1899474</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12084887</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/470d03f6-6a09-459a-a216-8af7cab6e577"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22325981</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/98a20e14-0e9f-470f-9ffc-fee3dfd2b355"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26817292</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27423595</dc:provenance>
        <rdfs:comment>Alhough therapy with desmopressin cannot be recommended based on the results of a single case, the outcome presented here is intriguing and suggests that larger studies in such patients is warranted to assess the broader application of such an intervention.</rdfs:comment>
      </obo:DDIEM_0000013>
    </obo:RO_0000056>
    <rdfs:label>Pramipexole</rdfs:label>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5243e4c3-330c-4c93-83c3-af49314aa5c1">
    <rdfs:label>Atherogenic dyslipidemia(Dyslipidemia)*</rdfs:label>
    <dc:identifier>HP:0003119*</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003119</ddiem:url>
  </ddiem:Phenotype>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/af7ef3e3-4821-4b1f-9f49-cc8b8ddbf9e5">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21483849</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27179999</dc:provenance>
    <obo:RO_0003304>E1506K</obo:RO_0003304>
    <dc:provenance>https://rarediseases.org/rare-diseases/lesch-nyhan-syndrome</dc:provenance>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/240800">
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/79a4ab26-af1c-4d68-9b28-b9eac158b063"/>
        <rdfs:label>HYPOGLYCEMIA, LEUCINE-INDUCED; LIH</rdfs:label>
        <dc:identifier>https://www.omim.org/entry/240800</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12593632</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15356046</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <obo:RO_0003304>R1353H</obo:RO_0003304>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29054473</dc:provenance>
    <obo:RO_0003304>delSer1387</obo:RO_0003304>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/65084b83-5349-48d3-b185-b9c2720ab857"/>
    <rdfs:comment>Treatment with allopurinol was associated with xanthine lithiasis. https://www.ncbi.nlm.nih.gov/pubmed/17065067 
https://www.ncbi.nlm.nih.gov/pubmed/16773422/</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24093206</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3202309</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/eb345fb0-e9f4-4420-9c6d-508b9ea1af0b"/>
  </obo:OGMS_0000112>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/32648543-f652-406a-87f0-84dc388ff1f7">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e1695f5c-b3bf-41de-965c-288bb5851be7">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0002148</dc:identifier>
        <rdfs:label>Hypophosphatasia</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002148</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/c3951163-c8e6-466e-8940-5830b567e782"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17339125</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/309000"/>
    <dc:provenance>https://www.paediatricaindonesiana.org/index.php/paediatrica-indonesiana/article/view/59/33</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19773212</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <rdfs:comment>If on supplemental bicarbonate or citrate, phosphorus or calcitriol or other vitamin D analog, need kidney function assessment 1 w/blood &amp; urine tests
May need serum vitamin D-25 hydroxy to assess for parent vitamin D deficiency</rdfs:comment>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/7e188929-412b-40db-a39f-a1326b779cbe">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/445544bc-da44-44a9-9208-c9b10f60b8a1"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/05d037f8-54d9-4b78-bc06-486b6a60a5ee"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
  </obo:OGMS_0000112>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/03b8a7f3-07de-41c7-9545-c79f80b1bc2b">
    <rdfs:label>rAAV8-mediated gene therapy expressing murine HMB-synthase</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/7d66e607-0873-4fd3-afe8-b67b6245cfee"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/4e98c19f-40fe-4452-94aa-bfc1fbacb78b">
    <dc:identifier>DB00328</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00328</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/33c4171d-3892-49b2-a5a5-9c66b26603d2"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/0ccbbff2-7f2f-46c4-940e-520d356f70c1"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/c52b008a-3d56-476f-b7ca-e59090b7dd64"/>
    <rdfs:label>Indometacin</rdfs:label>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/999ff09c-c730-4844-bcae-3ed5ae627af5">
        <dc:provenance>http://www.neurologyindia.com/article.asp</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/300971"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <dc:provenance>https://www.orpha.net/data/patho/GB/uk-Bartter.pdf</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/ba4fb4df-0390-4e86-ad94-68cb70436bd1"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2646391</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27120771</dc:provenance>
        <rdfs:comment>Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24260777</dc:provenance>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
  </ddiem:Drug>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/08cb4880-473d-433c-b3aa-e2a182d9ac93">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19755409</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/202110"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/9418c95c-d824-4d97-a29a-061dc04e8644">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/cf127040-83db-49b8-b304-ca1371fa48a6"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/30e4d0b4-0b04-4269-b3f6-198ef790a271"/>
    <dc:provenance>https://www.orpha.net/consor/cgi-bin/ResearchTrials_ClinicalTrials.php</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/61b2fbde-0c18-4d4a-bb94-ddeb670ed0fb">
        <dc:identifier>HP:0000855</dc:identifier>
        <rdfs:label>Insulin resistance</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000855</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <rdfs:comment></rdfs:comment>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00151710</dc:provenance>
  </obo:DDIEM_0000013>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/3cc8a93a-5484-4d8f-b91c-456440bdf64a">
    <obo:RO_0003304>F364C- alpha</obo:RO_0003304>
    <obo:RO_0003304>Y368C- alpha</obo:RO_0003304>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/248600"/>
    <obo:RO_0003304>Y393N- alpha</obo:RO_0003304>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a1cad489-6469-40a3-b75a-2e13b4f71a5a"/>
    <ddiem:failedToContributeToCondition>A209D-alpha</ddiem:failedToContributeToCondition>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/a23a0318-79e7-4e6b-a2e6-290467af740f">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/c44a274a-84ed-46cd-ab50-e989ef08f5c7"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000012"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11507102</dc:provenance>
    <rdfs:comment>Drugs has decreased rhe frequency of the tonic seizuress</rdfs:comment>
  </obo:OGMS_0000112>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/32c6d22b-6b9c-47b3-b4e9-6558beb3ef79">
    <dc:identifier>DB12351</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/bb6253e4-3ea8-4ada-9df2-83481c922779"/>
    <rdfs:label>Siagoside</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB12351</ddiem:url>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/98a20e14-0e9f-470f-9ffc-fee3dfd2b355">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/a296977b-49ef-40c2-acb4-81e412680ead"/>
  </rdf:Alt>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/92d0426c-451d-4509-a12b-7de1a788ba88">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d6e4bf81-12b6-4ace-9caf-9e1d3a1d25cd">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0007479</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0007479*</dc:identifier>
        <rdfs:label>Collodion membrane(Nonbullous congenital ichthyosiform erythroderma)*</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.researchgate.net/publication/8668575_A_successful_treatment_with_pyridoxal_phosphate_for_West_syndrome_in_hypophosphatasia</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/b86cdfcc-609e-44c1-b7c5-483868c7ef9a"/>
    <dc:provenance>was associated with improved findings on skeletal radiographs and improved pulmonary and physical function in infants and young children with life-threatening hypophosphatasia. (Funded by Enobia Pharma and Shriners Hospitals for Children; ClinicalTrials.gov number</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/7be818a5-134f-4c69-bd53-99ffc9f49b7f">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/77969c1a-2b27-4276-a7c6-b79ae7fa9d53"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:comment>Drug name: Treatment is under trial.</rdfs:comment>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d4be491a-166d-46a8-ba7d-6f5c96f15c06"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21981352</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/9b96bd0a-a2d5-437b-9970-24d9815345ae"/>
    <dc:provenance>"ENB-0040</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ef01e254-1edc-4c01-a474-b4159931037b"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
    <dc:provenance>NCT00744042.)."</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1e6edc48-e9ea-4976-809d-502e6a1262f1">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Scaling</rdfs:label>
        <dc:identifier>HP:0040189</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0040189</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>an enzyme-replacement therapy</dc:provenance>
    <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
    <dc:provenance>https://onlinelibrary.wiley.com/doi/abs/10.1111/pde.12170</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/4c461888-fa8a-4c1b-b67d-482882a9de49"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28979034</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/275630"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
  </obo:DDIEM_0000013>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/7156bc29-7673-4120-891d-bea6b8c71ca4">
    <obo:RO_0000056>
      <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/d5f6e0da-2203-4f12-a494-4959579aff36">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220407</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/aa52b47a-f9db-4ce7-bb91-26794191e368"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17628222</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2443756</dc:provenance>
        <rdfs:comment>The mainstays of treatment are moderate protein (leucine) restriction and avoidance of prolonged fasting and of excessive dietary fat intake, both of which increase fatty acid oxidation; these measures are generally effective in preventing acute decompensations.https://www.ncbi.nlm.nih.gov/pubmed/3128690</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26997609</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1886403</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f4bcaa8a-92d7-4328-92c3-e4514008f207"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/246450"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/5b5dfe2f-e35d-4a0d-8f01-72d9959d79f1"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000009"/>
      </obo:DDIEM_0000013>
    </obo:RO_0000056>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/29286523-6446-457b-aaab-0d65cc5b0c83"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01914</ddiem:url>
    <obo:RO_0000056>
      <obo:DDIEM_0000011 rdf:about="http://ddiem.phenomebrowser.net/3947091e-fe01-42f5-aa8e-451d17e411a5">
        <dc:provenance>https://link.springer.com/article/10.1007/s11940-011-0131-z</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18401027</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/aa52b47a-f9db-4ce7-bb91-26794191e368"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/300559"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/books/NBK1520</dc:provenance>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
        <rdfs:comment>In a different study IV administration of Glucose wasn't effective.https://www.ncbi.nlm.nih.gov/pubmed/22238410</rdfs:comment>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1059131117301243</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/70484379-4972-47a1-9b19-8363d46a21c7"/>
      </obo:DDIEM_0000011>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/3b082c4c-f331-4ce5-98b7-155a70899a2d">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17514432</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/232200"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18996862</dc:provenance>
        <rdfs:comment>Ad vectors, HDAd is completely devoid of all viral protein genes and has been shown to display markedly reduced toxicity in mice.https://www.ncbi.nlm.nih.gov/pubmed/15753292</rdfs:comment>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26835382</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/345f7321-2b9d-4b63-8db8-6f154976000d"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/aa52b47a-f9db-4ce7-bb91-26794191e368"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956916</dc:provenance>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <dc:identifier>DB01914</dc:identifier>
    <rdfs:label>D-glucose</rdfs:label>
  </ddiem:Drug>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/573ed8ec-588c-4bdd-adbd-f4c02f5f7b43">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29358012</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24578415</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/8665770e-d275-4841-8adc-7fc13c4ea20a">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/d65b6b34-e2bd-44d9-b96a-d152d854d032"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/5707897</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007764"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29480352</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f328a9f6-49d0-4637-9a72-57ec8c3c1e65"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25485164</dc:provenance>
    <rdfs:comment>Phenobarbital, clonazepam, valproate, and midazolam could not completely control seizures. https://www.ncbi.nlm.nih.gov/pubmed/20052547/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15895716</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/613163"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6a230479-4f2f-458b-9836-17eed4e505b3">
        <rdfs:label>elevated CSF GHB levels</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7814809</dc:provenance>
  </obo:OGMS_0000112>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4eff29ed-3869-48d7-b55a-0a52e49b0633">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Increased liver enzyme activities</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002910</ddiem:url>
    <dc:identifier>HP:0002910</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/9167cea4-da4f-4112-9c5f-bc483f444fe7">
    <ddiem:url>https://www.drugbank.ca/drugs/DB00571</ddiem:url>
    <rdfs:label>Propranolol</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/6ff879d2-b80a-49d6-a766-24aebc2ea938"/>
    <dc:identifier>DB00571</dc:identifier>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0d04ede6-5392-44d8-b501-9c5f9fc51007">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0008222</ddiem:url>
    <rdfs:label>Female infertility</rdfs:label>
    <dc:identifier>HP:0008222</dc:identifier>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/3240a58b-0b0c-4037-b83e-0cef2e1ce77d">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3202309</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/e20f6fda-b6c2-4aae-9b82-5ec42515ab17">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/005dbc56-22b0-4286-81ef-ecf7ce24b3b1"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02176733</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02805790</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5a5e021b-ff0e-4c51-8732-0d8bff12f4d1">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0025464</ddiem:url>
        <dc:identifier>HP:0025464</dc:identifier>
        <rdfs:label>Increased ROS production</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f8ef427c-5b22-49f1-b917-dd9ac8c66946">
        <rdfs:label>Decreased activity of mitochondrial complex IV</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0008347</ddiem:url>
        <dc:identifier>HP:0008347</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/220111"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21483849</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/bec0ffc7-d61c-481d-bc4d-4dfa8a7533e5">
        <dc:identifier>HP:0011923</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0011923</ddiem:url>
        <rdfs:label>Decreased activity of mitochondrial complex I</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24093206</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29054473</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25620325</dc:provenance>
    <rdfs:comment>The cyclosporine trial (taken immediately upon visual loss in the first eye) is in progress in Leber's optic atrophy to prevent involvement of the fellow eye.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21600768</dc:provenance>
  </obo:OGMS_0000112>
  <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/49f91a3c-b766-42af-b5a4-8ae1a4c96d46">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6206929</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/971536</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19622360</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3963001</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11067870</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/febbacba-2fdb-4fef-841a-6a9988ac7a84">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/26f2d863-3141-452a-a383-bbd761ceddb3"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:comment>"Oral tocofersolan was more bio available than the water-soluble formulation in children with chronic cholestasis and similarly bio available in CF. This suggests that water-soluble vitamin E may represent an alternative to painful intramuscular vitamin E injections in chronic cholestasis, or other oral formulations in CF. However, the mechanism responsible for fat malabsorption in CRD concerns the absorptive phase as opposed to the digestive phase in CF and cholestatic syndromes. To our knowledge, no specific studies with these new vitamin E preparations have been conducted in CRD." https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717/</rdfs:comment>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00004442</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e26cea2e-5830-4510-ad21-203ffcfc0e85"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/261515"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/805548af-9efd-4822-a8b8-b2f38190cf3e"/>
  </obo:DDIEM_0000007>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/f14690a9-f8f9-45ea-b68f-9285fc4d99b2">
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/direct_complementation_of_a_genetically_defective_protein_by_gene_therapy"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24933563</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648/#b96-tacg-8-201</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6358544</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/f272f06d-5ae2-4482-9ee3-5fd42a2148b1">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/83190cfa-3824-4860-9222-eae63d1aa697"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/fd9ee9c5-57db-4c39-bc46-3dea2c8677fd">
        <rdfs:label>Low PBGD expression in liver</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/176000"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15767622</dc:provenance>
    <rdfs:comment>There is a study for "Non-viral delivery of the porphobilinogen deaminase cDNA into a mouse model of acute intermittent porphyria{ ECO: 0005542} https://www.ncbi.nlm.nih.gov/pubmed/15110317</rdfs:comment>
  </obo:OGMS_0000112>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/ecf90cba-d2b6-41df-b4f0-b3335c627ba3">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4223155</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22832289</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21102543</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6169684</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/e090b3f8-5890-490f-8057-33d9f8be81e4"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a501c4d9-c7be-4ce9-be35-515371f6d3e7"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <rdfs:comment>There is a contraversy about effectivness of methotrexate in treating "Condrocalcinosis 2" .. Details are in https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4223155/ and https://www.ncbi.nlm.nih.gov/pubmed/22832286/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6411330</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/118600"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7520501</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
  </obo:OGMS_0000112>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/82b054ec-356e-4ba7-90ec-9446b0dbef75">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23772144</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/607364"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24260777</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/ef18207b-7bad-49c8-a109-fc8bb15ab3a4">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/6430a8d3-e88e-4db9-bdac-d9e61314044b"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/82e9b302-6732-48e7-9a67-ea1dcfa32214">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Defected ClC-Kb expression</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0003304>W610X</obo:RO_0003304>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
    <rdfs:comment>Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss</rdfs:comment>
    <dc:provenance>http://www.neurologyindia.com/article.asp</dc:provenance>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-Bartter.pdf</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2646391</dc:provenance>
  </obo:OGMS_0000112>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/c28390ad-02a9-4015-9b24-ef838bc92501">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/0515fb9d-e9ee-4d3f-91de-2e63156e7b22"/>
  </rdf:Alt>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/61b0d0b5-7e29-4ba0-89a3-e8e1e2ee43d9">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27884013</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/b4e2362c-7c52-413c-b59d-78befa344ae6">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/8ee814c7-105d-443c-8e90-8eb4e9d5753a"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/608747"/>
    <rdfs:comment>Mecasermin rinfabate, however, is no longer available in the USA or Europe for treating conditions involving short stature, because of a legal requirement</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19627167</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24639006</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/eb345fb0-e9f4-4420-9c6d-508b9ea1af0b"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17192294</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10549306</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5384eaaa-3cfe-482f-a11c-a6a5cf5a35bd">
        <rdfs:label>Low serum ICFBP level</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23887143</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00125190</dc:provenance>
  </obo:OGMS_0000112>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8fc77ec2-d685-4b6b-a7af-ef3e04545efe">
    <rdfs:label>Nonepileptic paroxysmal abnormalities</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/cd69663e-cb08-4a8e-800a-1a747442ac12">
    <rdfs:label>Abnormality of cardiovascular system physiology</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0011025</ddiem:url>
    <dc:identifier>HP:0011025</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f2e6455d-1896-4cf0-af42-1c98e666fdf8">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0008189</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0008189</dc:identifier>
    <rdfs:label>low insulin senstivity</rdfs:label>
  </ddiem:Phenotype>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/2709bb4a-4810-404c-b998-669dfe642bfd">
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <rdfs:comment>Due to its strong copper chelation capability, a copper salt should be added simultaneously</rdfs:comment>
    <dc:provenance>https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/a298fcb2-6e04-4335-bdff-d0b444f22cf1"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9511979</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b4c9fa5a-b486-45ce-81f9-51efae6e96f1">
        <rdfs:label>Copper storage abnormalities (Copper storage abnormalities)*</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0010836</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0010836*</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.sciencedirect.com/science/article/abs/pii/088789949190052M</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30384011</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/309400"/>
  </obo:OGMS_0000112>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/746dd21e-d928-4d35-80d5-b25eb5bba7b2">
    <rdfs:comment>Ad vectors, HDAd is completely devoid of all viral protein genes and has been shown to display markedly reduced toxicity in mice.https://www.ncbi.nlm.nih.gov/pubmed/15753292</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17430128</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/direct_complementation_of_a_genetically_defective_protein_by_gene_therapy"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/f549d827-95a3-4c12-8aea-6f62f3b9cbff">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/ef09429f-2497-4a05-91cd-7a9ffa6e8e18"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/345f7321-2b9d-4b63-8db8-6f154976000d"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17505475</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/232200"/>
  </obo:OGMS_0000112>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/6aa7ae7f-0ce9-43a5-a0cf-3305760283b1">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648/#b96-tacg-8-201</dc:provenance>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/bb2e900c-da5a-417b-a164-cfe0a4c17445">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/949a3471-0cc9-4981-9ae3-f142374cbf5b"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b1b5bd8b-2efb-4640-bfae-a7364d18dd21">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003455</ddiem:url>
        <rdfs:label>Elevated long chain fatty acids</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0003455</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://globenewswire.com/news-release/2015/03/30/720127/10126746/en/Sigma-Tau-Pharmaceuticals-Inc-Receives-Orphan-Drug-Designation-for-EZN-2279-for-Treatment-of-Adenosine-deaminase-Deficient-Severe-Combined-Immunodeficiency-Disease.html</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/300100"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28200172</dc:provenance>
    <rdfs:comment>The ability of these agents to affect VLCFA levels in a mammalian model was not explored. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5460829/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15670720</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28976817</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT03196765</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
  </obo:OGMS_0000112>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/96ca8a6c-d171-4d7d-8bcd-662320d9e250">
    <dc:provenance>https://www.paediatricaindonesiana.org/index.php/paediatrica-indonesiana/article/view/59/33</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/824d198f-f406-42b0-ad42-e2cfbd119256">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/daf3b3b3-9bf5-4195-86a1-b156f3afb5f7"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/4f8c5fb9-f813-4852-8017-a5f808513f9b"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/309000"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20301653</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17339125</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <rdfs:comment>If on supplemental bicarbonate or citrate, phosphorus or calcitriol or other vitamin D analog, need kidney function assessment 1 w/blood &amp; urine tests
May need serum vitamin D-25 hydroxy to assess for parent vitamin D deficiency</rdfs:comment>
  </obo:DDIEM_0000013>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/188ed29a-5505-459b-b5c7-d61c7a45907e">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/1bbb2414-97d9-47ab-bfa1-6b06ce60bf36"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01174</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/fd7d7db2-1649-4379-8d3e-8b944ac170af"/>
    <rdfs:label>Phenobarbital</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/84a78c3d-4157-4355-852c-db0ffd5d2a66"/>
    <obo:RO_0000056>
      <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/62127bb9-1faa-419d-9bae-a689a5c6d235">
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/610090"/>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8757046</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/92af90b3-792a-4779-90d5-b71bb9153912"/>
        <rdfs:comment>The drug was administered through intravitreal injection.</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21310277</dc:provenance>
        <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26095523</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/35b5c64e-9aaa-46fd-84a3-e5d483d4e101"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01212744</dc:provenance>
        <dc:provenance>https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117</dc:provenance>
      </obo:DDIEM_0000013>
    </obo:RO_0000056>
    <dc:identifier>DB01174</dc:identifier>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/a182e766-7ccd-4165-9ac5-68eb491d9521">
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/92af90b3-792a-4779-90d5-b71bb9153912"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/5a7380bb-31e6-44a5-8716-cdc5239d0ac5"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <rdfs:comment>Drugs has decreased rhe frequency of the tonic seizuress</rdfs:comment>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/615398"/>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0387760417301742</dc:provenance>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/d8e5f309-1c7f-48ca-865a-b81ae3360dbe">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29273094</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/615181"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/92af90b3-792a-4779-90d5-b71bb9153912"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/35b5c64e-9aaa-46fd-84a3-e5d483d4e101"/>
        <rdfs:comment>In a different study IV administration of Glucose wasn't effective.https://www.ncbi.nlm.nih.gov/pubmed/22238410</rdfs:comment>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/561941a1-2fa1-495a-8256-ef74af9761a9"/>
  </ddiem:Drug>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/4bd63489-0eb9-4b08-84db-222a2994f5c5">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2785251</dc:provenance>
    <dc:provenance>https://www.babysfirsttest.org/newborn-screening/conditions/3-methylcrotonyl-coa-carboxylase-deficiency</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/f60f7003-670c-4239-89f8-4ac59b0b1ead"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/261630"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/442c5348-4232-46c7-b1bb-6aeb9e703e49">
        <dc:identifier>HP:0007346</dc:identifier>
        <rdfs:label>Subcortical calcification</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0007346</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>It's an investigational therapy where Positive results from using a selective monoamine oxidase (MAO) B inhibitor or non-ergot dopamine agonist pramipexole as an adjunct therapy have been described in the medical literature. This use of such an inhibitor can allow for lower doses of neurotransmitter precursor to be used. However, the long-term safety (e.g. effects on neonatal brain development) and effectiveness of this therapy is unknown and more research is required to determine what role, if any, selective monoamine oxidase B inhibitors play in the treatment of individuals with tetrahydrobiopterin deficiency. https://rarediseases.org/rare-diseases/tetrahydrobiopterin-deficiency/. https://www.researchgate.net/publication/233414693_Deprenyl_in_6-Pyruvoyl_Tetrahydropterin_Synthase_Deficiency. https://www.degruyter.com/downloadpdf/j/pteridines.1995.6.issue-3/pteridines.1995.6.3.144/pteridines.1995.6.3.144.pdf</rdfs:comment>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000006"/>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/7530ea8f-f9fd-41cf-bbb5-0f1e70c1a7f8"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23138986</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12003346</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/9a645a24-bd59-44fb-96dd-75f97c1caac8"/>
  </obo:OGMS_0000112>
  <owl:Class rdf:about="http://purl.obolibrary.org/obo/DDIEM_0000010">
    <dc:date rdf:datatype="http://www.w3.org/2001/XMLSchema#dateTime">2019-07-15T18:04:54+00:00</dc:date>
    <rdfs:label xml:lang="en">dietary supplementation</rdfs:label>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000008"/>
    <dc:creator>leechuck</dc:creator>
    <obo:IAO_0000115 xml:lang="en">A therapeutic procedure in which the diet is supplemented with foodstuffs containing molecules closely related to the products or end processes of a genetically defective protein, which occur naturally in the diet. [PNS]</obo:IAO_0000115>
  </owl:Class>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/9fa9a16b-c1c0-4f6f-9e7a-561d0c196d35">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/eee992ce-4b7e-440c-980f-19aa12ced069">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>diarrhea</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002014</ddiem:url>
        <dc:identifier>HP:0002014</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/602473"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0022202X15352507</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e95bfb09-8ecd-45c4-b80e-72bb7816e68f"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/518b6d43-2c86-4354-bcc8-68383fdd91a7"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d856e87d-0719-4f09-972b-1c2c5527f853"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29526615</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20657580</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/09a71b4e-6ddc-43c4-a9cd-5b8e64eec05b"/>
    <rdfs:comment>Drug used as an aternate therapy with (Metronidazole+Acetylcysteine)</rdfs:comment>
  </obo:OGMS_0000112>
  <obo:DDIEM_0000011 rdf:about="http://ddiem.phenomebrowser.net/abdb1309-11aa-4fa1-a8d6-0ecebce089d0">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20301647</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/topics/medicine-and-dentistry/dopamine-beta-hydroxylase-deficiency</dc:provenance>
    <rdfs:comment>Topical retinoic acids, topical steroids, hydroquinone, tretinoin, and systemic retinoids have been used without success. https://www.ncbi.nlm.nih.gov/pubmed/2350982
https://www.ncbi.nlm.nih.gov/pubmed/3679816 https://www.ncbi.nlm.nih.gov/pubmed/29797344

Combination of Q-switched Nd: YAG and Fractional Carbon Dioxide Laser could be a promising therapy to pigmentation of Dowling-Degos diseaseÂ  https://www.ncbi.nlm.nih.gov/pubmed/28529428</rdfs:comment>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00889135</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/471b5c95-6070-43c6-8b98-36cb242656a5"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f816c23c-4ab3-4c65-ade4-d4464243e319">
        <rdfs:label>orthostatic hypotension</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001278</ddiem:url>
        <dc:identifier>HP:0001278</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/223360"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
  </obo:DDIEM_0000011>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/5ce1bdec-4c54-47ed-99fe-4cddd735ab48">
    <dc:provenance>https://link.springer.com/article/10.1007%2Fs11883-014-0440-2</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2065040</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/011c75ed-306d-4948-b3e2-0b076ced95dd">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/95a84012-eadf-44a4-8bd1-968d00cc739f"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:comment>clinicians might only switch to combination therapy in FD patients who remain severely hypertriglyceridemic and/or hypercholesterolemic on monotherapy instead of prescribing combined statin-fibrate therapy to all FD patients that do not meet the non-HDL-C target.https://www.ncbi.nlm.nih.gov/pubmed/25768710</rdfs:comment>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/62f13862-3b92-42cc-9dad-e958eef7c627"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3162680</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25079293</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/617347"/>
  </obo:OGMS_0000112>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/437b18d0-ebde-49cb-a62f-0d7a1b1e9116">
    <dc:identifier>DB01606</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/834ba610-4902-4dd7-9187-f7c1c0344c72"/>
    <rdfs:label>Tazobactam</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01606</ddiem:url>
  </ddiem:Drug>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/2b3d8a28-b48a-49d2-888e-e605edb533f2">
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/603358">
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/208</ddiem:iembaseUrl>
        <dc:identifier>https://www.omim.org/entry/603358</dc:identifier>
        <ddiem:iembaseAccessionNumber>208</ddiem:iembaseAccessionNumber>
        <rdfs:label>GRACILE SYNDROME</rdfs:label>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/a2762fd9-c9c7-4f3d-b43f-3942d930c838"/>
        <rdfs:comment></rdfs:comment>
      </ddiem:Disease>
    </obo:RO_0002599>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0eca5ed6-3401-4e36-aa2c-dd146ed3bf6d">
        <dc:identifier>HP:0003128</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003128</ddiem:url>
        <rdfs:label>lactic acidosis</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>The mechanisms of its effects in movement disorders are not well understood but probably reflect an increase in synthesis and release of dopamine, with perhaps some inhibition of dopamine uptake.</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22970607</dc:provenance>
    <dc:provenance>https://www.tandfonline.com/doi/full/10.3109/0886022X.2014.900422</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/7b517ff3-fc9a-449b-a7f3-1355c1eb4688"/>
  </obo:DDIEM_0000013>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3dff1795-dd8a-4336-ba60-51a3ff83c667">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0040084</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0040084</dc:identifier>
    <rdfs:label>Abnormal circulating renin</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/8a379409-af0b-493f-b5cc-c01f39d6c7ee">
    <dc:identifier>DB00118</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/1b216d69-4807-4a05-a2d6-3df42f85efb9"/>
    <obo:RO_0000056>
      <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/45394c29-b505-464b-ac60-b55ed308cf0b">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21483849</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29054473</dc:provenance>
        <rdfs:comment>The cyclosporine trial (taken immediately upon visual loss in the first eye) is in progress in Leber's optic atrophy to prevent involvement of the fellow eye.</rdfs:comment>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b08f44c8-b4e7-4579-941a-346c0c6c5f77"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27179999</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16906475</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/cb1ae896-014a-4fc5-b114-2a8fc115ebb2"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/300322"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24001191</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/14aa57e8-8de3-473e-94f8-3334e3c2b0a8"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3202309</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24093206</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24055166</dc:provenance>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
      </obo:DDIEM_0000013>
    </obo:RO_0000056>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00118</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/87a7f8be-f7fc-4caf-b37f-fa2211000aab"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/be1c15d8-7e70-4b08-82c6-3fd7f66edfaa"/>
    <rdfs:label>Ademetionine</rdfs:label>
  </ddiem:Drug>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/779b92df-cf0b-4e3e-a356-722f4a221f28">
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/a1c9459a-4272-4af9-9252-b2f5a029d733"/>
    <dc:provenance>https://www.semanticscholar.org/paper/The-Incidence-of-Transient-Neonatal-Tyrosinemia-a-Zea-Rey-Cruz-Camino/b66304a0a56304f686380af915a92b2b860e9305</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1895089</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/7b09e6b6-143d-4567-8234-c04e019ca44a"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007764"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
    <rdfs:comment>One of the studies that was carried on mice provides useful information for developing the optimal dosage regimen for HPBCD therapy when administered intravenously to NPC patients.https://www.ncbi.nlm.nih.gov/pubmed/26027824</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25717099</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/602390"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14632789</dc:provenance>
    <dc:provenance>https://www.researchgate.net/publication/314493225_Clinical_management_of_hemochromatosis_current_perspectives</dc:provenance>
    <dc:provenance>http://www.bloodjournal.org/content/107/7/2952.abstract</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19415691</dc:provenance>
  </obo:OGMS_0000112>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/e65ca958-7dee-4e8a-9d57-0cffa1003a22">
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/5744bf4c-656f-4a8f-ab7d-e7eb342fd4eb">
        <rdfs:label>N-octyl-4-epi-Î²-valienamine (NOEV)</rdfs:label>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/78b517c1-3f4d-40b2-afc6-e7e728633c62"/>
      </ddiem:Drug>
    </rdf:li>
  </rdf:Alt>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7ec2a0e3-6ad2-41a8-a86b-8d35d8f96e5e">
    <rdfs:label>Abnormality of metabolism</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001939</ddiem:url>
    <dc:identifier>HP:0001939</dc:identifier>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/03408d8b-7d44-412f-8409-63be720e1df9">
    <rdfs:label>fat soluble vitamin malabsorption*</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0002630</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002630</ddiem:url>
  </ddiem:Phenotype>
  <owl:Class rdf:about="http://purl.obolibrary.org/obo/DDIEM_0000011">
    <dc:creator>leechuck</dc:creator>
    <obo:IAO_0000115 xml:lang="en">A therapeutic procedure involving enteral, parenteral or transdermal provision of small molecules closely related to the products or end processes of a genetically defective protein. [PNS]</obo:IAO_0000115>
    <dc:date rdf:datatype="http://www.w3.org/2001/XMLSchema#dateTime">2019-07-15T18:06:25+00:00</dc:date>
    <rdfs:label xml:lang="en">metabolite replacement</rdfs:label>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000006"/>
  </owl:Class>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/49d963b8-da32-42b4-8288-08e8d28e196d">
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/307030">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>GLYCEROL KINASE DEFICIENCY; GKD</rdfs:label>
        <ddiem:iembaseAccessionNumber>542</ddiem:iembaseAccessionNumber>
        <dc:identifier>https://www.omim.org/entry/307030</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/ceecbe7b-3d12-4850-8a69-050e5ac8cb06"/>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/542</ddiem:iembaseUrl>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26962538</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16767100</dc:provenance>
    <rdfs:comment>The results of this study suggest that octreotide may aid in the acute or long-term treatment of congenital hyperinsulinism in a limited number of selected cases.https://www.ncbi.nlm.nih.gov/pubmed/8410522/</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4612542</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6dc61a59-c96b-416a-a36c-acdcbf0aa05b">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0001977</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001977</ddiem:url>
        <rdfs:label>Thrombosis</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25781533</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/5fac446c-5a6c-4991-836c-1393e3ea13cf">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/a3cadab9-6282-4407-ae45-8de3701bf3f6"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
  </obo:OGMS_0000112>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c5da313e-bea2-47c2-a1f1-f37794771dd5">
    <rdfs:label>UDP-glucuronosyltransferase gene defect</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/97383852-559b-4968-85fa-07445eb5aadd">
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/ef793511-4c79-4410-b52c-c820a422ac49">
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/8df101f0-5b26-4c61-880e-be4ddc8e0363"/>
        <ddiem:url>https://www.drugbank.ca/drugs/DB01109</ddiem:url>
        <rdfs:label>Heparin</rdfs:label>
        <dc:identifier>DB01109</dc:identifier>
      </ddiem:Drug>
    </rdf:li>
  </rdf:Alt>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/4daa42ca-a5d1-47d9-911d-136560f9c84b">
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/53099ecb-bb57-4f2c-9b1a-1251ef527911"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15726662</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC324959</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/e3a59696-57ee-47c9-98cc-341bc54f1e1d">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/417d98ef-f06b-4a22-a195-581a9ffe7e7d"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/610198">
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/1012</ddiem:iembaseUrl>
        <dc:identifier>https://www.omim.org/entry/610198</dc:identifier>
        <rdfs:label>3-METHYLGLUTACONIC ACIDURIA, TYPE V; MGCA5</rdfs:label>
        <ddiem:iembaseAccessionNumber>1012</ddiem:iembaseAccessionNumber>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/5d82a9bc-e70b-46d2-ada3-813714e1d179"/>
      </ddiem:Disease>
    </obo:RO_0002599>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/e643648c-e4ac-4141-86e1-d57f70bdf43f"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27928778</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583863</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2564511</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/6bb785ef-18d5-4569-a35b-4bb92a45e59e"/>
    <rdfs:comment>Treatment was stopped three days later because of lack of improvement and severe respiratory alkalosis with lactic acidosis (serum lactic acid 70 mg/dl, normal 4â20 mg/dl). https://www.ncbi.nlm.nih.gov/pubmed/12948744</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3306242</dc:provenance>
  </obo:OGMS_0000112>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7775db0e-efcf-4b49-aa67-551b966b5186">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0100022</ddiem:url>
    <dc:identifier>HP:0100022</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>movement disorders</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/a6f1970f-d085-4bd2-a613-eb0e5592e411">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/3ecab22e-86c3-429b-988c-b6611799c46d"/>
    <rdfs:label>Desmopressin</rdfs:label>
    <dc:identifier>DB00035</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00035</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/f06fc014-e20c-47b7-bb6f-836b13e054d4"/>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/697b2dc5-4716-441a-8b7f-4bd51c050758">
    <rdfs:label>Abnormal serum Methylfolate Level</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/a8036301-73e0-4267-9105-05e154afcae8">
    <rdfs:comment>Testosterone therapy needs to be carefully considered because of the risk of hepatic adenomas.https://www.ncbi.nlm.nih.gov/pubmed/28160246
Androgen receptors are expressed in the liver, and androgens can stimulate hepatocyte proliferation. Although rare, androgens have been shown in observational studies to induce adenoma development (Giannitrapani et al. 2006). Testosterone levels should be assessed for response 2â3 months after therapy is initiated.</rdfs:comment>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/c44c19cd-9713-4968-9e52-d37a3e45bfd3">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/cee2832d-9d77-45c8-8233-2b50cdc58d21"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/2f330e37-5bd8-44a3-ba42-94923b435485"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/232600"/>
    <dc:provenance>http://www.ncbi.nlm.nih.gov/pubmed/28932990</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25391139</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24493026</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17490880</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
  </obo:OGMS_0000112>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/e1cf19aa-20db-4f3e-864d-5fdf059fac8d">
    <dc:identifier>DB11981</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB11981</ddiem:url>
    <rdfs:label>Elamipretide</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/74c6f833-4c9c-439c-afef-6c80b2ba96c7"/>
    <obo:RO_0000056>
      <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/d701e3a2-6d12-4974-9145-1c3b808c439e">
        <dc:provenance>http://www.neurologyindia.com/article.asp</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d091746a-8de1-4d71-b5ed-b7cb0379d605"/>
        <dc:provenance>https://mitochondrialdiseasenews.com/2018/03/09/stealth-biotherapeutics-completes-enrollment-elamipretide-trial-barth-syndrome</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2646391</dc:provenance>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT03098797</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24260777</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f328a9f6-49d0-4637-9a72-57ec8c3c1e65"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/e3f8ef83-a890-423a-8dbd-a852b10c8f19"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
        <rdfs:comment>Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss</rdfs:comment>
        <dc:provenance>https://www.orpha.net/data/patho/GB/uk-Bartter.pdf</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/302060"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/c9106990-2dc9-4d0b-8b31-72009b8aa14f"/>
      </obo:DDIEM_0000007>
    </obo:RO_0000056>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/14516f12-619a-4962-8b81-f9af9648684b">
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0100660*</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0100660</ddiem:url>
    <rdfs:label>levodopaâinduced choreic dyskinesia(Dyskinesia)*</rdfs:label>
  </ddiem:Phenotype>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/1cebedcb-a513-4325-a25f-00d720afaffc">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/37f4be7e-4b78-4f36-98d1-12e4cf0ccf11">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/78187157-05f7-4139-99db-6bbf05026dd1"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:comment>The approach is (RNA interference-based, liver-targeted therapeutic), however this trial has been terminated.</rdfs:comment>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/609458">
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/175dcd8c-14f5-4713-a31a-4eef94ec3621"/>
        <rdfs:label>MANNOSIDASE, ALPHA, CLASS 2B, MEMBER 1; MAN2B1</rdfs:label>
        <dc:identifier>https://www.omim.org/entry/609458</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23494656</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26827607</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/51f416e5-2da1-40bd-827e-03f04ed8b856">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Elevated GFAP(Glial fibrillary acidic protein) level in CSF</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.clinicaltrialsregister.eu/ctr-search/search</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5d675399-d8e8-4bed-bd0f-d612aaca6403">
        <rdfs:label>Low FVC%</rdfs:label>
        <dc:identifier>HP:0030878*</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0030878</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f5a42017-cba1-4edb-913f-d75d2dc3a56e"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/52bfa71e-69f2-4000-8d16-c146fcc54f27">
        <rdfs:label>Elevated Tau-p level in CSF</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/37279a5e-07fe-402b-a7ab-de64c5f77043"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ab09dc28-4f70-4bfb-988f-64019cc2db6f">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0005952</ddiem:url>
        <rdfs:label>Reduced pulmonary function</rdfs:label>
        <dc:identifier>HP:0005952</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01681940</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02998879</dc:provenance>
    <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5508465</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f7c8a9ca-1564-48a4-b37e-18cca020f302">
        <rdfs:label>High NFL (neurofilament light signature ) in CSF</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </obo:OGMS_0000112>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5394a49d-b739-4b9b-ad02-5c32844dedad">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003040</ddiem:url>
    <rdfs:label>Arthropathy</rdfs:label>
    <dc:identifier>HP:0003040</dc:identifier>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/93fc8313-645f-46cb-ba2c-ec39d326c285">
    <rdfs:comment>Clonazepam is a useful adjunct for myoclonus and can be used in combination with lamotrigine to avoid lamotrigineâs myoclonic effects . 
Zonisamide should remain a second-line adjunct in the treatment of JME, owing to the lack of supportive data.
https://link.springer.com/article/10.1007/s11940-011-0131-z</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15637709</dc:provenance>
    <dc:provenance>https://link.springer.com/article/10.1007/s11940-011-0131-z</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/300559">
        <ddiem:iembaseAccessionNumber>563</ddiem:iembaseAccessionNumber>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/563</ddiem:iembaseUrl>
        <rdfs:label>GLYCOGEN STORAGE DISEASE, TYPE IXd; GSD9D</rdfs:label>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/c6c54f58-04d6-4c81-81e5-704f7f43bdd9"/>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>https://www.omim.org/entry/300559</dc:identifier>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/books/NBK1520</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/f0f9f12d-511e-4374-b6b7-1465d689c6d4">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/cfda5a8d-5141-4b57-894d-1ab1cc5aa491"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1059131117301243</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ae228e3c-023f-410d-8f0f-3f7da2bc934d"/>
  </obo:DDIEM_0000013>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/989c31df-6009-4727-9441-6af20df560d6">
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/2c5d1869-70e4-4a21-9ce0-1f028a9f7b45"/>
    <rdfs:comment>Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3249181</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23432031</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/cdec8137-0822-4811-8652-bbe062cd76d5"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/302060"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31239752</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e193387f-b9ef-4913-877f-8cbff03660de"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18632498</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15098233</dc:provenance>
  </obo:DDIEM_0000013>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/6627c40d-4fd4-41ad-be2f-e15121ad275b">
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30477028</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000012"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/3d0d5e32-833d-495e-aafe-2f3ae63a1923">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/6b518b0a-1889-4041-9b35-99a4a2994bf3"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30049652</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02900183</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5508465</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02363946</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23527792</dc:provenance>
    <rdfs:comment>The approach is (RNA interference-based, liver-targeted therapeutic), however this trial has been terminated.</rdfs:comment>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/613490"/>
  </obo:OGMS_0000112>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/da445398-6a36-4219-984e-2bbaff81e802">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17375984</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/ef33b7c9-f22d-4879-b991-0ff62161145f">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/c4a265d6-2ebf-452a-9036-f79a9796d989"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/922d70ca-1106-47ba-aa98-5e87308a337c">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Accumulated  plasma porphobilinogen</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15767622</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02180412</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/176000"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6358544</dc:provenance>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <rdfs:comment>The rh-HMBS-enzyme replacement therapy, however, had no effect on the patientsâ symptoms during acute attacks mainly due to constantly high plasma ALA levels. The potential development of rh-HMBS-enzyme replacement therapy should be focused on the delivery of an active enzyme into the liver ,the main site of ALA overproduction, restoring the normal HMBS activity and heme biosynthesis. https://www.ncbi.nlm.nih.gov/pubmed/17375984/</rdfs:comment>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/aa266118-fd36-47f2-ab86-e961ee16fe24"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648/#b96-tacg-8-201</dc:provenance>
  </obo:OGMS_0000112>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/b143ca20-f04d-4643-bbdc-7edf0869a093">
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00125190</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT03570931</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
    <dc:provenance>http://n.neurology.org/content/90/15_Supplement/P3.327</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d801e25f-c22c-4e1f-8048-7e310a97599b">
        <rdfs:label>Bulbar dysfunction</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001283</ddiem:url>
        <dc:identifier>HP:0001283</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/00cd9fb4-c7f1-4443-9269-0292bc35ee38"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10549306</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23887143</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8c704b65-6b8c-4a5d-b7a8-dc99eb4edfe5">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Defective eye motor function</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000496</ddiem:url>
        <dc:identifier>HP:0000496</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24639006</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19627167</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/dd20eb25-b25d-4804-92a8-a94faad9e52b">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0004302</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Functional motoe deficit</rdfs:label>
        <dc:identifier>HP:0004302</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/da184cec-d903-494e-a46f-a3dad76d2400"/>
    <rdfs:comment>The clinicl trial status is active and not recruiting and no results have been yet posted.

The drug is a patented, first-in-class, orally available D-PUFA, a deuterated polyunsaturated fatty acid, that incorporates into mitochondrial and cellular membranes and stabilizes them. It was discovered that lipid peroxidation, the free-radical damage of polyunsaturated fats (PUFAs) in mitochondrial and cellular membranes, may be the primary source of cell death in several degenerative diseases. The presence of D-PUFAs (RT001) can help protect (âfireproofâ) against this and potentially restore cellular health. https://inadcure.org/clinical-trials-research-studies/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17192294</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/9a93f2f5-82e0-4081-8173-67849a30b9c7">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/48963ea9-d89a-4c71-b88f-d1bbc0394b55"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/256600"/>
  </obo:OGMS_0000112>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/38865dc5-689b-4a5a-91b4-2adb6f803f18">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ef2e2f11-2204-486f-b992-8aec77f58b3a">
        <rdfs:label>spastic bladder</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0005340</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0005340</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/49152949-b69a-489e-be08-286538ca7b8c"/>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/611105">
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/3042faba-a8a1-4c09-972a-0793f1a132b7"/>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/446</ddiem:iembaseUrl>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>https://www.omim.org/entry/611105</dc:identifier>
        <ddiem:iembaseAccessionNumber>446</ddiem:iembaseAccessionNumber>
        <rdfs:label>LEUKOENCEPHALOPATHY WITH BRAINSTEM AND SPINAL CORD INVOLVEMENT AND LACTATE ELEVATION; LBSL</rdfs:label>
      </ddiem:Disease>
    </obo:RO_0002599>
    <rdfs:comment>Treatment with allopurinol was associated with xanthine lithiasis. https://www.ncbi.nlm.nih.gov/pubmed/17065067 
https://www.ncbi.nlm.nih.gov/pubmed/16773422/</rdfs:comment>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23644316</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
  </obo:DDIEM_0000013>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/80c9fcd3-ff0c-4089-84f3-199dd75ce62b">
    <dc:identifier>HP:0010836</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0010836</ddiem:url>
    <rdfs:label>hypocupraemia</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/f334672f-4dcf-4441-bfd6-54edb2823c83">
    <dc:identifier>DB08830</dc:identifier>
    <obo:RO_0000056>
      <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/ebae6393-f77b-4abd-9af2-fbea7fcdf902">
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/602473"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17712735</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/3e96db59-b4a5-4aa0-8b4a-070c29fa8d6a"/>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0005272811001447#bb0230</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0022202X15352507</dc:provenance>
        <rdfs:comment>It significantly reduces the inhibitory effect of sulfide on cytochrome c oxidase, resulting in higher rates of respiration and sulfide oxidation in rat mitochondria.</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29526615</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a83c8745-e772-48e0-adea-cd522082cf20"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
      </obo:DDIEM_0000013>
    </obo:RO_0000056>
    <rdfs:label>Dehydroascorbic acid</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB08830</ddiem:url>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/b503ae74-604c-4a0c-b3b1-58ba923e0293">
    <dc:identifier>DB02053</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB02053</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/d5011663-f751-441d-a9f5-b7c795dfe51f"/>
    <rdfs:label>Ribose-5-phosphate</rdfs:label>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/c44a274a-84ed-46cd-ab50-e989ef08f5c7">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/3cc8a93a-5484-4d8f-b91c-456440bdf64a"/>
    <rdfs:label>Trimethylaminoxid</rdfs:label>
    <dc:identifier>CHEBI_15724</dc:identifier>
    <ddiem:url>https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI_15724</ddiem:url>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/13720715-b575-4503-8922-b1f3f6942235">
    <dc:identifier>DB01032</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/ecf90cba-d2b6-41df-b4f0-b3335c627ba3"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01032</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/1a4a6fdf-50a9-4ca6-8ced-5c9cd89a675d"/>
    <rdfs:label>Probenecid</rdfs:label>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4f58f104-5672-4762-b3dc-5aa64b45cdc0">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0025303</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Recurrent repisode of flares (Recurrent)*</rdfs:label>
    <dc:identifier>HP:0025303</dc:identifier>
  </ddiem:Phenotype>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/f30eb1e8-9038-4959-aea4-8dee35d1bbf9">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26922636</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27179999</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/results/NCT01065558</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29054473</dc:provenance>
    <rdfs:comment>The cyclosporine trial (taken immediately upon visual loss in the first eye) is in progress in Leber's optic atrophy to prevent involvement of the fellow eye.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21483849</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/c4633604-cb41-4d90-84d5-44841bde9fef"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24093206</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3202309</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/300322"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00935753</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/7932c6ce-492b-4fc2-b676-294caeb78bf5"/>
  </obo:OGMS_0000112>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a495b198-7c73-4e46-a59c-ab9805502b87">
    <rdfs:comment>lifelong and diligent cysteamine therapy prevents hypothyroidism, enhances growth, depletes muscle parenchyma of cystine, and prevents a host of nonrenal complications</rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003678</ddiem:url>
    <dc:identifier>HP:0003678*</dc:identifier>
    <rdfs:label>development of extra-renal pathologies ( Progressive disorder)*</rdfs:label>
  </ddiem:Phenotype>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/500e29d7-eb6e-4c22-b781-ed71efc8bf24">
    <rdfs:comment>Recent studies, however, have suggested inverse associations between carotenoids and lung cancer mainly in smokers.
https://www.ncbi.nlm.nih.gov/pubmed/18689373/ https://www.ncbi.nlm.nih.gov/pubmed/19254833/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7758200</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19656325</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/73d8dfc1-8430-4c1a-8553-6dcc061f9109">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/c089f715-82d8-4a14-ab84-cc7be2f839ab"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23884489</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b5bb008d-8eaa-418e-b17d-d45a9a5a9856">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012187</ddiem:url>
        <rdfs:label>Abnormal  protoporphyrin enterhepatic circulation</rdfs:label>
        <dc:identifier>HP:0012187</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10189233</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/177000"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26979527</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22092997</dc:provenance>
  </obo:DDIEM_0000013>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/560ac420-cd02-4239-847e-6a03bbf0090c">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/57351e14-3467-4c43-956e-b5ea18576fdf"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00348</ddiem:url>
    <obo:RO_0000056>
      <obo:DDIEM_0000015 rdf:about="http://ddiem.phenomebrowser.net/1b97efd2-1241-4964-ae9f-7faceee4a136">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30049652</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/5048010f-10dc-4624-8720-aa3b9e6d66f0"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5508465</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ed1dca73-e755-47c3-a158-bb360995309c"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30477028</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/89c2524f-61fa-421d-8d5e-d50530c1c476"/>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01828463</dc:provenance>
        <rdfs:comment>Nitisonone, a triketone herbicide and high-dose vitamin C (ascorbic acid) have been prescribed, but their efficacy has not been proven , A recent study in Oct. 2018 https://www.ncbi.nlm.nih.gov/pubmed/30449931 #It should be noted that despite its potential beneficial effects, nitisinone causes a large increase in circulating tyrosine. https://www.ncbi.nlm.nih.gov/pubmed/26891864. #There are more cinical studies running about Alkaptnuria "for more information please check http://www.developakure.eu/index.html</rdfs:comment>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/203500"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/6ea7ea5d-702a-4935-9bca-ab603ce82e1d"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f6b404d9-7552-4b2b-8283-04982b0cc70b"/>
        <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26891864</dc:provenance>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28813744</dc:provenance>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00107783</dc:provenance>
      </obo:DDIEM_0000015>
    </obo:RO_0000056>
    <dc:identifier>DB00348</dc:identifier>
    <rdfs:label>Nitisinone</rdfs:label>
  </ddiem:Drug>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/a88f4fdf-6046-4921-86db-6dea2f7041fb">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31082797</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31196723</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31211405</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/8a97cf5f-ce12-41b2-8f91-84e8681b489e"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/direct_complementation_of_a_genetically_defective_protein_by_gene_therapy"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29122734</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31434105</dc:provenance>
    <rdfs:comment>The results of this study suggest that octreotide may aid in the acute or long-term treatment of congenital hyperinsulinism in a limited number of selected cases.https://www.ncbi.nlm.nih.gov/pubmed/8410522/</rdfs:comment>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/607015"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/4cb78531-60da-4c1f-9e48-ee718a9a5964">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/d80fa2ed-5c16-4bae-8921-43d3b7e0ad04"/>
      </rdf:Alt>
    </obo:RO_0000057>
  </obo:OGMS_0000112>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/63379667-4ede-4bc0-94d0-31b548a6d8ec">
    <obo:RO_0000056>
      <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/5eec5044-93d8-4689-8962-f68f92360b92">
        <rdfs:comment>From the biochemical viewpoint there is strong recommendation for giving patients with AADCD a trial of MAO inhibitors, although there is little evidence of clinical benefit. All patients had co-treatment with dopamine agonists and/ or pyridoxine https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5241937/</rdfs:comment>
        <dc:provenance>https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e95bfb09-8ecd-45c4-b80e-72bb7816e68f"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/608643"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5241937</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/fe8f2fc1-17c6-4934-a71e-98da9b1d94fb"/>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01395641</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23494656</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3955971</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23390030</dc:provenance>
        <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
      </obo:DDIEM_0000007>
    </obo:RO_0000056>
    <rdfs:label>Pargyline</rdfs:label>
    <dc:identifier>DB01626</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01626</ddiem:url>
  </ddiem:Drug>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/022c27f6-c878-4542-8819-54953a5e3254">
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/80c9fcd3-ff0c-4089-84f3-199dd75ce62b"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/387b9aa2-9a28-479d-a7f0-8ecfc6876a9c"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300</dc:provenance>
    <rdfs:comment>Treatment was stopped three days later because of lack of improvement and severe respiratory alkalosis with lactic acidosis (serum lactic acid 70 mg/dl, normal 4â20 mg/dl). https://www.ncbi.nlm.nih.gov/pubmed/12948744</rdfs:comment>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/121270"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1627787</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719215300895</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3306242</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15726662</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583863</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9156798</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/bfb85bc6-fa05-4576-b03f-b3762727a4f3"/>
  </obo:OGMS_0000112>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/84b533b0-705e-477c-ab1c-53b452808141">
    <rdfs:comment>There is a common note in different reserachs refers to the importance of early managment by Vitamin E supplements since it limits disease progression and it can reverse some of the clinical manifestation (e.x ataxia and the intellectual deficit), if it was interoduced early in life. Therefore, early diagnosis is paramount.</rdfs:comment>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/208900"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28318010</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17586848</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/cdec8137-0822-4811-8652-bbe062cd76d5"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15300460</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27906067</dc:provenance>
    <dc:provenance>https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813</dc:provenance>
    <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/4545c674-c3f0-46ca-9286-b2a815b064de"/>
  </obo:OGMS_0000112>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/79242f64-8513-41aa-a569-c865b581c7ae">
    <rdfs:label>Hemin</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB03404</ddiem:url>
    <dc:identifier>DB03404</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/00f5c594-d628-46c9-8acb-6914443d39ae"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/475bd8f9-ac7f-46fa-90a5-775acbb973f6"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/41b6f1f4-5afd-426f-9a62-99b753d09542"/>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/d70004cc-b749-443b-93a9-3be5f4683494">
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/16062da6-88a7-4ab2-8e3a-4fe8da29405f">
        <rdfs:label>Filgrastim</rdfs:label>
        <ddiem:url>https://www.drugbank.ca/drugs/DB00099</ddiem:url>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/fe641f47-9196-421c-9ed9-e373bb1ab120"/>
        <dc:identifier>DB00099</dc:identifier>
      </ddiem:Drug>
    </rdf:li>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/ed83e007-6618-4e03-8df0-8b5652a29252">
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/53f82b74-7488-4f7a-afda-45fc555b9c67">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18458702#</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/2bbf75d4-fef2-4cee-9721-00180f5a9273"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/452d33b0-eda6-4036-b2c4-ec40913689b6"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26161337#</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/202110"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/b3d1dd60-4560-4198-9ad4-ee47399e2d56"/>
        <rdfs:comment></rdfs:comment>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <dc:identifier>DB00603</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00603</ddiem:url>
    <rdfs:label>Medroxyprogesterone acetate</rdfs:label>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/135c16c6-28e6-4598-ab34-8776b5c49b01">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/d7ff5fd7-41ba-4307-91b6-77a33f6cf4d9"/>
    <obo:RO_0000056>
      <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/2a1f4d04-2ffa-4292-afa5-de036a5cc601">
        <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
        <dc:provenance>https://www.jci.org/articles/view/11948</dc:provenance>
        <dc:provenance>https://www.babysfirsttest.org/newborn-screening/conditions/3-methylcrotonyl-coa-carboxylase-deficiency</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/231530"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/22a94e91-2bbf-4989-b3db-f05af0e6a0a5"/>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5388644</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/c9106990-2dc9-4d0b-8b31-72009b8aa14f"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/4a0fce45-6bb5-4148-bbf9-b0107dc85fc4"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16835865</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/a5339c14-5cc3-41e8-b345-f78cf77e4e18"/>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/study/NCT01379625</dc:provenance>
        <rdfs:comment>Effect of glycine in treating the condition is variable among literatures.  "Case reports have noted variable results regarding the effect of glycine administration. Some studies have found that supplemental glycine results in increased excretion of 3-methylcrotonyl glycine, while others have not found a persistent effect; no studies have observed clinical improvement of symptoms on treatment and no randomized clinical trials have been published" https://www.sciencedirect.com/science/article/pii/S1096719207005975?via%3Dihub#bib11
https://www.ncbi.nlm.nih.gov/pubmed/8831079
https://www.ncbi.nlm.nih.gov/pubmed/7474896</rdfs:comment>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
      </obo:DDIEM_0000007>
    </obo:RO_0000056>
    <rdfs:label>Triheptanoin</rdfs:label>
    <obo:RO_0000056>
      <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/6e8206fd-81e4-4f25-8a36-ae8dff9abb89">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30804055</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/c762b710-067c-4cd1-b8a7-2cbf2e977d68"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28590052</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/aaae542c-5d24-4c2f-8cb6-a39dd5b01a81"/>
        <dc:provenance>PMC2676979</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ef277a72-cce9-4ec8-9f7e-cfc2700e6701"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18645163</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/255120"/>
        <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26153518</dc:provenance>
        <rdfs:comment>Drug name: Intranasal dDAVP, because of efficacy, long duration of action, and infrequent side effects, is the preferred treatment of neurogenic diabetes insipidus in children and adults.https://www.ncbi.nlm.nih.gov/pubmed/626447</rdfs:comment>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/a5339c14-5cc3-41e8-b345-f78cf77e4e18"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15131757</dc:provenance>
      </obo:DDIEM_0000007>
    </obo:RO_0000056>
    <ddiem:url>https://www.drugbank.ca/drugs/DB11677</ddiem:url>
    <dc:identifier>DB11677</dc:identifier>
    <obo:RO_0000056>
      <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/7ac2958f-9667-4c8c-ad2f-bbe5aed2f6ab">
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25455802</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/a5339c14-5cc3-41e8-b345-f78cf77e4e18"/>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02432768</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/232600"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25762569</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ace9b1fb-7f92-4b61-a04b-72adbeaa57ec"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a6d6b318-f238-4942-8a31-8aba1bfeec22"/>
        <dc:provenance>https://link.springer.com/article/10.1007%2Fs11940-017-0473-2</dc:provenance>
        <rdfs:comment>Testosterone therapy needs to be carefully considered because of the risk of hepatic adenomas.https://www.ncbi.nlm.nih.gov/pubmed/28160246
Androgen receptors are expressed in the liver, and androgens can stimulate hepatocyte proliferation. Although rare, androgens have been shown in observational studies to induce adenoma development (Giannitrapani et al. 2006). Testosterone levels should be assessed for response 2â3 months after therapy is initiated.</rdfs:comment>
      </obo:DDIEM_0000013>
    </obo:RO_0000056>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/d0203dab-cbbf-4efd-a5bb-d28a7e2c36b5"/>
    <obo:RO_0000056>
      <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/c25bdf63-b35d-4b19-b06a-4c0dce781e7f">
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/743b6ddd-3df7-4fe9-98a5-c3e47663c9b5"/>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02014883</dc:provenance>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26982753</dc:provenance>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02036853</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/7775db0e-efcf-4b49-aa67-551b966b5186"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23196212</dc:provenance>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02000960</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
        <rdfs:comment>The enteric carbohydrateâfree formula with or without fructose addition seems a very effective and safe measures for the rehydration. https://www.ncbi.nlm.nih.gov/pubmed/10404446. https://www.ncbi.nlm.nih.gov/pubmed/20486940</rdfs:comment>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02960217</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/606777"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22812641</dc:provenance>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01993186</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/387b9aa2-9a28-479d-a7f0-8ecfc6876a9c"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/8fc77ec2-d685-4b6b-a7af-ef3e04545efe"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/35b5c64e-9aaa-46fd-84a3-e5d483d4e101"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d377d68f-7274-4a1f-91a9-47055273f96d"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29303961</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/a5339c14-5cc3-41e8-b345-f78cf77e4e18"/>
      </obo:DDIEM_0000013>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/a5456401-1e2a-44dd-9f98-3f0fbf733afc">
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT03642860</dc:provenance>
        <rdfs:comment>A clinical trail studying the effect of Triheptanoin on excersise intolerance and fat metabolism, is currently under process. https://clinicaltrials.gov/ct2/show/NCT03642860?cond=Glycogen+Storage+Disease+VII&amp;rank=1</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19019309</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/512ed4ea-a90f-4140-b2ac-5658e89ee145"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/232800"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
        <dc:provenance>https://www.nature.com/articles/pr19842087</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25266922</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/a5339c14-5cc3-41e8-b345-f78cf77e4e18"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
      </obo:DDIEM_0000013>
    </obo:RO_0000056>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/e0bb620c-e9f5-4141-bc7d-240944dc3513">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/fcb2cc0c-fac7-498b-9164-96cd0d2a49fd"/>
  </rdf:Alt>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/dd79b64f-6425-43fb-89d4-076350231775">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0031951</ddiem:url>
    <rdfs:label>Short nocturnal tonic seizures</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0031951</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b200bc19-bf63-4052-914e-24afffd9a2ee">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Defected mucle plasma membrane</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/9cba78c5-ea99-4b35-8c70-0123a831e309">
    <obo:RO_0000056>
      <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/aedf5505-5678-4b6c-bcc5-d45bba965dca">
        <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/603471"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/books/NBK1181</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15670720</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648/#b96-tacg-8-201</dc:provenance>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/eed299ff-ef27-4499-9310-422a01a76278"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://globenewswire.com/news-release/2015/03/30/720127/10126746/en/Sigma-Tau-Pharmaceuticals-Inc-Receives-Orphan-Drug-Designation-for-EZN-2279-for-Treatment-of-Adenosine-deaminase-Deficient-Severe-Combined-Immunodeficiency-Disease.html</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d9054e8c-01a4-4bda-bd2b-78a630c0a2d0"/>
        <rdfs:comment>Medium-chain triglyceride (MCT) supplement therapy with a low-carbohydrate formula was effective in CTLN2 to prevent a relapse of hyperammonemic encephalopathy. https://www.ncbi.nlm.nih.gov/pubmed/29651749</rdfs:comment>
        <dc:provenance>https://www.sciencedirect.com/science/article/abs/pii/S1386634602003315</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5783980</dc:provenance>
      </obo:DDIEM_0000007>
    </obo:RO_0000056>
    <dc:identifier>DB00119</dc:identifier>
    <obo:RO_0000056>
      <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/c6dd4952-e582-48d5-b04b-75d509f81228">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30738201</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/530000"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a6bad8c1-50e3-4da9-97a9-89872d08b306"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/eed299ff-ef27-4499-9310-422a01a76278"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <rdfs:comment>MCT should be at least 70% of the total fat content of the diet.</rdfs:comment>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/3e75e7d3-5d65-419c-872f-c10284859178"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26884075</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/6aaa6529-f253-4775-9ccb-3c606450b0fd"/>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02473445</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e436fde1-15f0-49e5-94b6-6cf86019a5aa"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/9ffb64b7-74cc-49a8-a5e0-9f5ac23fee1b"/>
      </obo:DDIEM_0000013>
    </obo:RO_0000056>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00119</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/703325b0-e30a-4217-8c51-859c54d64d18"/>
    <rdfs:label>Pyruvic acid</rdfs:label>
  </ddiem:Drug>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/b75d90ae-08f6-435b-90f3-bec6b002ed43">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25922564</dc:provenance>
    <dc:provenance>https://acrabstracts.org/abstract/anakinra-compared-to-prednisone-on-the-treatment-of-acute-cppd-crystal-arthritis-a-randomized-controlled-double-blind-study</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/83b4c9e0-d923-4ce2-87e6-eb834a3e8f44">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0031375</ddiem:url>
        <rdfs:label>Refractory Arthritis</rdfs:label>
        <dc:identifier>HP:0031375</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6368924</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22832289</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/0cd08a38-f58b-41c1-b399-150103c7879b"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22658375</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19289295</dc:provenance>
    <rdfs:comment>Anakinra was administered as preventive therapy in one study" https://www.ncbi.nlm.nih.gov/pubmed/19289295". In another one, it was documented that the drug may be helpful to control flares in patients having CPP crystal-induced arthritis for which conventional therapies are ineffective or contra-indicated. https://www.ncbi.nlm.nih.gov/pubmed/23022422. 
The acute/subacute pseudogout or acute hydroxyapatite deposition arthritis should require extended duration of treatment with anakinra than in gouty arthritis . Moreover, adding anakinra to conventional drugs could show better efficacy than each drug alone. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4398911/
There have been case reports and case series of success with interleukin-1Î² inhibitors for both prophylaxis and treatment in patients with ESRD.15 16 However, there are no randomised controlled clinical studies to support efficacy. Furthermore, these therapies are only administered parenterally (which excludes our patient from treatment given her aversion to needles), and the cost of therapy can exceed US$100 000 annually. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6169684/</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22341584</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4311f94c-8a78-41b3-85bc-b0ea1e144496">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0100769</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0100769</dc:identifier>
        <rdfs:label>Synovitis</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6169684</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29675606</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/01bb9170-3776-470c-a893-54b20d5881c9">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/d5e5e5f4-af62-4267-8a57-b59bc814746f"/>
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/e3435067-bbc9-4cab-bca0-67cefcd6b816"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/118600"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18240249</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/4f58f104-5672-4762-b3dc-5aa64b45cdc0"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23022422</dc:provenance>
  </obo:OGMS_0000112>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/c63644d0-ba07-4a20-9b80-48b6e7672c86">
    <rdfs:label>Pegvaliase</rdfs:label>
    <dc:identifier>DB12839</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/5fca1ada-bb06-4b29-a3ad-7ab80da61769"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB12839</ddiem:url>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/fdc00c01-f727-4087-8068-242c2486bf89">
    <rdfs:label>High total plasma cholesterol leve</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/13535eeb-5cfc-4e79-80d5-76e5f65b05ea">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12003346</dc:provenance>
    <dc:provenance>https://link.springer.com/referenceworkentry/10.1007%2F978-3-540-29676-8_1729</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10078749</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/365baf88-333e-4b89-9798-3ea5b0de147d">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012446</ddiem:url>
        <dc:identifier>HP:0012446</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>depletion of cerebral folate</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/233910"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18276179</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20818608</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19234759</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/e26f58c5-3e77-453b-8c30-5df2c9c700e9"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7d8558cd-4576-46fd-ac8c-6908e477698f">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012335</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>abnormal folate homeostasis in the CNS</rdfs:label>
        <dc:identifier>HP:0012335</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>Sodium phenylbutyrate lowers the resynthesis of arginine from ornithine via the urea cycle.https://www.ncbi.nlm.nih.gov/pubmed/24268530</rdfs:comment>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719208000048</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
  </obo:OGMS_0000112>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f50f53b5-ca27-460d-b3a4-86c011836cec">
    <rdfs:label>NO revealed clinical benefit</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/b6440918-b260-473b-b8c6-f589e9af695b">
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/c37bc618-fe24-4884-8322-c7e7956e3df2">
        <ddiem:url>https://www.whocc.no/atc_ddd_index/?code=C09</ddiem:url>
        <rdfs:label>AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM</rdfs:label>
        <dc:identifier>C09</dc:identifier>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/f1fb8155-361e-4d81-97b2-90e1417cb412"/>
      </ddiem:Drug>
    </rdf:li>
  </rdf:Alt>
  <obo:direct_complementation_of_a_genetically_defective_protein_by_gene_therapy rdf:about="http://ddiem.phenomebrowser.net/0f3146b2-b384-4abf-892d-884c3106c970">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15753292</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10468611</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3306242</dc:provenance>
    <rdfs:comment>Information about the Study can be ound in https://gmoinfo.jrc.ec.europa.eu/bsnifs-gmo/B-NL-17-001.pdf</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9156798</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583863</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/218800"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15726662</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/c5da313e-bea2-47c2-a1f1-f37794771dd5"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/80180bcb-8119-4205-be1a-07640aaf3524">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/9281cffd-e565-427b-bab6-c752aa09d5d0"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
  </obo:direct_complementation_of_a_genetically_defective_protein_by_gene_therapy>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/5ac147b6-62f4-4845-875c-35a61a14f007">
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/f92d915b-8c47-46e3-9f0f-a50cfc171158">
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/220111"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25835550</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21600768</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/86a61a20-e2fd-4a8a-ab69-5351b5a5df68"/>
        <rdfs:comment>The cyclosporine trial (taken immediately upon visual loss in the first eye) is in progress in Leber's optic atrophy to prevent involvement of the fellow eye.</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21483849</dc:provenance>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3202309</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29054473</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/2e8910cc-790b-474e-b7d6-9c77b57adebf"/>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02805790</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24093206</dc:provenance>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02176733</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <dc:identifier>DB03766</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB03766</ddiem:url>
    <rdfs:label>Propanoic acid</rdfs:label>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/160f4bd8-666a-4563-a190-b38d862bf5fa">
    <dc:identifier>HP:0005961</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0005961</ddiem:url>
    <rdfs:label>Low plasma arginine levels</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f9f4b6f6-542c-41af-8894-52a46f046852">
    <dc:identifier>HP:0008281</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0008281</ddiem:url>
    <rdfs:label>Acute hyperammonemia</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/9f08ac5f-d2e5-4ae9-8e23-1d6cd2d8cdbc">
    <dc:identifier>DB00755</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/b1a106ee-bd29-4d21-8c14-9d5263c1751e"/>
    <rdfs:label>Tretinoin</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00755</ddiem:url>
  </ddiem:Drug>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/23f10114-fda7-4a99-afa5-cd5318d060f2">
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01212744</dc:provenance>
    <rdfs:comment>The cystoid changes responed to treatment with systemic immunosuppression and a topical carbonic anhydrase inhibitor (CAI), recurred when treated with topical CAI monotherapy.</rdfs:comment>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/9d5a672f-432b-45e0-908f-35fcc2a992bd">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/0a4c8439-0f54-4d0a-8de7-86bf9ca71341"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24746802</dc:provenance>
    <dc:provenance>https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/419e059b-400d-4433-8405-cdca012bbdf3"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/520000"/>
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5568973</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/ab40b279-0f5d-4198-a58e-1c3267a3cb10">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/04e88a9b-863c-49b6-a0d9-86007888602f"/>
      </rdf:Alt>
    </obo:RO_0000057>
  </obo:DDIEM_0000013>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/34ec616e-ba0d-436a-85e1-8a92697132d4">
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/520000"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/125518e4-68a3-4e63-b21a-ca9c990b4dbc">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Acid regurgitation</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002020</ddiem:url>
        <dc:identifier>HP:0002020</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28766015</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/86e157f0-aec1-46ef-aaa3-5fedc464d590">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0410019</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Epigastric pain</rdfs:label>
        <dc:identifier>HP:0410019</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/0d9221d8-ef76-45b4-aa1c-95abd8bbdce8"/>
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24746802</dc:provenance>
    <rdfs:comment>Effect of those two drugs was short-term response. Disease Name: There are many drugs with known detrimental effect on mitochondrial function. These include antibiotics like tetracycline and chloramphenicol; antiepileptics like valproate, phenytoin, antiretroviral agents and metformin. Overall their effects in patients with MIDD are not known. Statin therapy should be avoided in patients especially with myopathy. HMG Co-A reductase inhibitors can reduce both cholesterol and Co-enzyme Q via mevalonate pathway. These patients may have higher rate of lactic acidosis and intolerance to statins resulting in myalgia and may worsen the symptoms of existing myopathy. https://www.sciencedirect.com/science/article/pii/S1056872714000610?via%3Dihub#bb0115</rdfs:comment>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01212744</dc:provenance>
    <dc:provenance>https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117</dc:provenance>
  </obo:OGMS_0000112>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/2bb03ed1-d774-4555-97ad-b5e5fb09ba0c">
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/6deb8be6-1948-4911-adfb-a72f354c705b">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29631617</dc:provenance>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00028262</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/256730"/>
        <rdfs:comment>A combination therapy of Î´-tocopherol and HPBCD further improved the effect compared to that of either drug used as a single therapy.</rdfs:comment>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/1d498848-bc67-4b67-bc99-fa3ed972c469"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/21995aa8-c3c8-4edb-95a5-8169a50267bb"/>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <rdfs:label>Recombinant human palmitoyl-protein thioesterase 1 ( PPT1)</rdfs:label>
  </ddiem:Drug>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/66a186fc-08ec-45e1-84fa-567f23b24abe">
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/602473"/>
    <rdfs:comment>Drug used as an aternate therapy with (Metronidazole+Acetylcysteine)</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20657580</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29526615</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/caf409e9-bfa8-4cc5-a593-fd641d1ae512">
        <dc:identifier>HP:0003688</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Decreased activity of cytochrome C oxidase in muscle tissue</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003688</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/5634a50b-fb00-426a-b60d-3c73c68634d7"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0022202X15352507</dc:provenance>
  </obo:DDIEM_0000013>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/230650">
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/ddf24210-fd69-4e0c-949d-7256b7e881cd"/>
    <dc:identifier>https://www.omim.org/entry/230650</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>GM1-GANGLIOSIDOSIS, TYPE III</rdfs:label>
  </ddiem:Disease>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/258450">
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/418</ddiem:iembaseUrl>
    <rdfs:label>PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA WITH MITOCHONDRIAL DNA DELETIONS, AUTOSOMAL RECESSIVE 1; PEOB1</rdfs:label>
    <ddiem:iembaseAccessionNumber>418</ddiem:iembaseAccessionNumber>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/42910152-5855-4c4b-bc8a-f9d7f0ec1dba"/>
    <dc:identifier>https://www.omim.org/entry/258450</dc:identifier>
    <rdfs:comment></rdfs:comment>
  </ddiem:Disease>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/e2f53a0e-a2b7-4fde-a04c-cea7a2031422">
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000012"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25335805</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29058386</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/a2aa1b37-7101-4ee1-8237-02bdf07754b2">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/73e0c403-9fc8-4838-b4b1-8c8b2dfceabb"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/2b9ef1e9-2177-46ff-9309-63fff08ba2a3"/>
    <rdfs:comment>The regimen was accomapanied with a protein-restricted diet. https://www.ncbi.nlm.nih.gov/pubmed/27567650</rdfs:comment>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/222700"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21110863</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/db52afba-4429-4ca5-8182-d338bc66335b"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25859380</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28649527</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24886114</dc:provenance>
  </obo:OGMS_0000112>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/c9b0a777-a47f-4002-899f-f7420d6cb418">
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/601780">
        <rdfs:label>CEROID LIPOFUSCINOSIS, NEURONAL, 6; CLN6</rdfs:label>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/099ca942-54a3-4785-9822-416a281ecf6f"/>
        <ddiem:iembaseAccessionNumber>311</ddiem:iembaseAccessionNumber>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/311</ddiem:iembaseUrl>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>https://www.omim.org/entry/601780</dc:identifier>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31331814</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/d483648c-f215-4553-b821-8c5dc8244787">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/b03a674c-2c8e-4b9b-abf4-43c4d0e32569"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29631617</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02725580</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01399047</dc:provenance>
    <rdfs:comment>A combination therapy of Î´-tocopherol and HPBCD further improved the effect compared to that of either drug used as a single therapy.</rdfs:comment>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/direct_complementation_of_a_genetically_defective_protein_by_gene_therapy"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
  </obo:OGMS_0000112>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0525ffae-8cdc-4e24-87b4-7c7777bf2de5">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001324</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0001324</dc:identifier>
    <rdfs:label>Decline of muscle strength (Muscle weakness)</rdfs:label>
  </ddiem:Phenotype>
  <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/61fe05d5-79c7-47f2-833b-cd7e9bc9bca8">
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/db6d42d0-bc1e-458c-9a99-e1e2fe9a00d1"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11067870</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18570303</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20619503</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/887793b3-eacf-454d-9d75-36868d219b9e"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/53d81324-bc69-4ec5-bd3c-186d552927d4"/>
    <rdfs:comment>Many studies have reported early responce to l- dopa treatment as mentioned in https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4503963/, and other pointed to " prominent dyskinesia " as side effect to same treatment https://www.ncbi.nlm.nih.gov/pubmed/19087156/</rdfs:comment>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/94987563-bd7a-4c39-bf4c-1305d041276e"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/607765"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/202b2073-9e0f-4323-b4bc-9fcf095b645b"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4503963</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19087156</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3296980</dc:provenance>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b1aa6894-043a-4f5f-a8f0-1a27a5dfc2d8">
        <dc:identifier>HP:0001288</dc:identifier>
        <rdfs:label>Abnormal gait</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001288</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/64c2d03b-1002-44aa-8bcb-6162d508dd34"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/73ee989c-18fb-4d98-9b01-4fb03004069e"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/21ba206b-4ec3-4104-9c8a-670f005b9320"/>
  </obo:DDIEM_0000007>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/7cd8f8f6-01ba-458e-b3d6-c085fa9af27e">
    <rdfs:comment>An experimental study done on a mice with GMNT knocked out. suggesting considering Nicotinamide as atreatment option in patients with GNMT deficiency.  https://www.ncbi.nlm.nih.gov/pubmed/20578266/</rdfs:comment>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/b6dbcbad-d4cd-4e5e-8688-be82ca39795c"/>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/231950">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>https://www.omim.org/entry/231950</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/5089cd2c-b43d-4018-a82a-114fd27b208b"/>
        <rdfs:label>GLUTATHIONURIA</rdfs:label>
        <ddiem:iembaseAccessionNumber>214</ddiem:iembaseAccessionNumber>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/214</ddiem:iembaseUrl>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20578266</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19019309</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/1914597b-986e-4b14-852a-dca9d8654604"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/99a209f5-1ac8-4a30-b68d-ca33684e9a97"/>
    <dc:provenance>http://www.ncbi.nlm.nih.gov/pubmed/12757858</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f9e5e429-b751-4b0c-a45a-d7a875de6b14"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27207470</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
  </obo:OGMS_0000112>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d39b73fc-c8e4-4d80-a27a-83cc6236a9da">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001250</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0001250</dc:identifier>
    <rdfs:label>Lip-smacking automatisms(Epilepsy)*</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/45002508-45bd-4fc8-9481-41165ae84b18">
    <dc:identifier>DB12528</dc:identifier>
    <rdfs:label>Glyceryl Trierucate</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB12528</ddiem:url>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/0f32f1fa-45c0-4353-a70b-1041c2766e98">
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT03727555</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7666063</dc:provenance>
        <dc:provenance>https://globenewswire.com/news-release/2015/03/30/720127/10126746/en/Sigma-Tau-Pharmaceuticals-Inc-Receives-Orphan-Drug-Designation-for-EZN-2279-for-Treatment-of-Adenosine-deaminase-Deficient-Severe-Combined-Immunodeficiency-Disease.html</dc:provenance>
        <dc:provenance>https://www.myelin.org/tag/lenti-d</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15670720</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/0a3c2d56-4bf6-46e4-b337-848d29206bb1"/>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00545597</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b4f2b909-9165-4013-a2cb-82c920e8c0c1"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/2ba430dc-83b1-4d73-b598-9f2c69b34a12"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/300100"/>
        <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/2382da26-c19c-47c1-bc35-224b81e4c665"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16009761</dc:provenance>
        <rdfs:comment>It is used as an investigational treatment for asymptomatic patients, however, there are other controversial studies about the significance of this treatment 1: https://www.ncbi.nlm.nih.gov/pubmed/8350883. 2: https://www.ncbi.nlm.nih.gov/pubmed/10078732</rdfs:comment>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648/#b96-tacg-8-201</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28976817</dc:provenance>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d9b15a98-340c-4ce8-90f1-e24207a9147e">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001072</ddiem:url>
    <rdfs:label>Elbow skin thickening</rdfs:label>
    <dc:identifier>HP:0001072</dc:identifier>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <obo:direct_complementation_of_a_genetically_defective_protein_by_gene_therapy rdf:about="http://ddiem.phenomebrowser.net/7b03cde8-8481-4081-aa32-5051441cff51">
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/232200"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20163245</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/29bf3dfd-c250-4c80-a653-de8b69ef7feb">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>done</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/done</ddiem:url>
        <rdfs:label>"The study is still recruting. The primary objective of the study is to determine the safety of single doses of DTX401, including the incidence of dose-limiting toxicities (DLTs) at each dose level."</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT03517085</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/baebf566-e9c7-447c-8641-09b6a61a0007">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/53b5fa99-0c12-4228-82c5-889b1d78f4c3"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:comment>Uncooked Cornstarch usually is administered at bedtime, and every 6 hours during illness, to prevent morning hypoglycemia and ketosis. In children who are particularly active, a dose of cornstarch in the morning or 1 hour before strenuous or prolonged physical activity can improve stamina. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1474809/</rdfs:comment>
  </obo:direct_complementation_of_a_genetically_defective_protein_by_gene_therapy>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/7746e64b-e684-4573-9cf4-daaabbcfa2f7">
    <rdfs:label>Methotrimeprazine</rdfs:label>
    <dc:identifier>DB01403</dc:identifier>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/a6443e5d-d187-46de-8b2d-6fc1452d4652">
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/12ca8ace-629e-4724-8a4e-5288f478dec4"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24816443</dc:provenance>
        <rdfs:comment>The treatment regimen resulted in neuroleptic malignant syndrome.</rdfs:comment>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/c47fb591-5f95-477d-8519-6119dd0a644c"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/0c106a81-eb9e-43bc-b588-d86ea4579f34"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11449034</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29739138</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/125370"/>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01403</ddiem:url>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/bde99d42-21e2-477b-9cac-efa8d7f203d6">
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0000144</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000144</ddiem:url>
    <rdfs:label>low reproductive capacity (infertility)</rdfs:label>
  </ddiem:Phenotype>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/a2e3aeb5-3d0c-4217-8a95-e77cb101826e">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/de76267a-ca84-48e4-a176-627923a600d0">
        <rdfs:label>membrane fluidity alterations</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29923092</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/8d176e2b-da50-45f9-ba69-2a7194967007"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/204200"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <rdfs:comment>A combination therapy of Î´-tocopherol and HPBCD further improved the effect compared to that of either drug used as a single therapy.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29631617</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/bec7c878-4757-44de-a692-f6826ea72bc7">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/5336b7d1-1b02-4dc5-bb79-9d0fea1cf41f"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/110f277d-190c-4365-aeb9-f2c95a429ec7">
        <rdfs:label>Low cell autofluorescence</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/827b10b7-4f34-4498-82f4-3642c16e4704">
        <rdfs:label>Blood-brain barrier (BBB) impairment</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29660499</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01399047</dc:provenance>
  </obo:OGMS_0000112>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/d90f9a18-45af-45b6-a256-60d39edc153b">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17192294</dc:provenance>
    <rdfs:comment>The drug has some effects but hyponatremia is a troublesome side effect.</rdfs:comment>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00125190</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23887143</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19304794</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/dd79b64f-6425-43fb-89d4-076350231775"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10549306</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24639006</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19627167</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/271245"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/e44d719c-72fa-49ee-8a1d-3b73d9ef19c9"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20301746</dc:provenance>
  </obo:DDIEM_0000013>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/45b7e735-b77b-4e79-8c6b-7d55d881884d">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/dd902a9f-5bd6-425b-9c6d-d0fa954c2068"/>
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/2323d461-704d-43b4-b726-5330467b4233">
        <dc:identifier>DB00190</dc:identifier>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/b8cabd5f-20c3-4850-869f-63ddf9f84605"/>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/2381b3a4-d7e5-417b-a52b-73c7db884954"/>
        <ddiem:url>https://www.drugbank.ca/drugs/DB00190</ddiem:url>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/ae674513-4eb7-4498-b474-1ae006baad69"/>
        <rdfs:label>Carbidopa</rdfs:label>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/2e4474c9-8f76-4973-834f-7f1ad06c5c32"/>
      </ddiem:Drug>
    </rdf:li>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/c732e704-38a0-4883-9cab-a69af92ec036">
    <dc:identifier>DB12536</dc:identifier>
    <rdfs:label>N-acetylmannosamine</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/c64e8b92-df5e-4d34-86c4-0157affa78a5"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB12536</ddiem:url>
  </ddiem:Drug>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/22017a36-0618-4531-a513-a31721934235">
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/62f13862-3b92-42cc-9dad-e958eef7c627"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25781533</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26962538</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/307030"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4612542</dc:provenance>
    <rdfs:comment>The results of this study suggest that octreotide may aid in the acute or long-term treatment of congenital hyperinsulinism in a limited number of selected cases.https://www.ncbi.nlm.nih.gov/pubmed/8410522/</rdfs:comment>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/c3af4cca-0eea-44d8-9c18-121be136d146"/>
  </obo:DDIEM_0000013>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/8cc17e18-5fa0-4e2b-9597-93b54d7a1fc0">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/03c0a773-62f9-4a1a-8df7-51d2b17d3dde">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/df0d19b9-7e66-4c7f-9693-1d7e66c3a873"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.clinicaltrials.gov/ct2/show/NCT01554800</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/1a792c3c-c553-4730-84ba-907404091b6c"/>
    <rdfs:comment>Niacin DB00627 occasionally can be used with Fibrate and omega 3 fatty acid in treating hypertriglyceridiemia. https://www.ncbi.nlm.nih.gov/pubmed/21079616</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23391322</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5338723</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/245900"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02527343</dc:provenance>
  </obo:OGMS_0000112>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1cd3bef8-faf4-49ff-bb7c-b872015f26f3">
    <rdfs:label>Poor motor coordination</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0002275</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002275</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c5250210-9b39-4ec9-b5f0-69591519b9da">
    <dc:identifier>HP:0008765</dc:identifier>
    <rdfs:label>Auditory hallucinations</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0008765</ddiem:url>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5980f93c-9e16-40af-9af9-bf41cf24c4bd">
    <rdfs:label>hyperproteinemia</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0002152</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002152</ddiem:url>
  </ddiem:Phenotype>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/759fd62a-4cb6-4c6e-80f6-c02d9d30fa9b">
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/c7bbce4e-bbe2-4090-8287-ee48481c6418"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/921733</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/56f94b6a-f805-457a-aa19-2473ad045def"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/261000"/>
    <rdfs:comment>The standardized treatment consists of weekly to monthly intramuscular injections of vitamin B12. Hydroxocobalamin injections are preferred over cyanocobalamin as the latter may cause muscular pain and have ophthalmo-neurological side effects. Oral vitamin B12 supplementation may be ineffective and not recommended.

https://www.orpha.net/consor/cgi-bin/OC_Exp.php?Expert=332

Cyanocobalamin, a pharmacologic preparation requiring conversion to metabolically active cobalamins, is the form commonly available in the United States, whereas hydroxocobalamin, which requires less frequent injections,1,15 is preferred in parts of Europe. Methylcobalamin, a light-sensitive form, is rarely used.
https://www.ncbi.nlm.nih.gov/pubmed/6019807/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9694707</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/6823973</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24424200</dc:provenance>
  </obo:DDIEM_0000013>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/5336b7d1-1b02-4dc5-bb79-9d0fea1cf41f">
    <rdfs:label>Carbenoxolone</rdfs:label>
    <dc:identifier>DB02329</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB02329</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/a2e3aeb5-3d0c-4217-8a95-e77cb101826e"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/b26b2524-02fd-412e-b31e-bdc5bc7b62db">
    <ddiem:url>https://www.drugbank.ca/drugs/DB00145</ddiem:url>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/952bb8f6-5e9a-4f03-b52a-f48b1c5ddfb8">
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/210200"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/003a62bf-932a-417a-9887-b6b58bf0132f"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/c52bda41-e4a3-4d65-aeef-27e5f01b4af2"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7474896</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18155630</dc:provenance>
        <dc:provenance>https://www.babysfirsttest.org/newborn-screening/conditions/3-methylcrotonyl-coa-carboxylase-deficiency</dc:provenance>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8831079</dc:provenance>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <rdfs:comment>Effect of glycine in treating the condition is variable among literatures.  "Case reports have noted variable results regarding the effect of glycine administration. Some studies have found that supplemental glycine results in increased excretion of 3-methylcrotonyl glycine, while others have not found a persistent effect; no studies have observed clinical improvement of symptoms on treatment and no randomized clinical trials have been published" https://www.sciencedirect.com/science/article/pii/S1096719207005975?via%3Dihub#bib11
https://www.ncbi.nlm.nih.gov/pubmed/8831079
https://www.ncbi.nlm.nih.gov/pubmed/7474896</rdfs:comment>
        <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16835865</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e02374f7-4bab-4e05-a387-743736587a07"/>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <rdfs:label>Glycine</rdfs:label>
    <obo:RO_0000056>
      <obo:DDIEM_0000012 rdf:about="http://ddiem.phenomebrowser.net/606ab59c-f81d-4086-8a05-253c5e360e74">
        <rdfs:comment>The trial was done on cell culture not model animals, authors of this paper " https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5120323/" have mentioned that " Since betaine has already been used for pediatric patients, plenty of safety and dosage data are available, which will facilitate the therapeutic trial for AGU. However, it is not quite clear how efficiently betaine penetrates the blood-brain barrier, and it is unclear if it exerts an effect on the central nervous system".</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5120323</dc:provenance>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
        <dc:provenance>https://www.nature.com/articles/srep37583/figures/5</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23601642</dc:provenance>
        <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/003a62bf-932a-417a-9887-b6b58bf0132f"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28967191</dc:provenance>
        <dc:provenance>https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d3f96075-1275-416d-968f-4339da6a7e99"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/208400"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29247835</dc:provenance>
      </obo:DDIEM_0000012>
    </obo:RO_0000056>
    <dc:identifier>DB00145</dc:identifier>
  </ddiem:Drug>
  <obo:DDIEM_0000011 rdf:about="http://ddiem.phenomebrowser.net/84db0a1c-d5f4-42bb-9ef1-b6f6106e1feb">
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02534844</dc:provenance>
    <rdfs:comment>One of the studies that was carried on mice provides useful information for developing the optimal dosage regimen for HPBCD therapy when administered intravenously to NPC patients.https://www.ncbi.nlm.nih.gov/pubmed/26027824</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19415691</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28803710</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/2f24c83a-ea15-4963-bb24-78bea2820941"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15208706</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/257220"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11787939</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a46794ec-1317-472f-8794-114053d3b9bb">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0004345</ddiem:url>
        <rdfs:label>GM3 ganglioside accumulation (Ganglioside accumulation )*</rdfs:label>
        <dc:identifier>HP:0004345</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/587ea97a-1a07-4ab0-8d86-d274109a79dc">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003495</ddiem:url>
        <dc:identifier>HP:0003495</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>cortical GM2 ganglioside accumulation</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/d046be7f-8385-48c8-aefe-91fd23ce0110"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b4f2b909-9165-4013-a2cb-82c920e8c0c1"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19750228</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25717099</dc:provenance>
  </obo:DDIEM_0000011>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/005dbc56-22b0-4286-81ef-ecf7ce24b3b1">
    <rdfs:label>Trolox ornithylamide hydrochloride</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/3240a58b-0b0c-4037-b83e-0cef2e1ce77d"/>
  </ddiem:Drug>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/afba0f65-eda9-4038-81a9-89c950ce183f">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19019309</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/809aeb0f-b818-4ab4-badf-75a03e334500"/>
    <rdfs:comment>Testosterone therapy needs to be carefully considered because of the risk of hepatic adenomas.https://www.ncbi.nlm.nih.gov/pubmed/28160246
Androgen receptors are expressed in the liver, and androgens can stimulate hepatocyte proliferation. Although rare, androgens have been shown in observational studies to induce adenoma development (Giannitrapani et al. 2006). Testosterone levels should be assessed for response 2â3 months after therapy is initiated.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24493026</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/873eedfe-7d24-4562-86c6-c480c066621e">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/a1ff9a10-ef70-483b-b1ef-39349ff3e91f"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f0d2fee2-9a9e-4f4d-b1a7-bd3b689420d4">
        <dc:identifier>HP:0009020</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0009020</ddiem:url>
        <rdfs:label>Abnormal exercise physiology</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/232600"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18098237</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
  </obo:DDIEM_0000013>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e5e9da4c-e295-4408-8694-fe8876b00d89">
    <dc:identifier>HP:0100716</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0100716</ddiem:url>
    <rdfs:label>Self-injurious Behavior</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c7fcc2ff-0fe0-41f7-ba3c-e7a2a8f04b5c">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0008166</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0008166</dc:identifier>
    <rdfs:label>Abnormally decreased rate of beta-galactosidase activity</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/164bc286-561d-4819-b234-75cb6d8ff1ef">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/c9199baa-6af2-4c45-a6bc-244c7726b13b"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB14151</ddiem:url>
    <dc:identifier>DB14151</dc:identifier>
    <rdfs:label>Phosphorus</rdfs:label>
  </ddiem:Drug>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/3f146b67-1e90-4a9d-ba6f-a69f1daa7d4b">
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/6499bf4e-1966-42b9-baa3-5dac87a818c9"/>
    <dc:provenance>http://www.neurologyindia.com/article.asp</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/4f8c5fb9-f813-4852-8017-a5f808513f9b"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2646391</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24260777</dc:provenance>
    <rdfs:comment>Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss</rdfs:comment>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/5fb88a97-518b-41a2-ab75-63cc6752a28c">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/931a1ed7-a565-4c3a-a2c4-19b7d054d32e"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24189473</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/607364"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-Bartter.pdf</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0842b412-71c7-45b8-b825-dbc758b64074">
        <dc:identifier>HP:0002150</dc:identifier>
        <rdfs:label>High calcium excretion in urine</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002150</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
  </obo:DDIEM_0000013>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/08249b8c-9cf8-42f2-afc7-c6a363010f34">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003158</ddiem:url>
    <dc:identifier>HP:0003158</dc:identifier>
    <rdfs:label>Reduced urinary osmolality</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <obo:DDIEM_0000010 rdf:about="http://ddiem.phenomebrowser.net/85ee05c6-f571-4956-b4bc-de1db1ea3053">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2564511</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/e4fe8128-15d7-4874-b568-8ddad4ec30c7"/>
    <rdfs:comment>Treatment was stopped three days later because of lack of improvement and severe respiratory alkalosis with lactic acidosis (serum lactic acid 70 mg/dl, normal 4â20 mg/dl). https://www.ncbi.nlm.nih.gov/pubmed/12948744</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25266922</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15726662</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583863</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/306000"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC324959</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/19d18d16-d582-4b93-ad73-0788911e9fa8"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/eb318982-8e44-434a-92f2-7148303622aa"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/397a09b3-2d92-4bfa-8ddf-6f103f0e2656"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3306242</dc:provenance>
  </obo:DDIEM_0000010>
  <obo:DDIEM_0000012 rdf:about="http://ddiem.phenomebrowser.net/43610fcf-dd9f-4366-9d8b-d1b663bab843">
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/261600"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19323589</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20971365</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/c576bad9-b514-49c9-a2f8-c639d5e8fd3f"/>
    <ddiem:failedToContributeToCondition>Homozygotes of R252W ,Homozygotes of IVS4-1GâA ,Homozygotes of R413P</ddiem:failedToContributeToCondition>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/results/NCT01977820</dc:provenance>
    <obo:RO_0003304>P407S,A373T,R241C</obo:RO_0003304>
    <rdfs:comment>There is no clinical role for NaPBA at present; however, ongoing studies are assessing its efficacy https://www.ncbi.nlm.nih.gov/pubmed/28919799 Phenotypes corrected were based on invivo trial on mice not humans.</rdfs:comment>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/c4633604-cb41-4d90-84d5-44841bde9fef"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0022347699701381</dc:provenance>
  </obo:DDIEM_0000012>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/2d078c1d-a418-4550-8d95-46ef5ff4a27d">
    <obo:RO_0000056>
      <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/2225b727-24f1-4cc6-a826-7fe25aa5f1b3">
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/239500"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28285122</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/35b5c64e-9aaa-46fd-84a3-e5d483d4e101"/>
        <rdfs:comment>These inconsistent results have suggested that the response might depend on the specific gene mutations
 As the response was not sustained and serum ALP and PLP and urine PEA returned to baseline between 8 and 13 months of treatment 
In N461L mutation which led to complete disappearance of the bone isoenzyme, disease was not modified by PTH treatment.  

https://www.ncbi.nlm.nih.gov/pubmed/22218563?dopt=Abstract
https://www.ncbi.nlm.nih.gov/pubmed/20089612?dopt=Abstract (Lack of sustained response to teriparatide in a patient with adult hypophosphatasia_</rdfs:comment>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/eb5152ff-7294-4a87-a512-7b1cec024750"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24173411</dc:provenance>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
      </obo:DDIEM_0000013>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/3df44c22-1418-4327-8c8a-6a7ac5f8e1f5">
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b9dcf6b9-e742-496d-8df3-e6e4326dad97"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/238700"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23890588</dc:provenance>
        <rdfs:comment>The drug was accompanied with lysin restricted diet</rdfs:comment>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/eb5152ff-7294-4a87-a512-7b1cec024750"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24204001</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000009"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
      </obo:DDIEM_0000013>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <obo:DDIEM_0000012 rdf:about="http://ddiem.phenomebrowser.net/146b07dd-9443-48d5-98e9-d6a73e38e381">
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31196723</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31211405</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29119254</dc:provenance>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
        <obo:RO_0003304>"P49L, A114V, I278T, R266K, or R336H"</obo:RO_0003304>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/62b6a8f7-d946-4412-a84a-0f47bb5402d8"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30755342</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/236200"/>
        <rdfs:comment>pyridoxine-responsive patients exhibit higher residual CBS activity in their cultured fibroblasts (typically 1â9%) or in plasma (typically 4â22%) (Fowler et al. 1978; Alcaide et al. 2015).</rdfs:comment>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16619244</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24355692</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14739681</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/eb5152ff-7294-4a87-a512-7b1cec024750"/>
        <ddiem:failedToContributeToCondition>"R125Q, E176K, T191M, T262M, or G307S"</ddiem:failedToContributeToCondition>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31082797</dc:provenance>
      </obo:DDIEM_0000012>
    </obo:RO_0000056>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/12450700-608b-4313-8ac8-542ef8e93ea1"/>
    <rdfs:label>Pyridoxine</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/298154c2-7729-4435-bee9-302ed5ffca85"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/b684f820-1cee-44eb-bb7f-d71a8757c972"/>
    <dc:identifier>DB00165</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/a63a711a-9838-4a14-a486-e4bad808de53"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/bcfc1c50-19ac-431f-b31a-2729cd6a3514"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/081da9b8-3b6f-4ad6-9d5d-9fb8989c54be"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/6593ee5e-80cb-4fa7-bc52-a6f9467a3fbf"/>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/3d65f9d4-ab3e-4bcf-bb07-a83275b2f12c">
        <dc:provenance>https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/35b5c64e-9aaa-46fd-84a3-e5d483d4e101"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/610090"/>
        <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d39b73fc-c8e4-4d80-a27a-83cc6236a9da"/>
        <obo:RO_0003304>R229W</obo:RO_0003304>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8757046</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/320183b7-f2b9-4a23-979f-30e8feeeb10a"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/eb5152ff-7294-4a87-a512-7b1cec024750"/>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01212744</dc:provenance>
        <rdfs:comment>The drug was administered through intravitreal injection.</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26095523</dc:provenance>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00165</ddiem:url>
  </ddiem:Drug>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/ae674513-4eb7-4498-b474-1ae006baad69">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23690520</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25304915</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12003346</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
    <rdfs:comment>The patients should receive combination treatment with BH4 and neurotransmitter precursors as soon as possible to reduce neurological deterioration. https://www.ncbi.nlm.nih.gov/pubmed/16601879
In general, lâdopa is used with DCIs like as carbidopa or benserazide to block the peripheral conversion to dopamine. This coadministration not only increases bioavailability but also reduces peripheral side effectshttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6178724/</rdfs:comment>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/ff5e395d-975f-446c-a5c0-2c6349abf7a5"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/261640"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/50b11d07-6d6c-485b-b3af-1f6d0e4d644e"/>
    <dc:provenance>https://www.babysfirsttest.org/newborn-screening/conditions/3-methylcrotonyl-coa-carboxylase-deficiency</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16601879</dc:provenance>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000015"/>
  </obo:OGMS_0000112>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/5ebd87c6-80cd-477d-b65f-6b04828064a6">
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/264070"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24204001</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24848070</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c2cd2093-be16-4709-ac97-f5e54a3fa198">
        <dc:identifier>HP:0005978*</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0005978</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>PCBD1-diabetes (Noninsulin-dependent diabetes)*</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/25db1469-b177-45d8-bf6f-7c99f50ef59d"/>
    <rdfs:comment>Î±-Tocopherol should be given with the ascorbic acid(vit. C) as the latter helps The resultant tocopheroxil radical regeneration in getting back to reduced tocopherol .</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
  </obo:OGMS_0000112>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5b73731e-9140-4985-b706-30fe1e677197">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0010438</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Interventricular septal thickning (Ventricular septum abnormality)*</rdfs:label>
    <dc:identifier>HP:0010438*</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3fb47463-aac2-4ed8-8441-421613b22f08">
    <rdfs:label>Decreased life expectancy</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7184cc40-6dde-4532-9e3a-a61406e563d8">
    <rdfs:label>Low LONG-CHAIN 3-HYDROXYACYL-CoA DEHYDROGENASE activity</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/5bb8f405-7711-4917-850d-45a86c041a07">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16635485</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/246650"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17994020</dc:provenance>
    <rdfs:comment>A low fat regimen was added to metformin while treating the patient.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17339125</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/25966bae-a08b-4c45-99d2-d2452a5f047b">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/da94a65c-79b4-4a88-bc19-1165baf8924d"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/62f13862-3b92-42cc-9dad-e958eef7c627"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
  </obo:OGMS_0000112>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/33a05a6e-f046-4b2c-89f2-5db9adf5f018">
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0045082</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0045082</ddiem:url>
    <rdfs:label>Low lean body mass</rdfs:label>
  </ddiem:Phenotype>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/6bc4517c-156d-487b-8660-49bbff144493">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3202309</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b1a09a2e-6587-4395-bd53-8045be937480">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Self-mutilation</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000742</ddiem:url>
        <dc:identifier>HP:0000742</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24093206</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/300322"/>
    <rdfs:comment>Treatment with allopurinol was associated with xanthine lithiasis. https://www.ncbi.nlm.nih.gov/pubmed/17065067 
https://www.ncbi.nlm.nih.gov/pubmed/16773422/</rdfs:comment>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/72335a61-7f79-462c-87be-fe5a1ccb8243"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21483849</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29054473</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8870064</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27179999</dc:provenance>
    <dc:provenance>https://rarediseases.org/rare-diseases/lesch-nyhan-syndrome</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22198833</dc:provenance>
  </obo:OGMS_0000112>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/519f9a68-aa00-40a6-8c6c-0c408620a990">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20605907</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <rdfs:comment>rhLCAT was used in atrial and it has been found to increase the HDL-C and it was safe. https://www.ncbi.nlm.nih.gov/pubmed/24385512</rdfs:comment>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/3ae6c360-ca9c-4cc0-ae8f-f7d97ddf378d">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/3b4288ea-af75-4549-8066-24d0290941c7"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/136120">
        <rdfs:label>FISH-EYE DISEASE; FED</rdfs:label>
        <rdfs:comment>Fat restriction is recommended as it leads to progressive mesangial and glomerular sclerosis.https://www.ncbi.nlm.nih.gov/pubmed/2068059. 
and as well another author have suggested that low fat/calorie diet mainly consisting of vegetables may inhibit the progression of the renal disease.https://www.ncbi.nlm.nih.gov/pubmed/2634146</rdfs:comment>
        <ddiem:iembaseAccessionNumber>528</ddiem:iembaseAccessionNumber>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/528</ddiem:iembaseUrl>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/e38a459a-439a-4b5d-99a1-affdaa58dc23"/>
        <dc:identifier>https://www.omim.org/entry/136120</dc:identifier>
      </ddiem:Disease>
    </obo:RO_0002599>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a06f839b-c872-4599-8b1f-117e8943f338">
        <dc:identifier>HP:0003233</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003233</ddiem:url>
        <rdfs:label>Low HDL-C  level</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27491218</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29390242</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a8661ff7-3068-49dd-9102-b5a4c9f0bec8">
        <dc:identifier>HP:0010979</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Abnormal lipoprotein profile</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0010979</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </obo:OGMS_0000112>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/30306d09-ae88-4171-8e36-18a895108902">
    <rdfs:label>Cyclic vomiting (Vomiting)*</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0002013</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002013</ddiem:url>
  </ddiem:Phenotype>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/38306759-b3dc-409f-bc1d-e8d4fda7c18d">
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/86cf7124-48bb-4219-a0d4-fb5f0d46e917">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/0c6c04ae-7883-4eb1-9b6a-3dfa39ab9633"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26962538</dc:provenance>
    <rdfs:comment>The results of this study suggest that octreotide may aid in the acute or long-term treatment of congenital hyperinsulinism in a limited number of selected cases.https://www.ncbi.nlm.nih.gov/pubmed/8410522/</rdfs:comment>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/260920"/>
    <dc:provenance>https://link.springer.com/referenceworkentry/10.1007%2F978-3-540-29676-8_199</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22740624</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b6e84a25-4969-4f24-b1c9-a5378a1f15cd">
        <rdfs:label>Limited Efficacy of the drug.</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11504824</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
  </obo:OGMS_0000112>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/1fb174d8-4cc3-41f7-8184-96a9e6d9919b">
    <dc:identifier>DB06720</dc:identifier>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/c64fef7d-29a7-42e8-ac0a-549415f07e95">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29503270</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/2a0f8c3f-9a37-4c67-ba70-dea9fbebe563"/>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00391625</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/310381da-d0f6-4235-ab58-67a2e0ad6f4a"/>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02574286</dc:provenance>
        <rdfs:comment>Indomethacin was the most effective but can cause gastrointestinal intolerance and decreased eGFR. Amiloride and eplerenone have similar but lower efficacies and increase sodium depletion. The benefit/risk ratio of each drug should be carefully evaluated for each patient.          https://www.ncbi.nlm.nih.gov/pubmed/25012174
Despite a documented effect on hypokalemia, indomethacin and other nonsteroidal anti-inflammatory drugs should be used with caution due to their short- and long-term gastrointestinal side effects and nephrotoxicity.https://www.ncbi.nlm.nih.gov/pubmed/28003083</rdfs:comment>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/5a0c328a-f59d-4b1f-a946-7e84868e6024"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28381550</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/118dc3e6-ac06-47f8-be0a-2ea369af9b2c"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25801797</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/1e51fa61-e114-4251-992f-dbbd04d47a00"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21503667</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/129453a0-45bd-46a5-86db-c8c8fa6fffbc"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/3b8a7752-a33a-43df-8697-89f32c0f3e9e"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/230800"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f40d696f-5d8f-4640-acae-29df4cd8da64"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29471850</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/b2d7e801-3f9c-4720-821e-746dc2325437"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <ddiem:url>https://www.drugbank.ca/drugs/DB06720</ddiem:url>
    <rdfs:label>Velaglucerase alfa</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/c25781dc-0210-4b3f-b45a-ff48affc3ae5"/>
  </ddiem:Drug>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/ff45ab9b-8f9b-49f1-b569-d08e3410838e">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/direct_complementation_of_a_genetically_defective_protein_by_gene_therapy"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/923854b1-f75a-4221-bd2a-a91f6ebcb8e1">
        <rdfs:label>Growth Failure</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/345f7321-2b9d-4b63-8db8-6f154976000d"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20163245</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/1a90f43d-b719-49a2-ac58-06dcb7429074"/>
    <rdfs:comment>Uncooked Cornstarch usually is administered at bedtime, and every 6 hours during illness, to prevent morning hypoglycemia and ketosis. In children who are particularly active, a dose of cornstarch in the morning or 1 hour before strenuous or prolonged physical activity can improve stamina. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1474809/</rdfs:comment>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/732de449-3f25-43bd-9979-47137b6ce23b">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/1bd0d1bd-f6d5-4f35-b391-2461a5c1a4f6"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16672983</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/232200"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17430128</dc:provenance>
  </obo:OGMS_0000112>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/49b90546-1669-4b58-a79d-13cd00df85d7">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19622360</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11067870</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6206929</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/971536</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/220120"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26247153</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/7b517ff3-fc9a-449b-a7f3-1355c1eb4688"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/76e590fa-f89d-4d64-a7a3-c08485b7023c"/>
    <dc:provenance>http://www.scielo.br/scielo.php</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <rdfs:comment>"Oral tocofersolan was more bio available than the water-soluble formulation in children with chronic cholestasis and similarly bio available in CF. This suggests that water-soluble vitamin E may represent an alternative to painful intramuscular vitamin E injections in chronic cholestasis, or other oral formulations in CF. However, the mechanism responsible for fat malabsorption in CRD concerns the absorptive phase as opposed to the digestive phase in CF and cholestatic syndromes. To our knowledge, no specific studies with these new vitamin E preparations have been conducted in CRD." https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717/</rdfs:comment>
  </obo:OGMS_0000112>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d9a65178-e629-415d-8696-678aa37ba82a">
    <dc:identifier>HP:0003358</dc:identifier>
    <rdfs:comment>lifelong and diligent cysteamine therapy prevents hypothyroidism, enhances growth, depletes muscle parenchyma of cystine, and prevents a host of nonrenal complications</rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003358</ddiem:url>
    <rdfs:label>cystine accumulation in muscle parenchyma</rdfs:label>
  </ddiem:Phenotype>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/aa032ac9-071a-434c-88d2-324e689795ad">
    <rdfs:comment>"Oral tocofersolan was more bio available than the water-soluble formulation in children with chronic cholestasis and similarly bio available in CF. This suggests that water-soluble vitamin E may represent an alternative to painful intramuscular vitamin E injections in chronic cholestasis, or other oral formulations in CF. However, the mechanism responsible for fat malabsorption in CRD concerns the absorptive phase as opposed to the digestive phase in CF and cholestatic syndromes. To our knowledge, no specific studies with these new vitamin E preparations have been conducted in CRD." https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717/</rdfs:comment>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/c8eeb692-657b-4d0e-a03b-b983b4bac1bd">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/02ca5475-d96a-4956-b783-9bc9d602d5a2"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/971536</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6206929</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3963001</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11067870</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19622360</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/35b5c64e-9aaa-46fd-84a3-e5d483d4e101"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22149023</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/220110"/>
  </obo:OGMS_0000112>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2bbf75d4-fef2-4cee-9721-00180f5a9273">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000141</ddiem:url>
    <rdfs:label>Amenorrhea</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0000141</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/025b758b-4f35-4ceb-af73-650f5889b0eb">
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0001019</dc:identifier>
    <rdfs:label>Exfoliative erythema</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001019</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b6bfaa10-0e08-47f3-853d-cd0faff3ae50">
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0003119*</dc:identifier>
    <rdfs:label>Lipid accumulation( Abnorality in lipid meabolism)*</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003119</ddiem:url>
  </ddiem:Phenotype>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/d2586fea-356a-4a9b-9343-cb0d8a3e11d2">
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f50f53b5-ca27-460d-b3a4-86c011836cec"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00004450</dc:provenance>
    <dc:provenance>https://globenewswire.com/news-release/2015/03/30/720127/10126746/en/Sigma-Tau-Pharmaceuticals-Inc-Receives-Orphan-Drug-Designation-for-EZN-2279-for-Treatment-of-Adenosine-deaminase-Deficient-Severe-Combined-Immunodeficiency-Disease.html</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648/#b96-tacg-8-201</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/5a768312-a9f6-40cf-bd23-61547f0d9ac7">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/8d21b15c-3451-4afa-8872-297279a83d4d"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:comment>All therapeutic trials conducted so far to modify the inflammatory response did not reveal a relevant clinical benefit from beta interferon, cyclophosphamide, cyclosporin, immunoglobulins, pentoxifylline, and thalidomide. https://www.sciencedirect.com/science/article/pii/S0167488906001881?via%3Dihub</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/86cf7124-48bb-4219-a0d4-fb5f0d46e917"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/300100"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10870849</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15670720</dc:provenance>
  </obo:OGMS_0000112>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/6d7fdebf-c225-4c3e-97de-da8acf55fd43">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/607015"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d5243a73-1c8c-4e6e-a95b-fbbdfd24c415">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002180</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0002180*</dc:identifier>
        <rdfs:label>neurodegenerative astrogliosis</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f8eda793-515b-4be3-bbef-85b9f3b6a534">
        <dc:identifier>HP:0004371</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0004371</ddiem:url>
        <rdfs:label>glycosaminoglycan accumulation</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>GNeo-IDUA and IDUA injected intravenously resulted in reduced hepatic glycosaminoglycan accumulation but had no effect in the brain due to fast clearance from the circulation. In contrast, intranasally administered GNeo-IDUA entered the brain rapidly. Repetitive intranasal treatment with GNeo-IDUA reduced glycosaminoglycan storage, lysosome size and number, and neurodegenerative astrogliosis in the olfactory bulb and primary somatosensory cortex, whereas IDUA was less effective. The enhanced efficacy of GNeo-IDUA was not the result of increased nose-to-brain delivery or enzyme stability, but rather due to more efficient uptake into neurons and astrocytes. https://www.ncbi.nlm.nih.gov/pubmed/28958576</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31434105</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28958576</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31211405</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/50db0d3b-3988-4878-8b49-00ccb3ce7463">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/c1acad56-0e22-4c5f-a057-32e474936574"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31196723</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31082797</dc:provenance>
  </obo:OGMS_0000112>
  <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/babc72be-ad76-4b8c-a966-e462a6044a24">
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/c4633604-cb41-4d90-84d5-44841bde9fef"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27179999</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21483849</dc:provenance>
    <rdfs:comment>The cyclosporine trial (taken immediately upon visual loss in the first eye) is in progress in Leber's optic atrophy to prevent involvement of the fellow eye.</rdfs:comment>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/300322"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24093206</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3202309</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b31bba6f-a65e-46e6-b19c-899aeb26e18c">
        <rdfs:label>No result was accessible</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/855e3dfb-9632-49eb-80cf-89075c518898">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/30c09818-3fab-4010-9857-27ba8b1efbb2"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29054473</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/results/NCT01065558</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26922636</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3728152</dc:provenance>
  </obo:DDIEM_0000007>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d1eeec89-5531-457a-8e21-771e03895cc1">
    <dc:identifier>HP:0010918*</dc:identifier>
    <rdfs:label>Elevated intralysosomal cystine accumulation( abnormality of cysteine metabolism)</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0010918</ddiem:url>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/10de88c4-06a4-4b4f-911f-0014318071f5">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8881997</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/98a69309-00f5-4c38-8570-cacb7e2c44b1"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/e74097f3-0582-4fa5-a2ad-99e6aa15ef4d">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/dcb980cf-8916-4301-9dc7-b1d9184c1397"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <rdfs:comment>This combination therapy should be accompained with low lysin diet that is often combined with the use of lysine-free, tryptophan-reduced amino acids (AA) supplements. These supplements are given with the aim of preventing malnutrition by providing essential amino acids and (depending on the product) also minerals, trace elements and vitamins. https://www.ncbi.nlm.nih.gov/pubmed/10630918</rdfs:comment>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/60e571cc-027b-4707-a8ab-457a63b42b53">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/cadd1903-1f78-4e00-9156-4b1348aeed3c"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16368216</dc:provenance>
    <dc:provenance>http://www.ncbi.nlm.nih.gov/pubmed/16368216</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17397529</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/39e026c8-3518-488b-950b-ec15df629d6a"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/6b36ca46-5e87-4637-b6e9-73189ff35f01"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/231670"/>
  </obo:DDIEM_0000013>
  <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/f7f648dd-369f-4073-a9a3-88931ab5ece5">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583863</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/218800"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15726662</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/962d9867-8a82-476b-993a-3c85ab32e8ce"/>
    <rdfs:comment>Clinically relevant response to orlistat treatment was not correlated with age, sex, CN type, BMI, or co-treatment with phototherapy or phenobarbital, but appeared correlated with a relatively lower dietary fat intake.https://www.ncbi.nlm.nih.gov/pubmed/17957158. The Drug works through increasing fecal fat excretion so dietary fat intake may determine the responsiveness to orlistat treatment.</rdfs:comment>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00461799</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14517515</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17957158</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/0d795729-cd52-46a1-9df5-444a03c263c3"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3306242</dc:provenance>
  </obo:DDIEM_0000007>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/9025b6f7-ed36-45d7-a6ba-78fe5f66bad8">
    <ddiem:url>https://www.drugbank.ca/drugs/DB02959</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/227d9c64-4536-4d08-80ca-a4474e0f1ccb"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/5064d8a9-a718-4458-ac47-0cad1ba4b20a"/>
    <rdfs:label>Oxitriptan</rdfs:label>
    <dc:identifier>DB02959</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/73f62ed2-803e-4da5-baa1-d1f93b759935"/>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8f47d233-951e-46e2-ba52-9c03ec5da17e">
    <dc:identifier>HP:0025548</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0025548</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>High RBC's mean corpuscular volume</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/609ad081-cd8b-4e0a-a0a3-854be8e88831">
    <dc:identifier>HP:0002872*</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002872</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>"Epileptic apnea(Apneic episodes precipitated by illness, fatigue, stress)"</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/f0d5e99a-f1cf-4286-a6bd-92bf5a7af421">
    <dc:identifier>DB04854</dc:identifier>
    <rdfs:label>Febuxostat</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB04854</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/d123b314-9eb8-4f8c-97a4-1aea96f2a894"/>
  </ddiem:Drug>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/aa6e4a7e-de33-49ff-809a-10d5c8c11a38">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30297385</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00923247</dc:provenance>
    <rdfs:comment>Patient continued to have daily seizures on oxcarbazepine, topiramate and levetiracetam</rdfs:comment>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4886552</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/35b5c64e-9aaa-46fd-84a3-e5d483d4e101"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/de2f9565-d217-424d-b54d-5a9be0514a37"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/614080"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00704730</dc:provenance>
  </obo:OGMS_0000112>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/615558">
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/5e1f905f-9dac-4915-8e8c-3ceccff2b0d1"/>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>https://www.omim.org/entry/615558</dc:identifier>
    <rdfs:label>HYPOBETALIPOPROTEINEMIA, FAMILIAL, 1; FHBL1</rdfs:label>
  </ddiem:Disease>
  <obo:DDIEM_0000008 rdf:about="http://ddiem.phenomebrowser.net/44ca9cc9-d1c4-4a37-8fd8-244d0b22273d">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9c769ed0-7f17-4175-bd11-eb13cae985ea">
        <rdfs:label>Low endurance</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0025142</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0025142</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/da90cc2d-564b-4ebe-9014-4911276df60f">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Failurre to thrive</rdfs:label>
        <dc:identifier>HP:0001508</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001508</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/248360"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/776788bc-bf91-46c6-a300-6dd0ad177f80">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0031544</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0031544</dc:identifier>
        <rdfs:label>High blood malonylcarnitine level</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26858006</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28781843</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28649527</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25859380</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24886114</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/c148d200-9479-4b6a-a50f-1e30c7044a3f"/>
    <rdfs:comment>MCT should be at least 70% of the total fat content of the diet.</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2993d155-3965-4d88-9814-a410fdd7eb53">
        <rdfs:label>Cardiomyopathy progrssion</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0003679</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003679</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24613099</dc:provenance>
  </obo:DDIEM_0000008>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/ed74406f-cb3a-412d-bb67-211930709f61">
    <ddiem:url>https://www.drugbank.ca/drugs/DB00419</ddiem:url>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/c68e3754-b353-4cda-9551-6991e395e744">
        <dc:provenance>https://www.tandfonline.com/doi/full/10.3109/0886022X.2014.900422</dc:provenance>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000015"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/4359fd49-c128-4118-8b96-b9368bcb6de5"/>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02030015</dc:provenance>
        <rdfs:comment>The mechanisms of its effects in movement disorders are not well understood but probably reflect an increase in synthesis and release of dopamine, with perhaps some inhibition of dopamine uptake.</rdfs:comment>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/230650"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26766614</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/27ecf745-ac09-4ec2-bb9b-8a5f47caba15"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d3373f65-311e-48f4-a0a1-0e381c00021b"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <dc:identifier>DB00419</dc:identifier>
    <rdfs:label>Miglustat</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/87572a80-fabb-42d6-ae60-29677222be1f"/>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c8e04232-ea28-4fe2-be77-1f4a12d2f1b7">
    <rdfs:label>Myoclonic epilepsy</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002123</ddiem:url>
    <dc:identifier>HP:0002123</dc:identifier>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b60edcb3-25fd-458e-98ab-b10a76176de6">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Bone massÂ loss</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/17afc5d6-c85c-41a2-86a1-e14e15a4b30c">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/84b533b0-705e-477c-ab1c-53b452808141"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/12621df5-9e28-4635-a0d6-5ac00ab59261"/>
    <dc:identifier>DB00028</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00028</ddiem:url>
    <rdfs:label>Immune Globulin Human</rdfs:label>
  </ddiem:Drug>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/22a8fb2e-3dba-4e98-9f7e-5bd1fb8aeb97">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22734070</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/fcd214b1-eac0-4141-a6f4-a1534aaf2ab4"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/105650"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17562599</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15813920</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22791294</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/23a116c3-daff-45c0-ae94-7ebb7736134b">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/ef0ec09c-1da8-43f5-a150-cc1251aaab13"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25098371</dc:provenance>
    <rdfs:comment>There was no clinical effect, but amild reduction in the plasma level of desmosterol was observed.</rdfs:comment>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01034592</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
  </obo:DDIEM_0000013>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/216f2124-8795-462d-a98a-2ed16c06c927">
    <ddiem:url>https://www.drugbank.ca/drugs/DB04844</ddiem:url>
    <rdfs:label>Tetrabenazine</rdfs:label>
    <obo:RO_0000056>
      <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/3a8ce289-41e7-447a-bd15-9fa3e68dabc0">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27179999</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/300322"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3202309</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21483849</dc:provenance>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/263d66f6-657e-4c3f-85c2-b7b6e8033a90"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29054473</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/3c18c326-8c2f-4c78-98d3-9efaa17d68ff"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12593632</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2455472</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/98a69309-00f5-4c38-8570-cacb7e2c44b1"/>
        <rdfs:comment>Treatment with allopurinol was associated with xanthine lithiasis. https://www.ncbi.nlm.nih.gov/pubmed/17065067 
https://www.ncbi.nlm.nih.gov/pubmed/16773422/</rdfs:comment>
        <dc:provenance>https://rarediseases.org/rare-diseases/lesch-nyhan-syndrome</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24093206</dc:provenance>
      </obo:DDIEM_0000013>
    </obo:RO_0000056>
    <dc:identifier>DB04844</dc:identifier>
  </ddiem:Drug>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/817d528b-42ff-474d-bfe6-e74fd46bc60c">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583863</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/405afb44-d7a3-4f8d-abd4-18478b52c5e2">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0002904</dc:identifier>
        <rdfs:label>High serum  bilirubin concentration</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002904</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3306242</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/direct_complementation_of_a_genetically_defective_protein_by_gene_therapy"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT03466463</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6282099</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/d749ac05-3491-469f-b34f-8e747980d9b1"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4841061</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/606785"/>
    <rdfs:comment>Controversial benefits https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4158338/</rdfs:comment>
  </obo:OGMS_0000112>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/d6025189-ed02-4570-a4b6-9ea71e2381cd">
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.paediatricaindonesiana.org/index.php/paediatrica-indonesiana/article/view/59/33</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/509b4ec6-d32e-4821-9032-d0bd97b80f99">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/217dc0c7-e59b-47e8-9453-215e48cc02e9"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17339125</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f51b76a7-7bb0-4b11-afa0-bd15094fdfb9">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002148</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0002148</dc:identifier>
        <rdfs:label>Hypophosphatemia</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/309000"/>
    <rdfs:comment>If on supplemental bicarbonate or citrate, phosphorus or calcitriol or other vitamin D analog, need kidney function assessment 1 w/blood &amp; urine tests
May need serum vitamin D-25 hydroxy to assess for parent vitamin D deficiency</rdfs:comment>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/028877e1-4ce0-4c57-a840-66d3b88b0ccb">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/ec2f0f6c-2c56-4393-8aa7-a1c2132eb2b8"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e0c0eedf-910f-4246-afdf-131a2dafbe8a"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8333aea2-3e2e-4e08-b8b7-c426a4173c90">
        <dc:identifier>HP:0000867</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000867</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Hyperparathyrodism</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2017228</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20301653</dc:provenance>
  </obo:DDIEM_0000013>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a8b875fc-c819-4224-8757-195f15769f4e">
    <dc:identifier>HP:0002500</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002500</ddiem:url>
    <rdfs:label>White matter alteration</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/260455e5-7012-4723-b865-b82a79acbe2c">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/253800"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/c11d560a-4217-4cb7-9e8e-cb3ad286f095"/>
    <rdfs:comment>Phenobarbital, clonazepam, valproate, and midazolam could not completely control seizures. https://www.ncbi.nlm.nih.gov/pubmed/20052547/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21102543</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/direct_complementation_of_a_genetically_defective_protein_by_gene_therapy"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/c155a641-1459-44cf-b32c-03401d55a289">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/fc528ead-f534-46d5-a6ae-cc099f06cb0e"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27421908</dc:provenance>
  </obo:OGMS_0000112>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5a0c328a-f59d-4b1f-a946-7e84868e6024">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0010885</ddiem:url>
    <dc:identifier>HP:0010885</dc:identifier>
    <rdfs:label>avascular osteonecrosis</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/c25d2c17-1b66-4959-a629-046209ee1323">
    <ddiem:url>https://www.drugbank.ca/drugs/DB04540</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/4830b65d-510f-4fd2-b673-796a63fbfab2"/>
    <rdfs:label>Cholesterol</rdfs:label>
    <dc:identifier>DB04540</dc:identifier>
    <obo:RO_0000056>
      <obo:DDIEM_0000015 rdf:about="http://ddiem.phenomebrowser.net/ef1e6844-f52d-4458-a8e8-baaac9069fa8">
        <rdfs:comment>There was no clinical effect, but amild reduction in the plasma level of desmosterol was observed.</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10959439</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24816443</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/602398"/>
        <dc:provenance>https://jhu.pure.elsevier.com/en/publications/inborn-errors-of-cholesterol-biosynthesis-6</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/feee8175-af10-4f42-a7ed-b23be088eb74"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/3b7b768c-634c-4845-bbf7-1dbac52c9525"/>
      </obo:DDIEM_0000015>
    </obo:RO_0000056>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/8391be2e-5a2d-49ba-ab16-1275141e4056">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/c5ed9d76-d38f-43d3-9d59-ab120571f5df"/>
    <rdfs:label>Ad-hBUGT1</rdfs:label>
  </ddiem:Drug>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/36c84d6f-fb96-4f6b-9f9f-bb10339b2b69">
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00001749</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15813920</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/ce029482-6f75-40c2-91e9-e97cf736cbd2">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/9381dc87-4bbd-406a-8af3-fc73f9a3a268"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/fec0af46-08df-4c06-a764-9441665924ed"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22791294</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/105650"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17562599</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3a09d925-994c-4936-aafd-16054f1e5fd8">
        <rdfs:label>Pure red bllod cell aplasia</rdfs:label>
        <dc:identifier>HP:0012410</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012410</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22734070</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25098371</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <rdfs:comment>There was no clinical effect, but amild reduction in the plasma level of desmosterol was observed.</rdfs:comment>
  </obo:OGMS_0000112>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/b0e843e8-df30-42f3-9473-a52f35edd6dc">
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/dd794d53-d6b6-44ab-8d18-a597663945b2">
        <rdfs:label>AAV-SOD2 (adeno-associated viral vector containing the human mitochondrial superoxide dismutase (SOD2) gene)</rdfs:label>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/6bf7e3ec-de38-4971-bba8-4187e0d35a6c"/>
      </ddiem:Drug>
    </rdf:li>
  </rdf:Alt>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/096c2299-8ddb-45f7-bbd3-98235f7a2765">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002509</ddiem:url>
    <rdfs:label>limb hypertonia</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0002509</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/177f0e08-67e7-40f9-a95f-550a786c0af9">
    <dc:identifier>HP:0001396</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001396</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Defected bile flow(Cholestasis)*</rdfs:label>
  </ddiem:Phenotype>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/17467ef8-995a-404c-9689-070ccc840365">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3950820</dc:provenance>
    <dc:provenance>https://link.springer.com/article/10.1023/A:1005353530303</dc:provenance>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/277410">
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/316</ddiem:iembaseUrl>
        <ddiem:iembaseAccessionNumber>316</ddiem:iembaseAccessionNumber>
        <dc:identifier>https://www.omim.org/entry/277410</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/9354cf69-3bab-4ed0-ade6-7877b069c9f3"/>
        <rdfs:label>METHYLMALONIC ACIDURIA AND HOMOCYSTINURIA, cblD TYPE; MAHCD</rdfs:label>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5884027</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
    <rdfs:comment>Selection of this drug combinstion ""Methylprednisolone sodium succinate +
Immune Globulin "" was based on the presumption that the patient had autoimmune encephalopathy. https://www.ncbi.nlm.nih.gov/pubmed/25511120</rdfs:comment>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01793090</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/6fc54827-731b-4f29-af16-69f7389dcc25"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19821145</dc:provenance>
  </obo:OGMS_0000112>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/fd6538e5-b940-4e4e-a987-aa77472afe99">
    <dc:identifier>HP:0001897</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Normocytic anemia</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001897</ddiem:url>
  </ddiem:Phenotype>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/bb8d03ff-9844-4206-a627-86ad0011a5b2">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25012174</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21503667</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28381550</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/263800"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/abccd4d6-c26d-43f5-a1bb-09057b22362d"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2518128</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5507263</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23196212</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/379babc0-b14e-4f80-beba-b581bb9a9a9e"/>
    <rdfs:comment>Indomethacin was the most effective but can cause gastrointestinal intolerance and decreased eGFR. Amiloride and eplerenone have similar but lower efficacies and increase sodium depletion. The benefit/risk ratio of each drug should be carefully evaluated for each patient.          https://www.ncbi.nlm.nih.gov/pubmed/25012174
Despite a documented effect on hypokalemia, indomethacin and other nonsteroidal anti-inflammatory drugs should be used with caution due to their short- and long-term gastrointestinal side effects and nephrotoxicity.https://www.ncbi.nlm.nih.gov/pubmed/28003083</rdfs:comment>
  </obo:DDIEM_0000013>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/bb6c4fe8-8e23-4788-964c-2c4b7bd9cc5d">
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/520000"/>
    <rdfs:comment>Effect of those two drugs was short-term response. Disease Name: There are many drugs with known detrimental effect on mitochondrial function. These include antibiotics like tetracycline and chloramphenicol; antiepileptics like valproate, phenytoin, antiretroviral agents and metformin. Overall their effects in patients with MIDD are not known. Statin therapy should be avoided in patients especially with myopathy. HMG Co-A reductase inhibitors can reduce both cholesterol and Co-enzyme Q via mevalonate pathway. These patients may have higher rate of lactic acidosis and intolerance to statins resulting in myalgia and may worsen the symptoms of existing myopathy. https://www.sciencedirect.com/science/article/pii/S1056872714000610?via%3Dihub#bb0115</rdfs:comment>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/1e563444-127e-40f7-8c83-93768b346275"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/c1025b64-d3a9-4576-877c-822dbcfef47b"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28766015</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/adeca2db-1a9e-4221-933d-51dd3f739692">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/da53e565-a617-4285-8743-677e2bc2568a"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24746802</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01212744</dc:provenance>
    <dc:provenance>https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
  </obo:DDIEM_0000013>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/b6605cf9-8268-46f8-a530-f10bfb4e0d02">
    <dc:identifier>DB01098</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/b9bbd298-85b8-498d-90ed-31d45276866b"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/22017a36-0618-4531-a513-a31721934235"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01098</ddiem:url>
    <obo:RO_0000056>
      <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/20162dd0-42a7-4107-b120-f5f4107428e4">
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/c3af4cca-0eea-44d8-9c18-121be136d146"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
        <rdfs:comment>The drug was accompanied with lysin restricted diet</rdfs:comment>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00473655</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:00007121"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/9b40f17b-8b83-4f1d-9f9e-1476098ddc17"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000009"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/52f8bd48-691f-495f-8e00-ade205c145ba"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f9277694-636f-4bc6-ac3a-c23145d602c2"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24204001</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/144650"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/3d8af215-4dec-4f37-b192-4a2d6afeed11"/>
      </obo:DDIEM_0000013>
    </obo:RO_0000056>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/be019600-352d-427c-8235-085854043c0d"/>
    <obo:RO_0000056>
      <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/aa5fb8a2-5467-43ce-8de3-f2e689bb48b2">
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02705547</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/229300"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21597884</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/c3af4cca-0eea-44d8-9c18-121be136d146"/>
        <rdfs:comment>There is controversy about idebenone effect on LVM index ; although there were some studies suggested its effect on reducing LVM index and neurological problems, there are some that documented its faiure in acheiving this result. https://www.ncbi.nlm.nih.gov/pubmed/21392622
https://www.ncbi.nlm.nih.gov/pubmed/20697044</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18759345</dc:provenance>
      </obo:DDIEM_0000013>
    </obo:RO_0000056>
    <rdfs:label>Rosuvastatin</rdfs:label>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/a58e0143-a05f-48ec-bed3-91d780607e3e">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/4883477</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/144650"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19530961</dc:provenance>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/0de7da26-3b53-4723-995f-d2a262c8a852"/>
        <ddiem:failedToContributeToCondition>C-1131</ddiem:failedToContributeToCondition>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29695967</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0003304>TT-1131</obo:RO_0003304>
        <rdfs:comment>Hubacek et al. 2009 's results suggest that the APOA5 gene variants may play an important role in the pharmacogenetics of statin treatment. https://www.ncbi.nlm.nih.gov/pubmed/19530961/. https://www.ncbi.nlm.nih.gov/pubmed/25900265</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22129523</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f9277694-636f-4bc6-ac3a-c23145d602c2"/>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/ec2f0f6c-2c56-4393-8aa7-a1c2132eb2b8">
    <dc:identifier>DB00136</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/d6025189-ed02-4570-a4b6-9ea71e2381cd"/>
    <rdfs:label>Calcitriol</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00136</ddiem:url>
  </ddiem:Drug>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/9a2d0cde-a105-4dbf-a523-d70c74ffd899">
    <dc:provenance>https://clinicaltrials.gov/ct2/show/results/NCT01267422</dc:provenance>
    <obo:RO_0003304>G11778A</obo:RO_0003304>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT03153293</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30107658</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/3656f78e-5ead-473c-99b8-5caf00e68a99">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/8e4a0d78-fd2a-445b-bc7b-6697c0f42fa3"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ce8b5819-cb2d-4a37-bc4e-6a870f02a0c8"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/535000"/>
    <rdfs:comment>Dietry treatment supplementation</rdfs:comment>
  </obo:OGMS_0000112>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/9848620e-11c5-4572-ab51-a23e5f11d517">
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3550461</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/219800"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3505515</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27102039</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3016220</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/53d81324-bc69-4ec5-bd3c-186d552927d4"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c2d5afd0-4c81-45c4-9bbf-154dc85ed773">
        <rdfs:label>Phosphate imbalance (Abnormality of phosphate homeostasis)</rdfs:label>
        <dc:identifier>HP:0100529</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0100529</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19622360</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8444253</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/5bc9952b-dc92-47b3-abc8-913bf575f22b"/>
    <rdfs:comment>Controversial benefits https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4158338/</rdfs:comment>
  </obo:OGMS_0000112>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/4d770aea-2a7f-4592-881e-1c574d4ea434">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/0a6c54ac-a248-40b7-b0ea-db5d0cc373c3"/>
  </rdf:Alt>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/07542199-282a-4339-aa09-274957d35e9c">
    <dc:identifier>HP:0002181</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002181</ddiem:url>
    <rdfs:label>Brain oedema</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/4e7c72a6-363b-4d24-9f5d-3b6f268f425d">
    <ddiem:url>https://www.drugbank.ca/drugs/DB09422</ddiem:url>
    <dc:identifier>DB09422</dc:identifier>
    <rdfs:label>Soybean oil</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/9efd382a-66f2-4fbb-841f-aa12ab2a9ed3"/>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/50d7ec9d-44c4-472e-9516-11c0255e17e2">
    <dc:identifier>HP:0000488</dc:identifier>
    <rdfs:label>Progressive ataxic retinopathy</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000488</ddiem:url>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/28ffadde-9675-423a-bde8-f4c58e28f595">
    <dc:identifier>HP:0000630</dc:identifier>
    <rdfs:label>Retinal thickness</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000630</ddiem:url>
  </ddiem:Phenotype>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/78b517c1-3f4d-40b2-afc6-e7e728633c62">
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/256540"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7814809</dc:provenance>
    <obo:RO_0003304>SpDEx7];/p.[Q49R;Y395C]/c.[478_480delTTC];[?]* no mutation was in the second all</obo:RO_0003304>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29358012</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15895716</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/e65ca958-7dee-4e8a-9d57-0cffa1003a22"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22008912</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
    <rdfs:comment>Phenobarbital, clonazepam, valproate, and midazolam could not completely control seizures. https://www.ncbi.nlm.nih.gov/pubmed/20052547/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26259553</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15084520</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b67b56de-6d98-4bfa-8b0f-b99e3f441cd5"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25485164</dc:provenance>
  </obo:OGMS_0000112>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/ba857816-ac9a-4646-9995-71dad2c3a159">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28590052</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
    <rdfs:comment>Drug name: Treatment is under trial.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1316120</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/125700"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15131757</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30804055</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26153518</dc:provenance>
    <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1517999</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6234667e-9025-4d08-bee9-cb29c4664139">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000103</ddiem:url>
        <dc:identifier>HP:0000103</dc:identifier>
        <rdfs:label>Polyurea</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/855cf5b9-8721-485c-8070-7a064dba8967"/>
  </obo:DDIEM_0000013>
  <owl:Class rdf:about="http://purl.obolibrary.org/obo/DDIEM_0000005">
    <dc:date rdf:datatype="http://www.w3.org/2001/XMLSchema#dateTime">2019-07-15T17:59:32+00:00</dc:date>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/metabolic_disease_treatment"/>
    <obo:IAO_0000115 xml:lang="en">A therapeutic procedure which directly addresses the effects of a protein defect produced by the mutation, its structure, activity or end product. Therapies which target the local interaction or regulatory network or pathway in which the affected proten lies are also regarded as mechanistic therapies. [PNS]</obo:IAO_0000115>
    <dc:creator>leechuck</dc:creator>
    <rdfs:label xml:lang="en">mechanistically predicated therapeutic procedure</rdfs:label>
  </owl:Class>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/232800">
    <ddiem:iembaseAccessionNumber>491</ddiem:iembaseAccessionNumber>
    <rdfs:comment>The infantile form of PFK deficiency is characterized by the early onset of muscle weakness and multisystem involvement, which often leads to death in infancy or early childhood. Early diagnosis and improved understanding would enable clinicians to provide better clinical care. https://www.ncbi.nlm.nih.gov/pubmed/26108272</rdfs:comment>
    <rdfs:label>GLYCOGEN STORAGE DISEASE VII; GSD7</rdfs:label>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/217956c3-c849-4252-96ca-46d76ca449b7"/>
    <dc:identifier>https://www.omim.org/entry/232800</dc:identifier>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/491</ddiem:iembaseUrl>
  </ddiem:Disease>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/c43f70d4-ead6-4b24-b6fc-054db86db0ab">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14632789</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25717099</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19415691</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/12ff4ad4-d450-4dbb-8e73-cc526912926f">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/216bc8d9-3bfc-4434-aee7-d79e4b52292d"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00001203</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/cb989c15-d6bb-4a67-b6a8-413330e99b6b"/>
    <dc:provenance>https://www.semanticscholar.org/paper/The-Incidence-of-Transient-Neonatal-Tyrosinemia-a-Zea-Rey-Cruz-Camino/b66304a0a56304f686380af915a92b2b860e9305</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT03395704</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <rdfs:comment>One of the studies that was carried on mice provides useful information for developing the optimal dosage regimen for HPBCD therapy when administered intravenously to NPC patients.https://www.ncbi.nlm.nih.gov/pubmed/26027824</rdfs:comment>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/604250"/>
  </obo:OGMS_0000112>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/37d111b3-8fb7-4c7b-8ade-89aaf159641b">
    <dc:identifier>DB01348</dc:identifier>
    <rdfs:label>Spirapril</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/168bb830-63cf-4a6b-9a8f-c2638081c8b5"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01348</ddiem:url>
  </ddiem:Drug>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/f78e40d7-dfe6-449b-949e-3ab5dd053236">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15300460</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/834fd1de-a6c9-42e4-b793-afaa87151118">
        <rdfs:label>neurological malfunction</rdfs:label>
        <dc:identifier>HP:0000707</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000707</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>There is a common note in different reserachs refers to the importance of early managment by Vitamin E supplements since it limits disease progression and it can reverse some of the clinical manifestation (e.x ataxia and the intellectual deficit), if it was interoduced early in life. Therefore, early diagnosis is paramount.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17586848</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/acb8765f-e459-4a11-b2b1-f2682ffdcc96">
        <rdfs:label>immune dysfunctions</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002715</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0002715</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/a13af3ad-d010-4fa9-a9d4-6c7b282f1d6c">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/06ec2e92-c5f3-41fe-b49e-5a0509863fb5"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27906067</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/208900"/>
  </obo:DDIEM_0000013>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/c2bc6126-9297-47ac-b94e-f87be32732c0">
    <rdfs:label>antisense oligonucleotide (VMO AED cocktail)</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/a9f948f7-a921-4ae1-a6b1-337eac3a15a5"/>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ddb09534-bac9-4589-b31d-246c741bc1ce">
    <rdfs:label>Abnormal AGA processing</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/457b14e9-f936-42e0-b6ea-797acce6d01e">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17192294</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/605820"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01517880</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/f604812d-07fe-449e-a1dc-243ff066afa4"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20030229</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19627167</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28641925</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10549306</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26546927</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00125190</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/202b2073-9e0f-4323-b4bc-9fcf095b645b"/>
    <rdfs:comment>In the clinical trial: The trial is not enrolling by invitation, no results have been posted yet. update by Oct.7th 2019
Authors have stated that "The data indicate that the retromer and sphingolipid metabolism play a critical role in PLA2G6-associated diseases. These observations may be relevant to Parkinson disease (PD) given that loss of vps35 or gain of Î±-Syn also affects retromer function and causes ceramide accumulation." https://www.ncbi.nlm.nih.gov/pubmed/29909971</rdfs:comment>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/aa6eb3de-1312-4ec7-9d14-a29d9210b831"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/fefb524d-97ea-4cb9-aa35-a21ac15d1327"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
  </obo:OGMS_0000112>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ec071e40-a9de-42ba-9a0d-7ca4df468351">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Speech and languague delay</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/ff688d97-31af-4f2a-8328-264bd82a922d">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/a8a027e7-1dda-419c-92fc-0915be308ede"/>
    <rdfs:label>Rofecoxib</rdfs:label>
    <dc:identifier>DB00533</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00533</ddiem:url>
  </ddiem:Drug>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/d376b148-e2b6-4be7-befd-452e6e3232b3">
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00125190</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24639006</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19627167</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28662915</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20301643</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17192294</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f417713e-5e4d-4ea7-9f25-f0b8acab584e">
        <dc:identifier>HP:0002069</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>generalized tonic-clonic seizure</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002069</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>In the clinical trial: The trial is not enrolling by invitation, no results have been posted yet. update by Oct.7th 2019
Authors have stated that "The data indicate that the retromer and sphingolipid metabolism play a critical role in PLA2G6-associated diseases. These observations may be relevant to Parkinson disease (PD) given that loss of vps35 or gain of Î±-Syn also affects retromer function and causes ceramide accumulation." https://www.ncbi.nlm.nih.gov/pubmed/29909971</rdfs:comment>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/604369"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23887143</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/de2f9565-d217-424d-b54d-5a9be0514a37"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10549306</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
  </obo:DDIEM_0000013>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/4b7f9ab4-71fe-4d4a-87ae-5bdd5a1fcf5a">
    <dc:identifier>DB01390</dc:identifier>
    <obo:RO_0000056>
      <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/c2c83d41-3739-482e-9553-d3ed7f2d8050">
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/227810"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/7b517ff3-fc9a-449b-a7f3-1355c1eb4688"/>
        <rdfs:comment>Uncoooked cornstrach was introduced in small frequent meal and was accomapined with elimination of lactose in diet</rdfs:comment>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/21a46f47-c236-4521-abc9-f0e7a415b765"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27155573</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5338723</dc:provenance>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24912437</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7564233</dc:provenance>
      </obo:DDIEM_0000013>
    </obo:RO_0000056>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/e23d89a9-20ce-446b-9cce-8eeb6dcb83e2"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/a4f7199a-cae5-4eb8-8912-de25de6f3717"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/5f00e19d-b990-44e6-a76a-4aec412d5b56"/>
    <rdfs:label>Sodium bicarbonate</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/2b3d8a28-b48a-49d2-888e-e605edb533f2"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01390</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/49b90546-1669-4b58-a79d-13cd00df85d7"/>
  </ddiem:Drug>
  <obo:DDIEM_0000015 rdf:about="http://ddiem.phenomebrowser.net/c0c5bbb1-f14c-4f23-af58-d589418a6edd">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3415789</dc:provenance>
    <rdfs:comment>Investigational "Infertility investigation Abetalipoproteinaemia patients might benefit from progesterone supplementation, and further studies on this and hormonal profiles would benefit this pool of patients. Optimising the nutritional profile and body mass index of female patients will undoubtedly contribute to better chances at conception.:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4265040/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12044538</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24288038</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ff026e0d-ffdf-4fa8-aa62-206e0173575e"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/f22fe350-f8c5-4ce8-93ef-10c3339e7b10">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/a72e46d7-4c0e-420a-832f-7a539c18adb7"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a691efd5-4a3d-45e2-bf27-03484dad4419">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003281</ddiem:url>
        <rdfs:label>high brain and liver iron stores</rdfs:label>
        <dc:identifier>HP:0003281*</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/604290">
        <dc:identifier>https://www.omim.org/entry/604290</dc:identifier>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/872</ddiem:iembaseUrl>
        <ddiem:iembaseAccessionNumber>872</ddiem:iembaseAccessionNumber>
        <rdfs:label>ACERULOPLASMINEMIA</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/731f7536-3e68-450a-9737-344aa967656d"/>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/books/NBK1493</dc:provenance>
  </obo:DDIEM_0000015>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2a0f8c3f-9a37-4c67-ba70-dea9fbebe563">
    <rdfs:label>growth faliure</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001510</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0001510</dc:identifier>
  </ddiem:Phenotype>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/18b377b8-d59f-4c8f-83fc-bc71284b0187">
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/f70aeb4d-f5a3-453c-8a6a-bc6f196846ef">
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/cc9929d9-ce67-4b28-9243-df8923acb9e0"/>
        <rdfs:label>flavanols</rdfs:label>
      </ddiem:Drug>
    </rdf:li>
  </rdf:Alt>
  <obo:DDIEM_0000010 rdf:about="http://ddiem.phenomebrowser.net/de4fe07c-9247-4eda-b5c4-6519a2e8c0f9">
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/397a09b3-2d92-4bfa-8ddf-6f103f0e2656"/>
    <rdfs:comment>Treatment was stopped three days later because of lack of improvement and severe respiratory alkalosis with lactic acidosis (serum lactic acid 70 mg/dl, normal 4â20 mg/dl). https://www.ncbi.nlm.nih.gov/pubmed/12948744</rdfs:comment>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/345f7321-2b9d-4b63-8db8-6f154976000d"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/613027"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583863</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12930917</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2564511</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/8c7855e7-dce7-445f-b36a-fb6ddc2ab92e">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/cae65cd6-c319-4d1a-9241-6de48e9090ef"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15726662</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3306242</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25266922</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
  </obo:DDIEM_0000010>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/8dbc6d40-b260-4f09-97a5-45691fe6bd2a">
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/3b8a7752-a33a-43df-8697-89f32c0f3e9e"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/230800"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/fa29eff6-fa66-49a7-9bb3-9f2b5affb666">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>elevated Chemokine Ligand (CCL-18) Level [ng,mL]</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2c7b79d1-f53d-49e5-ad36-c7a3c88b3821">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001903</ddiem:url>
        <rdfs:label>primary low heamoglobin level</rdfs:label>
        <dc:identifier>HP:0001903*</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d8514def-4305-4727-8d45-83a1b83abd12">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0004356</ddiem:url>
        <dc:identifier>HP:0004356</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>high  Chitotriosidase Level(Abnormality of lysosomal metabolism)*</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/decc676b-2824-4cb3-97b5-0128c2a6f590"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/164c87bf-5a07-423b-a457-d4a49c757660"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29471850</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/64482499-b03b-44a4-8ed9-0c916e569b8d"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27102949</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21503667</dc:provenance>
    <rdfs:comment>Indomethacin was the most effective but can cause gastrointestinal intolerance and decreased eGFR. Amiloride and eplerenone have similar but lower efficacies and increase sodium depletion. The benefit/risk ratio of each drug should be carefully evaluated for each patient.          https://www.ncbi.nlm.nih.gov/pubmed/25012174
Despite a documented effect on hypokalemia, indomethacin and other nonsteroidal anti-inflammatory drugs should be used with caution due to their short- and long-term gastrointestinal side effects and nephrotoxicity.https://www.ncbi.nlm.nih.gov/pubmed/28003083</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/385cd5e1-2b34-4b25-98dc-ade44d23abf4">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0000841</dc:identifier>
        <rdfs:label>high angiotensin- converting enzyme</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000841</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/results/NCT02770625</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30066229</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28381550</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27499018</dc:provenance>
  </obo:OGMS_0000112>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/fa0fb973-0780-4b23-89a0-3a2461eb64ca">
    <ddiem:url>https://www.drugbank.ca/drugs/DB00091</ddiem:url>
    <rdfs:label>Ciclosporin</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/36c84d6f-fb96-4f6b-9f9f-bb10339b2b69"/>
    <dc:identifier>DB00091</dc:identifier>
    <obo:RO_0000056>
      <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/cb2525d7-6bef-418c-be83-5c38f3ac87b0">
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02176733</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b4f2b909-9165-4013-a2cb-82c920e8c0c1"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21483849</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29054473</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/fec0af46-08df-4c06-a764-9441665924ed"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/535000"/>
        <rdfs:comment>The cyclosporine trial (taken immediately upon visual loss in the first eye) is in progress in Leber's optic atrophy to prevent involvement of the fellow eye.</rdfs:comment>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24161764</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21600768</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24093206</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3202309</dc:provenance>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02805790</dc:provenance>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
      </obo:DDIEM_0000013>
    </obo:RO_0000056>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/a31c0648-1fd4-4102-aca3-5496408f861a"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/daf3b3b3-9bf5-4195-86a1-b156f3afb5f7">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/96ca8a6c-d171-4d7d-8bcd-662320d9e250"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB11098</ddiem:url>
    <rdfs:label>Potassium bicarbonate</rdfs:label>
    <dc:identifier>DB11098</dc:identifier>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d467a691-1658-450c-b260-dc3e7fe5b6e5">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Impaired nerve conduction</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0040129</ddiem:url>
    <dc:identifier>HP:0040129</dc:identifier>
  </ddiem:Phenotype>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/6bf7e3ec-de38-4971-bba8-4187e0d35a6c">
    <obo:RO_0003304>G11778A</obo:RO_0003304>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17296905</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/b0e843e8-df30-42f3-9473-a52f35edd6dc"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/eeb4580e-20d2-4ca8-8e7c-c24895ffc16f">
        <dc:identifier>HP:0012103</dc:identifier>
        <rdfs:label>Mitochondrial oxidative stress</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012103</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/535000"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c375e446-76ef-461b-ab08-b61aa7a5b328">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001138</ddiem:url>
        <rdfs:label>Optic nerve damage</rdfs:label>
        <dc:identifier>HP:0001138</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30107658</dc:provenance>
    <rdfs:comment>Dietry treatment supplementation</rdfs:comment>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
  </obo:OGMS_0000112>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/ef64aef2-384b-4689-92ec-10462ab2a3b5">
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/b9b97689-a315-4b70-b042-567777077f66">
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/2327783f-39d7-4fc2-9776-290d77526dba"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <rdfs:comment>There was no clinical effect, but amild reduction in the plasma level of desmosterol was observed.</rdfs:comment>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719213003661</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29506905</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8813986</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/66aa6980-9d73-4eee-8a52-f80a6ead8bf9"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18652077</dc:provenance>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719213003107</dc:provenance>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24268530</dc:provenance>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719212002971</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/612736"/>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/5e5c88d0-8916-4fd3-8530-8d2b7f8d362d"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/4dadb0b6-71d6-4706-bd84-dd525f6ac2ba"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/788a5e5e-9461-4ed1-8e84-45705866e03e"/>
    <rdfs:label>Creatine</rdfs:label>
    <dc:identifier>DB00148</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00148</ddiem:url>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/605328df-3f16-47f1-9315-f97e00fcba14">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Saccadic ocular movement abnormality (Abnormality of saccadic eye movements)</rdfs:label>
    <dc:identifier>HP:0000570</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000570</ddiem:url>
  </ddiem:Phenotype>
  <obo:direct_complementation_of_a_genetically_defective_protein_by_gene_therapy rdf:about="http://ddiem.phenomebrowser.net/337ad98d-1e19-4769-986d-863812ee5d01">
    <dc:provenance>https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/5a75ae43-ff10-4dd5-9b93-c31167d0efb2"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3073162</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23494656</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3955971</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02926066</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/608643"/>
    <rdfs:comment>Alternative pathway therapy has limited effectiveness in preventing hyperammonemia and must be combined with effective dietary management. https://www.ncbi.nlm.nih.gov/pubmed/11148549</rdfs:comment>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01395641</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e11ea79e-b956-4461-8409-baabffe55b99">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0002275</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002275</ddiem:url>
        <rdfs:label>motor malperformance</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/a8faaa8e-cadc-41b2-bca5-64e494d2258b">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/77ff7213-ffdd-4ca5-a5e6-e725226e502e"/>
      </rdf:Alt>
    </obo:RO_0000057>
  </obo:direct_complementation_of_a_genetically_defective_protein_by_gene_therapy>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d5308c60-31df-436b-897e-73d3f8e5a72f">
    <rdfs:label>retinal dystrophy</rdfs:label>
    <dc:identifier>HP:0000556</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000556</ddiem:url>
  </ddiem:Phenotype>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/3c113f3c-dd11-4c18-a658-90d2d1c7523a">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/e898f4cf-bf08-4190-ae4f-c8ed3d3352ab">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/71543ac5-30b8-46df-b5a4-ca29272703a4"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/232700"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25266922</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b3b6e59f-81cb-470d-b827-c474752c4e3f"/>
    <rdfs:comment>Testosterone therapy needs to be carefully considered because of the risk of hepatic adenomas.https://www.ncbi.nlm.nih.gov/pubmed/28160246
Androgen receptors are expressed in the liver, and androgens can stimulate hepatocyte proliferation. Although rare, androgens have been shown in observational studies to induce adenoma development (Giannitrapani et al. 2006). Testosterone levels should be assessed for response 2â3 months after therapy is initiated.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19019309</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000010"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
  </obo:OGMS_0000112>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/d4440823-9f31-4cd0-93f0-960b4cbc8a41">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/226a1444-8929-417a-846f-5efc57b02ab7"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00700)</ddiem:url>
    <dc:identifier>DB00700)</dc:identifier>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5658b3bd-ed44-4dd5-a5c4-25bfea01639f">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0011999</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0011999*</dc:identifier>
    <rdfs:label>Hallucinatory-paranoid state</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7eef4b38-b505-44b8-8185-5fd377d86a86">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0008064</ddiem:url>
    <rdfs:label>ichthyosiform erythematous plaques</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0008064</dc:identifier>
  </ddiem:Phenotype>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/d5b54632-b188-42cd-b522-cd9b8911f269">
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0387760417301742</dc:provenance>
    <rdfs:comment>Drugs has decreased rhe frequency of the tonic seizuress</rdfs:comment>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/5a7380bb-31e6-44a5-8716-cdc5239d0ac5"/>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/615398">
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/1147</ddiem:iembaseUrl>
        <ddiem:iembaseAccessionNumber>1147</ddiem:iembaseAccessionNumber>
        <dc:identifier>https://www.omim.org/entry/615398</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/dd4fb71a-d7bd-486a-8773-be5b5dd3a750"/>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>MULTIPLE CONGENITAL ANOMALIES-HYPOTONIA-SEIZURES SYNDROME 3; MCAHS3</rdfs:label>
      </ddiem:Disease>
    </obo:RO_0002599>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/3b27a130-fbf7-4aed-9711-fc7ffd5e687e">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/3dda176f-cf5d-4de3-9c15-7c3172698e14"/>
      </rdf:Alt>
    </obo:RO_0000057>
  </obo:DDIEM_0000013>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/fbe442f1-71f3-4160-be72-d58df5fe426f">
    <dc:identifier>HP:0004305</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0004305</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>involuntary movements</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d8305c91-39b5-4893-b88c-0a664ab3b871">
    <dc:identifier>HP:0000992</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000992</ddiem:url>
    <rdfs:label>photosensitivity</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/90ce7754-bb54-479a-8b0c-0a272912540f">
    <ddiem:url>https://www.drugbank.ca/drugs/DB00155</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/d4e3c435-2a1d-427e-923f-0841d481dec9"/>
    <dc:identifier>DB00155</dc:identifier>
    <rdfs:label>L-Citrulline</rdfs:label>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/4053765f-ff27-4433-bc2f-ad605a3f92a0">
    <rdfs:label>Cabozantinib</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB08875</ddiem:url>
    <dc:identifier>DB08875</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/d2907c91-b72d-4078-9040-5d7f2a32a43b"/>
  </ddiem:Drug>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/4f796926-d867-45f4-a4fc-e232609f9341">
    <dc:provenance>https://clinicaltrials.gov/ct2/show/study/NCT00572156</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24639006</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19627167</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10549306</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17192294</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00125190</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23887143</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27884013</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/77066bf1-0b44-448f-a183-61007143ccdc"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/608747"/>
    <rdfs:comment>The study is terminated (The study was prematurely terminated due to strategic reasons.)</rdfs:comment>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/c3951163-c8e6-466e-8940-5830b567e782"/>
  </obo:OGMS_0000112>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/d1b97875-bef3-4849-b5af-62eee072cce5">
    <obo:RO_0000056>
      <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/4acf39f1-0bc9-48cb-81eb-9c8a2cf9dbb2">
        <rdfs:comment>Synergism inmproves results</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22830360</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27775558</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/36c1fa40-979f-4e77-9931-51df096fd815"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25896882</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/266130"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/2bcc5c84-3370-4a95-a714-73f8dd07f160"/>
      </obo:DDIEM_0000007>
    </obo:RO_0000056>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/22f9df78-5708-4c04-9421-429251395c83"/>
    <obo:RO_0000056>
      <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/8327c221-b52e-4986-bd53-02d51f00ce9f">
        <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/208900"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17586848</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27906067</dc:provenance>
        <dc:provenance>https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/8bf9b165-a172-44b3-914a-a365374959cc"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15300460</dc:provenance>
        <rdfs:comment>There is a common note in different reserachs refers to the importance of early managment by Vitamin E supplements since it limits disease progression and it can reverse some of the clinical manifestation (e.x ataxia and the intellectual deficit), if it was interoduced early in life. Therefore, early diagnosis is paramount.</rdfs:comment>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/48f0eae9-c050-47a4-8918-9b66e9cc570d"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/36c1fa40-979f-4e77-9931-51df096fd815"/>
      </obo:DDIEM_0000013>
    </obo:RO_0000056>
    <ddiem:url>https://www.drugbank.ca/drugs/DB02701</ddiem:url>
    <rdfs:label>Nicotinamide</rdfs:label>
    <dc:identifier>DB02701</dc:identifier>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4c0a9a26-460a-4428-832c-76315509cea9">
    <rdfs:label>high glycogen levels in muscles</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0009051</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0009051</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/2c4a9be6-09bb-46a4-807d-cdc0e81041b9">
    <ddiem:url>https://www.drugbank.ca/drugs/DB15066</ddiem:url>
    <rdfs:label>Givosiran</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/f6ca8c2c-805a-446c-9d11-fa51a3068c70"/>
    <dc:identifier>DB15066</dc:identifier>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3685857e-2079-42cf-9817-f2f4104a8291">
    <rdfs:label>Abnormality of potassium homeostasis</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0011042</ddiem:url>
    <dc:identifier>HP:0011042</dc:identifier>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/94e3f1cd-5570-4a65-871f-f982b29c12fe">
    <rdfs:comment>Î±-Tocopherol should be given with the ascorbic acid(vit. C) as the latter helps The resultant tocopheroxil radical regeneration in getting back to reduced tocopherol .</rdfs:comment>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b72ba78c-27d6-4a5e-8db6-7e0d3fceb7c7"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8ffb51d1-f9fd-43c6-b7bb-7bc83c60e00c">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>cerebral cortex acetylcholinesterase inhibition</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/5634a50b-fb00-426a-b60d-3c73c68634d7"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24980685</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/706924fe-4859-486d-8d68-798b9bd3d9f8">
        <rdfs:label>impairment of reference</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e6080bb4-a703-4958-a2bb-891b675a4101">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>"hippocampal Na+, K+-ATPaseÂ reduced activity"</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/60348b12-7b29-4426-8d7a-fc853762a897"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16214240</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/48f0eae9-c050-47a4-8918-9b66e9cc570d"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/239500"/>
  </obo:DDIEM_0000013>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/23f68ba8-dce7-4b91-82ba-493282d97765">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19541498</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19066956</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/232220"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18172743</dc:provenance>
    <rdfs:comment>Anti-inflammatory medications, including derivatives of 5-aminosalicylic acid (5-ASA), might be a helpful adjunct for treating gastrointestinal complaints in GSD Ib patients, if renal function is carefully monitored . https://www.ncbi.nlm.nih.gov/pubmed/12373585</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/cf4db4f2-d411-4f52-b258-fd8950f0a77e">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0004387</dc:identifier>
        <rdfs:label>GSD-associated enterocolitis(enterocolitis)</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0004387</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/2ce812c4-bafa-4417-9564-38303dba2f7c"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25288127</dc:provenance>
  </obo:OGMS_0000112>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/d0c68d44-cc59-4b81-a786-2f94049a9730">
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00125190</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17192294</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10549306</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/31110a20-4503-4e5b-9ebd-d5416e01fd32">
        <rdfs:label>Lysosomal stress (Abnormality of lysosomal metabolism)*</rdfs:label>
        <dc:identifier>HP:0004356</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0004356</ddiem:url>
        <rdfs:comment>In the mouse model syudy</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/2cfb7d15-e552-4856-9f51-5e82353f1056">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/55605561-b5ce-4520-aafb-ae24e794ee79"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT03726996</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <rdfs:comment>In the clinical trial: The trial is not enrolling by invitation, no results have been posted yet. update by Oct.7th 2019
Authors have stated that "The data indicate that the retromer and sphingolipid metabolism play a critical role in PLA2G6-associated diseases. These observations may be relevant to Parkinson disease (PD) given that loss of vps35 or gain of Î±-Syn also affects retromer function and causes ceramide accumulation." https://www.ncbi.nlm.nih.gov/pubmed/29909971</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23887143</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/256600"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000015"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24639006</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19627167</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/688c2d42-f99c-4736-b0ae-21827fd43b87"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29909971</dc:provenance>
  </obo:OGMS_0000112>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/40390953-84c7-4dc4-9874-ee61f455992d">
    <rdfs:label>acute hyperammonemia</rdfs:label>
    <dc:identifier>HP:0008281</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0008281</ddiem:url>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2aa5c45c-0604-4694-9173-266bdb2d09b3">
    <rdfs:label>Trial is no longer available</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/8697a6fb-ff5a-4d56-b1ba-2ae1deecaa5f">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22740624</dc:provenance>
    <rdfs:comment>The results of this study suggest that octreotide may aid in the acute or long-term treatment of congenital hyperinsulinism in a limited number of selected cases.https://www.ncbi.nlm.nih.gov/pubmed/8410522/</rdfs:comment>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/230de6be-c297-4346-8702-82360f6be756">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/e3435067-bbc9-4cab-bca0-67cefcd6b816"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://link.springer.com/referenceworkentry/10.1007%2F978-3-540-29676-8_199</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1d8fa107-ce75-488e-a911-5defb3bc0630">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Elevated C-reactive protein</rdfs:label>
        <dc:identifier>HP:0011227</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0011227</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25758134</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1ef5ca6c-acc0-4137-bc95-14577650f3d9">
        <dc:identifier>HP:0001945</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Fever</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001945</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3fb4eba0-cf19-487a-ac0f-238475d57bd1">
        <rdfs:label>High serum amyloid A protein</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/260920"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26962538</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
  </obo:DDIEM_0000013>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/2f8804e7-5ba6-4bcb-bccf-a61f65d7e9cc">
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/606762"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10453735</dc:provenance>
    <rdfs:comment>Based on their study auhors of"  https://www.ncbi.nlm.nih.gov/pubmed/21354122?dopt=Abstract"  presume that the combination of these drugs may contribute to reduce LDL-C/HDL-C ratio effectively as well as lowering concentrations of serum triglyceride.</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10969108</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/2ce2a3f0-914c-481a-8b67-1c6a3499311d"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/de2f9565-d217-424d-b54d-5a9be0514a37"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/35b5c64e-9aaa-46fd-84a3-e5d483d4e101"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25781533</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26962538</dc:provenance>
  </obo:OGMS_0000112>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/75ac2cf3-40a1-4ff6-a295-d76387e9e4ee">
    <rdfs:comment>These inconsistent results have suggested that the response might depend on the specific gene mutations
 As the response was not sustained and serum ALP and PLP and urine PEA returned to baseline between 8 and 13 months of treatment 
In N461L mutation which led to complete disappearance of the bone isoenzyme, disease was not modified by PTH treatment.  

https://www.ncbi.nlm.nih.gov/pubmed/22218563?dopt=Abstract
https://www.ncbi.nlm.nih.gov/pubmed/20089612?dopt=Abstract (Lack of sustained response to teriparatide in a patient with adult hypophosphatasia_</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24980685</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/3f63683a-2be4-4200-b3fe-7c1eba292f0f">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/a104d565-c6fc-4a40-bf21-895086060bea"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27589827</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/239500"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7fea0de1-fc34-4a60-ab37-3cb13c2238c4">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0025464</ddiem:url>
        <dc:identifier>HP:0025464</dc:identifier>
        <rdfs:label>Oxidative Stress</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </obo:OGMS_0000112>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/67d676c6-8efa-4c4a-b6fd-ca0e6b3aef1a">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/5d4524d1-e130-470d-93ef-338b3552adab"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/448673b4-3581-4889-85dc-4213d76e645d"/>
    <rdfs:label>Starch, corn</rdfs:label>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/82852a83-9013-4185-adbb-ea2b7a26be94">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27155573</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/227810"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4353876</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7564233</dc:provenance>
        <rdfs:comment>Uncoooked cornstrach was introduced in small frequent meal and was accomapined with elimination of lactose in diet</rdfs:comment>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/e4fe8128-15d7-4874-b568-8ddad4ec30c7"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5338723</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/eb318982-8e44-434a-92f2-7148303622aa"/>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/e7d13feb-ebd0-481c-838b-22210bd30be8"/>
    <dc:identifier>DB11599</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB11599</ddiem:url>
    <obo:RO_0000056>
      <obo:DDIEM_0000010 rdf:about="http://ddiem.phenomebrowser.net/9766191b-18eb-493b-8b23-aef098b00f71">
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30804055</dc:provenance>
        <dc:provenance>PMC2676979</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/255120"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/345f7321-2b9d-4b63-8db8-6f154976000d"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26153518</dc:provenance>
        <rdfs:comment>Drug name: Intranasal dDAVP, because of efficacy, long duration of action, and infrequent side effects, is the preferred treatment of neurogenic diabetes insipidus in children and adults.https://www.ncbi.nlm.nih.gov/pubmed/626447</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15669684</dc:provenance>
        <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/92267d2a-63b6-464b-89e9-c9142118e506"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28590052</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15131757</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/e4fe8128-15d7-4874-b568-8ddad4ec30c7"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
      </obo:DDIEM_0000010>
    </obo:RO_0000056>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/dc38e1f2-d1b2-48ad-a0da-2805dbc5fba3">
    <dc:identifier>DB00620</dc:identifier>
    <rdfs:label>Triamcinolone</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/2dc61d48-f4f1-47db-8266-a3a5441ff2ea"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00620</ddiem:url>
  </ddiem:Drug>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/300971">
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/fd7a8cac-8831-4599-9ac9-ebd1d434f4cb"/>
    <dc:identifier>https://www.omim.org/entry/300971</dc:identifier>
    <rdfs:comment>Among antenatal Bartter syndrome, the transient form was defined as a regression of clinical symptoms and normalization of biologic parameters allowing the arrest of treatment. https://www.ncbi.nlm.nih.gov/pubmed/29146702
This condition can be successfully treated with close monitoring and fluid and electrolyte replacement, avoiding the potential harmful effects of indomethacin. This diagnosis is important for clinical management and parental counseling regarding overall patient prognosis. https://www.ncbi.nlm.nih.gov/pubmed/29594084</rdfs:comment>
    <rdfs:label>BARTTER SYNDROME, TYPE 5, ANTENATAL, TRANSIENT; BARTS5</rdfs:label>
  </ddiem:Disease>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/c4a265d6-2ebf-452a-9036-f79a9796d989">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/da445398-6a36-4219-984e-2bbaff81e802"/>
    <rdfs:label>rh-HMBS</rdfs:label>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/fc197a75-67d2-4434-b0fa-c860a229e3d6">
    <rdfs:label>Amiloride</rdfs:label>
    <dc:identifier>DB00594</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00594</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/226a1444-8929-417a-846f-5efc57b02ab7"/>
  </ddiem:Drug>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/49324341-6d6f-40e9-b87f-1aea5e56d846">
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/68c0f69e-a7af-4741-b049-35be43597d2c"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <rdfs:comment>The drug is effective in conjuction with phototherapy</rdfs:comment>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/553bc278-12d2-4cbe-b284-0c5980a34765"/>
    <dc:provenance>https://www.nature.com/articles/pr1989488</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19752526</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/topics/medicine-and-dentistry/crigler-najjar-syndrome</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583863</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/218800"/>
    <dc:provenance>http://pediatrics.aappublications.org/content/86/1/152</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3306242</dc:provenance>
  </obo:OGMS_0000112>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/df0d19b9-7e66-4c7f-9693-1d7e66c3a873">
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/92cdc6d4-795c-40de-86b4-b8afe70ad497">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8444253</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27102039</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3505515</dc:provenance>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/219800"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19622360</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3016220</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/03c0a773-62f9-4a1a-8df7-51d2b17d3dde"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/26d49ef3-1505-425f-b05e-53ded1abf58f"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3550461</dc:provenance>
        <rdfs:comment>Controversial benefits https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4158338/</rdfs:comment>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <rdfs:label>Polythiazide</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/8cc17e18-5fa0-4e2b-9597-93b54d7a1fc0"/>
    <dc:identifier>DB01324</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01324</ddiem:url>
  </ddiem:Drug>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/9d2e12c9-c443-4c3c-9e78-3a7be415996e">
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/49152949-b69a-489e-be08-286538ca7b8c"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25859380</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22402328</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/1c476a4d-15a8-481d-9c26-2bbe9a04823d"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/222700"/>
    <rdfs:comment>The role of corticosteroids also remains controversial, due to increase risk of infection. As well as, it's  ineffective against the respiratory symptoms. https://www.ncbi.nlm.nih.gov/pubmed/25335805</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/6777479</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25335805</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28057010</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
  </obo:OGMS_0000112>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/c8b34aff-5325-4b29-bff2-ac25fd9a0dae">
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/54cbae5f-8420-4c77-8464-a68be6276b97"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14213380</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28281899</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23649895</dc:provenance>
    <rdfs:comment>Drug name: Intranasal dDAVP, because of efficacy, long duration of action, and infrequent side effects, is the preferred treatment of neurogenic diabetes insipidus in children and adults.https://www.ncbi.nlm.nih.gov/pubmed/626447</rdfs:comment>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/2ce2a3f0-914c-481a-8b67-1c6a3499311d"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
    <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000012"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/13992367</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31392111</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/237300"/>
  </obo:OGMS_0000112>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/db15474a-93e2-47aa-9514-1067be82c80d">
    <ddiem:url>https://www.whocc.no/atc_ddd_index/?code=(DB00328</ddiem:url>
    <dc:identifier>(DB00328</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/226a1444-8929-417a-846f-5efc57b02ab7"/>
  </ddiem:Drug>
  <obo:DDIEM_0000008 rdf:about="http://ddiem.phenomebrowser.net/83bf2191-18af-44a6-b203-dda9548a7646">
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/232400"/>
    <rdfs:comment>Testosterone therapy needs to be carefully considered because of the risk of hepatic adenomas.https://www.ncbi.nlm.nih.gov/pubmed/28160246
Androgen receptors are expressed in the liver, and androgens can stimulate hepatocyte proliferation. Although rare, androgens have been shown in observational studies to induce adenoma development (Giannitrapani et al. 2006). Testosterone levels should be assessed for response 2â3 months after therapy is initiated.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8245377</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/14606524-8023-4f2b-b71d-1e06b511ab5c"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/31547f43-75ef-43a4-ac67-cfd4fba53569">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001510</ddiem:url>
        <rdfs:label>delayed growth</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0001510</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/8cfc8dee-db44-473a-b172-44891bebfc0a">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/65e9c779-2e4a-4fb1-ba8d-3900aa4fe198"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4302571</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/72e31d99-6722-4e05-aceb-c0c8a5bdba47">
        <dc:identifier>HP:0003198</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003198</ddiem:url>
        <rdfs:label>myopathy</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17514432</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24613482</dc:provenance>
  </obo:DDIEM_0000008>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/9897b42a-c20a-48c2-b814-56fe0dade2b4">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/fc7cfe0d-08c8-4ad4-bbca-e5fca9a43456"/>
  </rdf:Alt>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/a968e08d-b854-4ebe-933e-e9fb1bea72fa">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24683506</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19415691</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25717099</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f51b76a7-7bb0-4b11-afa0-bd15094fdfb9"/>
    <rdfs:comment>One of the studies that was carried on mice provides useful information for developing the optimal dosage regimen for HPBCD therapy when administered intravenously to NPC patients.https://www.ncbi.nlm.nih.gov/pubmed/26027824</rdfs:comment>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/509b4ec6-d32e-4821-9032-d0bd97b80f99"/>
    <dc:provenance>http://www.scielo.br/pdf/jiems/v5/2326-4594-jiems-5-e170016.pdf</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/140350"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28803710</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27488560</dc:provenance>
    <dc:provenance>https://www.semanticscholar.org/paper/The-Incidence-of-Transient-Neonatal-Tyrosinemia-a-Zea-Rey-Cruz-Camino/b66304a0a56304f686380af915a92b2b860e9305</dc:provenance>
  </obo:OGMS_0000112>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/d6fd6253-32ee-4df5-84f0-f420e3c6fe75">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/63a0f3fe-ac11-418e-805b-3f33485ee494"/>
  </rdf:Alt>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/bbd8b019-61c4-4c26-b662-d48f9377d392">
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/3ac40afd-9191-4124-a7f2-1dbd754716fe">
        <ddiem:url>https://www.drugbank.ca/drugs/DB14644</ddiem:url>
        <dc:identifier>DB14644</dc:identifier>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/0bcd37d6-b35a-4e26-96ca-e8db74aaf588"/>
        <rdfs:label>Methylprednisolone hemisuccinate</rdfs:label>
      </ddiem:Drug>
    </rdf:li>
  </rdf:Alt>
  <owl:Class rdf:about="http://purl.obolibrary.org/obo/DDIEM_0000009">
    <obo:IAO_0000115 xml:lang="en">A therapeutic procedure in which the diet is depleted in molecules closely related to the products or end processes of a genetically defective protein which occur naturally in the diet. [PNS]</obo:IAO_0000115>
    <dc:date rdf:datatype="http://www.w3.org/2001/XMLSchema#dateTime">2019-07-15T18:04:24+00:00</dc:date>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000008"/>
    <rdfs:label xml:lang="en">dietary exclusion</rdfs:label>
    <dc:creator>leechuck</dc:creator>
  </owl:Class>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/071aacb5-5257-437c-a404-abfd462b8f77">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18458702</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27853336</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/3dff1795-dd8a-4336-ba60-51a3ff83c667"/>
    <rdfs:comment></rdfs:comment>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/30e4d0b4-0b04-4269-b3f6-198ef790a271"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/eeaff26f-8a24-4819-80f8-bd78eaea0903"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b73b20fb-ced5-418b-94e2-15846e8ed820">
        <dc:identifier>HP:0040085</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0040085</ddiem:url>
        <rdfs:label>Abnormal plasma aldosterone</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/202110"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/4f8c5fb9-f813-4852-8017-a5f808513f9b"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18458702#</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b60edcb3-25fd-458e-98ab-b10a76176de6"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
  </obo:OGMS_0000112>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/86709fee-3ee6-4b98-8eb4-3771dfce1f6f">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/dd25e73c-ca54-47fa-9e12-d5c3c4e2d769"/>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/3df9bab4-d7df-48ee-8bff-965513d5ff9a">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3955971</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25001633</dc:provenance>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01395641</dc:provenance>
        <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/608643"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/72703028-0152-4c11-a949-9a8334366c2c"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000012"/>
        <rdfs:comment>Consider trial if pyridoxine gives too many side effects or is not effective. Chronic use in high dose can cause severe sensorimotor polyneuropathy. https://www.ncbi.nlm.nih.gov/pubmed/25001633/</rdfs:comment>
        <dc:provenance>https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ab059969-ff51-4629-9190-443b1616eb8f"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3073162</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23494656</dc:provenance>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <rdfs:label>Pyridoxal phosphate</rdfs:label>
    <obo:RO_0000056>
      <obo:DDIEM_0000011 rdf:about="http://ddiem.phenomebrowser.net/1dfd3344-a8d5-49e0-965d-ad4e984f2268">
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/5361854f-7f31-45a0-9196-7a2a5e838318"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12747882</dc:provenance>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01212744</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8757046</dc:provenance>
        <rdfs:comment>The drug was administered through intravitreal injection.</rdfs:comment>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/610090"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26095523</dc:provenance>
        <dc:provenance>https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/35b5c64e-9aaa-46fd-84a3-e5d483d4e101"/>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/72703028-0152-4c11-a949-9a8334366c2c"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
      </obo:DDIEM_0000011>
    </obo:RO_0000056>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00114</ddiem:url>
    <dc:identifier>DB00114</dc:identifier>
  </ddiem:Drug>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/145981">
    <dc:identifier>https://www.omim.org/entry/145981</dc:identifier>
    <rdfs:label>HYPOCALCIURIC HYPERCALCEMIA, FAMILIAL, TYPE II; HHC2</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/ba6d4cfa-e461-433e-8cc7-dcca4e5a9d6a"/>
  </ddiem:Disease>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/8730966e-4392-43d8-a010-c330a210f701">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28590052</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b2e4f205-7ff4-4c00-ab70-a6470c2b131f"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/92d19b97-fbe8-4552-a38b-3e5416a41450">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/2efa34cb-5893-4274-8a72-c583b8a7d5a6"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3940717</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/125700"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15131757</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1316120</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30804055</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26153518</dc:provenance>
    <rdfs:comment>Some patients could only be fully controlled by the combination of chlorpropamide and hydrochlorothiazide.</rdfs:comment>
    <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
  </obo:OGMS_0000112>
  <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/4ab58bc7-6f94-4176-aa41-1cb22a1ad394">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8187613</dc:provenance>
    <rdfs:comment>There is a common note in different reserachs refers to the importance of early managment by Vitamin E supplements since it limits disease progression and it can reverse some of the clinical manifestation (e.x ataxia and the intellectual deficit), if it was interoduced early in life. Therefore, early diagnosis is paramount.</rdfs:comment>
    <dc:provenance>https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17586848</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8317485</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15300460</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/209300"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/548720cd-8d60-4013-929d-3ae3d5d06aeb"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/615eec77-9894-4b4f-9dae-dd98bf04145a"/>
  </obo:DDIEM_0000007>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a1b7a961-3493-4a87-8f04-5d719892c297">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001635</ddiem:url>
    <rdfs:label>Heart failure</rdfs:label>
    <dc:identifier>HP:0001635</dc:identifier>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <obo:DDIEM_0000015 rdf:about="http://ddiem.phenomebrowser.net/a25c7392-7252-4063-9984-d6c21722b5ef">
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/8665770e-d275-4841-8adc-7fc13c4ea20a"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/4c0a9a26-460a-4428-832c-76315509cea9"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24613482</dc:provenance>
    <rdfs:comment>Testosterone therapy needs to be carefully considered because of the risk of hepatic adenomas.https://www.ncbi.nlm.nih.gov/pubmed/28160246
Androgen receptors are expressed in the liver, and androgens can stimulate hepatocyte proliferation. Although rare, androgens have been shown in observational studies to induce adenoma development (Giannitrapani et al. 2006). Testosterone levels should be assessed for response 2â3 months after therapy is initiated.</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17514432</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29223626</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b280332e-7198-436f-8b73-15dbc52c8664"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24509886</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/232400"/>
  </obo:DDIEM_0000015>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ce0d460b-91a7-4e2a-add5-e5af4c177c46">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000712</ddiem:url>
    <dc:identifier>HP:0000712</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>emotional disturbances</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/923ed828-4868-4006-bb14-6f80988f91c0">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>elevated serum toxic intermediates (</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001939</ddiem:url>
    <dc:identifier>HP:0001939</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/5c23f823-6244-46e7-8fd2-e2b17545110e">
    <ddiem:url>https://www.drugbank.ca/drugs/DB03756</ddiem:url>
    <dc:identifier>DB03756</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/2f3e1777-1d5b-46cc-ac1f-505d6eeee66c"/>
    <rdfs:label>Doconexent</rdfs:label>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/bcfc5f9b-3741-4029-a55e-240fb426ac26">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0007663</ddiem:url>
    <rdfs:label>Decreased visual acuity</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0007663</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/0d6f3fa7-b278-4f82-9564-c16d36937da9">
    <ddiem:url>https://www.drugbank.ca/drugs/DB00435</ddiem:url>
    <dc:identifier>DB00435</dc:identifier>
    <rdfs:label>Nitric Oxide</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/7b979497-be15-4f04-879b-dbbf2ca9fbf8"/>
  </ddiem:Drug>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/208920">
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/ea240189-f99d-44f6-bd66-461e5b58a5f8"/>
    <dc:identifier>https://www.omim.org/entry/208920</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>ATAXIA, EARLY-ONSET, WITH OCULOMOTOR APRAXIA AND HYPOALBUMINEMIA; EAOH</rdfs:label>
  </ddiem:Disease>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/c783a08f-d600-4d85-8963-bdcb15cfeaba">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28131618</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22916340</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28381550</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/58250b72-3547-4fc5-9ce4-6143de5e8f5d"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT03021941</dc:provenance>
    <rdfs:comment>Indomethacin was the most effective but can cause gastrointestinal intolerance and decreased eGFR. Amiloride and eplerenone have similar but lower efficacies and increase sodium depletion. The benefit/risk ratio of each drug should be carefully evaluated for each patient.          https://www.ncbi.nlm.nih.gov/pubmed/25012174
Despite a documented effect on hypokalemia, indomethacin and other nonsteroidal anti-inflammatory drugs should be used with caution due to their short- and long-term gastrointestinal side effects and nephrotoxicity.https://www.ncbi.nlm.nih.gov/pubmed/28003083</rdfs:comment>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/3b8a7752-a33a-43df-8697-89f32c0f3e9e"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/230800"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/1472642d-9775-456e-9cfc-5f388428428a">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/8d5d9680-dc88-4573-8997-a163a314b4e6"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/64482499-b03b-44a4-8ed9-0c916e569b8d"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23860343</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21503667</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27499018</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5507263</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/4b44c227-2a35-4378-90d7-84c67e42065f"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30066229</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/fef3599b-79c9-46bd-8aef-a8dfc88e44f9">
        <rdfs:label>low bone marrow fat fraction value</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/results/NCT01422187</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29388611</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27102949</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/129453a0-45bd-46a5-86db-c8c8fa6fffbc"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29471850</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27839981</dc:provenance>
  </obo:OGMS_0000112>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/047ae803-f6e6-4970-8bc1-c71d6d8c93cb">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Abnormal kidney function</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0012211</ddiem:url>
    <dc:identifier>HP:0012211</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c5b8d892-6014-439b-9f47-5ff1aef1ecdf">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002621</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Atherosclerosis</rdfs:label>
    <dc:identifier>HP:0002621</dc:identifier>
  </ddiem:Phenotype>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/ca5ac69a-0cf2-403b-b14f-7f546b262880">
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/302060"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31239752</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/e3a59696-57ee-47c9-98cc-341bc54f1e1d"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18632498</dc:provenance>
    <rdfs:comment>Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23432031</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1956fc85-1470-4df9-9d06-ab9f98dec433">
        <dc:identifier>HP:0005180</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0005180</ddiem:url>
        <rdfs:label>Tricusped incompetence</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3249181</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9f2ca354-7d2c-4aad-87c2-a44dca5e0cb6">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001653</ddiem:url>
        <rdfs:label>Mitral incomptence</rdfs:label>
        <dc:identifier>HP:0001653</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1025545</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/6bb785ef-18d5-4569-a35b-4bb92a45e59e"/>
  </obo:DDIEM_0000013>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/5a4097ab-e110-4e1a-9f15-fbe34bb9432c">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22142470</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/457d96e1-6a3d-4c84-acba-6aca3a1b0e7c"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20495831</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9a9c5740-3cca-4819-baf5-78304c513a08">
        <rdfs:label>high serum ionized calcium concentrations</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003072</ddiem:url>
        <dc:identifier>HP:0003072*</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28833550</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/057054e8-3498-4069-b295-e83a34a3c389"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000012"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/145981"/>
    <rdfs:comment>In individuals with allergies or intolerance to allopurinol, febuxostat may be considered; however, no data on the use of this medication in UMOD-associated kidney disease are available at present.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21289269</dc:provenance>
  </obo:OGMS_0000112>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/06f2a5b6-c0b3-422b-82b6-50857ca84b57">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/55bc9bd2-8784-4f12-9cbd-be0f558e1c6a"/>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/9d36cb46-ef35-4fbe-b892-9fcb1a8e78e9">
    <rdfs:label>Tocopherol</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/08293dea-0a75-4c17-8626-a3f045673225"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB11251</ddiem:url>
    <obo:RO_0000056>
      <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/d75fe523-f669-4b31-8e60-aed6f5ed06cf">
        <rdfs:comment>A combination therapy with cysteamine bitartrate and N-acetylcysteine is associated with delay of isoelectric EEG, depletion of GRODs, and subjective benefits as reported by parents and physicians. https://www.ncbi.nlm.nih.gov/pubmed/24997880</rdfs:comment>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f977a28e-c1d2-4e84-bf3f-2da24ed865af"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f5a42017-cba1-4edb-913f-d75d2dc3a56e"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/256730"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b6bfaa10-0e08-47f3-853d-cd0faff3ae50"/>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00028262</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/0b724f28-e827-4297-a715-fd5a37d544e8"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29631617</dc:provenance>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
      </obo:DDIEM_0000007>
    </obo:RO_0000056>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/bcf92d20-f9e3-4f9b-a583-2ee31adcaeb4"/>
    <dc:identifier>DB11251</dc:identifier>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e375431f-3965-4b53-b6a2-acbe377157fa">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Drug wasn't effective (Insignificant effect)</rdfs:label>
  </ddiem:Phenotype>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/f6f58dd7-20ec-4f56-9e07-53363a43f15e">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11787939</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/245010"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/34db54fc-0e1a-47d9-8054-2473acc37725">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/18276157-ff61-4cd3-8a18-2150cac4692c"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19750228</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/035a8a90-663c-468e-8ac4-4e97dc0dbfea"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25717099</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02534844</dc:provenance>
    <rdfs:comment>One of the studies that was carried on mice provides useful information for developing the optimal dosage regimen for HPBCD therapy when administered intravenously to NPC patients.https://www.ncbi.nlm.nih.gov/pubmed/26027824</rdfs:comment>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/735af7c0-3ade-4bf6-8e5a-cf8d26de569a">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/1a3dcd25-f742-43c4-8229-3cc542a2c4b0"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19415691</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/7be818a5-134f-4c69-bd53-99ffc9f49b7f"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28803710</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21393975</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/6db05be7-670b-423a-b3c2-b20539ad5d6f"/>
  </obo:DDIEM_0000013>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/9f416c86-ef43-4ebb-9d22-5dd14bf71a89">
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/233910"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719208000048</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10078749</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12003346</dc:provenance>
    <dc:provenance>https://link.springer.com/referenceworkentry/10.1007%2F978-3-540-29676-8_1729</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20818608</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19234759</dc:provenance>
    <rdfs:comment>Sodium phenylbutyrate lowers the resynthesis of arginine from ornithine via the urea cycle.https://www.ncbi.nlm.nih.gov/pubmed/24268530</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9c618024-2c5a-4760-b8cc-d83118833ae3">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012048</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>oromandibular dystonia</rdfs:label>
        <dc:identifier>HP:0012048</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/525b07c9-fc63-4fbc-ba39-c86cee1ed4b4"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
  </obo:OGMS_0000112>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/3ba70329-27af-452d-a7e2-d7107dae9287">
    <rdfs:label>GNT0003</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/817d528b-42ff-474d-bfe6-e74fd46bc60c"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/0c9b864d-5111-4161-a145-1e5e677fde9d">
    <ddiem:url>https://www.drugbank.ca/drugs/DB02745</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/ed2710dc-5fa6-473b-8152-c32981c0112f"/>
    <rdfs:label>Uridine</rdfs:label>
    <dc:identifier>DB02745</dc:identifier>
  </ddiem:Drug>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/508a5421-40bd-46dc-b5a9-21fb276a9adf">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24748909</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/01fa8626-809b-4cf3-83c5-08afb82ee344">
        <dc:identifier>HP:0000962</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>hyperkeratosis</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000962</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/92283a16-666b-42aa-9655-42435e5090ce">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0012500</dc:identifier>
        <rdfs:label>verrucous lesions</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012500</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7a30777f-1497-45f2-a55d-ee2fa355c271">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Skin papules</rdfs:label>
        <dc:identifier>HP:0200034</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0200034</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/7be818a5-134f-4c69-bd53-99ffc9f49b7f"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f930d75a-09c7-4a99-a4f9-a73448b3cd43">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Mucosal lesions</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28681064</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23259080</dc:provenance>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/247100">
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/5fb18f2f-4e68-44ed-91c4-34685738b771"/>
        <rdfs:label>LIPOID PROTEINOSIS OF URBACH AND WIETHE</rdfs:label>
        <dc:identifier>https://www.omim.org/entry/247100</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Disease>
    </obo:RO_0002599>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:comment>A low fat regimen was added to metformin while treating the patient.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28720532</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f23a4135-6049-42fd-8a30-b50362d2dd2d">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001609</ddiem:url>
        <rdfs:label>Hoarseness</rdfs:label>
        <dc:identifier>HP:0001609</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a22176ac-403e-49db-bfef-e41ce97b9cb4"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d9b15a98-340c-4ce8-90f1-e24207a9147e"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17339125</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18808438</dc:provenance>
  </obo:DDIEM_0000013>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/5e44101a-c1fd-434f-8470-59cc5e8446a6">
    <rdfs:label>AAV2 /1-mSeAP-propmyoD76A</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/fe436429-2571-4a8b-8a15-bb8957167380"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/e3435067-bbc9-4cab-bca0-67cefcd6b816">
    <rdfs:label>Canakinumab</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB06168</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/b75d90ae-08f6-435b-90f3-bec6b002ed43"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/8697a6fb-ff5a-4d56-b1ba-2ae1deecaa5f"/>
    <dc:identifier>DB06168</dc:identifier>
  </ddiem:Drug>
  <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/9cca75b4-333b-4064-b645-c297f95a4899">
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/602541"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1059131117301243</dc:provenance>
    <rdfs:comment>In a different study IV administration of Glucose wasn't effective.https://www.ncbi.nlm.nih.gov/pubmed/22238410</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26006750</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/books/NBK1520</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/c7568be9-e6b5-4e41-9ee1-202e43e5338f"/>
    <dc:provenance>https://link.springer.com/article/10.1007/s11940-011-0131-z</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a4a51327-9207-48cb-bc0e-54fe83c8682d">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003287</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0003287*</dc:identifier>
        <rdfs:label>Neurological disorder of mitochondrail dysfunction(mitochondrail dysfunction)*</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </obo:DDIEM_0000007>
  <obo:DDIEM_0000015 rdf:about="http://ddiem.phenomebrowser.net/c4a9165d-f343-4ef3-8373-0bcdcabb8c58">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/de20b7ee-2992-429b-a04a-1135b4bb2f98">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000722</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Obsessive-compulsive behavior</rdfs:label>
        <dc:identifier>HP:0000722</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/8b8142a8-4b90-4d8d-99fa-e7646f88aff9"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/3580d7a6-00c7-40dd-ad0b-525b8b4366d8"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12084887</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11346370</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8163996</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16361586</dc:provenance>
    <rdfs:comment>Topical retinoic acids, topical steroids, hydroquinone, tretinoin, and systemic retinoids have been used without success. https://www.ncbi.nlm.nih.gov/pubmed/2350982
https://www.ncbi.nlm.nih.gov/pubmed/3679816 https://www.ncbi.nlm.nih.gov/pubmed/29797344

Combination of Q-switched Nd: YAG and Fractional Carbon Dioxide Laser could be a promising therapy to pigmentation of Dowling-Degos diseaseÂ  https://www.ncbi.nlm.nih.gov/pubmed/28529428</rdfs:comment>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/128230"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1899474</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16891685</dc:provenance>
  </obo:DDIEM_0000015>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/2e8910cc-790b-474e-b7d6-9c77b57adebf">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/5ac147b6-62f4-4845-875c-35a61a14f007"/>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/03cd91e6-acaa-4034-83f1-86495fb4e3f3">
    <dc:identifier>DB04272</dc:identifier>
    <rdfs:label>Citric acid</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/c993d639-43fd-4972-a973-28de88950889"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB04272</ddiem:url>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/445544bc-da44-44a9-9208-c9b10f60b8a1">
    <dc:identifier>DB00282</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00282</ddiem:url>
    <rdfs:label>Pamidronic acid</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/32648543-f652-406a-87f0-84dc388ff1f7"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/02c0c401-8c22-4028-89cb-c658990a902b">
    <dc:identifier>DB09115</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/2ccbbc1a-a417-4a68-9c23-f6e5e28044f8"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB09115</ddiem:url>
    <rdfs:label>Diiodohydroxyquinoline</rdfs:label>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/dfd10d54-aae4-4804-9f08-f915a2c39e38">
    <rdfs:label>abnormal hepatic function tests</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002910</ddiem:url>
    <dc:identifier>HP:0002910</dc:identifier>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d5004306-17d4-4626-a632-5fca1c40f1bf">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000708</ddiem:url>
    <rdfs:label>Psychiatric disturbance</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0000708</dc:identifier>
  </ddiem:Phenotype>
  <obo:DDIEM_0000011 rdf:about="http://ddiem.phenomebrowser.net/4f4df79f-74ae-413d-aacf-e030c6b1da72">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22832064</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/4830e73a-2ac3-44c6-8ad5-c12948c22932"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/85ce138a-16dc-40c9-9eda-341dcb523a31"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/c4633604-cb41-4d90-84d5-44841bde9fef"/>
    <rdfs:comment>Effect of glycine in treating the condition is variable among literatures.  "Case reports have noted variable results regarding the effect of glycine administration. Some studies have found that supplemental glycine results in increased excretion of 3-methylcrotonyl glycine, while others have not found a persistent effect; no studies have observed clinical improvement of symptoms on treatment and no randomized clinical trials have been published" https://www.sciencedirect.com/science/article/pii/S1096719207005975?via%3Dihub#bib11
https://www.ncbi.nlm.nih.gov/pubmed/8831079
https://www.ncbi.nlm.nih.gov/pubmed/7474896</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12003346</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/c576bad9-b514-49c9-a2f8-c639d5e8fd3f"/>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23690520</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/261640"/>
    <dc:provenance>https://www.babysfirsttest.org/newborn-screening/conditions/3-methylcrotonyl-coa-carboxylase-deficiency</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19323589</dc:provenance>
  </obo:DDIEM_0000011>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/74c58ee6-583c-4c05-8b29-3c48a3b02245">
    <rdfs:label>Rotigotine</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/019c1890-a005-434d-937a-ca6f4baf3a1a"/>
    <dc:identifier>DB05271</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB05271</ddiem:url>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/ef084c4b-8daa-4216-bf61-9b96f7574128">
    <ddiem:url>https://www.drugbank.ca/drugs/DB13959</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/b54fba15-926e-47f6-bb82-a05bdbd32ced"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/44ca9cc9-d1c4-4a37-8fd8-244d0b22273d"/>
    <rdfs:label>Medium-chain triglycerides</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/d5d84a94-628a-4330-9ac0-dd81019862c2"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/a42fb22b-0839-4075-99c6-48d453862fe2"/>
    <dc:identifier>DB13959</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/6432703a-595f-4b25-8db8-024a899dc48c"/>
    <obo:RO_0000056>
      <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/c4180802-a8e3-4242-8fb4-21b8545cf71a">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0929693X16302044</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6169684</dc:provenance>
        <rdfs:comment>"Oral tocofersolan was more bio available than the water-soluble formulation in children with chronic cholestasis and similarly bio available in CF. This suggests that water-soluble vitamin E may represent an alternative to painful intramuscular vitamin E injections in chronic cholestasis, or other oral formulations in CF. However, the mechanism responsible for fat malabsorption in CRD concerns the absorptive phase as opposed to the digestive phase in CF and cholestatic syndromes. To our knowledge, no specific studies with these new vitamin E preparations have been conducted in CRD." https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717/</rdfs:comment>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f17eac09-dffe-464c-b40b-b5af8d2d5da7"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ee36264b-0445-4c6b-9b29-2bf96a526985"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4223155</dc:provenance>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/c148d200-9479-4b6a-a50f-1e30c7044a3f"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21102543</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22832289</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/246700"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23329770</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/732dff93-80b6-436f-bb35-dd701bcb6919"/>
      </obo:DDIEM_0000013>
    </obo:RO_0000056>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/b74773b2-06fe-48e2-9f59-bf2599c059a3"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/bf3a8e1e-5272-4998-8c1b-1dd583be7df8"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/0a19657b-11c8-4e4e-b80e-edbbd3cab970"/>
  </ddiem:Drug>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/a6e5c923-73c2-49e1-b70c-c4f2117f0996">
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/300438"/>
    <dc:provenance>https://www.semanticscholar.org/paper/Clinical-Diagnosis-and-Treatment-of-Dehydrogenase-A-Cui-Wang/f6e88d647f2e2c7df2897e939ec33f9d86899b37</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11102558</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/404c382f-7439-4041-b8fd-bad9d82109c5"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/50373d3b-99ee-4009-abff-ff795a004a58">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/6fadbc84-61b4-497e-9eaa-f5b824eafe06"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0303846712003952</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22840416</dc:provenance>
    <rdfs:comment></rdfs:comment>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
  </obo:OGMS_0000112>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ace9b1fb-7f92-4b61-a04b-72adbeaa57ec">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0004359</ddiem:url>
    <dc:identifier>HP:0004359</dc:identifier>
    <rdfs:label>abnormal fat metabolism</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d377d68f-7274-4a1f-91a9-47055273f96d">
    <rdfs:label>Dyskinesia</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0100660</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0100660</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/bc3e4180-e592-4ef1-b398-404c1a884ea8">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>abnormal microtubule assembly</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d77ccceb-eaa6-413b-8db8-ae63022fc6ea">
    <rdfs:label>Decreased body mass index</rdfs:label>
    <dc:identifier>HP:0045082</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0045082</ddiem:url>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/2853a523-e834-4c4a-9525-84646aa37f6e">
    <ddiem:url>https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI_26537</ddiem:url>
    <obo:RO_0000056>
      <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/64367b8d-fc69-4e2f-b358-74fd5c810cc2">
        <dc:provenance>NCT00744042.)."</dc:provenance>
        <rdfs:comment>Drug name: Treatment is under trial.</rdfs:comment>
        <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
        <dc:provenance>an enzyme-replacement therapy</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ee9b5128-d837-4f67-9f4e-8401a7835863"/>
        <dc:provenance>https://www.researchgate.net/publication/8668575_A_successful_treatment_with_pyridoxal_phosphate_for_West_syndrome_in_hypophosphatasia</dc:provenance>
        <dc:provenance>was associated with improved findings on skeletal radiographs and improved pulmonary and physical function in infants and young children with life-threatening hypophosphatasia. (Funded by Enobia Pharma and Shriners Hospitals for Children; ClinicalTrials.gov number</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29392821</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5096504</dc:provenance>
        <dc:provenance>"ENB-0040</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/308050"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/2358abbd-c070-417f-a985-0cc492b6ef0c"/>
      </obo:DDIEM_0000013>
    </obo:RO_0000056>
    <dc:identifier>CHEBI_26537</dc:identifier>
    <rdfs:label>retinoid</rdfs:label>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/f14eae07-de43-4384-ab54-270750e177d1">
    <dc:identifier>DB09130</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/022c27f6-c878-4542-8819-54953a5e3254"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB09130</ddiem:url>
    <rdfs:label>Copper</rdfs:label>
  </ddiem:Drug>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/0bcd37d6-b35a-4e26-96ca-e8db74aaf588">
    <rdfs:comment>Selection of this drug combinstion ""Methylprednisolone sodium succinate +
Immune Globulin "" was based on the presumption that the patient had autoimmune encephalopathy. https://www.ncbi.nlm.nih.gov/pubmed/25511120</rdfs:comment>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/bbd8b019-61c4-4c26-b662-d48f9377d392"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25511120</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/4545c674-c3f0-46ca-9286-b2a815b064de"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8f2513b2-6a40-4500-97f6-cb9403d2fe96">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001298,HP_0002960</ddiem:url>
        <rdfs:comment>Doctors prescribed these drugs combination""Methylprednisolone sodium succinate +
Immune Globulin "" as they presumed that the patient had autoimmune encephalopathy. https://www.ncbi.nlm.nih.gov/pubmed/25511120</rdfs:comment>
        <rdfs:label>Autoimmune encephalopathy(Encephalopathy)*,(Autoimmune disorder)*</rdfs:label>
        <dc:identifier>HP:0001298*,HP:0002960*</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/277400"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3950820</dc:provenance>
    <dc:provenance>https://link.springer.com/article/10.1023/A:1005353530303</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19821145</dc:provenance>
  </obo:OGMS_0000112>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/8badbb2a-2bd8-4dfb-8de3-f660cd927058">
    <rdfs:label>Galactose</rdfs:label>
    <dc:identifier>DB11735</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/19232490-fa0b-448a-8fd8-fcb126bfdedc"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/a5f80368-a5ab-4e33-bd31-c1d6be08bf49"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB11735</ddiem:url>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/328cca9e-db93-4544-b87d-172410b626d6">
    <dc:identifier>DB00860</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00860</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/81f520eb-74e5-4cac-8040-b53e9eacb0f0"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/20509ec1-bb30-49b4-a8ab-6b091544aadd"/>
    <rdfs:label>Prednisolone</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/759fd62a-4cb6-4c6e-80f6-c02d9d30fa9b"/>
  </ddiem:Drug>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/fe641f47-9196-421c-9ed9-e373bb1ab120">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25288127</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1719175</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1709246</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19066956</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f1330ea5-29c1-47d4-95b5-cab8823e4b15"/>
    <rdfs:comment>Long-term use of GCSF is associated with complications such as hypersplenism and malignancy. https://www.ncbi.nlm.nih.gov/pubmed/26835382</rdfs:comment>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/232220"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/d70004cc-b749-443b-93a9-3be5f4683494"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e193387f-b9ef-4913-877f-8cbff03660de"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8447561</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/cb40e28f-cc65-4e8a-ab4f-51e53eac530c"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26835382</dc:provenance>
  </obo:DDIEM_0000013>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1d498848-bc67-4b67-bc99-fa3ed972c469">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Enlarged lysosomes in NCL NSCs and fibroblasts (Abnormality of lysosomal metabolism)*</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0004356</ddiem:url>
    <dc:identifier>HP:0004356*</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/9cefedc4-c24c-49db-b23f-071fd0448346">
    <ddiem:url>https://www.drugbank.ca/drugs/DB00005</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/976a3d86-ed87-4a9b-bb1e-32542d3aacdd"/>
    <rdfs:label>Etanercept</rdfs:label>
    <dc:identifier>DB00005</dc:identifier>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/9e76f120-24a8-4513-8870-840fcc3af20c">
    <dc:identifier>DB11563</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB11563</ddiem:url>
    <rdfs:label>Sebelipase alfa</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/f0d77e34-8d80-439f-969f-3404d519f8a7"/>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e7f7d494-668a-416a-a291-ff8a51be51e5">
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0031377</ddiem:url>
    <rdfs:label>Abnormal cellular proliferation</rdfs:label>
    <dc:identifier>HP:0031377</dc:identifier>
  </ddiem:Phenotype>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/5e6f6120-18c5-49ed-ad8f-043d0c0bafba">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/0a65c7bf-ba73-4e38-8f89-10ddf07e5b40"/>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/da53e565-a617-4285-8743-677e2bc2568a">
    <ddiem:url>https://www.drugbank.ca/drugs/DB00458</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/bb6c4fe8-8e23-4788-964c-2c4b7bd9cc5d"/>
    <rdfs:label>Imipramine</rdfs:label>
    <dc:identifier>DB00458</dc:identifier>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/becd1919-f003-4f5a-ad3f-c3309585bb59">
    <rdfs:label>AAV-based gene therapy</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/2af1f93f-b53a-4db9-9420-4d84dfabd82a"/>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a557ad47-6ae9-46df-a282-57262d587828">
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0002749</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002749</ddiem:url>
    <rdfs:label>bone weakness</rdfs:label>
  </ddiem:Phenotype>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/3623de04-06af-425a-a4e4-879d011f3d99">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25511120</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17431913</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d5004306-17d4-4626-a632-5fca1c40f1bf"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/277400"/>
    <rdfs:comment>Selection of this drug combinstion ""Methylprednisolone sodium succinate +
Immune Globulin "" was based on the presumption that the patient had autoimmune encephalopathy. https://www.ncbi.nlm.nih.gov/pubmed/25511120</rdfs:comment>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://link.springer.com/article/10.1023/A:1005353530303</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19821145</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/72335a61-7f79-462c-87be-fe5a1ccb8243"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3950820</dc:provenance>
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
  </obo:DDIEM_0000013>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/7cb3be2c-0a89-4176-b2c8-2d07975753f6">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1801793</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/278000"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/73d8dfc1-8430-4c1a-8553-6dcc061f9109"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/efec2f9a-a4e4-4740-995f-09b674867b49"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/c1ba99ab-cc06-4a3f-8f61-65a683c970c2"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1521691810001101</dc:provenance>
    <rdfs:comment>Treatment success with statins has been mixed.</rdfs:comment>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/572fa1a7-378b-43af-af3b-8be975ce6911"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23432031</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28804516</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29374495</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31239752</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
  </obo:OGMS_0000112>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/02ca5475-d96a-4956-b783-9bc9d602d5a2">
    <dc:identifier>DB00593</dc:identifier>
    <rdfs:label>Ethosuximide</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00593</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/aa032ac9-071a-434c-88d2-324e689795ad"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/d592df82-5707-4b00-a919-1af9f54f6b4e">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/69c52cfa-07d3-4f71-9102-d5526f8712fa"/>
    <rdfs:label>Ad-mG6Pase</rdfs:label>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1009cd0f-b0d9-4ba6-8d42-18d63b35caeb">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003800</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Muscle abnormality related to mitochondrial dysfunction</rdfs:label>
    <dc:identifier>HP:0003800</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7a73f54d-09e8-4425-8e2e-9e85119166de">
    <rdfs:comment>lifelong and diligent cysteamine therapy prevents hypothyroidism, enhances growth, depletes muscle parenchyma of cystine, and prevents a host of nonrenal complications</rdfs:comment>
    <dc:identifier>HP:0000821</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000821</ddiem:url>
    <rdfs:label>hypothyroidism</rdfs:label>
  </ddiem:Phenotype>
  <obo:DDIEM_0000015 rdf:about="http://ddiem.phenomebrowser.net/623818b5-0ad1-470d-af86-e9dc06a586b5">
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5451251</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/4744026</dc:provenance>
    <rdfs:comment>These inconsistent results have suggested that the response might depend on the specific gene mutations
 As the response was not sustained and serum ALP and PLP and urine PEA returned to baseline between 8 and 13 months of treatment 
In N461L mutation which led to complete disappearance of the bone isoenzyme, disease was not modified by PTH treatment.  

https://www.ncbi.nlm.nih.gov/pubmed/22218563?dopt=Abstract
https://www.ncbi.nlm.nih.gov/pubmed/20089612?dopt=Abstract (Lack of sustained response to teriparatide in a patient with adult hypophosphatasia_</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18308659</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01406977</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f110ca01-418d-4f4b-a6a7-2b0f0192dac2">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0004349</ddiem:url>
        <dc:identifier>HP:0004349</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>low bone mineral density</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/45d6e372-5769-4625-a3ad-1f7cc48d46af">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>low bone formation biomarkers</rdfs:label>
        <dc:identifier>HP:0031429</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0031429</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a557ad47-6ae9-46df-a282-57262d587828"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19415691</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/241500"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25717099</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/cead6ea1-4a22-4b77-b7e3-c1ad35610ea4">
        <dc:identifier>HP:0002757</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002757</ddiem:url>
        <rdfs:label>bone fructure</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9110486</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/d0c59a8e-33f8-486e-a2ec-a552e7037822">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/944123b4-3a2e-49ec-a6f7-2066bd874578"/>
      </rdf:Alt>
    </obo:RO_0000057>
  </obo:DDIEM_0000015>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a22cab46-b0a0-4e03-b3af-06061b44fcd2">
    <dc:identifier>HP:0040134</dc:identifier>
    <rdfs:label>elevated liver iron concentration</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0040134</ddiem:url>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/36baf10e-8a8e-4509-96c3-dd412480c1ca">
    <rdfs:label>Ad5/CMV/hUG-Br1</rdfs:label>
    <obo:RO_0000056>
      <obo:direct_complementation_of_a_genetically_defective_protein_by_gene_therapy rdf:about="http://ddiem.phenomebrowser.net/db389ec6-168a-45fd-8781-60376077961a">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9156798</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/218800"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9525311</dc:provenance>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15726662</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583863</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15753292</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/32c8321a-ae48-463f-976f-b3142d42f2d5"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/145434e3-5330-4a0b-a874-7a048b64936a"/>
        <rdfs:comment>Information about the Study can be ound in https://gmoinfo.jrc.ec.europa.eu/bsnifs-gmo/B-NL-17-001.pdf</rdfs:comment>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3306242</dc:provenance>
      </obo:direct_complementation_of_a_genetically_defective_protein_by_gene_therapy>
    </obo:RO_0000056>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e652b778-e20e-4611-b3ad-455d936fa919">
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001112</ddiem:url>
    <rdfs:label>Abnormal retinal ganglion cell function</rdfs:label>
    <dc:identifier>HP:0001112</dc:identifier>
  </ddiem:Phenotype>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/123038b3-c566-46f4-9faf-97498a191b90">
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/230650"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26766614</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/fdc1c016-b0bd-485a-92b8-cc84eb663a27">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>elevated intraneuronal cholesterol</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>The mechanisms of its effects in movement disorders are not well understood but probably reflect an increase in synthesis and release of dopamine, with perhaps some inhibition of dopamine uptake.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19750228</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/18b5d3e6-5afc-447f-8785-65333ada2934">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>CD failed to ameliorate cholesterol or glycosphingolipid storage in GM1 gangliosidosis</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.tandfonline.com/doi/full/10.3109/0886022X.2014.900422</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/7d11f64a-c733-4317-be41-2350f6066b48"/>
  </obo:OGMS_0000112>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/27fca403-ba5b-4d68-a853-16724148481f">
    <dc:identifier>HP:0012649</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0012649</ddiem:url>
    <rdfs:label>Increased inflammatory response</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/50140c96-69da-4226-bb8c-e69e321cc7dd">
    <dc:provenance>https://link.springer.com/article/10.1007/s11940-011-0131-z</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b2e722ac-ef7a-428c-9e80-5a2a05c4a830"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15184894</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/253280"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1059131117301243</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/771666f5-dccc-4d6d-bdd9-8158f1ab0f07"/>
    <rdfs:comment>In a different study IV administration of Glucose wasn't effective.https://www.ncbi.nlm.nih.gov/pubmed/22238410</rdfs:comment>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/books/NBK1520</dc:provenance>
  </obo:DDIEM_0000007>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f977a28e-c1d2-4e84-bf3f-2da24ed865af">
    <rdfs:label>Lysosomal enlargment (Abnormality of lysosomal metabolism)*</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0004356</ddiem:url>
    <dc:identifier>HP:0004356*</dc:identifier>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d775e028-28b4-423c-86cc-ade0a57ad28e">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>skin thickening</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0100725</ddiem:url>
    <dc:identifier>HP:0100725</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c9fda279-6846-43e7-852e-e36ca6b91738">
    <dc:identifier>HP:0001941</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001941</ddiem:url>
    <rdfs:label>Acidemia</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/71543ac5-30b8-46df-b5a4-ca29272703a4">
    <rdfs:label>Beneprotein</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/3c113f3c-dd11-4c18-a658-90d2d1c7523a"/>
  </ddiem:Drug>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/236795">
    <rdfs:label>3-HYDROXYISOBUTYRIC ACIDURIA</rdfs:label>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/f08e7764-f73f-4558-91e7-093628ea759d"/>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>https://www.omim.org/entry/236795</dc:identifier>
  </ddiem:Disease>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/8ca9b146-5a58-4e7a-af60-ba0a8f8deab6">
    <rdfs:label>Isocarboxazid</rdfs:label>
    <dc:identifier>DB01247</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01247</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/26836019-e54b-4483-9790-601c42abce1e"/>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/35566c62-5c89-4437-bc21-3f5a674bf216">
    <dc:identifier>HP:0001943</dc:identifier>
    <rdfs:label>https:,www.ncbi.nlm.nih.gov,pubmed,19336674</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001943</ddiem:url>
  </ddiem:Phenotype>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/68261cc2-d661-4e7c-ade2-c852bb44acae">
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/269920"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/2cfb7d15-e552-4856-9f51-5e82353f1056"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT03726996</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19627167</dc:provenance>
    <rdfs:comment>In the clinical trial: The trial is not enrolling by invitation, no results have been posted yet. update by Oct.7th 2019
Authors have stated that "The data indicate that the retromer and sphingolipid metabolism play a critical role in PLA2G6-associated diseases. These observations may be relevant to Parkinson disease (PD) given that loss of vps35 or gain of Î±-Syn also affects retromer function and causes ceramide accumulation." https://www.ncbi.nlm.nih.gov/pubmed/29909971</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23887143</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00125190</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20301643</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17192294</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10549306</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24639006</dc:provenance>
  </obo:OGMS_0000112>
  <obo:direct_complementation_of_a_genetically_defective_protein_by_gene_therapy rdf:about="http://ddiem.phenomebrowser.net/99e11061-edcb-4d54-8d91-d2d5d2e25f71">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/11234729-7251-4902-8d13-a61332dc3bab">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/529e6ded-cfc8-4f87-8e3a-e18892a5a1b8"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/204500"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24938720</dc:provenance>
    <rdfs:comment>A combination therapy of Î´-tocopherol and HPBCD further improved the effect compared to that of either drug used as a single therapy.</rdfs:comment>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28589525</dc:provenance>
    <dc:provenance>https://emedicine.medscape.com/article/1178391-treatment</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01907087</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01161576</dc:provenance>
  </obo:direct_complementation_of_a_genetically_defective_protein_by_gene_therapy>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/46252de6-1c27-4993-9d9d-9e6630124c08">
    <dc:identifier>DB03485</dc:identifier>
    <rdfs:label>Alpha-D-Fucose</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/01267a92-1124-4e3b-adb8-f40b53ac7344"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB03485</ddiem:url>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/49a82ce1-00ef-4653-9d0f-710f6fe5b751">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/4bd63489-0eb9-4b08-84db-222a2994f5c5"/>
    <dc:identifier>DB03256</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB03256</ddiem:url>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/bc68f73c-e3e1-40ea-adb5-cd7f70a0b271">
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/261640"/>
        <rdfs:comment>It's an investigational therapy where Positive results from using a selective monoamine oxidase (MAO) B inhibitor or non-ergot dopamine agonist pramipexole as an adjunct therapy have been described in the medical literature. This use of such an inhibitor can allow for lower doses of neurotransmitter precursor to be used. However, the long-term safety (e.g. effects on neonatal brain development) and effectiveness of this therapy is unknown and more research is required to determine what role, if any, selective monoamine oxidase B inhibitors play in the treatment of individuals with tetrahydrobiopterin deficiency. https://rarediseases.org/rare-diseases/tetrahydrobiopterin-deficiency/. https://www.researchgate.net/publication/233414693_Deprenyl_in_6-Pyruvoyl_Tetrahydropterin_Synthase_Deficiency. https://www.degruyter.com/downloadpdf/j/pteridines.1995.6.issue-3/pteridines.1995.6.3.144/pteridines.1995.6.3.144.pdf</rdfs:comment>
        <dc:provenance>https://www.babysfirsttest.org/newborn-screening/conditions/3-methylcrotonyl-coa-carboxylase-deficiency</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/f60f7003-670c-4239-89f8-4ac59b0b1ead"/>
        <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8864759</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b136b220-6994-45d0-8d2a-05c601c4dea2"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12003346</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://rarediseases.org/rare-diseases/tetrahydrobiopterin-deficiency</dc:provenance>
        <dc:provenance>https://www.researchgate.net/publication/233414693_Deprenyl_in_6-Pyruvoyl_Tetrahydropterin_Synthase_Deficiency</dc:provenance>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <rdfs:label>(6R)-Folinic acid</rdfs:label>
  </ddiem:Drug>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/2668e0f0-2101-40b0-9bdd-705720370fcb">
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00962260</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/230800"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00705939</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28381550</dc:provenance>
    <rdfs:comment>Indomethacin was the most effective but can cause gastrointestinal intolerance and decreased eGFR. Amiloride and eplerenone have similar but lower efficacies and increase sodium depletion. The benefit/risk ratio of each drug should be carefully evaluated for each patient.          https://www.ncbi.nlm.nih.gov/pubmed/25012174
Despite a documented effect on hypokalemia, indomethacin and other nonsteroidal anti-inflammatory drugs should be used with caution due to their short- and long-term gastrointestinal side effects and nephrotoxicity.https://www.ncbi.nlm.nih.gov/pubmed/28003083</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29471850</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/2aa5c45c-0604-4694-9173-266bdb2d09b3"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27499018</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/results/NCT00376168</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21503667</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/8ef44a5f-00f5-478b-9397-572155b57824"/>
  </obo:OGMS_0000112>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6ea7ea5d-702a-4935-9bca-ab603ce82e1d">
    <dc:identifier>HP:0001367</dc:identifier>
    <rdfs:label>Joint disesae</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001367</ddiem:url>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/77969c1a-2b27-4276-a7c6-b79ae7fa9d53">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/92d0426c-451d-4509-a12b-7de1a788ba88"/>
    <rdfs:label>Acitretin</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/508a5421-40bd-46dc-b5a9-21fb276a9adf"/>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/0510924f-b5f4-443b-a11a-a6d9f8f6363f">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19750228</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28803710</dc:provenance>
        <rdfs:comment>One of the studies that was carried on mice provides useful information for developing the optimal dosage regimen for HPBCD therapy when administered intravenously to NPC patients.https://www.ncbi.nlm.nih.gov/pubmed/26027824</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2897870</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/7be818a5-134f-4c69-bd53-99ffc9f49b7f"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/035a8a90-663c-468e-8ac4-4e97dc0dbfea"/>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02534844</dc:provenance>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/245010"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19415691</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11787939</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25717099</dc:provenance>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <dc:identifier>DB00459</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00459</ddiem:url>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/db95ffb7-1fff-4344-8468-e7a3060cd676">
    <dc:identifier>DB12907</dc:identifier>
    <rdfs:label>Mannose</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/7a350ec8-bb3e-4e7c-87e0-2a7eebf6f08d"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB12907</ddiem:url>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4d1fe024-ca8a-40d1-b8ed-47652b3bacb5">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0040306</ddiem:url>
    <rdfs:label>decreased male libido</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0040306</dc:identifier>
  </ddiem:Phenotype>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/54abc5fd-235b-409b-bcbb-2c86cf1d3927">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28057010</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20301535</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/222700"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/fe677961-c0b0-4bff-9414-4510de13c516"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25859380</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23430827</dc:provenance>
    <rdfs:comment>The regimen was accomapanied with a protein-restricted diet. https://www.ncbi.nlm.nih.gov/pubmed/27567650</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27567650</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
  </obo:OGMS_0000112>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/df9628ff-0639-4dd4-88b2-9d9be7cf7a3c">
    <dc:identifier>HP:0000867</dc:identifier>
    <rdfs:label>secondary hyperparathyrodism</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000867</ddiem:url>
  </ddiem:Phenotype>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/d730af56-9761-4404-a75a-c8ffc4306093">
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31434105</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20356773</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31196723</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/78263499-ba82-4644-89d5-571742504995">
        <dc:identifier>HP:0012759</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012759</ddiem:url>
        <rdfs:label>Developmental abnormality</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31211405</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/514daef5-2da7-43bf-9104-76f2c9142713">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/2d4193b6-7b1f-493c-bd5d-2c3ac8a68f9f"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/eb5152ff-7294-4a87-a512-7b1cec024750"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30755342</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/603174"/>
    <rdfs:comment>Due to prenatal diagnosis ofthe patient, early treatment with B vitamins and betaine had a favorable outcome. https://www.ncbi.nlm.nih.gov/pubmed/20356773</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30081189</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00638547</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31082797</dc:provenance>
  </obo:OGMS_0000112>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/50c136bb-55e9-46e6-90e0-2aeb7904961c">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/8b05f86c-86f4-44cc-8f62-bdb8d6f02387"/>
    <dc:identifier>DB00213</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00213</ddiem:url>
    <rdfs:label>Pantoprazole</rdfs:label>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/6430a8d3-e88e-4db9-bdac-d9e61314044b">
    <ddiem:url>https://www.drugbank.ca/drugs/DB04263</ddiem:url>
    <rdfs:label>Geneticin</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/82b054ec-356e-4ba7-90ec-9446b0dbef75"/>
    <dc:identifier>DB04263</dc:identifier>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b9dcf6b9-e742-496d-8df3-e6e4326dad97">
    <rdfs:label>"No remarkable clinical improvement was observed and therefore, treatment was discontinued"</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/44fc10d8-d6b5-4b7f-85b3-459c8e9c4e74">
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/c659dc72-db4f-4b3c-867a-2d655336fcdb"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23884489</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26979527</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <rdfs:comment>The drug resulted in significant reduction of  both plasma PPIX and hepatic PPIX in a murine animal model but no effect in humans during clinical trial. thus, These results demonstrate that while INH can lower PPIX in an animal model of EPP, the standard dose used to treat TB is insufficient to affect levels in humans. https://www.ncbi.nlm.nih.gov/pubmed/31395332</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22092997</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a6c54fee-ebd7-419f-9ad1-27a1c494ae64"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31395332</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/177000"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00004940</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02979249</dc:provenance>
  </obo:DDIEM_0000013>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/f92241e7-3a9d-46e1-8e0d-d326408f934d">
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/1fb56fa2-ab65-4363-b8cd-378e44d0f43d">
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/a3bd3126-e986-4724-812f-9db116cef123"/>
        <dc:identifier>C03</dc:identifier>
        <ddiem:url>https://www.whocc.no/atc_ddd_index/?code=C03</ddiem:url>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/99e0db6e-f3c9-4992-bc20-33bdc8c75c8e"/>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/acac8c6f-cb7a-4997-a332-e8ecee2f6927"/>
        <rdfs:label>DIURETICS</rdfs:label>
      </ddiem:Drug>
    </rdf:li>
  </rdf:Alt>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3b12e910-9473-4fae-9294-fe5161e721bf">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0011025</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>cardiac dysfunction</rdfs:label>
    <dc:identifier>HP:0011025</dc:identifier>
  </ddiem:Phenotype>
  <owl:Class rdf:about="http://purl.obolibrary.org/obo/metabolic_disease_treatment">
    <rdfs:label xml:lang="en">metabolic disease treatment</rdfs:label>
    <obo:IAO_0000115 xml:lang="en">a treatment strategy or plan which the clinician beleives will cure or ameliorate a disease caused by a deleterious genetic variation in a patient, affecting their metabolism. It may modify some or all of its signs or symptoms, or alter the prognosis and course of the disease, either by severity, timecourse or phenotypic quality.</obo:IAO_0000115>
    <dc:creator xml:lang="en">https://orcid.org/0000-0002-5111-7263</dc:creator>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
  </owl:Class>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/db6bd57d-0841-4c91-9a96-19be27dd7842">
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/6ea9febb-d075-4c7a-bd74-a07a85bb0412">
        <dc:identifier>DB00321</dc:identifier>
        <ddiem:url>https://www.drugbank.ca/drugs/DB00321</ddiem:url>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/ac49d299-c683-4626-aede-48babc62c2d6"/>
        <rdfs:label>Amitriptyline</rdfs:label>
      </ddiem:Drug>
    </rdf:li>
  </rdf:Alt>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/56ad9674-86c0-401f-b038-cae5cfe6cbd1">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002097</ddiem:url>
    <dc:identifier>HP:0002097</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Progressive emphysema</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/203cdf74-876f-4478-9f4a-ddc684815990">
    <ddiem:url>https://www.drugbank.ca/drugs/DB00053</ddiem:url>
    <rdfs:label>Imiglucerase</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/8dbc6d40-b260-4f09-97a5-45691fe6bd2a"/>
    <dc:identifier>DB00053</dc:identifier>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a3d11a42-bba2-4264-8412-5058f26b2489">
    <rdfs:label>high plasma ferritin</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003281</ddiem:url>
    <dc:identifier>HP:0003281</dc:identifier>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/755d96ad-dc48-4266-bc82-d181d22b9e6f">
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0025142</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0025142</ddiem:url>
    <rdfs:label>low physical activity</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/450aeff4-e097-4eb5-83c7-6dd75cfc1fde">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/08de229f-8872-483a-9b95-0c9b0bf67ba9"/>
    <rdfs:label>Leucovorin</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/b0c9486a-d200-4e8d-815a-af6ada04370d"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/2950fb95-de9d-4907-bd00-c5446322db59"/>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/275abf50-2eae-4636-9165-ad2110262bb0">
        <rdfs:comment>MCT should be at least 70% of the total fat content of the diet.</rdfs:comment>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/1e9f4dcf-871e-4d53-84e3-ef1e040f5359"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28318733</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/530000"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a8b875fc-c819-4224-8757-195f15769f4e"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/e26f58c5-3e77-453b-8c30-5df2c9c700e9"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16365882</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/1b24759d-8982-4bfa-ad9b-db425e331d2e"/>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/13535eeb-5cfc-4e79-80d5-76e5f65b05ea"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00650</ddiem:url>
    <dc:identifier>DB00650</dc:identifier>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0b21626b-db68-48a4-b6f7-9a2248bba621">
    <dc:identifier>HP:0001369</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001369</ddiem:url>
    <rdfs:label>acute arthritis</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/9e99b755-8464-4f3a-aeb6-240668b80a07">
    <dc:identifier>H02</dc:identifier>
    <rdfs:label>CORTICOSTEROIDS FOR SYSTEMIC USE</rdfs:label>
    <obo:RO_0000056>
      <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/e30795dd-4800-4e0b-b886-2796af0e22aa">
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/535000"/>
        <rdfs:comment>The cyclosporine trial (taken immediately upon visual loss in the first eye) is in progress in Leber's optic atrophy to prevent involvement of the fellow eye.</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11723211</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24093206</dc:provenance>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3202309</dc:provenance>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02176733</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/c46957e5-6f3c-4908-b1ad-af5cba052500"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29054473</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/ca7be59b-f4b5-4edb-ba4e-bcc4021181b2"/>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02805790</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21600768</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/1f276314-6d55-472e-9836-840aebd446ce"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21483849</dc:provenance>
      </obo:DDIEM_0000013>
    </obo:RO_0000056>
    <ddiem:url>https://www.whocc.no/atc_ddd_index/?code=H02</ddiem:url>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/1def790f-b29e-4a10-952a-b5dbd1a33029">
    <dc:identifier>DB01306</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01306</ddiem:url>
    <rdfs:label>Insulin Aspart</rdfs:label>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/0d7fed3b-c679-4dbe-87ea-c6457a80d5b2">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25993639</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19770656</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28225998</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22142470</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21289269</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/145750"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/ca8a15d2-036b-48cd-a611-5d7fe2580d56"/>
        <rdfs:comment>In individuals with allergies or intolerance to allopurinol, febuxostat may be considered; however, no data on the use of this medication in UMOD-associated kidney disease are available at present.</rdfs:comment>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/62f13862-3b92-42cc-9dad-e958eef7c627"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20495831</dc:provenance>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/aae70f10-b4b9-4f59-9742-21ed07e2b569">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/d8cc9f2c-6151-4112-a6b7-bc7a15cc5cb3"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00936</ddiem:url>
    <rdfs:label>Salicylic acid</rdfs:label>
    <dc:identifier>DB00936</dc:identifier>
  </ddiem:Drug>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/e4960c7e-5f53-40ed-a85d-3f664d803db5">
    <dc:provenance>https://www.semanticscholar.org/paper/Clinical-Diagnosis-and-Treatment-of-Dehydrogenase-A-Cui-Wang/f6e88d647f2e2c7df2897e939ec33f9d86899b37</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11102558</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/300438"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/e09f749f-b422-417b-b60a-046134b4b361">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/3b11bc13-be0f-4578-9dc3-7a6b7e2008e9"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:comment></rdfs:comment>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22840416</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0303846712003952</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/cd69663e-cb08-4a8e-800a-1a747442ac12"/>
  </obo:DDIEM_0000013>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/1a785891-854b-4531-8cf4-c7715a8bd8ce">
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/ce2209c7-b64d-4182-acc1-91293e28deb0">
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/84059483-d9db-47d4-bfa8-88a98dcd8090"/>
        <rdfs:label>Recombinant apolipoprotein A-I</rdfs:label>
      </ddiem:Drug>
    </rdf:li>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/6a0265c0-e375-4ad6-9d5f-9ad89aef19f5">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/38865dc5-689b-4a5a-91b4-2adb6f803f18"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/bf3d253a-f4c4-43ab-bb10-3f99bbafd3cd"/>
    <rdfs:label>Amcinonide</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/9d2e12c9-c443-4c3c-9e78-3a7be415996e"/>
    <dc:identifier>DB00288</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/1c7c7814-6dbc-4553-8006-1ee75cc31a4c"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00288</ddiem:url>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/01df825e-19d2-4702-bcbe-19b226ddef30">
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/cf6191f9-d490-4244-81f6-c185147576f5">
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/193e2ad8-e459-48b6-bfb1-d71d5f67a679"/>
        <ddiem:url>https://www.whocc.no/atc_ddd_index/?code=B05BB01</ddiem:url>
        <rdfs:label>electrolytes</rdfs:label>
        <dc:identifier>B05BB01</dc:identifier>
      </ddiem:Drug>
    </rdf:li>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/8d8642d0-8ae6-4f18-93e0-efd5ccd12176">
    <dc:identifier>DB00020</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/989c31df-6009-4727-9441-6af20df560d6"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/68c36854-f1e2-4c4f-b335-59d8ec5ec50b"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00020</ddiem:url>
    <rdfs:label>Sargramostim</rdfs:label>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/a104d565-c6fc-4a40-bf21-895086060bea">
    <rdfs:label>Green tea leaf</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB14307</ddiem:url>
    <dc:identifier>DB14307</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/75ac2cf3-40a1-4ff6-a295-d76387e9e4ee"/>
  </ddiem:Drug>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/b3ccde5d-61cf-4c2b-b26f-eacf859d1654">
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/406fd0a7-51a9-4fb8-a284-8edd2f7834aa"/>
    <rdfs:comment>"A limitation of this study is that we did not use quantative measures, such as the Positive and Negative Syndrome Scale and the Brief Psychiatric Rating Scale, to evaluate severity of psychosis. This issue warrants further investigations for the benefit of SGAs to treat psychosis with DRPLA." https://www.ncbi.nlm.nih.gov/pubmed/29739138</rdfs:comment>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/125370"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0c106a81-eb9e-43bc-b588-d86ea4579f34">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000709</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Psychosis</rdfs:label>
        <dc:identifier>HP:0000709</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29739138</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/c5250210-9b39-4ec9-b5f0-69591519b9da"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/5658b3bd-ed44-4dd5-a5c4-25bfea01639f"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24816443</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
  </obo:OGMS_0000112>
  <obo:direct_complementation_of_a_genetically_defective_protein_by_gene_therapy rdf:about="http://ddiem.phenomebrowser.net/f50e904a-b7e7-45cd-8ec7-21c9ea44109a">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/13992367</dc:provenance>
    <dc:provenance>https://www.semanticscholar.org/paper/Cell-and-Gene-Therapy-for-Carbamoyl-Phosphate-1-Zhang-Li/2099b4f31e1fe5e8825f03deff088f7702694f02</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/237300"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
    <rdfs:comment>Drug name: Intranasal dDAVP, because of efficacy, long duration of action, and infrequent side effects, is the preferred treatment of neurogenic diabetes insipidus in children and adults.https://www.ncbi.nlm.nih.gov/pubmed/626447</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14213380</dc:provenance>
    <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/2ce2a3f0-914c-481a-8b67-1c6a3499311d"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23649895</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/e2eeb9b2-61cd-4fa3-886b-5fbb07a635c6">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/b69839e1-475a-4ed9-a3ca-ec6c44c92f46"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31392111</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
  </obo:direct_complementation_of_a_genetically_defective_protein_by_gene_therapy>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/720ced85-3098-4032-bc20-5a7d17ef1fbc">
    <dc:identifier>HP:0002789</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>tachypnea</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002789</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9874c736-0338-478b-9c63-135cdcccb01a">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0005952</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Decreased lung function</rdfs:label>
    <dc:identifier>HP:0005952</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/4039362c-307d-4a41-b469-35c971e7bbcb">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/f777a5a7-2350-4379-bc34-845e14b670fa"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/2709bb4a-4810-404c-b998-669dfe642bfd"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00166</ddiem:url>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/c3151717-4575-4a4b-be50-d0f34c95a494">
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/246900"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/6418873</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/4b6ca8f4-e6e9-4f08-8ea9-a95765bc7ba0"/>
        <rdfs:comment>Use of dichloroacetate to activate the pyruvate dehydrogenase complex led to a significant decline in lactate levels, but this was also transient.https://www.ncbi.nlm.nih.gov/pubmed/8652022</rdfs:comment>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/9d238f43-d7e4-44a5-b6e7-2cc0d83972a2"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/a298fcb2-6e04-4335-bdff-d0b444f22cf1"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23478190</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10970889</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25032271</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3024040</dc:provenance>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11687750</dc:provenance>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <dc:identifier>DB00166</dc:identifier>
    <rdfs:label>Lipoic Acid</rdfs:label>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/77ff7213-ffdd-4ca5-a5e6-e725226e502e">
    <rdfs:label>AAV2-hAADC ( Gene therapy)</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/337ad98d-1e19-4769-986d-863812ee5d01"/>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8b67285d-5885-4e5f-979c-820cf8510705">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001875+HP_0002037</ddiem:url>
    <rdfs:label>Neutropenia with IBD</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0001875+HP:0002037</dc:identifier>
  </ddiem:Phenotype>
  <obo:DDIEM_0000011 rdf:about="http://ddiem.phenomebrowser.net/cd781b84-61ec-43da-be63-fe333b2bbd0e">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ac39eeed-f535-40f4-8fd0-593fff2bf11a"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30804055</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26153518</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/213700"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/bb4f2778-cea9-4a4e-8305-854afc7a5ed5"/>
    <rdfs:comment>Drug name: Treatment is under trial.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
    <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b4f2b909-9165-4013-a2cb-82c920e8c0c1"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7964884</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28590052</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/1ad3c62e-1381-40c8-850d-b626ad244723"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/21ba206b-4ec3-4104-9c8a-670f005b9320"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15131757</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1316120</dc:provenance>
  </obo:DDIEM_0000011>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/d80fa2ed-5c16-4bae-8921-43d3b7e0ad04">
    <rdfs:label>Nanotechnology-based gene therapy</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/a88f4fdf-6046-4921-86db-6dea2f7041fb"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/f7198721-8a0f-471b-bd5b-d0b28ec4967f">
    <rdfs:label>Antiinflammatory preparations, non-steroids for topical use</rdfs:label>
    <obo:RO_0000056>
      <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/24c46b6f-d73d-46fe-9797-eae2ae787e5d">
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/02c820e4-f3ff-4f78-be44-6ec829d32927"/>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
        <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b1ffa798-38ac-48d4-a3ac-71b8b6debae6"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24746802</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01212744</dc:provenance>
        <dc:provenance>https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117</dc:provenance>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23806424</dc:provenance>
        <rdfs:comment>The drug was administered through intravitreal injection.</rdfs:comment>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/520000"/>
      </obo:DDIEM_0000013>
    </obo:RO_0000056>
    <dc:identifier>M02AA</dc:identifier>
    <ddiem:url>https://www.whocc.no/atc_ddd_index/?code=M02AA</ddiem:url>
  </ddiem:Drug>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/52cb8801-6629-486c-837e-45a827695758">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19415691</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/548720cd-8d60-4013-929d-3ae3d5d06aeb"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14632789</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a09a00cd-6976-42fb-986d-d6c4653a0a5d"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/604250"/>
    <dc:provenance>https://www.semanticscholar.org/paper/The-Incidence-of-Transient-Neonatal-Tyrosinemia-a-Zea-Rey-Cruz-Camino/b66304a0a56304f686380af915a92b2b860e9305</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29134618</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25717099</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <rdfs:comment>One of the studies that was carried on mice provides useful information for developing the optimal dosage regimen for HPBCD therapy when administered intravenously to NPC patients.https://www.ncbi.nlm.nih.gov/pubmed/26027824</rdfs:comment>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00001203</dc:provenance>
  </obo:DDIEM_0000013>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/79f0131d-af46-4301-b717-e7a29ae01921">
    <ddiem:url>https://www.drugbank.ca/drugs/DB08860</ddiem:url>
    <dc:identifier>DB08860</dc:identifier>
    <rdfs:label>Pitavastatin</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/a58e0143-a05f-48ec-bed3-91d780607e3e"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/2386b499-3a71-44c8-9968-0e811244de58">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/5786e82b-7375-42d4-ad60-71e8af7af152"/>
    <obo:RO_0000056>
      <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/e4e71fb7-3772-40b3-9a66-2e129dceaa03">
        <dc:provenance>https://www.babysfirsttest.org/newborn-screening/conditions/3-methylcrotonyl-coa-carboxylase-deficiency</dc:provenance>
        <dc:provenance>https://www.jci.org/articles/view/11948</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/1cbfe780-074e-4883-9c7d-c7b1847865a4"/>
        <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d467a691-1658-450c-b260-dc3e7fe5b6e5"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7748366</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b200bc19-bf63-4052-914e-24afffd9a2ee"/>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/088789949400109F</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/c9106990-2dc9-4d0b-8b31-72009b8aa14f"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16835865</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/231530"/>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
        <rdfs:comment>Effect of glycine in treating the condition is variable among literatures.  "Case reports have noted variable results regarding the effect of glycine administration. Some studies have found that supplemental glycine results in increased excretion of 3-methylcrotonyl glycine, while others have not found a persistent effect; no studies have observed clinical improvement of symptoms on treatment and no randomized clinical trials have been published" https://www.sciencedirect.com/science/article/pii/S1096719207005975?via%3Dihub#bib11
https://www.ncbi.nlm.nih.gov/pubmed/8831079
https://www.ncbi.nlm.nih.gov/pubmed/7474896</rdfs:comment>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/51958210-67c1-43cf-8fd4-2c4561420eb1"/>
      </obo:DDIEM_0000013>
    </obo:RO_0000056>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/ef2d0057-c1f4-411b-b885-139b904e529d"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/a7a5d6a5-b826-45c2-98f5-cbb86b0923a2"/>
    <dc:identifier>DB00635</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00635</ddiem:url>
    <rdfs:label>Prednisone</rdfs:label>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/938ab7e3-7316-43dc-97e5-cc71d53c6feb">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0012217</ddiem:url>
    <rdfs:label>Eevated porphyrin precursors porphobilinogen</rdfs:label>
    <dc:identifier>HP:0012217</dc:identifier>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/3a808368-bf1f-459a-9380-806271f4f98b">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/be2ef431-3d1e-43d0-b7f9-e487f823ba4a"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/3754ae1b-ee8c-4c0b-a2a1-3af0afb66885"/>
    <rdfs:label>L-Lysine</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/c62f313d-da26-478e-825e-a4a20e9017cc"/>
    <dc:identifier>DB00123</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00123</ddiem:url>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/ebce90cb-ac79-4453-95db-0381632f9143">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/d8dc90b5-7887-42e8-8454-2bd82c8b4414"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB11991</ddiem:url>
    <dc:identifier>DB11991</dc:identifier>
    <rdfs:label>Oprozomib</rdfs:label>
  </ddiem:Drug>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/ae1f95ff-0ccf-4e28-8d42-e0876ee7db03">
    <dc:provenance>https://www.researchgate.net/publication/8668575_A_successful_treatment_with_pyridoxal_phosphate_for_West_syndrome_in_hypophosphatasia</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3316461</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/1b5f05c7-e25c-4d2c-a328-36a91b1a6083">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/a76ec68c-b717-43f1-be48-69f420c9576d"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>"ENB-0040</dc:provenance>
    <dc:provenance>NCT00744042.)."</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>an enzyme-replacement therapy</dc:provenance>
    <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
    <rdfs:comment>Drug name: Treatment is under trial.</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>was associated with improved findings on skeletal radiographs and improved pulmonary and physical function in infants and young children with life-threatening hypophosphatasia. (Funded by Enobia Pharma and Shriners Hospitals for Children; ClinicalTrials.gov number</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5096504</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/241510"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f1c6f6c8-e3c7-4edc-aa68-a8454edffeb5"/>
  </obo:OGMS_0000112>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/259c3c7a-bfb5-46a6-9550-cebb62ced455">
    <rdfs:label>Oculomotor apraxia</rdfs:label>
    <dc:identifier>HP:0000657</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000657</ddiem:url>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/46f45806-9161-48b1-a91c-cb0d90cafd4f">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/489246cd-381b-44d8-80ba-73c440d34508"/>
    <dc:identifier>DB01026</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01026</ddiem:url>
    <rdfs:label>Ketoconazole</rdfs:label>
  </ddiem:Drug>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/bf0f2991-9794-49f5-8d7d-04b376acb513">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2850427</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28967191</dc:provenance>
    <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29247835</dc:provenance>
    <dc:provenance>https://www.semanticscholar.org/topic/amlexanox/510418</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000012"/>
    <dc:provenance>https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/b35c9192-bb1d-43b0-9fe1-c7879580c7d2">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/7ad88ed8-0af2-4bf8-aff2-ab80913a102e"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0003304>Ser72Pro/Trp168X</obo:RO_0003304>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/208400"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d3f96075-1275-416d-968f-4339da6a7e99">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Low AGA activity</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>Amlexanox, which inhibits NMD and causes a translational read-through, facilitated the synthesis of a full-length, functional AGA protein from the nonsense allele. This could be demonstrated as presence of the AGA polypeptide and increased enzyme activity upon Amlexanox treatment. Furthermore, in the Ser72Pro/Trp168X expressing cells, Amlexanox induced a synergistic increase in AGA activity and polypeptide processing due to enhanced processing of the Ser72Pro polypeptide. A potential therapy based on results of a study conducted by Banning et al. 2016 https://www.ncbi.nlm.nih.gov/pubmed/29247835 Consistently, AMX is currently under strong clinical development for rare metabolic diseases by the company Apteeus (Terence Beghyn, Apteeus, personal communication). The drug as released in Banning et al. study works by inhibiting NMD and causing a translational read-through, it facilitated the synthesis of a full-length, functional AGA protein from the nonsense allele. "This could be demonstrated as presence of the AGA polypeptide and increased enzyme activity upon Amlexanox treatment. Furthermore, in the Ser72Pro/Trp168X expressing cells, Amlexanox induced a synergistic increase in AGA activity and polypeptide processing due to enhanced processing of the Ser72Pro polypeptide. " It posses the ability to cross the BBB. "Our data show for the first time that Amlexanox might provide a valid therapy for AGU." https://www.ncbi.nlm.nih.gov/pubmed/29247835</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
  </obo:OGMS_0000112>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/2658d3cf-ee1d-4f73-a735-7de27097efb6">
    <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/207900"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8582405</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4052756/#S10title</dc:provenance>
    <dc:provenance>https://www.clinicaltrialsregister.eu/ctr-search/search</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/b0568ff3-8170-4e53-bcb4-8a44ed08af35"/>
    <rdfs:comment>Alternative pathway therapy has limited effectiveness in preventing hyperammonemia and must be combined with effective dietary management. https://www.ncbi.nlm.nih.gov/pubmed/11148549</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23494656</dc:provenance>
    <dc:provenance>https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ce708052-95fb-4a5d-a2c2-c6a43b75b00d">
        <rdfs:label>Abnormal renal nitrogen elimination</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0004364</ddiem:url>
        <dc:identifier>HP:0004364</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S109671921200265X</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
  </obo:OGMS_0000112>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/93c85b1d-5bb3-4695-aba6-b6fd5b92721e">
    <dc:identifier>HP:0002149</dc:identifier>
    <rdfs:label>High plasma uric acid levels</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002149</ddiem:url>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6911f58c-1e35-4b43-b3c9-b78987f02ebe">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>production of toxic bile acid metabolic intermediates</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/2ebf284e-e31f-41f7-abda-1d6132a32fb7">
    <ddiem:url>https://www.drugbank.ca/drugs/DB14872</ddiem:url>
    <dc:identifier>DB14872</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/d75149d3-7e54-442c-84ac-aa83023f1667"/>
    <rdfs:label>Lucerastat</rdfs:label>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/95a4d5e1-e93a-492f-b40f-38ec041cca0c">
    <dc:identifier>DB05294</dc:identifier>
    <rdfs:label>Vandetanib</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/d1650547-ce17-4db4-9b01-06d3175afe2c"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB05294</ddiem:url>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/099a15cb-8840-450b-ad8d-aad67f5cdd8e">
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/87e9b497-82a4-44df-9188-726650f80d44">
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/612073"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30723321</dc:provenance>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01458119</dc:provenance>
        <dc:provenance>https://www.nature.com/articles/s41436-019-0451-z</dc:provenance>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/books/NBK6803</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/f5919ed0-0d88-482f-843b-0e629ced7671"/>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01218659</dc:provenance>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00925301</dc:provenance>
        <rdfs:comment>The drug was more effective in some mutations than others, so if the results are analysed according to the mutation there is an advantage for migalastat.https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6370600/
 Miglustat stabilises specific mutant (amenable) forms of Î±-Gal to facilitate normal lysosomal trafficking. https://www.ncbi.nlm.nih.gov/pubmed/27834756/</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27834756</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/387b9aa2-9a28-479d-a7f0-8ecfc6876a9c"/>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <rdfs:label>Carbamazepine</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/f65ed097-57c8-40f4-92dc-10a4cd7db0f5"/>
    <dc:identifier>DB00564</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00564</ddiem:url>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/0a3c2d56-4bf6-46e4-b337-848d29206bb1">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/45002508-45bd-4fc8-9481-41165ae84b18"/>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/7aec2470-791a-449b-9860-c41bb133812d">
    <dc:identifier>DB08809</dc:identifier>
    <rdfs:label>Dichloroacetic acid</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB08809</ddiem:url>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/604b0f6d-a406-42d5-a942-ca3399c37669">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8652022</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23478190</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10970889</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25032271</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/a930ecd5-943e-4554-945e-fecf570f510f"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11687750</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/246900"/>
        <rdfs:comment>Use of dichloroacetate to activate the pyruvate dehydrogenase complex led to a significant decline in lactate levels, but this was also transient.https://www.ncbi.nlm.nih.gov/pubmed/8652022</rdfs:comment>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000012"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/9d238f43-d7e4-44a5-b6e7-2cc0d83972a2"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
  </ddiem:Drug>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/19a048c0-a44e-4b8b-af36-345b34badb89">
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/9ac596cb-17a1-49f7-901a-f7909ce6b1f1"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01212744</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b706b2c1-a9b1-4bf3-9df6-66acf3c5fa1f">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0004305</ddiem:url>
        <rdfs:label>Involuntary movement</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0004305</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28756475</dc:provenance>
    <dc:provenance>https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117</dc:provenance>
    <rdfs:comment>Effect of those two drugs was short-term response. Disease Name: There are many drugs with known detrimental effect on mitochondrial function. These include antibiotics like tetracycline and chloramphenicol; antiepileptics like valproate, phenytoin, antiretroviral agents and metformin. Overall their effects in patients with MIDD are not known. Statin therapy should be avoided in patients especially with myopathy. HMG Co-A reductase inhibitors can reduce both cholesterol and Co-enzyme Q via mevalonate pathway. These patients may have higher rate of lactic acidosis and intolerance to statins resulting in myalgia and may worsen the symptoms of existing myopathy. https://www.sciencedirect.com/science/article/pii/S1056872714000610?via%3Dihub#bb0115</rdfs:comment>
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/520000"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24746802</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
  </obo:OGMS_0000112>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/43c23ec3-0d77-4aef-9916-0389c3b6aca8">
    <rdfs:label>High prolactin level</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0000870</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000870</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5dbfe537-c8b4-454a-99c4-12e96e3a1f8e">
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0007010</ddiem:url>
    <rdfs:label>Poor fine motor skills</rdfs:label>
    <dc:identifier>HP:0007010</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/c1acad56-0e22-4c5f-a057-32e474936574">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/6d7fdebf-c225-4c3e-97de-da8acf55fd43"/>
    <rdfs:label>GNeo-IDUA</rdfs:label>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/443d08cb-553d-46c2-879b-9a71dc43fca5">
    <dc:identifier>HP:0001635</dc:identifier>
    <rdfs:label>congestive cardiac failure</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001635</ddiem:url>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/231690">
    <rdfs:label>GLUTARIC ACIDURIA III; GA3</rdfs:label>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/537</ddiem:iembaseUrl>
    <rdfs:comment></rdfs:comment>
    <ddiem:iembaseAccessionNumber>537</ddiem:iembaseAccessionNumber>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/edac7fdf-ffca-4fb9-8958-46a62247fdb5"/>
    <dc:identifier>https://www.omim.org/entry/231690</dc:identifier>
  </ddiem:Disease>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/600740">
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/19af0a65-bf6c-4cce-9946-7f35d87ac006"/>
    <dc:identifier>https://www.omim.org/entry/600740</dc:identifier>
    <rdfs:label>HYPOCALCIURIC HYPERCALCEMIA, FAMILIAL, TYPE III; HHC3</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Disease>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/b154a2a3-f029-41a8-837d-54e752322595">
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02430077</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/412123cc-a734-417a-8ce8-616f310590bc"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <rdfs:comment>Uncoooked cornstrach was introduced in small frequent meal and was accomapined with elimination of lactose in diet</rdfs:comment>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/151660"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5338723</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02211209</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/081c0ca0-12b3-45b5-83f7-f4e0e6021c57"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02527343</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/456dc4ec-7e98-4069-bf57-57c61d9b3a3b">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0003077*</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003077</ddiem:url>
        <rdfs:label>High liver triglyceride level(hyperlipidemia)*</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </obo:OGMS_0000112>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/c001d060-fe78-4d0a-9972-76ad77abba0e">
    <rdfs:label>CER 001, a recombinant high-density lipoprotein (HDL)</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/a1ae3ffe-16cd-49b4-9ecf-be377d244822"/>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e02374f7-4bab-4e05-a387-743736587a07">
    <rdfs:label>defected excertion of 3- MCG</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/e8997369-b875-4041-996a-b250b58f2832">
    <dc:identifier>DB01001</dc:identifier>
    <rdfs:label>Salbutamol</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/5d4ceb3c-8221-47ee-8d75-3d5d442f8857"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01001</ddiem:url>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ed1dca73-e755-47c3-a158-bb360995309c">
    <dc:identifier>HP:0030764</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0030764</ddiem:url>
    <rdfs:label>ochronosis</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/a021ad3d-e98c-4fad-ae7c-5214335bde9c">
    <rdfs:label>Glyoxal-bis(N(4)-methylthiosemicarbazonato)-copper(II) CuGTSM</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/d404eb57-79fa-4adc-a01a-6f071d3c2751"/>
  </ddiem:Drug>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/15e5ca1f-0baf-4652-9788-b3f1bff2a73b">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25859380</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28057010</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/222700"/>
    <rdfs:comment>Drug has no difference in terms of prognosis.</rdfs:comment>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d9054e8c-01a4-4bda-bd2b-78a630c0a2d0"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/cb5070a3-ac95-4c75-b102-192ca4b450a2"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27567650</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20301535</dc:provenance>
  </obo:OGMS_0000112>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/82154b2f-5714-4a2f-8e32-d29def2ade30">
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28516949</dc:provenance>
    <rdfs:comment>Patient continued to have daily seizures on oxcarbazepine, topiramate and levetiracetam</rdfs:comment>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/c1234c40-29ff-4bef-acf5-458f9098fc69"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/255e099f-1393-4401-b714-3371b8f16c98">
        <rdfs:label>Paroxysmal nocturnal hemoglobinuria</rdfs:label>
        <dc:identifier>HP:0004818</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0004818</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/300818"/>
  </obo:DDIEM_0000013>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e9cdf487-2c29-4164-8ff0-37f7364fcb63">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002240</ddiem:url>
    <rdfs:label>Abormal liver size</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0002240</dc:identifier>
  </ddiem:Phenotype>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/60a13a7f-ce7b-4392-9953-33827cfa8f52">
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/16ccf1e2-b510-47fb-939b-7c8be34c450b"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/3e051ecf-74f6-42e1-afca-52c032f0c662"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10779036</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22791294</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/3e1fb772-3868-4561-b538-7eabf3c84653"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29684566</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24744655</dc:provenance>
    <obo:RO_0003304>(c.356+3&gt;C)</obo:RO_0003304>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28883274</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <rdfs:comment>There was no clinical effect, but amild reduction in the plasma level of desmosterol was observed.</rdfs:comment>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/105650"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01328587</dc:provenance>
    <dc:provenance>http://www.bloodjournal.org/content/128/22/2682</dc:provenance>
  </obo:OGMS_0000112>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/27ecf745-ac09-4ec2-bb9b-8a5f47caba15">
    <dc:identifier>HP:0002066</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>ataxic gait</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002066</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/0af26475-da77-4fe5-867e-c5509cd684d2">
    <rdfs:label>L-Glutamine</rdfs:label>
    <dc:identifier>DB00130</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/fdbd2f2f-7b8e-4c8b-a377-7157ef48e7f0"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/5f074480-64dc-4b79-a96c-16ead706c46a"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00130</ddiem:url>
  </ddiem:Drug>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/8df101f0-5b26-4c61-880e-be4ddc8e0363">
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/62f13862-3b92-42cc-9dad-e958eef7c627"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1800965</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12114919</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28225998</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/97383852-559b-4968-85fa-07445eb5aadd"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/145750"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21289269</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9c91391a-3132-47dc-aea7-443b2ef74698">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Acute pancreatitis</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001735</ddiem:url>
        <dc:identifier>HP:0001735</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <rdfs:comment>Intravenous heparin 10,000 U per day is an effective, simple, and safe method of lowering the triglyceride level in hypertriglyceridemia-induced pancreatitis in pregnancy, However, the reduction of the triglyceride level by heparin is only temporary and long-term use may paradoxically result in an increase in the triglyceride level as a result of depletion of LPL. Heparin can be stopped once the triglyceride level falls below 11 mmol/L.https://www.ncbi.nlm.nih.gov/pubmed/12114919.  https://www.ncbi.nlm.nih.gov/pubmed/1800965</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20495831</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19770656</dc:provenance>
  </obo:OGMS_0000112>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/e54eea82-68ab-4047-a96b-4d89602cf451">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/a28a95b0-e791-4012-b97f-998450eb09c5"/>
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/8a976b2c-e088-45f1-b9a1-b0b8d7181535"/>
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/3a808368-bf1f-459a-9380-806271f4f98b"/>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/5650ffd5-d485-42a0-bd0e-cbece89b01e8">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/d4ada489-7dc6-415e-a7fa-30194e8af9ce"/>
    <rdfs:label>Methotrexate</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00563</ddiem:url>
    <dc:identifier>DB00563</dc:identifier>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/0a4c8439-0f54-4d0a-8de7-86bf9ca71341">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/23f10114-fda7-4a99-afa5-cd5318d060f2"/>
    <rdfs:label>Carbonic anhydrase inhibitors</rdfs:label>
    <ddiem:url>https://www.whocc.no/atc_ddd_index/?code=S01EC</ddiem:url>
    <dc:identifier>S01EC</dc:identifier>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/b749fb04-e4f9-4f5c-99a5-5afb15894ba2">
    <rdfs:label>Selenium</rdfs:label>
    <dc:identifier>DB11135</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/f1cb2ea6-408a-4ea5-9590-f4d46f2ae098"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB11135</ddiem:url>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/78cdf15b-1f28-4e18-9c47-41a91d9f8cf2">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/e66babb0-fc35-4389-9324-52c85654d6f3"/>
    <dc:identifier>DB00988</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00988</ddiem:url>
    <rdfs:label>Dopamine</rdfs:label>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/48fbe5a5-c316-49db-a9fb-6ca1c62a824b">
    <ddiem:url>https://www.drugbank.ca/drugs/DB13873</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/ec2f62de-c72f-4603-8dd9-f1ae0a22123f"/>
    <rdfs:label>Fenofibric acid</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/e10ea1b1-88e2-4e0e-8fad-40491a569860"/>
    <dc:identifier>DB13873</dc:identifier>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/50bbf25c-9376-4e3f-879a-ca29d093f0d4">
    <rdfs:label>Ursodeoxycholic acid</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/9036677d-0ab3-4044-a63d-964624078335"/>
    <dc:identifier>DB01586</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01586</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/dd840dd0-64af-4270-b65f-7934b9b29a4f"/>
  </ddiem:Drug>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/d9fd1cfb-34ae-49cb-8417-6408b8db9182">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15277402</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26962538</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/eb345fb0-e9f4-4420-9c6d-508b9ea1af0b"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/35566c62-5c89-4437-bc21-3f5a674bf216"/>
    <obo:RO_0003304>M197I</obo:RO_0003304>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8410522</dc:provenance>
    <ddiem:failedToContributeToCondition>GK-Y214C(De novo muttation)</ddiem:failedToContributeToCondition>
    <ddiem:failedToContributeToCondition>ins454A</ddiem:failedToContributeToCondition>
    <obo:RO_0003304>W99R</obo:RO_0003304>
    <obo:RO_0003304>G68V</obo:RO_0003304>
    <ddiem:failedToContributeToCondition>Y214C</ddiem:failedToContributeToCondition>
    <obo:RO_0003304>(Val455Met) at codon 455</obo:RO_0003304>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25781533</dc:provenance>
    <obo:RO_0003304>V452L</obo:RO_0003304>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19336674</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/65084b83-5349-48d3-b185-b9c2720ab857"/>
    <obo:RO_0003304>S64Y</obo:RO_0003304>
    <rdfs:comment>Based on their study auhors of"  https://www.ncbi.nlm.nih.gov/pubmed/21354122?dopt=Abstract"  presume that the combination of these drugs may contribute to reduce LDL-C/HDL-C ratio effectively as well as lowering concentrations of serum triglyceride.</rdfs:comment>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/602485"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/345f7321-2b9d-4b63-8db8-6f154976000d"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15133749</dc:provenance>
    <obo:RO_0003304>T65I</obo:RO_0003304>
    <dc:provenance>https://onlinelibrary.wiley.com/doi/epdf/10.1002/dmrr.448</dc:provenance>
    <obo:RO_0003304>A456V</obo:RO_0003304>
  </obo:OGMS_0000112>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/cf127040-83db-49b8-b304-ca1371fa48a6">
    <rdfs:label>Pioglitazone</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01132</ddiem:url>
    <dc:identifier>DB01132</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/08cb4880-473d-433c-b3aa-e2a182d9ac93"/>
  </ddiem:Drug>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/253601">
    <rdfs:label>MUSCULAR DYSTROPHY, LIMB-GIRDLE, AUTOSOMAL RECESSIVE 2; LGMDR2</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>https://www.omim.org/entry/253601</dc:identifier>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/3d321481-bef9-40d8-bf69-ecc0b534d543"/>
  </ddiem:Disease>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2279eec2-ec3a-4a24-81cb-e4082f1f688a">
    <dc:identifier>HP:0000639</dc:identifier>
    <rdfs:label>Nystagmus</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000639</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/33c18466-3423-48e5-9cdd-a226d34b2604">
    <dc:identifier>DB00149</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/d0f3d490-75cb-4b0a-b18c-c8ea6fcb7b35"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00149</ddiem:url>
    <rdfs:label>L-Leucine</rdfs:label>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c85c50cd-f5e2-4670-8106-eeaca985537f">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0006279</ddiem:url>
    <dc:identifier>HP:0006279</dc:identifier>
    <rdfs:label>Pancreatic beta-cell dysfunction</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/ed50ce6c-783a-45ad-be4a-1462fe689093">
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00025883</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25734254</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/c77c3a2c-1144-46a7-bc57-6323387f1d46">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/37b2e525-daca-4227-8ded-5e8d0ddfed89"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <rdfs:comment>Uncoooked cornstrach was introduced in small frequent meal and was accomapined with elimination of lactose in diet</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/bc25a0e2-9b17-4cd1-9796-5dc77beab238">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0040300</ddiem:url>
        <rdfs:label>abnormal free fatty acid levels</rdfs:label>
        <dc:identifier>HP:0040300</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26584826</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/fef22ecd-8b2f-4e91-9d45-c7d13b1261df">
        <rdfs:label>abnormal fasting glucose</rdfs:label>
        <dc:identifier>MP:0013277</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/MP_0013277</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5338723</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/151660"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/54b5710d-7726-42c3-8c5b-65f41bfe0a9e">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000287</ddiem:url>
        <dc:identifier>HP:0000287</dc:identifier>
        <rdfs:label>high facial soft tissue volume</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28993984</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b10bc4cb-b61c-484b-a1a0-27bb77d7b8a5">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>high  HbA1c levels</rdfs:label>
        <dc:identifier>HP:0040217</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0040217</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27155573</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29044799</dc:provenance>
  </obo:OGMS_0000112>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/c5730bf9-8156-435b-ab53-19961b45cc1b">
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/cd1e7f1c-8e58-4f11-b0b9-0baf12de5fa4"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20495831</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22142470</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/62f13862-3b92-42cc-9dad-e958eef7c627"/>
    <rdfs:comment>In individuals with allergies or intolerance to allopurinol, febuxostat may be considered; however, no data on the use of this medication in UMOD-associated kidney disease are available at present.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25993639</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21289269</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10925336</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/145750"/>
  </obo:OGMS_0000112>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/445dae4a-bd4d-4446-a14f-729f3519d194">
    <rdfs:label>Arginine-restricted diet</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/5955d8ca-0124-4554-8c7c-e2670ccaa0d9"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/0e2b3e26-d27a-4ba2-9e00-bde6d5349467">
    <rdfs:label>Metoclopramide</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/f154052e-2ba3-478a-8366-6aa4e7337260"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01233</ddiem:url>
    <dc:identifier>DB01233</dc:identifier>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/529e6ded-cfc8-4f87-8e3a-e18892a5a1b8">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/99e11061-edcb-4d54-8d91-d2d5d2e25f71"/>
    <rdfs:label>AAVrh.10CUhCLN2</rdfs:label>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/22cf93ec-99c7-4769-8fdd-1f6319557374">
    <dc:identifier>DB00112</dc:identifier>
    <rdfs:label>Bevacizumab</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00112</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/48d12dec-4fcc-45d7-ac7d-4174e4a2d132"/>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c14c9cdb-a32b-4147-9f19-ece5932e0aba">
    <rdfs:label>No result was added</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1c607842-cdc7-4aa6-ade9-fe73ef7ad88e">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>biochemical abnormalities</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001939</ddiem:url>
    <dc:identifier>HP:0001939*</dc:identifier>
  </ddiem:Phenotype>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/2d8eb481-b2bc-41f2-9cf0-f9b7287dbf27">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21403788</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26884075</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/40390953-84c7-4dc4-9874-ee61f455992d"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/54cbae5f-8420-4c77-8464-a68be6276b97"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/243500"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21207059</dc:provenance>
    <rdfs:comment>A clinical candidate for drug repuropsing. DGJNAc contains an N-acetyl group that sterically precludes it from binding to Î±-GAL A and GLB1, so it has improved selectivity for Î±-NAGAL and makes it superior to DGJ.</rdfs:comment>
  </obo:OGMS_0000112>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/512ed4ea-a90f-4140-b2ac-5658e89ee145">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Trial is still in the Recruiting stage.</rdfs:label>
  </ddiem:Phenotype>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/99e0db6e-f3c9-4992-bc20-33bdc8c75c8e">
    <dc:provenance>https://link.springer.com/article/10.1007/s11940-011-0131-z</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/books/NBK1520</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1059131117301243</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/f92241e7-3a9d-46e1-8e0d-d326408f934d"/>
    <rdfs:comment>In a different study IV administration of Glucose wasn't effective.https://www.ncbi.nlm.nih.gov/pubmed/22238410</rdfs:comment>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/253800"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21979053</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/bfaf1e07-f574-40e8-9df2-bc6c8860847c">
        <rdfs:label>Abnormal Fukutin function</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </obo:OGMS_0000112>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/f9fafe5f-a6f7-4abb-9dab-c422051f999d">
    <ddiem:url>https://www.drugbank.ca/drugs/DB00682</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/0a8e1c17-5584-43a8-99f4-0354704da621"/>
    <dc:identifier>DB00682</dc:identifier>
    <rdfs:label>Warfarin</rdfs:label>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/fffbf06a-fff9-4d59-9e4b-560ffd8434e2">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>hyperprolactinemia</rdfs:label>
    <dc:identifier>HP:0000870</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000870</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/878bf718-3e50-4307-90f4-0a896944c6e3">
    <dc:identifier>HP:0001336*</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001336</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Myoclonic abnormalities(Myoclouns)*</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/f891cd7f-935c-4d11-9e6f-0c3bcc589e62">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/4687d680-bca2-4dc0-b8bc-183d8e3b750b"/>
    <rdfs:label>Copper Histidine</rdfs:label>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1d362dce-e6e6-47b7-b112-2c542f81a603">
    <rdfs:label>Fat soluble vitamin  Malabsorption (Fat malabsorption)*</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002630</ddiem:url>
    <dc:identifier>HP:0002630</dc:identifier>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/29d08099-ee36-45ed-a955-50a8dfb9578e">
    <ddiem:url>https://www.drugbank.ca/drugs/DB00152</ddiem:url>
    <dc:identifier>DB00152</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/9cca75b4-333b-4064-b645-c297f95a4899"/>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/879b30ec-f403-47c2-bb16-aab30c85d9d1">
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000012"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10970889</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/246900"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/c7568be9-e6b5-4e41-9ee1-202e43e5338f"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20652410</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/2217ac19-bc29-478a-8c68-099b409d7ae6"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/1d0525b3-b9fd-407b-9d02-8f542aa34bb2"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25032271</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/8e2d217d-1911-4419-b266-3d6d0981f695"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10448086</dc:provenance>
        <obo:RO_0003304>p.I480M</obo:RO_0003304>
        <rdfs:comment>Beneficial effects were initially observed on parkinsonian symptoms. However, dyskinesia and dystonic features re-emerged after three months of treatment.</rdfs:comment>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/fac05802-fe1d-4052-aae0-7cb65537c2f8"/>
    <rdfs:label>Thiamine</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/f51da089-d6fc-40e5-a28c-2cbf21dbded7"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/a2e4dc0c-ff00-4df8-bbed-ee4353396f84">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/98aa10ce-d6bb-4987-8fd5-68ffdebdefc8"/>
    <rdfs:label>volanesorsen (IONIS-APOCIIIRx)</rdfs:label>
  </ddiem:Drug>
  <owl:Class rdf:about="http://purl.obolibrary.org/obo/direct_complementation_of_a_genetically_defective_protein_by_gene_therapy">
    <rdfs:label xml:lang="en">direct complementation of a genetically defective protein by gene therapy</rdfs:label>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000004"/>
    <obo:IAO_0000115 xml:lang="en">Insertion of one or more normal copies of a genetically defective gene into the genome of affected cells.</obo:IAO_0000115>
    <dc:creator>https://orcid.org/0000-0002-5111-7263</dc:creator>
  </owl:Class>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/92267d2a-63b6-464b-89e9-c9142118e506">
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0001507*</dc:identifier>
    <rdfs:label>Low growth rate (Abnormal growth)*</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001507</ddiem:url>
  </ddiem:Phenotype>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/ad990414-5b73-475b-a876-47cc32abc214">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/4cf4cfc6-2f57-404c-9d02-ec1a2ae8177e"/>
  </rdf:Alt>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7570198b-b602-4525-995b-a1791144f637">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Mitochondrial respiratory chain defects</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0200125</ddiem:url>
    <dc:identifier>HP:0200125</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/96b83758-081b-4bdc-89db-301c7493dadc">
    <dc:identifier>DB00103</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/ece9f5e0-41d1-45d8-a7f9-2b3d420359d1"/>
    <rdfs:label>Agalsidase beta</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00103</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/799e9cb8-ae4f-4130-b161-09585a1a47f9"/>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/241129d3-62d1-4eb5-95d7-33ff54bd00b6">
    <dc:identifier>HP:0002540</dc:identifier>
    <rdfs:label>inability to walk</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002540</ddiem:url>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8d831179-238a-40d7-9a5e-2aeed3ea4777">
    <dc:identifier>HP:0001939</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001939</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>high  short chain acyl-carnitine metabolite level</rdfs:label>
  </ddiem:Phenotype>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/003fb3b1-ae56-4595-bf7f-25846058cbf8">
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/177000"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26979527</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28003770</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25402764</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19656325</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/b2d72b1c-b616-4d87-a0d2-32a197527331">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/f88130fe-8a41-4332-bc2f-336d3ea9c47e"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/4c461888-fa8a-4c1b-b67d-482882a9de49"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/345ad4c5-f7b7-4b08-800d-2e98370e26bc">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000992</ddiem:url>
        <dc:identifier>HP:0000992</dc:identifier>
        <rdfs:label>Cutaneous photosensitivity</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23884489</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <rdfs:comment>https://www.ncbi.nlm.nih.gov/pubmed/8370580</rdfs:comment>
  </obo:DDIEM_0000013>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/db32a450-5e5a-4790-889b-c045f3c50657">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000817</ddiem:url>
    <rdfs:label>Poor eye contact</rdfs:label>
    <dc:identifier>HP:0000817</dc:identifier>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/cd85d73a-279f-4e57-a614-f1843f3c314d">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001510</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0001510</dc:identifier>
    <rdfs:label>growth impairment</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/3a5287c4-25e8-4b03-8b75-e70bff68a5ec">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/779b92df-cf0b-4e3e-a356-722f4a221f28"/>
    <rdfs:label>hepcidin</rdfs:label>
  </ddiem:Drug>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/890b4f39-ede6-43cc-90de-122585e031ae">
    <rdfs:comment>"Oral tocofersolan was more bio available than the water-soluble formulation in children with chronic cholestasis and similarly bio available in CF. This suggests that water-soluble vitamin E may represent an alternative to painful intramuscular vitamin E injections in chronic cholestasis, or other oral formulations in CF. However, the mechanism responsible for fat malabsorption in CRD concerns the absorptive phase as opposed to the digestive phase in CF and cholestatic syndromes. To our knowledge, no specific studies with these new vitamin E preparations have been conducted in CRD." https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717/</rdfs:comment>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a3d11a42-bba2-4264-8412-5058f26b2489"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6206929</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4925531</dc:provenance>
    <dc:provenance>http://www.ncbi.nlm.nih.gov/pubmed/15804998</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11067870</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19622360</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/224120"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/548720cd-8d60-4013-929d-3ae3d5d06aeb"/>
  </obo:OGMS_0000112>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/0b9f80c8-a9c9-4806-8c4e-50bd20525816">
    <ddiem:url>https://www.drugbank.ca/drugs/DB04173</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/23c0f345-1598-4dc8-a9e6-6b2b98712dfd"/>
    <rdfs:label>Fructose</rdfs:label>
    <dc:identifier>DB04173</dc:identifier>
  </ddiem:Drug>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/6cd410eb-48bc-44f5-8145-4e7b602b2ce7">
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/0149df37-2ef1-4a02-a69d-b3b6d96af936">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/e36f169e-4be7-44b6-9899-800086c04902"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24777537</dc:provenance>
    <rdfs:comment>A low fat regimen was added to metformin while treating the patient.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17339125</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/614462">
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/a4066a40-5cb3-4ced-bd39-92070e4df1e3"/>
        <rdfs:label>HYPERGLYCINEMIA, LACTIC ACIDOSIS, AND SEIZURES; HGCLAS</rdfs:label>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/836</ddiem:iembaseUrl>
        <ddiem:iembaseAccessionNumber>836</ddiem:iembaseAccessionNumber>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>https://www.omim.org/entry/614462</dc:identifier>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16635485</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/35b5c64e-9aaa-46fd-84a3-e5d483d4e101"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/aec43db9-f442-4101-818f-081f49d11b59"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
  </obo:OGMS_0000112>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1c9ea95a-c417-49ce-a9fc-30ce8afa0401">
    <rdfs:label>Nummular keratitis(keratitis)*</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000491</ddiem:url>
    <dc:identifier>HP:0000491</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a76b6ab4-7b49-4a86-86e3-b4f12d901624">
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0002375</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002375</ddiem:url>
    <rdfs:label>hypokinesia</rdfs:label>
  </ddiem:Phenotype>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/9348d05f-4431-43a7-a575-60d362338c33">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/8ee13c9b-e59d-463f-bde3-2bd87a8c1faf"/>
    <dc:provenance>https://www.tandfonline.com/doi/full/10.3109/0886022X.2014.900422</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27750150</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/57bbc463-fed5-41ab-975f-4db526979105">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/f09958cc-9667-40fc-842b-a2dc70c5bf68"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/230500">
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/284</ddiem:iembaseUrl>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/ddf24210-fd69-4e0c-949d-7256b7e881cd"/>
        <ddiem:iembaseAccessionNumber>284</ddiem:iembaseAccessionNumber>
        <dc:identifier>https://www.omim.org/entry/230500</dc:identifier>
        <rdfs:label>GM1-GANGLIOSIDOSIS, TYPE I</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Disease>
    </obo:RO_0002599>
    <rdfs:comment>The mechanisms of its effects in movement disorders are not well understood but probably reflect an increase in synthesis and release of dopamine, with perhaps some inhibition of dopamine uptake.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26766614</dc:provenance>
  </obo:OGMS_0000112>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/0ba5acf4-f36f-41da-91ea-e73d96d9b195">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/7e03991c-d67f-48a9-b7e0-9a52127ca7ff"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/52cb8801-6629-486c-837e-45a827695758"/>
    <dc:identifier>DB00746</dc:identifier>
    <rdfs:label>Deferoxamine</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00746</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/4ab58bc7-6f94-4176-aa41-1cb22a1ad394"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/890b4f39-ede6-43cc-90de-122585e031ae"/>
  </ddiem:Drug>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/fdf164ed-7fb0-444e-af82-f8f34ca171bd">
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/cd742dcc-22c6-425f-ad6d-b4ef0452aa6e"/>
    <rdfs:comment>A clinical candidate for drug repuropsing. DGJNAc contains an N-acetyl group that sterically precludes it from binding to Î±-GAL A and GLB1, so it has improved selectivity for Î±-NAGAL and makes it superior to DGJ.</rdfs:comment>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02473445</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/609242"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26884075</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23045655</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000012"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/EC0:0005542"/>
  </obo:OGMS_0000112>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/d8fd2091-587e-4d5a-80e6-e178cc32c9cf">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/4ea1c800-ae38-4ea3-a559-595e7f9634ec"/>
    <rdfs:label>Beta carotene</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB06755</ddiem:url>
    <dc:identifier>DB06755</dc:identifier>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/f88130fe-8a41-4332-bc2f-336d3ea9c47e">
    <ddiem:url>https://www.drugbank.ca/drugs/DB04931</ddiem:url>
    <rdfs:label>Afamelanotide</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/003fb3b1-ae56-4595-bf7f-25846058cbf8"/>
    <dc:identifier>DB04931</dc:identifier>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/156b74ba-acf8-483d-8917-cf00b2b0f1a7">
    <rdfs:label>Fluoxetine</rdfs:label>
    <dc:identifier>DB00472</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00472</ddiem:url>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/4643002d-d790-4fdd-96b6-ee3586d1b131">
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/7ee6dbfc-06e2-4b49-b8be-84a8489f7746"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19821145</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/db32a450-5e5a-4790-889b-c045f3c50657"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3950820</dc:provenance>
        <rdfs:comment>Bartholomwe et al. have suggested in their paper in 1988 that daily injections of OH-B12 are not necessary to maintain metabolic control and that orally administered OH-B12 is unlikely to be effective. Betaine appears to act synergistically with OH-B12 and should be part of the treatment regimen. Although there are theoretical reasons for using L-carnitine and folinic acid, we could not document their effectiveness in these two patients. https://www.ncbi.nlm.nih.gov/pubmed/3257264/</rdfs:comment>
        <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/a32e68e4-476e-4652-b714-f6245cda7918"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25511120</dc:provenance>
        <dc:provenance>https://link.springer.com/article/10.1023/A:1005353530303</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/277400"/>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
  </ddiem:Drug>
  <obo:direct_complementation_of_a_genetically_defective_protein_by_gene_therapy rdf:about="http://ddiem.phenomebrowser.net/85f32a56-dd48-4f95-81ab-94587f6c50b6">
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/606785"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/8938e65d-6865-4d44-9e15-b72cad773859"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT03223194</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4788912</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3306242</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4841061</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583863</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <rdfs:comment>Controversial benefits https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4158338/</rdfs:comment>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/405afb44-d7a3-4f8d-abd4-18478b52c5e2"/>
  </obo:direct_complementation_of_a_genetically_defective_protein_by_gene_therapy>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/613150">
    <rdfs:label>MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH BRAIN AND EYE ANOMALIES), TYPE A, 2; MDDGA2</rdfs:label>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/353</ddiem:iembaseUrl>
    <dc:identifier>https://www.omim.org/entry/613150</dc:identifier>
    <ddiem:iembaseAccessionNumber>353</ddiem:iembaseAccessionNumber>
    <rdfs:comment></rdfs:comment>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/1400970c-a38a-4c1c-951e-d5086e2a6070"/>
  </ddiem:Disease>
  <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/8d1c4a7c-5d60-4c41-b0d2-fade867c636f">
    <dc:provenance>https://clinicaltrials.gov/ct2/show/results/NCT01065558</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26922636</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27179999</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00004314</dc:provenance>
    <rdfs:comment>The cyclosporine trial (taken immediately upon visual loss in the first eye) is in progress in Leber's optic atrophy to prevent involvement of the fellow eye.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21483849</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3202309</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/c14c9cdb-a32b-4147-9f19-ece5932e0aba"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24093206</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/0f4e2817-5b66-44f8-9c56-5c3913a53fd7">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/fec748c2-84f3-4fa9-b149-56538e2e95ae"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/300322"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29054473</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
  </obo:DDIEM_0000007>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/37781719-d0f1-4a44-a381-4843ff83d638">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0020062</ddiem:url>
    <dc:identifier>HP:0020062</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Low Hemoglobin concentration</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/453e32d7-4f2e-4ce4-9e9e-eb250bd9b6b7">
    <rdfs:label>Cobalamin</rdfs:label>
    <dc:identifier>DB14098</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/5e7ec1d0-889d-4ed4-9c24-85adef85f206"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB14098</ddiem:url>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0f051b76-9e98-4ff3-bc3a-45a526c66b84">
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0100022</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0100022</ddiem:url>
    <rdfs:label>Abnormality of movement</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/5a31869e-4f2d-42a9-b854-eaed1512342b">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/a1f83fdd-a903-43d7-9614-fec6065218ae"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/d7678ddc-3824-46d7-a328-3b216d294a50"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00509</ddiem:url>
    <dc:identifier>DB00509</dc:identifier>
    <rdfs:label>Dextrothyroxine</rdfs:label>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e294f01c-8b2b-4446-9395-7b5b3282e0ef">
    <rdfs:label>Behavioural Disability</rdfs:label>
    <dc:identifier>HP:0000708</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000708</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/64b0d449-8916-49d3-b2e6-76b4033e5324">
    <rdfs:label>AEB1102(Pegzilarginase) â Co-ArgI-PEG modified human Arginase I</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/f93250a7-0a00-46b9-99dc-9ffbe57104f4"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/60343a50-9682-41d0-9a62-9a6da5d5594f">
    <dc:identifier>B01A</dc:identifier>
    <rdfs:label>ANTITHROMBOTIC AGENTS</rdfs:label>
    <ddiem:url>https://www.whocc.no/atc_ddd_index/?code=B01A</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/b35c4f98-48c3-4d4c-9ce9-125c420c0c5a"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/8538656a-d1c6-411f-9202-dc0839c05076">
    <ddiem:url>https://www.drugbank.ca/drugs/DB09269</ddiem:url>
    <rdfs:label>Phenylacetic acid</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/8aa4ff89-6380-4d93-a886-0033497a871e"/>
    <dc:identifier>DB09269</dc:identifier>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/6bbe19d7-d890-46c7-ad26-77a2f07e3fc0">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/18f9ae75-b5d5-4cde-aafb-4c2a35ee400a"/>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/9281cffd-e565-427b-bab6-c752aa09d5d0">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/0f3146b2-b384-4abf-892d-884c3106c970"/>
    <rdfs:label>Chimeric oligonucleotide(oligonucleotide-based gene therapy)</rdfs:label>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/d5e5e5f4-af62-4267-8a57-b59bc814746f">
    <dc:identifier>DB00026</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/b75d90ae-08f6-435b-90f3-bec6b002ed43"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00026</ddiem:url>
    <rdfs:label>Anakinra</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/e250bbf3-9b95-43ab-9c19-21c7c9fcdaaf"/>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8590b2f3-154e-4501-a7ea-0a25f700a3e4">
    <dc:identifier>HP:0001889</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001889</ddiem:url>
    <rdfs:label>Megalobalstic anaemia</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a24f2f9b-a84b-4954-868b-98bb7a4a86de">
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0012477</dc:identifier>
    <rdfs:label>Voice tremor</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0012477</ddiem:url>
  </ddiem:Phenotype>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/27543e68-6e40-4384-a81d-3638ddbede21">
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/c5914ada-577d-4a1e-8b3d-b37335e6a5d9">
        <ddiem:url>https://www.drugbank.ca/drugs/DB00244</ddiem:url>
        <rdfs:label>Mesalazine</rdfs:label>
        <dc:identifier>DB00244</dc:identifier>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/1f281ab5-6eb1-40de-b518-6c7b711ef24f"/>
      </ddiem:Drug>
    </rdf:li>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/7195c20d-7a1a-40c7-9b6e-06992fba3413">
    <ddiem:url>https://www.drugbank.ca/drugs/DB00067</ddiem:url>
    <rdfs:label>Vasopressin</rdfs:label>
    <dc:identifier>DB00067</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/f6322a80-aaab-4553-a6ea-da66ad561586"/>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a0f4c13b-5f5c-4a17-bc0b-2dd0fab0a2c8">
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0010553</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0010553</ddiem:url>
    <rdfs:label>Oculogyric crises</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/bc430260-22a3-4ec3-b844-89f245186339">
    <rdfs:label>dimethyldithiocarbamic acid anion</rdfs:label>
    <ddiem:url>https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI_84293</ddiem:url>
    <dc:identifier>CHEBI_84293</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/29761c75-aac7-458e-91a8-5046d97bfee0"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/cddbf40a-92a0-4ea1-9c32-e82f2e4fe718">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/b69f4667-a152-4ad8-8021-7648b066e7a4"/>
    <rdfs:label>Lovastatin</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/eefb88dd-4a16-4447-9edd-e7d3f847a3a9"/>
    <dc:identifier>DB00227</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/a625f425-f2a1-4566-9be5-989c40f316be"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00227</ddiem:url>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/4b3777e7-be02-4e38-8da1-60ea87b48621">
    <rdfs:label>Gentamicin C1a</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/3a23962d-5abc-4ca7-94ae-fa61f6317766"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB04729</ddiem:url>
    <dc:identifier>DB04729</dc:identifier>
  </ddiem:Drug>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/1ad88eda-bb2b-44bd-9b8c-3f710898f473">
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/direct_complementation_of_a_genetically_defective_protein_by_gene_therapy"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/613153"/>
    <dc:provenance>https://link.springer.com/article/10.1007/s11940-011-0131-z</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/4ce0dd72-9a12-4760-9585-86e11efe406a"/>
    <rdfs:comment>In a different study IV administration of Glucose wasn't effective.https://www.ncbi.nlm.nih.gov/pubmed/22238410</rdfs:comment>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1059131117301243</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/books/NBK1520</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S152500161632250X</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/a685fd84-36ad-4898-87b7-65efebef9b03">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/a7efe2d1-27cb-45e7-a136-338422ff6120"/>
      </rdf:Alt>
    </obo:RO_0000057>
  </obo:OGMS_0000112>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/4e9ec317-55ba-4ef0-9a72-c0be9f3e53d5">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/860a4c9a-77da-4ea8-b8f6-d1d5eeb333a1"/>
    <rdfs:label>Interferon Alfa-2a, Recombinant</rdfs:label>
    <dc:identifier>DB00034</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00034</ddiem:url>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/9f882a81-b6f9-4e86-9754-9dcc8291fa82">
    <rdfs:label>Activated charcoal</rdfs:label>
    <dc:identifier>DB09278</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB09278</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/cfadd4f8-81ec-44d7-bce4-564183cdd002"/>
  </ddiem:Drug>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/a53c752e-650b-45ce-9d1a-132d9a0ebc23">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a22cab46-b0a0-4e03-b3af-06061b44fcd2"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25717099</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19415691</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/5eba6314-73a1-4442-bddb-0461f73c966d">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/2ebbe810-ba3a-4e01-960f-301280814249"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00350662</dc:provenance>
    <dc:provenance>https://www.semanticscholar.org/paper/The-Incidence-of-Transient-Neonatal-Tyrosinemia-a-Zea-Rey-Cruz-Camino/b66304a0a56304f686380af915a92b2b860e9305</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00733811</dc:provenance>
    <rdfs:comment>One of the studies that was carried on mice provides useful information for developing the optimal dosage regimen for HPBCD therapy when administered intravenously to NPC patients.https://www.ncbi.nlm.nih.gov/pubmed/26027824</rdfs:comment>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/604250"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14632789</dc:provenance>
  </obo:DDIEM_0000013>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/bb1c5788-f6df-4bc9-bb94-c29e97fa0646">
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/203750"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/8a9318a8-6c5b-4a39-bf92-abcccacff65e"/>
    <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
    <rdfs:comment>Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss</rdfs:comment>
    <dc:provenance>http://www.babysfirsttest.org/newborn-screening/conditions/beta-ketothiolase-deficiency</dc:provenance>
    <dc:provenance>Abstract</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24260777</dc:provenance>
    <dc:provenance>http://www.neurologyindia.com/article.asp</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/b0568ff3-8170-4e53-bcb4-8a44ed08af35"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
  </obo:DDIEM_0000013>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/00267b03-ee2b-4aa5-a062-7d27685fc92f">
    <rdfs:label>cyclodextrins</rdfs:label>
    <dc:identifier>CHEBI_23456</dc:identifier>
    <ddiem:url>https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI_23456</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/123038b3-c566-46f4-9faf-97498a191b90"/>
  </ddiem:Drug>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/0cb7b8fa-56b5-475a-86d3-fdcc145b5632">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/230650"/>
    <rdfs:comment>The mechanisms of its effects in movement disorders are not well understood but probably reflect an increase in synthesis and release of dopamine, with perhaps some inhibition of dopamine uptake.</rdfs:comment>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/0313a104-6ef0-410c-b652-3e2ac46f3ace"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/c7fcc2ff-0fe0-41f7-ba3c-e7a2a8f04b5c"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17164772</dc:provenance>
    <dc:provenance>https://www.tandfonline.com/doi/full/10.3109/0886022X.2014.900422</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26766614</dc:provenance>
  </obo:OGMS_0000112>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/cb5d4538-9890-415f-9719-49f7fca28ad2">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/3c84013b-4633-4d36-b436-9a505ffee901"/>
  </rdf:Alt>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/79779c51-2983-450d-80b1-41483198c5e1">
    <rdfs:comment>The results of this study suggest that octreotide may aid in the acute or long-term treatment of congenital hyperinsulinism in a limited number of selected cases.https://www.ncbi.nlm.nih.gov/pubmed/8410522/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26962538</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17442906</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25781533</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4612542</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/81ef2c4d-b7c6-4946-9915-b9446d90401d"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/307030"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/35b5c64e-9aaa-46fd-84a3-e5d483d4e101"/>
  </obo:OGMS_0000112>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/9c64e16f-4768-4d55-91b3-6aace3b1b298">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/e3f77dbb-9f6e-4d46-bc11-4e66bf58d7d8"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/8bcac904-9764-4fe7-999f-4978e5385ce9"/>
    <dc:identifier>DB00200</dc:identifier>
    <rdfs:label>Hydroxocobalamin</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/41ddfa5a-ab90-4f54-8ddd-832c7f8f5018"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00200</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/0485ceb0-da17-47fb-af36-06d5d13d2d40"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/8b3157f4-514a-4424-9ea3-3760cdf23f2f">
    <dc:identifier>DB00129</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00129</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/c9411aa6-0eee-4e70-98d3-6f818ac466a0"/>
    <rdfs:label>Ornithine</rdfs:label>
  </ddiem:Drug>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/211c42f0-fcb2-4024-b3d6-13a1ae0d7f4a">
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/535000"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21483849</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22410442</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21600768</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/f02981c0-c7df-43c3-b1ca-d1df6b41908d"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29054473</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20943885</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26448041</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24093206</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3202309</dc:provenance>
    <rdfs:comment>Author: "The therapeutic potential of idebenone therapy is likely to have the highest impact if therapy is initiated early in the disease at a time when retinal ganglion cell loss is still minimal.https://www.ncbi.nlm.nih.gov/pubmed/21810891/</rdfs:comment>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/17f4178b-4525-4283-8ed7-569eae8e79cc"/>
  </obo:OGMS_0000112>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/7b1d3826-8e23-4e2d-af1b-dc84c8d8e06f">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/c8a0dad9-3d59-4c42-b83f-ed9d3e4b5ccd"/>
  </rdf:Alt>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/88352e00-abe7-4b89-a7cc-ce1be42b7c1b">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/f2925ecf-5485-44c7-b23d-ee99839bffd5"/>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/9a063cb9-8d23-4cf4-9630-4f9b5ffce7ae">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/2d8eb481-b2bc-41f2-9cf0-f9b7287dbf27"/>
    <rdfs:label>Carglumic acid</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB06775</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/c8b34aff-5325-4b29-bff2-ac25fd9a0dae"/>
    <dc:identifier>DB06775</dc:identifier>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/93fc5614-e6b3-44b3-bf6f-0dc09d0e21d5">
    <dc:identifier>HP:0001263</dc:identifier>
    <rdfs:label>Developmetal delay</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001263</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/7690efb8-56de-4721-affe-307ee96026ad">
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/549096de-1f5f-42f8-b060-187535b24066">
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/53099ecb-bb57-4f2c-9b1a-1251ef527911"/>
        <dc:provenance>https://www.semanticscholar.org/paper/Glycogen-storage-diseases%3A-Diagnosis%2C-treatment-and-Chen-Weinstein/439025d057229db1b3a117cb02b3c7e6f2bd3580</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17514432</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/232200"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18996862</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15963056</dc:provenance>
        <rdfs:comment>Ad vectors, HDAd is completely devoid of all viral protein genes and has been shown to display markedly reduced toxicity in mice.https://www.ncbi.nlm.nih.gov/pubmed/15753292</rdfs:comment>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a1de0e82-b7a6-4e9b-ad88-43c220bccc47"/>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/c00f7682-321d-4fce-afd0-6bed6fadd236">
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/136120"/>
        <rdfs:comment>The drug was accomapined with fat-restricted diet</rdfs:comment>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/2bb0f639-2813-43ec-9ab9-1b4af5cdc966"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/53099ecb-bb57-4f2c-9b1a-1251ef527911"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29390242</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27491218</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d6cb430b-2402-46ee-90f8-63247dbbf19c"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23522979</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a8661ff7-3068-49dd-9102-b5a4c9f0bec8"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/cbb2adde-3346-4273-8062-e0cd9da35ad7"/>
      </obo:DDIEM_0000013>
    </obo:RO_0000056>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/4daa42ca-a5d1-47d9-911d-136560f9c84b"/>
    <dc:identifier>C09C</dc:identifier>
    <ddiem:url>https://www.whocc.no/atc_ddd_index/?code=C09C</ddiem:url>
    <rdfs:label>ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), PLAIN</rdfs:label>
  </ddiem:Drug>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/46ad625a-7695-4e82-99a4-0c08a5f92093">
    <rdfs:comment>Sodium bicarbonate is not given routinely as any acidosis usually corrects quickly, but sodium bicarbonate may be needed if, after the initial bolus of glucose, the pH remains &lt;7.1 or the pH is deteriorating rapidly. https://www.ncbi.nlm.nih.gov/pubmed/29203193</rdfs:comment>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/136120"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ac5dd036-f5b9-4969-8b63-3aa9ba03f744">
        <dc:identifier>MP:0002647</dc:identifier>
        <rdfs:label>decreased cholesterol absorption</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/MP_0002647</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/bb4f2778-cea9-4a4e-8305-854afc7a5ed5"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24636183</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29390242</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27491218</dc:provenance>
  </obo:OGMS_0000112>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/f633c9b2-bafb-4221-bd9a-351b2b26a5f5">
    <dc:identifier>DB09154</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/2658d3cf-ee1d-4f73-a735-7de27097efb6"/>
    <rdfs:label>Sodium citrate</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB09154</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/bb1c5788-f6df-4bc9-bb94-c29e97fa0646"/>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c262357b-72d5-48da-928e-e13cd4b62fb4">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003750</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>lack of strenght</rdfs:label>
    <dc:identifier>HP:0003750</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9fff14ac-e607-4faf-9a06-f8fb3b58cf9a">
    <dc:identifier>HP:0007009</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0007009</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Central nervous degeneration</rdfs:label>
  </ddiem:Phenotype>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/ac49d299-c683-4626-aede-48babc62c2d6">
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/228000"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28275553</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/db6bd57d-0841-4c91-9a96-19be27dd7842"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/967285ad-a947-43fd-ba9f-55adcef75140">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Abnormal pulmonary ceramide level</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000305"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27155573</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000015"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5338723</dc:provenance>
    <rdfs:comment>The drug wasn't tried in animal model of Farber's disease, however, it seems to have an effect on ceraminde level in lungs.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18376404</dc:provenance>
  </obo:OGMS_0000112>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/9e89e51f-4567-49aa-9d16-9913106f8447">
    <rdfs:label>Uridine triacetate</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/345125e4-7990-480b-8d77-3415fd234a6b"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB09144</ddiem:url>
    <dc:identifier>DB09144</dc:identifier>
  </ddiem:Drug>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/a1c34d13-087c-421e-8305-261fa4273dc3">
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/f6c4ea4f-81bf-4605-8597-1437bffb1187">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/1a49a02e-55f4-4c16-865e-6003ba415bcf"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956916</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/232200"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/direct_complementation_of_a_genetically_defective_protein_by_gene_therapy"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/345f7321-2b9d-4b63-8db8-6f154976000d"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20163245</dc:provenance>
    <rdfs:comment>Uncooked Cornstarch usually is administered at bedtime, and every 6 hours during illness, to prevent morning hypoglycemia and ketosis. In children who are particularly active, a dose of cornstarch in the morning or 1 hour before strenuous or prolonged physical activity can improve stamina. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1474809/</rdfs:comment>
  </obo:OGMS_0000112>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/a1f3236c-cc8a-43d5-91bb-9d7df012bdca">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/20509ec1-bb30-49b4-a8ab-6b091544aadd"/>
    <dc:identifier>DB00993</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/54abc5fd-235b-409b-bcbb-2c86cf1d3927"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00993</ddiem:url>
    <rdfs:label>Azathioprine</rdfs:label>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/78187157-05f7-4139-99db-6bbf05026dd1">
    <rdfs:label>Velmanase alfa</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB12374</ddiem:url>
    <dc:identifier>DB12374</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/1cebedcb-a513-4325-a25f-00d720afaffc"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/9a1641b5-7d88-44d1-af58-0e5d79278094">
    <dc:identifier>N06AB</dc:identifier>
    <ddiem:url>https://www.whocc.no/atc_ddd_index/?code=N06AB</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/c4a9165d-f343-4ef3-8373-0bcdcabb8c58"/>
  </ddiem:Drug>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/b8cabd5f-20c3-4850-869f-63ddf9f84605">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22840416</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0303846712003952</dc:provenance>
    <rdfs:comment></rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30013934</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11102558</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/300438"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b6f8dc53-22dd-4e4f-a8eb-af0a1b6edf9e"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/ff5e395d-975f-446c-a5c0-2c6349abf7a5"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
  </obo:DDIEM_0000013>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/17f4b2f0-3187-4ab0-be92-9f8cea731df1">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/c5730bf9-8156-435b-ab53-19961b45cc1b"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/97da4084-237f-48bc-9355-8561d05e3676"/>
    <rdfs:label>Omega-3 fatty acids</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB11133</ddiem:url>
    <dc:identifier>DB11133</dc:identifier>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/e48c1312-ca63-4280-90e1-dd3a5fda59f4">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/ce58bc70-89f0-410c-87cc-246e17a2cda9"/>
    <rdfs:label>Etretinate</rdfs:label>
    <dc:identifier>DB00926</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00926</ddiem:url>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/931a1ed7-a565-4c3a-a2c4-19b7d054d32e">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/3f146b67-1e90-4a9d-ba6f-a69f1daa7d4b"/>
    <rdfs:label>Other antiinflammatory and antirheumatic agents, non-steroids</rdfs:label>
    <dc:identifier>M01AX</dc:identifier>
    <ddiem:url>https://www.whocc.no/atc_ddd_index/?code=M01AX</ddiem:url>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/44e9353a-2df9-4e73-bbc5-7bae176d7bbe">
    <dc:identifier>DB01345</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/88adc4f3-fcd3-48a9-a808-c6949da8ea66"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01345</ddiem:url>
    <rdfs:label>Potassium cation</rdfs:label>
  </ddiem:Drug>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/55fb719b-1523-4649-9ed0-0733a39f0aef">
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/bc62dda1-510b-4492-bea0-6fbf03639c22">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/d5de7a97-7cf5-4821-a56d-9d5568ed1f43"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30731125</dc:provenance>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <dc:provenance>https://ojrd.biomedcentral.com/articles/10.1186/1750-1172-3-20</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25488886</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24288038</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/0d04ede6-5392-44d8-b501-9c5f9fc51007"/>
    <rdfs:comment>Investigational "Infertility investigation Abetalipoproteinaemia patients might benefit from progesterone supplementation, and further studies on this and hormonal profiles would benefit this pool of patients. Optimising the nutritional profile and body mass index of female patients will undoubtedly contribute to better chances at conception.:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4265040/</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/200100"/>
  </obo:OGMS_0000112>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/c1ca269f-d653-4eee-9865-d869891a642f">
    <rdfs:comment>Patient continued to have daily seizures on oxcarbazepine, topiramate and levetiracetam</rdfs:comment>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/614080"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4886552</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00923247</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/35b5c64e-9aaa-46fd-84a3-e5d483d4e101"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/e44d719c-72fa-49ee-8a1d-3b73d9ef19c9"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00704730</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30297385</dc:provenance>
  </obo:DDIEM_0000013>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/cf1ed284-af61-4ea9-b813-440abbb99ed8">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/4d94d14a-54a8-41da-8824-b653cc661089"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00688</ddiem:url>
    <rdfs:label>Mycophenolate mofetil</rdfs:label>
    <dc:identifier>DB00688</dc:identifier>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/de269ab9-3502-4721-82c7-9e5c0891c8b5">
    <dc:identifier>HP:0002630</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002630</ddiem:url>
    <rdfs:label>Fat soluble vitamin  Malabsorption</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/87b12b7e-1be7-4fc8-a3d0-ffcb66cefb17">
    <rdfs:label>Somatotropin</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/9c0a10a4-979b-44c4-b46e-1b7b419baa1a"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00052</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/a0a73ff8-68e7-4e98-9adb-1ec7dd6ffa7b"/>
    <dc:identifier>DB00052</dc:identifier>
    <obo:RO_0000056>
      <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/b1f14fef-2532-41e5-a3ca-8d027e612f70">
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20301535</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/c3951163-c8e6-466e-8940-5830b567e782"/>
        <rdfs:comment>Although  there are resaerchs that have documented the correlation between LPI and GHD because of the known interaction between the amino acids (AA) arginine, ornithine, and lysine and GH secretion https://www.ncbi.nlm.nih.gov/pubmed/2903866/ https://www.ncbi.nlm.nih.gov/pubmed/14328387/ ,https://www.ncbi.nlm.nih.gov/pubmed/18029456/, https://www.ncbi.nlm.nih.gov/pubmed/6790230/ 
Other reasearchs find these supplements have neither obvious benefit nor difference in terms of prognosis. Arginine supplementation is unhelpful as oral arginine is not absorbed from intestinal mucosa.  https://www.ncbi.nlm.nih.gov/pubmed/27567650</rdfs:comment>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/cd85d73a-279f-4e57-a614-f1843f3c314d"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25859380</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/222700"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23430827</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16775724</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25614305</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/77066bf1-0b44-448f-a183-61007143ccdc"/>
      </obo:DDIEM_0000013>
    </obo:RO_0000056>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/acf41c04-7e4c-4c28-a90f-4f87c3f38c0b"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/4f796926-d867-45f4-a4fc-e232609f9341"/>
  </ddiem:Drug>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/84059483-d9db-47d4-bfa8-88a98dcd8090">
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/617347"/>
    <rdfs:comment>Based on their study auhors of"  https://www.ncbi.nlm.nih.gov/pubmed/21354122?dopt=Abstract"  presume that the combination of these drugs may contribute to reduce LDL-C/HDL-C ratio effectively as well as lowering concentrations of serum triglyceride.</rdfs:comment>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/1a785891-854b-4531-8cf4-c7715a8bd8ce"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3162680</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11425766</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12181212</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2065040</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/c5b8d892-6014-439b-9f47-5ff1aef1ecdf"/>
  </obo:OGMS_0000112>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/65bf1bc3-d9a6-42a6-a8a1-e78c384ff6cb">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0012011</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0012011</dc:identifier>
    <rdfs:label>EEG with parito-occipital spike waves</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/99cee34e-f0df-4e6c-a1f2-34bd50e87092">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/1762f74f-3028-435e-95c8-147b1419a61d"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00783</ddiem:url>
    <rdfs:label>Estradiol</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/211c42f0-fcb2-4024-b3d6-13a1ae0d7f4a"/>
    <dc:identifier>DB00783</dc:identifier>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/64ab1e0d-dd13-4b2a-85be-6d5f44770bf2">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/293bd9b6-3ded-49a0-a1d5-8f4b07c0929a"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00083</ddiem:url>
    <dc:identifier>DB00083</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/3d07024e-09c5-488c-a015-f2cafb51e35c"/>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/fe6f5468-da1e-4389-b717-93c08e236d8e">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21735565</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27491218</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/2f1e6dfb-57db-4ca8-9592-fe629a28c757"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29390242</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/612319"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/6bdf2690-f7c2-41df-9393-f052702e25fe"/>
        <rdfs:comment>rhLCAT was used in atrial and it has been found to increase the HDL-C and it was safe. https://www.ncbi.nlm.nih.gov/pubmed/24385512</rdfs:comment>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <rdfs:label>Botulinum toxin type A</rdfs:label>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/2cdad9eb-2251-47b0-9b23-d918d3be13c5">
    <rdfs:label>Olanzapine</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/07470974-abc5-43ff-ad64-fc6a62044b32"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00334</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/b3ccde5d-61cf-4c2b-b26f-eacf859d1654"/>
    <dc:identifier>DB00334</dc:identifier>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/26c5d310-6abb-44d2-841c-6eaa3c176ae1">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/1f6cc1f4-2d37-48ac-9c28-7dc442364d24"/>
    <rdfs:label>Flavin adenine dinucleotide</rdfs:label>
    <dc:identifier>DB03147</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB03147</ddiem:url>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/556086b0-d359-4545-ab69-d1e548bee32d">
    <obo:RO_0000056>
      <obo:direct_complementation_of_a_genetically_defective_protein_by_gene_therapy rdf:about="http://ddiem.phenomebrowser.net/344c0895-3aee-4a9c-8aad-a991143e0fda">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3306242</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10603107</dc:provenance>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/27fca403-ba5b-4d68-a853-16724148481f"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/c1ba99ab-cc06-4a3f-8f61-65a683c970c2"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6282099</dc:provenance>
        <rdfs:comment>Coupling AAV-mediated promoterless gene targeting to SaCas9 nuclease to efficiently correct liver metabolic diseases</rdfs:comment>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/405afb44-d7a3-4f8d-abd4-18478b52c5e2"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/0a23a4f8-511f-47f4-b99d-7143be8ddfee"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583863</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15753292</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/606785"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/7ec2a0e3-6ad2-41a8-a86b-8d35d8f96e5e"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26692114</dc:provenance>
      </obo:direct_complementation_of_a_genetically_defective_protein_by_gene_therapy>
    </obo:RO_0000056>
    <rdfs:label>AAV-mediated gene therapy</rdfs:label>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/d65b6b34-e2bd-44d9-b96a-d152d854d032">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/a25c7392-7252-4063-9984-d6c21722b5ef"/>
    <rdfs:label>Sirolimus</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/573ed8ec-588c-4bdd-adbd-f4c02f5f7b43"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00877</ddiem:url>
    <dc:identifier>DB00877</dc:identifier>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/da222349-df55-4748-b551-89d56b9bc55a">
    <rdfs:label>Diazepam</rdfs:label>
    <dc:identifier>DB00829</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/7ba0ddaf-3653-43e7-bae9-d53b41c895eb"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00829</ddiem:url>
  </ddiem:Drug>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/193e2ad8-e459-48b6-bfb1-d71d5f67a679">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-Bartter.pdf</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/300971"/>
    <dc:provenance>http://www.neurologyindia.com/article.asp</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24260777</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ae17bf38-53c8-4c7b-9225-a4c33855bb0a">
        <rdfs:label>Renal salt wasting</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000127</ddiem:url>
        <dc:identifier>HP:0000127</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27120771</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2646391</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/01df825e-19d2-4702-bcbe-19b226ddef30"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
  </obo:OGMS_0000112>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/6bb634fb-8a44-4034-9abe-de3e174835e2">
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/ffc2b486-caa0-4010-b6b3-fdffd9440b83">
        <rdfs:label>(5aR)-5a-C-Pentyl-4-epi-isofagomine</rdfs:label>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/ab738592-9d40-4919-ae83-983204a7fdf1"/>
      </ddiem:Drug>
    </rdf:li>
  </rdf:Alt>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/96bf6f59-45eb-4a90-84c5-ce6234302c48">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Exercise-induced muscle cramps</rdfs:label>
    <dc:identifier>HP:0003710</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003710</ddiem:url>
  </ddiem:Phenotype>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/4685fd96-331a-4176-a78f-86a8fb161721">
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/f13914b7-5a31-43dd-b14c-2c7559dd2b32">
        <dc:identifier>DB00133</dc:identifier>
        <ddiem:url>https://www.drugbank.ca/drugs/DB00133</ddiem:url>
        <rdfs:label>Serine</rdfs:label>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/60af4ee2-2e54-4ca9-bd2a-b7da8a5a6fa0"/>
      </ddiem:Drug>
    </rdf:li>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/385e274a-0b58-4975-b44b-4569424e049e">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/42ad7b50-a3a0-4ca2-b250-b9157ec53a75"/>
    <ddiem:url>https://www.whocc.no/atc_ddd_index/?code=A11EA</ddiem:url>
    <rdfs:label>Vitamin B-complex, plain</rdfs:label>
    <dc:identifier>A11EA</dc:identifier>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/885bff2e-4e95-4955-beed-a07e9203a8c0">
    <ddiem:url>https://www.drugbank.ca/drugs/DB01783</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/3568ee74-1d10-4246-bbeb-24b29d73c247"/>
    <dc:identifier>DB01783</dc:identifier>
    <rdfs:label>Pantothenic acid</rdfs:label>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/53f38532-7575-4d09-8bbb-7f69f487e5ff">
    <dc:identifier>CHEBI_17012</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/457b14e9-f936-42e0-b6ea-797acce6d01e"/>
    <rdfs:label>NeuAc</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/4339cd54-a844-457b-aadf-ae96a3f965db"/>
    <ddiem:url>https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI_17012</ddiem:url>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/cee2832d-9d77-45c8-8233-2b50cdc58d21">
    <rdfs:label>Sucrose</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB02772</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/a8036301-73e0-4267-9105-05e154afcae8"/>
    <dc:identifier>DB02772</dc:identifier>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/492c790e-9d09-4105-9c0d-f6ba519ad0b8">
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0031034</dc:identifier>
    <rdfs:label>Abnormal circulating IGFBP level</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0031034</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/606175">
    <dc:identifier>https://www.omim.org/entry/606175</dc:identifier>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/b2a371f3-1268-414c-809b-3dfe566a4d48"/>
    <ddiem:iembaseAccessionNumber>671</ddiem:iembaseAccessionNumber>
    <rdfs:label>CARNITINE ACETYLTRANSFERASE DEFICIENCY</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/671</ddiem:iembaseUrl>
  </ddiem:Disease>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0866fbe4-a4b2-4d29-bee8-18df8eb8fd02">
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0001300</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001300</ddiem:url>
    <rdfs:label>parkinsonism</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/b6fdd131-13af-4866-ab68-56bc4992c9be">
    <ddiem:url>https://www.drugbank.ca/drugs/DB01022</ddiem:url>
    <dc:identifier>DB01022</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/069994f7-dfc3-4ec4-8386-8d864f386472"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/61fe05d5-79c7-47f2-833b-cd7e9bc9bca8"/>
    <rdfs:label>Phylloquinone</rdfs:label>
  </ddiem:Drug>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/db539f7a-9e76-454f-85ad-edd5457017dd">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17628222</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2443756</dc:provenance>
    <rdfs:comment>In the clinical trial: The trial is not enrolling by invitation, no results have been posted yet. update by Oct.7th 2019
Authors have stated that "The data indicate that the retromer and sphingolipid metabolism play a critical role in PLA2G6-associated diseases. These observations may be relevant to Parkinson disease (PD) given that loss of vps35 or gain of Î±-Syn also affects retromer function and causes ceramide accumulation." https://www.ncbi.nlm.nih.gov/pubmed/29909971</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/246450"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7abe47cc-82d0-4989-9cf3-9b5052c8fe87">
        <dc:identifier>HP:0007103</dc:identifier>
        <rdfs:label>White matter changes</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0007103</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220407</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26997609</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000009"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29565174</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1886403</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/1fd48bf1-072d-46f3-b8cb-eca452ece678">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/5a568158-1873-4a99-9518-08c1b27b4d29"/>
      </rdf:Alt>
    </obo:RO_0000057>
  </obo:OGMS_0000112>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/b877cfaf-9375-4780-80f3-ae09f2f6ae59">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/a96b845e-f3a9-4996-9d56-c9b0ffc6a41c"/>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/da66d84d-0bc6-4d27-b9ac-4b88f7fa62e7">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/6e659e6e-9814-4447-a640-046e49861cf5"/>
    <rdfs:label>Bortezomib</rdfs:label>
    <dc:identifier>DB00188</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/4f55fa5d-5fc2-403f-a8b3-77b6c6824db2"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00188</ddiem:url>
  </ddiem:Drug>
  <obo:DDIEM_0000012 rdf:about="http://ddiem.phenomebrowser.net/4e8383a7-7796-4ea9-85f7-d08415770192">
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/9a9c5740-3cca-4819-baf5-78304c513a08"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20495831</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21289269</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25993639</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/457d96e1-6a3d-4c84-acba-6aca3a1b0e7c"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/600740"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22142470</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/057054e8-3498-4069-b295-e83a34a3c389"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/27f10747-7fa5-4fca-97f6-85cc7e1a736d"/>
    <rdfs:comment>In individuals with allergies or intolerance to allopurinol, febuxostat may be considered; however, no data on the use of this medication in UMOD-associated kidney disease are available at present.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27050234</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5367245</dc:provenance>
  </obo:DDIEM_0000012>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/cb39e50a-d4be-40a7-a2c6-9e575ca1a2b2">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/a155753b-ac50-4984-acd5-80ae6865850b"/>
    <dc:identifier>DB05123</dc:identifier>
    <rdfs:label>Gemcabene</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB05123</ddiem:url>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/982a81c2-937e-4a52-9c00-eb7c934eccf6">
    <ddiem:url>https://www.whocc.no/atc_ddd_index/?code=N05A</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/a3b84acb-5f1f-4d5e-9a39-9bb7708f86f6"/>
    <dc:identifier>N05A</dc:identifier>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/51958210-67c1-43cf-8fd4-2c4561420eb1">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Defected neuronal plasma membrane</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/e9d9b4d9-29be-4f65-a32d-a59a787defac">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/aa6e4a7e-de33-49ff-809a-10d5c8c11a38"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/2f8804e7-5ba6-4bcb-bccf-a61f65d7e9cc"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/5821bf5b-2c57-4fa9-b6bd-abd65d5546c5"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/24f4695f-cb83-4e74-acd9-eab279a88b0d"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/d376b148-e2b6-4be7-befd-452e6e3232b3"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01202</ddiem:url>
    <dc:identifier>DB01202</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/cd79cc74-6a3c-48e8-8df9-5a5e2ff7d990"/>
    <rdfs:label>Levetiracetam</rdfs:label>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/fdd06c3c-85e9-443a-95f1-920d6181e2fd">
    <rdfs:label>Chlorpromazine</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/73f9876c-f8d3-485d-8ef0-afefebc47c68"/>
    <dc:identifier>DB00477</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00477</ddiem:url>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/04bcdc35-6bd5-4dfe-92e6-456151791f87">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/a9630580-c9df-44e2-9626-1870a8b4bdae"/>
  </rdf:Alt>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a1fb420a-d6cf-449b-a8c4-1aa3226131de">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Movement Disability</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0100022</ddiem:url>
    <dc:identifier>HP:0100022</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/23c2b1cc-9dd5-4e89-b0bf-949fdd721453">
    <dc:identifier>CHEBI_2786</dc:identifier>
    <ddiem:url>https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI_2786</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/0f3c959c-7845-4aa4-891c-483c0c0c562f"/>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/bf015380-56f8-4899-9caf-e4cc2494b777">
    <rdfs:label>Ataxia</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001251</ddiem:url>
    <dc:identifier>HP:0001251</dc:identifier>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/162ba303-ba46-441f-9dc7-04381fa1a886">
    <rdfs:label>gouty arthritis</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001997</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0001997</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/26f2d863-3141-452a-a383-bbd761ceddb3">
    <dc:identifier>DB14555</dc:identifier>
    <rdfs:label>Ursadiol</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/49f91a3c-b766-42af-b5a4-8ae1a4c96d46"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB14555</ddiem:url>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4c56e2fe-60b3-4ebd-aa93-32527bd55148">
    <rdfs:label>Abnormal mental status</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0100543</ddiem:url>
    <dc:identifier>HP:0100543</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/406e6587-ca15-434f-8d63-4d0ad326bd84">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000083</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0000083</dc:identifier>
    <rdfs:label>Kidney failure</rdfs:label>
  </ddiem:Phenotype>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/76bc34fd-3b2b-4e02-92f5-a26b7ea0ff5a">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/abccd4d6-c26d-43f5-a1bb-09057b22362d"/>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-Bartter.pdf</dc:provenance>
    <rdfs:comment>Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/books/NBK442019</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/379babc0-b14e-4f80-beba-b581bb9a9a9e"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24260777</dc:provenance>
    <dc:provenance>http://www.neurologyindia.com/article.asp</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2646391</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/602522"/>
  </obo:OGMS_0000112>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/609286">
    <rdfs:comment></rdfs:comment>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/8d52e39b-1eef-42a7-ac2d-bbf9181101e1"/>
    <dc:identifier>https://www.omim.org/entry/609286</dc:identifier>
    <rdfs:label>PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA WITH MITOCHONDRIAL DNA DELETIONS, AUTOSOMAL DOMINANT 3; PEOA3</rdfs:label>
  </ddiem:Disease>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/13589aab-a04f-4985-b232-346074e51c74">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/704a84f0-21bd-4ce7-9c3c-77250cd6307c"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB05018</ddiem:url>
    <rdfs:label>Migalastat</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/fdf164ed-7fb0-444e-af82-f8f34ca171bd"/>
    <dc:identifier>DB05018</dc:identifier>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/73e0c403-9fc8-4838-b4b1-8c8b2dfceabb">
    <dc:identifier>DB05386</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/e2f53a0e-a2b7-4fde-a04c-cea7a2031422"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB05386</ddiem:url>
    <rdfs:label>Regramostim</rdfs:label>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f4f41d47-6c09-46fa-861f-5ca2030e515b">
    <rdfs:label>High left ventricular mass index ( Left ventricular hypertrophy)*</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001712</ddiem:url>
    <dc:identifier>HP:0001712*</dc:identifier>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/0de7da26-3b53-4723-995f-d2a262c8a852">
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/d04ff30b-6bb0-409d-bce2-6b31e9418c73">
        <rdfs:label>Atorvastatin</rdfs:label>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/64e75e0d-bd7c-4fc6-9cdd-2cfd6721c9c3"/>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/a58e0143-a05f-48ec-bed3-91d780607e3e"/>
        <ddiem:url>https://www.drugbank.ca/drugs/DB01076</ddiem:url>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/a82b315c-8702-41da-8137-cd4a4b073685"/>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/71513e08-ee54-4066-a806-3d015b05822d"/>
        <dc:identifier>DB01076</dc:identifier>
      </ddiem:Drug>
    </rdf:li>
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/79f0131d-af46-4301-b717-e7a29ae01921"/>
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/b6605cf9-8268-46f8-a530-f10bfb4e0d02"/>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/d37012a9-445b-4a7e-8f4a-eddbf92b9d19">
    <ddiem:url>https://www.drugbank.ca/drugs/DB00126</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/8d2a5f35-d4c6-460e-af7b-13b7f2ca28ec"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/b88e7307-3738-460f-9691-2585fc859af9"/>
    <rdfs:label>Ascorbic acid</rdfs:label>
    <dc:identifier>DB00126</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/94d482af-3bba-4b51-9c93-8745358cd8a1"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/66a186fc-08ec-45e1-84fa-567f23b24abe"/>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9b40f17b-8b83-4f1d-9f9e-1476098ddc17">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0025201</ddiem:url>
    <dc:identifier>HP:0025201*</dc:identifier>
    <rdfs:label>High Apoliporprotein B level(Abnormal abpolipoprotein level)*</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/417d98ef-f06b-4a22-a195-581a9ffe7e7d">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/ca5ac69a-0cf2-403b-b14f-7f546b262880"/>
    <dc:identifier>DB00390</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00390</ddiem:url>
    <rdfs:label>Digoxin</rdfs:label>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/f868e865-2488-4093-b4c9-84bceb48f6d9">
    <rdfs:label>Ferrous sulfate anhydrous</rdfs:label>
    <obo:RO_0000056>
      <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/1b5d9415-793d-498f-ae65-c1404c1c7e25">
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/6d989658-5b5e-4911-b532-6acf9fd05b86"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8317485</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28895280</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17586848</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/209300"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
        <rdfs:comment>Oral iron is given as a supplementary treatment to improve the outcome of Plasma transufsion. "Plasma transfusion, as a natural source of transferrin, leads to Hb synthesis. Since the excess iron is unavailable for erythropoiesis in this disease, and transferrinâbound iron uptake by TfR1 is the only known means of iron delivery for erythropoiesis,3 iron supply during the period in which serum transferrin molecules are present may increase the amount of iron transported to marrow and augment Hb synthesis. https://www.ncbi.nlm.nih.gov/pubmed/28895280</rdfs:comment>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15300460</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/1517f03f-f0d6-4a65-9532-e0c51fcb0d90"/>
        <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
        <dc:provenance>https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/7f736de3-7d79-4a1d-91c3-890afd504412"/>
      </obo:DDIEM_0000013>
    </obo:RO_0000056>
    <ddiem:url>https://www.drugbank.ca/drugs/DB13257</ddiem:url>
    <dc:identifier>DB13257</dc:identifier>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d091746a-8de1-4d71-b5ed-b7cb0379d605">
    <dc:identifier>HP:0003287</dc:identifier>
    <rdfs:label>abnormal energy production in damaged mitochondria</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003287</ddiem:url>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/3697f7e6-ee9a-4399-950b-84ea5dca7805">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/d36e5949-8122-4617-b716-e6404f3a0a88"/>
    <rdfs:label>Phenytoin</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/5ec37888-edcb-4d73-b5c1-005bbcc1df06"/>
    <dc:identifier>DB00252</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00252</ddiem:url>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/8ee814c7-105d-443c-8e90-8eb4e9d5753a">
    <ddiem:url>https://www.drugbank.ca/drugs/DB14751</ddiem:url>
    <dc:identifier>DB14751</dc:identifier>
    <rdfs:label>Mecasermin rinfabate</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/61b0d0b5-7e29-4ba0-89a3-e8e1e2ee43d9"/>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e8aa9f47-a95b-4ab5-b52b-395f8167324e">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001251</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>High ataxia score ( Ataxia)*</rdfs:label>
    <dc:identifier>HP:0001251*</dc:identifier>
  </ddiem:Phenotype>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/82b3806c-e554-4b52-a8fa-58587a104fef">
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/42b3c7f4-2832-462e-bfb9-064bdbe9f458">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/9b5940f1-1250-4854-9edd-4f18a5e32c16"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://musculardystrophynews.com/resolaris-atyr1940</dc:provenance>
    <rdfs:comment>Corticosteriods might be beneficial in heterozygous mutations as patients have milder phenotypes.</rdfs:comment>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/0bbe452a-4761-4f1e-acf4-525fc01bce3a"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02579239</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/253601"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17339125</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
  </obo:OGMS_0000112>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/6b518b0a-1889-4041-9b35-99a4a2994bf3">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/6627c40d-4fd4-41ad-be2f-e15121ad275b"/>
    <rdfs:label>ARC-AAT</rdfs:label>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/4813d17c-f655-4b23-9362-bd373f8fef16">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/bb8d03ff-9844-4206-a627-86ad0011a5b2"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/76bc34fd-3b2b-4e02-92f5-a26b7ea0ff5a"/>
    <dc:identifier>DB00761</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00761</ddiem:url>
    <rdfs:label>Potassium chloride</rdfs:label>
  </ddiem:Drug>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/d520d108-057f-4c1c-8b02-f9e8b02730fc">
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b10bc4cb-b61c-484b-a1a0-27bb77d7b8a5"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27155573</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29044799</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26584826</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/03ce7809-f0bf-45ec-a084-e9d8e9396fc5">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/ad487164-e257-4cf4-96a5-ac5ed8285d9c"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <rdfs:comment>Uncoooked cornstrach was introduced in small frequent meal and was accomapined with elimination of lactose in diet</rdfs:comment>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/fef22ecd-8b2f-4e91-9d45-c7d13b1261df"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5338723</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/151660"/>
  </obo:OGMS_0000112>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/615181">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH BRAIN AND EYE ANOMALIES), TYPE A, 11; MDDGA11</rdfs:label>
    <dc:identifier>https://www.omim.org/entry/615181</dc:identifier>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/d32f3640-0389-49c1-9d27-bcc700dcc924"/>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/1121</ddiem:iembaseUrl>
    <ddiem:iembaseAccessionNumber>1121</ddiem:iembaseAccessionNumber>
  </ddiem:Disease>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/72f059a6-3bac-48bf-94b5-4c9d231090d7">
    <dc:identifier>HP:0003200</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Mitochondrial proliferation in the muscle</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003200</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/543ff07e-c42c-49b1-b540-885acf72b1eb">
    <dc:identifier>DB09105</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/0f3272bc-fb15-41f4-8eac-71e965f83cdc"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/355e1d36-e0fb-4fa8-afc6-ee67c65359c7"/>
    <rdfs:label>Asfotase alfa</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB09105</ddiem:url>
  </ddiem:Drug>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/6afae260-d8aa-41c1-9bfa-6e2fb7319265">
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/eeaff26f-8a24-4819-80f8-bd78eaea0903"/>
    <rdfs:comment>In a different study IV administration of Glucose wasn't effective.https://www.ncbi.nlm.nih.gov/pubmed/22238410</rdfs:comment>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e7f7d494-668a-416a-a291-ff8a51be51e5"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10947080</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/162300"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3491070</dc:provenance>
  </obo:OGMS_0000112>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/a7efe2d1-27cb-45e7-a136-338422ff6120">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/1ad88eda-bb2b-44bd-9b8c-3f710898f473"/>
    <rdfs:label>Adeno-associated Virus 9 Mediated FKRP Gene Therapy</rdfs:label>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/86d114c9-1172-42ff-a7c9-a4ba82a71ca2">
    <rdfs:label>Reduction of WBC cystine levels</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/9af01061-73f2-4d95-96e6-3b1842e2184c">
    <ddiem:url>https://www.drugbank.ca/drugs/DB00994</ddiem:url>
    <dc:identifier>DB00994</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/222ea346-1024-42c3-9bc5-92d3ecb249a1"/>
    <rdfs:label>Neomycin</rdfs:label>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/d85aaa45-4f49-49b2-b267-3c8ccf5f064b">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/25968082-87b6-4f3c-b39c-b264615da92c"/>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/d9ca7f8c-bc0c-4b1e-83c3-efb3019fae77">
    <dc:identifier>DB01592</dc:identifier>
    <rdfs:label>Iron</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/ff0cc9c3-8522-4a9d-b2b1-fe5dbe719eef"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/44fc10d8-d6b5-4b7f-85b3-459c8e9c4e74"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01592</ddiem:url>
  </ddiem:Drug>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/ae91a719-a635-4d11-be2d-adc705e20942">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19622360</dc:provenance>
    <rdfs:comment>"Oral tocofersolan was more bio available than the water-soluble formulation in children with chronic cholestasis and similarly bio available in CF. This suggests that water-soluble vitamin E may represent an alternative to painful intramuscular vitamin E injections in chronic cholestasis, or other oral formulations in CF. However, the mechanism responsible for fat malabsorption in CRD concerns the absorptive phase as opposed to the digestive phase in CF and cholestatic syndromes. To our knowledge, no specific studies with these new vitamin E preparations have been conducted in CRD." https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16141353</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/5eba6314-73a1-4442-bddb-0461f73c966d"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6206929</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/224120"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4925531</dc:provenance>
    <dc:provenance>http://www.ncbi.nlm.nih.gov/pubmed/15804998</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/19fb6344-0f70-4a55-9b6e-4cfdf79fc9e6"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11067870</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
  </obo:DDIEM_0000013>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/8e66fe3e-2d3d-4aa4-aa4b-714f7e983001">
    <rdfs:label>Midazolam</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/561941a1-2fa1-495a-8256-ef74af9761a9"/>
    <dc:identifier>DB00683</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00683</ddiem:url>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/470d03f6-6a09-459a-a216-8af7cab6e577">
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0100022</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0100022</ddiem:url>
    <rdfs:label>movement disability</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/610006">
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/63</ddiem:iembaseUrl>
    <rdfs:label>2-METHYLBUTYRYL-CoA DEHYDROGENASE DEFICIENCY</rdfs:label>
    <ddiem:iembaseAccessionNumber>63</ddiem:iembaseAccessionNumber>
    <rdfs:comment></rdfs:comment>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/ec0ee0bd-a4d2-4278-86f1-d129c73c5e85"/>
    <dc:identifier>https://www.omim.org/entry/610006</dc:identifier>
  </ddiem:Disease>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/817ea5b8-c59c-41a7-948f-1454e84f0b05">
    <dc:identifier>DB09125</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/ff144509-5e7b-430b-9424-11af05afc4b9"/>
    <rdfs:label>Potassium Citrate</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB09125</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/7b538f8f-852e-47bc-911d-27bcbe45d276"/>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2ba430dc-83b1-4d73-b598-9f2c69b34a12">
    <rdfs:label>Functional disability(Constitutional symptom)*</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0025142</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0025142</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/c63a4a34-e965-4817-936d-bcd898fabd05">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/94ea5744-6403-47db-9924-75fde9114dc8"/>
    <rdfs:label>Gene therapy *</rdfs:label>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/949a3471-0cc9-4981-9ae3-f142374cbf5b">
    <ddiem:url>https://www.drugbank.ca/drugs/DB07425</ddiem:url>
    <dc:identifier>DB07425</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/6aa7ae7f-0ce9-43a5-a0cf-3305760283b1"/>
    <rdfs:label>Sobetirome</rdfs:label>
  </ddiem:Drug>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/d0de03aa-dbfd-4061-a90a-a9b6b4434a81">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/e622192b-63ec-4de4-a56a-ddea9e5f2412">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/4289ff94-4d7d-40dd-98f6-c5d46e3b1e6f"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23022422</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/4f58f104-5672-4762-b3dc-5aa64b45cdc0"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18240249</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/118600"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25922564</dc:provenance>
    <rdfs:comment>Anakinra was administered as preventive therapy in one study" https://www.ncbi.nlm.nih.gov/pubmed/19289295". In another one, it was documented that the drug may be helpful to control flares in patients having CPP crystal-induced arthritis for which conventional therapies are ineffective or contra-indicated. https://www.ncbi.nlm.nih.gov/pubmed/23022422. 
The acute/subacute pseudogout or acute hydroxyapatite deposition arthritis should require extended duration of treatment with anakinra than in gouty arthritis . Moreover, adding anakinra to conventional drugs could show better efficacy than each drug alone. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4398911/
There have been case reports and case series of success with interleukin-1Î² inhibitors for both prophylaxis and treatment in patients with ESRD.15 16 However, there are no randomised controlled clinical studies to support efficacy. Furthermore, these therapies are only administered parenterally (which excludes our patient from treatment given her aversion to needles), and the cost of therapy can exceed US$100 000 annually. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6169684/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6169684</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6368924</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22832289</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
  </obo:DDIEM_0000013>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f20a37e0-f929-4af5-93a7-3349dbb12776">
    <rdfs:label>Metabolic Decompensation</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001939</ddiem:url>
    <dc:identifier>HP:0001939</dc:identifier>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/7ad88ed8-0af2-4bf8-aff2-ab80913a102e">
    <ddiem:url>https://www.drugbank.ca/drugs/DB01025</ddiem:url>
    <rdfs:label>Amlexanox</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/bf0f2991-9794-49f5-8d7d-04b376acb513"/>
    <dc:identifier>DB01025</dc:identifier>
  </ddiem:Drug>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/1f281ab5-6eb1-40de-b518-6c7b711ef24f">
    <rdfs:comment>Anti-inflammatory medications, including derivatives of 5-aminosalicylic acid (5-ASA), might be a helpful adjunct for treating gastrointestinal complaints in GSD Ib patients, if renal function is carefully monitored . https://www.ncbi.nlm.nih.gov/pubmed/12373585</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19066956</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25288127</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/232220"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/d70004cc-b749-443b-93a9-3be5f4683494"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/8b67285d-5885-4e5f-979c-820cf8510705"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19541498</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/27543e68-6e40-4384-a81d-3638ddbede21"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12373585</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
  </obo:OGMS_0000112>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/509d7f32-98f4-4b0b-8f9e-9e436755e86f">
    <obo:RO_0000056>
      <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/fc57cf93-39e5-4e8a-922d-649824bae112">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3202309</dc:provenance>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00528151</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21600768</dc:provenance>
        <rdfs:comment>Author: "The therapeutic potential of idebenone therapy is likely to have the highest impact if therapy is initiated early in the disease at a time when retinal ganglion cell loss is still minimal.https://www.ncbi.nlm.nih.gov/pubmed/21810891/</rdfs:comment>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21483849</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/48f0eae9-c050-47a4-8918-9b66e9cc570d"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29054473</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/6dbbe4eb-a199-4640-b05b-b395ed9ac4d1"/>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02805790</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24093206</dc:provenance>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02693119</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/535000"/>
      </obo:DDIEM_0000013>
    </obo:RO_0000056>
    <ddiem:url>https://www.drugbank.ca/drugs/DB11672</ddiem:url>
    <dc:identifier>DB11672</dc:identifier>
    <rdfs:label>Curcumin</rdfs:label>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/dab7ddb9-5505-4be0-b330-1839922f8082">
    <dc:identifier>DB00360</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/f30eb1e8-9038-4959-aea4-8dee35d1bbf9"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/3f91c4b6-1a5c-4f12-9966-c81850c29755"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00360</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/4f4df79f-74ae-413d-aacf-e030c6b1da72"/>
    <rdfs:label>Sapropterin</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/f1771b30-6187-4248-b24b-b63626f1afbc"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/63e8e915-be88-4a94-8cfa-e479295a9d17"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/43610fcf-dd9f-4366-9d8b-d1b663bab843"/>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/162de3ca-5932-410a-8797-34b69655ebad">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/23780b08-fd12-4f13-8a48-864a499b1762"/>
  </rdf:Alt>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/310381da-d0f6-4235-ab58-67a2e0ad6f4a">
    <dc:identifier>HP:0004348</dc:identifier>
    <rdfs:label>abnormality in bone mineral density</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0004348</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Evidence rdf:about="http://ddiem.phenomebrowser.net/EC:0007121">
    <ddiem:url>http://purl.obolibrary.org/obo/EC_0007121</ddiem:url>
    <dc:identifier>EC:0007121</dc:identifier>
  </ddiem:Evidence>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/84ef5cc2-fde1-430e-83fc-fa699c3fbac1">
    <rdfs:label>Developmental impairment</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001270</ddiem:url>
    <dc:identifier>HP:0001270</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/e45ad19e-1b5b-4f87-af9c-7196d6432f6a">
    <rdfs:label>Dextrose, unspecified form</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/3e366340-3aa0-46da-8123-2f5c9717c356"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB09341</ddiem:url>
    <dc:identifier>DB09341</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/f564969c-7ca8-4afd-a01a-02c40ea0f659"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/04e88a9b-863c-49b6-a0d9-86007888602f">
    <dc:identifier>L04</dc:identifier>
    <rdfs:label>IMMUNOSUPPRESSANTS</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/23f10114-fda7-4a99-afa5-cd5318d060f2"/>
    <ddiem:url>https://www.whocc.no/atc_ddd_index/?code=L04</ddiem:url>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/32c8321a-ae48-463f-976f-b3142d42f2d5">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/36baf10e-8a8e-4509-96c3-dd412480c1ca"/>
  </rdf:Alt>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b08f44c8-b4e7-4579-941a-346c0c6c5f77">
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0100716</ddiem:url>
    <rdfs:label>Self-injurious behaviour</rdfs:label>
    <dc:identifier>HP:0100716</dc:identifier>
  </ddiem:Phenotype>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/60af4ee2-2e54-4ca9-bd2a-b7da8a5a6fa0">
    <rdfs:comment>There was no studies, but since there is an observation of low plasma serine conc. in untreated CBS-deficient patients that merits further exploration since supplementation with serine might be a novel and safe component of treatment of homocystinuria.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30755342</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16619244</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31082797</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31196723</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14739681</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31211405</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/4685fd96-331a-4176-a78f-86a8fb161721"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/236200"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24355692</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007764"/>
  </obo:DDIEM_0000013>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/695c65b7-9e50-49f8-97c2-6689e760ea7b">
    <dc:identifier>HP:0000938</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>osteopenia</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000938</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/17bcb986-ac14-4c99-b516-c896eb289d7c">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/b35c4f98-48c3-4d4c-9ce9-125c420c0c5a"/>
    <ddiem:url>https://www.whocc.no/atc_ddd_index/?code=C09CA</ddiem:url>
    <rdfs:label>Angiotensin II receptor blockers (ARBs), plain</rdfs:label>
    <dc:identifier>C09CA</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/acac8c6f-cb7a-4997-a332-e8ecee2f6927"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/d99a8de9-c48d-4bbc-a946-3b6835c8a0c0">
    <rdfs:label>Rituximab</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00073</ddiem:url>
    <dc:identifier>DB00073</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/0fd9f588-0f30-4cef-aec2-ee5286cfc053"/>
  </ddiem:Drug>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/2607a8a9-8aee-4629-a15a-5cedf3cde3b0">
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/208900"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15300460</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/fad2a160-41b1-4c68-afe1-6d8368a40b8e">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001249</ddiem:url>
        <rdfs:label>Poor intelligibility</rdfs:label>
        <dc:identifier>HP:0001249</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17586848</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27906067</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/5dbfe537-c8b4-454a-99c4-12e96e3a1f8e"/>
    <dc:provenance>https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
    <rdfs:comment>There is a common note in different reserachs refers to the importance of early managment by Vitamin E supplements since it limits disease progression and it can reverse some of the clinical manifestation (e.x ataxia and the intellectual deficit), if it was interoduced early in life. Therefore, early diagnosis is paramount.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26232052</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/9ac596cb-17a1-49f7-901a-f7909ce6b1f1"/>
    <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a7a047a0-cbcb-48dd-a447-103ec14fe040"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a24f2f9b-a84b-4954-868b-98bb7a4a86de"/>
  </obo:OGMS_0000112>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/eff6781c-a268-4cf8-b68b-b98073449da3">
    <ddiem:url>https://www.drugbank.ca/drugs/DB00273</ddiem:url>
    <dc:identifier>DB00273</dc:identifier>
    <obo:RO_0000056>
      <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/87ceaafb-6feb-45ac-b7b6-f91a31bcfd1c">
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/220110"/>
        <rdfs:comment>"Oral tocofersolan was more bio available than the water-soluble formulation in children with chronic cholestasis and similarly bio available in CF. This suggests that water-soluble vitamin E may represent an alternative to painful intramuscular vitamin E injections in chronic cholestasis, or other oral formulations in CF. However, the mechanism responsible for fat malabsorption in CRD concerns the absorptive phase as opposed to the digestive phase in CF and cholestatic syndromes. To our knowledge, no specific studies with these new vitamin E preparations have been conducted in CRD." https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717/</rdfs:comment>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/aec43db9-f442-4101-818f-081f49d11b59"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/35b5c64e-9aaa-46fd-84a3-e5d483d4e101"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3963001</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19622360</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22149023</dc:provenance>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/971536</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6206929</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11067870</dc:provenance>
      </obo:DDIEM_0000013>
    </obo:RO_0000056>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/5d7719e6-7144-4f65-b30f-5fb38b572808"/>
    <rdfs:label>Topiramate</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/d0d26044-d250-44ef-8ea9-c09cbeb2859f"/>
  </ddiem:Drug>
  <owl:Class rdf:about="http://purl.obolibrary.org/obo/DDIEM_0000006">
    <rdfs:label xml:lang="en">compensatory complementation of a genetically defective protein</rdfs:label>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000002"/>
    <dc:date rdf:datatype="http://www.w3.org/2001/XMLSchema#dateTime">2019-07-15T18:02:30+00:00</dc:date>
    <dc:creator>leechuck</dc:creator>
    <obo:IAO_0000115 xml:lang="en">A therapeutic procedure in which the normal product of a defective enzyme or protein is provided to alter its concentration or availability by delivery, stabilisation or modulation of turnover. [PNS]</obo:IAO_0000115>
  </owl:Class>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c184d5a2-3421-4a16-8dad-13864d5ffd5e">
    <dc:identifier>HP:0001266</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001266</ddiem:url>
    <rdfs:label>choreoathetosis</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <obo:direct_complementation_of_a_genetically_defective_protein_by_gene_therapy rdf:about="http://ddiem.phenomebrowser.net/b0a8999b-15d6-462d-8446-ae2d89a0ca3a">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17330087</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/253600"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3cb140ca-da04-48fd-a782-a73c2e20aea1">
        <rdfs:label>Low muscle mass</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17339125</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
    <rdfs:comment>Corticosteriods might be beneficial in heterozygous mutations as patients have milder phenotypes.</rdfs:comment>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/cb5dca51-e4f3-47ed-9d4b-2a4436aa2203">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/ec4e6420-90d1-4f2e-bb29-0fed9beba5dc"/>
      </rdf:Alt>
    </obo:RO_0000057>
  </obo:direct_complementation_of_a_genetically_defective_protein_by_gene_therapy>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0d297136-dbde-489d-b8d2-222bb6b7a502">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Misfolded AGA</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/c68c043c-4105-442c-88ea-27e9f1dcd0ea">
    <ddiem:url>https://www.drugbank.ca/drugs/DB01373</ddiem:url>
    <dc:identifier>DB01373</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/4bbcfe79-8115-452b-809e-847ed6b16d89"/>
    <rdfs:label>Calcium</rdfs:label>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/37b2e525-daca-4227-8ded-5e8d0ddfed89">
    <rdfs:label>Metreleptin</rdfs:label>
    <dc:identifier>DB09046</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB09046</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/ed50ce6c-783a-45ad-be4a-1462fe689093"/>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3777dea7-eaa5-4e11-a748-466065fb774a">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0012664</ddiem:url>
    <rdfs:label>Reduced ejection fraction</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0012664</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/46e2bd6a-fb4e-4833-8ddc-e9b4c169e97a">
    <dc:identifier>DB08834</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB08834</ddiem:url>
    <rdfs:label>Tauroursodeoxycholic acid</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/45a0c078-9109-4c43-ac94-6b6422acf06d"/>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/fca28bfd-f73e-46d5-9b61-30eae9d1577c">
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001943</ddiem:url>
    <dc:identifier>HP:0001943*</dc:identifier>
    <rdfs:label>Nocturnal Hypoglycemia(Hypoglycemia)*</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/a3cadab9-6282-4407-ae45-8de3701bf3f6">
    <ddiem:url>https://www.whocc.no/atc_ddd_index/?code=B01</ddiem:url>
    <dc:identifier>B01</dc:identifier>
    <rdfs:label>ANTITHROMBOTIC AGENTS</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/49d963b8-da32-42b4-8288-08e8d28e196d"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/83190cfa-3824-4860-9222-eae63d1aa697">
    <rdfs:label>AAV2/5-PBGD</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/f14690a9-f8f9-45ea-b68f-9285fc4d99b2"/>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/d6753414-6547-47da-af01-5b9310596be6">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/74166c99-82ed-4fa7-8022-ab10061b6a9b"/>
  </rdf:Alt>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/ab738592-9d40-4919-ae83-983204a7fdf1">
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/6bb634fb-8a44-4034-9abe-de3e174835e2"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/230500"/>
    <rdfs:comment>The mechanisms of its effects in movement disorders are not well understood but probably reflect an increase in synthesis and release of dopamine, with perhaps some inhibition of dopamine uptake.</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0217090c-96d9-442c-8a24-0b83bdc3ab95">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0000707</dc:identifier>
        <rdfs:label>Neurologic abnormalities</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000707</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.tandfonline.com/doi/full/10.3109/0886022X.2014.900422</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000012"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27750150</dc:provenance>
  </obo:OGMS_0000112>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/2f375b71-847b-4bb3-b3c7-68fd65bbb0f1">
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1059131117301243</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/books/NBK1520</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1490314</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2bc221f2-9c6e-42ab-8b51-7c69e4315ebd">
        <dc:identifier>HP:0100022</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0100022</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Asterixis-like movement(Abnormality of movement)</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>Clonazepam is a useful adjunct for myoclonus and can be used in combination with lamotrigine to avoid lamotrigineâs myoclonic effects . 
Zonisamide should remain a second-line adjunct in the treatment of JME, owing to the lack of supportive data.
https://link.springer.com/article/10.1007/s11940-011-0131-z</rdfs:comment>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/545000"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://link.springer.com/article/10.1007/s11940-011-0131-z</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/9ac596cb-17a1-49f7-901a-f7909ce6b1f1"/>
  </obo:DDIEM_0000013>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/72c43a87-f6e8-4f8f-a543-147632aabb51">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Abnormal neurodevelopmental profile</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0012759</ddiem:url>
    <dc:identifier>HP:0012759</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/33e09300-c93e-4566-b3d2-7d1d1ee239e1">
    <rdfs:label>Histological abnormalitiesÂ (Abnormal test result)*</rdfs:label>
    <dc:identifier>HP:0500014</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0500014</ddiem:url>
  </ddiem:Phenotype>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/d5f18d72-4f0b-41ab-b2ca-4669a8c36e28">
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/220110"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/35b5c64e-9aaa-46fd-84a3-e5d483d4e101"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/7b2414e5-89bd-428d-8c06-916ebcc5641a"/>
    <rdfs:comment>"Oral tocofersolan was more bio available than the water-soluble formulation in children with chronic cholestasis and similarly bio available in CF. This suggests that water-soluble vitamin E may represent an alternative to painful intramuscular vitamin E injections in chronic cholestasis, or other oral formulations in CF. However, the mechanism responsible for fat malabsorption in CRD concerns the absorptive phase as opposed to the digestive phase in CF and cholestatic syndromes. To our knowledge, no specific studies with these new vitamin E preparations have been conducted in CRD." https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22149023</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19622360</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3963001</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11067870</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6206929</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/971536</dc:provenance>
  </obo:OGMS_0000112>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/deab5bfe-615f-4f9e-bf66-96f67c839755">
    <ddiem:url>https://www.drugbank.ca/drugs/DB00973</ddiem:url>
    <dc:identifier>DB00973</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/b5ec7393-9c9a-4eae-8f27-be52d68952cc"/>
    <rdfs:label>Ezetimibe</rdfs:label>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/c089f715-82d8-4a14-ab84-cc7be2f839ab">
    <ddiem:url>https://www.drugbank.ca/drugs/DB01432</ddiem:url>
    <dc:identifier>DB01432</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/500e29d7-eb6e-4c22-b781-ed71efc8bf24"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/7cb3be2c-0a89-4176-b2c8-2d07975753f6"/>
    <rdfs:label>Cholestyramine</rdfs:label>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/af32c57f-9aa2-4697-8ff1-4ccd3cecc042">
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0004359*</dc:identifier>
    <rdfs:label>Abnormal Fatty acid oxidation</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0004359</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f3f9a6a8-94d8-44d0-91b8-89d6241b686a">
    <rdfs:label>Abnormal facial expression</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0005346</ddiem:url>
    <dc:identifier>HP:0005346</dc:identifier>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/1e2621f0-7627-409f-b884-3130d9a972fb">
    <ddiem:url>https://www.drugbank.ca/drugs/DB12449</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/0e1776ae-9638-4224-80a0-d34fbb52a9c2"/>
    <dc:identifier>DB12449</dc:identifier>
    <rdfs:label>Tempol</rdfs:label>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/056cd8cc-9967-4f9f-b425-f97ec923aae6">
    <dc:identifier>DB01045</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01045</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/ed83bf45-456e-4147-89a7-42c07d77dd28"/>
    <rdfs:label>Rifampicin</rdfs:label>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/b3d1dd60-4560-4198-9ad4-ee47399e2d56">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/ed83e007-6618-4e03-8df0-8b5652a29252"/>
  </rdf:Alt>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9a35c519-df14-4ac7-a536-4ddc9c2d5c1c">
    <rdfs:label>Low tetrahydrobiopterin level</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0040210</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0040210</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/b4b6762d-3909-458d-96a4-75a0632f69be">
    <ddiem:url>https://www.drugbank.ca/drugs/DB00311</ddiem:url>
    <rdfs:label>Ethoxzolamide</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/eabeb264-e565-44bd-bf6f-d98c7be41c0a"/>
    <dc:identifier>DB00311</dc:identifier>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6d2b5557-7b18-4300-aa41-73dcc0f17c44">
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001290</ddiem:url>
    <dc:identifier>HP:0001290</dc:identifier>
    <rdfs:label>Generalized muscular hypotonia</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/ef0ec09c-1da8-43f5-a150-cc1251aaab13">
    <rdfs:label>Lenalidomide</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00480</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/22a8fb2e-3dba-4e98-9f7e-5bd1fb8aeb97"/>
    <dc:identifier>DB00480</dc:identifier>
  </ddiem:Drug>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/0621b2f3-a731-4816-b108-1d068c0e1797">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30090842</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/7de0dca0-98e1-43c3-b01b-fc3342072c86">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/f0b6904c-6261-41d4-baf3-3457c9e30f04"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
    <dc:provenance>https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117</dc:provenance>
    <rdfs:comment>Pharmaceutical studies are needed to reduce the adverse enteral effects.https://www.ncbi.nlm.nih.gov/pubmed/30127521</rdfs:comment>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/249900">
        <rdfs:label>METACHROMATIC LEUKODYSTROPHY DUE TO SAPOSIN B DEFICIENCY</rdfs:label>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/293</ddiem:iembaseUrl>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/567920d4-ffcc-445c-a1e0-a9a577b4cfff"/>
        <dc:identifier>https://www.omim.org/entry/249900</dc:identifier>
        <ddiem:iembaseAccessionNumber>293</ddiem:iembaseAccessionNumber>
        <rdfs:comment></rdfs:comment>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30384011</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/abs/pii/088789949190052M</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9511979</dc:provenance>
  </obo:OGMS_0000112>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f17eac09-dffe-464c-b40b-b5af8d2d5da7">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Low weight,growth</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0004325</ddiem:url>
    <dc:identifier>HP:0004325</dc:identifier>
  </ddiem:Phenotype>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/a3bd3126-e986-4724-812f-9db116cef123">
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/720ced85-3098-4032-bc20-5a7d17ef1fbc"/>
    <dc:provenance>https://link.springer.com/article/10.1007/s11940-011-0131-z</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/f92241e7-3a9d-46e1-8e0d-d326408f934d"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1059131117301243</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/613150"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28980384</dc:provenance>
    <rdfs:comment>In a different study IV administration of Glucose wasn't effective.https://www.ncbi.nlm.nih.gov/pubmed/22238410</rdfs:comment>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/443d08cb-553d-46c2-879b-9a71dc43fca5"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/books/NBK1520</dc:provenance>
  </obo:DDIEM_0000013>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7c3dc3a0-a898-4e31-b438-6fa587720a72">
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001939</ddiem:url>
    <rdfs:label>production of bile acid toxic intermediates</rdfs:label>
    <dc:identifier>HP:0001939*</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/ad487164-e257-4cf4-96a5-ac5ed8285d9c">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/d520d108-057f-4c1c-8b02-f9e8b02730fc"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB09043</ddiem:url>
    <rdfs:label>Albiglutide</rdfs:label>
    <dc:identifier>DB09043</dc:identifier>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/c8036f60-2aff-47df-83f5-a6575c761301">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/8797b3f3-24e7-4963-9370-dd14e661cbcf"/>
    <dc:identifier>DB06742</dc:identifier>
    <rdfs:label>Ambroxol</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB06742</ddiem:url>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/d833f998-6293-4be6-b311-7d772f121821">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/d8cc9f2c-6151-4112-a6b7-bc7a15cc5cb3"/>
    <dc:identifier>DB03904</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB03904</ddiem:url>
    <rdfs:label>Urea</rdfs:label>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/5a568158-1873-4a99-9518-08c1b27b4d29">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/db539f7a-9e76-454f-85ad-edd5457017dd"/>
    <rdfs:label>leucine-restricted diet</rdfs:label>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/3dfdb754-349e-49b4-af5d-9edbde0f22ce">
    <dc:identifier>DB04815</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/2880ac2e-1ada-423f-9688-6b79cf903ea2"/>
    <rdfs:label>Clioquinol</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB04815</ddiem:url>
  </ddiem:Drug>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/59bb4256-c3a9-4acb-852e-e77f19d77b52">
    <rdfs:comment>Drugs has decreased rhe frequency of the tonic seizuress</rdfs:comment>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/9ac596cb-17a1-49f7-901a-f7909ce6b1f1"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/615398"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0387760417301742</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/5a7380bb-31e6-44a5-8716-cdc5239d0ac5"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
  </obo:OGMS_0000112>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b136b220-6994-45d0-8d2a-05c601c4dea2">
    <rdfs:label>Abnormal serum folate</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0040087</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0040087</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f6b404d9-7552-4b2b-8283-04982b0cc70b">
    <rdfs:label>High circulating HGA (homogentisic acid)level</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/b03a674c-2c8e-4b9b-abf4-43c4d0e32569">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/c9b0a777-a47f-4002-899f-f7420d6cb418"/>
    <rdfs:label>scAVV9.CB.CLN6</rdfs:label>
  </ddiem:Drug>
  <obo:DDIEM_0000010 rdf:about="http://ddiem.phenomebrowser.net/3fbfa270-4b95-4795-ad6b-5fd83faead1d">
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/96bf6f59-45eb-4a90-84c5-ce6234302c48"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/600890"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:comment>The drug has been reported to be unbeneficial in one patient . https://www.ncbi.nlm.nih.gov/pubmed/30097991</rdfs:comment>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/5c86cc0e-266b-4b9b-aa18-960029be00c5">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/5a2374ac-f711-4d00-8b44-84550c2b74f9"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e662c40c-ee73-496d-8467-681602293075"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24997711</dc:provenance>
  </obo:DDIEM_0000010>
  <owl:Class rdf:about="http://purl.obolibrary.org/obo/DDIEM_0000002">
    <rdfs:label xml:lang="en">complementation therapy</rdfs:label>
    <obo:IAO_0000115 xml:lang="en">A therapeutic procedure in which a treatment directly or indirectly compensates for the loss or gain of activity of a genetically defective protein within the network or pathway of which that protein is a member. [PNS]</obo:IAO_0000115>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000005"/>
  </owl:Class>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/99956867-9a65-48f8-98a2-c0b2981bb0df">
    <ddiem:url>https://www.drugbank.ca/drugs/DB06819</ddiem:url>
    <rdfs:label>Phenylbutyric acid</rdfs:label>
    <dc:identifier>DB06819</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/ded36b62-43d7-4fce-9dda-6fe79e428fbe"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/d81a647b-dd6f-4997-bd22-a2e066a76ae7"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/cced0042-f26c-4163-aa50-6d29c1b97b5c"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/79779c51-2983-450d-80b1-41483198c5e1"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/c3cad2b7-54ab-4d62-8adf-1793dfe62029">
    <rdfs:label>Modified Atkins diet</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/46def950-dcac-4479-9cac-ac007d92e730"/>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4b6ca8f4-e6e9-4f08-8ea9-a95765bc7ba0">
    <rdfs:label>pyruvic acidemia</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001941</ddiem:url>
    <dc:identifier>HP:0001941</dc:identifier>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/10987cc8-b8de-47dd-860a-680d24d8bc7a">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/787fe4ca-2069-4fc7-80f7-a7b38c947603"/>
    <rdfs:label>6S-NBI-DGJ</rdfs:label>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/3b4288ea-af75-4549-8066-24d0290941c7">
    <rdfs:label>r LCAT</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/519f9a68-aa00-40a6-8c6c-0c408620a990"/>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1cd39339-6a58-41f1-937b-a74f800b5081">
    <dc:identifier>HP:0001249</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001249</ddiem:url>
    <rdfs:label>Diminished intellectual abilities</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/ceac9bcd-9659-44c1-a5a5-5897a8716e30">
    <dc:identifier>DB09241</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/7ce84530-4b65-4812-9be7-caf4f77515ff"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB09241</ddiem:url>
    <rdfs:label>Methylene blue</rdfs:label>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/9381dc87-4bbd-406a-8af3-fc73f9a3a268">
    <dc:identifier>DB00098</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00098</ddiem:url>
    <rdfs:label>Antithymocyte immunoglobulin (rabbit)</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/36c84d6f-fb96-4f6b-9f9f-bb10339b2b69"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/944123b4-3a2e-49ec-a6f7-2066bd874578">
    <ddiem:url>https://www.drugbank.ca/drugs/DB14778</ddiem:url>
    <dc:identifier>DB14778</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/623818b5-0ad1-470d-af86-e9dc06a586b5"/>
    <rdfs:label>Setrusumab</rdfs:label>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/953aefcd-fbaa-4081-88aa-3ad90fe2ec5b">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Cerebellar dysfunction</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2382da26-c19c-47c1-bc35-224b81e4c665">
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0003455</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003455</ddiem:url>
    <rdfs:label>Abnormal elevated level of VLCFA in plasma</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/4ab240b8-315a-4c76-82d5-2adb708ae883">
    <ddiem:url>https://www.drugbank.ca/drugs/DB01083</ddiem:url>
    <rdfs:label>Orlistat</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/e31b9160-7c05-437e-b3f4-a02ffa53907d"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/f7f648dd-369f-4073-a9a3-88931ab5ece5"/>
    <dc:identifier>DB01083</dc:identifier>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/55605561-b5ce-4520-aafb-ae24e794ee79">
    <dc:identifier>DB01151</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/68261cc2-d661-4e7c-ade2-c852bb44acae"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/d0c68d44-cc59-4b81-a786-2f94049a9730"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01151</ddiem:url>
    <rdfs:label>Desipramine</rdfs:label>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1d0525b3-b9fd-407b-9d02-8f542aa34bb2">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Ptosis</rdfs:label>
    <dc:identifier>HP:0000508</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000508</ddiem:url>
  </ddiem:Phenotype>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/72ca8f73-e2fb-4cfc-b715-49e5def05917">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/0add3a4c-60fe-493e-97a8-037666cfcbb9"/>
  </rdf:Alt>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2b6e16eb-1d7e-4840-aa42-f0a5e3328249">
    <rdfs:label>Abnormality of muscle physiology</rdfs:label>
    <dc:identifier>HP:0011804</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0011804</ddiem:url>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/7aaf69ad-d88e-4ca6-b752-3c0134a319d9">
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/86977261-bae0-4ad0-a364-da0da512853f">
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/7d81ee63-e46c-48ce-8773-2d711e8eedfd"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/222700"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/6777479</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/406e6587-ca15-434f-8d63-4d0ad326bd84"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16868861</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22402328</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25335805</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25859380</dc:provenance>
        <rdfs:comment>THe drug is well known to be a putative therapy for severe osteopenia, but more reliable protocols are needed.</rdfs:comment>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f47b0595-c3dc-4c80-a8c3-1ead78d36c33"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/9b019a1a-e8c3-45f5-ab16-32b11896eee9"/>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <rdfs:label>Benazepril</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00542</ddiem:url>
    <dc:identifier>DB00542</dc:identifier>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/a0ad4968-b2f4-4c46-9602-76b8d9450348">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/1bea97c1-9392-4fb3-9dd8-d3f8caf82d17"/>
  </rdf:Alt>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/fb34fc8a-25c6-476c-821d-911cbddff26b">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000953</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0000953</dc:identifier>
    <rdfs:label>Hyperpigmentation</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/a7f7bc12-b1b9-41aa-abf2-9bb8d0b91eeb">
    <rdfs:label>Eliglustat</rdfs:label>
    <dc:identifier>DB09039</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/c0215cda-323a-4d31-8b11-a37cd7faa483"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/4c73028d-a140-4d88-923b-7e0c52f45224"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB09039</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/19da86b3-b99e-4dab-9073-218045a8b6db"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/cadd1903-1f78-4e00-9156-4b1348aeed3c">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/10de88c4-06a4-4b4f-911f-0014318071f5"/>
    <rdfs:label>Chloral hydrate</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01563</ddiem:url>
    <dc:identifier>DB01563</dc:identifier>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/66a81dc6-3063-43ca-8e1e-0397cdd7d364">
    <rdfs:label>iminosugar DGJNAc( 2-acetamido-1,2-dideoxy-d-galactonojirimycin)</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/43354398-6b69-46ec-a3d3-afc3e3995a46"/>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/fe8f2fc1-17c6-4934-a71e-98da9b1d94fb">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/63379667-4ede-4bc0-94d0-31b548a6d8ec"/>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/d814410e-e2d2-4d45-898b-7a26bd0bbe0c">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/85f32a56-dd48-4f95-81ab-94587f6c50b6"/>
    <rdfs:label>AT342</rdfs:label>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4024886d-ee0a-41d3-bd11-0989827e2078">
    <rdfs:label>Low levels of serum vitamin B12</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0100502</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0100502</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/bb9470e1-f07f-4939-bc9e-aee21ea40d71">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/32f0dabc-b2ad-42b5-a592-11479540ed61"/>
    <rdfs:label>Norleucine</rdfs:label>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2d18b821-1e47-46ed-84ee-326484f2b08b">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Atypical bile acid synthesis</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/8d5d9680-dc88-4573-8997-a163a314b4e6">
    <dc:identifier>DB08876</dc:identifier>
    <rdfs:label>Taliglucerase alfa</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/c783a08f-d600-4d85-8963-bdcb15cfeaba"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB08876</ddiem:url>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/945a1f69-a783-40b5-94e6-6bdae2e9666a">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/d8acc973-6d08-45d5-80e1-e9dc9ec4af67"/>
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/1fb56fa2-ab65-4363-b8cd-378e44d0f43d"/>
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/a168b583-4467-494e-adf1-d5226dfd5cee"/>
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/17bcb986-ac14-4c99-b516-c896eb289d7c"/>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/6fadbc84-61b4-497e-9eaa-f5b824eafe06">
    <dc:identifier>DB01329</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/a6e5c923-73c2-49e1-b70c-c4f2117f0996"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01329</ddiem:url>
    <rdfs:label>Cefoperazone</rdfs:label>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/5ce34dc9-4a8a-4d27-8ab6-1973175f870b">
    <rdfs:label>Chloroquine</rdfs:label>
    <dc:identifier>DB00608</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/0f46a7ea-e156-4b53-8b66-868e3d7281dc"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00608</ddiem:url>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/4d04e19f-76cb-477e-81fd-bb199a14aa0b">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/33ca4976-b103-4d63-beb2-bfdd454e09f0"/>
  </rdf:Alt>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b123f4a7-4b1c-41db-b28f-deef7db8017f">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000572</ddiem:url>
    <rdfs:label>Functional loss of vision</rdfs:label>
    <dc:identifier>HP:0000572</dc:identifier>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/cfda5a8d-5141-4b57-894d-1ab1cc5aa491">
    <dc:identifier>DB14681</dc:identifier>
    <rdfs:label>Cortisone</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB14681</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/93fc8313-645f-46cb-ba2c-ec39d326c285"/>
  </ddiem:Drug>
  <owl:Class rdf:about="http://purl.obolibrary.org/obo/DDIEM_0000004">
    <dc:date rdf:datatype="http://www.w3.org/2001/XMLSchema#dateTime">2019-07-15T10:19:07+00:00</dc:date>
    <rdfs:label xml:lang="en">direct complementation of genetically defective protein</rdfs:label>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000002"/>
    <obo:IAO_0000115 xml:lang="en">A therapeutic procedure in which a genetically defective protein is replaced by a canonical source of the same protein, genetically as in gene therapy, or by some other means of delivery, whose completion is hypothesized by a health care provider to eliminate a disorder or to alleviate the signs and symptoms of a disorder or pathological process. [PNS]</obo:IAO_0000115>
    <dc:creator>leechuck</dc:creator>
  </owl:Class>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a1de0e82-b7a6-4e9b-ad88-43c220bccc47">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0012212</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Glomerular hyperfilteration (Abnormal glomerular filtration rate)</rdfs:label>
    <dc:identifier>HP:0012212</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/617070">
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/60786166-eacf-44ea-a8d2-9d2985227fb7"/>
    <rdfs:label>PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA WITH MITOCHONDRIAL DNA DELETIONS, AUTOSOMAL RECESSIVE 4; PEOB4</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>https://www.omim.org/entry/617070</dc:identifier>
  </ddiem:Disease>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/5ef47c3a-a81d-41f9-9c6f-b0643e63a592">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/8df72417-da07-4b70-bf14-ec23750e72b4"/>
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/d04ff30b-6bb0-409d-bce2-6b31e9418c73"/>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/9be468ec-2460-4755-bf68-ca3955c90631">
    <rdfs:label>Haloperidol</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/a6443e5d-d187-46de-8b2d-6fc1452d4652"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00502</ddiem:url>
    <dc:identifier>DB00502</dc:identifier>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/499d67b6-f538-4bbd-8045-1b48cfc2e5e2">
    <rdfs:label>VITAMINS</rdfs:label>
    <ddiem:url>https://www.whocc.no/atc_ddd_index/?code=A11</ddiem:url>
    <dc:identifier>A11</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/8a1e0d96-8f8c-44af-aea4-eb960c300e6d"/>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/490e25b1-b763-4344-a256-b6035e150a12">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Hypoalbuminemia</rdfs:label>
    <dc:identifier>HP:0003073</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003073</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/87dc720b-201b-42f6-9941-23efd491ab26">
    <rdfs:label>Unstable AGA enzyme</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/dcb980cf-8916-4301-9dc7-b1d9184c1397">
    <ddiem:url>https://www.drugbank.ca/drugs/DB00679</ddiem:url>
    <dc:identifier>DB00679</dc:identifier>
    <rdfs:label>Thioridazine</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/10de88c4-06a4-4b4f-911f-0014318071f5"/>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/dcf61289-0c08-45ed-b0c6-390829910eea">
    <rdfs:label>Decreased muscle mass</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/3dda176f-cf5d-4de3-9c15-7c3172698e14">
    <rdfs:label>Kaliumbromid</rdfs:label>
    <dc:identifier>CHEBI_32030</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/d5b54632-b188-42cd-b522-cd9b8911f269"/>
    <ddiem:url>https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI_32030</ddiem:url>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/3b11bc13-be0f-4578-9dc3-7a6b7e2008e9">
    <dc:identifier>DB13191</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/e4960c7e-5f53-40ed-a85d-3f664d803db5"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB13191</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/5e5c88d0-8916-4fd3-8530-8d2b7f8d362d"/>
    <rdfs:label>Phosphocreatine</rdfs:label>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/97024237-35c1-4a27-88e6-df46878e676d">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/cd781b84-61ec-43da-be63-fe333b2bbd0e"/>
    <rdfs:label>Pravastatin</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/46ad625a-7695-4e82-99a4-0c08a5f92093"/>
    <dc:identifier>DB00175</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00175</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/e2f9394c-3abe-476b-be21-4b6640913c43"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/d5de7a97-7cf5-4821-a56d-9d5568ed1f43">
    <ddiem:url>https://www.drugbank.ca/drugs/DB00396</ddiem:url>
    <dc:identifier>DB00396</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/55fb719b-1523-4649-9ed0-0733a39f0aef"/>
    <rdfs:label>Progesterone</rdfs:label>
  </ddiem:Drug>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/609283">
    <rdfs:comment></rdfs:comment>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/1372</ddiem:iembaseUrl>
    <dc:identifier>https://www.omim.org/entry/609283</dc:identifier>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/5f3085ff-bea4-4b9a-b389-306846f61b37"/>
    <rdfs:label>PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA WITH MITOCHONDRIAL DNA DELETIONS, AUTOSOMAL DOMINANT 2; PEOA2</rdfs:label>
    <ddiem:iembaseAccessionNumber>1372</ddiem:iembaseAccessionNumber>
  </ddiem:Disease>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/a1213c99-08f3-4506-96d2-0a61a5d1586a">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/6986a6d4-c93c-4e19-afa3-f237fb45e577"/>
    <dc:identifier>DB00996</dc:identifier>
    <rdfs:label>Gabapentin</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00996</ddiem:url>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/6711d4e7-07e9-44e7-8dd2-8026fc68a3b2">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/4db6097c-8707-48ca-91d4-0cb0b56e1871"/>
    <dc:identifier>DB00169</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00169</ddiem:url>
    <rdfs:label>Cholecalciferol</rdfs:label>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6bdf2690-f7c2-41df-9393-f052702e25fe">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001257</ddiem:url>
    <rdfs:label>abnormal muscular co-contraction</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0001257</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9bcd6e8e-7a61-4aba-b55e-d5650fc3b3f0">
    <rdfs:label>Decreased activity of mitochondrial ATP synthase complex</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0011925</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0011925</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/393ded8e-5aec-4d99-8233-5ac8509e4432">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003128</ddiem:url>
    <rdfs:label>hyperlactatemia</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0003128</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/fb062757-de94-4052-b65b-0a3757c278e0">
    <ddiem:url>https://www.drugbank.ca/drugs/DB11917</ddiem:url>
    <rdfs:label>Vatiquinone</rdfs:label>
    <dc:identifier>DB11917</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/e3bd99d8-e18d-4c49-8e39-aa4439ac45a3"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/17467ef8-995a-404c-9689-070ccc840365"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/46cb02cd-4e31-4b65-a7eb-1b26764cfae2"/>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/12f5dbc6-5253-4e3d-a6f7-d406147f769b">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/637d9771-4d1a-4965-8581-d339b0b8b2ba"/>
  </rdf:Alt>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8e2d217d-1911-4419-b266-3d6d0981f695">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003750</ddiem:url>
    <dc:identifier>HP:0003750</dc:identifier>
    <rdfs:label>Increased muscle fatiguability</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/2dfbbd8b-c34d-4c46-98d4-e75f66ffc981">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/da222349-df55-4748-b551-89d56b9bc55a"/>
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/59201c4e-ef95-4492-81f6-233c60073a8d"/>
  </rdf:Alt>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ca2edda0-57e5-42f4-b076-fbff004f56f1">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Poor sleep quality(Sleep disturbance)*</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002360</ddiem:url>
    <dc:identifier>HP:0002360*</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0bcb89bc-df90-4229-9021-71a188057e6f">
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0012622</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0012622</ddiem:url>
    <rdfs:label>renal function declines</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4a0fce45-6bb5-4148-bbf9-b0107dc85fc4">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003326</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0003326</dc:identifier>
    <rdfs:label>Myalgia</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/78ecd39d-7157-41bf-ac78-ab63a8603a54">
    <dc:identifier>HP:0003473</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003473</ddiem:url>
    <rdfs:label>Low energy level</rdfs:label>
  </ddiem:Phenotype>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/ff1cb1db-7fb7-436f-b430-14e30e2cac47">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/2243874d-50d6-4070-a74c-ac838c71fe13"/>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/7cfa2b4b-4c95-4231-89be-de2e569f0f0d">
    <rdfs:label>NA</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/85ee05c6-f571-4956-b4bc-de1db1ea3053"/>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5137e1c4-c9c3-4a62-a26e-a86c20f4d54e">
    <dc:identifier>HP:0100022*</dc:identifier>
    <rdfs:label>Voluntary movement abnormalities(Abnormality of movement)*</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0100022</ddiem:url>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/c0ca5200-1b24-4fdb-a8e6-f874136a34df">
    <dc:identifier>S01BC</dc:identifier>
    <ddiem:url>https://www.whocc.no/atc_ddd_index/?code=S01BC</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/7214f0e0-a52d-4a9f-9c31-02d4504f4f51"/>
    <rdfs:label>Antiinflammatory agents, non-steroids</rdfs:label>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/ef09429f-2497-4a05-91cd-7a9ffa6e8e18">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/746dd21e-d928-4d35-80d5-b25eb5bba7b2"/>
    <rdfs:label>HDAd-G6Pase</rdfs:label>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1f276314-6d55-472e-9836-840aebd446ce">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001129</ddiem:url>
    <rdfs:label>Large central visual field defect</rdfs:label>
    <dc:identifier>HP:0001129</dc:identifier>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/fa24eff3-c401-4324-b234-88444910ba26">
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0000739</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000739</ddiem:url>
    <rdfs:label>anxiety</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/2ebbe810-ba3a-4e01-960f-301280814249">
    <rdfs:label>Deferiprone</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/ae91a719-a635-4d11-be2d-adc705e20942"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/a53c752e-650b-45ce-9d1a-132d9a0ebc23"/>
    <dc:identifier>DB08826</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB08826</ddiem:url>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/66432d86-5496-4976-a3aa-07f19bf8ed9d">
    <rdfs:label>hydroxypropyl-Î²-cyclodextrin (HPBCD)</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/0967de03-d801-46be-aacd-78b8275d71f5"/>
  </ddiem:Drug>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/118610">
    <rdfs:label>CHONDROCALCINOSIS DUE TO APATITE CRYSTAL DEPOSITION</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>https://www.omim.org/entry/118610</dc:identifier>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/12f64661-8448-4e7d-9971-2ca66c9cbf2c"/>
  </ddiem:Disease>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/48963ea9-d89a-4c71-b88f-d1bbc0394b55">
    <rdfs:label>RT001 (11,11-di-deutero-linoleic acid ethyl ester)</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/b143ca20-f04d-4643-bbdc-7edf0869a093"/>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/e7a14bec-cbbe-4f50-81cf-23f0a4cc0357">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/c85ea16f-6b04-4d05-bec5-58b18a6930f3"/>
  </rdf:Alt>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/02264d42-2607-4e15-9bc4-44e3dadef4e2">
    <rdfs:label>tissue damage</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/618098">
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/1336</ddiem:iembaseUrl>
    <rdfs:label>PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA WITH MITOCHONDRIAL DNA DELETIONS, AUTOSOMAL RECESSIVE 5; PEOB5</rdfs:label>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/29d89d9f-550a-48c7-9dd3-de3279a6612e"/>
    <ddiem:iembaseAccessionNumber>1336</ddiem:iembaseAccessionNumber>
    <dc:identifier>https://www.omim.org/entry/618098</dc:identifier>
    <rdfs:comment></rdfs:comment>
  </ddiem:Disease>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/d0542023-4c46-4cb6-a410-d2b442fab8af">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/b2720941-fbd3-4bab-854d-7936df4f8ede"/>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/ba84977f-9f90-4112-8534-8ef4bbdcfda8">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/24676602-e5fa-43d9-8ba1-4c1908093dce"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB04552</ddiem:url>
    <dc:identifier>DB04552</dc:identifier>
    <rdfs:label>Niflumic acid</rdfs:label>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/bda33a97-8ee2-47ee-a072-c0849fe7f38b">
    <rdfs:label>CoCarbs + HPro</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/552f4b3f-f4d6-4d25-b402-5ea5ce0cfe28"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/2efa34cb-5893-4274-8a72-c583b8a7d5a6">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/8730966e-4392-43d8-a010-c330a210f701"/>
    <rdfs:label>Pitressin tannate in oil</rdfs:label>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/af919467-55e5-4c67-8978-a38be6a20fd3">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000155</ddiem:url>
    <dc:identifier>HP:0000155</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Oral ulceration</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9c657128-2cd0-473e-a63f-5ed2bd58c719">
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0012656</ddiem:url>
    <dc:identifier>HP:0012656</dc:identifier>
    <rdfs:label>dopamine deficiency</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/a83d37f1-7679-47a7-8dd4-7319c09fc2a3">
    <rdfs:label>Linoleic acid</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB14104</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/8006073f-4b36-4903-b56c-bda9ff8c0d7e"/>
    <dc:identifier>DB14104</dc:identifier>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/0f107f09-8101-4951-88e4-487c1b79e6a4">
    <ddiem:url>https://www.drugbank.ca/drugs/DB09539</ddiem:url>
    <dc:identifier>DB09539</dc:identifier>
    <rdfs:label>Omega-3-acid ethyl esters</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/3051ea53-afa8-4e57-8f18-e90651baa0b5"/>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/874d1dda-4066-4783-ad21-5e5ac8eaf174">
    <rdfs:label>mitochondrial toxicity*</rdfs:label>
    <dc:identifier>HP:0012103</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0012103</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/f09958cc-9667-40fc-842b-a2dc70c5bf68">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/9348d05f-4431-43a7-a575-60d362338c33"/>
    <rdfs:label>Î²-galactosidase:RTB lectin fusion</rdfs:label>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e436fde1-15f0-49e5-94b6-6cf86019a5aa">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0200125</ddiem:url>
    <rdfs:label>High lactate ,pyruvate ratio(Mitochondrial respiratory chain defects)*</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0200125</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/337febda-56f7-43af-922e-bfc888891d84">
    <rdfs:label>D-alpha-Tocopherol acetate</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB14002</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/a58cd49f-a2e2-419e-8f18-4381e016f383"/>
    <dc:identifier>DB14002</dc:identifier>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/c23cf81d-b12a-4d91-aec2-09b105f5a452">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/c8ed1994-7ecc-4d57-aefe-69678e728b46"/>
    <rdfs:label>Complex carbohydrates+Beneprotein+Low fats</rdfs:label>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/6b1e2c3d-796f-4767-8ba4-5cce6cd7e5c2">
    <rdfs:label>Cinacalcet</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01012</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/73316025-17ba-4432-8743-d4268c2c7478"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/4e8383a7-7796-4ea9-85f7-d08415770192"/>
    <dc:identifier>DB01012</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/5a4097ab-e110-4e1a-9f15-fbe34bb9432c"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/cae65cd6-c319-4d1a-9241-6de48e9090ef">
    <rdfs:label>Uncooked cornstarch+ Beneprotein</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/de4fe07c-9247-4eda-b5c4-6519a2e8c0f9"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/60fbebfd-e179-4b97-a8ad-ba77e43a20e5">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/6e02a1ec-4fab-4072-9c59-43b0d895616b"/>
    <dc:identifier>DB06667</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB06667</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/2668e0f0-2101-40b0-9bdd-705720370fcb"/>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/3e96db59-b4a5-4aa0-8b4a-070c29fa8d6a">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/f334672f-4dcf-4441-bfd6-54edb2823c83"/>
  </rdf:Alt>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/cec6807d-8ad6-4b23-9641-ec2acb30c053">
    <rdfs:label>Progressive ataxic neuropathy</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003434</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0003434</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/a40e80e3-8202-4845-b5ae-0a286711a4f4">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/3c07775f-5982-40cb-b084-5bb7503b7c8d"/>
    <dc:identifier>DB01394</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01394</ddiem:url>
    <rdfs:label>Colchicine</rdfs:label>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8682b3f2-bb5b-41c6-8ed1-0b9195cb0d13">
    <rdfs:label>Abnormal Unified Parkinson's Disease Rating Scale (UPDRS )score(Abnormality of neurotransmitter metabolism)*</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/a491cfe0-7651-4e28-9024-a9858f09bec6">
    <dc:identifier>DB06281</dc:identifier>
    <rdfs:label>Torcetrapib</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/64e75e0d-bd7c-4fc6-9cdd-2cfd6721c9c3"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB06281</ddiem:url>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/c47fb591-5f95-477d-8519-6119dd0a644c">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/9be468ec-2460-4755-bf68-ca3955c90631"/>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/76493a1c-30e6-47ad-9be1-35b97ddf6308">
    <rdfs:label>Selegiline</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01037</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/630766ca-42fc-4280-90ec-7feb9c89590a"/>
    <dc:identifier>DB01037</dc:identifier>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/568e015d-ad9b-43a7-8959-f7dd5cfabd7e">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/cd79cc74-6a3c-48e8-8df9-5a5e2ff7d990"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/2607a8a9-8aee-4629-a15a-5cedf3cde3b0"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/561941a1-2fa1-495a-8256-ef74af9761a9"/>
    <dc:identifier>DB01068</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/2f375b71-847b-4bb3-b3c7-68fd65bbb0f1"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/59bb4256-c3a9-4acb-852e-e77f19d77b52"/>
    <rdfs:label>Clonazepam</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01068</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/19a048c0-a44e-4b8b-af36-345b34badb89"/>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d67d2f2d-7b95-4084-b84d-2428758cada7">
    <dc:identifier>HP:0032367</dc:identifier>
    <rdfs:label>Abnormal circulating GH level</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0032367</ddiem:url>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1b24759d-8982-4bfa-ad9b-db425e331d2e">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Low 5âMTHF level</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/a1ff9a10-ef70-483b-b1ef-39349ff3e91f">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/afba0f65-eda9-4038-81a9-89c950ce183f"/>
    <dc:identifier>DB00178</dc:identifier>
    <rdfs:label>Ramipril</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00178</ddiem:url>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/537f6c64-f94d-4074-a7af-3e8b26ce516e">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/84db0a1c-d5f4-42bb-9ef1-b6f6106e1feb"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB11859</ddiem:url>
    <dc:identifier>DB11859</dc:identifier>
    <rdfs:label>Brexanolone</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/2e5b82f7-d1a9-48ce-a8f6-359b9be6c412"/>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8f550abf-822b-4d32-8ea0-305414162fbe">
    <rdfs:label>Elevated serum toxic intermediates in isoleucine pathway</rdfs:label>
    <dc:identifier>HP:0001939</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001939</ddiem:url>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/5a2374ac-f711-4d00-8b44-84550c2b74f9">
    <dc:identifier>CHEBI_32362</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/3fbfa270-4b95-4795-ad6b-5fd83faead1d"/>
    <rdfs:label>enanthate</rdfs:label>
    <ddiem:url>https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI_32362</ddiem:url>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/068a5a16-3193-49f1-8f7a-0fa9fdb7a5ee">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/0c776f5d-bb37-426d-96a9-2cfc234d16f4"/>
    <dc:identifier>DB00230</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00230</ddiem:url>
    <rdfs:label>Pregabalin</rdfs:label>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7cf5eabc-4037-4e73-811e-e9c98e038fe3">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000934</ddiem:url>
    <dc:identifier>HP:0000934</dc:identifier>
    <rdfs:label>chondrocalcinosis</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/e68fb053-4af7-4e91-b463-a709aec705e3">
    <dc:identifier>DB00421</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00421</ddiem:url>
    <rdfs:label>Spironolactone</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/7b17e3cd-6da9-4687-80cb-45b834826e2b"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/5e136d21-8aa6-4476-aa6e-7e2633b9d956">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/647abb1a-1232-4443-a8ca-045b3c38a563"/>
    <rdfs:label>MTS-AAV carrying the wild type ND4 gene (mitochondrial targeting signal peptide Adeno-Associated Virus)</rdfs:label>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/6d2800e4-9e6b-4277-ab21-dc7495676942">
    <rdfs:label>Ad5-LARGE-eGFP</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/50140c96-69da-4226-bb8c-e69e321cc7dd"/>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/7c200429-0109-4440-a775-d43f27a7e6a5">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/f7c463a4-e4bf-423f-b387-c3c11b9a2c4d"/>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/b69839e1-475a-4ed9-a3ca-ec6c44c92f46">
    <rdfs:label>Gene Therapy ??</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/f50e904a-b7e7-45cd-8ec7-21c9ea44109a"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/85359197-0b8f-40bb-9e89-95e1179f1e64">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/af7ef3e3-4821-4b1f-9f49-cc8b8ddbf9e5"/>
    <dc:identifier>DB01119</dc:identifier>
    <rdfs:label>Diazoxide</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01119</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/2bf57f0a-bd09-496a-9846-f61f30ffadbe"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/d9fd1cfb-34ae-49cb-8417-6408b8db9182"/>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/320183b7-f2b9-4a23-979f-30e8feeeb10a">
    <rdfs:comment>There was partial improvement then patients died</rdfs:comment>
    <rdfs:label>Clonic contractions</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/fbeede9d-4d57-4d82-a798-23b4be82825f">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000707</ddiem:url>
    <rdfs:label>neurologic dysfunction</rdfs:label>
    <dc:identifier>HP:0000707</dc:identifier>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/1a3dcd25-f742-43c4-8229-3cc542a2c4b0">
    <ddiem:url>https://www.drugbank.ca/drugs/DB01015)</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/f6f58dd7-20ec-4f56-9e07-53363a43f15e"/>
    <dc:identifier>DB01015)</dc:identifier>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/a72e46d7-4c0e-420a-832f-7a539c18adb7">
    <rdfs:label>Deferasirox</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01609</ddiem:url>
    <dc:identifier>DB01609</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/c0c5bbb1-f14c-4f23-af58-d589418a6edd"/>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ee3816ba-6d5c-4944-a831-dc8f54588617">
    <dc:identifier>HP:0008972*</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Reduced electron transport chain activity(Decreased activity of mitochondrial respiratory chain)*</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0008972</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/246387c5-4a08-4db9-8134-ea1389cefe0a">
    <dc:identifier>HP:0001260</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001260</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>dysarthric speech</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/6adbdbc8-1dc2-4104-8ec6-9d3913be420f">
    <dc:identifier>DB00909</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/d5f18d72-4f0b-41ab-b2ca-4669a8c36e28"/>
    <rdfs:label>Zonisamide</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/cd79cc74-6a3c-48e8-8df9-5a5e2ff7d990"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/161c603a-7011-40f9-b330-df8ee711a4c9"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00909</ddiem:url>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/e907c231-979c-4358-97a9-3902b925b2f6">
    <ddiem:url>https://www.drugbank.ca/drugs/DB0084</ddiem:url>
    <dc:identifier>DB0084</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/e66babb0-fc35-4389-9324-52c85654d6f3"/>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/48f32ce4-16cf-4278-9b03-79e206da83cd">
    <ddiem:url>http://purl.obolibrary.org/obo/MP_0004144</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>MP:0004144</dc:identifier>
    <rdfs:label>Drawing inabiliity</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b7c17761-3831-457e-9e7c-e4b77150a029">
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0001875</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001875</ddiem:url>
    <rdfs:label>neutropenia</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9ffb64b7-74cc-49a8-a5e0-9f5ac23fee1b">
    <rdfs:label>Generalized tonic-clonic seizures</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002069</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0002069</dc:identifier>
  </ddiem:Phenotype>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/1815b4f2-d633-4f48-8127-6e84004fd906">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/ef9725c0-f378-4a53-9958-a2d773fb1608"/>
  </rdf:Alt>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/40f0bb66-20b6-4d0d-a45e-8a2eb01a7ed3">
    <rdfs:label>shorter life expectancy</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5b5dfe2f-e35d-4a0d-8f01-72d9959d79f1">
    <rdfs:label>Nonketotic hypoglycemia</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001958</ddiem:url>
    <dc:identifier>HP:0001958</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/8e4a0d78-fd2a-445b-bc7b-6697c0f42fa3">
    <rdfs:label>rAAV2-ND4 (recombinant Adeno-Associated Virus-NADH dehydrogenase, subunit 4 (complex I)ï¼rAAV2-ND4))</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/9a2d0cde-a105-4dbf-a523-d70c74ffd899"/>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4610bccc-ba63-4ff6-b73c-fd7909dd9a0d">
    <rdfs:label>High serum osmolality</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/7cc88ce2-482d-4c14-bde0-bc78b38b66fc">
    <ddiem:url>https://www.drugbank.ca/drugs/DB00111</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/63569027-a160-491e-ac6a-27e46f038469"/>
    <dc:identifier>DB00111</dc:identifier>
    <rdfs:label>Daclizumab</rdfs:label>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2dc2eaee-14fc-4715-94c9-6e4d02b067d9">
    <rdfs:label>secondary carnitine deficiency</rdfs:label>
    <dc:identifier>HP:0003234*</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003234</ddiem:url>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/610090">
    <dc:identifier>https://www.omim.org/entry/610090</dc:identifier>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/76</ddiem:iembaseUrl>
    <rdfs:label>PYRIDOXAMINE 5-PRIME-PHOSPHATE OXIDASE DEFICIENCY; PNPOD</rdfs:label>
    <ddiem:iembaseAccessionNumber>76</ddiem:iembaseAccessionNumber>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/afb655f4-dfaf-440d-95ba-511a2ec0c523"/>
    <rdfs:comment></rdfs:comment>
  </ddiem:Disease>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/61c6e3d4-2575-4537-9df3-fc8a7920ad59">
    <rdfs:label>Fatiguability</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003750</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0003750</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a349c290-e541-4978-99b5-7fc1cff3485c">
    <dc:identifier>HP:0002066*</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002066</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>paroxysmal exercise-induced gait ataxia(exercise-induced episodic ataxia )</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b5f1c85c-c10f-4784-8074-331163733442">
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002167</ddiem:url>
    <dc:identifier>HP:0002167</dc:identifier>
    <rdfs:label>Speech problem</rdfs:label>
  </ddiem:Phenotype>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/3c18c326-8c2f-4c78-98d3-9efaa17d68ff">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/216f2124-8795-462d-a98a-2ed16c06c927"/>
  </rdf:Alt>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/0a23a4f8-511f-47f4-b99d-7143be8ddfee">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/556086b0-d359-4545-ab69-d1e548bee32d"/>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/13e1a867-614d-46ac-9d99-e6e4c61f9431">
    <rdfs:label>rAAV-GPE-G6PT</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/58b82c4c-b4f4-4cfd-b855-3f84e7938ef6"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/bd620ab2-51a0-408b-b8ec-ad1515fb6b11">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/e1df26dc-d9f9-4019-a4e6-9ffa77f8ab55"/>
    <rdfs:label>Gene therapy (wild-type Ad-AGA)</rdfs:label>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/9603ac77-75ca-4a7c-afc3-2d3d527ae515">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/0c17e08a-9934-4738-8459-a790e2525b99"/>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/05d3b8ca-0254-45d5-a239-61ba97888e45">
    <dc:identifier>DB03085</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/95f2afa4-cdae-4066-b51c-abd28a71181b"/>
    <rdfs:label>Glycolic acid</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB03085</ddiem:url>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c762b710-067c-4cd1-b8a7-2cbf2e977d68">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>abnormal SF-36 physical composite scores</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/a25ea26d-5b4b-4d09-b1ed-cd8e752a02c9">
    <ddiem:url>https://www.drugbank.ca/drugs/DB13245</ddiem:url>
    <dc:identifier>DB13245</dc:identifier>
    <rdfs:label>Thiram</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/29761c75-aac7-458e-91a8-5046d97bfee0"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/bc447ce0-3a80-4b07-998a-504612d2780c">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/10b75bc7-4534-449b-b6ea-2eca3f42f0eb"/>
    <rdfs:label>Vigabatrin</rdfs:label>
    <dc:identifier>DB01080</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/1ea8d660-3b1e-4bc5-8924-dffbfe5da7ab"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01080</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/dd5b5d4a-f382-487f-b736-8e265fc675ae"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/995f04a2-db93-47be-afbd-9278effe22a0"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/30c09818-3fab-4010-9857-27ba8b1efbb2">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/babc72be-ad76-4b8c-a966-e462a6044a24"/>
    <rdfs:label>Hypoxanthine</rdfs:label>
    <dc:identifier>DB04076</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB04076</ddiem:url>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/025c1012-5b89-4794-911f-22655ff93abe">
    <dc:identifier>A06AA</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/92d0426c-451d-4509-a12b-7de1a788ba88"/>
    <ddiem:url>https://www.whocc.no/atc_ddd_index/?code=A06AA</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/c03074f5-1fe2-4ebd-99ae-fd33a76ed96f"/>
    <rdfs:label> Softeners, emollients</rdfs:label>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5b53f2f0-5ffd-4058-8a71-a8aca22b32e5">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003808</ddiem:url>
    <rdfs:label>Abnormal muscle tone</rdfs:label>
    <dc:identifier>HP:0003808</dc:identifier>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/a76ec68c-b717-43f1-be48-69f420c9576d">
    <ddiem:url>https://www.drugbank.ca/drugs/DB00147</ddiem:url>
    <rdfs:label>Pyridoxal</rdfs:label>
    <dc:identifier>DB00147</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/ae1f95ff-0ccf-4e28-8d42-e0876ee7db03"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/c80ee7ca-5d28-4c6e-9341-0bcacadb1df0">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/281c851d-beed-4f31-8759-d7016456e4b3"/>
    <rdfs:label>Recombinant adeno-associated virus serotype 9 (rAAV9)-ATP7A +sc copper histidine</rdfs:label>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/06ec2e92-c5f3-41fe-b49e-5a0509863fb5">
    <rdfs:label>Inositol</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB13178</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/f78e40d7-dfe6-449b-949e-3ab5dd053236"/>
    <dc:identifier>DB13178</dc:identifier>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4121c319-d513-4227-9c2c-d300d5664f61">
    <rdfs:label>psychotic  disorder</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0000725</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000725</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/1db5ab2f-74fa-447a-adb1-d9292dd7ca8e">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/a330d0cc-3d0e-4fb8-947e-de6a1fcba5e3"/>
    <rdfs:label>recombinant canine Î±-l-fucosidase enzyme</rdfs:label>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/b7dc0bbb-b1d1-42ac-ab75-af2168fcc0b3">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/b17feafd-d8a2-42ff-8d1b-019fdbb79410"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00061</ddiem:url>
    <dc:identifier>DB00061</dc:identifier>
    <rdfs:label>Pegademase</rdfs:label>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/1bd0d1bd-f6d5-4f35-b391-2461a5c1a4f6">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/ff45ab9b-8f9b-49f1-b569-d08e3410838e"/>
    <rdfs:label>AAV-cG6PGH</rdfs:label>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d73da1be-4e31-4139-961d-d01bc7298b7b">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001954</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Periodic fever</rdfs:label>
    <dc:identifier>HP:0001954</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/216bc8d9-3bfc-4434-aee7-d79e4b52292d">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/c43f70d4-ead6-4b24-b6fc-054db86db0ab"/>
    <rdfs:label>LJPC-401(Synthetic human hepcidin)</rdfs:label>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/241ba9f8-91b0-43e1-8a4d-d22ad535e893">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/23f68ba8-dce7-4b91-82ba-493282d97765"/>
    <rdfs:label>Adalimumab</rdfs:label>
    <dc:identifier>DB00051</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00051</ddiem:url>
  </ddiem:Drug>
  <owl:Class rdf:about="http://purl.obolibrary.org/obo/DDIEM_0000013">
    <obo:IAO_0000115 xml:lang="en">A therapeutic procedure aimed at amelioration of one or more abnormal phenotypes generated as a consequence of a defective protein or process by a means unrelated to the immediate pathway or network environment of the defective protein. Generally working at the level of the tissue or overall organismal physiology. [PNS]</obo:IAO_0000115>
    <dc:creator>leechuck</dc:creator>
    <rdfs:label xml:lang="en">symptomatic treatment procedure</rdfs:label>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/metabolic_disease_treatment"/>
    <dc:date rdf:datatype="http://www.w3.org/2001/XMLSchema#dateTime">2019-07-15T18:07:49+00:00</dc:date>
  </owl:Class>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/a056a20b-318d-4a47-abbb-120f75ccf738">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/eabeb264-e565-44bd-bf6f-d98c7be41c0a"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00586</ddiem:url>
    <dc:identifier>DB00586</dc:identifier>
    <rdfs:label>Diclofenac</rdfs:label>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7b1a34a3-4d87-4e9e-a5fa-17af70e20bce">
    <dc:identifier>HP:0001939</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001939</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Liver biochemical abnormalitiesÂ (Laboratory abnormalities)*</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/35f486d8-eee3-429e-bda3-31bff1a41d4e">
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002630</ddiem:url>
    <rdfs:label>fat soluble vitamin malabsorption (Fat malabsorption)*</rdfs:label>
    <dc:identifier>HP:0002630*</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/28629e44-daca-4eef-91a6-0ae1a2a2d0a8">
    <rdfs:label>Abnormal linear growth (Decreased linear growth ,Abnormal body height)*</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000002</ddiem:url>
    <dc:identifier>HP:0000002</dc:identifier>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/863c211f-57c5-401c-9a9b-3e3a77a77154">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/87adf1e7-97c5-4143-a2cd-03d8b7fad426"/>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/ec4e6420-90d1-4f2e-bb29-0fed9beba5dc">
    <rdfs:label>(r) AAV2/1-mediated calpain 3</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/b0a8999b-15d6-462d-8446-ae2d89a0ca3a"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/0c6c04ae-7883-4eb1-9b6a-3dfa39ab9633">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/d2586fea-356a-4a9b-9343-cb0d8a3e11d2"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/38306759-b3dc-409f-bc1d-e8d4fda7c18d"/>
    <rdfs:label>Thalidomide</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01041</ddiem:url>
    <dc:identifier>DB01041</dc:identifier>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/4289ff94-4d7d-40dd-98f6-c5d46e3b1e6f">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/d0de03aa-dbfd-4061-a90a-a9b6b4434a81"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB06372</ddiem:url>
    <rdfs:label>Rilonacept</rdfs:label>
    <dc:identifier>DB06372</dc:identifier>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/5e56fac8-1f7a-4e2f-ae8c-42ccfcccf559">
    <rdfs:label>Metronidazole</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/9fa9a16b-c1c0-4f6f-9e7a-561d0c196d35"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00916</ddiem:url>
    <dc:identifier>DB00916</dc:identifier>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e1ab1408-3f0b-412a-9df4-30ad7a784975">
    <dc:identifier>HP:0003737</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003737</ddiem:url>
    <rdfs:label>Mitochondrial myopathy</rdfs:label>
  </ddiem:Phenotype>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/02c820e4-f3ff-4f78-be44-6ec829d32927">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/f7198721-8a0f-471b-bd5b-d0b28ec4967f"/>
  </rdf:Alt>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/b3a9bc45-182d-4528-8449-039d11c72c40">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/02f3615f-cc8f-4c0c-8b7e-30c95714ea35"/>
  </rdf:Alt>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/c46957e5-6f3c-4908-b1ad-af5cba052500">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/9e99b755-8464-4f3a-aeb6-240668b80a07"/>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/f0b6904c-6261-41d4-baf3-3457c9e30f04">
    <rdfs:label>No medical treatment is available in DDIEM</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/0621b2f3-a731-4816-b108-1d068c0e1797"/>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/7f736de3-7d79-4a1d-91c3-890afd504412">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/f868e865-2488-4093-b4c9-84bceb48f6d9"/>
  </rdf:Alt>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4077cef1-24e3-4ea7-b2ac-6ba6073bfc1e">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002155</ddiem:url>
    <rdfs:label>high fasting triglycerides</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0002155*</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/bbfcd248-0ca9-4260-9064-0e23c5cb04e1">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/d90f9a18-45af-45b6-a256-60d39edc153b"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/03e103d6-1737-467d-b750-17ec586d84fe"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/c1ca269f-d653-4eee-9865-d869891a642f"/>
    <dc:identifier>DB00776</dc:identifier>
    <rdfs:label>Oxcarbazepine</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00776</ddiem:url>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/3fbdd6dc-ab64-4c45-8cdb-af53eadb93d1">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/a168b583-4467-494e-adf1-d5226dfd5cee"/>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/53b5fa99-0c12-4228-82c5-889b1d78f4c3">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/7b03cde8-8481-4081-aa32-5051441cff51"/>
    <rdfs:label>DTX401</rdfs:label>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/86a61a20-e2fd-4a8a-ab69-5351b5a5df68">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Palmitate plus lactate-induced cell death</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/95a84012-eadf-44a4-8bd1-968d00cc739f">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/5ce1bdec-4c54-47ed-99fe-4cddd735ab48"/>
    <dc:identifier>DB13961</dc:identifier>
    <rdfs:label>Fish oil</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB13961</ddiem:url>
  </ddiem:Drug>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/cc9929d9-ce67-4b28-9243-df8923acb9e0">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25717099</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/604250"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14632789</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/18b377b8-d59f-4c8f-83fc-bc71284b0187"/>
    <dc:provenance>https://www.semanticscholar.org/paper/The-Incidence-of-Transient-Neonatal-Tyrosinemia-a-Zea-Rey-Cruz-Camino/b66304a0a56304f686380af915a92b2b860e9305</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00733811</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a09a00cd-6976-42fb-986d-d6c4653a0a5d"/>
    <rdfs:comment>Quercetin which is one of the polyphenols can reduce hepatic iron deposition in mice that were exposed to either ethanol or excess iron. They found that quercetin increased BMP6, intranuclear SMAD4, SMAD4 binding to the HAMP promoter, and hepcidin expression, which led to decreased hepatic iron levels and reduced iron-related damage. https://www.ncbi.nlm.nih.gov/pubmed/27393927</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19415691</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT03453918</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
  </obo:DDIEM_0000013>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/6dbbe4eb-a199-4640-b05b-b395ed9ac4d1">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/509d7f32-98f4-4b0b-8f9e-9e436755e86f"/>
  </rdf:Alt>
  <owl:Class rdf:about="http://purl.obolibrary.org/obo/DDIEM_0000012">
    <obo:IAO_0000115 xml:lang="en">A therapeutic procedure in which  generally small molecules are delivered to the organism in order to to directly increase, decrease or alter the activity or stability of a genetically defective protein.[PNS]</obo:IAO_0000115>
    <dc:date rdf:datatype="http://www.w3.org/2001/XMLSchema#dateTime">2019-07-15T18:07:23+00:00</dc:date>
    <rdfs:label xml:lang="en">activity modification of a genetically defective protein</rdfs:label>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000006"/>
    <dc:creator>leechuck</dc:creator>
  </owl:Class>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/217dc0c7-e59b-47e8-9453-215e48cc02e9">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/a968e08d-b854-4ebe-933e-e9fb1bea72fa"/>
    <dc:identifier>DB14573</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB14573</ddiem:url>
    <rdfs:label>Phosphate ion P-32</rdfs:label>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/8f2fac9e-079d-442e-b3fa-da52ed3ba548">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/43aa786f-e798-438b-b392-a1906bbaf93c"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00393</ddiem:url>
    <rdfs:label>Nimodipine</rdfs:label>
    <dc:identifier>DB00393</dc:identifier>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/eaa48ea4-c25a-404d-a98c-ae4f6bcc0847">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/b63488c0-d0d4-4e1f-9ad0-2f831d21012c"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01325</ddiem:url>
    <dc:identifier>DB01325</dc:identifier>
    <rdfs:label>Quinethazone</rdfs:label>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/bdbf1fa3-7b52-426f-aa22-297cd770126e">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/23b28ce0-8a30-437c-8bd1-9fa02752e27f"/>
    <rdfs:label>Recombinant human Aspartylglucosamidase</rdfs:label>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8c3518e1-0d7b-4d48-9398-efe2e9615f68">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003648</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>high Lactic acid</rdfs:label>
    <dc:identifier>HP:0003648</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/8d21b15c-3451-4afa-8872-297279a83d4d">
    <ddiem:url>https://www.drugbank.ca/drugs/DB00060</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/d2586fea-356a-4a9b-9343-cb0d8a3e11d2"/>
    <rdfs:label>Interferon beta-1a</rdfs:label>
    <dc:identifier>DB00060</dc:identifier>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/aaae542c-5d24-4c2f-8cb6-a39dd5b01a81">
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003201</ddiem:url>
    <rdfs:label>rhabdomyolysis</rdfs:label>
    <dc:identifier>HP:0003201</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/59774fa1-be7d-4e44-b3e8-a5f2306f3c83">
    <rdfs:label>AAV9-TAZ</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/f5d80de6-d928-430d-8875-2421d716f081"/>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/65e4b303-5c3d-4abd-b46f-fae588d029d5">
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000095</ddiem:url>
    <dc:identifier>HP:0000095*</dc:identifier>
    <rdfs:label>glomerular damage</rdfs:label>
  </ddiem:Phenotype>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/d82b8cdd-3a56-4922-a399-3eb49f821bbd">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/24956bb3-4333-45e5-bf91-a05325926e64"/>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/8309fc89-d7d4-4be6-ac49-188ae08c8211">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/20cd649c-b2c3-4f4a-8fa0-2440c045a70a"/>
    <rdfs:label>mitochonic acid 5</rdfs:label>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/a32e68e4-476e-4652-b714-f6245cda7918">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/156b74ba-acf8-483d-8917-cf00b2b0f1a7"/>
  </rdf:Alt>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/2d4db577-7053-4a23-b269-de343a037157">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/71be84df-584f-45ef-8a49-f350b1768e70"/>
  </rdf:Alt>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1e51fa61-e114-4251-992f-dbbd04d47a00">
    <dc:identifier>HP:0100712</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>changes in lumbar spine (LS)</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0100712</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/1775622c-ffec-4e91-bc61-82add3b4b6ea">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/15e5ca1f-0baf-4652-9788-b3f1bff2a73b"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/291630fc-7f05-4e92-8b0d-11766b1469ca"/>
    <dc:identifier>DB03793</dc:identifier>
    <rdfs:label>Benzoic Acid</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB03793</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/f4dfde87-7666-455f-b3f2-2e09da6e9da6"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/22c021ab-1d82-4720-91df-555fbdf1a827">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/75a8e592-13c4-4465-9546-45b5da1da0e5"/>
    <rdfs:label>recombinant humanÂ LCAT (ACP-501)</rdfs:label>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/1a49a02e-55f4-4c16-865e-6003ba415bcf">
    <rdfs:label>FIV-hAAT-G6Pase</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/a1c34d13-087c-421e-8305-261fa4273dc3"/>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3bbae410-ef54-490a-a352-cf314d34232c">
    <dc:identifier>HP:0025521</dc:identifier>
    <rdfs:label>Abnormal Body fat composition</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0025521</ddiem:url>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/83308d11-c117-4f8d-9b7f-c0bb0a8882d6">
    <rdfs:label>Hyperchylomicronemia</rdfs:label>
    <dc:identifier>HP:0012238</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0012238</ddiem:url>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/12860d8a-7844-4608-a964-071cd16777c3">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003678</ddiem:url>
    <rdfs:label>Disease progression (Rapid progression)*</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0003678</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/9b5940f1-1250-4854-9edd-4f18a5e32c16">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/82b3806c-e554-4b52-a8fa-58587a104fef"/>
    <rdfs:label>Resolaris (ATYR1940)</rdfs:label>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8963e454-ea8f-4ca5-8ebb-59ed11987c54">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Terminated (Sponsor decision to end development of RP103 for mitochondrial disease due to lack of efficacy demonstrated in base study RP103-MITO-001</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b1cc2163-3a0c-4c32-976b-29a7aca7cd10">
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0007166</ddiem:url>
    <dc:identifier>HP:0007166</dc:identifier>
    <rdfs:label>Paroxysmal movements</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/4a271ff0-afec-4cbe-8842-16d73920e19c">
    <rdfs:label>Gene therapy</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/bd1cb0d2-f088-4186-9d1e-e5e56f7d7b1a"/>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/2358abbd-c070-417f-a985-0cc492b6ef0c">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/2853a523-e834-4c4a-9525-84646aa37f6e"/>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/ecb8e3c3-1f5f-4379-af17-3a5725fe77e7">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/99cd5214-3e53-41d3-8acd-d6d99a20746c"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB08909</ddiem:url>
    <rdfs:label>Glycerol phenylbutyrate</rdfs:label>
    <dc:identifier>DB08909</dc:identifier>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/4d209536-2375-4bb0-bb98-141fa60ea117">
    <dc:identifier>DB00672</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00672</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/ba857816-ac9a-4646-9995-71dad2c3a159"/>
    <rdfs:label>Chlorpropamide</rdfs:label>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/50b13d74-1819-4baf-a663-a65f46baeb91">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/3223c78d-7e37-4e46-ba44-14a8d29275ab"/>
  </rdf:Alt>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9a3fef61-43d9-455a-86b5-c613837079b4">
    <rdfs:label>concommitant low vit D level</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0100512</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0100512*</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6015addb-cdd5-4f53-9355-4829d71058ab">
    <rdfs:label>Hypsarrhythmia</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002521</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0002521</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/65e9c779-2e4a-4fb1-ba8d-3900aa4fe198">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/83bf2191-18af-44a6-b203-dda9548a7646"/>
    <rdfs:label>high protein diet</rdfs:label>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/eaf3c29f-5dcd-474f-8932-fe14bf52f918">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/fdbd2f2f-7b8e-4c8b-a377-7157ef48e7f0"/>
    <dc:identifier>DB09393</dc:identifier>
    <rdfs:label>Amino acids</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB09393</ddiem:url>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f9b2227e-9132-42b6-8a45-18e2fb98c1b7">
    <rdfs:label>Chronic diarrhea</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002028</ddiem:url>
    <dc:identifier>HP:0002028</dc:identifier>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/1ec53405-6dc6-4c8b-a9f9-346b194ba998">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/edace8ef-6023-46de-b03a-89ca8401b022"/>
  </rdf:Alt>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/eb6d66cc-8ce1-4560-a099-984a6c49ce26">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/11e9507e-52cf-4fab-9119-9bfce5929ed1"/>
  </rdf:Alt>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c2d60072-04c0-47f8-9777-ab6a06113853">
    <dc:identifier>HP:0000613</dc:identifier>
    <rdfs:label>Photophobia</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000613</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b40f8b8f-4bb8-4c27-847f-53fdc4ac6b14">
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0001324</dc:identifier>
    <rdfs:label>decrease muscle strenght</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001324</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/743b6ddd-3df7-4fe9-98a5-c3e47663c9b5">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0011197</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>EEG with focal spike waves</rdfs:label>
    <dc:identifier>HP:0011197</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/b46f82cf-aa1c-4cb4-b80f-154c70d7658b">
    <rdfs:label>AAV-GLUT1</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/a3ac990b-3cd4-445c-9a2e-4445ed7e50f1"/>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ea816f1e-27b7-4b8d-a28d-1ca7085d73d4">
    <dc:identifier>HP:0500014</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0500014</ddiem:url>
    <rdfs:label>Histologic abnormalities in liver(Abnormal test result)*</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/617069">
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/6f8239fa-1a03-4c85-b2d2-77ab97e55f9f"/>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>https://www.omim.org/entry/617069</dc:identifier>
    <rdfs:label>PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA WITH MITOCHONDRIAL DNA DELETIONS, AUTOSOMAL RECESSIVE 3; PEOB3</rdfs:label>
  </ddiem:Disease>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/e6938ced-9c66-43eb-b30b-8be0c174fcbc">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/6b1e7436-7f5c-40a1-bec8-009f6ed8839e"/>
  </rdf:Alt>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7178af06-55cd-4314-b898-c4ec7482bc7a">
    <dc:identifier>HP:0000708</dc:identifier>
    <rdfs:label>behavioral disability</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000708</ddiem:url>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/8b35eca0-6a41-437d-81e2-1ff6182e89d9">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/32664135-6368-4082-8eb4-65fc836514ab"/>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/da94a65c-79b4-4a88-bc19-1165baf8924d">
    <rdfs:label>Metformin</rdfs:label>
    <dc:identifier>DB00331</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00331</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/5bb8f405-7711-4917-850d-45a86c041a07"/>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d71d717f-c80f-418b-9945-36bca70ad305">
    <dc:identifier>HP:0002011</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002011</ddiem:url>
    <rdfs:label>nervous system abnormalities</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/66a62fbe-a604-41f7-8f0b-7161dd56326f">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001640</ddiem:url>
    <rdfs:label>Cardiomegaly</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0001640</dc:identifier>
  </ddiem:Phenotype>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/6d8d1fbb-ae08-4c88-9451-d15672f5fcd2">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/9fc7f902-2a88-42ce-b4dd-e0597a191642"/>
  </rdf:Alt>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c9c8acb8-94f5-4915-9298-e25ad3912769">
    <dc:identifier>HP:0025464</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Increased ROS formation</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0025464</ddiem:url>
  </ddiem:Phenotype>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/778ed03e-3afa-486e-916a-68611d1fa0d8">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/5beb0a2b-4689-48d9-9bc6-5694dd831ea4"/>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/18276157-ff61-4cd3-8a18-2150cac4692c">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/f6f58dd7-20ec-4f56-9e07-53363a43f15e"/>
    <dc:identifier>(DB00440</dc:identifier>
    <ddiem:url>https://www.whocc.no/atc_ddd_index/?code=(DB00440</ddiem:url>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/2d4193b6-7b1f-493c-bd5d-2c3ac8a68f9f">
    <dc:identifier>DB6756</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/d730af56-9761-4404-a75a-c8ffc4306093"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB6756</ddiem:url>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d6cb430b-2402-46ee-90f8-63247dbbf19c">
    <dc:identifier>HP:0000093</dc:identifier>
    <rdfs:label>Proteinuria</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000093</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1e7b5e33-54bf-43fc-a4c9-de6e00ad2200">
    <rdfs:label>Susceptibility to Bacterial infection</rdfs:label>
    <dc:identifier>HP:0002718</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002718</ddiem:url>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/3c742415-210d-4972-838a-e1442e7e2c47">
    <ddiem:url>https://www.drugbank.ca/drugs/DB00158</ddiem:url>
    <dc:identifier>DB00158</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/ac5af18a-3c15-4d21-8690-f4752a5a3300"/>
    <rdfs:label>Folic acid</rdfs:label>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ed8e0af1-38f7-483a-a7b8-ef9ae8094f42">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>PL-induced cytotoxicity</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/fec748c2-84f3-4fa9-b149-56538e2e95ae">
    <rdfs:label>aminomidazole carboxamide riboside</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/8d1c4a7c-5d60-4c41-b0d2-fade867c636f"/>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a3578176-5857-4639-9400-801bf27a0c6d">
    <dc:identifier>HP:0011123</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0011123</ddiem:url>
    <rdfs:label>skin inflammation</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/7d81ee63-e46c-48ce-8773-2d711e8eedfd">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/7aaf69ad-d88e-4ca6-b752-3c0134a319d9"/>
  </rdf:Alt>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/43698ab0-afd0-4ca5-a1ee-dae492cfa56e">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/79f2b593-fd23-49cb-a100-2fcf406dc6a8"/>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/9ec00ca6-95f3-491c-ae38-7869891deab7">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/02a923b3-8e05-42fb-b1eb-13d0d8a020d5"/>
    <rdfs:label>keto-analogues of essential amino acids</rdfs:label>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/fc528ead-f534-46d5-a6ae-cc099f06cb0e">
    <rdfs:label>AAV9-MCK-fukutin</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/260455e5-7012-4723-b865-b82a79acbe2c"/>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/19722b60-4092-407f-8f30-f4965e74968f">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/75d0767b-42ad-40da-9d02-989a91b4e497"/>
  </rdf:Alt>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/12ca8ace-629e-4724-8a4e-5288f478dec4">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/7746e64b-e684-4573-9cf4-daaabbcfa2f7"/>
  </rdf:Alt>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/5001be32-bd9d-4986-a0a0-2fb2906aba35">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/2795b7d5-b30d-45bf-ba20-82524d79f867"/>
  </rdf:Alt>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/21995aa8-c3c8-4edb-95a5-8169a50267bb">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/2bb03ed1-d774-4555-97ad-b5e5fb09ba0c"/>
  </rdf:Alt>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/7c727f93-656f-47e3-ac58-a3d4c1af8dc8">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/7e844da0-0572-4d9d-939b-4f70ab3af4ec"/>
  </rdf:Alt>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a83c8745-e772-48e0-adea-cd522082cf20">
    <rdfs:label>Sulfide toxicity</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/d205d39b-6523-40eb-a352-c903ebd7a86e">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/fbbbef9b-4812-487c-a159-45f751afa222"/>
  </rdf:Alt>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/0fb835fb-b796-4f5c-bcbd-5e24b59fe9a7">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/5ce7f4a3-fc46-48d8-8e23-8665010c19d3"/>
  </rdf:Alt>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/ce191990-c6b3-4fe3-92b8-bdae0025b829">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/a91afdeb-e22e-486b-b02d-d44de165d1a4"/>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/bfca260a-87a6-4b7e-b709-7ecd501a9af6">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/71ebea66-2f22-4e9b-b87b-976e3a069b56"/>
    <rdfs:label>rAAV-PPCR</rdfs:label>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/e36f169e-4be7-44b6-9899-800086c04902">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/6cd410eb-48bc-44f5-8145-4e7b602b2ce7"/>
    <dc:identifier>DB00555</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00555</ddiem:url>
    <rdfs:label>Lamotrigine</rdfs:label>
  </ddiem:Drug>
</rdf:RDF>
